 
i 
Republic of Ghana
Ministry of Health 
Ghana National Drugs Programme 
(GNDP)
Standard Treatment Guidelines
Ministry of Health
Seventh Edition (7th), 2017

 
Standard  Treatment Guidelines, 7th Edition, 2017
ii© 2017 Ministry of Health (GNDP) Ghana
All rights reserved. No part of this publication may be reproduced, stored 
in any retrieval system, or transmitted in any form or by any means, 
electronic, mechanical, photocopying, recording and/or otherwise, 
without prior written permission of the Ministry of Health.
Essential Drugs List & National Formulary with Therapeutic Guidelines, 
1st Edition, 1988
Essential Drugs List & National Formulary with Therapeutic Guidelines, 
2nd Edition, 1993
Essential Drugs List & National Formulary with Therapeutic Guidelines, 
3rd Edition, 1996
Standard Treatment Guidelines , 4th Edition, 2000
Standard Treatment Guidelines , 5th Edition, 2004
Standard Treatment Guidelines , 6th Edition, 2010
Standard Treatment Guidelines , 7th Edition, 2017
ISBN 978-9988-2-5787-3
For all enquiries write to the publishers:
Ghana National Drugs Programme (GNDP) 
Ministry of Health
P . O. Box MB-582, Accra, Ghana, West Africa 
Tel: +233 (0) 30 2661 670/1
Fax: +233 (0) 30 2664 309 
E-mail: gndp@ghndp.org
Website: www.ghndp.org
Legal Disclaimer
Care has been taken to confirm the accuracy of the information presented 
and to describe generally accepted practices. However, the authors, 
editors and publishers are not responsible for errors and omissions or 
any consequences from application of the information in this booklet and 
make no warranty, expressed or implied, with respect to the content of 
the publication.
Printed by:
Yamens Press Limited, P . O. Box AF 274, Accra 
Tel: 0302-223 222
E-mail: yamenspresslimited@gmail.com
Cover Design:
Q-elements Limited, Accra
Tel:  0302-719432, 0268-080618
E-mail: creative@q-elementsghana.com

iiiTable of Contents
 
Preface  ..................................................................................................... xii
Acknowledgement  ................................................................................... xiii
Introduction  ��������������������������������������������������������������������������������������������������� 1
How to use this book  ................................................................................. 2
Prescribing for NHIS reimbursement  ......................................................... 3
Notes on cost-effectiveness  ....................................................................... 3
Referral  ...................................................................................................... 4
Abbreviations  ............................................................................................ 4
Prescription writing  ................................................................................... 5
Dosing and medication based on Age and body weight in children  .......... 7
Pharmacovigilance and Adverse Drug Event Reporting  ............................ 7
Important contacts  ................................................................................... 8
Chapter 1. Disorders of the Gastrointestinal Tract ��������������������������������� 11
1. Diarrhoea  ......................................................................................... 11
2. Rotavirus Disease and Diarrhoea  ..................................................... 18
3. Constipation   ................................................................................... 19
4. Peptic Ulcer Disease  ......................................................................... 22
5. Gastro-oesophageal Reflux Disease  ................................................. 25
6. Pain Originating from the Oesophagus  ............................................ 28
7. Haemorrhoids  .................................................................................. 29
Chapter 2. Disorders of the Liver  �������������������������������������������������������������� 33
8. Amoebic Liver Access  ....................................................................... 33
9. Jaundice  .......................................................................................... 35
10. Acute Hepatitis  ................................................................................. 37
11. Chronic Hepatitis  .............................................................................. 38
12. Hepatic Encephalopathy  .................................................................. 42
13. Ascites  .............................................................................................. 46
14. Vomiting   ......................................................................................... 48
15. Hepatocellular Carcinoma  ................................................................ 53
16. Drugs and the Liver  .......................................................................... 55
Chapter 3. Nutritional Disorders  �������������������������������������������������������������� 58
17. Malnutrition  .................................................................................... 58
Chapter 4. Haematological Disorders  ������������������������������������������������������� 62
17. Anaemia  ........................................................................................... 62
18. Bleeding Disorders  ........................................................................... 65
19. Sickle Cell Disease  ............................................................................ 69
20. Plasma Cell Myeloma  ....................................................................... 73
21. Leukaemia  ........................................................................................ 75
22. Malignant Lymphoma  ...................................................................... 77
Chapter 5. Immunisable Diseases  ���������������������������������������������������������������� 80

 
Standard Treatment Guidelines, 7th Edition, 2017
iv23. Immunisation  .................................................................................. 80
24. Measles  ............................................................................................ 82
25. Pertussis  .......................................................................................... 84
26. Tetanus  ............................................................................................. 86
27. Poliomyelitis  ..................................................................................... 89
28. Diphtheria  ........................................................................................ 90
29. Yellow Fever  ..................................................................................... 92
30.	 Haemophilus	Influenzae  type b Disease  ........................................... 94
31. Pneumococcal Disease  ..................................................................... 95
32. Hepatitis  ........................................................................................... 96
33. Rotavirus Disease  ............................................................................. 96
Chapter 6. Problems of the Newborn (Neonate)  ��������������������������������������� 97
34. Sick newborn  ................................................................................... 97
35. Neonatal Hypoglycaemia   ............................................................. 100
36. Neonatal Jaundice  ......................................................................... 101
37. Birth Injuries   ................................................................................. 104
38. Neonatal conjunctivitis   ................................................................. 106
39. Retinoblastoma  ............................................................................. 108
40. Wilms Tumour  ............................................................................... 110
Chapter 7. Disorders of the Cardiovascular System  �������������������������������� 113
41. Chest Pain ....................................................................................... 113
42. Ischaemic Heart Disease   .............................................................. 115
43. Dyspnoea  ....................................................................................... 121
44. Deep Vein Thrombosis (DVT)  ......................................................... 123
45. Pulmonary Embolism  ..................................................................... 127
46. Stroke  ............................................................................................. 129
47. Heart Failure ................................................................................... 134
48. Congenital Heart Disease  ............................................................... 140
49. Hypercyanotic attack  ...................................................................... 143
50. Pericarditis  ..................................................................................... 145
51. Hypertension  ................................................................................. 146
52. Hypertension in children and adolescents  .................................... 151
53. Hypertension in Pregnancy  ........................................................... 154
54. Hypertensive Emergencies  ............................................................. 154
55. Arrhythmias  ................................................................................... 156
56. Acute Rheumatic Fever  .................................................................. 161
57. Dizziness and Blackouts .................................................................. 164
Chapter 8. Disorders of the Respiratory System  ��������������������������������������� 167
58. Common Cold  ................................................................................ 167
59. Pneumonia  ..................................................................................... 169
60. Bronchial Asthma  ........................................................................... 175
61. Acute Bronchitis  ............................................................................. 180
62. Chronic Bronchitis  ......................................................................... 183
63. Bronchiectasis  ................................................................................ 187
64. Lung Abscess  .................................................................................. 189
Chapter 9. Disorders of the Central Nervous System ������������������������������� 193
65. Headache  ....................................................................................... 193
66. Seizures  .......................................................................................... 196
67. Epilepsy  ......................................................................................... 200
68. The Unconscious Patient  ................................................................ 203
Chapter 10. Psychiatric Disorders  ��������������������������������������������������������������� 207
69. Attention Deficit Hyperactivity Disorder (ADHD)  ........................... 207
70. The Acutely Disturbed Patient  ....................................................... 209
71. Psychogenic Seizures  ...................................................................... 213

 
Table of Contents
v72. Insomnia  ........................................................................................ 214
73. Depression  ..................................................................................... 216
74. Schizophrenia  ................................................................................. 220
75. Bipolar Disorder  ............................................................................. 226
76. Alcohol Withdrawal Syndromes   ................................................... 229
77. Alcoholic Delirium Tremens  .......................................................... 231
78. Anxiety Disorders   ......................................................................... 233
79. Substance Use Disorders  ................................................................ 239
80. Autistic Spectrum Disorder  ............................................................ 242
Chapter 11. Disorders of the Skin  ��������������������������������������������������������������� 245
Bacterial Skin Infections  ������������������������������������������������������������� 245
81. Boils   .............................................................................................. 245
82. Impetigo  ........................................................................................ 246
83.   Cellulitis and Erysipelas  ................................................................ 249
84. Buruli Ulcer  .................................................................................... 249
85. Yaws  .............................................................................................. 250
Fungal Skin Infections  ����������������������������������������������������������������� 252
86. Superficial Fungal Skin Infections  ................................................... 252
87. Pityriasis Versicolor  ........................................................................ 255
Viral Skin Infections  ������������������������������������������������������������������� 257
88. Herpes Simplex Infections  ............................................................. 257
89. Herpes Zoster Infections  ............................................................... 259
90. Chicken pox  ................................................................................... 261
Non-Specific Skin Infections  ������������������������������������������������������� 265
91. Large Chronic Ulcers ....................................................................... 265
92. Pruritus ........................................................................................... 267
93. Urticaria  ......................................................................................... 272
94. Reactive Erythema and Bullous Reaction   ..................................... 274
95. Acne Vulgaris  ................................................................................. 276
96. Eczema  .......................................................................................... 279
97. Intertrigo  ........................................................................................ 283
Chapter 12. Endocrine and Metabolic Disorders  ��������������������������������������� 287
98. Diabetes Mellitus  ........................................................................... 287
99. Diabetic Ketoacidosis  ..................................................................... 293
100. Diabetes in Pregnancy  ................................................................... 297
101. Treatment-Induced Hypoglycaemia  ............................................... 298
102. Dyslipidaemia  ................................................................................. 300
103. Goitre   ........................................................................................... 302
104. Hypothyroidism   ............................................................................ 303
105. Hyperthyroidism ............................................................................ 305
106. Adrenal Insufficiency   .................................................................... 307
107. Cushing’s Syndrome   ..................................................................... 310
108. Overweight and Obesity  ................................................................ 311
Chapter 13. Obstetric Care and Obstetric Disorders  ��������������������������������� 314
109. Antenatal Care ............................................................................... 314
110. Hyperemesis Gravidarum  ............................................................... 322
111. Hypertension in Pregnancy  ............................................................ 323
112. Pre-eclampsia  ................................................................................. 325
113. Severe Pre-Eclampsia and Imminent Eclampsia  ............................. 326
114. Eclampsia  ....................................................................................... 328
115. Malaria in Pregnancy  ..................................................................... 331
116. Anaemia in Pregnancy  ................................................................... 331
117. Sickle Cell Disease in Pregnancy  .................................................... 334
118. Diabetes Mellitus in Pregnancy  ...................................................... 338

 
Standard Treatment Guidelines, 7th Edition, 2017
vi119. Cardiac Disease in Pregnancy  ......................................................... 341
120. Jaundice in Pregnancy  ................................................................... 343
121. Post-Partum Haemorrhage ............................................................ 344
122. Post-Partum Pyrexia  ...................................................................... 349
123. Analgesia in Labour  ........................................................................ 352
124. Preterm Labour in Premature Delivery  ......................................... 354
125. Premature Rupture of the Membranes  ......................................... 356
Chapter 14. Gynaecological Disorders  ������������������������������������������������������ 358
126. Dysmenorrhoea ............................................................................. 358
127. Abortion  ......................................................................................... 359
128. Abnormal Vaginal Bleeding  ............................................................ 371
129. Abnormal Vaginal Discharge  .......................................................... 373
130. Acute Lower Abdominal Pain  ......................................................... 379
131. Female Infertility  ............................................................................ 382
132. Menopause  .................................................................................... 384
133. Carcinoma of the Cervix  ................................................................ 386
Chapter 15. Disorders of the Kidney and Genitourinary System  ��������������� 388
134. Acute Glomerulonephritis  .............................................................. 388
135. Nephrotic Syndrome  ...................................................................... 390
136. Acute Kidney Injury  ........................................................................ 392
137. Chronic Kidney Disease  ................................................................. 396
138.  Anaemia in Chronic Kidney Disease  .............................................. 399
139. Urinary Tract Infection  ................................................................... 401
140. Medicines and the Kidney  .............................................................. 403
141. Acute Cystitis  ................................................................................. 406
142. Benign Prostatic Hyperplasia   ........................................................ 408
143. Bacterial Prostatitis  ........................................................................ 410
144. Scrotal Masses  ............................................................................... 413
145. The Empty Scrotum  ........................................................................ 414
146. Priapism  ........................................................................................ 416
147. Posterior Urethral Valves  ............................................................... 417
148. Urinary Tract Calculi  ....................................................................... 419
149. Urethral Stricture  ........................................................................... 421
150. Vasectomy (Male Sterilisation)  ...................................................... 422
151. Acute Epididymo-orchitis  ............................................................... 423
152. Testicular Torsion (Torsion of Spermatic Cord)  ............................... 425
153. Fournier’s Gangrene  ...................................................................... 427
154. Bladder Cancer  ............................................................................... 429
155. Carcinoma of Prostate  .................................................................... 431
156. Erectile Dysfunction  ....................................................................... 433
157. Male Infertility  ............................................................................... 435
158. Haematuria  ................................................................................... 437
159. Urinary Schistosomiasis  ................................................................. 439
160. Persistent or Recurrent Urethral Discharge  ................................... 440
161. Retention of Urine  .......................................................................... 440
Chapter 16. Sexually Transmitted Infections  ��������������������������������������������� 442
162. Sexually Transmitted Infections in Adults  ...................................... 442
163. STI-related Urethral Discharge in Males  ........................................ 443
164. Mycoplasma genitalum  .................................................................. 443
165. STI-related Persistent or Recurrent Urethral Discharge  ................. 444
166. STI-related Vaginal Discharge  ........................................................ 445
167. STI-related Lower Abdominal Pain in Women ................................ 447
168. STI-related Genital Ulcer  ................................................................ 448
169. STI-related Scrotal Swelling  ............................................................ 450

 
Table of Contents
vii170. STI-related Inguinal Bubo  ...............................................................
 ....................................................................................................... 451
171. STI-related Genital Warts  .............................................................. 452
172. STI-related Ano-rectal Related Syndromes  .................................... 453
173. Sexually Transmitted Infections in Children  .................................. 455
174. STI-related Neonatal Conjunctivitis (Opthalmia Neonatorum)  ...... 455
Management of specific STI and STI syndromes in children  ��������� 456
175. STI-related Urethral Discharge Syndrome in Children  .................... 456
176. STI-related Vaginal Discharge Syndromes in Children  .................... 456
177. STI-related Lower Abdominal Pain or Pelvic Inflammatory Disease 
Syndrome in Children  ..................................................................... 457
178. STI-related Genital Ulcer Syndrome in Children  ............................. 458
179. STI-related Ano-Rectal Related Syndromes in Children .................. 459
180. HIV Infection and AIDS  ................................................................... 461
Chapter 17. HIV Infections and AIDS  ������������������������������������������������������������ 461
181. HIV Post Exposure Prophylaxis (PEP) for exposed healthcare personel 
 ....................................................................................................... 464
Chapter 18. Infectious Diseases and Infestations  ��������������������������������������� 468
182. Fever   ............................................................................................. 468
183. Tuberculosis  .................................................................................. 471
184. Drug resistant tuberculosis (DR-TB)  .............................................. 476
185. Typhoid Fever   ............................................................................... 479
186. Malaria  ........................................................................................... 482
187. Uncomplicated Malaria  .................................................................. 483
188. Severe Malaria  ............................................................................... 486
189. Malaria in Pregnancy  ..................................................................... 491
190. Seasonal Malaria Chemoprevention (SMC)  ................................... 494
191. Meningitis  ...................................................................................... 494
192. Worm Infestation (Intestinal)   ....................................................... 498
Chapter 19. Eye Disorders  ���������������������������������������������������������������������������� 503
193. Neonatal Conjunctivitis   ................................................................ 503
194. Xerophthalmia  ............................................................................... 503
195. Foreign body in the eye  .................................................................. 504
196. Red Eye  ........................................................................................... 506
197. Glaucoma  ....................................................................................... 508
198. Cataract  .......................................................................................... 510
199. Exposure Keratopathy  .................................................................... 511
200. Strabismus  ...................................................................................... 512
201. Sickle Cell Disease – Retinopathy  .................................................. 513
202. Endocrine and metabolic disorders with eye complications  .......... 514
Chapter 20. Ear, Nose and Throat Disorders  ���������������������������������������������� 515
203. Stridor  ............................................................................................ 515
204. Acute Epiglottitis  ............................................................................ 519
205. Retropharyngeal Abscess  ............................................................... 521
206. Pharyngitis and Tonsillitis  .............................................................. 523
207. Acute Sinusitis  ................................................................................ 526
208. Acute Otitis Media  ......................................................................... 529
209. Chronic Otitis Media  ...................................................................... 531
210. Epistaxis .......................................................................................... 532
Chapter 21. Oral and Dental Conditions ���������������������������������������������������� 534
211. Dental Caries  ................................................................................. 534
212.  Oral Candidiasis  ............................................................................ 535
213. Acute Necrotising Ulcerative Gingivitis  .......................................... 536
214. Bacterial Endocarditis and Prophylaxis in Dentistry  ...................... 538

 
Standard Treatment Guidelines, 7th Edition, 2017
viii215. Acute Bacterial Sialoadenitis   ........................................................ 539
216. Ludwig’s Angina/Cervico-Facial Abscess   ...................................... 540
217. Chronic Periodontal Infections    .................................................... 543
218. Mouth Ulcers  ................................................................................. 544
219. Odontogenic Infections   ................................................................ 545
220. Oral Squamous Cell Carcinoma   .................................................... 548
221. Temporo-mandibular Joint dysfunction and masticatory muscle 
dysfunction  .................................................................................... 549
222. Trigerminal Neuralgia   ................................................................... 550
Chapter 22. Disorders Of The Musculoskeletal System  ������������������������������ 552
223. Osteoarthritis  ................................................................................. 552
224. Rheumatoid arthritis  ...................................................................... 554
225. Juvenile Idiopathic Arthritis    ......................................................... 557
226. Back pain  ........................................................................................ 560
227. Fibromyalgia  ................................................................................... 563
228. Idiopathic inflammatory myopathies  ............................................. 568
229. Management of the Hot Swollen Joint  .......................................... 570
230. Gout  ............................................................................................... 572
231. Pseudo-gout (chondrocalcinosis)  ................................................... 575
232. Systemic lupus erythematosus  ....................................................... 577
Chapter 23. Trauma And Injuries  ����������������������������������������������������������������� 582
233. Head Injuries   ................................................................................ 582
234. Acute Abdomen  ............................................................................. 585
235. Abdominal Trauma  ......................................................................... 588
236. Closed Fractures  ............................................................................. 590
237. Open Fractures  ............................................................................... 592
238. Dislocations  .................................................................................... 595
239. Acute orthopaedic infections  ......................................................... 597
240. Chronic Osteomyelitis and Chronic Septic Arthritis  ....................... 601
241. Cellulitis  .......................................................................................... 604
242. Necrotizing Fasciitis  ........................................................................ 608
243. Hand Infections  .............................................................................. 610
244. Tuberculosis in orthopaedics  ......................................................... 615
245. Rickets and Osteomalacia  .............................................................. 616
246. Scurvy  ............................................................................................. 618
247. Osteoporosis  .................................................................................. 619
248. Sickle-cell Vaso-occlusive Crisis  ...................................................... 620
249. Avascular Necrosis  ......................................................................... 621
250. Osteogenesis Imperfecta  ............................................................... 623
251. Burns  ............................................................................................. 624
252. Wounds  .......................................................................................... 630
253. Bites and Stings  ............................................................................. 632
254. Shock  .............................................................................................. 641
Chapter 24. General Emergencies  ���������������������������������������������������������������� 644
255. Acute Allergic Reaction (Anaphylaxis)  ........................................... 644
Chapter 25. Antibiotic Prophylaxis In Surgery  ������������������������������������������ 647
256. Antibiotic Prophylaxis in Surgery  ................................................... 647
Chapter 26. Management of Acute Pain  ������������������������������������������������������ 651
257. Management of Acute Pain ............................................................ 651
Chapter 27. Common Malignancies  ������������������������������������������������������������� 655
258. Breast Cancer  ................................................................................ 655
259. General Management of Poisoning  ............................................... 657
Chapter 28. General Management Of Poisoning  ���������������������������������������� 657
260. Medicines Use in the Elderly  ......................................................... 662

 
Table of Contents
ixChapter 29. Medicines Use In The Elderly  ���������������������������������������������������� 662
Chapter 30. Local Anaesthetic Agents  �������������������������������������������������������� 664
261. Local Anaesthetic Agents  ............................................................... 664
Chapter 31. Structured Approach to the Seriously Ill Child  ���������������������� 666
262. Structured Approach to the Seriously Ill Child  ............................... 666
Forms ........................................................................................................... 671
Index  ������������������������������������������������������������������������������������������������������������� 675

 
Standard Treatment Guidelines, 7th Edition, 2017
xlist of Tables
Table 0-1:   Table of medical abbreviations for prescribing  ...............................  ...4
Table 0-2:   Dosing and Medication based on body weight in children  ................ 7
Table 0-3:   Table of important contacts and referral centres  ............................... 8
Table 1-1:   Assessment of degree of dehydration in children with diarrhoea ....12
Table 1-2:   Treatment by Fluid Therapy - Plan A  ................................................. 16
Table 1-3:   Treatment by Fluid Therapy - Plan B  ................................................. 17
Table 1-4:   Treatment by Fluid Therapy - Plan C  ................................................. 18
Table 1-5:   Helicobacter pylori  Eradication Therapy  ........................................... 24
Table 2-1:   Post-exposure management of healthcare workers after occupational 
exposure to Hepatitis B infection  ..................................................... 41
Table 5-1:   Schedule for routine Immunisation of children under 5 years  ......... 80
Table 6-1:   Maintenance fluid requirement  ..................................................... 101
Table 7-1:    Well’s Score Interpretation for DVT  ................................................ 124
Table 7-2:    Well’s Score Interpretation for PE  ................................................... 127
Table 7-3:   Treatment flowchart for acute medical management of stroke  .....132
Table 7-4:   New York Heart Association (NYHA) Classification for Heart Failure
 ........................................................................................................ 134
Table 10-1:  Guide to pharmacological treatment of the unconscious patient  .204
Table 12-1:  Regime for managing Diabetic Ketoacidosis in Adults  .................... 295
Table 12-2:  Regime for managing Diabetic Ketoacidosis in Children  ................. 296
Table 13-1:  Recommended schedule for Antenatal Visits for a Normal Healthy 
Woman  ........................................................................................... 315
Table 13-2:  Antenatal Care Protocol Chart  ........................................................ 320
Table 14-1:  Dosage regimes for Mifepristone and Misoprostol for various 
gestational ages  .............................................................................. 368
Table 14-2:  Misoprostol Uses and Dosage in Management of Pregnancy 
Complications  ................................................................................. 369
Table 14-1:  Stages of Chronic Kidney Disease  ................................................... 396
Table 14-2:  Summary of management of various stages of CKD  ....................... 399
Table 14-3:  Distinguishing between Torsion and Epididymo-orchitis  ................ 426
Table 14-4:  Causes of Male Infertility  ................................................................ 435
Table 17-1:  Other baseline tests for HIV  ........................................................... 462
Table 17-2:  Standard Treatment (1st Line Treatment) for HIV-AIDS  ................... 463
Table 17-3:  Standard Treatment (2nd Line Treatment) for HIV-AIDS  ................ 463
Table 17-4:  Standard Treatment in special conditions for HIV-AIDS  .................. 464
Table 17-5:  Recommended Monitoring of Drug Toxicity & HIV Serology of 
Exposed Health Care Personnel  ...................................................... 467
Table 18-1:  Guidelines for the treatment of the patient with fever  .................. 470
Table 18-2:  Dosing for TB Medicines  ................................................................. 475
Table 18-3:  Treatment Protocol for Other Resistant Types  ................................ 478
Table 18-4:  Dosing of Second-Line Medicines  ................................................... 479
Table 18-5:  Artesunate + Amodiaquine co-blistered formulation (Regimen for 
ONCE DAILY DOSING)  ...................................................................... 484
Table 18-6:  Artesunate + Amodiaquine co-blistered formulation (Regimen for 
TWICE DAILY DOSING)  .................................................................... 484
Table 18-7:  Artesunate and Amodiaquine Fixed Dose Combination (Standard 
Regimen, using the 3 available dosing strengths)  ........................... 484
Table 18-8:  Artemether and Lumefantrine (Dosing Regimen)  ........................... 485
Table 18-9:  Dihydroartemisinin and Piperaquine (Dosing Regimen)  ................. 485
Table 18-10: Dosing Regimen for Quinine IM Injection in young Children  ......... 487
Table 18-11: Rectal Artesunate (Pre-Referral Treatment in Children)  ................ 488
Table 18-12: Approximate quantities for dilution  .............................................. 490
Table 18-13: Summary of treatment options for Bacterial Meningitis  ............... 498

 
List of tables
xiTable 19-1:  Characterising Acute Red Eye with no history of injury  .................. 506
Table 19-2:  Summary of the common types of Conjunctivitis and their 
management  .................................................................................. 507
Table 19-3:  Characteristics of the various types of the common types of 
Glaucoma  ........................................................................................ 509
Table 22-1:  Recommendations for use of conventional immunosuppressive drugs 
in lupus  ........................................................................................... 580
Table 23-1:  Indication for use of Rabies Immunoglobulin and Rabies vaccine  . .640
Table 25-1:  Choice of Antibiotics for prophylaxis  .............................................. 648
Table 28-1:  Presentation of common Poisons and their Antidotes  ................... 659
List of Figures
Fig 7-1:    Flowchart: Angina Pectoris  ................................................................. 117
Fig 7-4:    Flowchart: Stroke  ................................................................................ 132
Fig 7-5:    Flowchart: Heart Failure  ..................................................................... 140
Fig 7-8:    Flowchart: Hypertension ..................................................................... 151
Fig 7-9:    Flowchart: Arrhythmias  ...................................................................... 161
Fig 13-3:  Flowchart: management of anaemia in pregnancy  ............................ 334
Fig 13-5:  Flowchart: Post partum haemorrhage  ................................................ 348
Fig 13-6:  Flowchart: Postpartum pyrexia  ........................................................... 351
Fig 14-2:  Flowchart: Abnormal Vaginal Discharge (Without Speculum)  ............ 377
Fig 14-3:  Flowchart: Vaginal Discharge with Speculum And Bimanual Examination
 ........................................................................................................ 378
Fig 14-5:  Flowchart: Acute Lower Abdominal Pain  ............................................ 381
Fig 22-2:  Fibromyalgia tender points  ................................................................. 567

 
Standard Treatment Guidelines, 7th Edition, 2017
xiiPreface 
Standard Treatment Guidelines (STGs) are systematically developed 
statements that assist healthcare providers in deciding on appropriate 
treatments for specific clinical problems. They usually reflect the 
consensus on the optimal treatment options within a health system and 
aim at beneficially influencing prescribing behaviour at all levels of care.
Health systems, particularly in developing countries, are faced with 
growing health needs on one hand and limited resources on the other. 
Policy makers at various levels are therefore engaged in designing cost-
effective health interventions that ensure accessible and affordable 
quality care for all, in particular the poor and vulnerable groups.
Inappropriate prescribing is one of the manifestations of irrational 
medication use behaviour. It occurs when medicines are not prescribed 
in accordance with guidelines that are based on scientific evidence to 
ensure safe, effective, and economic use. STGs provide the tool for health 
care providers to give quality standardised care at affordable cost.
For Ghana’s growing National Health Insurance Scheme, a standard 
treatment guideline is seen as a cost containment tool to ensure that 
inefficiencies, fraud and poly-pharmacy, often associated with Health 
Insurance Schemes, are minimised.
Regular, objective and transparent reviews of STGs are very important 
because the development process is a continual effort and not limited 
to a one-time production. This process includes gaining acceptance of 
the concept and preparing the text for wide consultation and consensus 
building. This is to ensure that users identify with and collectively own the 
process of development.
This document is the seventh edition of the Ministry of Health’s 
officially approved prescribers’ and dispensers’ guide for all levels of 
healthcare. Great effort has been put into aligning the prevailing health 
insurance benefits package to this edition. The official release of this 
edition would be the e-copy, available at http://www.ghndp.org.This 
edition is also available on compact disk.
The Ministry of Health is particularly grateful to its development 
partners, experts, and other stakeholders for their continuous support to 
the health sector.
I am confident that all users of this document would find this edition 
very useful.
Hon. Kwaku Agyeman-Manu
Minister for Health 
June 2017

 
xiiiAcknowledgement
The review of the Standard Treatment Guidelines and Essential 
Medicines List 2017 by the Ministry of Health with its agencies has 
been successfully completed as a result of the recommendations and 
contributions received from: 
Ministry of Health and its agencies
Hon. Kwaku Agyeman-Manu Minister of Health
Hon. Tina Mensah Deputy Minister of Health
Hon. Kingsley Aboagye Gyedu Deputy Minister of Health
Mr. Alexander P . Segbefia Former Hon. Minister of Health
Dr. Victor Bampoe Former Hon. Deputy Minister of Health
Dr. Afisah Zakariah Chief Director, Ministry of Health (MOH)
Dr. Anthony Nsiah-Asare Director General, Ghana Health Service (GHS)
Dr. Ebenezer Appiah-Denkyira Former Director General, Ghana Health Service 
(GHS)
Mrs. Martha Gyansa-Lutterodt Director, Pharmaceutical Services, MOH/GHS
Dr. Emmanuel Odame Ag. Director, Policy Planning Monitoring and 
Evaluation (PPME), MOH
Mr. Samuel Boateng Former Director Procurement and Supply,Ministry of 
Health (MOH)
Mrs. Joycelyn Azeez Ag. Director, Procurement and Supply, MOH
Mr. Isaac Agyekum Asare Financial Controller, MOH
Mr. Herman Dusu Former Financial Controller, MOH
Dr. Samuel Yaw Annor CEO, National Health Insurance Authority (NHIA)
Mr. Nathaniel Otoo Former CEO, National Health Insurance Authority 
(NHIA)
Mrs Delese M. Darko CEO, Food and Drugs, Authority
Mr. Hudu Mogtari Former CEO, Food and Drugs Authority
Dr. Felix Anyah CEO, Korle Bu Teaching Hospital (KBTH)
Dr. Oheneba Owusu-Danso CEO, Komfo Anokye Teaching Hospital (KATH)
Dr. Daniel Asare CEO, Cape Coast Teaching Hospital (CCTH)
Dr. David Zawumya Kolbilla CEO, Tamale Teaching Hospital (TTH)
Dr. Akwasi Osei CEO, Mental Health Authority

 
Standard Treatment Guidelines, 7th Edition, 2017
xivSchools of Medicine and Pharmacy Executives
Prof. Margaret Lartey Dean, University of Ghana School of Medicine & 
Dentistry (UGSMD)
Prof. Yaw Adu-Sarkodie Dean, School of Medical Sciences (SMS), Kwame 
Nkrumah University of Science and Technology 
(KNUST)
Prof. Francis W. Ofei Dean, School of Medical Sciences (SMS), University 
of Cape Coast (UCC)
Prof. Francis Abantanga Dean, School of Medicine and Health Sciences, 
University of Development Studies
Prof. Harry Tagbor Dean, School of Medicine, University of Health and 
Allied Sciences
Prof. Rita Dickson Dean, Faculty of Pharmacy and Pharmaceutical 
Sciences, KNUST
Dr. Isaac Asiedu Gyekye Dean, University of Ghana School of Pharmacy
Prof. Afua Hesse Dean, Accra College of Medicine
Dr. Kwesi Ohemeng Dean, School of Pharmacy, Central University 
College
Prof. T. C. Fleischer Dean, School of Pharmacy, University of Health and 
Allied Sciences
Ghana National Drugs Programme (GNDP)
Ms. Edith E. Gavor Programme Manager, GNDP , MOH
Dr. Augustina Koduah Programme Officer, GNDP , MOH
Mr. Brian Adu Asare Programme Officer, GNDP , MOH
Mrs. Flora Baah Principal Programme Accountant
Ms. Agnes Osei Konadu Account Officer
Mr. Walter Equandoh Account Officer
Ms. Diana Edusei Office Manager
Ms. Dorothy Opoku Front Desk Manager
National Medicines Selection Committee (NMSC) 
Prof. Francis W. Ofei (Chairman) Department of Internal Medicine and Therapeutics, 
SMS, UCC
Dr. Ken Aboah Department of Surgery, SMS, KNUST

 
xvMr. Osei B. Acheampong NHIA
Dr. Mrs. Naa Okaikor Addison Department of Microbiology, KBTH 
Dr. Victoria Adabayeri Department of Child Health, UGSMD
Prof. Joseph Addo-Yobo Department of Child Health, SMS, KNUST
Dr. Vincent Adjetey Department of Obstetrics and Gynaecology, SMS, 
UCC
Dr. Stephen Akafo Department of Surgery, UGSMD
Dr. Albert Akpalu Department of Medicine and Therapeutics, UGSMD
Mrs. Edith A. Annan World Health Organisation Country Office for Ghana
Mrs. Ruby A.Mensah Annan Provider Payment Directorate, NHIA
Dr. Philip Anum National Drug Information Resource Centre
Dr. Timothy N.A. Archampong Department of Medicine, UGSMD
Mr. Brian A. Asare Ghana National Drugs Programme (GNDP), MOH
Dr. Harold Ayetey Department of Internal Medicine and Therapeutics, 
SMS, UCC
Prof. Henry Baddoo Department of Anaesthesia, UGSMD
Dr. Ebenezer V. Badoe Department of Child Health, UGSMD
Dr. Michael O. Boamah 37 Military Hospital, Ministry of Defence (MOD)
Prof. Joe-Nat Clegg-Lamptey Department of Surgery, UGSMD
Dr. Sylvia Deganus Department of Obstetrics and Gynaecology
Dr. Ida D. Dey Department of Medicine, KBTH
Dr. Mark Dzradosi Central University College (CUC)
Prof. Mrs. Ivy Ekem Department of Haematology, UCC, SMS
Dr. Akye Essuman Family Medicine Unit, Department of Community 
Health, School of Public Health, University of Ghana
Dr. Mrs. Audrey Forson Department of Medicine and Therapeutics, UGSMD
Ms. Edith E. Gavor Ghana National Drugs Programme (GNDP), MOH
Prof. Mrs. Bamenla Q. Goka Department of Child Health, UGSMD
Mrs. Martha Gyansa-Lutterodt Ministry of Health

 
Standard Treatment Guidelines, 7th Edition, 2017
xviProf. Emmanuel D. Kitcher Department of Surgery, UGSMD
Dr. Francis Kwamin Department of Oral Pathology-Oral Medicine, 
UGSMD
Dr. James E. Mensah Department of Surgery, UGSMD
Mrs. F. Amah Nkansah Department of Pharmacy, KBTH
Prof. Mrs. Angela L. Ofori-Atta Department of Psychiatry, UGSMD / Ghana Health 
Service
Dr. Sammy Ohene Department of Psychiatry, UGSMD
Dr. Mrs. Charlotte Osafo Department of Medicine and Therapeutics, UGSMD
Dr. Isaac Owusu Department of Medicine, SMS, KNUST
Prof. Mrs. Lorna Renner Department of Child Health, UGSMD
Dr. Michael Segbefia Department of Surgery, UGSMD
Mr. Raymond Tetteh Department of Pharmacy, KBTH
Dr. Lilly Wu Department of Surgery, UGSMD
Co-opted experts
Mrs. Ruby Awittor GHS, Ashaiman
Mrs. Dorcas Poku Boateng Cardio-Thoracic Pharmacy, KBTH
Mrs. Priscilla Ekpale Child Health Pharmacy, KBTH
Mrs. Obedia Seaneke Child Health Pharmacy, KBTH
Dr. Ama Vortia Family Physician, Nyaho Medical Centre
National Evidence Synthesis sub-group of NMSC
Dr. Kwame Adu-Bonsaffoh Department of Obstetrics and Gynaecology, KBTH
Mrs. Edith A. Annan World Health Organisation Country Office for Ghana
Mr. Brian A. Asare GNDP , MOH
Dr. Kwodwo Nkromah Department of Medicine, KBTH
Dr. Yaw Ofori-Adjei Department of Medicine, KBTH

 
xviiEditorial Committee 
Prof. Francis W. Ofei Department of Internal Medicine and Therapeutics, 
SMS, UCC
Mr. Brian A. Asare GNDP , MOH
Dr. Yaw A. Awuku Department of Internal Medicine and Therapeutics, 
SMS, UCC
Dr. Ebenezer V. Badoe Department of Child Health, UGSMD
Dr. Kwame O. Buabeng Faculty of Pharmacy and Pharmaceutical Sciences, 
KNUST
Dr. Marc Dzradosi Department of Pharmacy, Central University College
Ms. Edith E. Gavor GNDP , MOH
Dr. Michael Osei-Boamah 37 Military Hospital, Ministry of Defence
Dr. Yaw Ofori-Adjei Department of Medicine, KBTH
Prof. Alex Nii Otoo Dodoo WHO Collaborating Centre for Pharmacovigilance
Dr. Augustina Koduah GNDP , MOH
Public Health Programmes
Expanded Programme on Immunisation (EPI), GHS
Eye Care Programme, GHS
National AIDS/STI Control Programme (NACP)
National Malaria Control Programme (NMCP), GHS
National Tuberculosis Programme (NTP), GHS
National Yaws Eradication Programme (NYEP)
Neglected Tropical Diseases Control Programme
Non-communicable Diseases Control Programme
Reproductive Health Unit, GHS 
Contributors
Child Health, GHS
Christian Health Association of Ghana
Family Planning, GHS

 
Standard Treatment Guidelines, 7th Edition, 2017
xviiiGhana Association of Quasi-Government Health Institutions
Ghana Medical Association 
Head, Disease Control Unit, GHS
Nurses and Midwives Association of Ghana
National Blood Service of Ghana
Pharmaceutical Society of Ghana
Society of Private Medical and Dental Practitioners
Supporting Development Partners
European Union Commission 
United Kingdom Department for International Development
World Health Organisation Country Office for Ghana

1Introduction
The Government of Ghana, through the National Medicine Policy, 
remains committed to ensuring the availability of and accessibility to, 
affordable and good quality medicines for all Ghanaians; and it is expected 
that these medicines would be used rationally. Achieving these objectives 
require a comprehensive strategy that not only includes supply and 
distribution, but also appropriate and thoughtful prescribing, dispensing 
and use of medicines.
The Ministry of Health since 1983 has been publishing a list of 
Essential Drugs with Therapeutic Guidelines to aid the rational use of 
drugs. This document has been reviewed in response to new knowledge 
on drugs and diseases and changes in the epidemiology of diseases in 
Ghana. The Ministry has also produced guidelines for specific disease 
control programmes, diseases and identifiable health providers.
The Standard Treatment Guidelines have been prepared as a tool 
to assist and guide prescribers (including doctors, medical assistants, 
and midwives), pharmacists, dispensers, and other healthcare staff who 
prescribe at primary care facilities in providing quality care to patients. 
The guidelines list the preferred treatments for common health problems 
experienced by people in the health system and were subjected to 
stakeholder discussions before being finalised to ensure that the opinion 
of the intended users were considered and incorporated.
The guidelines are designed to be used as a guide to treatment 
choices and as a reference book to help in the overall management of 
patients, such as when to refer. The guidelines are meant for use at all 
levels within the health system, both public and private.
It is recognised that the treatment guidance detailed in this book may 
differ from current practice. It is emphasised that the choices described 
here have the weight of scientific evidence to support them, together 
with the collective opinion of a wide group of recognised national and 
international experts. The recommendations have been rated on the 
following basis:
Evidence Rating A – requires at least one randomised control trial 
as part of a body of scientific literature of overall good quality and 
consistency addressing the specific recommendation.

 
Standard Treatment Guidelines, 7th Edition, 2017
2Evidence Rating B – requires the availability of well-conducted clinical 
studies but no randomised clinical trials on the topic of recommendation.
Evidence Rating C – requires evidence obtained from expert 
committee reports or opinions and/or clinical experience of respected 
authorities. This indicates an absence of directly applicable clinical studies 
of good quality.
To use treatment other than those recommended here may have to 
be justified to colleagues, managers, or in law.
The content of these treatment guidelines will undergo a process 
of continuous review. Comments or suggestions for improvement are 
welcome. Those comments or suggestions for addition of diseases should 
include evidence of prevalence as well as a draft treatment guideline using 
the format set out in this book. In the case of a request for a new drug or 
replacing a listed product with another product, the evidence base must 
be clearly defined and included with the request.
These suggestions should be sent to:
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
PO Box MB 582
Accra, Ghana
West Africa
Website: www.ghndp.org
How to use this book
To use these guidelines effectively, it is important that you become 
familiar with the contents. Take time to read the book and understand the 
content and layout.
The contents of this book have been arranged in approximately 
alphabetical order of ‘body systems’. Within each section, a number 
of disease states, which are significant in Ghana have been identified. 
For each of these disease states the structuring of the information and 
guidance has been standardised to include a brief description of the 
condition or disease and the more common signs and symptoms. In 
each case the objectives of treatment have been set out, followed by 
recommended non-pharmacological as well as the pharmacological 
treatment choices.
The choice of treatment guidance used here is based on the principles 
of ‘evidence based medicine’. That is, it is based on the international 
medical and pharmaceutical literature, which clearly demonstrates the 
efficacy of the treatment choices.
The treatment guidelines try to take the user through a sequence 
of diagnosis, treatment, treatment objectives, and choice of treatment 

 
Introduction
3and review of outcome. Prescribers are strongly recommended to adopt a 
similar approach to practice. Care should be taken to avoid symptomatic 
management of uncertain diagnoses.
When treating patients, the final responsibility for the well-being of 
the individual patient remains with the prescriber. Prescribers must take 
steps to ensure that they are competent to manage the most common 
conditions presenting at their practice and familiarise themselves 
particularly with those aspects of the treatment guidelines relating to 
those conditions. It is important to remember that the guidance given in 
this book is based on the assumption that the prescriber is competent to 
handle patients at this level, including the availability of diagnostic tests 
and monitoring equipment.
This edition uses the Recommended International Non-Proprietary 
Name (rINN) in line with WHO recommendations and practice. In most 
cases, the British Approved Name (BAN) and rINN are similar but in a few 
instances there are differences. Where these differences occur, the BAN 
has been put in parentheses to permit easy reference.
Prescribing for NHIS reimbursement
The National Health Insurance Scheme (NHIS) operates with a 
defined benefits package and reimburses healthcare providers for 
services rendered to its members according to the treatment protocols 
outlined in the STG. It is important for prescribers to be adept with the 
benefit package and also with the operational manuals of the scheme to 
ensure members benefit appropriately and facilities receive full payment 
for services rendered. 
The Tariff Operational Manual and the NHIS Medicines List (NHIS ML) 
are important reference documents for service providers. They indicate 
the individual conditions that are covered, the medicines available on the 
scheme’s formulary and the tariffs to be used for billing. 
Prescribers must note that for every condition that is covered, there 
are medicines listed in the NHIS ML in line with the STG recommendations. 
In addition, the NHIS ML states the level of prescribing attached to each 
medicine as indicated in the Essential Medicines List of the MOH.  
Medicines should be prescribed by the generic names on the ML and 
prescribers must indicate the quantity of medicines to be supplied on the 
prescription. This is a normal requirement for prescribing and will be very 
helpful in claims processing for reimbursement. 
Notes on cost-effectiveness

 
Standard Treatment Guidelines, 7th Edition, 2017
4Referral
These guidelines also make provision for referral of patients to other 
health facilities. Patients should be referred when the prescriber is not 
able to manage the patient either through lack of personal experience 
or the availability of appropriate facilities. Patients should be referred, in 
accordance with agreed arrangements, to facilities where the necessary 
competence, diagnosis and support facilities exist. The patient should be 
given a letter or note indicating the problem and what has been done so 
far, including laboratory tests and treatment. When indicated, emergency 
treatment must be given before referring the patient. It may also be 
necessary for the patient to be accompanied by a member of health staff  
and it should be remembered that the act of referral does not remove 
from the prescriber the responsibility for the well-being of the patient.
Abbreviations
The following are abbreviations commonly used in general 
prescribing of medicines. While several of them may be found in this 
treatment guideline, it has not been necessary to use all of them in the 
text of this book.
Table 0-1:   Table of medical abbreviations for prescribing 
Abbreviation Connotation 
IV Intravenous
IM Intramuscular
SC Subcutaneous
p.o. or oral per os (by mouth)*
kg Kilogram
g Gram
mg Milligram
L Litre
dl Decilitre
ml Millilitre
mmol Millimole
mEq Milliequivalent
hr(s) Hour(s)
min(s) Minute(s)

 
Introduction
5Abbreviation Connotation 
sec(s) Second(s)
m Metre(s)
cm Centimetre(s)
BW Body weight
°C Degree celcius
mmHg Millimetres of mercury
a.c. Ante cibum (before food)
b.d. Bis die (12 hourly)
o.d. Omni die (daily)
o.m. Omni mane (in the morning)
o.n. Omni nocte (at night)
p.c. Post cibum (after food)
p.r.n. Pro re nata (when required)
q.d.s Quarter die sumendus 
(6 hourly)
q.q.h Quarta quaque hora 
(4 hourly)
stat. Statim (immediately, as initial dose)
t.d.s. Ter die sumendus 
(8 hourly)
* medicines written as p.o. or oral could be tablets, capsules, caplets, suspensions or syrups.
Prescription writing
Medicines should be prescribed only when they are necessary in 
treatment following a clear diagnosis. Not all patients need a prescription 
for a medicine; non-pharmacological treatment may be suitable and this 
has been highlighted in these guidelines.
In all cases the benefit of administering the medicine should be 
considered in relation to the risk involved. This is particularly important 
during pregnancy where the risk to both mother and foetus must be 
considered.
Prescriptions should
 y be written legibly in ink or otherwise so as to be indelible
 y be written by the prescriber and not left for another person to 

 
Standard Treatment Guidelines, 7th Edition, 2017
6complete
 y be dated
 y state the full name and address of the patient
 y specify the age and weight of the patient (especially in the case of 
children)
 y be signed in ink by the prescriber
 y bear the contact details of the prescriber (e.g. name and telephone 
number)
When writing a prescription the following should be noted:
 y Name of medicines and preparations should be written in full. 
Unofficial abbreviations should not be used because there is a high 
risk of misinterpretation.
 y Non-proprietary (generic) names are given in the book and they 
should always be used in prescribing
 y Avoid the unnecessary use of decimal points, e.g. 3 mg, not 3.0 mg.
 y Quantities of 1 gram or more should be written 1 g.
 y Quantities less than 1 gram should be written in milligrams, e.g. 500 
mg, and not 0.5 g.
 y Quantities less than 1mg should be written in micrograms, e.g. 100 
microgram, not 0.1 mg.
 y Where decimals are unavoidable a zero should be written in front 
of the decimal point where there is no other figure, e.g. 0.5 ml, not 
.5ml.
 y ‘Micrograms’ and ‘nanograms’ should NOT be abbreviated. Similarly, 
‘units’ should NOT be abbreviated.
 y Use the term ‘millilitre’ (ml or mL) NOT cubic centimetre (cc, or cm3).
 y State dose and dose frequency. In the case of ‘as required’, a 
minimum dose interval should be specified, e.g. ‘every 4-6 hrs as 
required for pain’.
 y State the quantity to be supplied or indicate the number of days of 
treatment required.
 y Write directions, preferably in English without abbreviation. It 
is recognised that some Latin abbreviations are used and these 
are detailed in the section on abbreviations. Do NOT use other 
abbreviations 
 y Avoid combination drugs, unless there is a significant therapeutic 
advantage over single ingredient preparations (e.g. Co-trimoxazole).
 y Avoid the use of symptomatic treatments for minor self-limiting 
conditions.
 y Avoid, where possible, the prescribing of placebos. Spend some time 
educating and reassuring the patient.
 y Avoid multiple prescribing (polypharmacy), especially when the 
diagnosis is not clear.
 y Avoid the use of the parenteral route of administration except where 

 
Introduction
7there are clear, clinical indications for this route. Use the oral route 
whenever possible.
Dosing and medication based on Age and body weight in children
Table 0-2:   Dosing and Medication based on body weight in children 
Age Body weight in kg
Children 
12 years 39
7 years 23
5 years 18
3 years 15
1 year 10
6 months 7.7
3 months* 5.6 
1 month* 4.2
Newborn* 3.5
* These figures relate to full term and not preterm infants. A reduced dosage may be required 
in preterm infants. 
Pharmacovigilance and Adverse Drug Event Reporting 
The development of an undesirable medical condition such as a 
new symptom, sign, laboratory or other test alteration, deterioration of 
a pre-existing medical condition, disability or death during or following 
administration of a medicinal product (allopathic or herbal) or use of 
a medical device, or the lack of effect of the product, is considered an 
adverse event that needs to be reported, whether or not considered 
causally related to the product.
Spontaneous, voluntary reporting of adverse events relating to 
the use of prescription only medicines and vaccines, over-the-counter 
medicines and medical devices is now generally considered a norm 
in many countries for healthcare professionals and consumers alike. 
For health professionals, the need to report adverse reactions to these 
products is also a moral and professional obligation. 
Although most medicines undergo rigorous safety monitoring 
during clinical trials before approval is given for their registration 
and use in any country, such trials have some limitations including 
the relatively small number of individuals involved. Post-marketing 
adverse drug event monitoring and reporting enables detection of less 

 
Standard Treatment Guidelines, 7th Edition, 2017
8commonly encountered, but potentially serious adverse events among a 
larger population. Older medicines and devices, with which healthcare 
practitioners may have experience with use, and newer ones with which 
they may not, can all give rise to adverse events in susceptible individuals.
This edition of the Standard Treatment Guidelines, like the previous 
edition, includes copies of the Ghana Food and Drugs Authority (FDA) 
adverse reaction reporting form. Extra copies of the adverse reaction 
reporting form may be obtained from the FDA or through its Institutional 
Contact Persons at various health facilities throughout the country.           
Patients may also report directly through Patient Safety Centres in 
designated community pharmacies nationwide. Online submission of 
reports by both health professionals and patients can also be done 
through the SafetyWatch System at http://adr.fdaghana.gov.gh/ or http://
fdaghana.gov.gh/adr/ or www.fdaghana.gov.gh. An e-mail of a report may 
also be sent to the National Pharmacovigilance Centre at drug.safety@
fdaghana.gov.gh. A phone call to 0244 310 297 or to short code 4015 
could be made for any assistance regarding drug safety issues. 
Assigning causality to each reported event is carried out by a 
committee of experts from several disciplines in medicine and pharmacy 
and others representing the pharmaceutical industry and consumer 
interests, selected by the FDA. The process is anonymous and handled 
with the strictest confidence and is linked to a World Health Organization 
pharmacovigilance system.
The early identification of warning signals for a particular product 
from adverse event reporting and pharmacovigilance activities enables 
timely interventions to forestall any potential harm to the public.
Important contacts 
Table 0-3:   Table of important contacts and referral centres
Unit/Department/Referral Centre Contacts
Food And Drugs Authority (FDA)
Adverse drug reactions: 
Please report any adverse drug reactions 
to the Pharmacovigilance Unit of the 
Food and Drugs Authority (FDA). 0302-235100, 0302-233200, 
0544-341222
TOLL-FREE: 0800 151 000 (Vodafone/
Airtel)
HOTLINE: 0299-802932, 0299-802933
Fax: 030-2229 794
Website: www.fdaghana.gov.gh
Email: fda@fdaghana.gov.gh
Twitter: ghfda@gh_fda
Whatsapp: 0206-973065
SMS short code: 4015
Facebook: Food and Drugs Authority-GH
National Aids Control Programme (NACP) 030-2678456/7/8/9
Website: www.tbghana.gov.gh

 
Introduction
9Unit/Department/Referral Centre Contacts
National Malaria Control Programme 030-2661484/2681418
Website: www.ghanahealthservice.org/
malaria
National Tubercolosis Control Programme 030-2660023
Website: www.tbghana.gov.gh
National Yaws Control Programme 030-2660023
National Buruli Ulcer  Control Programme 030-2660023/2686337
Fax: 030-2686336
Website: www.burulighana.org
Expanded Programme for Immunisation 030-2660023
National Ambulance Service 030-2684201, 030-2684251, 
030-2684259
National Drug Information Resource Centre 030-2678557, 030-2678559
Fax: 030-2678 557
Website: www.ghanadruginformation.org
National Poisons Control Centre 030-2238 636, 030-2243 552
National Blood Service 030-2663 702/030-2663 701
Website: www.nbsghana.org
Ghana Police Service 191, 999, 027-7522288 
Website: www.ghanapolice.info
Teaching Hospitals
Cape Coast Teaching Hospital 033-23401015, 020-1380902
Korle-Bu Teaching Hospital 030-2667759/2673034/2675401
Komfo Anokye Teaching Hospital 032-2022301
Tamale Teaching Hospital 037-2000180
Regional Hospitals
Greater Accra Regional Hospital 
(Ridge Hospital)030-228382
Central Regional Hospital 
(Winneba Trauma Specialist Hospital)033-2094727
Volta Regional Hospital 020-6241929/8161310/7984537
Upper West Regional Hospital 039-2022007/2664/2529, 
020-0041573 
Northern Region 037-2000180 (Tamale Teaching Hospital)
Upper East Regional Hospital 038-2022461

 
Standard Treatment Guidelines, 7th Edition, 2017
10Unit/Department/Referral Centre Contacts
Brong-Ahafo Regional Hospital 035-2028456/456/461, 0266331214
Ashanti Regional Hospital (Kumasi South) 050-1266827, 020-7227655
Western Regional Hospital (Effia Nkwanta) 031-2023151-4, 031-2092180, 
020-0041573
Eastern Regional Hospital 034-2023021/11 
Laboratory
National Reference Laboratory 030-2677696/020-8168903
Ghana National Drugs Programme
Comments and suggestions should be sent to: 
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P .O. Box MB-582, Accra, Ghana 
Telephone number: (0) 302-661 670/1
Fax number: (0) 302-664 309 
E-mail: gndp@ghndp.org
Website: www.ghndp.org

1Chapter
11Disorders of the 
Gastrointestinal Tract 
8� Diarrhoea
Diarrhoea  is defined as the passage of frequent, loose, watery stools 
3 or more times a day. Diarrhoea may be accompanied by vomiting . 
In children, the commonest cause is viral. There is therefore usually 
no need to prescribe antibiotics. Other diseases like malaria, pneumonia, 
ear infections and urinary tract infections, may be associated with 
diarrhoea. Fluid loss occurs quickly in this age group because of their size. 
If not corrected, it may result in dehydration , which can be fatal.  
A complaint of diarrhoea should be taken seriously. Always ask 
about the frequency and the texture of the stools. Giving antibiotics in all 
cases of diarrhoea may worsen or prolong the condition except in special 
circumstances (See section on ‘Causes’ below). Enemas and laxatives 
should not be given to patients with diarrhoea. 
Causes 
Acute diarrhoea (< 2 weeks)
 y Infections
 y Viral: e.g. rotavirus , norovirus
 y Bacterial: e.g. Salmonella  spp.,  Shigella , Campylobacter , E. coli , 
Vibrio cholerae
 y Protozoal: e.g. Entamoeba	histolytica  (amoebiasis )
 y Drug-induced:  e.g. penicillins
Chronic diarrhoea (> 2 weeks)
 y Chronic infections: e.g. amoebiasis , tuberculosis, opportunistic 
infections with HIV
 y Functional: e.g. irritable bowel syndrome
 y Inflammatory: e.g. ulcerative colitis, Crohn’s disease
 y Malabsorption syndromes: e.g. chronic pancreatitis 
 y Malignancy: e.g. colon cancer
 y Endocrine: e.g. hyperthyroidism , diabetic autonomic neuropathy 
 y Drug-induced: e.g. laxatives, NSAIDs
Symptoms
 y Frequent watery stools
 y Blood or mucus in the stool

— Diarrhoea —
Standard  Treatment Guidelines, 7th Edition, 2017
12 y Presence of fever
 y Reduced urine output
 y Associated vomiting
Signs
Adults
 y Anaemia  
 y Weight loss
 y Anorexia
 y Oral lesions e.g. oral ulcers, candidiasis
 y Skin lesions e.g. erythema nodosum
 y Signs of dehydration  (dry mucous membranes, reduction in skin 
turgor, capillary refill > 2 seconds, tachycardia, postural hypotension)
 y Enlarged thyroid
 y Abdominal masses
 y Rectal mass 
Box 1-1:   Diagnostic clues for Diarrhoea
 yDiarrhoea  WITH vomiting , low grade fever with no mucus in stools: consid -
er viral infection
 yDiarrhoea  WITH vomiting , fever, abdominal cramps, blood and mucus in 
stools: consider  bacterial infection
 yDiarrhoea  WITH blood and mucus in stool WITHOUT fever: consider amoe -
biasis
 yProfuse diarrhoea present (rice water stools) WITH vomiting : consider chol -
era
 yDiarrhoea  WITH excessive vomiting  (especially if in more than one member 
of the household or group): consider  food poisoning
 yDiarrhoea  presenting with oral and/or skin lesions, weight loss etc. over 
long period: consider HIV
 yDiarrhoea  alternating with constipation in adults: consider bowel malig -
nancy 
The following table can be used to assess the degree of dehydration  in 
children with diarrhoea:
Table 1-1:   Assessment of degree of dehydration  in children with diarrhoea
Assessment of degree of dehydration  in children with diarrhoea
% DEHYDRATION <5%
Nil5-10%
Mild-moderate >10%
Severe
LOOK AT
Condition Well, alert Restless, 
irritableLethargic, 
unconscious, floppy
Eyes Normal Sunken Very sunken and 
dry
Mouth and tongue Moist Dry Very dry

— Diarrhoea —Chapter 1:  Disorders of the Gastrointestinal Tract 
13Assessment of degree of dehydration  in children with diarrhoea
% DEHYDRATION <5%
Nil5-10%
Mild-moderate >10%
Severe
Thirst Drinks normally, 
not thirsty Thirsty, drinks 
eagerlyDrinks poorly
FEEL
Skin Goes back 
quickly after 
pinchingGoes back slowly 
after pinchingGoes back very 
slowly after 
pinching
DECIDE
The patient 
has no signs of 
dehydrationIf the patient has 
two or more signs, 
including at least 
one sign underlined, 
there is some 
dehydrationIf the patient 
has two or more 
signs, including 
at least one sign 
underlined, there is 
severe dehydration
TREATMENT PLAN Weigh patient 
and use 
Treatment Plan A Weigh patient and 
use Treatment 
Plan B Weigh patient and 
use Treatment 
Plan C 
Adapted from Integrated Management of Childhood Illnesses, WHO
Investigations
 y FBC
 y Blood film for malaria parasites
 y Stool routine examination
 y Stool for culture and sensitivity
 y Blood urea and creatinine
Treatment 
Treatment objectives
 y To prevent dehydration
 y To replace lost fluid
 y To maintain nutrition by ensuring adequate dietary intake during 
illness
 y To maintain personal hygiene
 y To eliminate infecting organisms where appropriate
Non-pharmacological treatment
 y Keep surroundings clean
 y Improve personal hygiene e.g. hand washing after toilet
 y Adequate fluid intake - oral and intravenous as necessary (See 
section on ‘Fluid management for children with diarrhoea’)
 y Maintain adequate nutrition as can be tolerated

— Diarrhoea —
Standard  Treatment Guidelines, 7th Edition, 2017
14Pharmacological treatment 
A.     Bacterial gastroenteritis  (fever, abdominal cramps, blood and  
mucus in stools) 
Note 1-1  
No antibiotics are required for suspected viral gastroenteritis . Adequate rehy -
dration is the main requirement.
1st Line Treatment
Evidence Rating: [A]
 y Ciprofloxacin , oral, 
Adult s
500 mg 12 hourly for 5 days
Children  (for all child age groups)
15 mg/kg 12 hourly for 5 days
2nd Line Treatment
Evidence Rating: [A]
 y Cefuroxime , IV,
Adult s
750 mg 8 hourly
Children  
25 mg/kg body weight 12 hourly 
Neonate s
> 7 days;   25 mg/kg body weight 8 hourly 
< 7 days;   25 mg/kg body weight 12 hourly 
Then
 y Cefuroxime , oral,
Adult s
250 mg 12 hourly for 5-7days
Children
12-18 years;  250 mg 12 hourly for 5-7 days
2-12 years;   15 mg/kg body weight for 5-7 days (max. 
250 mg 12 hourly) 
3 months-2 years;  10 mg/kg body weight for 5-7 days (max. 
125 mg 12 hourly) 
Note 1-2
Suspension can only be given to children above 3 months, however the IV can 
be given to neonates.
B.      Amoebic dysentery  suspected (patient failing to respond to 
empirical treatment for bacterial gastroenteritis  within 2 days or 
based on stool microscopy) 
Evidence Rating: [A]
 y Metronidazole , oral,
Adult s
800 mg 8 hourly for 5 days
Children

— Diarrhoea —Chapter 1:  Disorders of the Gastrointestinal Tract 
158-12 years;   400 mg 8 hourly for 5 days
4-7 years;  200 mg 8 hourly for 5 days
0-3 years;  100 mg 8 hourly for 5 days
C�     Cholera : profuse diarrhoea (rice water stool) + vomiting
1st Line Treatment
Evidence Rating: [A]
 y Tetracycline , oral,
Adult s
500 mg 6 hourly for 3 days
Children
Not recommended
Or
 y Doxycycline , oral,
Adult s
100 mg 12 hourly for 3 days
Children
Not recommended
Or
 y Erythromycin , oral,
Adult s
500 mg 8 hourly for 5 days
Children
> 13 years;  500 mg 8 hourly for 5 days
6-12 years;  250-500 mg 8 hourly for 5 days
2-6 years;  250 mg 6 hourly for 5 days
1 month-2 years;   125 mg 6 hourly for 5 days
Neonate s;   12.5 mg/kg 6 hourly for 5 days
D�     Zinc  supplementation for diarrhoea
Evidence Rating: [A]
 y Zinc supplement, oral, 
Adult s
Not required
Children
> 6 months;  20 mg/day for 10-14 days
< 6 months;  10 mg/day for 10-14 days
Referral Criteria 
Refer patients who fail to improve, or get worse, despite therapy for 
acute diarrhoea. Refer all patients with chronic diarrhoea to a specialist 
for further evaluation and management.
Treatment algorithm
Fluid management for children with diarrhoea
Treatment Plan A – No dehydration
 y Child can be treated safely at home
 y Instruct mother to give home-based fluids like rice water, koko, soup, 

— Diarrhoea —
Standard  Treatment Guidelines, 7th Edition, 2017
16water, and Oral Rehydration Salt (ORS ). 
 y Breastfed babies should be given breast milk and ORS
 y Give as much as child wants of all the fluids
 y Child should continue to feed
 y Ask the mother to return to the health facility if the child gets worse, 
passes more watery stools, vomits repeatedly, becomes very thirsty, 
eats or drinks poorly or is not better in 2 days
 y Instruct mother on how to prevent diarrhoea
ORS currently recommended for use in mild to moderate diarrhoea 
has a reduced sodium and glucose concentration (low osmolarity).
How to prepare ORS
ORS: Dissolve the contents of one sachet of ORS in 600 ml or 1000 
mls depending on type of ORS.
 y To get 600 ml, use 2 small (300 ml) soft drink bottles or 1 big beer 
bottle 
 y To get 1000 ml, use 1L mineral water bottle 
The child or adult should drink AS MUCH of it as he/she wants. If the 
child vomits, the mother should wait about 10 minutes and give it again.
Table 1-2:   Treatment by Fluid Therapy - Plan A
Age ORS Basic Amount ORS for every extra stool 
passed
<2 years 500 ml or more 50–100 ml
2–10 years 1000 ml or more 100–200 ml
>10 years 2000 ml or more 100–200 ml
Treatment Plan B – mild to moderate dehydration
For the ch ild with m ild-mode rate dehydration , use t reatment  Plan B
 y Child to be treated in the health facility
 y Give ORS  over the first 4 hours as shown in the Table for Plan B
 y If child vomits, wait 10 minutes and start again
 y Continue with other fluids the child will accept
 y Instruct mother to continue breast feeding if child is breastfeeding
 y Observe stools passed and record quantity
 y Check for signs of worsening dehydration
 y If eyes become puffy, it means too much fluid has been given so stop 
ORS and re-evaluate
 y Reassess state of dehydration  after 4 hours
 y If clinical state has improved with no dehydration  - go to plan A
 y If there is still mild-moderate dehydration  repeat plan B
 y If condition is worsening - go to plan C

— Diarrhoea —Chapter 1:  Disorders of the Gastrointestinal Tract 
17Table 1-3:   Treatment by Fluid Therapy - Plan B
Weight <6 kg 6 <10 kg 10-<12 kg 12–19 kg
Age* Up to 4 months 4 months up to 
12 months12 months up to 
2 years2 years up to 5 
years
Amount
of ORS200-400 ml 400-700 ml 700-900 ml 900-1400 ml
*Use the child’s age only when you do not know the weight.  The approximate amount of ORS  
required (in ml) can also be calculated by multiplying the child’s weight (in kg) by 75
Treatment Plan C – Severe dehydration
 y A child with severe dehydration  requires urgent treatment with IV 
fluids in hospital
 y If the child can drink, give ORS  by mouth while the IV line is being 
set up
 y Start IV fluids immediately. Give 100 ml/kg Ringer’s lactate  solution 
or, if not available, normal saline or cholera replacement fluid (5:4:1), 
divided as shown in the Table for Plan C below: 
 y If you cannot give the above treatment and cannot pass a nasogastric 
tube, refer to a health facility that can do so.
 y Reassess the child every 1-2 hours.  If hydration status is not 
improving, give the IV fluid more rapidly than as stated in the Table 
for Plan B
 y Also give ORS  (about 5 ml/kg body weight/hour) as soon as the child 
can drink: usually after 3-4 hours (infants) or 1–2 hours (children)
 y Reassess an infant after 6 hours and a child after 3 hours. Classify 
dehydration .  Then choose the appropriate plan (A, B, or C) to 
continue treatment
 y Assess child hourly. If not improving or dehydration  is worse, increase 
drip rate
 y Do not stop the IV fluids until the child has been observed to retain 
the ORS  for at least 1 hour and there is improvement in the clinical 
condition
 y Continue ORS  on treatment plan B and continue to observe child 
until child has no signs of dehydration , then move to Plan A
 y Severe   diarrhoea   may   be   complicated   by   marked   fluid   loss 
accompanied by loss of potassium (hypokalaemia) or on the other 
hand, impaired renal function leading to acidosis and elevated blood 
potassium (hyperkalaemia)
 y When the patient is passing adequate amounts of urine, probably 
indicating good renal function, start potassium containing foods such 
as coconut water and fresh fruits (e.g. banana)
 y If there is clinical and/or laboratory evidence of severe hypokalaemia, 
potassium should be given by the intravenous route using potassium 
chloride but only in a hospital. Potassium containing fluids such as 

— Rotavirus Disease and Diarrhoea —
Standard  Treatment Guidelines, 7th Edition, 2017
18half strength Darrow’s solution or Ringer’s lactate  may be added
 y If possible infants and children should continue to breastfeed or eat 
during the period of diarrhoea
Table 1-4:   Treatment by Fluid Therapy - Plan C
Age First give 30 ml/kg in: Then give 70 ml/kg in:
Infants (< 12 months) 1 hour* 5 hours
Children
(12 months up to 5 years) 30 minutes* 2½ hours
*Repeat once if radial pulse is still very weak or not detectable.
Note 1-3
Anti-diarrhoeal medicines like Mist Kaolin , diphenoxylate /atropine , codeine , 
loperamide  should not be used in the treatment of diarrhoea in children and 
are likely to do more harm than good. Similarly, antibiotic preparations with 
kaolin or pectin are of no therapeutic value in the management of diarrhoea.
9� Rotavirus  Disease and Diarrhoea
Rotavirus  is the most common cause of severe diarrhoea in young 
children. It accounts for more than a third of all hospitalizations of 
children less than 5 years. It occurs year round with peaks between the 
dry months (December - March). Children are infected by age 2 to 3 years 
and re-infections are common.  
Causes 
 y Rotavirus : 5 types of rotavirus are known to cause >90% of all cases 
worldwide
Symptoms
 y Fever  
 y Vomiting  
 y Profuse watery diarrhoea
 y Thirst 
Signs
 y Sunken eyes 
 y Diminished skin turgor 
 y Altered consciousness, depending on the degree of dehydration
Investigations
 y Detection of rotavirus antigen in stool by an enzyme immunoassay 
(EIA)
Treatment 
Treatment objectives
 y Correction of fluid and electrolyte deficits 

— Constipation   —Chapter 1:  Disorders of the Gastrointestinal Tract 
19 y Replacement of on-going fluid losses 
 y Adequate nutrition to prevent malnutrition
Non-pharmacological treatment
 y Home-based fluids e.g. breast milk, porridges, coconut drink
 y Nutrition: feed as can be tolerated during the episode, give an extra 
meal per day for 2 weeks after the episode
Pharmacological treatment 
A. ORS  and Zinc  supplementation
(See section on ‘Diarrhoea ’)
Referral Criteria 
 y Poor response to rehydration process (passing more stools than 
drinking) 
 y Poor drinking
 y Blood in stool
 y Poor feeding
 y Altered consciousness/convulsions
 y Diarrhoea  and vomiting  continuing for > 3 days
Note 1-4
Prevention:
Two (2) doses of Rotavirus  vaccine,  given at 6 - 10 weeks, is effective in prevent -
ing rotavirus diarrhoea. The 2nd dose should be given by 16 weeks, and not 
later than 24 weeks. Rotavirus vaccine is now currently given as part of routine 
immunization in Ghana. (See section on ‘Immunisation’).
10� Constipation   
In general, constipation refers to bowel movements that are 
infrequent or stools that are difficult to pass. There is great individual 
variation in normal bowel habits; therefore emphasis should be laid on 
changes in the bowel habit. 
 Diarrhoea  alternating with constipation may indicate a large bowel 
cancer especially in those aged 40 years and above. In children and the 
elderly, this may indicate chronic constipation with spurious diarrhoea.
The habitual use of laxatives is very common in the community. This 
practice must be discouraged to avoid hypokalaemia and its consequences.
Causes 
Medical
 y Diet deficient in roughage
 y Ignoring the urge to defaecate e.g. due to immobility
 y Hypothyroidism
 y Irritable bowel syndrome
 y Hypercalcaemia
 y Drugs e.g. atropine , codeine , morphine , tricyclic antidepressants, 

— Constipation   —
Standard  Treatment Guidelines, 7th Edition, 2017
20disopyramide
 y Lazy bowel from chronic laxative use including ‘herbal’ preparations 
 y Lack of exercise
 y Dehydration  and starvation (particularly in children) 
Surgical
 y Gastrointestinal obstruction 
 y Anal fissure and other painful perianal lesions
 y Carcinoma of the rectum and sigmoid colon
 y Foreign body in the gut
 y Pelvic mass e.g. fibroid, foetus
 y Aganglionic and acquired megacolon
 y Pseudo-bowel obstruction (Ogilvie syndrome ) following immobility 
from any cause 
Symptoms
 y Inability to move bowels
 y Passing hard stools
 y Infrequent passing of stools 
 y Straining to pass stools 
 y Feeling of incomplete evacuation of bowel
 y Inability to pass flatus, colicky abdominal pain with or without 
vomiting
Signs
 y Frequent high pitched bowel sounds - suspect mechanical bowel 
obstruction
 y Absent bowel sounds - suspect paralytic ileus 
 y Signs of peritonitis (generalised tenderness, guarding and rebound 
tenderness, refer appropriate section) -`suspect gangrenous bowel
Investigations
 y Digital rectal examination  (must be carried out in all patients with 
suspected diagnosis of constipation)
 y Stool for occult blood
 y Plain abdominal X-ray (erect and supine)
 y Proctoscopy /proctosigmoidoscopy /colonoscopy  (must not be done 
if acute intestinal obstruction is suspected)
Treatment 
Treatment objectives
 y To identify possible cause of constipation
 y To relieve constipation
Non-pharmacological treatment
 y Adherence to regular exercise
 y High fibre diet
 y Adequate fluid intake (minimum of 3.2L of water per day if no 
contraindications exist)

— Constipation   —Chapter 1:  Disorders of the Gastrointestinal Tract 
21Pharmacological treatment
A. Management of Constipation in Adults
1st Line Treatment
Evidence Rating: [C]
 y Bisacodyl , oral, 10-20 mg at night
Or
 y Senna , oral, 15-30 mg at bedtime (maximum 70-100 mg daily). Doses 
above 70 mg should be divided 12 hourly
Or
 y Lactulose , oral, 15-30 ml daily until response, then 10-20 ml daily
2nd Line Treatment
Evidence Rating: [C]
 y Bisacodyl , rectal, 10 mg in the morning
Or
 y Glycerol  suppositories, rectal, 4 g at night
Or
 y Liquid paraffin , oral, 10-30 ml at night 
Or
 y Milk of Magnesia , oral, 5-10 ml in a glass of water, 12-24 hourly
B� Management of Constipation in Children
1st Line Treatment
Evidence Rating: [C]
 y Lactulose , oral,
10-18 years;   15 ml 12 hourly
5-10 years;  10 ml 12 hourly
1-5 years;   5 ml 12 hourly
< 1 year;   2.5 ml 12 hourly
Or
 y Glycerol  suppositories, rectal,
2-5 years;   2 g at night
< 1 year;   1 g at night
Or
 y Bisacodyl , rectal, 
> 10 years;   5 mg in the morning
< 10 years;  on medical advice only
Or
 y Senna , oral,
6-12 years;  5-40 ml at bedtime 
2-6 years;   2.5-20 ml at bedtime  
Note 1-5
Do not use magnesium salts in patients with impaired renal function.

— Peptic Ulcer Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
22Referral Criteria 
The following categories of patients should be referred to a surgeon:
 y Patients with absent bowel sounds, vomiting  or not passing flatus
 y Cases resistant to medical treatment
 y Any suspected surgical cause
11� Peptic Ulcer  Disease
Peptic ulcer  may be duodenal or gastric. Duodenal ulcers  are more 
common and occur more often in younger adults. Gastric ulcers  usually 
occur after middle age. Gastric ulcers should be taken seriously because 
they may be malignant. 
Peptic ulcers may lead to life threatening complications of bleeding, 
perforation and gastric outlet obstruction.
Causes 
 y Helicobacter pylori  (H. pylori ) infection
 y Excessive secretion of gastric acid
 y Inadequate protection of the lining of the stomach and duodenum 
against digestion by acid and pepsin
 y Medicines e.g. non-steroidal anti-inflammatory drugs (NSAIDs ), 
corticosteroids
Symptoms
 y Episodic abdominal pain (often aggravated by dietary indiscretions 
and lifestyle)
 y May be a minor discomfort, gnawing, burning, dull ache or very 
severe pain
 y Typically pain is in the epigastrium or right hypochondrium 
 y Occasionally high up behind the sternum or low down around 
the umbilicus
 y In duodenal ulcer, pain typically comes on when the patient is 
hungry and may wake the patient up in the middle of the night.
 y In gastric ulcer, it is typically worsened by food, and may be re -
lieved by vomiting
 y Is relieved by alkalis and food in duodenal ulcer
 y Vomiting  may occur in both duodenal and gastric ulcers. It is usually 
a complication in duodenal ulcer (gastric outlet obstruction) but may 
be self-induced in gastric ulcer to relieve pain
In children 
 y Pain may be peri-umbilical 
Signs
 y There may be no abdominal signs 
 y Weight loss (sometimes in gastric ulcer)
 y Weight gain (sometimes in duodenal ulcer)
 y Tenderness - epigastrium, right hypochondrium or umbilical region

— Peptic Ulcer Disease —Chapter 1:  Disorders of the Gastrointestinal Tract 
23Investigations
 y Haemoglobin
 y H. pylori  stool antigen
 y Oesophago-gastro-duodenoscopy (endoscopy)
 y Barium meal  (in the absence of endoscopy)
 y Stool examination (to exclude intestinal parasites) 
Treatment 
Treatment objectives
 y To relieve pain (dyspepsia) and reduce gastric acid secretion
 y To eradicate H. pylori  if present
 y To promote healing of the ulcer
 y To prevent recurrence of the ulcer
 y To prevent and manage complications 
Non-pharmacological treatment
 y Avoid alcohol and tobacco intake
 y Avoid foods that aggravate the pain
 y Allay anxiety  and stress
 y Surgical treatment: for chronic cases with severe periodic attacks, 
failed medical treatment and complications e.g. perforation, gastric 
outlet obstruction and haemorrhage) 
Pharmacological treatment
A. Dyspepsia
1st Line treatment 
Evidence Rating: [A]
 y Magnesium trisilicate , oral, 15 ml 8 hourly (in-between meals and at 
bedtime to control dyspepsia)
Or
 y Aluminium hydroxide, oral, 500 mg 6 hourly (in-between meals and 
at bedtime)
Note 1-6
Avoid taking antacids within 2 hours of proton pump inhibitors (PPIs) e.g. ome -
prazole, esomeprazole, pantoprazole
2nd Line treatment 
Evidence Rating: [A]
 y Omeprazole , oral, 
Adult s
20 mg daily for 4 weeks. Repeat course if ulcer is not fully healed.
B.     NSAID-associated duodenal or gastric ulcer and gastro-duodenal 
erosions
Evidence Rating: [A]
 y Esomeprazole , oral, 

— Peptic Ulcer Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
24Adult s
20 mg daily for 4 weeks. Repeat course if ulcer is not fully healed.
Or
 y Omeprazole , oral, 
Adult s
20 mg daily for 4 weeks. Repeat course if ulcer is not fully healed.
Or
 y Pantoprazole , oral, 
Adult s
20-40 mg daily for 4 weeks. Repeat course if ulcer is not fully healed.
C�     Bleeding  peptic ulcer  (may be an indication for surgery)
Evidence Rating: [A]
 y Esomeprazole , IV, 
Adult s 
40 mg daily
Or 
 y Omeprazole , IV, 
Adult s 
40 mg 12 hourly for up to 5 days 
D�     Helicobacter pylori 	Eradication
Majority of patients presenting with duodenal ulcer are infected with 
Helicobacter pylori . Eradication of H. pylori  should therefore be done using 
a 10-14 day course of treatment consisting of a PPI  plus a combination of 
two of the antibiotics indicated in the table below.
Table 1-5:   Helicobacter pylori  Eradication Therapy
Helicobacter pylori  Eradication therapy
PPI Antibiotic
Amoxicillin , 
oral ξClarithromycin , oral Metronidazole , 
oral
Esomeprazole , oral 
20 mg 12 hourly1 g 12 hourly 500 mg 12 hourly ------------
----------- 500 mg 12 hourly 400 mg 12 hourly
Or
Omeprazole , oral
20 mg 12 hourly1 g 12 hourly 500 mg 12 hourly ----------
500 mg 8 hourly ---------- 400 mg 8 hourly
---------- 500 mg 12 hourly 400 mg 12 hourly
Or
Pantoprazole , oral 
40 mg 12 hourly1 g 12 hourly 500 mg 12 hourly ----------
---------- 500 mg 12 hourly 400 mg 12 hourly
ξ Avoid treatment regimens including Amoxicillin in patients with penicillin allergy
Referral Criteria 
Refer for specialist care when there is failure of H. Pylori  eradication 

— Gastro-oesophageal Reflux Disease —Chapter 1:  Disorders of the Gastrointestinal Tract 
25or if surgery is indicated as stated above.
12� Gastro-oesophageal Reflux Disease
Gastro-oesophageal Reflux Disease (GORD) is caused by backflow of 
gastric and/or duodenal contents past the lower oesophageal sphincter 
into the oesophagus without belching or vomiting .
The disease is classified into two groups based on endoscopy findings 
as non-erosive gastro-oesophageal disease (non-erosive GORD) and 
erosive gastro-oesophageal disease (erosive GORD). Failure to treat may 
result in oesophagitis , ulceration, strictures and rarely adenocarcinoma.
Causes 
 y Obesity
 y Hiatus hernia
 y Increased intra-abdominal pressure e.g. in pregnancy
 y Long term use of nasogastric tube
 y Agents that decrease lower oesophageal sphincter pressure e.g. 
alcohol, cigarettes, anticholinergics (e.g. Hyoscine butylbromide , 
Propantheline bromide ), other drugs – Morphine , Diazepam , 
Pethidine  and Calcium  channel blockers
 y Children with chronic neurological disease (e.g. cerebral palsy)
Symptoms
 y Heartburn  (worsens with vigorous exercise, bending forward, lying; 
relieved by antacids and sitting upright)
 y Dyspepsia
 y Early satiety
 y Retrosternal and epigastric pain (mimics angina pectoris by radiating 
to neck, jaws and arms. The pain is worse on bending down e.g. 
sweeping)
 y Pain on swallowing
 y Difficulty swallowing
 y Nocturnal regurgitation (wakes patients up with coughing, choking 
and filling of the mouth with ‘saliva’)
 y Asthma -like (may be worse at night)
In children
 y Failure to thrive/refusing food
 y Vomiting
 y Coughing 
 y Forceful regurgitation which may lead to aspiration pneumonia
 y Iron deficiency anaemia  
 y Wheezing 
Signs
 y May be none

— Gastro-oesophageal Reflux Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
26 y Epigastric tenderness occasionally
 y Chest signs (e.g. wheezing)
Investigations
 y Oesophago-gastro-duodenoscopy (OGD), i.e. upper gastro-intestinal 
tract endoscopy
 y Chest X-ray to exclude other causes
 y Abdominal ultrasound (to exclude other diseases)
 y Barium swallow  with fluoroscopy (especially useful in children)
 y Oesophageal pH monitoring (in cases that are difficult to diagnose)
 y Lower oesophageal sphincter manometry (in cases that are difficult 
to diagnose)
Treatment 
Treatment objectives
 y To relieve symptoms
 y To prevent complications
Non-pharmacological treatment
Lifestyle changes:
 y Elevate head of bed by about 30 degrees or sleep on pillows
 y Avoid sleeping within 3 hours after eating
 y Avoid over-eating and heavy meals before bedtime
 y Avoid foods that aggravate symptoms e.g. fatty and spicy food
 y Avoid smoking and alcohol 
 y Avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs )
 y Encourage moderate exercise
 y Weight reduction in overweight and obese individuals
 y Avoid corsets, instead wear loose clothing
 y Surgical treatment: Fundoplication (for severe cases, treatment 
failures and complications) 
Pharmacological treatment 
A. Non-erosive GORD
Evidence Rating: [B]
 y Magnesium trisilicate, oral, 15 ml 8 hourly (in between meals and at 
bedtime to control dyspepsia) 
Or
 y Antacids containing Aluminum hydroxide, Magnesium hydroxide, 
Simethicone, Calcium alginates 
Or
 y Omeprazole , oral,
Adult s 
20 mg daily for 4-8 weeks
Children
> 20 kg;   20 mg daily for 4-8 weeks
10-20 kg;   10 mg daily for 4-8 weeks
5-10 kg;   5 mg daily for 4-8 weeks

— Pain Originating from the Oesophagus —Chapter 1:  Disorders of the Gastrointestinal Tract 
27Or
 y Esomeprazole , oral,
Adult s
40 mg daily for 4 to 8 weeks
Or
 y Rabeprazole , oral,
Adult s
20 mg daily for 4 to 8 weeks
B.      Severe or Erosive GORD
 y Omeprazole , oral,
Adult s 
20 - 40 mg daily for 8 weeks
Children  
> 20 kg;   20 mg daily for 4-8 weeks
10-20 kg;   10 mg daily for 4-8 weeks
5-10 kg;   5 mg daily for 4-8 weeks
Or
 y Esomeprazole , oral,
Adult s
40 mg daily for 8 weeks
Or
 y Rabeprazole , oral,
Adult s
20-40 mg daily for 8 weeks
C.     Severe or Erosive GORD  (with bloating)
 y Use medications in Section B above for ‘Severe GORD’
And 
 y Metoclopramide , oral, 
Adult s
10 - 20 mg 6-8 hourly 
Or 
 y Domperidone , oral, 
Adult s
10 mg 6-8 hourly
Referral Criteria 
Refer cases not responding to the measures above to a physician 
or surgical specialist, as well as severe cases, treatment failures and 
individuals with complications.
13� Pain Originating from the Oesophagus
Oesophageal pain  is usually burning in quality and tends to be 
localised behind the sternum. Oesophageal pain may be associated with 
difficulty in swallowing (dysphagia ). Dysphagia  to water suggests achalasia, 

— Pain Originating from the Oesophagus —
Standard  Treatment Guidelines, 7th Edition, 2017
28while that to solids and not water suggests mechanical obstruction by 
tumour or stricture. It may sometimes be confused with other causes of 
chest pain  (See section on ‘Chest Pain ’).
Causes 
 y Irritation of the oesophageal mucosa by reflux of the acidic contents 
of the stomach (Gastro-oesophageal Reflux Disease  (GORD)
 y Oesophageal candidiasis
 y Hiatus hernia
 y Achalasia
 y Spasm of the oesophageal muscle in response to obstruction. 
 y Oesophageal tumours
Symptoms
 y Retrosternal chest pain  worsened by swallowing (pain worse on lying 
flat may suggest GORD)
 y Regurgitation of ingested material 
 y Difficulty in swallowing
Signs
 y Usually none
 y Patient may be obese or severely underweight in the case of GORD
 y Severe weight loss may suggest tumour or candidiasis from immune 
suppression
 y There may be oral candidiasis in the case of oesophageal candidiasis
Investigations
 y Barium swallow
 y Oesophago-gastroduodenoscopy (upper GI endoscopy)
 y Oesophageal manometry  when achalasia is suspected
Treatment 
Treatment objectives
 y To relieve pain
 y To treat identified cause
Non-pharmacological treatment
 y Bland foods and milk (may sometimes relieve the pain)
Pharmacological treatment
A. For GORD
1st Line Treatment
Evidence Rating: [B]
 y Omeprazole , oral,
Adult s 
20 mg 12 hourly for 14 days
Or 
 y Esomeprazole
Adult s

— Haemorrhoids —Chapter 1:  Disorders of the Gastrointestinal Tract 
2920-40 mg daily for 14 days
B.     For patients not responding to monotherapy with PPI  
Evidence Rating: [B] 
 y Omeprazole , oral, 20 mg 12 hourly for 14 days
Or 
 y Esomeprazole , oral, 20-40 mg daily for 14 days
And
Magnesium trisilicate , oral, 10 ml 8 hourly for 10 days
C�     For oesophageal candidiasis
Evidence Rating: [A]
 y Nystatin , oral, (swish in mouth for several minutes and then swallow)
Adult s
400,000-600,000 units 6 hourly for 7 days
Or
 y Fluconazole , oral,
Adult s
200 mg stat.
Then 
100 mg daily for 14 days
Referral Criteria 
Refer to a specialist for confirmation of diagnosis and management.
14. Haemorrhoids
Haemorrhoids  or “piles” are enlarged, displaced anal cushions 
derived from engorged veins, which primarily presents with anal bleeding. 
First-degree haemorrhoids remain in the anal canal. Second-degree 
haemorrhoids prolapse, but reduce spontaneously, whereas third degree 
haemorrhoids prolapse and have to be replaced manually or remain 
prolapsed permanently until surgically treated. 
The history is very important. The nature of the bleeding, associated 
pain and other symptoms help differentiate haemorrhoids from other 
more sinister conditions. Always do a digital rectal examination to exclude 
carcinoma and other conditions when a patient complains of pain or 
bleeding from the anus. Altered or dark blood, or blood mixed with stools, 
should raise suspicion of bleeding higher up in the rectum or colon.
No treatment is required for haemorrhoids that are asymptomatic.  
Avoid the use of purgatives.
Causes 
 y Increased intra-abdominal pressure e.g. chronic cough, pregnancy, 
intra-abdominal or pelvic tumours
 y Excessive straining at stools from constipation or diarrhoea
 y Familial predisposition

— Haemorrhoids —
Standard  Treatment Guidelines, 7th Edition, 2017
30 y Chronic liver disease with portal hypertension 
 y Anorectal tumours 
Symptoms
 y Passage of bright red blood at defaecation
 y Not mixed with stools
 y May spray the toilet bowl or only found on the toilet paper after 
cleaning
 y Mucoid discharge
 y Swelling at anus
 y Perianal irritation or itch (pruritus  ani)
 y Discomfort after opening bowels 
 y Anal pain (occurs during an acute attack of prolapse with thrombosis, 
congestion and oedema)
 y Symptoms of anaemia
Signs
 y May be none (inspection of the anus and digital rectal examination 
may be normal)
 y Redundant folds of skin (skin tags) seen in the position of the 
haemorrhoids. Straining may show the haemorrhoids
 y Swelling at the anus (in third degree haemorrhoids) 
 y Palpable thrombosed internal haemorrhoids on rectal examination
 y Signs of complications (profuse bleeding with anaemia or 
haemorrhagic shock, prolapse, strangulation, thrombosis, infection 
or ulceration)
 y Pallor
Investigations
 y FBC
 y Proctoscopy  (the gold standard for diagnosis)
 y Sigmoidoscopy  (to exclude carcinoma of rectum)
Treatment 
Treatment objectives
 y To correct anaemia, if present
 y To relieve symptoms
 y To prevent complications
Non-pharmacological treatment
 y Increase intake of fluid and roughage 
 y Avoid prolonged straining at defecation
 y For prolapsed haemorrhoids, lie patient down and elevate the foot 
end of the bed. Try gentle digital reduction after application of local 
anaesthetic cream. If this fails, apply cold compresses. Sedation of 
the patient may be required
 y For infected haemorrhoids, warm sitz baths 2-3 times a day
 y Surgical treatment: 

— Haemorrhoids —Chapter 1:  Disorders of the Gastrointestinal Tract 
31 y Rubber band ligation for second-degree haemorrhoids.
 y Haemorrhoidectomy for third degree haemorrhoids.
 y Haemorrhoids  developing during pregnancy should be man -
aged conservatively as most will resolve after delivery
Pharmacological treatment
A. When associated with constipation
Evidence Rating: [C]
 y Liquid paraffin , oral, 
Adult s
10-30 ml at night
Or
 y Senna  granules, oral, 
Adult s
1 sachet with water after supper
B�     When associated with local itching or discomfort
 y Soothing agent (with or without steroids) , applied or inserted rec -
tally, 
Adult s
One suppository 12 hourly for 7-10 days
C�     For infected haemorrhoids 
1st Line treatment
Evidence Rating: [B]
 y Gentamicin , IV,
Adult s
40-80 mg 8 hourly for 5 to 7 days
And
 y Metronidazole , oral,
Adult s
400 mg 8 hourly for 5 to 7 days 
2nd Line treatment
Evidence Rating: [B]
 y Ciprofloxacin , oral, 
Adult s
500 mg 12 hourly
And
 y Metronidazole , oral,
Adult s
400 mg 8 hourly for 5 - 7 days
3rd Line treatment
Evidence Rating: [B]
 y Amoxicillin , oral,
Adult s
500 mg 8 hourly

— Haemorrhoids —
Standard  Treatment Guidelines, 7th Edition, 2017
32And
 y Metronidazole , oral,
Adult s
400 mg 8 hourly for 5 to 7 days
D�     When associated with anaemia
 y Iron preparation  (ferrous sulphate/fumarate) (See section on ‘Anae -
mia’)
Or
 y Blood transfusion  as indicated 
Referral Criteria 
The patient should be referred to a facility with resources for rubber 
band ligation or operative treatment if indicated.

2Chapter
33Disorders of the Liver 
8� Amoebic Liver Access
Amoebic liver abscess is a collection of typically brownish coloured 
fluid in the liver, occurring often as a single mass in the right lobe and 
a complication of intestinal infection with Entamoeba	 histolytica . Lung, 
heart and brain infections are uncommon sequelae. Occasionally, 
pyogenic abscesses may have a similar clinical presentation.
Treatment of amoebic abscesses should be initiated with a tissue 
agent active against the trophozoite form followed by a luminal agent to 
eliminate intra-luminal cysts.
Causes 
 yEntamoeba	histolytica 
Symptoms
 y Right upper abdominal pain referable to the epigastrium, right chest 
or right shoulder
 y Fever
 y Malaise 
 y Sweats 
 y Cough
 y Hiccups
 y Anorexia
 y Weight loss
 y Jaundice  (uncommon)
 y Concurrent diarrhoea (less than one-third of patients)
Signs
 y Large tender liver 
 y Tenderness and/or bulging at right intercostal spaces
 y Jaundice  
 y Dullness to percussion on the right lower chest zones with basal 
crepitations
 y Amoebic empyema  following extension into the chest cavity 
 y Peritonitis (uncommon)

— Amoebic Liver Access —
Standard  Treatment Guidelines, 7th Edition, 2017
34Investigations
 y Abdominal ultrasound
 y Chest X-ray
 y FBC
 y ESR
 y Stool examination
 y Abdominal CT scan
 y Serology (amoebic antibodies) 
Treatment 
Treatment objectives
 y To eradicate Entamoeba	histolytica  infection 
 y To prevent further destruction of liver tissue 
 y To prevent further complications (e.g. rupture of abscess into pleural, 
pericardial or peritoneal space)
Non-pharmacological treatment
 y Therapeutic aspiration may be required in patients with poor 
response to therapy
Pharmacological treatment
1st Line Treatment
Evidence Rating: [A]
 y Metronidazole , oral,
Adult s
800 mg 8 hourly for 10 days (tissue agent)
Children
15 mg/kg 8 hourly for 10 days (tissue agent)
Then
 y Diloxanide furoate , oral, 
Adult s
500 mg 8 hourly for 10 days (luminal agent)
Children  
6-8 mg/kg 8 hourly for 10 days (luminal agent)
2nd Line Treatment
Evidence Rating: [A]
 y Tinidazole , oral, 
Adult s
2 g once daily for 5 days (tissue agent) 
Children  
> 3 years; 50 mg/kg (max. 2 g) once daily for 5 days (tissue agent)
Then
 y Paromomycin , oral, 
Adult s
8-10 mg/kg 8 hourly for 7 days (luminal agent)
Children  
8-10 mg/kg 8 hourly for 7 days (luminal agent)

— Jaundice  —Chapter 2:  Disorders of the Liver 
35Referral Criteria 
Patients with abscesses that are large or not responding to treatment 
will need to be referred to a specialist.
9� Jaundice  
Jaundice  refers to yellow pigmentation of skin, palms and the sclerae 
as a result of elevated levels of bilirubin  in blood. It may be visible when 
serum levels exceed 35 micromol/L in adults and 100 micromol/L in 
children. The symptoms and signs that accompany jaundice often provide 
helpful clues to the underlying cause.
In adults and children, hyperbilirubinaemia  may result in hepatic 
encephalopathy (See sections on ‘Acute and Chronic Hepatitis ’ and ‘Hepatic 
Encephalopathy’) . Jaundice  in neonates can result in kernicterus  (bilirubin  
encephalopathy ) because of the consequences of hyperbilirubinaemia on 
the brain of the newborn . (See section on ‘Neonatal Jaundice ’)
Causes 
Adults
 y Hepatitis  - viral, alcoholic, drug-induced including allopathic and 
herbal preparations
 y Haemolysis  - various causes including malaria, Glucose-6-Phosphate 
Dehydrogenase (G6PD ) deficiency  and sickle cell disease, allopathic 
drugs and herbal preparations
 y Chronic liver diseases - decompensated cirrhosis, biliary cirrhosis, 
chronic hepatitis, hepatocellular carcinoma
 y Liver malignancies - hepatocellular carcinoma, metastatic liver 
disease
 y Hepatic congestion from heart failure
 y Gall bladder diseases - stones, infections
 y Carcinoma of head of pancreas
 y Septicaemia
Children
 y Haemolysis  - sickle cell disease, G6PD  deficiency, drugs   
 y Infections - malaria, hepatitis, urinary tract infections, typhoid fever  
and other septicaemic illnesses
Pregnancy 
(See section on ‘Jaundice  in Pregnancy’)
Neonates
(See section on ‘Neonatal Jaundice ’)
Symptoms
 y Yellow or greenish discolouration of the eyes or skin
 y Deep yellow discolouration of urine
 y Itching
 y Pale stools

— Jaundice  —
Standard  Treatment Guidelines, 7th Edition, 2017
36Signs
 y Pallor (may indicate haemolysis, chronic disease or malignancy)
 y Scratch marks (indicative of cholestasis)
 y Stigmata of chronic liver disease (e.g. palmar erythema, clubbing, 
spider naevi)
 y Hepatomegaly  (may be tender)
 y Splenomegaly  in portal hypertension
 y Palpable gall bladder
 y Ascites
 y Bleeding  (cephalhaematoma , subgaleal haematoma, upper 
gastrointestinal bleeding)
 y Hepatic flap (indicative of liver failure)
Investigations
Adults and children 
 y FBC 
 y INR 
 y Sickling status
 y G6PD  status
 y Blood film for red cell anomalies, malaria parasites
 y Liver function tests
 y Urea and electrolytes
 y Hepatitis  screen (HBsAg, HCV Antibody, Hepatitis A IgM, Hepatitis E 
IgM)
 y Blood culture 
 y Urinalysis
 y Abdominal ultrasound
 y Abdominal CT scan  
Treatment 
Treatment objectives
 y To identify and treat cause of jaundice
 y To relieve symptoms associated with jaundice
 y To prevent complications associated with elevated levels of bilirubin  
in the blood
Non-pharmacological treatment
Adults and children
(See section on ‘Hepatic encephalopathy’, Hepatitis’)
 y Avoid alcohol and other hepatotoxic agents
 y Ensure adequate hydration
Pharmacological treatment 
A. Cholestatic jaundice  with severe pruritus  while investigating for 
underlying aetiology
1st Line Treatment
Evidence Rating: [A]

— Acute Hepatitis —Chapter 2:  Disorders of the Liver 
37 y Cholestyramine , oral,
Adult
4 g 12 hourly (titrate dose to response and tolerance: max. 16 g/day)
Children  and Adolescent s
2-4 g 12 hourly (max. 8 g/day) 
Referral Criteria 
Refer patients with unexplained jaundice to a specialist for further 
evaluation and management. 
10� Acute Hepatitis
Hepatitis  is defined as inflammation of the liver and has multiple 
causes. It may present as an acute illness with jaundice and altered liver 
function tests. When symptoms, signs or laboratory abnormalities persist 
for more than 6 months it is considered chronic.
Causes 
 y Viruses (Hepatitis  A, B, C, D and E, Yellow Fever  etc.)
 y Drugs (allopathic, alternative and herbal preparations)
 y Alcohol 
 y Autoimmune
Symptoms
 y Right hypochondrial pain
 y Fever  (occurring 1 to 4 weeks before the jaundice appears)
 y Malaise 
 y Anorexia
 y Nausea
 y Vomiting
 y Yellow or dark coloured urine
 y Pale stools
 y Itching
 y Fatigue
 y Confusion 
Signs
 y Jaundice
 y Right hypochondrial tenderness
 y Hepatomegaly
 y Asterixis  
Investigations
 y FBC
 y Liver function tests
 y Hepatitis  screen (HBsAg, HCV Antibody, Hepatitis A IgM, Hepatitis E 
IgM)
 y Antinuclear Antibody, Anti-smooth muscle Antibody 

— Chronic Hepatitis —
Standard  Treatment Guidelines, 7th Edition, 2017
38 y Abdominal Ultrasound
Treatment 
Treatment objectives
 y To identify and eliminate the precipitating cause 
 y To relieve symptoms
Non-pharmacological treatment
 y Rest
 y High calorie fluids (especially glucose drinks, fruit juice, light porridge, 
koko, rice-water, mashed kenkey)
 y Intravenous fluids if volume deplete
 y Any food that the patient can tolerate
 y Avoid alcohol
Pharmacological treatment 
 y Supportive care (analgesia, fluid replacement, etc. as required)
Note 2-1
Avoid hepatotoxic drugs such as paracetamol  and high doses of anxiolytic-hyp -
notics.
Referral Criteria 
Refer patients with rapidly progressing symptoms and signs to a 
physician specialist.
11� Chronic Hepatitis
This refers to chronic inflammation of the liver of more than 6 
months duration, with persistently elevated liver function tests. Chronic 
hepatitis can progress to liver cirrhosis, portal hypertension with upper 
gastrointestinal bleeding, hepatic encephalopathy and hepatocellular 
carcinoma.
Immunisation  against Hepatitis  B is now available for children under 
the Expanded Programme on Immunisation (EPI) .  Adults in endemic 
areas including Ghana should be immunised against Hepatitis B infection 
after initial assessment of their immunological status regarding previous 
exposure to the virus.
Long-term monitoring for disease activity and hepatocellular 
carcinoma screening with six-monthly Hepatitis  B viral DNA quantification, 
LFTs, abdominal ultrasound and alpha fetoprotein is mandatory for 
patients with chronic hepatitis B.  
Causes 
 y Hepatitis  B virus (HBV)
 y Hepatitis  C virus (HCV)
 y Hepatitis  E virus (genotype 3)

— Chronic Hepatitis —Chapter 2:  Disorders of the Liver 
39Symptoms
 y Usually asymptomatic
 y Mild non-specific symptoms
 y Recurrent fever
 y Arthralgia
 y Malaise
 y Jaundice
 y Lethargy
Signs
Stigmata of chronic liver disease
 y Palmar erythema
 y Clubbing
 y Dupuytren’s contracture
 y Parotid enlargement 
 y Gynaecomastia
 y Testicular atrophy  
 y Spider naevi
Signs of decompensated liver disease
 y Jaundice
 y Ascites
 y Encephalopathy
 y Peripheral oedema (hypoalbuminaemia )
 y Purpura /skin bruising (coagulopathy)
Investigations 
 y FBC
 y LFTs
 y INR
 y HIV 
 y Baseline Alpha-Feto-protein 
 y Abdominal ultrasound scan
 y Liver biopsy
Chronic Hepatitis  B
 y Hepatitis  B surface Antigen (HBsAg)
 y HBc IgG
 y Hepatitis -B-e-antigen (HBeAg) & Anti-HBe
 y Hepatitis  B Viral Load 
Chronic Hepatitis  C 
 y Hepatitis  C Virus (HCV) antibody testing 
 y HCV RNA
 y HCV genotyping
Treatment 
Treatment objectives
 y To prevent disease progression and complications
 y To prevent hepatic encephalopathy

— Chronic Hepatitis —
Standard  Treatment Guidelines, 7th Edition, 2017
40 y To improve synthetic liver function through viral suppression
 y To prevent transmission
Non-pharmacological treatment 
 y Prevention of transmission to partners (e.g. protected sex, not 
sharing of toothbrushes and sharps, blades, needles, body piercings, 
tattoos, cultural scarification practices, circumcisions etc.)
 y Lifestyle/dietary advice
 y Spouse/household screening
Pharmacological treatment 
A. Chronic Active Hepatitis  B (HBeAg positive or HBeAg negative)
1st Line Treatment
Evidence Rating: [A]
 y Pegylated Interferon  alfa-2a , subcutaneous,
Or
 y Tenofovir , oral,
Or
 y Entecavir , oral,
2nd Line Treatment
Evidence Rating: [A]
 y Lamivudine , oral,
B�     Decompensated liver cirrhosis / Fulminant Liver failure  from 
Chronic Hepatitis  B
1st Line Treatment
Evidence Rating: [A]
 y Tenofovir , oral,
Or
 y Entecavir , oral,
2nd Line Treatment
Evidence Rating: [A]
 y Lamivudine , oral,
C.     Patients with Chronic Hepatitis  B undergoing chemotherapy or 
immunosuppressive treatment 
1st Line Treatment 
Evidence Rating: [A]
 y Tenofovir , oral, 
Or
 y Entecavir , oral, 
2nd Line Treatment
Evidence Rating: [A]
 y Lamivudine , oral,

— Chronic Hepatitis —Chapter 2:  Disorders of the Liver 
41Referral Criteria 
Refer all cases of chronic hepatitis B infection to a specialist, 
especially those who have failed first-line anti-viral therapy or had 
adverse reactions to anti-viral therapy or have liver-related complications 
(e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, 
ascites , peripheral oedema, hypoalbuminaemia ). Pregnant individuals 
and patients with hepatitis B co-infections (e.g. HIV /Hepatitis  C) as well 
as those requiring chemotherapy or other immunosuppressive therapy 
should also be referred to a specialist.
Post-exposure management of healthcare workers after occupational 
exposure to Hepatitis  B infection
Table 2-1:   Post-exposure management of healthcare workers after 
occupational exposure to Hepatitis  B infection
*HCW Status Post-Exposure Testing Post-Exposure Prophylaxis Post-Vac -
cination 
Anti-HBs Source 
Patient*HCW 
Anti-HBs§HBIG HBV 
Vaccination
Documented 
Responder
(> 3 Doses 
Received)No action required
Documented 
Non-
Responder 
(After > 6 
Doses)Positive -§HBIG Twice
(One 
Month 
Apart)- No
Negative - No Action Required
Response 
Unknown 
(After >3 
Doses)Positive/
Unknown<10 MIU/ml§HBIG Once Revaccinate Yes
Negative <10 MIU/ml None Revaccinate Yes
Any Result >10 MIU/ml No action required
Unvaccinated/
Incomplete 
VaccinationPositive/
Unknown- HBIG once Complete 
VaccinationYes
Negative - None Complete 
VaccinationYes
*HCW: Healthcare worker
§HBIG: Hepatitis  B Immunoglobulin as soon as possible when indicated (0.06 ml/kg IM)
Note 2-2
Anti-HBs Titre should be performed 1-2 months after last dose of HBV vaccina -
tion series but ~ 4-6 months after HBIG to avoid detection of passively admin -
istered Anti-HBs.
Responder: person with Anti-HBs > 10 MIU/ml after 3 or more HBV vaccination 
doses

— Hepatic Encephalopathy —
Standard  Treatment Guidelines, 7th Edition, 2017
42Non-responder: person with Anti-HBs < 10 MIU/ml after 6 or more HBV vacci -
nation doses.
Note 2-3
All HCWS who have Anti-Hbs < 10 MIU/ml, unvaccinated or incomplete vaccina -
tion and sustain exposure to a source patient who is HBsAg-positive/ unknown 
HBsAg status should undergo HBsAg screening as soon as possible after expo -
sure and follow up testing ~ 6 months later (HBsAg + Anti-HBc). 
A. Chronic Hepatitis  C (Genotype 2 & 3)
1st Line Treatment
Evidence Rating: [A]
 y Pegylated Interferon  alfa-2a , subcutaneous,  
Or 
 y Pegylated Interferon  alfa-2b , subcutaneous,
And 
 y Ribavirin , oral, 
B.     Chronic Hepatitis  C (Genotype 1 & 4)
1st Line Treatment
Evidence Rating: [A]
 y Pegylated Interferon  alfa-2a , subcutaneous, 
Or 
 y Pegylated Interferon  alfa-2b , subcutaneous, 
And
 y Ribavirin , oral,
Referral Criteria 
Refer all cases of chronic hepatitis C infection to a specialist, 
especially those who have failed first-line anti-viral therapy or had 
adverse reactions to anti-viral therapy or have liver-related complications 
(e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, 
ascites , peripheral oedema, hypoalbuminaemia ). Pregnant individuals 
and patients with hepatitis C co-infections (e.g. HIV /Hepatitis  B) as well 
as those requiring chemotherapy or other immunosuppressive therapy 
should also be referred to a specialist.
12� Hepatic Encephalopathy
This condition is a complication of either acute or chronic liver 
disease. It presents with disordered central nervous system function, due 
to inability of the liver to detoxify ammonia and other chemicals.
Causes 
 y Viral hepatitis
 y Alcoholic hepatitis

— Hepatic Encephalopathy —Chapter 2:  Disorders of the Liver 
43 y Cirrhosis of the liver
 y Hepatocellular carcinoma
 y Drugs   e.g. halothane , isoniazid , paracetamol  overdose, herbal 
preparations
 y Fatty liver of pregnancy
 y Precipitating factors in a patient with pre-existing liver disease:
 y Fever
 y Hypotension
 y Infection
 y Fluid and electrolyte imbalance (excessive use of loop diuretics)
 y Sedatives
 y Increased gastrointestinal tract (GIT) protein load e.g. heavy GIT 
bleeding, alcoholic binge
Symptoms
 y Jaundice
 y Confusion
 y Disturbed consciousness which progresses as follows: disorder 
of sleep, hypersomnia and inversion of sleep rhythm, apathy and 
eventually coma
 y Personality changes
Signs
 y Cyanosis
 y Fetor hepaticus
 y Signs of chronic liver disease
 y Neurological abnormalities:
 y Speech impairment
 y Asterixis  (a flapping tremor) indicates pre-coma  and strongly 
supports the diagnosis of encephalopathy
 y Inability to draw or construct objects e.g. a 5-pointed star
 y Incoordination
 y Lethargy  
 y Encephalopathy
 y Grade 1: Mild confusion, irritable, tremor, restless
 y Grade 2: Lethargic responses, decreased inhibitions, dis -
orientation, agitation, asterixis
 y Grade 3: Stuporous but arousable, aggressive bursts, inar -
ticulate speech and marked confusion
 y Grade 4: Coma
Investigations
 y FBC
 y Blood glucose
 y Liver function tests
 y Blood urea and electrolytes
 y Hepatitis  B-surface-Antigen
 y Hepatitis  C screen

— Hepatic Encephalopathy —
Standard  Treatment Guidelines, 7th Edition, 2017
44 y Prothrombin time , INR
 y Infection screen (blood culture, urine RE, chest X-Ray, diagnostic 
ascitic tap) 
Treatment 
Treatment objectives
 y To identify and correct precipitating factors promptly
 y To treat underlying cause of liver disease
Non-pharmacological treatment
 y Place in the coma  position if unconscious
 y Maintain fluid and electrolyte balance (avoid dehydration  and 
electrolyte abnormalities such as hypokalaemia)
 y Monitor temperature, pulse  and  respiratory  rate,  blood  pressure, 
pupils, urine output and blood glucose regularly
 y Avoid alcohol, paracetamol  and other hepatotoxic agents
 y Avoid sedatives such as benzodiazepines and drugs that impair the 
coagulation system
 y Patients should NOT have their protein intake restricted
 y Maintain an adequate protein intake of 1.2-1.5 g/kg per day
 y Encourage intake of high carbohydrate diet by mouth or NG tube 
Pharmacological treatment 
A. Measures to correct hydration status and nutrition 
Evidence Rating: [A]
Adults
 y Dextrose  saline   (5-10% dextrose in 0.9% saline), IV, 500 ml 8 hourly 
(according to requirements)
And
 y High potency Vitamin B , IV, (formulated as two separate vials) One 
pair of vials daily  (added to glucose IV solution)
Children 
 y Dextrose  saline   (4.3% in 0.18% saline), IV, 
And
 y High potency Vitamin B , IV, (formulated as two separate vials) 
B.     Measures to lower blood ammonia concentration
1st Line Treatment
Evidence Rating: [A]
 y Lactulose , oral, 
Adult s
Start with 30-45 ml (20-30 g), 6-12 hourly 
(Review dose to maintain 2-3 semi-solid stools per day)
Children  and Adolescent s
Start with 5-20 ml 6-12 hourly 
(Review dose to maintain 2-3 semi-solid stools per day)
Neonate s

— Hepatic Encephalopathy —Chapter 2:  Disorders of the Liver 
45Start with 0.5-5 ml 6-12 hourly 
(Review dose to maintain 2-3 semi-solid stools per day)
Or 
 y Lactulose , rectal, 
300 ml diluted in 700 ml water (via rectal balloon catheter) 4-6 hour -
ly, retain in the rectum for 30-60 minutes.
(Review dose to maintain 2-3 semi-solid stools per day)
And
 y Metronidazole , oral, 
Adult s
400 mg 8 hourly 
Children
15 mg/kg 12 hourly
Neonate s
> 2 kg;   15 mg/kg 12 hourly
1-2 kg;   7.5 mg/kg 12 hourly
2nd Line Treatment
Evidence Rating: [A]
 y Rifaximin , oral, 
Adult s
550 mg 12 hourly 
Children
> 12 years;  200 mg 8 hourly 
< 12 years;   not recommended 
C.     Hepatic encephalopathy  associated with active bleeding (INR  > 1�5 
or platelet count < 50 x 109 /L)
Adults and Children (liaise with Haematology)
 y Fresh frozen plasma , IV, (for INR  >1.5)
Or
 y Platelet concentrate, IV, (platelet count < 50 x 109 /L)
D.     Antibiotic prophylaxis  in Hepatic encephalopathy  (associated with 
cirrhosis and upper gastro-intestinal haemorrhage) 
Patients in whom oral administration is not possible,
Evidence Rating: [A]
 y Ciprofloxacin , IV, 
Adult s
400 mg 8-12 hourly (administered over 60 minutes)
Or
 y Ceftriaxone , IV, 1 g daily for 7 days 
Or
 y Ciprofloxacin , oral, 500 mg 12 hourly 
Or
 y Norfloxacin , oral, 400 mg 12 hourly for 7 days

— Ascites —
Standard  Treatment Guidelines, 7th Edition, 2017
46E.     Hepatic encephalopathy  precipitated by bacterial infection
Note 2-4  
A diagnosis of SBP is established if the neutrophil count in the ascitic fluid is 
> 250 cells/mL, culture results positive and surgically treatable causes are ex -
cluded.
Patients with suspected SBP should be started on empiric antibiotics immedi -
ately after ascitic fluid is obtained pending results:
Evidence Rating: [A]
1st Line treatment 
 y Ciprofloxacin , IV, 400 mg 8-12 hourly for 2 days (to be administered 
over 60 minutes)
Then
 y Ciprofloxacin , oral, 500 mg 12 hourly for 5 days 
Note 2-5
Avoid in patients with prior fluoroquinolone therapy as SBP prophylaxis or his -
tory of resistance.
2nd Line treatment 
 y Cefotaxime , IV, 2 g  8 hourly for 7 days
Or
 y Ceftriaxone , IV, 2 g  daily for 7 days   
Referral Criteria 
Refer patients if the condition does not improve. All children with 
hepatic encephalopathy must be referred to a specialist.
13� Ascites
Ascites  is the accumulation of excess fluid within the peritoneal 
cavity. 
Causes 
 y Portal hypertension secondary to liver cirrhosis 
 y Renal failure
 y Nephrotic syndrome
 y Cardiac failure
 y Abdominal tuberculosis
 y Intra-abdominal or pelvic malignancies
Symptoms
 y Abdominal enlargement
 y Abdominal discomfort or pain
 y Difficulty breathing
Signs
 y Distended abdomen

— Ascites —Chapter 2:  Disorders of the Liver 
47 y Shifting dullness
 y Fluid thrill
 y Abdominal tenderness
 y Signs relating to the underlying causes (See appropriate section)
Investigations
 y FBC
 y BUE & Creatinine 
 y LFTs
 y INR
 y Urinalysis
 y Abdomino-pelvic ultrasound
 y Chest X-ray
 y Diagnostic paracentesis
 y Appearance and colour
 y Gram stain
 y Cell count and differential
 y Biochemistry e.g. Albumin
 y Microscopy, culture (with bedside inoculation of aerobic & an -
aerobic blood culture bottles)
 y Acid fast bacilli
 y Cytology
Treatment 
Treatment objectives
 y To relieve symptoms 
 y To identify and manage underlying cause
Non-pharmacological treatment
 y Bed rest
 y Salt restriction <2 g/day 
 y Fluid restriction to ≤1.5 L/day
 y Avoid NSAID-use
 y Alcohol abstinence
 y Therapeutic paracentesis (sterile abdominal tap) if ascites  is tense 
and/or there is respiratory embarrassment
Note 2-6
Removal of up to 5 litres of ascitic fluid without concomitant colloid infusion is 
a safe short-term option and unlikely to have haemodynamic consequences.
Pharmacological treatment 
A. Control of ascitic fluid accumulation  
1st Line Treatment
Evidence Rating: [A] 
 y Spironolactone , oral,
Adult s
50-200 mg daily 

— Vomiting   —
Standard  Treatment Guidelines, 7th Edition, 2017
48Children  
0.3-3 mg/kg daily
And
 y Furosemide , oral,
Adult s
20-80 mg daily
Children
1-2 mg/kg daily 
B�     Massive ascites  in liver cirrhosis with respiratory embarrassment 
requiring more than 5 litres of fluid drainage 
1st Line Treatment
Evidence Rating: [A]
 y Salt-poor human albumin solution , IV, 6-8 g per litre of ascitic fluid 
drained 
Referral Criteria
Patients with the following conditions must be referred to a 
specialist.  Poor response to diuretic therapy or diuretic-refractory ascites , 
complicated cirrhotic ascites with suspected spontaneous bacterial 
peritonitis, hepato-renal syndrome, and hepatic encephalopathy.
Also refer when an underlying cause cannot be identified.
14. Vomiting   
Vomiting  can be induced by a variety of disease processes including 
gastrointestinal, neurologic, renal, psychiatric, cardiovascular, endocrine, 
pain and the effects of drugs. The best course of action in identifying 
the underlying cause is to carry out a detailed clinical evaluation and 
management plan, looking out for the aetiology, consequences and 
potential complications of vomiting .    
Severe uncontrolled vomiting  can result in significant dehydration  
and electrolyte imbalance accompanied by renal complications.
Anti-emetics should be prescribed only when the cause of vomiting  
is known as they may delay diagnosis.
Causes 
 y Disorders of the gastro-intestinal tract (GIT) and liver: intestinal 
obstruction, peptic ulcer, pancreatitis, cholecystitis, gastroenteritis , 
hepatitis
 y Neurological disorders: severe pain, migraine, raised intracranial 
pressure (i.e. tumours, haemorrhage; meningitis ); seizures, stroke
 y Endocrine and metabolic: diabetic ketoacidosis, uraemia, 
hypercalcaemia , intestinal pseudo-obstruction
 y Psychiatric: anxiety , depression , severe emotional upset, psychogenic 
vomiting
 y Drugs: cancer chemotherapy, aspirin , allopurinol, digoxin, 

— Vomiting   —Chapter 2:  Disorders of the Liver 
49erythromycin, anticonvulsants, opioids
 y Infections: malaria, urinary tract infections
 y Cardiovascular: acute myocardial infarction 
 y Renal: uraemia from acute or chronic kidney disease
 y Miscellaneous: pregnancy, cyclical vomiting  syndrome, myocardial 
infarction, labyrinthitis, otitis media
Symptoms
Vomiting  may be associated with:
 y Abdominal pain 
 y Diarrhoea : gastroenteritis
 y Abdominal distension: suspected bowel obstruction
 y Heartburn : suspected gastro-oesophageal reflux disease
 y Chest pain
 y Jaundice : hepato-biliary disease
 y Vertigo  and nystagmus : suspected vestibular neuronitis
 y Anxiety
 y Depression
Vomiting  may have diagnostic clues e.g.:
 y Vomiting  of food eaten several hours earlier: gastroparesis or gastric-
outlet obstruction
 y Vomiting  with blood: oesophageal, gastric or duodenal lesion 
 y Early morning vomiting : pregnancy
 y Faeculent vomiting : intestinal obstruction, gastro-colic fistula
 y Projectile: if pyloric stenosis
Signs
 y Abdominal tenderness
 y Dehydration  (reduced skin turgor, dry tongue, hypotension, 
tachycardia)
 y Abdominal distension
 y Succussion splash
 y Jaundice  
 y Signs of peritonitis (rebound tenderness, rigidity, guarding)
 y Miscellaneous: e.g. vertigo , nystagmus , focal neurological signs, 
Kussmaul breathing (uraemia, diabetic ketoacidosis)
Investigations
 y FBC
 y BUE and Creatinine 
 y LFT
 y Blood glucose
 y Serum amylase 
 y Urine RE
 y Urine Pregnancy test
 y ECG (if myocardial infarction suspected)
 y Abdominal X-ray: Intestinal obstruction

— Vomiting   —
Standard  Treatment Guidelines, 7th Edition, 2017
50 y Erect Chest X-ray: bowel perforation with air under diaphragm
Persistent Vomiting : 
 y Upper gastro-intestinal endoscopy
 y Serum calcium level
 y CT scan of brain   
Treatment 
Treatment objectives
 y To identify and treat the underlying cause
 y To prevent dehydration  and electrolyte imbalance
 y To maintain nutrition by ensuring adequate dietary intake during 
illness
 y To maintain personal hygiene
 y To eliminate infecting organisms where appropriate
Non-pharmacological treatment
 y Maintain adequate oral fluid intake (if tolerated)
 y Maintain adequate nutrition 
 y Place naso-gastric tube when needed
 y Surgical intervention in suspected intestinal obstruction, peritonitis
Pharmacological treatment 
A. Suggested Anti-Emetics for use in Migraine
Evidence Rating: [B]
 y Metoclopramide , oral/IV/IM, 
Adult s
10 mg 8 hourly 
Or
 y Domperidone , oral, 
Adult s
10 mg, 8 hourly
Children
> 12 years (Body weight ≥ 35 kg); 10 mg 8-12 hourly (max. 30 mg 
per day) 
1 month-12 years (Body weight ≤ 35 kg); 250 micrograms/kg 8-12 
hourly (max. 750 microgram/kg per day) 
Or 
Note 2-7
Domperidone should be used at the lowest effective dose for the shortest pos -
sible duration. The maximum duration of treatment should not exceed 7 days).
Or
 y Promethazine, IV/IM
Adult s 
12.5-25 mg 6-8 hourly as needed (max. 100 mg in 24 hours)
Or
 y Promethazine, oral, 
Children  

— Vomiting   —Chapter 2:  Disorders of the Liver 
512-12 years;  0.25-1 mg 6-8 hourly as needed (max. 25 mg per 
dose)  
< 2 years; Not recommended
B. Suggested Anti-Emetics for use in Vestibular Nausea  and Vomiting
 y Promethazine, oral, 
Adult s
20-25 mg 12 hourly
Children  
2-12 years;  0.25-1 mg 6-8 hourly as needed (max. 25 mg per 
dose)  
< 2 years; Not recommended
Or
 y Promethazine, IV/IM
Adult s 
12.5-25 mg 6-8 hourly as needed (max. 100 mg in 24 hours)
Or
 y Cyclizine , oral, 
Adult s
50 mg 8 hourly as needed
Children
6-12 years; 25 mg 8 hourly as needed (max. 75 mg in 24 hours) 
Or
 y Cinnarizine , IV/IM, 
Adult s and children > 12 years
30 mg 8 hourly as needed
Children
5-12 years;  15 mg 8 hourly as needed
< 5 years; not recommended
C. Suggested Anti-Emetics for use in Gastroenteritis
 y Metoclopramide , oral/IV/IM, 
Adult s
10 mg 8 hourly 
Or
 y Domperidone , oral, 
Adult s
10 mg, 8 hourly
Children
> 12 years (Body weight ≥ 35 kg); 10 mg 8-12 hourly (max. 30 mg 
per day) 
1 month-12 years (Body weight ≤ 35 kg); 250 micrograms/kg 8-12 
hourly (max. 750 microgram/kg per day) 
D. Suggested Anti-Emetics for use in Post-Operative Vomiting
 y Metoclopramide , oral/IV/IM, 
Adult s
10 mg 8 hourly

— Vomiting   —
Standard  Treatment Guidelines, 7th Edition, 2017
52Or
 y Cyclizine , oral/IV/IM,
Adult s
50 mg 8 hourly as needed
Children
6-12 years; 25 mg 8 hourly as needed (max. 75 mg in 24 hours) 
E. Suggested Anti-Emetics for use in Chemotherapy-Induced 
Vomiting  
 y Ondansetron , IV, 
Adult s
8 mg/ 0.15 mg/kg (pre-chemotherapy) infused over 15 minutes 
Children  
> 6 months;   0.15 mg/kg (pre-chemotherapy) infused 
over 15 minutes, then repeated 4 and 8 hours after first dose. (max 
is 16 mg/dose)
Or
 y Ondansetron , oral, 
Adult s
8 mg 12 hourly
Children  
4-12 years;   4 mg 30 minutes before chemotherapy, 
then 4 mg 8 hourly for 24-48 hours as needed
< 4 years;  not recommended 
Or
 y Granisetron , IV, 
Adult s
1mg/10 microgram/kg (30 minutes before Chemotherapy)
Children
2-16 years;  same as adults 
<2 years;  not recommended
Or
 y Granisetron , oral, 
Adult s 
1mg 1 hour before chemotherapy, then 1 mg 12 hours after 1st dose
Or
2 mg 1 hour before chemotherapy
Children  
Not recommended
Or
 y Dexamethasone , oral/IV, 
Adult s
8-12 mg before chemotherapy, then 8 mg 24 hourly from days 2-4 
Children
Not recommended
Or
 y Lorazepam , oral/IV, 
Adult s 

— Hepatocellular Carcinoma —Chapter 2:  Disorders of the Liver 
530.5-2 mg 6 hourly as required 
Children  
Consult a specialist 
F. Suggested Anti-Emetics for use in Pregnancy
 y Promethazine  teoclate, oral, 
10-20 mg 8 hourly as needed
Or
 y Promethazine , IM,
12.5-25 mg 8 hourly as needed 
Or
 y Metoclopramide , oral, 
10 mg 8 hourly
Or
 y Metoclopramide , IV/IM, 
10 mg 8 hourly as needed
Referral Criteria 
Refer all patients in whom vomiting  persists or who show signs of 
progression in disease, patients with unexplained or persistent vomiting, 
and patients with suspected surgical cause of vomiting for specialist or 
surgical assessment and management.
15� Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is a primary malignancy of the 
liver cell and must be differentiated from malignancies elsewhere 
that metastasize to the liver. Hepatocellular carcinoma occurs more 
commonly in men than in women and is often diagnosed several years 
after establishment of the initial causative condition. The disease has a 
poor prognosis resulting from metastatic or locally advanced disease. 
Complications include liver failure, variceal bleeding or tumour rupture 
with bleeding into the peritoneum. The tumour is often resistant to 
chemotherapy. Current strategies to prevent or treat hepatitis B and C 
infections and liver cirrhosis can potentially reduce the prevalence of HCC 
in the long term. 
Causes 
 y Cirrhosis of the liver 
 y Alcoholic liver disease
 y Chronic hepatitis B virus infection
 y Chronic hepatitis C virus infection
 y Chronic exposure to hepatic carcinogens e.g. aflatoxin
Symptoms
 y Jaundice  
 y Itching  
 y Anorexia

— Hepatocellular Carcinoma —
Standard  Treatment Guidelines, 7th Edition, 2017
54 y Early satiety
 y Feeling of a mass in the upper abdomen
 y Right upper abdominal pain
 y Weight loss 
 y Haematemesis
 y Abdominal distension
 y Bone pain
 y Dyspnoea  
Signs
 y Jaundice  
 y Cachexia
 y Hepatomegaly  (irregular surface, multiple nodules, may be tender)
 y Ascites  
 y Hepatic bruit
Investigations
 y FBC 
 y LFTS
 y INR
 y Serum Alpha-Fetoprotein
 y Hepatitis  B-Surface Antigen (HBsAg)
 y Hepatitis  C Antibody (HCVab)
 y Chest X-Ray
 y Abdominal ultrasound scan
 y CT/MRI scan (if ultrasound inconclusive)
Treatment 
Treatment objectives
Curative
 y To assess for potential resectability 
Palliative
 y To relieve pain 
 y To relieve discomfort from gross ascites
 y To prevent or treat hepatic encephalopathy (See section on ‘Hepatic 
Encephalopathy ’)
Non-pharmacological treatment
 y Surgical resection of non-metastatic localised lesions
 y Paracentesis for tense ascites  (See section on ‘Ascites’)
 y Supportive care (multi-vitamin supplements)
Pharmacological treatment 
A. Pain control in patients with Hepatocellular Carcinoma
1st Line Treatment
Evidence Rating: [B]
 y Tramadol , oral, 50 mg 12 hourly  (titrate further as tolerated to de -
sired effect: maximum 300 mg daily)
Or

— Drugs and the Liver —Chapter 2:  Disorders of the Liver 
55 y Morphine  sulphate, oral, 5-10 mg 8-12 hourly 
Referral Criteria 
Refer all patients with suspected HCC, especially those with small 
solitary lesion (< 5 cm) who may be considered for percutaneous alcohol 
injection or surgical resection, to a specialist.
16� Drugs and the Liver
Drug-Induced Liver Injury (DILI)  can occur following the use of a 
variety of either prescription or over-the-counter medications. A high 
index of suspicion is often necessary in establishing the diagnosis. Early 
recognition of drug toxicity is important to permit withdrawal of the 
offending drug, assessment of severity and monitoring for acute liver 
failure. Drug-induced liver injury can be dose-dependent or idiosyncratic.
The hallmark for the treatment of DILI is early withdrawal of the 
offending drug.
Causes 
 y Allopathic drugs (prescription, over-the-counter, anaesthetic 
agents, e.g. paracetamol , statins, isoniazid , halothane , amiodarone , 
azathioprine , carbamazepine , phenytoin , nevirapine , ketoconazole , 
flucloxacillin  etc.)
 y Herbal preparations 
 y Dietary supplements
Symptoms
 y Asymptomatic
 y Right upper quadrant pain
 y Nausea
 y Anorexia
 y Malaise
 y Lethargy
 y Pruritus  
Signs
 y Occasionally none 
 y Jaundice
 y Scratch marks
 y Bruising
 y Asterixis
 y Altered mental state
 y Signs of pre-existing chronic liver disease
Investigations
 y FBC
 y LFTS
 y BUE and Creatinine 

— Drugs and the Liver —
Standard  Treatment Guidelines, 7th Edition, 2017
56 y INR
 y Serum glucose
 y Urinalysis
 y Hepatitis  screen (A, B, C, E) for exclusion 
 y Abdominal ultrasound scan
Treatment 
Treatment objectives
 y To identify and withdraw the offending agent
 y To report as adverse drug event to Food and Drugs Authority (FDA) 
promptly 
 y To assess severity of liver disease
 y To administer antidote where applicable or feasible
Non-pharmacological treatment
(See section on ‘Hepatic Encephalopathy’)
Pharmacological treatment
A. Drug-induced liver injury following paracetamol  toxicity
1st Line Treatment
Evidence Rating: [A]
 y N-Acetylcysteine  
(See section on ‘Management algorithm for Acute Paracetamol  
Poisioning ’) 
Referral Criteria 
All patients failing to improve or showing progression in liver injury 
despite withdrawal of offending drug should be referred to a specialist. 
Management algorithm for Acute Paracetamol  Poisioning
Box 2-1:   Management algorithm for Acute Paracetamol  Poisioning 
Clinical presentation
Nausea  and vomiting  are common early symptoms
Patients that subsequently develop hepatic injury and death may be asymptomatic for 
hours after an acute ingestion
Investigations
In all patients with suspected paracetamol  toxicity, obtain the following: 
Serum paracetamol  concentration, baseline liver function tests (AST, ALT, total bilirubin ), 
PT and INR , urea and electrolytes
In all patients with a suspected intentional overdose, obtain serum salicylate 
concentration, serum glucose, ECG, and pregnancy test in women of childbearing age
Treatment regimen
Secure airway, breathing, and circulation as necessary

— Drugs and the Liver —Chapter 2:  Disorders of the Liver 
57Give activated charcoal  (AC) 50 g to all adult patients presenting within 4 hours of 
ingestion, unless contraindicated; AC may be useful for co-ingestants beyond 4 hours
Treat with N-Acetylcysteine  (NAC) If:
• Serum paracetamol  concentration drawn at 4 hours or more after a single acute 
ingestion is above the “treatment” line of the treatment nomogram for paracetamol 
poisoning
• Serum paracetamol  concentration is unavailable or will not return within 8 hours of 
time of ingestion and paracetamol ingestion is suspected
• Time of ingestion is unknown and serum paracetamol  level is greater than 10 
microgram/ml (66 micromol/L)
• There is evidence of any hepatotoxicity with a history of paracetamol  ingestion
• Patient reports or clinician suspects repeated excessive paracetamol  ingestions, 
patient has risk factors for paracetamol-induced hepatotoxicity, and the serum 
paracetamol concentration is greater than 10 microgram/ml (66 micromol/L)
Oral Dosing Of NAC:
• Oral dosing is acceptable for non-pregnant patients with a functional GI tract and no 
evidence of hepatotoxicity
• Dose 140 mg/kg loading dose, followed by 17 doses of 70 mg/kg every 4 hours
• If vomiting  occurs within 1 hour of NAC dosing, a full NAC dose should be repeated as 
rapidly as possible
• Therapy may be terminated by 24 to 36 hours after ingestion if the paracetamol  level 
is below 10 micrograms/ml, and the patient does not develop evidence of hepatotox -
icity and remains clinically well
Intravenous (IV) dosing of NAC:
• In patients with no biochemical evidence of liver failure (i.e., those with INR  <2), use 
21 hour IV protocol: 150 mg/kg loading dose over 60 minutes, followed by 50 mg/kg 
infused over 4 hours, with the final 100 mg/kg infused over the remaining 16 hours
• In patients with biochemical evidence of liver failure (i.e., those with INR  >2), 
administer the 21 hour IV protocol (150 mg/kg loading dose over 60 minutes, 
followed by 50 mg/kg infused over 4 hours, followed by 100 mg/kg infused over the 
next 16 hours) followed by a continuous IV NAC infusion at 6.25 mg/kg per hour until 
INR is < 2
• IV dosing is acceptable in all cases of paracetamol  toxicity, but should be used instead 
of oral dosing in patients unable to tolerate oral NAC (e.g., intractable vomiting ), 
patients with a medical condition precluding administration of oral NAC (eg, corrosive 
ingestion, GI bleed), patients with significant hepatotoxicity (INR  >2), and pregnant 
patients
Antiemetic therapy: 
• May give IV metoclopramide 10 mg 8 hourly

3Chapter
58Nutritional Disorders  
17� Malnutrition  
Malnutrition  occurs when there is a deficiency in intake of essential 
nutrients (i.e. proteins, carbohydrates, fats, vitamins and minerals). It is 
most commonly seen in children less than five years, particularly after 
weaning. Malnutrition reduces the individual’s ability to fight disease and 
infection thereby increasing the likelihood of the patient presenting with 
diarrhoea, vomiting , fever, worm infestation, pneumonia, tuberculosis, 
otitis media , urinary tract infection etc.   In adults, malnutrition frequently 
occurs in association with chronic alcoholism. 
Protein energy malnutrition  (PEM), when severe, presents in 
different forms such as marasmus , kwashiorkor  or marasmic-kwashiokor.
Birth-spacing, through family planning, as well as exclusive breast-
feeding for up to 6 months, followed by Introduction of a weaning diet at 
6 months and continuation with complimentary foods for up to 2 years, 
may be helpful measures in preventing malnutrition in young children. 
Encouraging a balanced diet for the family, including pregnant and 
lactating women, and nutrition education in schools and villages may help 
reduce the prevalence of malnutrition in the community.
Causes 
 y Poverty 
 y Inadequate quality and/or quantity of food intake
 y Social neglect 
 y Repeated or chronic infections
 y Repeated diarhoeal illness
 y Worm infestations 
 y HIV, pulmonary tuberculosis, measles, pertussis
 y Chronic illness and cancers
 y Alcoholism (adults)
Symptoms
 y Poor weight gain 
 y Weight loss (drop or flattening in weight on the child health record)
 y Body swelling (kwashiorkor )

— Malnutrition  —Chapter 3:  Nutritional Disorders 
59 y Child plays less because of lack of energy
 y Disinterest in food and surroundings 
Signs
Marasmus
 y Thin (reduced muscle bulk)
 y Prominent bones
 y Hanging skin folds especially over the buttocks
 y Unusually alert
 y Looks like an old man 
Kwashiorkor
 y Thin and wasted arms
 y Puffy face and legs due to oedema
 y Brownish or reddish hair
 y Flaky skin rash especially on the legs
 y Sores on the oedematous parts of the body in severe cases
 y Miserable and disinterested appearance
 y Disinterest in food
 y Anthropometric measurements
Moderate Acute Malnutrition   
 y Mid Upper Arm Circumference: 11.5 - < 12.5 cm
 y Weight for Age: < - 2 Z - Score but > - 3 Z Score
 y Weight for Height: < - 2 Z - Score but > - 3 Z Score 
Severe Acute Malnutrition
 y Mid Upper Arm Circumference: < 11.5 cm (Age 6-59 months)
 y Weight for Age: < - 3 Z - Score
 y Weight for Height: < - 3 Z - Score
Investigations
 y FBC
 y Urea and electrolytes
 y Serum albumin
 y Urine culture and sensitivity
 y Blood culture and sensitivity
 y Chest X-ray
 y HIV testing
 y Gastric lavage for acid fast bacilli
 y Screen for common infections such as tuberculosis, pneumonia, 
urinary tract infections, etc. (See relevant sections)
Treatment 
Treatment objectives
 y To identify and treat associated infections and complications
 y To correct fluid and electrolyte imbalance and other complications
 y To correct the nutritional deficiency including Vitamin A
 y To prevent recurrence by educating caregivers
 y To adequately manage chronic illnesses

— Malnutrition  —
Standard  Treatment Guidelines, 7th Edition, 2017
60Non-pharmacological treatment
 y Nutritional rehabilitation 
 y Out-patient Care
 y Malnourished children who have appetite, and do not 
have any overt medical condition, which requires admis -
sion, should be managed as outpatients with Ready-to-
Use Therapeutic Food (RUTF )
 y In-patient Care
 y Admit all severely malnourished children who have medi -
cal conditions requiring inpatient care 
 y Stabilisation Phase
 y Frequent feeding with F75
 y Introduce Ready-To-Use Therapeutic Food - RUTF  
 y Progressively return to acceptable balanced family meals
 y Participation of parents and caregivers in nutrition educa -
tion 
Pharmacological treatment 
A.     Vitamin A  supplementation  (children)
Evidence Rating: [A]
 y Vitamin A , oral, 
Children
> 1 year;   200,000 units daily for 2 days
6-11 months;  100,000 units daily for 2 days 
< 6 months;  50,000 units daily for 2 days
Note 3-1
Vitamin A  supplementation  should be given to replace body stores, EXCEPT if 
the child is on RUTF  made according to WHO specifications, which already con -
tains adequate vitamin A.
B.     Treatment of underlying infections (children) 
Inpatients
Evidence Rating: [B]
 y Cefuroxime , IV, 20 mg/kg 8 hourly for 48-72 hours
Then 
 y Cefuroxime , oral,
3 months-12 years; 15 mg/kg 12 hourly for 5-7 days
Outpatients 
Evidence Rating: [B]
 y Amoxicillin , oral, 
5-18 years;  500 mg 8 hourly for 10 days
1-5 years;  250 mg 8 hourly for 10 days
1 month-1 year; 125 mg 8 hourly for 10 days
C.     Immunisation  (children) 
(See section on ‘Immunisation ’ and National Expanded Programme 

— Malnutrition  —Chapter 3:  Nutritional Disorders 
61on Immunisation (EPI)  guidelines)
D.     Treatment of worm infestations
(See section on ‘Worm Infestations’)
Referral Criteria 
Refer to appropriate specialist for management of the underlying 
cause. Also refer to Reproductive and Child Health (RCH) unit for family 
planning services and Social welfare department within the health facility, 
district or region.

4Chapter
62Haematological Disorders  
17� Anaemia
Anaemia  is defined as decreased concentration of haemoglobin for 
the age and sex of the individual (i.e. below 13 g/dL in adult males, 12 g/dL 
in adult females, 11 g/dL in children, and below 13.5 g/dL in the 1st week 
of life). Anaemia always has a cause, which must be identified and properly 
managed.  The cause must be investigated before initiating treatment. 
In an emergency, blood samples must be taken for investigations before 
blood transfusion.
Causes 
Nutritional micronutrient and vitamin deficiency 
 y Iron
 y Folic acid
 y Vitamin B12
Bleeding  
 y Heavy menstruation
 y Haemorrhoids  (piles)
 y Peptic ulcer
 y Infestations e.g. hookworm, bilharzia 
 y Solid organ malignant tumours e.g. colonic cancer
 y Haematological malignancies: e.g. leukaemia
Haemolysis
 y Severe malaria
 y Sickle cell disease
 y G6PD  deficiency
 y Hypersplenism
 y Autoimmune 
 y Drugs 
Bone Marrow Failure
 y Disease infiltration e.g. leukaemia, lymphoma, tuberculosis
 y Aplasia – primary or secondary e.g. due to cytotoxics 
Chronic Diseases 
 y Kidney disease
 y Tuberculosis

— Anaemia —Chapter 4:  Haematological Disorders 
63 y Hypothyroidism
Autoimmune Disease
 y SLE
 y Pernicious anaemia
Symptoms
 y Easy fatigability
 y Dizziness
 y Shortness of breath on exertion
 y Palpitations
 y Fresh blood in stools
 y Black tarry stools (malaena)
 y Haematuria
 y Cola-like urine
Signs
 y Pale mucous membranes and palms
 y Angular stomatitis
 y “Spoon shaped” and ridged finger and toe nails
 y Spleen, liver and lymph nodes may be palpable
 y Signs of heart failure (in severe anaemia)
 y Jaundice  (in haemolysis)
 y Petechiae  and purpura  (bone marrow failure)
 y Hyperpigmentation of palms and soles of feet
Investigations
 y FBC 
 y Reticulocyte count and blood film comment
 y Sickling test and HB electrophoresis if indicated 
 y Blood film for malaria parasites
 y Kidney function tests 
 y Serum iron, Vitamin B12  and folate levels
 y Direct Coomb’s test
 y Stool for hookworm ova
 y Stool for occult blood
 y Urine for schistosoma ova
 y Specialized tests depending on the suspected cause e.g. bone 
marrow examination, antinuclear antibody (ANA) test, upper and 
lower GI endoscopy
Treatment 
Treatment objectives
 y To treat underlying cause of anaemia 
 y To restore haemoglobin levels to normal
 y To replenish iron stores after correction of anaemia in iron deficiency
 y To restore haemoglobin to steady state level in sickle cell disease 
patients 
 y To correct anaemia in proven vitamin B12 and folate deficiency and 

— Anaemia —
Standard  Treatment Guidelines, 7th Edition, 2017
64maintain normal levels throughout life 
Non-pharmacological treatment 
 y Advise on a balanced diet. Regular intake of leafy foods as well as 
fresh fruits and vegetables, beans, liver, meat, eggs, fish
 y High fibre diets to reduce bleeding from haemorrhoids
 y Surgical treatment
 y Where applicable e.g. haemorrhoids, tumours, hypersplenism etc.
Pharmacological treatment 
A.     Iron Deficiency Anaemia
1st Line Treatment
Evidence Rating: [B]
 y Ferrous sulphate  (dried or anhydrous), oral,
Adult s
200 mg (65 mg elemental iron) 8 hourly for 3-6 months
Children
> 10 years; 200 mg 12 hourly for 3-6 months
8-10 years; 200 mg daily for 3-6 months
5-7 years; 80-120 mg 8-12 hourly for 3-6 months
1-4 years; 45-90 mg 8-12 hourly for 3-6 months
< 1 year;  30-60 mg 8-12 hourly for 3-6 months
Or
 y Ferrous fumarate , oral, 
Adult s
200 mg (65 mg elemental iron) 8 hourly
Children
3-6 mg elemental iron/kg per day for 3-6 months
2nd Line Treatment
Evidence Rating: [B]
Note 4-1
Parenteral iron has no advantage over oral iron preparations except in the rare 
case of malabsorption.
Or
 y Iron sucrose , IV, (as a slow bolus injection over 2-5 minutes)
Adult s
200 mg every 3 days for 5 doses
Children
0.5 mg/kg every 4 weeks for 12 weeks (max. 100 mg per dose), cal -
culated based on body weight and iron deficit and the target Hb
Or
 y Iron dextran , IV, (as a slow bolus or IM by deep intramuscular) in -
jection
Adult s
25-100 mg daily as needed
Children

— Bleeding Disorders —Chapter 4:  Haematological Disorders 
65Not recommended
B�     Vitamin B12 Deficiency
Evidence Rating: [B]
 y Vitamin B12 (Hydroxocobalamin) , IM,
Adult s
1 mg every other day for 6 doses 
Then
1 mg every 3 months for life
Children
1 mg stat. 
Then
1 mg every 3 months for life
C.     Folate Deficiency
 y Folic Acid , oral, 
Adult s  
5 mg daily
Children
2.5-5 mg daily 
D.     Severe Symptomatic Anaemia
 y Blood transfusion  with packed cells
And
Treat for cardiac failure if signs of cardiac failure.  (See section on 
‘Heart failure’)
Referral Criteria 
Refer patients with haemoglobin levels that do not improve after two 
weeks on the above treatment or with severe anaemia from any cause, 
which recurs, to a specialist. Patients with suspected aplastic anaemia, 
anaemia due to uncontrolled bleeding, including heavy menstrual loss, 
would also require referral to a specialist.
18� Bleeding  Disorders
Bleeding  disorders may present at birth or develop later in life. The 
bleeding may be spontaneous or follow trauma or surgery and may be due 
to defective blood vessels, platelet disorders or clotting factor deficiency. 
Past episodes of excessive bleeding e.g. following circumcision, a family 
history of bleeding and drug therapy may be important clues to the 
diagnosis.  
The pattern of bleeding is a helpful guide to its cause. In platelet 
and vessel wall defects, bleeding is usually into skin and mucosal surfaces 
like the gums, nose, gastrointestinal tract, whereas in coagulation factor 
deficiency (e.g. haemophilia), bleeding is into deep tissues like the brain, 
joints and muscles. 

— Bleeding Disorders —
Standard  Treatment Guidelines, 7th Edition, 2017
66In newborns with vitamin K  deficiency (which leads to multiple 
coagulation factor deficiency) spontaneous bleeding occurs from various 
sites such as the umbilical cord, gastrointestinal tract, scalp and brain. 
Causes 
 y Haemophilia
 y Von Willebrand disease
 y Liver disease 
 y Vitamin K  deficiency especially in newborns
 y Bone marrow failure e.g. aplastic anaemia and leukaemia
 y Low platelet count from any cause
 y Disseminated Intravascular Coagulation (DIC ) from any cause
 y Drug induced - herbal preparations, aspirin , clopidogrel , warfarin , 
rivaroxaban , heparin
Symptoms
 y Spontaneous bleeding from mucous membranes or cuts
 y Easy bruising, bleeding from orifices
 y Excessive bleeding from cuts or incisions 
 y Deformed joints from recurrent joint bleeds
 y Swelling at site of blood collection (pseudotumours)
 y Pain limiting movement
Signs
 y Pallor
 y Excessive bleeding
 y Localised swelling due to bleeding into body spaces e.g. Joints
 y Tenderness
 y Limitation of movement and joint deformities
 y Purpura , petechiae , ecchymosis
Investigations
 y FBC and blood film comment
 y Platelet count 
 y Liver function tests 
 y Prothrombin time , INR , partial thromboplastin time
 y Bleeding  time
Treatment 
Treatment objectives
 y To prevent or arrest bleeding
 y To identify and correct underlying cause
Non-pharmacological treatment
 y Apply regulated pressure dressing and/or ice packs to minimise 
bleeding where possible
 y Stop any event/drugs responsible for bleeding or which may 
aggravate bleeding
 y Educate haemophiliacs on their disease, encouraging them to 

— Bleeding Disorders —Chapter 4:  Haematological Disorders 
67minimise trauma-prone activities, and to inform doctors of their 
condition before any surgical procedure
 y Avoid unnecessary injections and surgical procedures in all patients 
(especially, those with a family history of bleeding tendencies)
 y Physiotherapy  on affected joints
 y Surgery
Pharmacological treatment 
A. General Measures: fluid replacement following acute severe blood 
loss
Sodium Chloride  0.9%, IV, 
Adult s 
(See Section on ‘Shock’)
Children  and Neonate s 
20 ml/kg bolus stat.
Repeat if there is no clinical improvement 
And
 y Concentrated red cell transfusion , IV, 
Adult s, Children  and Neonate s
3 ml/kg for each expected 1 g/dL haemoglobin rise 
B�     Bleeding  due to underlying liver disease 
1st Line Treatment
Evidence Rating: [A]
 y Vitamin K , IV,
Adult s
5-10 mg stat.
Children
3-5 mg stat.
Neonate s (irrespective of history of vitamin K  injection)
Term;   1 mg stat.
Preterm;  500 micrograms stat.
And
 y Fresh Frozen Plasma , IV, 
Adult s, Children , Neonate s
15-20 ml/kg 
C.     Haemophilia A
 y Recombinant Factor VIII, intravenous, 
1 international unit raises % of Factor VIII on average by 2 per kg 
body weight
Required units = body weight (kg) x desired factor rise x 0.5 
(Repeated as needed) 
Or
 y Desmopressin , Intranasal, 150 microgram spray into each nostril, 12 
hourly. May be repeated for 3 days 

— Bleeding Disorders —
Standard  Treatment Guidelines, 7th Edition, 2017
68D�     Haemophilia B  
 y Recombinant Factor IX
Administration of 1 unit/kg factor IX (recombinant) generally in -
creases factor IX levels by approximately 0.8% in adults and 0.7% in 
children <15 years of age
E�     Von Willebrand Disease  
 y Desmopressin , Intranasal, 150 microgram spray into each nostril, 12 
hourly. May be repeated for 3 days 
F�      DIC  
Treat underlying cause.
 y Fresh Frozen Plasma
Adult s, Children , Neonate s
15-20 ml/kg
Or
 y Coagulation factor , red cell and platelet concentrates  as needed
G�     Thrombocytopaenia  requiring platelet transfusion
 y Platelet Concentrate  
Adult s, Children , Neonate s
10 ml/kg (raises platelet count by 5 x 109/L) 
Prevention of local fibrinolysis
 y Tranexamic Acid , oral and IV,
100 mg/kg 
Then  
10 mg/kg 
Adult s 
1300 mg oral 8 hourly 
2nd Line Treatment
Evidence Rating: [A]
Haemophilia A
 y Purified factor VIII
 y Cryoprecipitate , IV,  
Adult s, Children , Neonate s
1.5-2.0 packs/10 kg       
Haemophilia B
 y Purified factor IX
 y Fresh frozen plasma
Referral Criteria 
Refer all haemophiliacs and all patients with unexplained recurring 
bleeding episodes and those requiring surgery to the physician specialist 
or haematologist for initial assessment, treatment plan and scheduled 
comprehensive review.

— Sickle Cell Disease —Chapter 4:  Haematological Disorders 
6919� Sickle Cell Disease
This is an inherited disease characterized by the possession of two 
abnormal haemoglobins, at least one of which is haemoglobin S.  There 
are various types, including HBSS , HBSC  and HBS βthalassaemia . The 
possession of one normal haemoglobin (haemoglobin A) together with one 
abnormal haemoglobin (e.g. AS or AC) constitute a haemoglobinopathy 
trait and not sickle cell disease.
The use of the word ‹sickler› to describe patients with sickle cell 
disease must be avoided. Sickle cell disease  patients may present either 
in the steady state, in crises or with complications.   The crisis is commonly 
vaso-occlusive bone pain crisis. Other types of crises include acute chest 
syndrome , hyper-haemolytic crisis, aplastic crisis and sequestration crises. 
In vaso-occlusive crises there is occlusion of small vessels by sickled cells 
causing infarction and pain; in Acute Chest Syndrome (ACS) , the patient 
presents with sudden onset of cough, difficulty in breathing and fever; in 
aplastic crises, infection with parvovirus causes sudden severe anaemia 
with a low reticulocyte count; in sequestration crises the spleen and liver 
enlarge rapidly due to trapping of red blood cells.  
Patients with sickle cell disease should be encouraged to have 
periodic check-ups at a sickle cell clinic.
Causes 
 y Inheritance of two abnormal haemoglobin genes from both parents, 
at least one of which is an S.  
 y Crises are typically precipitated by: 
 y cold weather
 y dehydration
 y infection
 y physical exertion 
 y mental stress
Symptoms
 y Joint and bone pain, especially during cold wet seasons
 y Easy fatiguability 
 y Pallor 
 y Jaundice
 y Difficulty in breathing with or without chest pain
 y Chronic leg ulcer
 y Abdominal pain, especially in the splenic area
 y Spontaneous sustained erection without sexual arousal in male 
patients (See section on ‘Priapism ’)
Signs
 y Jaundice
 y Pallor
 y Hepatomegaly

— Sickle Cell Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
70 y Splenomegaly  (may be absent in older patients)
 y Old or recent scarification marks by traditional healers, particularly 
over the abdominal wall and joints
 y Venous ulcers
 y Bossing 
 y Dactylitis (hand and foot syndrome)
 y Gnathopathy
 y Growth delay or tall, lanky stature (‘marfanoid’ habitus)
Investigations
 y FBC
 y Blood film comment
 y Reticulocyte count
 y Sickling test
 y Haemoglobin electrophoresis
 y Urine examination
 y Chest X-ray in case of ACS
 y Blood and urine C/S when infection suspected 
 y G6PD assay
Treatment 
Treatment objectives
 y To prevent the development of sickle cell crises
 y To relieve pain
 y To identify and manage the precipitating cause of crises 
 y To maintain a good steady state haemoglobin
 y To prevent long term complications and organ damage
 y To manage sickle cell crises and complications once developed
Non-pharmacological treatment
 y Good hydration at all times by drinking adequate water/fluids 
 y Avoidance of common precipitating causes of crises such as malaria 
(bed nets etc.), dehydration , stress, excessive exercise, and exposure 
to extremes of weather
 y Maintenance of good nutrition
 y Client education
 y Parental/guardian education
 y Genetic counselling with voluntary family size restriction 
 y General public knowledge
Pharmacological Treatment 
A.     Vaso-occlusive bone pain crises
1st Line Treatment
Evidence Rating: [B]
Mild to moderate pain
 y Paracetamol , oral,
Adult s

— Sickle Cell Disease —Chapter 4:  Haematological Disorders 
71500 mg-1 g 6 - 8 hourly  
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or
 y Paracetamol , rectal,
Adult s and Children
Doses as above
Or
 y Ibuprofen , oral,
Adult s
400 mg 6-8 hourly
Children
6-12 years;   200-400 mg 6-8 hourly
1-5 years;   100-200 mg 6-8 hourly
3 months-1 year;  not recommended
Or
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;   50 mg 12 hourly
< 12 years;   not recommended
Or
 y Diclofenac , rectal,
Adult s 
100 mg daily up to a maximum of 200 mg daily in divided doses
Children  
75-100 mg daily
Note 4-2
If the pain is not controlled by the measures above within 12 hours, consult a 
specialist. Pethidine is no longer the recommended drug of choice. Morphine 
may be used but specialist consultation is required. 
 y Morphine  sulphate, oral/IV, consult specialist 
Caution 4-1.
Caution: long term NSAIDS (for more than two weeks) e.g. Diclofenac  and Ibu -
profen  may cause renal impairment, and gastritis
And
 y Dextrose in Sodium Chloride , IV Infusion,
Adult s
 y 5% Dextrose in 0.9% Sodium Chloride   2-4 L daily 
Children
 y 5% Dextrose  in 0.9% Sodium Chloride  150 ml/kg daily

— Sickle Cell Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
72Or
Adult s
Normal Saline  alternating with 5% Dextrose  2-4L daily 
Children
Normal Saline  alternating with 5% Dextrose  150 ml/kg daily
Box 4-1:  Fluid requirement in children according to age
< 1 year 50 ml/kg
1 year 140 ml/kg
2 years 130 ml/kg
4 years 110 ml/kg
6 years 100 ml/kg
8 years 90 ml/kg
10 years 85 ml/kg
12 years 70 ml/kg
Severe Pain
2nd Line Treatment 
Evidence Rating: [B]
 y Diclofenac  sodium, IM,
Adult s 
75-150 mg daily in divided doses
Then
 y Codeine  phosphate , oral,  
Adult s and Children  over 12 years
30-60 mg 4-6 hourly
Or
 y Tramadol , oral, 50-100 mg 8 hourly 
And
 y Blood transfusion  (packed cells ) when needed, but not routine. 
Transfusion will be necessary if haemoglobin level is < 5 g/dL
B�     Steady State
 y Folic Acid , oral,
Adult s
5 mg daily 
Children
> 1 year;   5 mg daily
< 1 year;   2.5 mg daily

— Plasma Cell Myeloma —Chapter 4:  Haematological Disorders 
73C�     Severe Disease
Note 4-3
Patients with suspected acute chest syndrome  should have an urgent chest 
X-ray, blood and urine C/S, blood for grouping and cross-matching  
 y Amoxicillin + Clavulanic Acid, IV, 1.2 g and urgently transferred to a 
tertiary centre
 y Hydroxycarbamide , Aspirin , Opiates and /or Chronic transfusion 
therapy may be used under specialist care
D.     Prevention of pneumococcal infections
 y Pneumococcal conjugate vaccine 13 (PCV 13) vaccination in infancy, 
booster at 6 years
Referral Criteria 
Refer all sickle cell patients with bleeding into the eye, priapism, 
haematuria or renal disease and stroke  to a specialist. The presence of 
osteomyelitis, aseptic necrosis of the hip, acute chest syndrome  and 
persistent jaundice after initial management as recommended above 
should also warrant a referral to a specialist centre.  
Patients with CNS events, unexplained high white cell and platelet 
counts (more than 15 and 500 x 109/L respectively), intractable morbid 
pain, repetitive crises or recurrent severe anaemia interfering with their 
lives should be referred to a specialist.
20� Plasma Cell Myeloma
Plasma cell myeloma (previously referred to as multiple myeloma ), 
is cancer affecting the plasma cells in the bone marrow.  These abnormal 
plasma cells occur in increased numbers and produce abnormal non-
functional immunoglobulins leading to impaired ability to fight infections 
in the patient affected, hyperviscosity and renal failure. In the bone 
marrow the increased plasma cells result in a reduction in normal blood 
cell production and erosion of bone with resultant peripheral blood 
cytopaenias, osteolytic lesions, pathological fractures and hypercalcaemia .   
The disease is commonest in the sixth decade and rare below the age of 
40 years.
Causes 
 y Unknown
 y Potential precipitants:
 y Chemicals e.g. dioxins, formaldehyde, and nitrobenzene found 
in solvents and cleaning agents
 y Ionizing radiation
 y Viruses e.g. Herpes Virus  8, Epstein-Barr , HIV , Hepatitis  Virus

— Plasma Cell Myeloma —
Standard  Treatment Guidelines, 7th Edition, 2017
74Symptoms
 y Bone pain
 y Easy fatiguability
 y Excessive weakness
 y Recurrent infections 
 y Bony swellings
Signs
 y Pallor
 y Fever
 y Dehydration  
 y Bony lumps
 y Paraplegia  
 y Paresis
 y Renal Impairment
 y Unprovoked fractures
Investigations
 y FBC and blood film comment
 y ESR
 y Blood urea, electrolytes, creatinine
 y Plasma calcium levels
 y Serum uric acid
 y Bone marrow aspirate
 y Skeletal survey including skull X-ray
 y Serum protein levels 
 y Serum protein electrophoresis 
 y Urine Bence Jones protein 
Treatment 
Treatment objectives
 y To reduce the number of abnormal plasma cells to normal and 
reduce their rate of increase
 y To treat anaemia
 y To reduce bone pain
 y To manage pathological fracture
 y To improve or maintain good bone mineral density
 y To treat infections
 y To prevent and treat renal complications 
Non-pharmacological treatment
 y Patients should drink at least 3 litres of fluid each day throughout the 
course of their disease
 y Physiotherapy
 y Orthopaedic supports

— Leukaemia —Chapter 4:  Haematological Disorders 
75Pharmacological treatment 
A. To reduce number of plasma cells and rate of increase 
Available at specialized centres only
B�     To reduce bone pain
Pain relief (avoid NSAIDS)
C�     To treat anaemia
Packed red cells  transfusion and platelet transfusion  when indicated
D.     To prevent and treat renal complications 
IV and oral fluids
E.     To mitigate tumour lysis 
Allopurinol  to mitigate tumour lysis
F.      To treat infections
(See appropriate section)
Referral Criteria 
All patients suspected to have plasma cell myeloma should be 
referred to a haematologist at a specialised tertiary centre for further 
evaluation and definitive management.  Subsequent follow-up can be 
done by a physician specialist with guidance from the haematologist.
21� Leukaemia
Leukaemia  is cancer of the blood cells.  There are two main types 
of leukaemia, which are lymphoid leukaemia and myeloid leukaemia.  
Each type of leukaemia can be classified as acute (where the patient falls 
suddenly ill) and chronic (where the patient may have been harbouring 
the disease for months without knowing).  Thus in all, there are 4 main 
types of leukaemia: acute lymphoid leukaemia (ALL) , chronic lymphoid 
leukaemia (CLL) , acute myeloid leukaemia (AML)  and chronic myeloid 
leukaemia (CML) .  
ALL is commonest in children especially boys, CLL is commonest in 
the elderly, AML and CML cut across all age groups and sexes.  
The abnormal leukaemic cells especially in acute leukaemia, fill the 
marrow and prevent the marrow from producing the normal blood cells 
i.e. red cells, white cells and platelets leading to anaemia, neutropaenia 
and thrombocytopaenia, respectively.  
Causes 
 y Usually unknown
 y Associated factors 
 y Viruses e.g. human T lymphotrophic virus type 1 (HTLV-1) and 
epstein barr virus (EBV)
 y Chemicals e.g. benzene, industrial solvents, pesticides (lin -

— Leukaemia —
Standard  Treatment Guidelines, 7th Edition, 2017
76dane ), dyes, 
 y Drugs e.g. alkylating agents such as melphalan
 y Ionizing radiation 
Symptoms
Acute Leukaemia
 y Fever
 y Lymph node swelling
 y Easy fatiguability
 y Bruising tendencies
 y Bone and joint pain (especially in children)
Chronic Leukaemia
 y Asymptomatic
 y Dragging sensation (left side of abdomen) 
 y Easy satiety
 y Lymph node swelling
 y Weight loss
 y Generalized itch 
 y Excessive sweating
 y Priapism
 y Hearing loss
Signs
Acute Leukaemia
 y Pallor
 y Fever
 y Skin and mucosal haemorrhages  
 y Gum hypertrophy (AML subtype 5)
 y Firm, rubbery, non-tender lymph nodes (lymphoid leukaemia)
 y Splenomegaly  
Chronic Leukaemia
 y Splenomegaly
 y Weight loss
 y Pallor
 y Generalized lymph node enlargement in CLL
Investigations
 y FBC and blood film comment
 y Bone marrow aspirate
 y Uric acid levels
 y LDH
 y BUE and creatinine
 y Liver function tests
 y Septic screen (especially in acute leukaemia)
 y LP for CSF cytology (especially in acute lymphoid leukaemia)

— Malignant Lymphoma —Chapter 4:  Haematological Disorders 
77Treatment 
Treatment objectives
 y To aim for a cure in ALL in both children and adults
 y To achieve remission and prolong good quality life in AML
 y To aim for a complete haematological remission or cure in 
philadelphia positive CML
 y To control white cell counts, symptoms and prolong good quality of 
life in philadelphia negative CML 
 y To provide supportive treatment  (pain relief, transfusion support, 
treat infections, counselling)
Non-pharmacological treatment
 y Ensure good hydration
 y Ensure good nutrition and food hygiene 
 y Ensure good oral and personal hygiene
Pharmacological treatment 
A. Treatment of the newly diagnosed patient  
Supportive treatment 
 y Pain relief (avoid NSAIDS)
 y Packed red cells  transfusion and platelet transfusion  when indicated
 y IV and oral fluids 
 y Allopurinol  to mitigate tumour lysis
 y Treatment of infections
Specific treatment 
 y Available at specialized tertiary centres only
Referral Criteria 
Refer all patients to the haematologist at a specialized tertiary centre 
for confirmation of diagnosis and start of management.  Follow-up can 
continue at a regional centre by a physician under the distant guidance 
of a haematologist.   
22� Malignant Lymphoma
This refers to a group of disorders characterized by malignant 
proliferation of lymphoid tissue usually presenting as lymph node 
swellings. There are 2 major histological types distinguished by the 
presence or absence of the Reed Sternberg (RS) cell .  The 2 main groups 
are Hodgkin’s lymphoma  (RS cell present) and non-Hodgkin’s lymphoma  
(RS cell absent).  No age is exempt although generally the incidence of non-
Hodgkin’s lymphoma (NHL) increases with age and immunosuppression 
while Hodgkin’s lymphoma (HL) shows a bimodal peak, in that there is a 
high incidence in the third and seventh decades.
Burkitt’s lymphoma , a subtype of NHL, is one of the fastest growing 

— Malignant Lymphoma —
Standard  Treatment Guidelines, 7th Edition, 2017
78tumours known in man.  There are three clinical variants - the endemic, 
sporadic and immunodeficiency associated forms.  The endemic form is 
found in tropical and malaria endemic regions like Ghana and commonly 
presents as a jaw swelling with loosening of the associated teeth.  In 
Ghana, it is the commonest childhood malignancy.  It has a peak age 
incidence at 4-7 years with a male preponderance.
Causes 
 y Often unknown
 y Associated aetiological agents
 y Chronic antigenic stimulation by Helicobacter pylori  infection in 
gastric lymphoma 
 y Viruses e.g. herpes virus 8, epstein-barr virus, HTLV-1
 y Chemicals e.g. pesticides, herbicides 
 y Wood dust 
Symptoms
 y Lymph node swelling which may wax and wane
 y Jaw swelling (in Burkitts)
 y Fever
 y Night sweats
 y Weight loss
 y Easy fatiguability
 y Abdominal distension, intestinal obstruction  (in abdominal 
lymphomas)
Signs
 y Firm, rubbery, non-tender lymph nodes
 y Splenomegaly
 y Superior vena cava syndrome (if bulky mediastinal masses are 
present)
 y Pallor (if marrow has been involved)
Investigations
 y Lymph node biopsy (of a significantly enlarged node)
 y Fine needle aspiration (in Burkitts)
 y FBC and blood film comment
 y Chest X-ray, abdominal USG, CT scan when necessary
 y Bone marrow aspirate and trephine biopsy
Treatment 
Treatment objectives
 y To provide a cure 
 y To provide supportive treatment  (pain relief, transfusion support, 
treat infections, counselling)
Non-pharmacological treatment
 y Ensure good hydration

— Malignant Lymphoma —Chapter 4:  Haematological Disorders 
79 y Counselling and education
Pharmacological treatment 
A. Hodgkin’s Lymphoma  (HL) and Non-Hodgkin’s Lymphoma  (NHL)
1st Line Treatment
Evidence Rating: [A]
Supportive treatment 
 y Pain relief (avoid NSAIDS)
 y Packed red cells  transfusion and platelet transfusion  when indicated
 y IV and oral fluids
 y Allopurinol  to mitigate tumour lysis
 y Treatment of infections
Specific treatment
 y Available at specialized tertiary centres only
Referral Criteria 
All patients should be referred to a haematologist at a specialised 
tertiary centre.

5Chapter
80Immunisable Diseases
23� Immunisation  
Immunisation  against vaccine preventable diseases through the 
national Expanded Programme for Immunisation (EPI) is one of the most 
effective measures of reducing morbidity, disability and mortality in the 
population, especially, in children.
Ghana currently has 12 (twelve) vaccines in the immunisation 
schedule, namely, BCG , oral poliomyelitis, diphtheria, pertussis, tetanus, 
hepatitis B, haemophilus	 influenzae  type B, pneumococcus, rotavirus, 
measles, rubella and yellow fever. Newer vaccines may be introduced in 
the near future as they are discovered and found effective.
Immunisation  is recommended for the following persons: 
 y High risk groups (e.g. during a disease outbreak or by virtue of being 
exposed)
 y Young children 
 y Elderly
 y The malnourished
The current schedule for routine Immunisation for children under 5 
years is as follows:
Evidence Rating [A]
Table 5-1:   Schedule for routine Immunisation of children under 5 years
Age Vaccine (Dose)
BIRTH BCG (0.05 ml Intradermally)
Polio  ’O’ (2 Drops Orally)
6 weeks “Five In One ” (Or Penta-Vaccine ) 1 (0.5 ml IM)
Pneumococcal (PCV)  1 (0.5 ml IM)
Polio  ’1’ (2 Drops Orally)
Rotavirus  (Rotarix)

— Immunisation  —Chapter 5:  Immunisable Diseases
81Age Vaccine (Dose)
10 weeks “Five In One ”2 (Or Penta-Vaccine ) 2 (0.5 ml IM)
PCV 2  (0.5 ml IM)
Polio  ‘2’ (2 drops orally)
Rotavirus  (Rotarix)
14 weeks “Five In One ”2 (Or Penta-Vaccine ) 2 (0.5 ml IM)
PCV 3  (0.5 ml IM)
Polio  ‘3’ (2 drops orally)
9 months Measles /Rubella (0.5 ml deep SC or IM)
Yellow Fever  (0.5 ml IM)
18 months Measles  (0.5 ml deep SC or IM)
*Five in One ” Vaccine or Penta-Vaccine  contains Diphtheria , Pertussis , Tetanus , Haemophilus 
Influenzae  B and Hepatitis  B Antigens in one vaccine.
Measles /Rubella is presented as a combined vaccine.
Box 5-1:   Notes on Vaccine use 
 yWrong method of administration reduces efficacy
 yIf Immunisation course is interrupted, resume with the same brand 
of vaccine, else restart with different brand
 yThere are no contraindications to the immunisation of the sick 
child if he/she is well enough to go home
 yChildren with diarrhoea who are due for oral vaccines: give but 
don’t count, then repeat after 4 weeks and record this one as given
 yDon’t give OPV 0 after 15 days (disturbs regular immunisation 
schedule)
 yDon’t give Rotarix 1st dose after 12 weeks, 2nd dose after 24 weeks
Immunisation  of preterm babies:
 y Consider all premature babies for full immunisation course.
 y Start immunisation in 2nd month after birth (after 4 weeks) 
irrespective of degree of prematurity. Give BCG on discharge. 
 y Delay OPV in neonatal unit since there is a small chance of transfer of 
OPV virus to other babies. Hence give OPV on discharge from nursery 
- not while still on admission.
Contraindications to Immunisation :
 y Current serious febrile illness:  delay vaccine
 y History of severe reaction after previous dose  (e.g. anaphylactic 
reaction) - avoid
 y Evolving neurological disease (e.g. uncontrolled epilepsy ) - avoid 
whole cell pertussis vaccine  
 y No DPT  or DPT/HepB/Hib to child with convulsion /shock within 3 
days of the most recent dose of DPT or DPT/HepB/Hib
 y No DPT  or DPT/HepB/Hib to child with recurrent convulsions or 
active CNS disease

— Measles —
Standard  Treatment Guidelines, 7th Edition, 2017
82 y Yellow fever vaccine should not be given if there is history of 
anaphylaxis  with ingestion of egg  
 y Individuals with symptomatic HIV  infection should not receive BCG  
and yellow fever vaccines since these are live vaccines. BCG vaccine 
can be given at birth since the HIV infected newborn  is asymptomatic
Live vaccines should not be given to the following: 
 y Pregnant women - for risk of teratogenic effect
 y Patients with malignant disease e.g. leukaemia, Hodgkins disease
 y Malignant disease of the reticuloendothelial system, 
 y Patients with immune suppression, including Symptomatic HIV  
patients
 y Patients on chemotherapy (defer for 6 months after stopping 
chemotherapy treatment)
However:
 y Measles  vaccine should be given to HIV  positive patients even though 
it is a live vaccine because the benefit outweighs the risk
Referral Criteria 
Refer all problems related to Immunisation to a paediatrician or EPI 
specialist.
24. Measles
Measles  is an acute infectious disease, which usually occurs in 
children between 6 months and 3 years who have not been immunised, 
or completed the full immunisation schedule. It is prevented by 2 doses of 
measles vaccination at 9 and 18 months. The condition is very infectious 
from up to 7 days before, to 5 days after, appearance of the rash.
Complications include otitis media , with or without deafness, 
bronchopneumonia, croup, diarrhoea, vitamin A deficiency leading 
to xerophthalmia and blindness, malnutrition and activation of latent 
tuberculosis. Seriously ill measles patients requiring admission should be 
isolated. There is no specific treatment for measles. Antibiotics are not 
required, except for some specific complications.
Measles  diagnosis is mainly clinical. The disease is now uncommon 
because of immunisation. However, high immunisation coverage needs to 
be maintained to keep the disease under control. Report all cases to the 
District Disease Control Officer for appropriate action.
Cause 
 y Measles  virus 
Symptoms
 y Runny nose
 y Cough
 y Red eyes

— Measles —Chapter 5:  Immunisable Diseases
83 y Sore mouth 
 y High fever, present before the rash appears
 y Rash - starts on face and neck
 y Diarrhoea
 y Child is generally miserable
Signs
 y Fever
 y Conjunctivitis
 y Koplik spots  (white grain-like spots  on the buccal mucosa 2 days 
before rash)
 y Rash - itchy, generalised maculo-papular
Investigations
 y Usually none
 y Measles  immunoglobulin M (IgM) antibody assay if required  
Treatment objectives
 y To relieve symptoms
 y To maintain good nutrition
 y To prevent and treat complications
Non-pharmacological treatment
 y Tepid sponging for fever
 y Encourage oral hygiene with frequent saline mouth wash
 y Continue feeding with soft high calorie foods
 y Wash eyes with clean water
 y Discourage use of harsh items on skin
Pharmacological treatment
A. For pain and fever
Evidence Rating: [C]
 y Paracetamol , oral, 
Adult s
500 mg-1g 6-8 hourly
Children
6-12 years;  250-500 mg 6-8 hourly 
1-5 years;  120-250 mg 6-8 hourly 
3 months-1 year; 60-120 mg 6-8 hourly
B. To prevent eye complications due to Vitamin A  deficiency
Evidence Rating: [A] 
 y Vitamin A , oral,  
Children
> 1 year;   200,000 units daily for 2 days
6-11 months;  100,000 units daily for 2 days
< 6 months;  50,000 units daily for 2 days
C. For management of associated diarrhoea with dehydration  
(See section on ‘Diarrhoea’)

— Pertussis  —
Standard  Treatment Guidelines, 7th Edition, 2017
84D. For management of associated pneumonia and otitis media   
(See relevant sections)
E. For relief of skin irritation
 y Calamine lotion  (apply liberally to the whole skin)
Referral Criteria 
Refer patients with complications such as a black (haemorrhagic) 
rash, stridor , pneumonia, coma , great difficulty in eating or drinking, 
dehydration  or malnutrition to the hospital.  
25� Pertussis  
This is a highly contagious bacterial respiratory tract infection 
common in children and adults. The incubation period is 7-21 days. 
Complications include subconjunctival haemorrhage, otitis media , 
apnoea, pneumonia, bronchiectasis, activation of latent tuberculosis, 
dehydration , fever, convulsions, rectal prolapse, and malnutrition. Admit 
to hospital when complications are present. 
Pertussis  can be prevented by the “five-in-one” Immunisation  
recommended for all children (See section on ‘Immunisation’).
In the event of a child developing pertussis before immunisation, the 
“five in one” vaccine should still be given to protect against the four other 
diseases.
During epidemics, or when there is a clear history of contact in a 
child with catarrh, appropriate antibiotics may help reduce the period of 
infectivity and transmission. All cases should be reported to the District 
Disease Control Officer.
Cause
 y Bordetella pertussis  
Symptoms 
Catarrhal Phase: Initial 1-2 weeks 
 y Low grade fever
 y Nasal discharge
 y Mild cough
Paroxysmal phase: within the following 6-10 weeks 
 y Episodes of violent repetitive cough ending with inspiratory whoop 
or vomiting  (whoop may be absent in babies and adults)
Recovery (convalescent) phase: next 2-3 weeks
 y Gradual reduction in bouts of coughing
Signs
 y Apnoea  (long pause in breathing) common in babies
 y Cyanosis

— Pertussis  —Chapter 5:  Immunisable Diseases
85Investigations
 y FBC - high total lymphocyte count
 y Chest X-ray (to exclude other causes of chronic cough)
Treatment
Treatment objectives
 y To reduce transmission
 y To prevent complications
Non-pharmacological treatment
 y Feed frequently between coughing spasms
 y Encourage adequate oral fluid intake
Pharmacological treatment
A.     Patients and close contacts within 14 days of onset of symptoms 
1st Line Treatment
Evidence Rating: [A]
 y Erythromycin , oral, 
Adult s
500 mg 6 hourly for 7 days
Children  
8-12 years;  250-500 mg 6 hourly for 7 days
2-8 years;  250 mg of suspension 6 hourly for 7 days 
6 months-2 years; 125 mg of suspension 6 hourly for 7 days
< 6 months;  not recommended (risk of pyloric 
stenosis).  
Consider Trimethoprim/Sulphamethoxazole  instead. (See below).
Or
Evidence Rating: [B]
 y Azithromycin , oral,
Adult s
500 mg daily for 3 days
Children
10 mg/kg body weight daily for 3 days
(not recommended for children less than 6 months because of a risk 
of pyloric stenosis ). 
Consider Trimethoprim/Sulphamethoxazole  instead. (See below).
Or
Evidence Rating: [C]
 y Clarithromycin , oral,
Adult s
500 mg 12 hourly for 7 days 
Children
7.5 mg/kg 12 hourly for 7 days
2nd Line Treatment
Evidence Rating [C]
 y Trimethoprim/Sulphamethoxazole , oral,

— Tetanus —
Standard  Treatment Guidelines, 7th Edition, 2017
86Adult s
160/800 mg 12 hourly for 7 days  
Children
4/20 mg/kg 12 hourly for 7 days
B�     Oxygen  therapy when oxygen saturation <92%
 y Oxygen , intranasal or face mask, (if the patient has difficulty in 
breathing or is cyanosed)
Referral Criteria 
Refer infants who have an episode of apnoea or cyanosis after initial 
resuscitation to a specialist.
26� Tetanus
Tetanus  is a disease caused by a bacterium, which produces a 
neurotoxin responsible for the clinical features. These bacteria live 
predominantly in the soil, so it is easy to get this infection whenever a 
break in the skin is not cleaned properly. Tetanus-prone wounds include 
burns, puncture injuries, or those contaminated by soil/manure, septic 
wounds, and those with much devitalised tissue and compound fractures. 
The use of non-sterilised instruments or dressings on the umbilical cord 
predisposes to neonatal tetanus. The incubation period is 3-21 days. 
Tetanus  should be treated as a medical emergency. Tetanus 
immunisation is the key for prevention (See section on ‘Immunisation ’).
Cause 
 y Clostridium tetani  
Symptoms
 y Difficulty or inability to open mouth
 y Constipation
 y Stiff body
 y Spasms- these are painful and are triggered by noise, bright light or 
touch; spontaneous in severe cases.
Signs
 y Umbilicus may be infected
 y Presence of wound (but may have healed)
 y Irritability
 y Cyanosis  during spasms
 y Sardonic (mocking) smile
 y Lock jaw (cannot open the mouth)
 y Opisthotonus  (stiff arched back)
 y Rigid abdomen and stiff neck and limbs
Investigations
 y No confirmatory test (diagnosis is clinical)

— Tetanus —Chapter 5:  Immunisable Diseases
87Treatment 
Treatment objectives
 y To prevent further spasms
 y To eliminate Clostridium tetani  to stop further toxin production
 y To neutralise circulating toxin
 y To provide adequate hydration and nutrition
 y To provide supportive care till spasms cease completely 
Non-pharmacological treatment
 y Always admit a suspected case of tetanus 
 y Maintain a clear airway
 y Avoid noise, bright light and unnecessary physical examination of the 
patient
 y Clean the infected umbilicus or wound with soap and water or 
antiseptic solution (See section on ‘Wound management’)
 y Surgical debridement of the wound when necessary
Pharmacological treatment 
A. Eradication of bacteria in a patient diagnosed to have tetanus 
1st Line Treatment
Evidence Rating: [A]
 y Metronidazole , IV,
Adult s
500 mg 6 hourly for 7-10 days 
Children
> 1 month 7.5 mg/kg 8 hourly for 7-10 day 
Neonate s
> 7 days;  7.5 mg/kg 12 hourly
< 7 days;  7.5 mg/kg 48 hourly 
2nd Line Treatment
Evidence Rating: [B]
 y Benzylpenicillin , IV, 
Adult s
50,000 units/kg stat, then 4 MU 6 hourly for 5 days 
Children
50,000 units/kg 6 hourly for 5 days
Neonate s
250,000 units 6 hourly for 7 days 
And 
 y Gentamicin , IV, (neonates only), 4 mg/kg 24 hourly 
B. To neutralize free circulating toxin
Evidence Rating: [B]
 y Human Tetanus  Immunoglobulin, IM or IV, 
Adult s and Children
500 units stat.
Neonate s 

— Tetanus —
Standard  Treatment Guidelines, 7th Edition, 2017
88250 units stat.
And
 y Tetanus  Toxoid, IM, (inject at different site from Human Tetanus Im -
munoglobulin ) 
Adult s and Children
> 2 years;   0.5 ml stat. Repeat at 4-8 weeks (2nd dose) and at 
6-12 months (3rd dose)
< 2 years;   3 doses of Pentavalent vaccine at 
intervals of four weeks
C� To control spasms
Evidence Rating: [C]
Adults
 y Chlorpromazine , IM, 50 mg 4-8 hourly 
And 
 y Diazepam , IV or IM, (by slow IV at a rate of not more than 5 mg/
minute), 5-10 mg 3-6 hourly when required
Or
 y Phenobarbitone , IM, 200 mg 8-12 hourly, gradually reduce sedation 
after about 2 weeks 
Children
 y Chlorpromazine , IM or oral (via nasogastric tube), 12.5-25 mg 8 
hourly 
And 
 y Diazepam , IV/IM/nasogastric tube/suppository, 0.3 mg/kg 3-6 hourly 
when required (by slow IV at a rate of not more than 5 mg/minute)
Or
 y Phenobarbitone , IM or oral (via nasogastric Tube), 10 mg/kg stat., 
then 2.5 mg/kg 12 hourly 
Neonates
 y Chlorpromazine , IM or oral (via nasogastric tube), 7.5 mg 8 hourly 
And
 y Phenobarbital  (Phenobarbitone ), IM or oral (via nasogastric tube), 
30 mg stat. then 7.5 mg 12 hourly
Neonates-if spasms are not controlled with the above treatment
Add
 y Diazepam , rectal, 0.5 mg/kg 3-6 hourly when required
Box 5-2:   Tetanus Immunisation
 yStart Immunisation  before discharge from hospital in all patients because 
tetanus infection does not provide immunity against future episodes
 yAn adult who has received a total of 5 doses of tetanus toxoid is likely to 
have life-long immunity

— Poliomyelitis —Chapter 5:  Immunisable Diseases
89Box 5-2:   Tetanus Immunisation
 yA course of tetanus toxoid vaccinations should be given to any previously 
unimmunised patient older than 2 years of age. Dose: 0.5 ml, IM or deep 
SC, repeat at 4 weeks and 8 weeks (primary course) 
 yIf 10 or more years (5 or more years for children below age 15 years) have 
elapsed since primary course or last booster, give booster dose of 0.5 ml 
 yIn tetanus-prone wounds start the primary course in the non-immunised 
patient. A booster dose may be given if more than five years have elapsed 
since the last dose 
 ySurvivors of neonatal tetanus should follow the normal schedule for “Five-
in-One” (Penta-) vaccine
 yPreviously unimmunised children below the age of 2 years should receive 3 
doses of 5 in 1 at intervals of four weeks.
 yCut umbilical cord with sterile instrument, clean with methylated spirit (al -
cohol) and leave uncovered 
 yTo prevent tetanus in patients with potentially contaminated wounds (tet -
anus prone wound), provide adequate wound toileting (See section on 
‘Wounds’) and also provide tetanus prophylaxis
 yTetanus  Immunisation  in pregnancy (See section on ‘Antenatal Care ’)
Referral Criteria 
Refer patients to a specialist if spasms cannot be controlled.
27� Poliomyelitis
Poliomyelitis  is a viral disease, which is spread by faecal-oral or oral-
to-oral transmission. Insanitary disposal of excreta and use of unsafe 
drinking water contribute to the spread. The disease is characterised by 
varying degrees of acute flaccid paralysis, which commonly persists.
Paralysis commonly affects one lower limb but any group of skeletal 
muscles, including the muscles of respiration and bulbar cells in the brain 
may be affected.
Poliomyelitis  is commonly acquired in childhood. The infection is 
often sub-clinical and may only appear as a mild flu-like illness. Only few 
cases progress to develop paralysis. However, injections during periods of 
the febrile illness are associated with an increased incidence of paralytic 
poliomyelitis. 
Poliomyelitis  is preventable by Immunisation . Prevention is almost 
certain if 4 doses of oral polio vaccine are given as in the EPI schedule. 
Rarely Vaccine-Associated Paralytic Poliomyelitis (VAPP)  may occur in 
recipients of oral polio vaccines and their unimmunised contacts. This is 
usually associated with polio virus type 2. 
Note 5-1
All cases of poliomyelitis should be reported to the District Disease Control Of -
ficer for follow-up.

— Diphtheria —
Standard  Treatment Guidelines, 7th Edition, 2017
90Causes 
 y Poliovirus  serotypes 1, 2 or 3 
Symptoms
 y Fever
 y Headache
 y Sore throat
 y Muscle pain
 y Flaccid paralysis
Signs
 y Acute flaccid paralysis of affected muscles
 y Diminished or absent muscle reflexes
Investigations
 y Two fresh stool samples taken 24-48 hours apart (to be sent on ice 
to the Regional Public Health Reference Laboratory for confirmation)
Treatment 
Treatment objectives
 y To provide supportive care till patient recovers from acute illness
 y To avoid or limit the extent of paralysis
 y To provide rehabilitation in paralytic cases 
Non-pharmacological treatment
 y Bed rest
 y Avoid injections during febrile illness in children
 y Physiotherapy
 y Provision of appropriate appliances to aid mobility
Pharmacological treatment 
 y No specific antiviral treatment
Referral Criteria 
Refer all patients with difficulty in breathing and swallowing for 
hospital admission. 
28� Diphtheria
The bacteria responsible for this disease produces a toxin that 
damages human body tissues and organs. It commonly affects the tonsils 
and sometimes the skin causing ulcers. It is spread mainly by respiratory 
droplets from person to person, and less commonly through skin contact.
Infected patients may recover after initial symptoms and signs or 
develop severe weakness and die within 6-10 days. Complications may 
develop in the early phase of the disease or weeks later such as abnormal 
heartbeat and heart failure, damage to valves of the heart, or respiratory 
obstruction leading to death.  

— Diphtheria —Chapter 5:  Immunisable Diseases
91The disease is now uncommon because of immunisation. However, 
high immunisation coverage needs to be maintained to keep the disease 
under control because it has a high mortality rate.
Note 5-2
All cases of diphtheria should be reported to the District Disease Control Officer.
Causes 
 y Corynebacterium diphtheriae  
Symptoms
 y Sore throat
 y Loss of appetite
 y Slight fever
 y Dysphagia
 y Difficulty in breathing with or without stridor
Signs
 y Greyish white membrane or patch in the throat and on tonsils within 
2-3 days of the onset of symptoms. Membrane may bleed, become 
greyish green or black.  
Investigations
 y Throat/nasal swabs for culture for index case and close contacts
 y Repeat swabs after antibiotic treatment course (treatment may need 
to be extended).
Treatment 
Treatment objectives
 y To neutralise the effect of circulating antitoxins before they become 
fixed to the tissues 
 y To provide supportive care respiratory and feeding where indicated
 y To eradicate the organism from the pharynx
 y To prevent spread 
Non-pharmacological treatment
 y Bed rest
 y Feeding by nasogastric tube for patients who cannot swallow
 y Strict isolation of suspected patients
Pharmacological treatment 
A. All patients clinically diagnosed with diphtheria
Evidence Rating: [C]
 y Diphtheria  antitoxin , IV infusion, (following an intradermal test dose 
of 0.1 ml of 1 in 10 dilution of antitoxin in Sodium Chloride  0.9%)
Adult s
10,000 to 20,000 units
Children
> 10 years;   10,000-20,000 units

— Yellow Fever —
Standard  Treatment Guidelines, 7th Edition, 2017
92< 10 years;   5,000-10,000 units
Note 5-3
Reactions are common so resuscitation facilities should be available immedi -
ately
And
 y Benzyl Penicillin , IV,
Adult s
1.2 g 6 hourly for 48 hours
Children  and Neonate s   
1 month-18 years;  50 mg/kg 6 hourly for 48 hours
Then 
 y Amoxicillin , oral,
Adult s
1 g 12 hourly for 5 days
Children
5-18 years;   500 mg 12 hourly for 10 days
1-5 years;   250 mg 12 hourly for 10 days
1 month-1 year;  125 mg 12 hourly for 10 days
Or 
 y Azithromycin , oral,  
Adult s
500 mg daily for 5 days
Children  
10 mg/kg body weight daily for 5 days. 
Not recommended for children less than 6 months because of a risk 
of pyloric stenosis .
B.     All close contacts
 y Amoxicillin , oral, for 14 days (refer dosing above) 
Or 
For patients who may not tolerate penicillins:
 y Azithromycin , oral, for 5 days (refer dosing above)
Referral Criteria 
Refer patients with laryngeal obstruction or respiratory paralysis to 
an ENT specialist. 
29� Yellow Fever
Yellow fever is caused by a virus transmitted to man by a species of 
mosquitoes ( Aedes	aegypti ) from infected monkeys. The disease is not 
spread from person to person. Classical yellow fever is usually fatal. 
After the onset of symptoms, there is a brief remission of 2-24 
hours, following which the symptoms may recur with the development of 
epigastric pain, jaundice, renal insufficiency, cardiovascular instability and 

— Yellow Fever —Chapter 5:  Immunisable Diseases
93bleeding from various sites (e.g. gums and needle-puncture sites).
Yellow fever vaccination is protective against the disease and needs 
to be repeated every ten years. Yellow fever vaccination is a requirement 
for travel from Ghana to several countries. 
Note 5-4
All cases of yellow fever should be reported to the District Disease Control Of -
ficer. 
Causes 
 y Yellow fever virus
Symptoms
 y Fever
 y Muscle pain, particularly backache 
 y Headache
 y Shivering
 y Loss of appetite
 y Nausea  or vomiting
 y Diarrhoea
Signs
 y Congestion of the conjunctivae 
 y Jaundice
 y Bleeding  from various sites (petechiae , ecchymosis , etc.)
 y Right upper abdominal quadrant tenderness
 y Signs of renal failure
Investigations
 y Urinalysis - proteinuria and raised urobilinogen levels
 y Liver function test 
 y Blood urea, electrolytes and creatinine
 y Blood sample for yellow fever virus serology (at the Regional Public 
Health Reference Laboratory)
Treatment 
Treatment objectives
 y To provide supportive care for hepatic, renal and circulatory failure
 y To manage bleeding disorder
Non-pharmacological treatment
 y If yellow fever is suspected in a patient, admit immediately to an 
isolation ward
 y Full supportive treatment for hepatic failure and acute renal failure
Pharmacological treatment 
A. Antiviral therapy
 y There is no specific treatment

— Haemophilus Influenzae type b Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
94B.     For bleeding patients
 y Fresh frozen plasma  
Referral Criteria 
Refer to a hospital, preferably one with an isolation unit.
30� Haemophilus	Influenzae  type b Disease
The Haemophilus	 influenzae  type b (Hib) bacterium is an important 
cause of infections such as acute bacterial meningitis , pneumonia, acute 
epiglottitis and otitis media  in children less than 5 years old. Hib disease is 
not common beyond 5 years of age.
Hib infections are preventable by the five-in-one (penta-) vaccine 
(See EPI ‘Schedule for routine Immunisation of children under 5 years’).
Causes 
 yHaemophilus	influenzae  type b (Hib)
Symptoms
 y Fever
 y Other symptoms associated with pneumonia, otitis media , 
meningitis , septicaemia  
Signs
(See signs and symptoms of the specific diseases in other sections)
Investigations
 y Culture and sensitivity of appropriate body fluids (e.g. pus from the 
ear in suppurative otitis media , cerebrospinal fluid in meningitis , 
pleural aspirate in empyema , blood). 
Note 5-5
Blood culture is only relevant in invasive disease and would not be helpful in 
uncomplicated pneumonias.
Treatment 
Treatment objectives
 y To eliminate the bacteria 
 y To provide supportive care
Non-pharmacological treatment
 y Refer to relevant sections on the presenting illness e.g. meningitis , 
pneumonia 
Pharmacological treatment 
 y Refer to relevant sections on the presenting illness e.g. meningitis , 
pneumonia
Referral Criteria 
All patients who fail to show remarkable signs of improvement in 3 

— Pneumococcal Disease —Chapter 5:  Immunisable Diseases
95days following drug treatment, or present with complications should be 
referred for higher-level care.
31� Pneumococcal Disease
Pneumococcal disease presents more commonly as non-invasive 
disease in the form of non-bacteraemic pneumonia, middle-ear infections, 
sinusitis, or bronchitis. However, it may also manifest as Invasive 
Pneumococcal Diseases (IPD)  in the form of pneumonia with empyema  
and/or bacteraemia or meningitis  as a result of haematogenic spread.  In 
developing countries, non-bacteraemic pneumonia causes the majority 
of pneumococcal deaths. Ninety distinct serotypes have been identified.
Pneumococcal disease is effectively prevented with Pneumococcal 
Conjugate Vaccine (PCV)  at 6,10 and 14 weeks for infants. Pneumococcal 
Polysaccharide Vaccine (PPSV23)  is recommended for persons older than 
2 years with underlying medical conditions such as Sickle Cell Disease . 
Adults with immunocompromising conditions, functional or anatomic 
asplenia, cerebrospinal fluid leaks, or cochlear implants should receive 
PCV13 followed by PPSV23.
Causes 
 y Streptococcus  pneumoniae
Symptoms
 y Fever
 y Other symptoms associated with pneumonia, otitis media , 
meningitis , septicaemia  
Signs
 y Please refer to signs and symptoms of the specific diseases in other 
sections
Investigations
 y Culture and sensitivity of appropriate body fluids (e.g. pus from the 
ear in suppurative otitis media , cerebrospinal fluid in meningitis , 
pleural aspirate in empyema , blood). 
Note 5-6
Blood culture is only relevant in invasive pneumococcal disease and would not 
be helpful in uncomplicated pneumonias.
Treatment 
Treatment objectives
 y To eliminate the bacteria 
 y To provide supportive care
Non-pharmacological treatment
(See relevant sections on the presenting illness e.g. meningitis , 
pneumonia) 

— Hepatitis —
Standard  Treatment Guidelines, 7th Edition, 2017
96Pharmacological treatment 
(See relevant sections on the presenting illness e.g. meningitis , 
pneumonia)
Referral Criteria 
All patients who fail to show remarkable signs of improvement in 3 
days following drug treatment, or present with complications should be 
referred for higher-level care.
32� Hepatitis
(See section on ‘Acute and Chronic Hepatitis under Disorders of the 
Liver’)  
33� Rotavirus Disease
(See section on ‘Rotavirus Disease and Diarrhoea’ under Disorders of 
the Gastrointestinal Tract)  

6Chapter
97Problems of the Newborn 
(Neonate) 
34. Sick newborn  
The term newborn  (neonate ) refers to a baby in the first month of 
life. At birth all healthy newborns are active with a strong cry. Any baby 
born ill will show signs of poor activity or may be described as “being flat” 
or floppy in severe cases. The newborn with one or more abnormal vital 
signs is unwell. These include colour, activity, temperature, respiration, 
heart rate, blood sugar, urine output, nature of bowel movements, signs 
of distress (pain).
Causes 
 y Birth asphyxia
 y Prematurity
 y Neonatal infections
 y Congenital malformations e.g. heart, central nervous system, bowel 
etc.
 y Birth injury
 y Maternal sedation or analgesia during labour
 y Metabolic e.g. hypoglycaemia, hypocalcaemia
Symptoms
 y Weak cry or inability to cry
 y Difficulty in breathing or recurrent cessation of breathing (apnoea)
 y Reduced spontaneous movements or being very floppy
 y Refusal of feeds
 y Vomiting
 y Abdominal distension
 y Convulsions  
 y Blood in stools 
 y Reduced urine output
Signs
 y Raised body temperature (> 37.5 °C axillary )
 y Low body temperature (< 36.5 °C axillary)
 y Pallor
 y Cyanosis

— Sick newborn  —
Standard  Treatment Guidelines, 7th Edition, 2017
98 y Jaundice
 y Bradycardia  (< 100 beats/minute)
 y Tachycardia  (> 160 beats/minute)
 y Heart murmurs
 y Respiratory distress (> 60 breaths/minute, chest indrawing)
 y Respiratory rate < 20 breaths/minute 
 y Apnoea  
 y Abdominal distension
 y Drowsiness or unconsciousness
 y Seizures
 y Tenderness of any part of the body 
Investigations
 y FBC
 y Random blood glucose
 y Blood urea and electrolytes
 y Blood cultures
 y Urine culture
 y Swab of any lesions for culture and sensitivity
 y Chest X-ray
 y Plain abdominal X-ray, erect and supine if indicated
 y Cerebrospinal fluid biochemistry and culture and sensitivity
Treatment 
Treatment objectives
 y To diagnose and treat underlying cause appropriately
 y To identify and urgently correct hypoglycaemia 
 y To prevent permanent organ damage
Non-pharmacological treatment
 y Establish airway, ensure breathing and adequate circulation (ABC )
 y Keep baby warm either wrapped up in dry clothes or in an incubator 
Pharmacological treatment
Evidence Rating: [A]
A. Oxygen  Therapy
 y Oxygen  by face mask or nasal prongs, 1-2 L/minute if available, 
(monitor and maintain oxygen saturation between 92-95%)
B�     Maintenance Fluid
 y Dextrose  10%, IV, on day of delivery, 2 drops/minute/kg (60 ml/kg/
day)
 y Normal Saline  0.18% with Dextrose  10% (60-150 ml/kg/day after day 
1)
C.     Correction of Hypoglycemia
If hypoglycaemic, correct (See section on ‘Neonatal Hypoglycaemia’ )

— Sick newborn  —Chapter 6:  Problems of the Newborn (Neonate) 
99D�     For neonates having seizures (convulsions)
 y Phenobarbitone , IV/IM, 10 mg/kg stat. then 5 mg/kg 12 hourly
E�     To treat sepsis (other than cord sepsis)
 y Ampicillin , IM/IV,
Neonate s
> 7 days of age;  50 mg/kg 8 hourly for 5-7 days
< 7 days of age;  50 mg/kg 12 hourly for 5-7 days
And
 y Gentamicin , IM/IV, 4 mg/kg daily for 7 days (irrespective of age after 
birth)
Or
 y Ampicillin , IM/IV,
Neonate s
> 7 days of age;   50 mg/kg 8 hourly for 5-7 days
< 7 days of age;   50 mg/kg 12 hourly for 5-7 days
And
 y Cefotaxime , IV, 25-50 mg/kg 8 hourly for 7 days  (irrespective of age 
after birth)
F�      For cord sepsis
 y Cloxacillin , IM/IV,
Neonate s
> 7 days of age;  25-50 mg/kg 8 hourly
< 7 days of age;  25-50 mg/kg 12 hourly 
And
 y Gentamicin , IM/IV, 4 mg/kg 24 hourly for 7 days (irrespective of age 
after birth)
G�     For bowel related sepsis
 y Ampicillin , IM/IV,
Neonate s
> 7 days of age;  50 mg/kg 8 hourly for 5-7 days
< 7 days of age;  50 mg/kg 12 hourly for 5-7 days
And
 y Gentamicin , IM/IV, 4 mg/kg daily for 7 days (irrespective of age after 
birth)
And
 y Metronidazole, IV (over 20–30 minutes)
Neonate  
> 34 weeks corrected gestational age; 15 mg/kg as a single loading 
dose followed after 8 hours by 7.5 mg/kg every 8 hours
26-34 weeks corrected gestational age; 15 mg/kg as a single loading 
dose followed after 12 hours by 7.5 mg/kg every 12 hours
< 26 weeks corrected gestational age; 15 mg/kg as a single loading 

— Neonatal Hypoglycaemia   —
Standard  Treatment Guidelines, 7th Edition, 2017
100dose followed after 24 hours by 7.5 mg/kg daily 
Referral Criteria 
Refer the patient urgently to a specialist for further investigations 
and treatment if no improvement after 48 hours.
35� Neonatal Hypoglycaemia   
Neonatal hypoglycaemia refers to a random blood glucose level 
below 2.6 mmol/L in the newborn . 
As the clinical signs may be variable, or indeed absent, for small or 
sick babies or infants of diabetic mothers the random blood glucose level 
should be checked every three hours for the first 24 hours until it stays 
above 3.5 mmol/L for a further 24 hours. 
Neonatal hypoglycaemia may result in death if not promptly treated 
and should therefore be managed as soon as suspected. Successful 
treatment results in prompt response. To prevent hypoglycaemia, 
breastfeeding should be encouraged soon after birth. If the neonate  is 
unable to suck, a nasogastric tube may be passed and expressed breast 
milk given. If enteral feeds are contraindicated, intravenous fluids should 
be started immediately.
Causes 
 y Prematurity
 y Intra uterine growth retardation 
 y Baby born to a diabetic mother
 y Infection
 y Asphyxia  
Symptoms
 y Irritability and restlessness 
 y Tremors
 y Sweating 
 y Seizures  
 y Lethargy   
Signs
 y Sweating 
 y Tremor
 y Tachycardia  
 y Seizures  
 y Unconsciousness
Investigations
 y Random blood glucose (RBS) 
 y Using bed-side glucose meter
 y Check within 2 hours after birth and at regular 3 hourly intervals 
in infants at risk

— Neonatal Jaundice  —Chapter 6:  Problems of the Newborn (Neonate) 
101 y Other investigations depend on the suspected underlying cause
Treatment 
Treatment objectives
 y To maintain blood glucose levels within normal limits
 y To identify and treat underlying cause of hypoglycaemia 
 y To prevent complications e.g. brain damage  
Non-pharmacological treatment
 y Blood glucose monitoring ½ to 2 hourly in hypoglycaemic infants 
until normal levels attained
Pharmacological treatment
Evidence Rating: [A]
A.     Initial management 
 y Dextrose  10%, IV, 4 ml/kg as a bolus
B.     Maintenance treatment following immediately after initial man 
 agement 
 y Saline 0.18% in Dextrose  10%, 60-150 ml/kg/day depending on the 
age of the newborn  (See table below).
Table 6-1:   Maintenance fluid requirement
Day Premature Term
1 60 ml/kg/day 50 ml/kg/day
2 90 ml/kg/day 70 ml/kg/day
3 110 ml/kg/day 90 ml/kg/day
4 130 ml/kg/day 120 ml/kg/day
≥ 5 150 ml/kg/day 120 ml/kg/day
C.     Additional management 
Depends on the underlying cause.
Referral Criteria 
Refer to a specialist if patient does not respond promptly in spite of 
adequate treatment.
36� Neonatal Jaundice  
Jaundice  in the neonate  may be visible when the serum bilirubin  
level exceeds 100 micromol/L. Neonatal jaundice is important because 
of the consequences of hyperbilirubinaema on the brain of the newborn . 
This condition is called kernicterus  (bilirubin encephalopathy ) and may 
cause death. Infants who survive may be handicapped with cerebral palsy, 
and associated deafness, mental retardation and motor incoordination. 

— Neonatal Jaundice  —
Standard  Treatment Guidelines, 7th Edition, 2017
102Approximately 80% of newborns will be jaundiced in the first week of 
life and most of this is physiological. This occurs on day 3 and lasts up to 10 
days. This jaundice is mild and the baby remains healthy. 
Jaundice  in the neonate  is likely to be pathological if it is present 
within the first day of life; or conjugated (direct) bilirubin  is more than 
40 micromol/L; or total bilirubin is more than 170 micromol/L in preterm 
and more than 260 micromol/L in the term infant; or the neonate is 
significantly jaundiced beyond 14 days or has jaundice with fever. 
Exchange transfusion  is the definitive treatment for 
hyperbilirubinaemia  that has reached the level where kernicterus  may 
occur.
Causes 
 y Physiological
 y Haemolysis  - Rhesus , ABO  incompatibility, G6PD  deficiency
 y Blood extravasation - cephalhaematoma , subgaleal haematoma 
 y Sepsis
 y Congenital infections 
 y Liver disease 
 y Metabolic disorders - galactosemia, hypothyroidism
 y Enhanced extra hepatic circulation - GIT obstruction, inadequate 
feeding
 y Congenital defects of bilirubin  metabolism
 y Breast milk related jaundice
Symptoms
 y Yellow eyes
 y Yellow skin, hands and feet 
 y Pale stools (biliary atresia likely) 
Signs
 y Jaundice
 y Yellow pigment in skin
 y Yellow palms +/- yellow soles of feet  
 y Pale stools (biliary atresia likely) 
Investigations
 y Total and direct serum bilirubin  concentration 
 y Other investigations as below, dependent on age at presentation and 
suspected cause: 
Early onset (within first 24 hours of birth)
 y Blood group and rhesus (Rh) group of both infant and mother
 y Direct Coombs test, Indirect Coombs test, FBC, G6PD
 y Blood film for red cell anomalies, malaria parasites
 y Cultures of blood, urine, and spinal fluid may be indicated by the 
history, physical examination or initial laboratory findings
Prolonged jaundice (after 14 days)
 y Liver Function tests

— Neonatal Jaundice  —Chapter 6:  Problems of the Newborn (Neonate) 
103 y Thyroid Function tests 
 y Urine for reducing substances
 y Urine R/E and C/S
 y TORCH (congenital infections) screen
 y Hep B  
 y Abdominal ultrasound scan (exclude biliary atresia) 
Treatment 
Treatment objectives
 y To prevent kernicterus  (bilirubin  encephalopathy )
 y To detect and treat underlying cause
Non-pharmacological treatment
 y Phototherapy  (See note below on ‘Phototherapy’)
 y Exchange blood transfusion (See note below on ‘Exchange 
transfusion’)
Box 6-1:  Phototherapy
Phototherapy  is started if: 
 yJaundice  is visible on day 1
 yJaundice  involves palms and soles of feet
 yJaundice  in prematurity
 yAfter day 2, measured level of unconjugated bilirubin  is more than 170 mi -
cromol/L in preterm or more than 260 micromol/L in term neonate . 
A phototherapy unit with blue fluorescent tube lights is preferred. If unavail -
able, white fluorescent tubes may be used. The baby’s eyes must be covered 
but should be examined daily for any infection. Continue breastfeeding during 
this time. Ensure adequate fluid intake. Prevent hypothermia or hyperthermia. 
Phototherapy  should be continued till unconjugated bilirubin  levels remain be -
low phototherapy levels for at least 24 hours. 
Box 6-2:  Exchange transfusion
Use warm blood (37°C), cross-matched against maternal and infant serum (160 
ml/kg over 2-3 hours). Monitor heart rate, respiratory rate, bilirubin  and blood 
glucose levels during the procedure.  Further exchanges may be needed if the 
bilirubin level continues to rise. Stop the exchange transfusion if the heart rate 
fluctuates by more than 20 beats/minute.
Lower levels of bilirubin  than stated above should be considered for interven -
tion by phototherapy or exchange transfusion in the following cases: sick or low 
birth weight babies, or following asphyxia, prolonged hypoxemia, acidosis and 
sepsis.
Since there is no exact test to determine the risk of kernicterus , and hence the 
level at which exchange transfusion is necessary, the following rule of thumb 
has proved useful as a guide;

— Birth Injuries   —
Standard  Treatment Guidelines, 7th Edition, 2017
104 ySerum bilirubin  of more than 340 micromol/L in term infant more than 2 kg 
 yIn newborns weighing less than 2 kg, serum bilirubin  exceeding the follow -
ing would require exchange transfusion 
 y< 1 kg - 170 micromol/L
 y1-2 kg - 250 micromol/L
 yCord Hb < 12 g/dL or cord bilirubin  > 80 micromol/L
 yRapid progression of anaemia in presence of resolving jaundice
 yHydrops foetalis  (requires immediate exchange transfusion with packed 
cells )
Pharmacological treatment 
A.     Treatment of underlying sepsis
(See section on ‘the Sick Newborn’)
Referral Criteria 
Refer immediately, all babies who develop jaundice within 24 hours 
of life or who have prolonged jaundice to a paediatrician. 
Refer all patients requiring exchange transfusion to an appropriate 
facility.
37� Birth Injuries   
Birth injuries include extensive caput succedaneum, 
cephalhaematoma , subgaleal haemorrhage, nerve palsies and fractures. 
The presentation varies depending on type and site of injury. Excessive 
traction may result in injury to the brachial plexus and may be associated 
with fracture or injury of the humerus or shoulder joint.
Causes 
 y Difficult delivery (including instrumental delivery) 
Symptoms
 y Swelling of head
 y Inability to move a limb properly
 y Pallor
Signs
Extensive Caput Succedaneum  
 y Diffuse swelling of the presenting part of the scalp that may extend 
beyond cranial suture lines 
Cephalhaematoma  
 y Large swelling of the scalp that is restricted to one half and does not 
extend beyond the midline 
Subgaleal haemorrhage
 y Diffuse swelling of the scalp which may result in a distorted shape of 
the head and face
 y Severe pallor

— Birth Injuries   —Chapter 6:  Problems of the Newborn (Neonate) 
105 y Jaundice  
Nerve injuries
 y Erbs Palsy  - Whole upper limb does not move. There is movement 
only in the fingers
 y Klumpke’s Palsy  - Fingers of the affected hand do not move (claw 
hand) but there is active movement in the arm and forearm
Fractures  
 y Reduced movement of affected limb
 y Swelling of the affected limb
 y Abnormal position of limb
 y Pain and tenderness on movement of limb
Investigations
 y Haemoglobin level for subgaleal haemorrhage
 y Serum bilirubin  if jaundiced
 y X-ray of relevant part if fracture is suspected  
Treatment 
Treatment objectives
 y To arrest further bleeding 
 y To treat complications of anaemia and jaundice
 y To re-establish near normal movement in affected limb 
 y To promote normal healing of fracture
Non-pharmacological treatment
Extensive caput succedaneum
 y Reassure parents
 y Leave swelling alone (spontaneous resolution over 3-4 days)
Cephalhaematoma
 y Reassure parents 
 y Leave swelling alone (spontaneous resolution with time)
 y Do not perform incision and drainage 
 y Phototherapy  if jaundiced
Subgaleal Haemorrhage
 y Phototherapy  if jaundice levels require this (See section on ‘Neonatal 
Jaundice ’)
Nerve injuries
 y Physiotherapy
Fractures
 y May require splinting
Pharmacological treatment 
A. Cephalhaematoma  and Subgaleal haematoma
To reduce bleeding 
Evidence Rating: [A]

— Neonatal conjunctivitis   —
Standard  Treatment Guidelines, 7th Edition, 2017
106 y Phytomenadione  (Vitamin K ), IM, 1 mg stat. even if baby received a 
dose at birth
To correct Anaemia  if Hb < 12 gm/dl
 y Blood transfusion , 15-20 ml/kg 
Referral Criteria 
Refer severe cases to an appropriate specialist facility.
38� Neonatal conjunctivitis   
Neonatal conjunctivitis  or ophthalmia neonatorum is an acute 
purulent conjunctivitis during the first month of life. It is usually contracted 
from infected genital secretions of the mother. 
Cleaning of the neonate ’s eyes immediately after birth and the 
application of 1% tetracycline ointment into the eyes, is effective in 
preventing the condition. This must be implemented as a policy in all 
health facilities in which child deliveries are undertaken.
Causes 
 y Neisseria gonorrhoea
 yChlamydia	trachomatis
 y Staphylococci
 y Streptococci
 y Herpes Simplex  virus
 y Chemical e.g. silver nitrate  
Symptoms
 y Eye discharge
 y Swelling of the eye lids
Signs
 y Eye discharge, which may be purulent
 y Redness and swelling of the conjunctivae
 y Oedema and redness of the eyelids
Investigations
 y Conjunctival swabs for Gram staining and culture 
Treatment 
Treatment objectives
 y To treat the infection
 y To prevent blindness 
Non-pharmacological treatment
 y Clean the eyelids frequently (every 2 hours) with cotton wool dipped 
in sterile saline solution. In the absence of sterile saline solution, use 
boiled water that has been left to cool

— Neonatal conjunctivitis   —Chapter 6:  Problems of the Newborn (Neonate) 
107Pharmacological treatment 
A.     Treatment of baby
Evidence Rating: [B]
 y Ceftriazone, IM or IV, 50 mg/kg stat. (max. 125 mg) 
Or
 y Cefotaxime, IM, 100 mg/kg stat.
And
 y Erythromycin, oral, 12.5 mg/kg 6 hourly for 14 days
And
 y Chloramphenicol  eye drops, 0.5% applied to each eye every 2 hours 
for 48 hours (after cleaning away discharge-saline irrigation)
Then
 y Chloramphenicol  eye drops, 0.5% applied to each eye 6 hourly 
And 
 y Chloramphenicol  eye ointment, 1% applied to each eye at night 
B�     Treatment of mother 
Evidence Rating: [A]
 y Ceftriazone,IM, 250 mg stat.                                                       
And
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
C�     Treatment of mother’s partner(s) for gonorrhoea and chlamydia
 y Ceftriazone, IM, 250 mg stat.
Or
 y Cefixime, oral, 400 mg stat.
Or
 y Ciprofloxacin, oral, 500 mg stat.
And
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
Or 
 y Azithromycin, oral, 1 g stat.
Referral Criteria 
Refer all neonates with corneal involvement and or severe neonatal 
conjuctivitis not responding to treatment to a paediatrician and or an 
ophthalmologist.

— Retinoblastoma  —
Standard  Treatment Guidelines, 7th Edition, 2017
10839� Retinoblastoma  
Retinoblastoma  is a congenital malignant tumour originating from 
the retina of the eye. This tumour may be hereditary, particularly the 
bilateral form which forms about 30% of cases. Most tumours however 
are sporadic (spontaneous mutation). This is the third commonest cancer 
seen amongst children in Ghana. Most children present before five 
years of age. It rarely occurs in older children. The prognosis with early 
presentation is excellent with a 95% chance of long term cure. There is 
a high rate of development of tumours of other organs later in life in the 
hereditary form.
Causes 
 y Genetic (up to 40% of cases)
 y Sporadic  (in about 60% of cases) 
Symptoms
 y White, shiny spot (leukocoria) in the pupil, also known as the cat’s 
eye reflex is usually the first symptom in most patients
 y Squint  (strabismus )
 y Visual loss 
 y Protruding eyeball 
 y Redness of the eye  
Signs
 y Absent red reflex
 y Tumour in the retina on fundoscopy
 y Vitreous haemorrhage and retinal detachment on fundoscopy
 y Increased intraocular pressure (glaucoma)
 y Orbital cellulitis  
Investigations
 y Ultrasound scan of orbit
 y Head CT or MRI scan 
 y Lumbar puncture for cerebrospinal fluid cytology
 y Bone marrow aspirate 
Treatment 
Treatment objectives
 y To arrest the progression of the tumour
 y To prevent distant spread of tumour
 y To achieve long term cure
 y To provide adequate supportive and palliative care in advanced 
disease  
Non-pharmacological treatment
 y Enucleation of the affected eye is curative in the early stages 
 y Prosthetic eye insertion 

— Retinoblastoma  —Chapter 6:  Problems of the Newborn (Neonate) 
109 y Laser therapy for focal control
 y Radiotherapy for local spread of the tumour
 y Counselling to help cope with psychological impact of the disease  
Pharmacological treatment 
A.     Intraocular and extraocular retinoblastoma
Chemotherapy
Evidence Rating: [A]
 y Vincristine , IV,
 y Etoposide , IV,
 y Carboplatin , IV,
Or  
 y Vincristine , IV,
 y Etoposide , IV,
 y Cyclophosphamide , IV,
B.     Advanced disease with intracranial metastases
Palliative care with adequate pain and other symptom control
(See section on palliative care)
C.     For treatment of vomiting  
Evidence Rating: [A]
 y Metoclopramide , IV or oral, 100-400 microgram/kg 8 hourly
Or
 y Granisetron , IV, 40 microgram/kg (max. 3 mg) stat.
May repeat 12 hourly if necessary
Or
 y Granisetron , oral, 
20 microgram/kg (max. 1 mg) within 1 hour before start of treatment 
Then  
20 microgram/kg 12 hourly for up to 5 days
Or
 y Ondansetron , IV,
Adult
5 mg/m2 stat. 
Repeat 8 hourly if necessary
Children  
12-18 years;  8 mg stat. (immediatley before chemotherapy)
Or
 y Ondansetron , oral,
Adult  
8 mg 8 hourly, administared 30 minutes before the start of chemo -
therapy 
Children
12-18 years;  8 mg 8-12 hourly up to 5 days
1-12 years;   4 mg 8-12 hourly up to 5 days

— Wilms Tumour  —
Standard  Treatment Guidelines, 7th Edition, 2017
110D�     For treatment of febrile neutropenia
 y Ceftriaxone , IV, 100 mg/kg daily
And
 y Gentamicin , IV, 5 mg/kg daily
And (if still febrile after 48 hours, add)
 y Cloxacillin , IV, 25-50 mg/kg 6 hourly
And (if still febrile after 5 days, add)
 y Fluconazole , oral, 10 mg/kg daily
E�     For treatment of anaemia and thrombocytopenia
 y Blood and blood product transfusions 
(See section on ‘Bleeding disorders’)
Referral Criteria 
All patients should be referred to a tertiary centre that can effectively 
treat retinoblastoma. 
40. Wilms Tumour  
Wilms tumour (nephroblastoma ) is a malignant embryonal tumour 
of renal tissue. It is the fourth commonest cancer amongst children 
in Ghana. About 80% of children with Wilms tumour present before 5 
years of age. It can present soon after delivery. It may be associated with 
congenital anomalies such as hemihypertrophy  and the absence of the 
iris (aniridia ). Wilms tumour  has a very good prognosis with an over 80% 
chance of long-term cure. 
Causes 
 y Sporadic gene mutation
Symptoms
 y Visible and or palpable abdominal mass
 y Fever
 y Blood in urine 
Signs
 y Abdominal mass (palpate with care to prevent rupture or 
dissemination)
 y Haematuria  (macroscopic or microscopic)
 y Hypertension
 y Associated congenital anomalies 
Investigations
 y Abdominal ultrasound scan
 y Abdominal CT scan
 y Chest X-ray 
 y Full Blood Count
 y Blood Urea, electrolytes and creatinine 

— Wilms Tumour  —Chapter 6:  Problems of the Newborn (Neonate) 
111Treatment 
Treatment objectives
 y To obtain long term cure
 y To provide adequate supportive and palliative care
Non-pharmacological treatment
 y Nephrectomy
 y Radiotherapy post-surgery for advanced cases 
Pharmacological treatment 
A.     Pre-operative treatment
1st Line Treatment
Evidence Rating: [A]
 y Vincristine , IV,
And
 y Actinomycin D , IV,
And
 y Doxorubicin , IV, (if presence of metastases)
B.     Post-operative treatment
Evidence Rating: [A] 
 y Vincristine , IV,
And
 y Actinomycin D , IV,
And
 y Doxorubicin , IV, (depending on stage and risk category)
Or  
 y Carboplatin , IV, 
 y Etoposide , IV, 
 y Doxorubicin , IV, Cyclophosphamide  IV in combination (For high risk 
tumours)
C.     For treatment of vomiting  
Evidence Rating: [A]
 y Metoclopramide , IV or oral, 100-400 microgram/kg 8 hourly
Or
 y Granisetron , IV, 40 microgram/kg (max. 3 mg) stat.
May repeat 12 hourly if necessary
Or
 y Granisetron , oral, 20 microgram/kg (max. 1 mg) within 1 hour before 
start of treatment 
Then  
20 microgram/kg 12 hourly for up to 5 days
Or
 y Ondansetron , IV,
Adult s
5 mg/m2 stat. 
Repeat 8 hourly if necessary

— Wilms Tumour  —
Standard  Treatment Guidelines, 7th Edition, 2017
112Children  
12-18 years; 8 mg stat. (immediatley before chemotherapy)
Or
 y Ondansetron , oral,
Adult s 
8 mg 8 hourly, administared 30 minutes before the start of chemo -
therapy 
Children
12-18 years;  8 mg 8-12 hourly up to 5 days
1-12 years;   4 mg 8-12 hourly up to 5 days
D�     For treatment of febrile neutropenia
 y Ceftriaxone , IV, 100 mg/kg daily
And
 y Gentamicin , IV, 5 mg/kg daily
And (if still febrile after 48 hours, add)
 y Cloxacillin , IV, 25-50 mg/kg 6 hourly
And (if still febrile after 5 days, add)
 y Fluconazole , oral, 10 mg/kg daily
E�     For treatment of anaemia and thrombocytopenia
 y Blood and blood product transfusions 
(See section on ‘Bleeding disorders’)
Referral Criteria 
All patients should be referred to specialist centres for appropriate 
treatment.

7Chapter
113Disorders of the 
Cardiovascular System
41. Chest Pain
Chest pain is a common patient complaint and must be treated as 
a medical emergency until proven otherwise as there are several life-
threatening underlying causes. The top priority is to exclude or promptly 
treat serious cardiac and non-cardiac causes. A good history and 
examination is very helpful in this endeavour. 
Causes 
Common Cardiac
 y Stable Angina
 y Acute Coronary Syndrome
 y Pericarditis
Non-cardiac
 y Gastro-oesophageal reflux disease
 y Pulmonary Embolus (PE)
 y Pneumonia
 y Peptic Ulcer  
 y Oesophageal spasm
 y Pleural effusion
Others to consider
 y Aortic dissection
 y Mitral valve prolapse  (other valvular problem) 
 y Coronary vasospasm
 y Sickle cell disease  - acute chest syndrome
 y Hiatus hernia
 y Oesophageal tear with mediastinitis
 y Biliary tree disease
 y Costochondritis
 y Nerve root compression
 y Cardiac neurosis /DaCosta’s syndrome  
 y Herpes Zoster

— Chest Pain —
Standard  Treatment Guidelines, 7th Edition, 2017
114Symptoms
Myocardial 
IschaemiaAortic 
DissectionPericarditis Pleuritic Pain Peptic 
painMusku -
lo-skeletal 
pain
Quality of 
PainCrushing, 
tight, heavy 
or band-likeTearing Sharp Sharp Burning Sharp or dull 
Site of Pain Central 
anterior 
chestCentral Central 
anteriorAnywhere in 
chestCentral Anywhere 
on chest 
wall
Radiation To throat, 
jaw, arms or 
nowhereBack Usually no 
radiationUsually none To throat 
occasion -
allyTo arms 
or around 
chest to 
back
Exacerbat -
ing FactorsExertion, 
anxiety , 
cold None lying supine, Exacerbated 
by inspira -
tion, coughin,Spicy 
food, 
alcohol Pressure 
on chest 
or moving 
neck
Relieving 
FactorsRest, 
nitratesNone Sitting 
forwardNone Bland 
food and 
antacidsRestriction 
of move -
ment
Associated 
featuresNausea , 
vomiting , 
sweating, 
dyspnoea, 
shockShock, 
cyanosis, 
sweating, right 
& left arm BP 
difference, 
new aortic 
regurgitation 
murmurFever , recent 
viral illnessCough , 
haemoptysis, 
dyspnoea 
and shock (in 
massive PE)Bloating, 
windPatient looks 
well
Signs
 y Shock, pallor, sweating - MI, Dissecting aneurysm, PE
 y Dyspnoea  - MI with LVF, PE, Pneumonia
 y Blood pressure 
 y Normal or high 
 y Low - suggests cardiogenic shock  
 y Difference > 30 mmHg between arms suggests aortic dissection
 y Pulse - rate high, low or normal; regular or irregular
 y Murmurs - consider valvular heart disease 
 y Pericardial rub - suggests pericarditis
 y Unequal chest expansion - pneumonia and pneumothorax
 y Reduced/absent breath sounds - pneumothorax
 y Bronchial breathing - pneumonia
 y Pleural rub - consider pneumonia, PE 
 y Abdominal (epigastric) tenderness - Peptic Ulcer  Disease
 y Guarding - perforated ulcer, peritonitis
 y Reduced bowel sounds - paralytic Ileus
 y Chest wall tenderness - musculo-skeletal cause
Investigations 
(See sections for specific disease conditions) 

— Ischaemic Heart Disease   —Chapter 7:  Disorders of the Cardiovascular System
115Treatment 
Treatment objectives
 y Symptomatic relief of chest pain
 y Reassurance to minimise anxiety
 y Treatment of underlying cause (See sections for specific disease 
conditions)
Non-pharmacological treatment
(See sections for specific disease conditions) 
Pharmacological treatment 
(See sections for specific disease conditions)
Referral Criteria 
Persistent unexplained chest pain . 
42. Ischaemic Heart Disease   
Ischaemic heart disease  is a condition whereby there is reduced 
blood supply to the heart muscle. It comprises of stable angina pectoris 
and the acute coronary syndromes. 
STABLE ANGINA PECTORIS
Stable angina pectoris is pain or discomfort that occurs in the 
front of the chest, and may radiate to the neck, shoulders, jaw or arms. 
The chest pain  is typically induced by exertion or emotional stress and 
relieved by rest or glyceryl trinitrate. Individuals who experience stable 
angina pectoris are at a high risk of developing acute coronary syndromes 
or a heart attack. Risk factors include diabetes mellitus, hypertension, 
cigarette smoking, plasma lipid abnormalities, obesity, family history of 
heart disease and persistently elevated markers of inflammation such as 
C-reactive protein .
Risk factors for this condition include obesity, diabetes mellitus, 
hypertension, smoking, hyperlipidaemia.
Causes 
 y Atherosclerosis  with narrowing of the coronary blood vessels 
 y Spasms of the coronary arteries 
Symptoms
 y Central or precordial chest pain  
 y May radiate into the left arm, neck or jaw
 y Relieved by rest 
 y Relieved by glyceryl trinitrate
Signs
 y No typical signs
Investigations
 y 12-lead ECG

— Ischaemic Heart Disease   —
Standard  Treatment Guidelines, 7th Edition, 2017
116 y Cardiac enzymes: creatinine kinase-MB (CK-MB ) and troponins
 y Blood glucose
 y Blood lipid profile
 y FBC
 y Chest X-ray
 y Stress ECG
 y Echocardiography
 y Coronary angiography
Treatment 
Treatment objectives
 y To minimise symptoms
 y To prevent progression to acute coronary syndromes 
 y To identify and manage modifiable risk factors
 y To improve quality of life
Non-pharmacological treatment
 y Educate and reassure patient 
 y Healthy lifestyle modifications
 y Diet
 y Exercise
 y Weight management 
 y Reduction in alcohol consumption
 y Avoid or quit smoking 
Pharmacological treatment 
A.     Treating the acute chest pain
Evidence Rating: [A]
 y Glyceryl trinitrate , sublingual, 500 microgram stat. then as required 
And
 y Aspirin , oral, 300 mg stat. then 75 mg daily
Or
 y Clopidogrel , oral, 300 mg stat. then 75 mg daily 
And 
 y Atenolol , oral, 50-100 mg daily 
Or
 y Bisoprolol , oral, 5-10 mg daily 
Or
 y Metoprolol , oral, 50-100 mg 8-12 hourly
Note 7-1  
Avoid betablockers in bronchial asthma, bradycardia, and hypotension; avoid 
atenolol in heart failure.
Or
 y Verapamil , oral, 80-120 mg 8 hourly 

— Ischaemic Heart Disease   —Chapter 7:  Disorders of the Cardiovascular System
117Note 7-2  
Avoid in bradycardia, hypotension and in patients already on beta-blockers
 y Optimise or initiate treatment for hypertension
 y Optimise or initiate treatment for diabetes mellitus
 y Use statins to treat abnormal blood lipids to target levels
B�     If beta blockers or verapamil are contraindicated
 y Isosorbide dinitrate , oral, 10 mg 8-12 hourly
Referral Criteria 
Refer the following patients
 y Those with no significant improvement in symptoms after the initial 
treatment above
 y Those with worsening risk factors
Flowchart
Fig 7-1:  Flowchart: Angina Pectoris
ACUTE CORONARY SYNDROME  
Acute Coronary Syndrome  (ACS) is a term that describes symptoms 
resulting from severe acute myocardial ischaemia. The ischaemia may, 
or may not, lead to myocardial infarction (heart attack). ACS is classified 


— Ischaemic Heart Disease   —
Standard  Treatment Guidelines, 7th Edition, 2017
118as ST segment elevation on an electrocardiogram (ST-segment elevation 
myocardial infarction - STEMI ) or a non-ST-segment elevation myocardial 
infarction (NSTEMI ) and unstable angina (an ACS without elevation of 
cardiac enzymes). The risk factors for ACS are identical to those for, and 
include previous episodes of, stable angina pectoris. 
Risk factors for this condition include obesity, diabetes mellitus, 
hypertension, smoking and hyperlipidaemia.
Causes
 y Atherosclerosis  or obstruction of the coronary blood vessels leading 
to reduction in blood supply to the heart muscle
Symptoms
 y Chest pain  
 y Sudden onset
 y Varying degree but often severe and described as tightness, 
heaviness or constrictive in nature.
 y Persisting for more than 30 minutes
 y Not relieved by rest or glyceryl trinitrate  
 y May radiate to the left arm, the neck or jaw
 y Nausea
 y Vomiting
 y Shortness of breath or fatigue (this may be the only presentation in 
diabetics and the elderly)
 y Loss of consciousness
Signs
 y Restlessness and apprehension
 y Excessive sweating
 y Peripheral or central cyanosis
 y Pulse may be thready, fast, irregular, slow or normal
 y Blood pressure may be high, low or unrecordable (following extensive 
damage to heart muscle)
 y Bilateral crepitations in the chest (with left ventricular failure) 
 y Presence of a third or fourth heart sound (suggests heart failure)
 y Confusion in the elderly
Investigations
 y Standard 12 lead ECG
 y Cardiac enzymes: CK-MB , troponins  T and I
 y Myoglobin 
 y Serum lipid profile
 y Chest X-ray
 y Random blood glucose
 y FBC, ESR
 y Serum uric acid
 y Blood urea, electrolytes and creatinine 
 y C-reactive protein

— Ischaemic Heart Disease   —Chapter 7:  Disorders of the Cardiovascular System
119 y Echocardiography
 y Coronary angiography
Treatment
Treatment objectives
 y To relieve distress and pain
 y To limit infarct size
 y To prevent and treat complications
 y To reverse cardiac remodelling
 y To prevent re-infarction
 y To identify and manage modifiable risk factors
 y To improve quality of life
Non-pharmacological treatment
 y Reassure patient and encourage bed rest in the first 48 hours
 y Encourage cessation of smoking
 y Ensure weight reduction (in overweight and obese individuals) in the 
long term
Pharmacological treatment 
A.     Initial treatment on admission 
Evidence Rating: [A]
 y Oxygen , intranasal, by face mask or nasal cannula
And
 y Aspirin , oral (chewable), 300 mg stat. 
And
 y Clopidogrel , oral, 300 mg stat.
And
 y Glyceryl trinitrate , sublingual, 500 microgram stat.
And
 y Morphine , IV, 5-10 mg stat.
And
 y Metoclopramide , IV, 10 mg stat. (to prevent vomiting  induced by 
morphine )
B.     Maintenance treatment following immediately after initial 
treatment 
 y Aspirin , oral, 75-300 mg daily indefinitely
And 
 y Clopidogrel , oral, 75 mg daily (patients who receive revascularisation 
therapy will require treatment for up to 12 months)
C.     Anticoagulation  
 y Enoxaparin , SC, 1 mg/kg (100 units/kg) 12 hourly 
D.     Prevention of cardiac arrhythmias and reduction of myocardial 
workload
 y Atenolol , oral, 25-100 mg daily (avoid only if beta-blockers are con -

— Ischaemic Heart Disease   —
Standard  Treatment Guidelines, 7th Edition, 2017
120traindicated)
Or 
 y Bisoprolol , oral, 5-20 mg daily 
Or 
 y Metoprolol , oral, 50-100 mg 8-12 hourly
And
 y Lisinopril , oral, 2.5-20 mg daily 
Or 
 y Losartan , oral, 25-50 mg daily 
Or 
 y Candesartan , oral, 4-16 mg daily
And 
In patients with STEMI :
 y Fibrinolytic agents may be given as reperfusion therapy in patients 
presenting with STEMI  under specialist care. 
 y Manage acute complications such as pulmonary oedema, cardiogenic 
shock  and cardiac arrhythmias 
 y Manage hyperglycaemia with insulin. Change diabetic patients 
previously on oral hypoglycaemic agents to insulin 
E.     Long-term treatment (secondary prevention)
 y Aspirin , oral, 75-150 mg daily indefinitely
And
 y Atenolol , oral, 25-100 mg daily (avoid only if beta-blockers are con -
traindicated)
Or 
 y Bisoprolol , oral, 5-20 mg daily 
Or 
 y Metoprolol , oral, 50-100 mg 8-12 hourly
F�     To prevent cardiac remodelling and improve survival
 y Lisinopril , oral, 2.5-20 mg daily 
Or
 y Losartan , oral, 25-50 mg daily 
Or 
 y Candesartan , oral, 4-16 mg daily 
Note 7-3
Avoid ACE inhibitors and Angiotenin receptor blockers in patients with BP < 100 
mmHg
G�    To stabilise the clot and reduce blood cholesterol levels
 y Atorvastatin , oral, 20-40 mg daily 
Or 
 y Rosuvastatin , oral, 10-20 mg daily 
Or 

— Dyspnoea —Chapter 7:  Disorders of the Cardiovascular System
121 y Simvastatin , oral, 40-80 mg daily. Statins are indicated irrespective 
of lipid levels 
H.     To improve coronary dilatation and reduce myocardial workload
 y Isosorbide dinitrate , oral, 10 mg 8-12 hourly
I.      Control of hypertension and hyperglycaemia, if present
(See appropriate sections) 
Referral Criteria 
All patients with suspected ACS require an urgent ECG. If ECG is not 
available or cannot be interpreted, refer immediately to a higher facility.
Patients with confirmed STEMI  in any facility should be referred 
urgently to a Physician Specialist or Cardiologist for reperfusion therapy 
(after an initial oral dose of 300 mg of aspirin ).
Other patients with N-STEMI  and unstable angina should be referred 
to a physician specialist or cardiologist after the initial management 
above. 
43. Dyspnoea
Dyspnoea  is an uncomfortable awareness of one’s own breathing. 
It is often the main symptom of cardiopulmonary disease although the 
differential diagnosis extends beyond these two systems. Dyspnoea of 
sudden onset should be treated as a medical emergency.
Causes 
 y Cardiac
 y Heart Failure
 y Coronary Heart Disease
 y Valvular Heart Disease  - mitral stenosis, aortic stenosis
 y Cardiac Arrhythmias
 y Pericardial effusion
 y Respiratory
 y Pneumonia
 y Pulmonary Embolus (PE)
 y Obstructive lung disease - Chronic Obstructive Pulmonary Dis -
ease (COPD) , Asthma
 y Restrictive lung disease - Intestitial lung disease eg cryptogenic 
fibrolysing alveolitis and the occupational lung diseases
 y Pneumothorax
 y Pleural Effusion
 y Chest wall function limitation - myopathy, neuropathy, kypho -
scoliosis
 y Other
 y Anaemia
 y Psychogenic hyperventilation
 y Acidosis - e.g. uraemia, Diabetic Ketoacidosis , drug overdose

— Dyspnoea —
Standard  Treatment Guidelines, 7th Edition, 2017
122 y Foreign body aspiration
 y Massive abdominal distension 
Symptoms
 y Breathlessness
 y Quality 
 y continuous or intermittent 
 y exertional - suggests cardiopulmonary cause 
 y positional - suggests paroxysmal nocturnal dyspnoea, or -
thopnoea and a cardiac cause 
 y nocturnal - suggests cardiac or bronchial asthma
 y Time since onset - recent (acute) or longstanding (chronic)
 y Duration of episode(s) 
 y minutes to hours - suggests asthma, pneumothorax, pul -
monary oedema, pneumonia, pulmonary oedema, ana -
phylaxis
 y weeks to months - suggests pleural effusion, pericardial 
effusion, pulmonary fibrosis, lung cancer, recurrent PE, 
cardiac failure, anaemia, neuromuscular disease, tuber -
culosis
 y years - COPD , lung fibrosis
 y Associated features 
 y cough (suggests acute heart failure, pneumonia)
 y sputum, haemoptysis
 y wheeze (asthma, heart failure)
 y ankle oedema (heart, kidney, liver)
Signs
 y Fever - pneumonia, less commonly PE
 y Pallor - severe anaemia acute heart failure, PE, myocardial infarction 
or cardiogenic shock
 y Sweating - acute heart failure, pneumonia, PE, myocardial infarction
 y Clubbing - infections, cyanotic congenital heart disease, lung fibrosis
 y Cyanosis  - hypoxia e.g. in COPD , heart failure, PE, pneumonia etc.
 y Peripheral oedema - heart, liver or renal failure
 y Wheeze - heart failure or bronchial asthma
 y Barrel shaped chest - COPD
 y Ascites  - cardiac, renal, gastrointestinal, hepatic or intra-abdominal 
lesion
 y Pulse - fast (suggests tachyarrhythmia, PE) or slow (bradyarrhythmia)
 y Blood pressure - may be high, normal or low
 y Heart murmurs - valvular heart disease
 y Other signs - features of pneumonia, pneumothorax, pleural effusion
Investigations
 y Full Blood Count 
 y Urea, Electrolytes, Creatinine 
 y Chest X-ray 

— Deep Vein Thrombosis (DVT) —Chapter 7:  Disorders of the Cardiovascular System
123 y ECG 
 y Pulse oximetry 
 y Peak flow rate measurement
 y Cardiac enzymes, Troponin  T, CK-MB  if ischaemic heart disease is 
suspected
 y Echocardiogram 
 y Lung Function Tests (spirometry) 
 y CT pulmonary angiogram useful for confirming PE
Treatment 
Treatment objectives
 y Treat underlying cause - see relevant chapters
 y Maintain oxygen saturation above 95% - caution if there is underlying 
COPD , as these patients are dependent on hypoxic drive
Non-pharmacological treatment 
 y Based on underlying cause. (See relevant sections)
Pharmacological treatment 
 y Based on underlying cause. (See relevant sections)
Referral Criteria 
Refer to the next level of care if cause cannot be identified
44. Deep Vein Thrombosis  (DVT )
Deep Vein Thrombosis (DVT ) is a common disease although often 
asymptomatic. The deep veins of the lower limbs are affected most 
commonly, but thrombosis may affect other sites, including the upper 
limbs, intracranial and splanchnic veins. Complications include pulmonary 
thromboembolism , which can be life-threatening. It is therefore essential 
to have a reliable method for establishing the DVT risk of patients and to 
take active steps to provide prophylactic treatment as necessary. Common 
risk factors for DVT include obesity, smoking, prolonged immobility (e.g. 
bed rest, long haul flights), major surgery e.g. orthopaedic, abdominal 
and pelvic surgery, pregnancy and the puerperium , after caesarean 
section, malignancies, inherited blood disorders, oestrogen therapy  and 
medical conditions, e.g. congestive cardiac failure, myocardial infarction, 
nephrotic syndrome, stroke , systemic lupus erythematosus. 
In cases of confirmed DVT , treatment with anticoagulants must not 
be delayed unnecessarily unless there are significant contraindications to 
their use such as recent intracerebral bleed, severe liver disease, active 
peptic ulcer, bleeding disorders, and severe hypertension. 
Causes 
 y Stagnation of blood in the vein
 y Increased viscosity of blood 
 y Inflammation of the blood vessel causing damage

— Deep Vein Thrombosis (DVT) —
Standard  Treatment Guidelines, 7th Edition, 2017
124Symptoms
 y Swelling or firmness of affected limb (usually unilateral)
 y Pain in the affected limb
 y Mild fever
Signs
 y Swelling of affected limb
 y Differential warmth
 y Tenderness
 y Redness 
 y Pitting oedema
 y Prominent superficial veins
Box 7-2:  Well’s Scoring for DVT probability
The Well’s scoring system for DVT  probability objectifies clinical suspicion of 
DVT risk and provides criteria for initiating treatment.  
The presence or absence of the clinical features below are computed to give a 
pre-testing probability score for that particular patient which is used to priori -
tise investigation and treatment. 
 yParalysis, paresis or recent orthopedic casting of lower extremity (1 point)
 yRecently bedridden (more than 3 days) or major surgery within past 4 
weeks (1 point)
 yLocalized tenderness in deep vein system (1 point)
 ySwelling of entire leg (1 point)
 yCalf swelling 3 cm greater than other leg (measured 10 cm below the tibial 
tuberosity) (1 point)
 yPitting oedema greater in the symptomatic leg (1 point)
 yCollateral non varicose superficial veins (1 point)
 yActive cancer or cancer treated within 6 months (1 point)
 yAlternative diagnosis more likely than DVT  (Baker’s cyst, cellulitis, muscle 
damage, superficial venous thrombosis, post phlebitic syndrome, inguinal 
lymphadenopathy, external venous compression) (-2 points)
Table 7-1:  Well’s Score Interpretation for DVT
3-8 Points: High probability of DVT
1-2 Points: Moderate probability
-2-0 Points: Low Probability
Low probability: D-Dimer test  is recommended. Low pre-test probability combined with a neg -
ative D-Dimer test essentially rules out a DVT .
Moderate or High Probability: D-Dimer test  with additional Doppler/compression ultra sound 
scan is recommended.
Investigations
 y D-Dimer test
 y Doppler ultrasound  
 y Thrombophilia screen e.g. protein C, protein S levels (in patients with 
recurrent DVT ) 
 y FBC  

— Deep Vein Thrombosis (DVT) —Chapter 7:  Disorders of the Cardiovascular System
125Treatment 
Treatment objectives
 y To prevent clot propagation and pulmonary embolism
 y To prevent recurrence 
Non-pharmacological treatment
 y Avoidance of prolonged recumbency and dehydration
 y Avoidance of excess amounts of coffee, tea and alcohol, especially 
on long journeys
 y Increase water intake during long journeys or periods of immobility
 y Regular exercise during long journeys e.g. stopping on road journeys 
to take a walk or moving about on a plane during long flights and leg 
flexing exercises while seated
 y Avoid crossing legs for long periods on long journeys
 y Use of elastic compression stockings 
Pharmacological treatment
A.     DVT  Prophylaxis
1st Line treatment
Evidence Rating: [A]
 y Heparin , SC, 
Adult s
5,000 units 8-12 hourly 
Children  
1 month-18 years; 250 units/kg 12 hourly 
2nd Line Treatment
Evidence Rating: [A]
 y Enoxaparin , SC, 
Adult s
40 mg daily 
Children  
2 months-18 years;      500 microgram /kg 12 hourly (max 40 mg)
1-2 months;               750 microgram /kg 12 hourly 
B�     DVT  Treatment
1st Line Treatment
Evidence Rating: [A]
 y Heparin , SC, 
Children  
1 month-18 years; 250 units /kg 12 hourly 
Or 
 y Heparin , IV, 
Adult s
80 units/kg stat. continue with 18 units/kg / hour
Or 
250 units/kg, SC, continue with 250 units /kg 12 hourly

— Deep Vein Thrombosis (DVT) —
Standard  Treatment Guidelines, 7th Edition, 2017
126Children  
1-18 years; 75 units/kg stat. continue with 20 units/kg/hour
1 month-1 year; 75 units/kg stat. continue with 25 units/kg/ hour
Neonate s (term baby); 75 units/kg stat. continue with 25 units/kg/
hour
Neonate s (< 35 weeks); 50 Units /kg stat. continue with 25 units/
kg/hour
2nd Line Treatment
Evidence Rating: [A]
 y Enoxaparin , SC, 
Adult s
1.5 mg/kg (150 units/kg) daily
Children  
2 months-18 years; 1 mg/kg 12 hourly
1-2 months;  1.5 mg/kg 12 hourly 
Neonate s;  1.5-2 mg/kg 12 hourly 
Or
 y Dalteparin , SC,
Adult s
200 mg/kg (max. of 18,000 units) daily
Children  
12-18 years;     200 units/kg once daily (max 18,000 units 
daily)
1 month-12 years; 100 units/kg 12 hourly 
Neonate s;  100 units/kg 12 hourly 
And 
 y Warfarin , oral,
Adult s 
Loading Dose
DAY DOSE INR
1 10 mg -
2 10 mg -
3 5 mg Check INR
Note 7-4  
Wafarin is not to be given in pregnancy.
Continue 5 mg daily INR  until a target INR of 2 to 3 is achieved. After this the 
low molecular weight heparin  is stopped and a maintenance warfarin  dose of 
2.5 mg to 5 mg (some patients may require 7.5 mg) is continued guided at all 
times by a target INR of 2 to 3.
Long-term treatment requires continuation of warfarin  for three to six months 
if the risk factor is temporary or unknown. Recurrent DVT  and permanent risk 
factors such as thrombophilia may require long-term anticoagulation .

— Pulmonary Embolism —Chapter 7:  Disorders of the Cardiovascular System
127Referral Criteria 
Refer to physician specialist for management and monitoring. 
45. Pulmonary Embolism
Pulmonary Embolism (PE) results from thrombi, often from the deep 
veins of the lower limbs or pelvis, which are transported via the right heart 
into the pulmonary vasculature. Large emboli may cause obstruction to 
blood flow and result in life-threatening hypoxia and high mortality. PE 
should therefore be managed as a medical emergency. 
The risk factors and management for PE are similar to those for DVT .   
(See section on ‘DVT’). 
Causes 
(See section on ‘DVT’)
Symptoms
 y Dyspnoea
 y Pleuritic pain
 y Cough
 y Haemoptysis  (due to pulmonary infarction)
 y Presyncope, syncope or collapse (massive PE)
 y Unilateral swelling of a limb
Signs
 y Tachypnoea
 y Tachycardia  (may be regular or irregular)
 y Blood pressure - low/unrecordable (suggests massive PE), normal or 
high
 y Pleural effusion  
 y Low oxygen saturation on pulse oximetry <90%
 y Pleural rub
 y Cyanosis
 y Unilaterally swollen calf or thigh of DVT
Box 7-3:   Well’s scoring for PE probability
 ySymptoms of DVT  (3 points)
 yNo alternative diagnosis better explains the illness (3 points)
 yTachycardia  with pulse > 100 (1.5 points)
 yImmobilization (>= 3 days) or surgery in the previous four weeks (1.5 points)
 yPrior history of DVT  or pulmonary embolism (1.5 points)
 yPresence of hemoptysis (1 point)
 yPresence of malignancy (1 point)
 

— Pulmonary Embolism —
Standard  Treatment Guidelines, 7th Edition, 2017
128Table 7-2:  Well’s Score Interpretation for PE
Score > 6: High probability
Score >= 2 and <= 6: Moderate probability
Score < 2: Low Probability
Low probability: D-Dimer test  is recommended.
Moderate or High Probability: D-Dimer test  with additional CT Pulmonary angiogram is rec -
ommended.
Investigations
 y Chest X-ray 
 y ECG 
 y D-Dimer 
 y CT Pulmonary angiogram
 y Echocardiography
 y Doppler Ultrasound of the affected limb and pelvis
 y FBC
Treatment 
Treatment objectives
 y To stabilise cardio-respiratory function
 y To prevent further clot formation and embolisation
 y To prevent recurrence and development of pulmonary hypertension
Non-pharmacological treatment
 y Elevate affected leg on a pillow if DVT  present
 y Apply compression stockings - after pain subsides if DVT  present
 y Surgical techniques e.g. embolectomy, inferior vena caval filters etc.
Pharmacological treatment 
A.     Clinical suspicion of pulmonary embolus
1st Line Treatment 
Evidence Rating: [A]
 y Oxygen , by face mask or nasal prongs or via non-rebreather mask 
(keep oxygen saturation > 95%)
And
 y Morphine , IV, 5-10 mg stat. 
And
 y Enoxaparin , SC, 
Adult s
1.5 mg/kg (150 units/kg) daily
Or
 y Dalteparin , SC, 
Adult
200 mg/kg (max. 18,000 units) daily

— Stroke —Chapter 7:  Disorders of the Cardiovascular System
129 y Warfarin , oral, simultaneously (NOT in pregnancy)
Adult s 
Loading Dose
DAY DOSE INR
1 10 mg -
2 10 mg -
3 5 mg Check INR
Note 7-5
Continue 5 mg daily INR  until a target INR of 2 to 3 is achieved. After this the 
low molecular weight heparin  is stopped and a maintenance warfarin  dose of 
2.5 mg to 5 mg (some patients may require 7.5 mg) is continued guided at all 
times by a target INR of 2 to 3.
Long-term treatment requires continuation of warfarin  for three to six months if 
the risk factor is temporary or unknown. Recurrent embolisms and permanent 
risk factors such as thrombophilia requires long term anticoagulation .
Referral Criteria 
Refer all patients with suspected pulmonary embolism, where 
facilities are unavailable for confirmation, to a physician specialist or 
cardiologist for expert management after stabilisation.
46. Stroke
A stroke  can be defined as a sudden global or focal neurological 
deficit resulting from spontaneous haemorrhage or infarction of the 
central nervous system, with objective evidence of an infarction or 
haemorrhage, irrespective of the duration of clinical symptoms. A CT or 
MRI scan is required to make the diagnosis and exclude other intracranial 
lesions that could present similarly.
A Transient Ischaemic Attack (TIA ), on the other hand, is a transient 
episode of neurologic dysfunction caused by focal brain, spinal cord, or 
retinal ischemia. There is no objective evidence of acute infarction in the 
affected region of brain or retina. 
In adults, hypertension, diabetes, dyslipidaemia, atrial fibrillation  
and smoking, increase the risk for strokes. In children sickle cell disease 
and cyanotic heart disease are important risk factors for strokes.
Patients should ideally have multidisciplinary care.
Causes 
 y Cerebral infarction 
 y Thrombosis of a cerebral vessel 
 y Embolism from a distant site (e.g. atrial fibrillation )
 y Intracerebral haemorrhage
 y Subarachnoid haemorrhage

— Stroke —
Standard  Treatment Guidelines, 7th Edition, 2017
130Symptoms
 y Weakness of one side of the body including the face
 y Inability to rise up from a sitting or lying position
 y Sudden fall/collapse
 y Loss of speech
 y Loss of vision
 y Severe headache and/or neck pain (subarachnoid haemorrhage )
 y Unconsciousness  in some patients
 y Seizures  
Signs
 y Paralysis of a limb 
 y Facial paralysis (lower half)
 y Initial flaccidity of limbs, but later spasticity and exaggerated reflexes 
 y Hemianopia  (loss of one-half of visual field)
 y Hemi-anaesthesia (loss of sensation of one-half of body) 
 y Extensor plantar response
 y Dysarthria /dysphasia  (alteration of speech)
 y Neck stiffness (in subarachnoid haemorrhage )
Investigations
 y FBC, ESR
 y Blood glucose
 y Serum lipid profile
 y Blood urea, electrolytes and creatinine
 y Uric acid
 y ECG
 y CT scan/MRI of the head 
 y Chest X-ray
Treatment 
Treatment objectives
 y To limit the area of brain damage
 y To protect patients from the dangers of unconsciousness and 
immobility
 y To prevent aspiration
 y To treat the underlying cause if possible
 y To identify and manage modifiable risk factors (hypertension, high 
cholesterol, diabetes mellitus etc.)
 y To institute measures to improve functional recovery
 y To support and rehabilitate patients who survive with residual 
disability
 y To minimise adverse effects of drug therapy
Non-pharmacological treatment
 y Admit and monitor patient`s vital signs and neurological signs 
frequently (4 hourly)

— Stroke —Chapter 7:  Disorders of the Cardiovascular System
131 y Establish adequate airway in unconscious patients
 y Swallowing test in an upright position (use 10-15ml of water)
 y Insert nasogastric tube as early as possible for feeding and 
medications in unconscious patients or those with swallowing 
difficulties to prevent aspiration
 y Nurse in the lateral position with suctioning where necessary 
 y Elevate head of bed to 30 degrees to reduce intracranial 
pressure 
 y Prevent pressure sores by regular turning (every 2 hours) in bed
 y Maintain adequate hydration 
 y Keep patient clean and dry by frequent use of bedpan/urine pot, 
diapers, condom catheter as required. Urethral catheter should be 
used only if absolutely necessary
 y Start physiotherapy as soon as practicable
Pharmacological treatment 
A.     Infarctive Strokes  and TIA s
1st Line Treatment
Evidence Rating: [B]
 y Aspirin , oral, 
Adult s 
300 mg stat.
Then  
75 mg daily
Children
> 16 years; same as adult dose
< 16 years; not recommended
And
 y Atorvastatin , oral, 
Adult s 
40-80 mg daily
Children  
Not recommended 
Or 
 y Rosuvastatin , oral, 
Adult s 
20-40 mg daily
Children  
Not recommended 
B�     Haemorrhagic Stroke  with evidence of cerebral oedema present
1st Line Treatment
Evidence Rating: [B]
 y Mannitol , IV, 
Adult s
0.5-1 g/kg 6 hourly (up to 2 g/kg per dose)

— Stroke —
Standard  Treatment Guidelines, 7th Edition, 2017
132Children
1 month-18 years; 0.5-1.5 g/kg Or 2.5-7.5 ml/kg of 20% solution
(See treatment flowchart for acute medical management of stroke 
below)
C.     Control of co-morbidities (e.g. hypertension, diabetes etc.)
(See appropriate sections)
Referral Criteria 
Patients with worsening symptoms and signs should be urgently 
referred for specialist evaluation and care.  All stable patients with 
neurological deficits should be referred to a speech therapist, occupational 
therapist or physiotherapist as appropriate. 
Flowchart
Fig 7-4:  Flowchart: Stroke
Table 7-3:   Treatment flowchart for acute medical management of stroke
History and 
examinationIdentify risk factors, site and extent of the stroke     
Consider sources of embolism
Investigations FBC, Urine R/E, BUE, +Cr, Fasting glucose, Fasting cholesterol, 
CT Scan, CXR, ECG
Hydration Aiming for euvolaemia (2.5-3 L per day on average) 
Use normal saline or dextrose saline
Avoid dextrose 5% or 10% unless hypoglycaemic.

— Stroke —Chapter 7:  Disorders of the Cardiovascular System
133Table 7-3:   Treatment flowchart for acute medical management of stroke
Stress ulcer 
prophylaxisGive proton pump inhibitor
Glucose control Keep RBS (4-10) mmol/L
May need insulin sliding scale to control or supplement oral 
medications (avoid oral metformin if diabetic)
Pyrexia If > 37.5 oC manage with regular paracetamol  to control pyrexia
Consider source (chest, urine, malaria, other) and manage 
accordingly
Blood pressure 
managementOften rises as direct result of stroke  and may partially settle 
with no action.  If > 180/110 mmHg aim for gradual reduction 
of no more than 20% over 24 hours. Continue pre-stroke 
medication if indicated. DO NOT USE SUBLINGUAL NIFEDIPINE.  
Sudden reduction in BP can lead to extension of stroke.  
Treatment of infarcts Start aspirin  300 mg stat as soon as infarct identified via (oral/
NG) if no contraindications.  Reduce dose to 75 mg daily after 1 
week, and consider further anti-platelet medication.  
Atrial Fibrillation Consider rhythm control for acute onset; anticoagulation  
Mobilisation of 
patientsEarly referral of all patients to the physiotherapist (even if 
unconscious)
Aspiration 
pneumoniaLook for signs of this regularly (rising respiratory rate, 
tachycardia, chest signs).  Treat with IV Amoxicillin + Clavulanic 
Acid and IV metronidazole for first 48 hours then review 
DVT and Pulmonary 
embolism Prophylactic heparin  if infarct detected on CT scan 
Seizures Terminate seizures as per protocols.  Regular anticonvulsant if 
more than one seizure occurs
Change in conscious 
levelUrgently consider possibilities such as; cerebral oedema/
hypoglycaemia/metabolic/drug causes that can be reversed
Rising ICP Nurse at 30 degrees head up, IV mannitol +/- Dexamethasone   
as required
High cholesterol Start high dose statins as per guidelines

— Heart Failure —
Standard  Treatment Guidelines, 7th Edition, 2017
13447. Heart Failure
This is a condition in which the heart is unable to produce adequate 
cardiac output, and in so doing, is unable to meet the body’s metabolic 
requirements.  The cardiac dysfunction may predominantly involve the 
left or the right ventricle individually or both ventricles simultaneously. 
This later case is termed Biventricular Failure (BVF)  or Congestive Cardiac 
Failure (CCF) . 
The functional classification of heart failure using the New York Heart 
Association (NYHA ) Classification  is described in the table below.
Table 7-4:   New York Heart Association (NYHA) Classification for Heart 
Failure
CLASS I No limitation of physical activity. Ordinary physical activity does not 
cause undue fatigue, palpitation, or dyspnoea
CLASS II Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in fatigue, palpitation or Dyspnoea
CLASS III Marked limitation of physical activity. Comfortable at rest, but slight 
activity causes fatigue, palpitation or dyspnoea
CLASS IV Unable to carry out any physical activity without discomfort. 
Symptoms of cardiac insufficiency are present at rest. If any physical 
activity is undertaken, discomfort is increased
Causes 
 y Systemic arterial hypertension
 y Rheumatic heart disease
 y Cardiomyopathies
 y Severe anaemia
 y Ischaemic heart disease
 y Thyrotoxicosis
 y Congenital heart disease
 y Pulmonary arterial hypertension
 y Cardiac arrhythmia
Symptoms
Left Heart Failure
 y Breathlessness 
 y On exertion
 y On lying flat (orthopnoea)
 y At night (paroxysmal nocturnal dyspnoea)
 y Easy fatiguability
 y Cough  with frothy blood-stained sputum
 y Wheezing 
Right Heart Failure
 y Swelling of the feet and lower extremities (may be absent in children 
below 6 months)
 y Abdominal swelling 

— Heart Failure —Chapter 7:  Disorders of the Cardiovascular System
135 y Right hypochondrial pain from an enlarging liver
Signs
Left Heart Failure
 y Tachypnoea
 y Tachycardia  
 y Basal crepitations
 y Gallop rhythm
 y Displaced apex beat
 y Cardiac murmur
 y Rhonchi
Right Heart Failure
 y Tachycardia  
 y Pitting pedal oedema (may be absent in children below 6 months)
 y Ascites
 y Tender, smooth, soft hepatomegaly
 y Raised jugular venous pressure
 y Gallop rhythm
 y Cardiac murmur
In children
 y Failure to thrive
 y Difficulty in feeding
Investigations
 y FBC
 y ECG
 y Chest X-ray
 y Blood urea, electrolytes and creatinine and eGFR (estimated 
glomerular filtration rate)
 y Liver function test 
 y Fasting blood sugar
 y Fasting lipids
 y Echocardiography
 y Thyroid function tests
 y Cardiac enzymes, if myocardial infarction is suspected 
 y Coronary angiography
Treatment 
Treatment objectives
 y To relieve symptoms and improve quality of life
 y To treat the precipitating cause
 y To treat complications
 y To prevent recurrence of symptoms
 y To reduce need for hospital re-admissions
 y To reduce mortality
Non-pharmacological treatment
 y Reduce salt intake

— Heart Failure —
Standard  Treatment Guidelines, 7th Edition, 2017
136 y Reduce weight in overweight and obese individuals
 y Avoid alcohol
 y Avoid or quit smoking
 y Encourage moderate exercise 
 y Bed rest (only in acute heart failure or exacerbations of chronic heart 
failure)
 y Prop up in bed
Pharmacological treatment 
A.     Acute heart failure  - initial treatment
1st Line Treatment
Evidence Rating: [A]
 y Oxygen , by nasal cannula or face mask if there is hypoxaemia (SpO2 
< 90%)
And
 y Furosemide , IV, 
Adult s
40-80 mg, repeat after 30 minutes if necessary
Children  
12-18 years;   20-40 mg repeated 8 hourly as necessary 
1 month-12 years;  0.5-1 mg/kg repeated 8 hourly (max 4 mg/
kg/dose)
B.     Acute heart failure  - maintenance treatment after stabilisation
 y Furosemide , IV, 
Adult s
40-80 mg 12 hourly
Children  
12-18 years;   20-40 mg repeated 8 hourly as necessary 
1 month-12 years;  0.5-1 mg/kg repeated 8 hourly (max 4 mg/
kg/dose)
C.     Acute heart failure  - patient not improving after initial treatment
 y Furosemide  (Frusemide), IV, 
Adult s
40-80 mg 12 hourly 
Children  
12-18 years;   20-40 mg repeated 8 hourly as necessary 
1 month-12 years;  0.5-1 mg/kg repeated 8 hourly (max 4 mg/
kg/dose)
And
 y Morphine , IV, 
Adult s
5-10 mg slowly 
Children  
Not recommended for this condition as safety is not well established 
And 

— Heart Failure —Chapter 7:  Disorders of the Cardiovascular System
137 y Metoclopramide , IV, 
Adult s
10 mg to prevent vomiting
Children  
Not required
D.     Acute heart failure  - patient improving after initial treatment
 y Furosemide , oral, 
Adult s
40-80 mg 12 hourly
Children  
0.5-2 mg/kg 8-12 hourly 
E.      Acute heart failure  - patient with fast atrial fibrillation  or in sinus 
rhythm with systolic dysfunction
Evidence Rating: [C]
 y Digoxin , oral, 
Elderly
125 micrograms 12 hourly for 24-48 hours
Adult s
250 micrograms 12 hourly for 24-48 hours
Then  
250 micrograms daily
Then  
125 micrograms daily 
Children  > 10 years
0.5-1 mg in 3 divided doses over 24 hours
Then
62.5-250 microgram daily
Children  2-10 years
20-30 microgram/kg in 3 divided doses over 24 hours
Then
8-10 microgram/kg daily 
Children  < 2 years
30-40 microgram/kg in 3 divided doses over 24 hours
Then
10-12 microgram /kg daily  
Neonate s (full term)
20 microgram/kg in 3 divided doses in 24 hours
Then
8-10 microgram/kg daily 
Neonate s ( < 1.5 kg)
25 microgram/kg in 3 divided doses in 24 hours
Premature
15 microgram/kg daily
Then
5 microgram/kg daily

— Heart Failure —
Standard  Treatment Guidelines, 7th Edition, 2017
138F.      Acute heart failure  - patients in cardiogenic shock  (adult 
systolic blood pressure <85 mmHg) with hypotension and or 
hypoperfusion 
 y Dobutamine , IV infusion, 
Adult s
2.5-10 micrograms/kg per minute
Note 7-6
ECG should be monitored continuously because inotropic agents can cause ar -
rhythmias and myocardial ischaemia
G.     Prophylactic anticoagulation  against venous thrombosis
 y Enoxaparin , SC, 
Adult s
1.5 mg/kg (150 units/kg) daily
Children  
2 months-18 years; 1 mg/kg 12 hourly
1-2 months;  1.5 mg/kg 12 hourly 
Neonate s;  1.5-2 mg/kg 12 hourly 
 y Identify and treat (if possible) precipitating causes such as 
hypertension, myocardial infarction, anaemia or thyrotoxicosis
H.     Symptomatic Heart Failure  
1st Line Treatment
 y Furosemide , oral,  
Evidence Rating: [C]
Adult s
40-80 mg daily  
Children
1-2 mg/kg daily
And
 y Lisinopril , oral, 
(only when systolic blood pressure > 100  mmHg) 
Evidence Rating: [A]
Adult s
2.5-20 mg daily
Or
 y Ramipril , oral, 
(only when systolic blood pressure > 100 mmHg )  
Evidence Rating: [A]
Adult s
2.5-10 mg daily
And
 y Carvedilol , oral,
Evidence Rating: [A]
Adult s 
3.125-12.5 mg 12 hourly (maximum 25mg 12 hourly)

— Heart Failure —Chapter 7:  Disorders of the Cardiovascular System
139Or
 y Bisoprolol , oral, 
Evidence Rating: [A]
Adult s
1.25-10 mg daily
Or
 y Metoprolol , oral,
Evidence Rating: [A]
Adult s
25-100 mg daily
I.      Patients not tolerating ACE inhibitors (replace Lisinopril  or 
Ramipril  with the following in the 1st line treatment above)
 y Losartan , oral,
Evidence Rating: [A]
Adult s          
25-50 mg daily
Or
 y Candesartan , oral, 
Evidence Rating: [A]
Adult s          
4-16 mg daily
J.      Patients with fast atrial fibrillation  or in sinus rhythm with systolic 
dysfunction;
Add 
 y Digoxin , oral,  
Evidence Rating: [B]
Elderly
125 micrograms 12 hourly for 24-48 hours, 
Then  
125 micrograms 24 hourly 
Adult s
250 micrograms 12 hourly for 24-48 hours, 
Then  
250 micrograms once daily
Children
5 micrograms/kg 12 hourly
K.     Symptomatic patients, inspite of the above medications
And 
 y Spironolactone , oral,                                                   
Evidence Rating: [A]
Adult s         
25-50 mg daily
Referral
All patients must be referred to a specialist when clinically stable 

— Congenital Heart Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
140for the identification and treatment of the underlying cause of the heart 
failure and for long-term maintenance therapy.
Flowchart 
Fig 7-5:  Flowchart: Heart Failure
48. Congenital Heart Disease
Congenital malformation of the heart, commonly referred to as 
“Hole-in-Heart ”, is quite a common malformation with an incidence of 
8 out of 1000 live births. There are two main groups of congenital heart 
disease namely, acyanotic and cyanotic. The acyanotic types include 
ventricular septal defect, atrial septal defect, patent ductus arteriosus 
as well as aortic stenosis, pulmonary stenosis and coarctation of the 
aorta.  The cyanotic types are associated with a mixing of deoxygenated 
blood with oxygenated blood and include Tetralogy of Fallot (TOF)  and 
Transposition of the Great Arteries (TGA) . 
Early recognition of the specific type and appropriate medical or 
surgical intervention is important in improving the quality of life and 
reducing morbidity from complications.
Causes 
 y Idiopathic 
 y Genetic (higher risk with increasing maternal age)

— Congenital Heart Disease —Chapter 7:  Disorders of the Cardiovascular System
141 y Maternal infections due to viruses in early pregnancy, notably rubella 
 y Maternal diabetes
 y Alcohol, smoking, and use of drugs during early pregnancy
 y Exposure to X-rays and other radiation during early pregnancy
 y Prematurity
 y Multiple pregnancy
Symptoms
Acyanotic
 y Easy fatiguability
 y Breathlessness
 y Poor feeding/Interruption of sucking in babies during feeding
 y Poor growth
 y Cold sweat on forehead
 y Puffy eyelids, swollen feet (however, these are uncommon in infants)
 y Distended abdomen 
 y Exertion may lead to chest pains, syncope or sudden death   
Cyanotic
 y All symptoms of acyanotic heart disease, plus the following:
 y Blue tongue and fingernails (cyanosis) at birth or becoming worse 
with exertion in older children
 y Squatting several times during play in toddlers 
Signs
Acyanotic
 y Signs of heart failure for moderate to severe lesions:
 y Cold sweaty skin 
 y Puffy eyelids
 y Distended neck veins and ankle oedema (in 
 y older children) 
 y Tachycardia  
 y Tachypnoea  
 y Weak thready pulse
 y Cardiomegaly
 y Gallop rhythm 
 y Crepitations, rhonchi
 y Hepatomegaly
 y Heart murmur (not always present)
Cyanotic
 y Signs of heart failure as above, plus
 y Finger clubbing 
 y Cyanosis  (low peripheral oxygen saturation measured by pulse 
oximetry)
 y Heart murmur
 y Hypercyanotic attack  i.e. respiratory distress with deepening 
cyanosis, loss of consciousness and convulsions 

— Congenital Heart Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
142Investigations
 y FBC
 y Chest X-ray 
 y ECG 
 y Echocardiography
Treatment 
Treatment objectives
 y Early recognition of the problem
 y Prompt treatment of heart failure 
 y Early surgical correction if indicated
 y Prevention of endocarditis 
Non-pharmacological treatment
 y Ensure good nutrition, good oral and dental hygiene
 y Avoid excessive physical exertion  (notify parents and teachers)
Pharmacological treatment 
A.     Symptomatic congenital heart disease
Evidence Rating: [C]
 y Oxygen , by face mask or nasal prongs, 2 L/minute if available, 
(monitor oxygen saturation)
Note 7-7
For patients in heart failure or with hypercyanotic attack
B.     Treatment of heart failure in symptomatic congenital heart disease
(See section on ‘Heart Failure’)
C.     To improve blood flow into the lungs for patients with Tetralogy of 
Fallot
 y Propranolol , oral,
Children  1 month-12 years 
0.25-1 mg/kg 6-8 hourly (max. 5 mg/kg daily)
Neonate s
0.25-1 mg/kg 8-12hourly (max. 2mg/kg 8 hourly) 
 y Propranolol , slow IV with ECG monitoring,
Children  1 month - 12 years
15-20 microgram/kg 6-8 hourly (max. 200 microgram/kg) repeated 
every 6-8 hours if necessary
Neonate s
15-20 microgram/kg (max. 100 microgram/kg) repeated every 12 
hours if necessary 
D.     Congenital heart disease with hypercyanotic attack  
(See section on ‘Hypercyanotic Attack’)

— Hypercyanotic attack —Chapter 7:  Disorders of the Cardiovascular System
143Referral Criteria 
Refer all children with congenital heart disease to a paediatric 
cardiologist or paediatrician for further clinical assessment and 
management.
49. Hypercyanotic attack
This is a life threatening paediatric cardiac emergency. 
It usually occurs in infants with a peak incidence between 4 and 6 
months. A severe episode may lead to limpness, seizures, cerebrovascular 
accident or even death. Spells may be brief (1-2 minutes) and self-correct 
or may progress to a severe, life-threatening episode. Prompt recognition 
by parents and medical staff is important. The attack is often early in the 
morning with no apparent reason. It may be precipitated following a bath, 
by prolonged crying, defaecation, dehydration , febrile illness or induction 
of anaesthesia.
Causes 
 y Congenital heart disease e.g. Tetralogy of Fallot, pulmonary stenosis, 
double outlet right ventricle, tricuspid atresia, Eisenmenger 
syndrome
Symptoms
 y Irritability and prolonged crying 
 y Deep rapid breathing
 y Increased severity of cyanosis
Signs
 y Tachycardia  
 y Systolic murmur 
 y Coma
 y Convulsions  
 y Hemiparesis
Investigations
 y FBC
 y Chest X-ray 
 y ECG 
 y Echocardiography
Treatment 
Treatment objectives
 y To recognise the problem early
 y To reverse obstruction 
 y To correct metabolic derangement in severe hypoxia
 y To prevent complications and death from severe hypoxia
Non-pharmacological treatment
 y Hold in knee chest position (teach parents)

— Hypercyanotic attack —
Standard  Treatment Guidelines, 7th Edition, 2017
144 y The above actions increase peripheral vascular resistance and help 
to reduce cyanosis.
Pharmacological treatment 
A.     All children with hypercyanotic attack
Evidence Rating: [C]
 y Oxygen  (100%), by face mask or nasal prongs, 
2 L/minute (monitoring oxygen saturation if possible)-to all patients 
to reduce hypoxia
And  
 y 0.9% Normal Saline  or Ringers’ Lactate , IV, 10 ml/kg, over 30 minutes 
then assess response
And
 y Morphine  sulphate, slow IV (preferred), or IM, if IV line not accessi -
ble, 100-200 micrograms/kg stat.
B.     For patients with poor response to above measures, Add 
 y Propranolol , oral,
Children  1 month-12 years 
500 microgram/kg 8 hourly (max. 5 mg/kg daily)
Neonate s
500 microgram/kg 8 hourly (max. 2 mg/kg 8 hourly) 
C.     To correct acidosis in cyanotic patients with no improvement after 
10 minutes of above treatment, Add
 y Sodium Bicarbonate , IV, 
For all age groups  
1-2 mmol/kg
Note 7-8  
Emergency surgical shunt may be required
D.     Maintenance treatment to prevent recurrent attacks pending 
surgery
 y Propranolol , oral,
Children  1 month-12 years 
0.25-1 mg/kg 6-8 hourly (max. 5 mg/kg daily)
Neonate s
0.25-1 mg/kg 8-12 hourly (max. 2 mg/kg 8 hourly) 
 y Propranolol , slow IV with ECG monitoring,
Children  1 month-12 years
15-20 microgram/kg 6-8 hourly (max. 200 microgram/kg) repeated 
every 6-8 hours if necessary
Neonate s
15-20 microgram/kg (max. 100 microgram/kg) repeated every 12 
hours if necessary 

— Pericarditis —Chapter 7:  Disorders of the Cardiovascular System
145Referral Criteria 
Hypercyanotic attack  is an indication for early surgery. Refer urgently 
to a paediatric specialist or cardiothoracic surgeon
50� Pericarditis
Pericarditis  is inflammation of the pericardium. It may be dry, 
fibrinous, effusive or constrictive. It may be acute or chronic (>3 months).
Causes 
 y Viral
 y Bacterial
 y Tuberculous
 y Fungal 
 y Rheumatic fever
 y Post-cardiotomy
 y Postmyocardial infarction
 y Uraemia
 y Autoimmune diseases
Symptoms
 y Retrosternal or left precordial chest pain  (worsens with lying down 
and improves with sitting and leaning forward)
 y Palpitation
 y Fatigue 
Signs
 y Fever
 y Malaise
 y Myalgia
 y Pericardial friction rub
 y Fast and regular heart rate
 y Distant heart sounds (if there is a large effusion)
Investigations
 y FBC and ESR
 y ASO titre
 y 12-lead ECG 
 y Chest X-ray
 y Echocardiogram
 y Chest CT scan
Treatment 
Treatment objectives
 y To relieve pain
 y To treat underlying cause
 y To prevent cardiac tamponade 

— Hypertension  —
Standard  Treatment Guidelines, 7th Edition, 2017
146Non-pharmacological treatment
Bed rest
Pericardiocentesis (indicated when there is cardiac tamponade, large 
or symptomatic pericardial effusion). Evidence Rating: [B]
Pharmacological treatment 
A.     Acute pericarditis
1st Line Treatment
Evidence Rating: [B]
 y Ibuprofen , oral, 
Adult s
300-800 mg 6-8 hourly
Children
7-18 years;  200 mg 6-8 hourly
2-7 years;  100 mg 6-8 hourly 
1-2 years;    50 mg 6-8 hourly
6-12 months;    50 mg 8 hourly
1-6 months;      5 mg/kg 6-8 hourly
And  
 y Colchicine , oral, 
Adult s 
0.5 mg 12 hourly
Children
Not recommended
Or
 y Prednisolone , oral, (restricted to connective tissue diseases and 
uraemic pericarditis)
Adult s
40 mg daily for 14 days and taper off 
Children
2 mg/kg daily for 14 days and taper off 
B�     For treatment of underlying cause
(See appropriate section)
Referral Criteria 
Refer all patients to a Cardiologist for further evaluation after the 
inital treatment. Patients with large effusions or cardiac tamponade 
require urgent pericardiocentesis under echocardiographic guidance and 
they should be referred immediately.
51� Hypertension  
Hypertension  or ‘high blood pressure’ carries an increased risk of 
early death from stroke , heart attack, heart failure and kidney failure if it is 
not detected early and properly controlled. Owing to this, the focus must 

— Hypertension  —Chapter 7:  Disorders of the Cardiovascular System
147be on when to initiate treatment, rather than how hypertension should 
be defined.
Since there are often no specific symptoms associated with 
hypertension, there is the need for regular blood pressure (BP) screening 
in the adult population for early detection. 
In the general adult population, treatment must be initiated at a 
BP of 140/90 mmHg or higher for individuals below 60 years of age, and 
150/90 mmHg or higher in those above 60 years. For individuals with 
diabetes mellitus or non-diabetics with Chronic Kidney Disease (CKD ), 
treatment for hypertension must be initiated at a BP of 140/90 mmHg, 
irrespective of age. 
In the majority of patients with hypertension, no specific underlying 
cause is identified (primary hypertension). In these individuals, increasing 
age, family history, excess body weight, lack of physical activity and 
excessive alcohol intake may be possible predisposing factors. In about 
10% of cases of hypertension, there may be an underlying kidney disease, 
endocrine disorder, renal artery stenosis or coarctation of the aorta 
(secondary hypertension). 
Once a diagnosis of hypertension is made, the individual should 
be evaluated to exclude secondary causes and to identify other existing 
cardiovascular risk factors e.g. diabetes, dyslipidaemia, hyperuricaemia, 
etc.
 
Box 7-6:   Cardiovascular Risk Factors
 yAge (men ≥ 55 years; women ≥ 65)
 yFamily history of premature cardiovascular disease (men aged < 55 years; 
women aged < 65)
 yDyslipidaemia  
 yObesity  (BMI ≥ 30 kg/m2)
 yDiabetes mellitus
 ySmoking
 yPulse pressure (in the elderly) ≥ 60mmHg
 yMicroalbuminuria or proteinuria
 yLeft ventricular hypertrophy
 yLeft bundle branch block and other electrocardiographic features suggesi -
tive of ischaemic heart disease
 yPrevious stroke  or transient ischaemic attack
 yPeriperal arterial disease
 yHeart failure
 yCoronary artery disease
 yChronic kidney disease
 yAdvanced retinopathy: haemorrhages or exudates, papilloedema
Causes 
 y Primary hypertension
 y Secondary hypertension 
 y Kidney related- CKD , polycystic kidney disease
 y Endocrine - phaeochromocytoma, Cushing’s syndrome , Conn’s 
syndrome, hypothyroidism , hyperthyroidism , acromegaly

— Hypertension  —
Standard  Treatment Guidelines, 7th Edition, 2017
148 y Vascular - renal artery stenosis, coarctation of the aorta
Symptoms
 y Usually none
 y Occasionally,
 y Headaches
 y Palpitations
 y Dizziness
 y Easy fatiguability
Signs
 y Blood pressure ≥ 140/90 mmHg 
 y Displaced apex beat
 y Signs pointing to a specific cause for secondary hypertension 
Investigations
 y FBC
 y Urinalysis 
 y Blood urea, electrolytes and creatinine 
 y Blood glucose
 y Serum lipids
 y Serum uric acid
 y Chest X-ray 
 y 12-lead ECG
 y Ultrasound scan of kidneys and adrenals (in suspected secondary 
hypertension)
 y Echocardiogram
Treatment 
Treatment objectives
 y To reduce blood pressure levels to recommended targets: 
 y < 140/90 mmHg for age below 60 years, diabetes, CKD  
 y < 150/90 mmHg for age above 60 years
 y To manage co-morbid conditions e.g. obesity, diabetes, lipids etc. 
 y To prevent cardiovascular, cerebrovascular and renal complications
 y To promote therapeutic lifestyle changes e.g. smoking cessation, 
regular physical activity, reduction in alchohol intake
 y To identify and manage secondary hypertension appropriately 
Non-pharmacological treatment
 y Reduce salt intake
 y Reduce animal fat intake 
 y Ensure regular fruit and vegetable intake
 y Weight reduction in obese and overweight individuals
 y Regular exercise e.g. brisk walking for 30 minutes 3 times a week 
 y Reduction in alcohol consumption
 y Avoid or quit smoking 

— Hypertension  —Chapter 7:  Disorders of the Cardiovascular System
149Pharmacological treatment 
A.     Treatment of hypertension
1st Line Treatment
Evidence Rating: [A]
Box 7-7:   Notes on anti-hypertensive medicines
Any of the five classes of major antihypertensive drugs can be used as first-line 
treatment. These are:
 yThiazide Diuretics  
 yCalcium  Channel Blockers  
 yAngiotensin Converting Enzyme Inhibitors
 yAngiotensin Receptor Blockers  
 yBeta-blockers
In the general black population thiazide diuretics or c alcium channel blockers, 
either as monotherapy or in some combination therapy, is preferrable. Angio -
tensin converting enzyme Inhibitor s are not recommended as first-line drugs for 
uncomplicated hypertension in black patients.
Dual therapy should be started earlier when the blood pressure exceeds 
180/110 mmHg.
Additional anti-hypertensive drugs should be used if target blood pressure 
levels are not achieved. Add-on drugs should be chosen from first-line choices 
bearing in mind compelling indications and contraindications. 
Compelling indications for the choice of antihypertensives
 yLeft ventricular hypertrophy: ACE-I or ARB, CCB preferably Amlodipine  
 yMicroalbuminuria: ACE-I or ARB
 yRenal dysfunction: ACE-I or ARB; Caution- if eGFR <15min/ml without renal 
replacement therapy
 yPrevious stroke : Any of the first-line drugs, especially ACE-I
 yCoronary artery disease (Angina/Myocardial infarction): ACE-I or ARB, Be -
ta-blocker, CCB.
 yHeart failure: ACE-I or ARB, Cardio-selective B-Blockers- bisoprolol, metop -
rolol, carvedilol; Loop diuretics, Spironolactone in advanced heart failure
 yPeripheral artery disease: CCB, ACE-I or ARB
 yDiabetes mellitus : ACE-I or ARB
 yAtrial fibrillation: ARB or ACE-I or B-blockers
Compelling  Contraindications
 yGout : Thiazide diuretics
 yBeta-blockers : Asthma , 2 and 3 AV block
 yCCB: Heart failure
 yACE-I or ARB: Bilateral renal artery stenosis and hyperkalaemia
 Thiazide Diuretics :  
 y Bendroflumethiazide , oral, 2.5 mg daily
Or 
 y Hydrochlorothiazide , oral, 12.5 mg-25 mg daily
And/Or

— Hypertension  —
Standard  Treatment Guidelines, 7th Edition, 2017
150 Calcium  Channel Blockers : 
 y Amlodipine , oral, 5-10 mg daily 
Or
 y Nifedipine  retard, oral, 10-40 mg 12 hourly
And/Or 
 Angiotensin-converting enzyme (ACE) inhibitors
 y Lisinopril , oral, 5-40 mg daily
Or
 y Ramipril , oral, 2.5-10 mg daily
Or 
 Angiotensin receptor blockers
 y Losartan , oral, 25-100 mg daily
Or
 y Candesartan , oral, 4-32 mg daily
Or
 y Valsartan , oral, 80-160 mg daily
And/Or 
 Beta-blockers :
 y Atenolol , oral, 50 -100 mg daily 
Or
 y Bisoprolol , oral, 5-20 mg daily
Or
 y Metoprolol , oral, 50-200 mg 12 hourly
Or 
 y Carvedilol , oral, 12.5-50 mg daily
Or 
 y Labetalol , oral, 100-400 mg 12 hourly
2nd Line Treatment
Evidence Rating: [C]
 Centrally acting agents  
 y Methyldopa , oral, 250 mg-1g 8-12 hourly 
And/Or
 Vasodilators
 y Hydralazine , oral, 25-50 mg 12 hourly     
And/Or
 Alpha-blockers
 y Prazosin , oral, 0.5 mg 8-12 hourly and increasing gradually to a max. 
dose of 20 mg 
And/Or
 Aldosterone antagonists
 y Spironolactone , oral, 25-50 mg daily 

— Hypertension  —Chapter 7:  Disorders of the Cardiovascular System
151Referral Criteria 
Refer the following categories of hypertensive patients to an 
appropriate specialist:
 y Those not achieving the target blood pressure (BP) level after several 
months of treatment
 y Those on three or more anti-hypertensive drugs, yet have poor BP 
control
 y Those with worsening of BP over a few weeks or months 
 y Those with plasma creatinine levels above the upper limit of normal 
 y Those with diabetes mellitus 
 y Those with multiple risk factors (diabetes, dyslipidaemia, obesity, 
family history of heart disease) 
 y Those not on diuretics but have persistently low potassium on 
repeated blood tests
 y All children, young adults and pregnant women with elevated BP
Flowchart
Fig 7-8:  Flowchart: Hypertension

— Hypertension in children and adolescents  —
Standard  Treatment Guidelines, 7th Edition, 2017
15252� Hypertension  in children and adolescents  
Hypertension  in children is defined as an average systolic and/or 
diastolic blood pressure that is ≥ 95th percentile for gender, age, and 
height on 3 or more separate occasions taken in the right arm (in view 
of possibility of coarctation of aorta). An appropriate cuff size that covers 
two thirds (⅔) of the length of the arm (between shoulder and elbow) and 
encircling the whole arm, should be used. 
In general, a blood pressure of > 110/70 mmHg in children aged 2-5 
years and > 115/76 mmHg in those aged 6-12 years and more than 128/82 
mmHg in adolescents is considered abnormal and would require a referral 
to, and evaluation by a paediatrician.
Most adolescent and childhood hypertension, especially in infants 
and younger children, is due to secondary causes (See section on 
‘Hypertension  in Adults’). Adolescents, however, may have early onset 
primary hypertension.
Causes
 y Renal e.g. chronic pyelonephritis , hydronephrosis 
 y Vascular e.g. coarctation of aorta, renal artery stenosis 
 y Endocrine e.g. phaeochromocytoma , Cushing’s syndrome , adrenal 
disorders
 y Obesity
 y Primary hypertension
Symptoms
 y Chest pain 
 y Headaches 
 y Dyspnoea  on exertion
 y Excessive sweating
 y Leg swelling
 y Palpitations 
 y Haematuria
 y Unconsciousness  (hypertensive encephalopathy )
Signs
 y BP >110/70 mmHg in children aged 2-5 years
 y       >115/76 mmHg in children aged 6-12 years
 y       >128/82 mmHg in adolescents
 y Signs pointing to a specific cause for secondary hypertension 
Investigations 
(See section on ‘Hypertension  in Adults’)
Treatment 
Treatment objectives
 y To reduce blood pressure (BP) to a target of < 95th percentile for age, 
gender and height in the absence of end organ-damage (to < 90th 

— Hypertension in children and adolescents  —Chapter 7:  Disorders of the Cardiovascular System
153percentile if end organ damage present)
 y To prevent complications
 y To manage underlying secondary cause
 y To encourage weight reduction in obese and overweight children 
Non-pharmacological treatment 
 y Therapeutic lifestyle changes 
 y weight control
 y regular exercise
 y low fat intake
 y low sodium diet
 y regular fruit and vegetable intake
Pharmacological treatment
Evidence Rating: [A]
 Angiotensin-converting enzyme (ACE) inhibitors 
 y Enalapril , oral,  
Children
12-18 years;   initially 2.5 mg daily (increased to max. 10-
20 mg daily in 1-2 divided doses)
1 month-12 years;  initially 100 micrograms per kg daily (in -
creased to max. 1 mg/kg daily in 1-2 divided doses)
Neonate
10 microgram/kg daily (increased to max. 500 microgram/kg daily in 
1-3 divided doses)
 Diuretics
 y Bendroflumethiazide , oral,  
Children
12-18 years;  2.5 mg daily
2-12 years;  50-100 microgram/kg daily
1 month-2 years; 50-100 microgram/kg daily
 Beta blockers
 y Propranolol , oral,  
Children
12-18 years;   80-160 mg 12 hourly 
1 month-12 years;  250 microgram-1 mg/kg 8 hourly 
Neonate ;  250 microgram/kg 8 hourly
Or
 y Atenolol , oral,  
Children
0.5-1 mg/kg daily (max. 2 mg/kg daily)
 Calcium  channel blockers 
 y Nifedipine , oral,  
Children
12-18 years;   5-20 mg 8 hourly
1 month-12 years;    200-300 microgram/kg 8 hourly (max. 100 
mg daily)

— Hypertension in Pregnancy  —
Standard  Treatment Guidelines, 7th Edition, 2017
154Or
 y Amlodipine , oral,
Children
12-18 years;  5-10 mg daily
1 month-12 years;  100-400 microgram/kg daily (max. 10 mg 
daily)
 Vasodilators
 y Hydralazine , oral,
Children
12-18 years;   25 mg 12 hourly increased to usual max. 50-
100 mg 12 hourly
1 month-12 years;  250-500 microgram/kg 8-12 hourly in -
creased as necessary to max. 7.5 mg/kg daily (not exceeding 200 mg)
Neonate
250-500 microgram/kg 8-12 hourly increased as necessary to max. 
2-3 mg/kg every 8 hours 
IV, 250-500 microgram/kg diluted in 10 ml normal saline given over 
20 minutes, then 100-200 microgram/kg 4-6 hourly (max 3 mg/kg 
in 24 hours)
 Angiotensin-receptor blockers
 y Losartan , oral,  
Children
Initial dose;  0.7 mg /kg daily (max. 50 mg)
Maintenance dose; 1.4 mg /kg daily (max. 100 mg)
Referral Criteria 
Refer all cases of hypertension in children to a specialist for 
investigation and further treatment.
53� Hypertension in Pregnancy 
(See section on ‘Hypertension in Pregnancy’ under ‘Obstetric care 
and Obstetric Disorders’) 
54. Hypertensive Emergencies
A hypertensive crisis is a severe and potentially life threatening 
increase in blood pressures (BP) which may result in an acute stroke , 
subarachnoid haemorrhage , seizures (hypertensive encephalopathy ), 
heart attack, acute dissection of aorta, heart failure, renal damage or 
eclampsia (during pregnancy).  The underlying cause may be primary 
hypertension; however, secondary causes of hypertension must be 
excluded.
In adult patients this often occurs with a BP > 180/120 mmHg, while 
in children this may occur at lower BP levels. 

— Hypertensive Emergencies —Chapter 7:  Disorders of the Cardiovascular System
155These patients need careful examination to exclude target organ 
damage. Rapid correction of blood pressure with careful monitoring to 
avoid a precipitous drop is indicated to prevent organ damage. 
Symptoms
 y Headache  
 y Chest pain
 y Shortness of breath
 y Nausea
 y Vomiting
 y Confusion 
 y Seizures
 y Unconsciousness   
Signs
 y Severely elevated blood pressure (for age)
 y Unconsciousness   
 y Seizures
 y Neck rigidity 
 y Lung crepitations
Investigations
 y Chest X-ray
 y 12-lead ECG
 y FBC
 y Urinalysis 
 y Blood urea, electrolytes and creatinine 
 y Brain CT scan (for stroke )
 y Chest CT scan with angiography (for suspected aortic dissection)
 y Cardiac enzymes: creatinine kinase-MB (CK-MB ), serum aspartate 
transaminase (AST), serum lactic dehydrogenase (LDH) and troponins  
(for acute coronary syndrome)
 y Echocardiography
Treatment 
Treatment objectives
 y To limit further organ-related complications by controlled reduction 
of BP
 y To control and subsequently prevent seizures if present
 y To manage identified target organ damage 
Non-pharmacological treatment
 y Strict bed rest
Pharmacological treatment 
Evidence Rating: [A]
 y Labetalol , IV, 
Adult s
20-50 mg stat. (over a 2 minute period) 

— Arrhythmias —
Standard  Treatment Guidelines, 7th Edition, 2017
156Repeat at 10 minute intervals, if necessary, to a max. of 200 mg
Children
12-18 years; 10-30 mg stat. (over a 2 minute period). Repeat at 15 
minute intervals, if necessary (max. 200 mg)
1 month-12 years (by IV infusion); initially 500-1000 microgram /kg 
body weight / hour adjusted at intervals of at least 15 minutes ac -
cording to response. Max. 3 mg /kg/hour.
Note 7-9
Monitor BP every 5 minutes following each injection for all age groups. 
Cease Labetalol  injections if BP < 140/90 mmHg and/or pulse <60 BPM in adults, 
(for children consult a paediatrician) or wheezing and bronchospasm occurs.
Or
 y Hydralazine , IV, 
Adult s
5-10 mg slowly (over a 2 minute period), diluted with 10 ml Normal 
Saline  (0.9%). 
Repeat at 20-30 minute intervals, if necessary 
Children
12-18 years;   5-10 mg stat.
Repeat every 4-6 hours, if necessary
1 month-12 years;  100-500 microgram/kg 
Repeat every 4-6 hours, if necessary; max. 3 mg/kg daily (not ex -
ceeding 60 mg per day)
< 1 month;  100-500 microgram/kg 
Repeat every 4-6 hours, if necessary; max. 3 mg/kg daily
Note 7-10
Monitor BP every 5 minutes following each injection for all age groups. 
Do not use short-acting nifedipine (e.g. sublingual) in the management of hy -
pertensive crises as it lowers the BP too rapidly and may cause ischaemia of 
vital organs.
Referral Criteria 
Refer all patients to a physician specialist for further evaluation. 
55� Arrhythmias
Arrhythmias  are disorders of cardiac rate, rhythm and conduction. 
They can be classified as bradyarrhythmias (heart rate < 60 per minute) 
and tachyarrhythmias (heart rate > 100 per minute). 
Bradyarrhythmias  include sinus bradycardia , sinus pauses and 
atrioventricular blocks. The tachyarrhythmias can further be classified 
into supraventricular and ventricular arrhythmias, based on their site 
of origin. Tachyarrhythmias include atrial fibrillation , atrial flutter , 
paroxysmal supraventricular tachycardia, ventricular tachycardia and 
ventricular fibrillation. 

— Arrhythmias —Chapter 7:  Disorders of the Cardiovascular System
157Prior to drug treatment of a suspected cardiac arrhythmia, a 12-lead 
ECG must be done to confirm the rhythm abnormality. It is dangerous 
to use an antiarrhythmic drug without doing an ECG. Refer symptomatic 
patients to hospital immediately. The choice of drug treatment depends 
on the type of arrhythmia and severity of symptoms.
Causes 
 y Rheumatic heart disease
 y Other valvular heart diseases
 y Hypertensive  heart disease
 y Ischaemic heart disease
 y Thyrotoxicosis
 y Hypothyroidism  
 y Cardiomyopathies
 y Complete heart block
 y Electrolyte abnormalities particularly hypokalaemia 
 y Pericardial disease
 y Drugs
 y Smoking, alcohol, coffee, tea, etc.
 y Pulmonary embolism
 y Post cardiac surgery
 y Idiopathic
Symptoms
 y Palpitations 
 y Dizziness
 y Chest discomfort/pain
 y Fatigue 
 y Difficulty in breathing
 y Sudden collapse
 y Sudden death
Signs
 y Pulse 
 y Rate may be fast, slow or normal
 y Rhythm
Regular Regularly irregular Irregularly irregular
Sinus tachycardia
Sinus bradycardia 
Complete heart block
Supraventricular tachycardia 
Ventricular tachycardiaSupraventricular or 
ventricular ectopic 
beatsAtrial fibrillation 
Atrial flutter (with variable 
atrio-ventricular block)
Multiple supraventricular or 
ventricular ectopic beats
 y Pulse deficit (apical rate faster than radial pulse rate; seen in 
fast atrial fibrillation  or flutter)
 y Hypotension or blood pressure may be unrecordable
 y Signs of heart failure (may be present)

— Arrhythmias —
Standard  Treatment Guidelines, 7th Edition, 2017
158Investigations
 y 12-lead ECG 
 y Serum electrolytes (including magnesium, calcium)
 y Thyroid function tests
 y Chest X-ray
 y Ambulatory ECG (Holter) 
 y Echocardiography
Treatment 
Treatment objectives
 y To control ventricular rate
 y To restore sinus rhythm
 y To relieve symptoms
 y To improve functional capacity and quality of life
 y To prevent or treat associated complications
 y To treat the underlying condition e.g. thyrotoxicosis  
 y To prevent stroke  or systemic thromboembolism
 y To reduce morbidity and mortality
Non-pharmacological treatment
 y Reassure the patient
 y Avoid excessive intake of alcohol, coffee or tea and stop smoking (if 
these are possible precipitating factors)
 y Massage of the carotid sinus on one side for a few seconds. This may 
terminate an attack of paroxysmal supraventricular tachycardia
 y Electrical cardioversion 
Pharmacological treatment 
A.     Fast atrial fibrillation  or atrial flutter -for rate control
1st Line Treatment
Evidence Rating: [A]
 y Atenolol , oral, 
Adult s
50-100 mg daily
Children  
12-18 years;   25-50 mg daily 
1 month-12 years;  12.5-50 mg daily 
Neonate s
Refer to a paediatrician
Or
 y Bisoprolol , oral, 
Adult s
2.5-10 mg daily
Children  
Safety not establised in children 
Or 
 y Metoprolol  tartrate, oral, 

— Arrhythmias —Chapter 7:  Disorders of the Cardiovascular System
159Adult s
50-100 mg 8 or 12 hourly daily (max. 300 mg daily)
Children  
12-18 years;  50 mg 8 or 12 hourly daily (max. 300 mg daily)
< 12 years;  refer to a paediatrician
Note 7-11
Avoid if beta-blockers are contraindicated e.g. bronchial asthma, hypotension 
Or
 y Verapamil , oral, 
Adult s
40-120 mg 6-8 hourly (max. 480 mg daily)
Children  
Refer to a paediatrician
Note 7-12
Avoid use in patients already on beta-blocker
2nd Line Treatment
Evidence Rating: [A]
 y Digoxin , oral, 
Adult s
125-250 micrograms daily 
Children
Refer to a paediatrician
B.     Fast atrial fibrillation  or atrial flutter -for rhythm control
This is required to restore sinus rhythm. 
Refer to a cardiologist, physician specialist or paediatrician as 
appropriate.
C�     Paroxysmal supraventricular tachycardia
1st Line Treatment
Evidence Rating: [A]
 y Atenolol , oral, 
Adult s
50-100 mg daily
Children  
12-18 years;   25-50 mg daily 
1 month-12 years;  12.5-50 mg daily 
Neonate s
Refer to a paediatrician
Or
 y Bisoprolol , oral, 
Adult s
2.5-10 mg daily
Children  
Safety not establised in children 

— Arrhythmias —
Standard  Treatment Guidelines, 7th Edition, 2017
160Or 
 y Metoprolol  tartrate, oral, 
Adult s
50-100 mg 8 or 12 hourly daily (max. 300 mg daily)
Children  
12-18 years;   50 mg 8 or 12 hourly daily (max. 300 mg dai -
ly)
<12 years;   refer to a paediatrician
Note 7-13
Avoid if beta-blockers are contraindicated e.g. bronchial asthma, hypotension 
Or
 y Verapamil , oral, 
Adult s
40-120 mg 6-8 hourly (max. 480 mg daily)
Children  
Refer to a paediatrician
Note 7-14
Avoid use in patients already on beta-blocker
2nd Line Treatment
Evidence Rating: [A]
 y Digoxin , oral, 
Adult s
125-250 micrograms daily 
Children
Refer to a paediatrician
D.     Prevention of stroke  or systemic thromboembolism  in atrial 
fibrillation  or flutter  
Patients should be given long-term anticoagulation .
(See options for long-term anticoagulation in section on ‘DVT ’ or 
‘Pulmonary Embolism ’).
Referral Criteria 
Refer all patients to a cardiologist, physician specialist or paediatrician 
for further evaluation and management after the initial treatment.
All symptomatic patients, as well as those who cannot have an ECG 
done or interpreted, or who present with heart failure, should be referred 
immediately.
Flowchart 

— Acute Rheumatic Fever —Chapter 7:  Disorders of the Cardiovascular System
161
Fig 7-9:  Flowchart: Arrhythmias
56� Acute Rheumatic Fever
Acute rheumatic fever is an illness caused by an immunological 
reaction to group A streptococcal infection of the throat. The onset of 
symptoms occurs 1-3 weeks after an untreated or inadequately treated 
throat infection. The disease occurs mainly in children and adolescents 
with a peak age of 5-15 years. Acute rheumatic fever often results in 
lasting damage to heart valves leading to the chronic form, which is 
known as rheumatic heart disease. 
Individuals who have had acute rheumatic fever previously are more 
likely to have subsequent episodes. These recurrences may cause further 
heart valve damage. Following treatment of an acute episode, secondary 
prophylaxis should be continued for a minimum of 10 years after the 
recent episode of acute rheumatic fever or until age 21 years (whichever 
is longer). For those with severe rheumatic heart disease secondary 
prophylaxis should be continued indefinitely.
Rheumatic heart disease  is an important cause of heart failure and 
premature death. In Ghana, acute rheumatic fever may mimic malaria, 
typhoid fever  and other febrile conditions, while the joint symptoms may 
mimic sickle cell disease. 
Jones criteria is used for diagnosis of rheumatic fever. 

— Acute Rheumatic Fever —
Standard  Treatment Guidelines, 7th Edition, 2017
162Box 7-10:   Jones criteria for diagnosis of Acute Rheumatic Fever
For diagnosis of initial acute rheumatic fever:
Evidence of preceeding group A streptococcal infection,
And
2 major criteria
Or 
1 major criterion and 2 minor criteria
For diagnosis of recurrent aute rheumatic fever:
Evidence of preceeding group A streptococcal infection,
And
2 major criteria 
Or 
1 major criterion and 2 or 3 minor criteria
(See symptoms and Signs below for major and minor criteria)
Causes 
 y Group A streptococcal infection 
Symptoms
 y Fever 
 y Malaise 
 y Joint pain which moves from one joint to another (knees, ankles, 
wrists, elbows)
 y Palpitations
 y Easy fatiguability
 y Chest pain 
 y Skin rash
 y Abnormal body movements (chorea)
Signs
 y Fever > 38°C (minor criteria)
 y Single joint tenderness and or swelling (minor criteria)
 y Rapid heart rate ( > 100/minute), murmur, heart failure, pericardial 
rub (suggests carditis) (major criteria)
 y Skin rash
 y Subcutaneous nodules over bony prominences
Investigations
 y FBC 
 y ESR > 30 or C-reactive protein > 3 mg/dL  (minor criteria)
 y Sickling status
 y Chest X-ray 
 y Throat swab for culture
 y Anti-streptolysin O titre 
 y 12-lead ECG (prolonged PR interval for age - minor criteria)
 y Echocardiogram evidence of carditis (major criteria)

— Acute Rheumatic Fever —Chapter 7:  Disorders of the Cardiovascular System
163Treatment 
Treatment objectives
 y To eradicate streptococcal throat infection
 y To suppress inflammatory response
 y To prevent recurrent episodes of rheumatic fever and further heart 
valve damage
 y To treat heart failure if co-existent
Non-pharmacological treatment
 y Bed rest
Pharmacological treatment 
A.     Treatment of Acute Rheumatic Fever
1st Line Treatment
Evidence Rating: [C]
 y Benzathine benzylpenicillin , IM,
≥ 30 kg body weight;  1,200,000 U as a single dose
< 30 kg body weight;  600,000 U as a single dose
Or 
 y Phenoxymethyl penicillin  (Penicillin V ), oral,
Adult s
500 mg 12 hourly for 10 days  
Children  
6-12years;  250 mg 12 hourly for 10 days 
1-5 years;  125 mg 12 hourly for 10 days
Or
 y Erythromycin , oral, (for patients allergic to penicillin) 
Adult s
500 mg 12 hourly for 10 days  
Children  
8-12 years;  500 mg 12 hourly for 10 days 
3-8 years;  250 mg 12 hourly for 10 days 
1-2 years;  125 mg 12 hourly for 10 days 
And
Evidence Rating: [B]
 y Aspirin , oral,                
Adult s
300-900 mg 4-6 hourly until joint symptoms relieved, and gradually 
withdraw over 1-2 weeks.
Children  
1 month-18 years;  25 mg/kg 6 hourly until joint symptoms re -
lieved, and gradually withdraw over 1-2 weeks.
Or
Evidence Rating: [B] 
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly (max. 2400 mg daily)

— Dizziness and Blackouts —
Standard  Treatment Guidelines, 7th Edition, 2017
164Children
10-15 mg/kg 6-8 hourly (max. 40 mg per kg daily)
B.     Treatment of Acute Rheumatic Fever  with Carditis
As in ‘treatment option A’ above 
And
 y Prednisolone , oral, 
Adult s and Children  
2 mg/kg daily for 2 weeks and then gradually taper off by 20-25% per 
week for 1-3 weeks.
C.     Treatment of Acute Rheumatic Fever  with Heart Failure
As in ‘treatment option A’ above 
And
Treatment for heart failure (See section on ‘Heart failure’)
D.     Secondary prevention (prophylaxis) of acute rheumatic fever and 
rheumatic heart disease
1st Line Treatment
 y Benzathine benzylpenicillin , IM,
≥ 30 kg body weight;  1,200,000 U
< 30 kg body weight;  450 mg (600,000 U) 4-weekly
2nd Line Treatment 
 y Phenoxymethyl penicillin  (Penicillin V ), oral,
Adult s
500 mg 12 hourly daily
Children  
6-12years;  250 mg 12 hourly 
1-5 years;  125 mg 12 hourly
Or
 y Erythromycin , oral, (for patients allergic to penicillin) 
Adult s
500 mg 12 hourly
Children  
8-12 years;  500 mg 12 hourly 
3-8 years;  250 mg 12 hourly 
1-2 years;  125 mg 12 hourly 
Referral Criteria 
Refer all patients to a paediatrician, physician specialist or cardiologist 
as necessary for further management.
57� Dizziness  and Blackouts
Dizziness  is a nonspecific term that refers to abnormal sensation 
of body orientation or position in space. These include feeling of 
unsteadiness, light-headedness and vertigo . Patients often find these 

— Dizziness and Blackouts —Chapter 7:  Disorders of the Cardiovascular System
165sensations difficult to describe. Dizziness is almost always associated 
with other symptoms, therefore a careful history and focused physical 
examination should be performed in all cases to identify the cause.
Like dizziness, “blackouts ” is a vague, descriptive term implying 
either altered consciousness, visual disturbance or a sensation of falling. 
A careful history, particularly from an eye-witness, is essential. 
Episodes of transient disturbance of consciousness and falls are 
common clinical problems. It is usually possible to distinguish between 
a fit (a seizure), an episode of fainting and other types of attack from the 
history given by the patient and the account of an eye witness.
Causes 
Cardiovascular
 y Vasovagal - (fainting)
 y Postural hypotension
 y Acute haemorrhage
 y Cardiac arrhythmias
 y Severe aortic stenosis
 y Complete heart block with Stokes-Adams attacks
 y Vertebro-basilar insufficiency
Cerebral 
 y Transient Ischaemic Attacks (TIA )
 y Stroke
 y Epilepsy
Others
 y Drug-induced 
 y Severe anaemia
 y Hypoglycaemia  
 y Middle ear disease
 y Meniere’s disease
 y Conversion disorder  (Hysterical fainting/Hyperventilation)
Symptoms
 y Light-headedness
 y Loss of consciousness 
 y Sense of motion or spinning of body 
 y Unsteadiness 
 y Nausea
 y Vomiting
 y Tinnitus
Signs
 y Sweating (suggests vasovagal episode/hypoglycaemia)
 y Tachycardia  or bradycardia (suggest cardiac arrhythmia) 
 y Hypotension 
 y Postural hypotension 
 y Pallor 

— Dizziness and Blackouts —
Standard  Treatment Guidelines, 7th Edition, 2017
166 y Nystagmus, dysdiadochokinesis, ataxia , hypotonia, dysarthria 
(suggests cerebellar cause)
 y Focal neurological signs suggests stroke , TIA
Investigations
 y These vary depending on the cause
 y FBC
 y Random blood sugar
 y X-ray of cervical spine 
 y ECG
Treatment 
Treatment objectives
 y To identify and appropriately manage the possible underlying 
cause(s)
Non-pharmacological treatment
 y Postural hypotension - review medications
 y Hyperventilation syndrome - breathing control exercise
 y Counseling 
 y Cervical collar 
 y Moulded cervical pillows
Pharmacological treatment 
 y Treat the underlying cause. (See appropriate section) 
Referral Criteria 
Refer patients to a physician specialist for evaluation if the cause is 
difficult to determine. If the cause is identified, refer to the appropriate 
specialist for further evaluation and management. 

8Chapter
167Disorders of the 
Respiratory System
58� Common Cold
This is a self-limiting infection of the upper respiratory tract, 
particularly the nasopharyngeal mucosa and sinuses. It is contagious 
and spread by airborne droplets, as well as from hands and contact 
with contaminated surfaces. The symptoms resolve without antibiotic 
treatment, usually within a week. 
If the ‘cold’ lasts longer than a week and there is persistent fever and 
cough, a diagnosis of influenza may be considered. With influenza, fever, 
systemic symptoms and prostration are more pronounced. Secondary 
bacterial infection may be associated with purulent phlegm or offensive 
nasal discharge and fever. 
Occasionally, the common cold is complicated by otitis media  and 
pharyngotonsillitis, particularly in children, in which case one should refer 
to the appropriate sections for treatment.
Causes 
 y Rhinoviruses
 y Corona viruses
 y Respiratory Syncytial Virus (RSV)
Symptoms
 y Runny nose (rhinorrhea)
 y Sneezing 
 y Nasal congestion
 y Mild fever
 y Headaches
 y Sore throat 
 y Muscle aches 
 y Cough
 y Fatigue 
 y Malaise
Signs
 y Low grade fever
 y Nasal discharge

— Common Cold —
Standard  Treatment Guidelines, 7th Edition, 2017
168 y Nasal mucosa reddening
 y Watering of eyes
Investigations
 y No investigations required
Treatment 
Treatment objectives
 y To relieve symptoms
 y Resolution of infection in the shortest possible time
Non-pharmacological treatment
 y Rest
 y Encourage adequate fluid intake
 y Gargle lukewarm salt solution 
 y Steam inhalation
Pharmacological treatment 
A.     Uncomplicated common cold
1st Line Treatment
Evidence Rating: [C]
 y Paracetamol , oral,
Adult s
500-1g 6-8 hourly
Children
10-15 mg/kg/dose 6-8 hourly
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
And
 y Sodium Chloride  0.9%, nasal drops,
Adult  and Children  
2 drops, into each nostril, 4 hourly to relieve congestion as necessary
Or
 y Xylometazoline , nasal,
Adult s (0.1% preparation)
1-2 drops 12 hourly into each nostril
Children  (0.05% preparation)
> 3 months;  1-2 drops 12 hourly into each nostril
And
 y Cetirizine , oral,
Adult s
10 mg daily 
Children
> 12 years;   10 mg daily
6-2 years;   5 mg daily 
2-6 years;   2.5 mg daily

— Pneumonia —Chapter 8:  Disorders of the Respiratory System
169Or
 y Chlorpheniramine  maleate, oral, 
Adult
4 mg 12 hourly 
Children
6-12 years;   2 mg 6-12 hourly daily (max. 12 mg daily)
2-6 years;   1 mg 6-8 hourly (max. 6 mg daily)
1-2 years;    not recommended 
Note 8-1
Antibiotics are not indicated for common cold. 
Referral Criteria 
Refer cases suspected to have measles, influenza or complications to 
a paediatrician or physician for management.
59� Pneumonia
Pneumonia  is an infection of the lung tissue caused by various 
bacteria, viruses or fungi. Identification of the causative organism and 
drug sensitivity testing is the key to correct treatment. However, because 
of the serious nature of the infection, antibiotic treatment should be 
started immediately based on knowledge of the most probable causative 
organism and the antibiotics used for its treatment.  Local knowledge of 
drug resistance patterns are also taken into account.  Treatment may be 
maintained or changed based on culture results and assessment of the 
patient’s response to initial treatment.  In the event that the cultures of 
blood or sputum prove negative, empiric treatment is continued with 
clinical response as a guide. 
The severity of the illness is a key factor in the decision for admission, 
and the choice of first or second-line treatment.  
Box 8-1:  Severity score for community acquired pneumonia (CURB-65)
Severity score may be based on the following, assigning one point to each of the 
following factors (maximum 5 points);
 yConfusion, restlessness, or excessive drowsiness
 yBlood Urea Nitrogen ( > 7 mmol/L)
 yRespiratory rate ( ≥ 30 per minute in adults, and ≥ 50 in children)
 yLow BP (Systolic BP < 90 and/or diastolic BP < 60 mmHg)
 yPatients at the extremes of age, (< 5yr or  ≥ 65yr)
0-1; consider home treatment
2-3; consider short inpatient hospitalisation
> 3; admit and consider intensive care

— Pneumonia —
Standard  Treatment Guidelines, 7th Edition, 2017
170Box 8-1:  Severity score for community acquired pneumonia (CURB-65)
In the presence any of the following additional factors, all cases of pneumonia 
would warrant hospitalisation.
Additional factors
 yCoexisting diseases such as chronic lung disease, heart failure or renal dis -
ease
 yExtensive disease, multiple lobes involved
 yLow oxygen saturation SpO2, < 92% on room air
 ySevere tachycardia
Causes 
Community acquired pneumonia
 y Streptococcus  pneumonia
 y Streptococcus  pyogenes
 yHaemophilus	influenza
 y Klebsiella  pneumoniae
 y Mycoplasma pneumonia  and Legionella pneumophila  (tend to occur 
in epidemics)
 y Staphylococcus aureus  (in children after viral illness like measles, in 
diabetics or in the elderly during ‘flu’ epidemics)
Aspiration pneumonia
 y Anaerobic and/or gram negative organisms (associated with 
aspiration e.g. stroke , seizures, unconsciousness)
Hospital acquired pneumonia
 y Gram-negative bacteria e.g. Pseudomonas  aeruginosa  
 y MRSA (Methicillin resistant)  
 y VRSA (Vancomycin  resistant)  
 y Staphylococcus aureus  
Others
 yPneumocystis	 jiroveci  pneumonia and other fungi (in 
immunocompromised states e.g. haematological malignancies, HIV /
AIDS )
 y Viruses
Symptoms 
 y Fever  - short history 
 y Productive cough 
 y Sputum - rusty or blood stained, yellowish, greenish
 y Pleuritic chest pain  - worse on deep breathing or coughing
 y Breathlessness
 y Sweating
 y Muscle aches
 y Elderly and immunocompromised patients may have minimum or no 
symptoms
Signs
 y Rapid breathing 

— Pneumonia —Chapter 8:  Disorders of the Respiratory System
171 y Grunting (in children)
 y Use of accessory muscles of respiration and flaring of the nasal 
margins
 y Lower chest wall indrawing (in children)
 y Restricted movement of the affected side of the chest (due to pain)
 y Fever
 y Rapid pulse rate
 y Blood pressure may be normal or low
 y Signs of consolidation or pleural effusion on chest examination
 y Restlessness or confusion, drowsiness
 y Low blood oxygen saturation by pulse oximetry < 92%
Complications  
 y Pleural effusion  
 y Lung abscess
 y Empyema
 y Pericardial effusion /pericarditis
 y Pneumothorax  particularly Staph. aureus  infection, Pneumocystis	
jiroveci  pneumonia
 y Meningitis
 y Septicaemia with multi organ failure
 y Adult respiratory distress syndrome (ARDS)
Investigations
 y FBC
 y C-reactive protein  (CRP)
 y Chest X-ray
 y Sputum gram stain and culture and sensitivity
 y Ziehl-Neelsen stain  for acid-fast bacilli (to exclude TB)
 y Blood culture and sensitivity
 y Blood urea and electrolytes
Treatment 
Treatment objectives
 y To identify patients at greater risk who require in-hospital 
management 
 y To alleviate symptoms
 y To treat and eradicate the infection 
 y To prevent and/or manage complications 
Non-pharmacological treatment
 y Nurse in comfortable position, usually with head raised
 y Sponging to control fever, especially in children < 5 years (who are at 
risk of febrile convulsions)
 y Adequate oral hydration (if it can be tolerated)
 y Chest physiotherapy

— Pneumonia —
Standard  Treatment Guidelines, 7th Edition, 2017
172Pharmacological treatment 
A. Ambulatory patient: low severity score < 2 (see above)
1st Line Treatment
Evidence Rating: [A]
 y Amoxicillin  (Amoxycillin ), oral,
Adult s
1 g 8 hourly for 7 days (high dose)
Children
5-12 years;   500 mg 8 hourly for 7 days
1-5 years;   250 mg 8 hourly for 7 days
6 months-1 year;  125 mg 8 hourly for 7 days
And
 y Azithromycin , oral,
Adult
500 mg daily for 6 days
Children
10 mg/kg daily for 6 days
Or  
 y Erythromycin , oral, (if patient is allergic to penicillin)
Adult
500 mg 6 hourly for 7 days
Children
8-18 years;   250-500 mg 6 hourly for 7 days
2-8 years;   250 mg 6 hourly for 7 days
6 months-2 years;  125 mg 6 hourly for 7 days
2nd Line Treatment
Evidence Rating: [A]
 y Cefuroxime , oral,
Adult s
500 mg 12 hourly for 7 days
Children
3 months-12 years;  30 mg/kg/day in two divided doses for 7 
days
> 12 years;  250-500 mg 12 hourly for 7 days
Or
 y Doxycycline , oral,
Adult s
100 mg 12 hourly for 7-14 days depending on severity
Note 8-2
Not recommended in pregnancy, lactating mothers and in children < 8 years 
of age.

— Pneumonia —Chapter 8:  Disorders of the Respiratory System
173B.     Hospitalised patient: Severity score, ≥ 2 or with additional factors 
as mentioned above 
 y Oxygen , by face mask or nasal prongs,
Adult s and Children  
Maintain oxygen saturation > 92%
And
 y IV fluids as normal saline and dextrose saline to replace estimated 
insensible loss
And
 y Paracetamol , oral,
Adult s
500 mg-1g 6-8 hourly 
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or
 y Paracetamol  suppository
Adult s and children
doses as above
And 
 y Amoxicillin + Clavulanic Acid , IV, (change to oral route when patient 
improves)
Adult s
1.2 g 8 hourly for 7-10 days
Children
3 months-18 years; 30 mg/kg 8 hourly, max. 1.2 g 8 hourly for 
7-10 days
< 3 months;   30 mg/kg 12 hourly for 7-10 days
And
 y Azithromycin , oral,  
Adult
500 mg daily for 3-7 days
Children
10 mg/kg once daily for 3-7 days
Or
 y Azithromycin , IV,  
Adult
500 mg daily for 3 days 
Revert to oral azithromycin, when clinically stable to complete 7 days 
of treatment. (See section on treatment for ambulatory patients 
above).  
Children
IV route not recommended in children for pneumonia treatment

— Pneumonia —
Standard  Treatment Guidelines, 7th Edition, 2017
174Note 8-3
Azithromycin  infusion should not be given in shorter than 1 hour. It should not 
be given as an IV bolus or as an intramuscular injection.
2nd line treatment 
Evidence Rating: [A]
 y Ceftriaxone , IV,
Adult
2 g daily for 7-10 days
Children
All ages 25 mg/kg 12 hourly (max. 75 mg/kg daily)
And
 y Azithromycin , IV  (as above) 
C.     Treatment for aspiration pneumonia
1st Line treatment 
Evidence Rating: [B]
 y Ceftriaxone , IV,
Adult
2 g daily for 7-10 days 
Children
All ages 50-75 mg/kg/day in divided 12 hourly doses 
Or
 y Amoxicillin + Clavulanic Acid , IV, (change to oral route when patient 
improves)
Adult s
1.2 g 8 hourly for 7-10 days
Children
3 months-18 years; 30 mg/kg 8 hourly, max 1.2 g 8 hourly for 
7-10 days
< 3 months;   30 mg/kg 12 hourly for 7-10 days
Or
 y Ciprofloxacin , IV, (to be administered over 60 minutes)
Adult s
400 mg 8-12 hourly for 7 days 
Children
10 mg/kg (max. 400 mg) 12 hourly for 7 days
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7 days
Children
7.5 mg/kg 8 hourly for 7 days
Or
 y Clindamycin , IV,
Adult s
300-600 mg 6 hourly for 7 days

— Bronchial Asthma —Chapter 8:  Disorders of the Respiratory System
175Children
3-6 mg/kg 6 hourly for 7 days
Referral Criteria 
Refer to the paediatrician or physician specialist if no improvement 
occurs (i.e. fever remains high, patient is still breathless, or repeat X-rays 
show complications or no resolution). 
60� Bronchial Asthma
Asthma  is a chronic inflammatory disease of the bronchial airways, 
which manifests as recurrent episodes of wheeze, cough, chest tightness 
and shortness of breath, which is usually reversible with treatment. It 
is characterised by increased sensitivity to many environmental agents. 
Asthma is variable and may be associated with seasons like the rainy 
season or harmattan. Bronchial asthma occurs at all ages but peaks in 
childhood. It is classified as an allergic disease, and may be associated 
with a personal or family history of allergic rhinitis  (hay fever), eczema  or 
allergic conjunctivitis. 
Complications of asthma include pneumomediastinum, 
pneumothorax, subcutaneous emphysema and pneumonia. 
Causes 
 y Allergens e.g. house dust mite, cockroach droppings, grass, pollen 
and animal hair
 y Environmental factors e.g. air pollution, climatic changes, strong 
scents and smoke (including cigarette smoke and car fumes)
 y Viral infections 
 y Exercise
 y Emotions and hyperventilation 
 y Drugs e.g. aspirin , NSAIDS and beta-blockers such as propranolol
 y Occupational exposure to industrial chemicals, dust and drug 
manufacturing
Symptoms
 y Episodic breathlessness
 y Tightness of the chest
 y Cough  - often nocturnal
 y Wheeze
 y Nocturnal symptoms. Any of the above symptoms waking up the 
patient at night
Signs
 y Tachypnoea  (fast breathing)
 y Use of accessory muscles of respiration; neck and/or abdominal 
muscles
 y Rhonchi/wheeze 

— Bronchial Asthma —
Standard  Treatment Guidelines, 7th Edition, 2017
176 y Signs of severe attack
 y Inability to complete full sentences in one breath
 y Rapid pulse > 110/minute in adults and adolescents or >130/
minute in children 2-5 years
 y Rapid respiration > 30/minute in adults and adolescents or or > 
50/minute in children 2-5 years
 y Peak Expiratory Flow Rate (PEFR) is reduced < 50% of expected 
(for age, sex and height)
 y Signs of a life-threatening attack are:
 y Cyanosis
 y Pulsus paradoxus
 y Silent chest on auscultation
 y Drowsiness or confusion
 y Exhaustion
 y Peak Expiratory Flow Rate (PEFR) less than 33 % of expected 
value
 y SpO2 less than 92% on room air
Investigations
 y No investigation required in most cases
 y FBC, mildly high eosinophil count
 y Chest X-ray (only for the exclusion of other diagnoses or complications)
 y Spirometry  - reduction in FEV1 and FEV1/FVC ratio with reversibility 
demonstrated after bronchodilator use  (a normal spirometry 
between attacks does not exclude asthma).
 y Tests for atopy - skin prick test or specific IgE for common allergens
 y Stool examination, exclude helminthiasis
Treatment 
Treatment objectives
 y To relieve bronchospasm
 y To prevent complications and recurrence
 y To treat underlying inflammation or infection
Non-pharmacological treatment
 y Avoid known triggers/allergens, such as dust (dust mite) where 
possible
 y Avoid smoking
 y Education on asthma self management, device use and technique
Pharmacological treatment 
A.     Acute Exacerbation of Asthma : Initial Management in the 
Community
Evidence Rating: [C]
 y Salbutamol  inhaler, using pressurized metered dose inhaler (pMDI) 
with a spacer
Adult s and Children
Give 1-2 puffs via a spacer and mask if needed (e.g. Volumatic Or 

— Bronchial Asthma —Chapter 8:  Disorders of the Respiratory System
177Aerochamber, or large plastic mineral water bottle) with the patient 
taking 3-4 breaths after each puff.  
Repeat after every 15-30 minutes maximum 10 doses.
If there is no improvement seek care at a health facility with a nebu -
liser.
B.     Acute Moderate/Severe Exacerbation of Asthma : Initial 
Management in Hospital
1st Line Treatment
Evidence Rating: [A]
 y Oxygen  
 By nasal prongs 2-6 L/min
Or 
 Face mask 4-8 L/min 
Or 
 Non-rebreather mask  10-15 L/min
And
 y Salbutamol , nebulised,
Adult s
2.5-5 mg repeated initially after 15-30 minutes, then every 2-4 hours 
until improved
Children
2.5-5 mg every 2-4 hours until improved
And
 y Ipratropium bromide , nebulised,
Adult s
500 microgram 4-6 hourly
Children
6-12 years;  250 microgram 4-6 hourly
1-5 years;   125 microgram 4-6 hourly
(max. dose for children is 1 mg/24 hours)  
And
 y Hydrocortisone , IV, 
Adult s
200 mg stat. then 100 mg 6 hourly until clinical improvement
Children
12-18 years;  100 mg 6-8 hourly
1 month-12 years; 2-4 mg/kg 8 hourly
Then 
C.     Acute Moderate/Severe Exacerbation of Asthma : Maintenance 
Treatment in Hospital
 y Salbutamol , nebulised,
Adult s
2.5-5 mg repeated every 6 hours until improved
Children

— Bronchial Asthma —
Standard  Treatment Guidelines, 7th Edition, 2017
1782.5-5 mg every 6 hours until improved
And
 y Ipratropium bromide , nebulised,
Adult s
500 microgram 4-6 hourly
Children
6-12 years;  250 microgram 4-6 hourly
1-5 years;   125 microgram 4-6 hourly
(max. dose for children 1 mg/24 hours) 
Note 8-4
For children < 12 years with severe symptoms consider; 
Ipratropium bromide , 250 microgram repeated every 20-30 minutes, for the 
first 2 hours, then 4-6 hourly as necessary 
And
 y Prednisolone , oral, initial dose given on admission and subsequently 
given as a morning dose. (Once on prednisolone, stop IV hydrocorti -
sone  after 24 hours)
Adult s
30-40 mg daily for 7 days until stable. Taper off dose over a period of 
2 weeks if patient has been on long term steroids.
Children
1-2 mg/kg for 3-5 days
D.     Acute Moderate/Severe Exacerbation of Asthma : Maintenance 
Treatment in Hospital (where patient is still distressed after 3-4 
initial doses of nebulised salbutamol)
 y Aminophylline , IV, 
Adult s
250 mg slow injection over 20 minutes
Repeat after 30 minutes with a continuous infusion by perfusor, if 
necessary, at a rate not exceeding 0.5 mg/kg/hour over 24 hours
Or 
 y Aminophylline , IV infusion, 250 mg in 500 ml of 5% Dextrose  or 0.9% 
Sodium Chloride , 6 hourly for 24 hours
Children
5 mg/kg over 20 minutes as a slow infusion or by perfusor at 1mg/
kg/hour (max. 500 mg)
E.     Chronic Asthma  - Initial management
Evidence Rating: [A]
 y Salbutamol , inhaled, 
Adult s and children 
100 microgram, 2 puffs as often as needed
And 
(If inhaled Salbutamol  is needed more than once daily)
 y Budesonide , inhaled,
Adult s 

— Bronchial Asthma —Chapter 8:  Disorders of the Respiratory System
179200 microgram (one puff 12 hourly)
Children  
> 10 years;  200 microgram (one puff 12 hourly)
< 10 years;  100 microgram (one puff 12 hourly)
Or
 y Fluticasone , Inhaled - MDI,
Adult s
125-250 microgram (2 puffs 12 hourly)
Children
50 microgram (2 puffs 12 hourly)
Or
 y Beclometasone  (Beclomethasone ), inhaled,
Adult s and Children
100 microgram (2 puffs 12 hourly)
F.     Chronic Asthma  - Maintenance treatment
 y Salbutamol , inhaled, 
Adult s and children 
100 microgram, 2 puffs as often as needed
And
 y Fluticasone /Salmeterol, inhaled,
Adult s and children over 5 years
100/50-250/50 microgram; 1 puff 12 hourly 
Or
 y Budesonide /Formoterol , inhaled,
Adult s
160/4.5 microgram (1-2 puffs 12 hourly)
Children  over 5 years
80/4.5 microgram (1-2 puffs 12 hourly)
And 
 y Montelukast , oral,
Adult
10 mg daily
Children
4 or 5 mg granules daily
And
 y Prednisolone , oral,
Adult s
30-40 mg daily and tail down slowly over 2-3 week period to a low 
maintenance daily dose of 5 mg daily.
Children
1 mg/kg tailed off by 5 mg every third day, reducing to 5-10 mg daily 
or alternate daily, lowest dose possible without provoking attacks

— Acute Bronchitis —
Standard  Treatment Guidelines, 7th Edition, 2017
180Note 8-5
Review treatment every 3-6 months with a view to stepping down treatment if 
client is symptom-free or has minimal symptoms (<1-2 times a month).
All patients with chronic Asthma  should receive continuous education and 
counselling by the medical team.
Referral Criteria 
In acute exacerbation, refer patients if not improving or rapidly 
deteriorating after initial management to a specialist.
All discharged clients should be followed up within one week and 
referred to a specialist clinic for continued care.
For chronic asthma refer patients with persistent symptoms to a 
specialist clinic in a regional or tertiary hospital, and patients who have 
recurrent acute exacerbations within a few days/ weeks of each other for 
specialist care and review of their treatment. 
Also refer when a patient requires more than one course of oral 
prednisolone in 3 months.
61� Acute Bronchitis
This refers to an acute inflammation of the bronchial mucosa. It is 
often found in association with upper respiratory tract infection. Most 
cases do not require antibiotics, however, they may be prescribed if the 
patient’s SPO2 is less than 92% or if there is an underlying co-morbidity 
like malnutrition, measles, rickets, anaemia, diabetes mellitus, chronic 
bronchitis or HIV /AIDS .
Causes 
 y Viruses e.g. Influenza virus , Corona virus  (common cold)
 y Bacteria e.g. Streptococcus  pneumoniae ,  H.	influenza , Moraxella 
catarrhalis , Staph. aureus   (tends to cause post-influenza chest 
infections, including bronchitis)
Symptoms
 y Dry cough
 y Sputum production
 y Sore throat
 y Pleuritic chest pain
 y Low grade fever
Signs
 y Fever
 y Rhinorrhoea
 y Rhonchi (wheeze)  
 y Crepitations (rare)
Investigations
 y FBC

— Acute Bronchitis —Chapter 8:  Disorders of the Respiratory System
181 y Sputum culture and gram stain
 y Sputum AFBs (2 samples) for tuberculosis if symptoms have lasted 
more than 2 weeks
 y Sinus X-ray for rhinosinusitis (with post nasal drip) as a possible cause 
for prolonged cough
Treatment 
Treatment objectives
 y To relieve symptoms
 y To treat suspected bacterial infection if any
Non-pharmacological treatment
 y Bed rest
 y Oral fluids to keep well hydrated
 y Humidified air or steam inhalation if necessary 
Pharmacological treatment 
A.     Uncomplicated acute infections 
1st Line Treatment
Evidence Rating: [C]
 y Paracetamol , oral,
Adult s
500 mg-1g 6-8 hourly
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or
 y Paracetamol , rectal, 
Adult s
500 mg-1g 6-8 hourly
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
B.     Uncomplicated acute infections-for irritating or chesty coughs
 y Guaifenesin  containing expectorant, oral, 
Adult  
200-400 mg 4 hourly (max. 2.4 g per day)
Children  
>12 years;  100-400 mg 4 hourly (max. 2.4 g per day)
6-11 years;  100-200 mg 4 hourly (max. 1.2 g per day)
2-5 years;  50-100 mg 4 hourly (max. 600 mg per day)
6 months-2 years; 25-50 mg 4 hourly (max. 300 mg per day)
Or 
 y Simple linctus , oral,
Adult s (adult formulation)
5 ml 6-8 hourly

— Acute Bronchitis —
Standard  Treatment Guidelines, 7th Edition, 2017
182Children  (paediatric formulation)
1 month-12 years;   2.5-5 ml 6-8 hourly
Or
 y Carbocysteine , oral, 
Adult
500-750 mg 6-8 hourly
Children
2-5 years;   62.5-125 mg 6 hourly 
<2 years;       not recommended  
C.     Uncomplicated acute infections-for non-productive or dry cough
 y Dextromethorphan  containing cough preparations
Adult  
10-20 mg 6-8 hourly 
Children  
7-12 years;  15 mg 6-8 hourly (max. 60 mg per day)
4-6 years;  7.5 mg 6-8 hourly (max. 30 mg per day)
< 4 years; not recommended 
Or
 y Codeine  containing cough preparations
Adult  
7.5 -20 mg 4-6 hourly as needed (max. 120 mg per day)
Children  
7-12 years;  1-1.5 mg/kg per day in 4-6 divided doses 
(max. 60 mg per day)
2-6 years;  1-1.5 mg/kg per day in 4-6 divided doses (max. 30 mg 
per day)
< 2 years; not recommended
D.     For complicated acute infections with co-morbidities or secondary 
bacterial infection
1st Line Treatment
Evidence Rating: [C]
 y Amoxicillin  (Amoxycillin), oral,
Adult s
500 mg 8 hourly for 5-7 days
Children
6-12 years;   250 mg 8 hourly for 7 days
1-5 years;   125 mg 8 hourly for 7 days
<1 year;   62.5 mg 8 hourly for 7 days
Or
 y Amoxicillin + Clavulanic Acid , oral,
Adult s
1 g 12 hourly for 5-7 days
Children
> 12 years;  One 500/125 tablet 12 hourly for 7 days
4-12 years; 5 ml of 400/57 suspension 12 hourly for 7 days
1-4 years;  5 ml of 200/28 suspension 12 hourly for 7 days

— Chronic Bronchitis  —Chapter 8:  Disorders of the Respiratory System
1833 months-1 year; 20 mg/kg (of amoxicillin) 12 hourly for 7 days 
< 3 months;  15 mg/kg (of amoxicillin) 12 hourly for 7 days 
For children double the dose of the above antibiotic in severe infec -
tions (bronchopneumonia)
Or
 y Erythromycin , oral, (for individuals allergic to penicillin)
Adult s
250-500 mg 6 hourly for 7 days
Children
8-18 years;   250-500 mg 6 hourly 7 days
2-8 years;   250 mg 6 hourly 7 days
6 months-2 years;  125 mg 6 hourly 7 days
Or
 y Azithromycin , oral,
Adult s
500 mg once daily for 3 days
Children
10 mg/kg once daily for 3 days
And 
 y Oxygen  
By nasal prongs, 2-6 L/min
Or 
Face mask, 4-8 L/min
Or 
Non-rebreather mask, 10-15 L/min
Referral Criteria 
Refer all complicated cases of acute bronchitis to a specialist.
62� Chronic Bronchitis  
This is chronic inflammation of the bronchial mucosa due to irritants 
such as tobacco smoke. It occurs after the age of 40 years and is part of 
the syndrome of chronic obstructive pulmonary disease (COPD ). There is 
progressive worsening with age, eventually resulting in chronic respiratory 
failure. It is aggravated by recurrent viral and bacterial infections.
Oxygen  therapy in these patients must be given with caution to 
prevent carbon dioxide retention due to depression  of respiration.  High 
flow rates remove the central hypoxic drive that maintains respiratory 
effort and can be harmful.
Causes 
 y Cigarette smoking
 y Industrial dust
 y Chemical irritants
 y Inhaled smoke from use of biomass fuels (eg. charcoal, wood)

— Chronic Bronchitis  —
Standard  Treatment Guidelines, 7th Edition, 2017
184Symptoms
 y Shortness of breath, particularly on exertion
 y Wheeze 
 y Fever  
 y Cough  with production of sputum for most of the year
 y Infective exacerbation associated with increased quantity of thick 
purulent sputum
Signs
 y May be none 
 y Barrel chest
 y Pursed lip breathing
 y Clubbing 
 y Cyanosis
 y Increased respiratory rate
 y Use of assessory muscles i.e.  neck and/or abdominal muscles, for 
breathing 
 y Hyperresonance on percussion and loss of cardiac dullness
 y Wheeze or rhonchi
 y Reduced Peak Expiratory Flow Rate (PEFR) 
Investigations
 y FBC
 y Spirometry , shows reduced lung volumes, particularly FEV1 which is 
not reversed post-bronchodilator administration
 y Chest X-ray
 y Sputum culture and gram stain
Treatment 
Treatment objectives
 y To minimise or stop cough
 y To prevent or minimise wheeze and shortness of breath
 y To reduce quantity of sputum produced 
 y To prevent infective exacerbations
Non-pharmacological treatment
 y Smoking cessation
 y Physical exercise
 y Good nutrition
 y Use of face mask in high risk occupations
Pharmacological treatment 
A.     Stable chronic bronchitis
Evidence Rating: [B]
 y Salbutamol , inhaled, (via pMDI)
Adult s
100 microgram (2 puffs) 4-6 hourly as required

— Chronic Bronchitis  —Chapter 8:  Disorders of the Respiratory System
185Children  (by nebulisation)
2.5-5 mg 4-6 hourly as required
And
 y Tiotropium , inhaled (dry powder inhaler),
Adult s
18 microgram (2 puffs) daily
Children  
> 12 years;  18 microgram (2 puffs) daily
< 12 years;  not recommended 
And
 y Fluticasone /salmeterol, inhaled (via accuhaler or pMDI),
Adult s
100/50 microgram or 250/50 microgram or 500/50 microgram, 1 
puff 12 hourly
Children  
4-12 years; 100/50 microgram, 1 puff 12 hourly
< 4 years;  safety not established 
Or
 y Budesonide /formoterol, inhaled (via accuhaler or pMDI),
Adult s
160/4.5 microgram 1-2 puffs 12 hourly
Children  
>12 years;  160/4.5 microgram 1-2 puffs 12 hourly
<12 years;  efficacy not established
B.     Chronic bronchitis with infective exacerbation
Evidence Rating: [C]
 y Oxygen  
By nasal prongs, 2-6 L/min
Or 
Face mask, 4-8 L/min
Or 
Non-rebreather mask, 10-15 L/min
And
 y Salbutamol , nebulised,
Adult s
2.5-5 mg repeated initially after 15-30 minutes, then every 2-4 hours 
until improved
Children
2.5-5 mg 4-6 hourly
And
 y Ipratropium bromide , nebulised,
Adult s
500 microgram 4-6 hourly, until improved
Children
6-12 years;  250 microgram 4-6 hourly

— Chronic Bronchitis  —
Standard  Treatment Guidelines, 7th Edition, 2017
1861-5 years;   125 microgram 4-6 hourly
(max. dose for children 1 mg/24 hours) 
And 
 y Amoxicillin  (Amoxycillin), oral,
Adult s
500 mg 8 hourly for 7-14 days
Children
6-12 years;   250 mg 8 hourly for 7-14 days
1-5 years;   125 mg 8 hourly for 7-14 days
<1 year;   62.5 mg 8 hourly for 7-14 days
Or
 y Erythromycin , oral,
Adult s
500 mg 6 hourly for 7-14 days
Children
8-18 years;   250-500 mg 6 hourly 7-14 days
2-8 years;   250 mg 6 hourly 7-14 days
6 months-2 years;  125 mg 6 hourly 7-14 days
Or
 y Azithromycin , oral,
Adult
500 mg daily for 6 days
Children
10 mg/kg daily for 6 days
Or
 y Amoxicillin + Clavulanic Acid , oral,
Adult s
1 g 12 hourly for 7-10 days
Children
> 12 years;  One 500/125 tablet 12 hourly for 7-10 days
4-12 years;  5 ml of 400/57 suspension 12 hourly for 7-10 days
1-4 years;  5 ml of 200/28 suspension 12 hourly for 7-10 days
3 months-1 year; 20 mg/kg (of amoxicillin) 12 hourly for 7-10 days 
< 3 months; 15 mg/kg (of amoxicillin) 12 hourly for 7-10 days
And 
 y Prednisolone , oral, 
Adult s
30-40 mg for 7 days 
Then 
20 mg daily for 5 days, 10 mg daily for 5 days, 5 mg daily for 5 days. 
Tail down over 2-3 weeks and stop.
Children
1-2 mg/kg for 3-5 days. Tail down over 2-3 weeks and stop.
And 
 y Acetylcysteine , oral, 

— Bronchiectasis —Chapter 8:  Disorders of the Respiratory System
187Adult s
10 ml 8 hourly for 5-7 days
Children  (paediatric formulation)
5-10 ml 8 hourly for 5-7 days
Or
 y Carbocysteine , oral, 
Adult
500-750 mg 6-8 hourly
Children
2-5 years;    62.5-125 mg 6 hourly 
< 2 years;        not recommended  
Referral Criteria 
Refer all patients not improving on initial management, with acute 
exacerbation, recurrent infective exacerbations or rapidly deteriorating to 
a specialist. 
63� Bronchiectasis
In bronchiectasis, the medium and smaller sized bronchi and 
bronchioles are damaged. Their ciliated epithelium is destroyed by 
inflammation and scarring, which in a vicious cycle of infection and further 
scarring leads to permanent dilatation and bronchial wall thickening. The 
mucus lining of these airways become colonized by bacteria and generate 
copious amounts of purulent and often offensive sputum. The disease, 
if not treated is characterized by frequent infective exacerbations with 
progressively worsening lung function.
Causes 
 y Childhood pneumonia e.g. whooping cough, post measles
 y Post-pulmonary tuberculosis 
 y Chronic rhinosinusitis with post-nasal drip 
 y Asthma  and COPD
 y Fibrosing lung disease of any cause e.g. rheumatoid lung disease 
 y Immune deficiency states e.g. HIV  infection, agammaglobulinaemia
 y Inherited disorders e.g. cystic fibrosis, primary ciliary dyskinesia 
should be considered in young children presenting with bronchiectasis
Symptoms
 y Persistent cough over many months
 y Copious purulent sputum which is sometimes offensive 
 y Haemoptysis  in over one third of cases during exacerbations
 y Intermittent systemic symptoms - fever, night sweats and weight loss
 y Chest pain 
 y Difficulty in breathing
Signs
 y Weight loss

— Bronchiectasis —
Standard  Treatment Guidelines, 7th Edition, 2017
188 y Fever
 y Clubbing
 y Dull percussion note 
 y Bronchial breath sounds 
 y Coarse crepitations
Investigations
 y FBC, ESR
 y Sputum culture and sensitivity, gram stain
 y Sputum AFBs
 y Chest X-ray 
 y CT scan of the chest
 y Pulse oximetry
Treatment 
Treatment objectives
 y To treat infection
 y To aid sputum clearance
 y To minimize cough and sputum production
 y To prevent exacerbations
 y To diagnose and treat underlying disorders
Non-pharmacological treatment
 y Chest physiotherapy - Postural drainage, Sputum clearance 
techniques 
 y Breathing exercises 
 y Improve nutrition
 y Encourage adequate fluid intake
 y Encourage physical exercise 
Pharmacological treatment 
A.     Acute infective exacerbation
1st Line Treatment
Evidence Rating: [C]
 y Amoxicillin + Clavulanic Acid , oral,  
Adult s
1 g 12 hourly for 14 – 21 days
Children
>12 years;  One 500/125 tablet 12 hourly
6-12 years;  5ml of 400/57 suspension 12 hourly 
1-6 years;  2.5ml of 400/57 suspension 12hourly 
1month-1 year; 0.25ml/kg body weight of 125/31
suspension 8 hourly 
< 1 month;  0.25ml/kg body weight of 125/31
suspension 8 hourly 
And
 y Azithromycin , oral, (for patients allergic to penicillin, given as mono -
therapy)

— Lung Abscess —Chapter 8:  Disorders of the Respiratory System
189Adult s
500 mg once daily for 6-14 days
Children
10 mg/kg once daily for 6-14 days
Referral Criteria 
Refer all suspected cases to a specialist for confirmation and further 
management.
64. Lung Abscess
A lung abscess is defined as necrosis of the pulmonary parenchyma 
and formation of cavities containing necrotic tissue or purulent fluid, 
usually caused by microbial infection. Antibiotic management should be 
considered as soon as it is diagnosed, while awaiting confirmation of the 
causative organism and must be continued for 4-6 weeks.
Causes 
 y Aspiration of infected secretions or tissue from the mouth and upper 
respiratory tract in the unconscious or semi-conscious patient e.g. in 
alcoholics, epileptics, anaesthetised or dental patients 
 y Foreign body aspiration e.g. inhaled peanut, dentures, fish bone
 y Inadequately treated bacterial pneumonia especially, gram 
negative bacteria like Klebsiella  pneumoniae , and beta-haemolytic 
streptococci
 y Staphylococcus aureus  causing multiple lung abscesses
 y Penetrative lung injury
 y Partial obstruction of an airway by tumour or lymph node
 y Septic emboli from other infected areas of the body e.g. right sided 
bacterial endocarditis
 y Bronchiectasis
 y Infected bullae in chronic lung disease
Symptoms
 y Fever  with swinging temperatures
 y Cough , productive of copious amounts of purulent foul smelling 
sputum
 y Haemoptysis
 y Chest pain 
 y Breathlessness
 y Easy fatiguability
Signs
 y Fever
 y Tachycardia
 y Tachypnoea
 y Chest wall tenderness
 y Dull percussion note

— Lung Abscess —
Standard  Treatment Guidelines, 7th Edition, 2017
190 y Diminished breath sounds
 y Increased vocal resonance 
Investigations
 y FBC
 y Sputum culture and sensitivity, gram stain
 y Sputum AFBs
 y Chest X-ray 
Treatment 
Treatment objectives
 y To drain abscess collection
 y To treat underlying infection
 y To treat predisposing conditions
Non-pharmacological treatment
 y Chest physiotherapy 
 y Improve nutritional status
 y Ensure adequate fluid intake 
 y Surgical drainage of abscess
Pharmacological treatment 
A.     Initial treatment 
1st Line Treatment
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 4 weeks
Children  
5-12 years;   250 mg 6 hourly for 2-4 weeks
1-5 years;   125 mg 6 hourly for 2-4 weeks
< 1 year;   62.5 mg 6 hourly for 2-4 weeks 
And
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 8 hourly for 4 weeks  
Children
3 months -18 years; 30 mg/kg 8 hourly, max. 1.2g 8 hourly
< 3 months;   30 mg/kg 12 hourly for 2-4 weeks
And
 y Ceftriaxone , IV, 
Adult
2 g daily for 4 weeks
Children
All ages 50-75mg /kg per day in divided 12 hourly doses for 4 weeks
Or
 y Gentamicin , IV,
Adult s

— Lung Abscess —Chapter 8:  Disorders of the Respiratory System
19140-80 mg 8 hourly for 14 days
Children
1-12 years;   2.5 mg/kg 8 hourly for 14 days
< 1 year;   2.5 mg/kg 12 hourly for 14 days
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 4 weeks
Children
7.5 mg/kg 8 hourly for 4 weeks
Or
 y Clindamycin , IV,
Adult s
300-600 mg 6 hourly for 4 weeks or until clinical improvement
Children
3-6 mg/kg 6 hourly for 2-4 weeks
B.     Continuation treatment 
 y Flucloxacillin , oral, 
Adult s
500 mg 6 hourly for 2 weeks
Children  
5-12 years;   250 mg 6 hourly for 2 weeks
1-5 years;   125 mg 6 hourly for 2 weeks
< 1 year;   62.5 mg 6 hourly for 2 weeks 
And
 y Amoxicillin + Clavulanic Acid , oral,  
Adult s
1 g 12 hourly for 14-21 days.
Children
> 12 years;   One 500/125 tablet 12 hourly
6-12 years;   5 ml of 400/57 suspension 12 hourly 
1-6 years;   2.5 ml of 400/57 suspension 12 hourly 
1 month-1 year;  0.25ml/kg body weight of 125/31 suspen -
sion 8 hourly 
< 1 month;   0.25 ml/kg body weight of 125/31 suspen -
sion 8 hourly 
And 
 y Clindamycin , oral, 
Adult
300 mg 6 hourly for 14 days
Children
> 3 months; 15-40 mg/kg/day, in 3 divided doses,
(Minimum dose - not less than 300 mg/day)
Referral Criteria 
Refer to a specialist or higher-level facility if there is no clinical 

— Lung Abscess —
Standard  Treatment Guidelines, 7th Edition, 2017
192improvement within the first 2 weeks of initiating antibiotic therapy.

9Chapter
193Disorders of the Central 
Nervous System
65� Headache
Headache  is caused by traction, displacement, inflammation, vascular 
spasm or distension of the pain sensitive structures in the head or neck. 
Headaches that are new in onset and clearly different from any the patient 
has experienced previously are commonly a symptom of serious illness 
and therefore demand prompt evaluation. The precipitating factors, 
associated symptoms and clinical findings on examination, together with 
the results of appropriate investigations, can provide a guide to the cause 
of the headache. 
Causes 
Acute
 y Subarachnoid haemorrhage and other cerebrovascular diseases
 y Infections e.g. malaria, typhoid fever , viral infections
 y Meningitis  or encephalitis
 y Ocular disorders (glaucoma, acute iritis, refractive errors)
 y Post-seizures
 y Post-lumbar puncture
 y Hypertensive encephalopathy
Subacute
 y Lesions of the middle ear (otitis media , mastoiditis)
 y Intracranial mass (tumour, subdural haematoma, abscess)
 y Idiopathic intracranial hypertension
 y Trigeminal neuralgia
 y Post-herpetic neuralgia
 y Severe hypertension
 y Atypical facial pain
 y Medication
 y Post trauma 
 y Giant cell temporal arteritis 
Chronic
 y Migraine
 y Cluster headache
 y Tension headache

— Headache —
Standard  Treatment Guidelines, 7th Edition, 2017
194 y Cervical spine disease
 y Sinusitis
 y Dental disease
 y Psychogenic causes
Symptoms
 y Visual e.g. photophobia, flashes of light, floaters
 y Aura e.g. visual, auditory, gustatory, tactile
 y Accompanying features e.g. nausea, vomiting , fever, collapse
 y Site of pain e.g. occipital, ocular, unilateral, bilateral
 y Characteristics e.g. pulsating, throbbing, sharp, dull
 y Relieving or exacerbating factors e.g. cough, coitus, lying flat
Signs
 y Usually none
 y Local tenderness
 y Fever
 y Neck stiffness
 y Positive Kernigs
 y Markedly elevated blood pressure 
 y Drowsiness 
 y Excessive lacrimation 
 y Conjunctival redness
 y Papilloedema 
 y Focal neurologic deficit e.g. cranial nerve deficit, hemiparesis
Investigations
 y FBC
 y ESR
 y Skull X-ray
 y Cervical X-ray
 y X-ray of the paranasal sinuses
 y Lumbar puncture (meningitis , subarachnoid bleed)
 y Eye tests (tonometry, refraction, fundoscopy)  
 y Cranial CT scan or MRI if warranted
Treatment 
Treatment objectives
 y To relieve pain
 y To identify and treat underlying cause
 y To prevent complications relating to the underlying cause
 y To improve quality of life
Non-pharmacological treatment
 y Relaxation techniques
 y Avoidance of stress
 y Psychotherapy
 y Identification and elimination of trigger factors

— Headache —Chapter 9:  Disorders of the Central Nervous System
195Pharmacological treatment 
A.     Acute symptomatic treatment of headaches
1st Line Treatment
Evidence Rating: [B]
 y Paracetamol , oral,
Adult s
500 mg-1 g 6 - 8 hourly  
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or 
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
>12 years;   50 mg 12 hourly
<12 years;   not recommended
Or
 y Ibuprofen , oral,
Adult s
400 mg 6-8 hourly
Children
6-12 years;   200-400 mg 6-8 hourly
1-5 years;   100-200 mg 6-8 hourly
3 months-1 year;  not recommended
Or
 y Tramadol , oral,
Adult s
50-100 mg 4-6 hourly (max. 400 mg daily)
Children
> 12 years;  50-100 mg 4-6 hourly 
< 12 years;  not recommended
B.     Prophylaxis for Migraine  headaches
1st Line Treatment 
Evidence Rating: [B]
 y Propranolol , oral,
Adult s
Initial; 40 mg 12 hourly, maintenance; 80-120 mg 12 hourly 
Children
Initial; 20-40 mg 12 hourly, maintenance; 40-80 mg 12 hourly 
Referral Criteria 
Refer recurrent, unresolving or unexplained headaches to a specialist 
for evaluation and appropriate management.

— Seizures —
Standard  Treatment Guidelines, 7th Edition, 2017
19666� Seizures
A seizure is a clinical event caused by a transient disturbance of 
brain function due to an abnormal paroxysmal neuronal discharge in 
the brain. If these episodes are recurrent without an identifiable cause, 
they are commonly described as epilepsy .  The term status epilepticus 
is used for repeated seizures, which occur without the patient regaining 
consciousness between attacks. (See section on ‘Epilepsy  and Status 
epilepticus’).
The clinical presentation depends on the part of the brain affected. 
Patients may sometimes describe the warning signals (termed a prodrome 
or aura), which they experienced before the event.  A detailed description 
by a witness is key. 
General anaesthesia and ventilation may be required in severe cases 
and where high doses of anticonvulsants are required.
Causes 
 y Congenital, prenatal or perinatal injury
 y Fevers, especially in children aged 6 months to 6 years (febrile 
convulsion )
 y Cerebral malaria
 y Infections e.g. meningitis , TB, HIV , abscesses in the brain
 y Metabolic causes: hypoglycaemia, hypocalcaemia, hyponatraemia, 
hyperosmolar diabetic state, uraemia, hepatic failure
 y Idiopathic epilepsy   (See section on ‘Epilepsy ’)
 y Eclampsia
 y Vascular diseases: hypertensive encephalopathy , stroke , myocardial 
infarction
 y Space occupying lesions: tumour or malformations of the brain
 y Head trauma
 y Drugs and toxins: alcohol, antidepressants, metronidazole, drug and 
alcohol withdrawal
 y Degenerative diseases e.g. dementia 
 y Psychogenic:  (See section on ‘Psychogenic Seizures ’)
Symptoms
 y Loss of consciousness 
 y Tongue biting 
 y Foaming at the mouth
 y Incontinence of stool and/or urine
 y Aura (may include a strange gut feeling, somatosensory 
manifestations - visual, olfactory, gustatory or auditory e.g. strange 
smells/flashing lights)
 y Muscle twitching and movements which may be focal or generalized
 y After a seizure, the patient may be confused (post-ictal confusion) or 
may sleep for some time (post-ictal sleep)

— Seizures —Chapter 9:  Disorders of the Central Nervous System
197Signs
 y A prodrome or aura with automatism (lip smacking, picking at items)
 y Muscle twitching and movements which may be focal or generalized
 y Post-ictal sleep 
 y Post-ictal confusion
 y Todd’s paralysis  (stroke -like weakness) may rarely occur
 y Examine carefully for evidence of neurological localizing signs, 
tongue laceration and evidence of trauma to the face or other parts 
of the body
Investigations
 y FBC, ESR 
 y Blood glucose
 y BUE
 y Calcium
 y LFTs
 y Chest X-ray
 y Electroencephalogram (EEG)
 y CT scan (head) 
Treatment 
Treatment objectives
 y To stop the seizure
 y To treat underlying cause
 y To prevent injury
Non-pharmacological treatment
 y Move sharp objects, fire etc. away from patient during seizures
 y Ensure clothing around the neck is loose
 y Ensure the airway is clear, wipe or suction any secretions or vomitus 
from the mouth or nose. 
 y Do not force a spoon or tongue depressor into mouth!
 y Remove false teeth if present
 y After convulsions cease, turn the patient into semi-prone position 
by turning the patient on the side, with one leg bent and the other 
leg straight
 y Monitor fits (fits chart)
Pharmacological treatment 
A.     Acute Seizures  (immediate emergency measures)
1st Line Treatment
Evidence Rating: [A]
 y Oxygen  
By nasal prongs, 2-6 L/min
Or 
Face mask, 4-8 L/min
Or 
Non-rebreather mask, 10-15 L/min

— Seizures —
Standard  Treatment Guidelines, 7th Edition, 2017
198And
 y Lorazepam , slow IV,
Adult s
4 mg as a single dose, repeated once after 10 minutes if necessary. 
Given into a large vein slowly over 3-5 minutes.
Children  
12-18 years;   4 mg as a single dose, repeated once after 
10 minutes if necessary. Given into a large vein slowly over 3-5 min -
utes.
1 month-12 years;  100 microgram/kg (max. 4 mg) as a single 
dose, repeated once after 10 minutes if necessary.
Neonate s;   100 microgram/kg (max. 4 mg) as a single 
dose, repeated once after 10 minutes if necessary.
Or
 y Midazolam , IV,
Adult s
150-300 microgram/kg, may repeat every 10-15 minutes as required 
Children
1 month-18 years;  initially 150-200 microgram, followed by 
followed by continuous infusion of 60 microgram/kg per hour. May 
increase by 60 microgram /kg per hour every 15 minutes until sei -
zures are controlled. (max. 300 microgram/kg per hour)
Neonate s;   150-200 microgram/kg followed by contin -
uous infusion of 60 microgram/kg per hour. May increase by 60 mi -
crogram /kg per hour every 15 minutes until seizures are controlled. 
(max. 300 microgram/kg per hour)
Or
 y Midazolam , buccal,
Adult s
10 mg
Repeat after 10 minutes if necessary.
A third dose must not be given sooner than 12 hours after the sec -
ond dose.
Children
6 months-18 years; 200-500 microgram/kg (max. single dose 10 
mg) 
Repeat after 10 minutes if necessary.
A third dose must not be given sooner than 6 hours after the second 
dose in children < 40 kg.
2nd Line Treatment 
 y Diazepam , IV,
Adult s
10 mg slowly over 2-3 minutes (approximately 2.5 mg every 30 sec -
onds) 
Children
200-300 microgram/kg slowly over 2-3 minutes.
This may be repeated 10 minutes later if the fit continues. 
Or

— Seizures —Chapter 9:  Disorders of the Central Nervous System
199 y Diazepam , rectal,
Children
>12 years;  0.2 mg/kg 
6-12 years;  0.3 mg/kg 
2-6 years;  0.5 mg/kg 
1 month-2 years;  2.5 mg 
Neonate s;   1.25-2.5 mg
This may be repeated 10 minutes later if the fit continues. (max. 10 
mg)
Note 9-1
If a rectal formulation is not immediately available, draw up the injectable form 
directly into a syringe and administer it into the rectum (after removing the 
needle). 
B.     If seizures continue (Status Epilepticus )
 y Phenytoin , IV, (with ECG monitoring)
Adult s
15 mg/kg slowly at rate no greater than 50 mg/minute. (max. 2 g 
loading dose),
Then
Maintenance, 100 mg 6-8 hourly
Children  
1-12 years; initially, 18 mg/kg slowly at a rate no greater than 50 mg/
minute. 
Then
Maintenance, 5-10 mg/kg daily (max. 300 mg daily)
1-6 months; initially, 18 mg/kg slowly at a rate no greater than 1 mg/
kg/minute.
Then
Maintenance, 2.5-5 mg/kg 12 hourly
Neonate s; initially, 18 mg/kg slowly at a rate no greater than 1 mg/
kg/minute. 
Then
Maintenance, 2.5-5 mg/kg 12 hourly
Note 9-2
May cause cardiac arrhythmias if given faster than 25 mg/minute.
Caution 9-1.
Never mix phenytoin  with 5% Dextrose , to minimise the risk of crystallisation. 
Instead, phenytoin must be put in Normal Saline .
Or
 y Phenobarbitone , IV,
Adult s
10-20 mg/kg, repeat dose at 20 minute intervals if necessary (max. 
total dose 30 mg/kg)
Then (starting 12 hours after initial dose) 

— Epilepsy  —
Standard  Treatment Guidelines, 7th Edition, 2017
2000.5-1.5 mg/kg 12-24 hourly
Children  
1 month-12 years;  10 mg/kg at a rate not more than 1 mg/kg/
minute. Repeat after 15 minutes if necessary. 
Neonate s 
Initially, 15-20 mg/kg stat. 
May repeat dose of 5-10 mg /kg at 20 minute intervals (max. total 
dose 40 mg/kg) 
Then (starting 12 hours after initial dose) 
3-4 mg/kg 24 hourly
Referral Criteria 
If seizures remain uncontrolled within 30 minutes after they began, 
refer immediately for specialist attention. Note that oxygenation should 
be continued during transfer. 
67� Epilepsy  
Epilepsy  is a disorder of the central nervous system (CNS), which is 
characterized by spontaneous recurrent seizures or the tendency to have 
seizures. Epilepsy  is now classified as Generalized (tonic, clonic, absence, 
atonic or myoclonic) with aura and loss of consciousness or Focal.
Traditionally, a single seizure has been regarded as an indication 
for investigation and assessment, but not for drug treatment unless the 
circumstances of the seizure necessitate it.
Drug treatment should certainly be considered after two seizures, or 
if the second seizure follows closely from the first. The type of drug used 
depends on the type of seizure. 
Drug treatment of epilepsy  should be guided by the following 
general principles. Begin with a single drug at the lowest dosage range 
and increase dose gradually to the upper limit of dosage range or until 
side-effects appear, if seizures are not controlled.
Subsequently, if seizures still remain uncontrolled, change to a 
different drug by gradually reducing the dose of the initial agent while 
simultaneously introducing the new one. This usually takes 3-4 weeks.
Try three separate drugs in this fashion if no clinical response is 
observed, before resorting to drug combinations.
Anticonvulsant drug treatment can be totally withdrawn (gradually) 
in a patient with epilepsy  only after a 2-year seizure-free period and after 
a full evaluation and discussion with the patient.
Patients with epilepsy  should be advised not to drive a vehicle if 
not certified to be seizure-free, swim alone, work at heights, operate 
machines, cook by open fire alone, nor ingest alcohol excessively.
Causes 
 y Idiopathic

— Epilepsy  —Chapter 9:  Disorders of the Central Nervous System
201Symptoms
(See section on ‘Seizures ’)
Signs
(See section on ‘Seizures ’)
Investigations
(See section on ‘Seizures ’)
Treatment 
Treatment objectives
(See section on ‘Seizures ’)
Non-pharmacological treatment
(See section on ‘Seizures ’)
Pharmacological treatment 
A.     Management of Epilepsy  - Acute Generalized seizures
 y Phenytoin, IV,
Adult
10-15 mg/kg stat. over 20-30 minutes 
Then 
100 mg 6-8 hourly PRN
Children
3-5 mg/kg
Or
 y Phenobarbital  (daily), IM,
Adult
60-180 mg at night 
Children
2.5-5 mg/kg daily by slow IV or oral
Or
 y Carbamazepine
Adult
100-200 mg once or 12 hourly
Then 
Increase gradually to 0.8-1.2 g 8-12 hourly 
Children
1 month-12 years;  2.5-5 mg/kg at night or 12 hourly
Increase when necessary
Then (maintenance)
5 mg/kg 8-12 hourly
Or
 y Sodium valproate  (12 hourly)
Adult
600 mg (max. 2 g)
Children
> 12 years;   600 mg (max. 2g)
1 month-12 years;  10-15 mg/kg, daily or two divided doses 
Then (maintenance)

— Epilepsy  —
Standard  Treatment Guidelines, 7th Edition, 2017
20225-30 mg/kg daily in two divided doses
Or 
 y Lamotrigine
Adult
25-50 mg 12 hourly 
Children  
25-50 mg daily 
Or 
 y Levetiracetam
Adult
25-50 mg 12 hourly 
Children  
25-50 mg daily 
B.     Management of Epilepsy  - Generalized absence seizure
 y Sodium valproate  (8-12 hourly)
Adult
600 mg (max. 2 g)
Children
> 12 years;   600 mg (max. 2 g)
1 month-12 years;    10-15 mg/kg, daily or two divided doses 
Then (maintenance)
25-30 mg/kg daily in two divided doses
Or
 y Ethosuximide  (daily)
Adult
250 mg 12 hourly, incease by 250 mg every 5-7 days to 1-1.5 g daily 
in two divided doses
Children
> 6 years;   250 mg 12 hourly, incease by 250 mg every 
5-7 days to 1-1.5 g daily in two divided doses
1 month-6 years;    5 mg/kg (max. 125 mg 12 hourly)
C.     Management of Epilepsy  - Focal seizure
 y Carbamazepine , oral, 
Adult
100-200 mg once or 12 hourly, 
Then 
Increase gradually to 0.8-1.2 g 8-12 hourly
Children1 month-12 years; 2.5-5 mg/kg at night or 12 hourly.Increase when necessaryThen (maintenance) 5 mg/kg 8-12 hourly
Or
 y Sodium valproate  (8-12 hourly)
Adult
600 mg (max. 2 g)
Children

— The Unconscious Patient —Chapter 9:  Disorders of the Central Nervous System
203> 12 years;   600 mg (max. 2 g)
1 month-12 years;    10-15 mg/kg, daily or two divided doses 
Then (maintenance)
12.5-15 mg/kg 12 hourly
Note 9-3
Where available slow release preparations are preferred
All patients with epilepsy  should receive continous education and counselling 
by the Pharmacist.
Referral Criteria 
Refer all patients with intractable seizures to the specialist
68� The Unconscious Patient
Unconsciousness  is a common clinical problem and may be associated 
with diseases of several organs in the body. The cause of unconsciousness 
is often not immediately evident, and a systematic approach to its 
diagnosis and management is therefore important. Obtaining a thorough 
history from accompanying relatives, friends and the police is essential.
Causes 
 y Infections e.g. meningitis , cerebral malaria
 y Hypoglycaemia  (diabetes-related or alcohol induced)
 y Diabetic ketoacidosis
 y Severe hypertension with encephalopathy
 y Cerebrovascular Accident (CVA) or stroke
 y Drug ingestion or overdose e.g. alcohol, salicylates, barbiturates, 
cocaine
 y Electrolyte imbalance
 y Epilepsy - status epilepticus
 y Head injury
 y Major organ failure e.g. hepatic failure, renal failure and myocardial 
infarction
 y Hypoxia from severe anaemia
 y Poisoning e.g. kerosene, pesticides, herbicides
Symptoms
 y Depends on the underlying cause (See appropriate sections)
Signs
 y Depends on the underlying cause (See appropriate sections)
Investigations
Tests depend on suspected cause 
 y FBC 
 y BF for MPs
 y Blood glucose
 y Urea and electrolytes

— The Unconscious Patient —
Standard  Treatment Guidelines, 7th Edition, 2017
204 y Liver function tests 
 y Blood culture and sensitivity 
 y Urine culture and sensitivity
 y ECG
 y Toxicology: drug screen, alcohol levels
 y Lumbar puncture 
 y Head CT scan
Treatment 
Treatment objectives
 y To support life until consciousness is regained
 y To prevent complications e.g. aspiration, hypoxia 
 y To determine the underlying cause and manage it appropriately
Non-pharmacological treatment
 y Ensure the airway is patent and clear of secretions
 y Examine and stabilize the cervical spine if any history or sign of injury
 y Catheterise and monitor urine output if necessary
 y Place the patient in a position that would prevent aspiration in case 
of vomiting  or pass an NG tube if no contraindications exist
Pharmacological treatment 
Table 9-1:   Guide to pharmacological treatment of the unconscious patient 
Complaints Diagnosis Action
History of diabetes, use 
of oral anti-diabetic or 
ingestion of alcoholHypoglycaemia * (See section on ‘Hypoglycaemia’ )
History of ingestion of 
medication (tablets or 
liquid). There may be 
smell of alcohol or other 
substance on breathDrug overdose e.g. 
AlcoholSupport respiration
IV Dextrose  10% 50-100 ml 
to prevent hypoglycaemia.  In 
chronic alcoholics. Precede IV 
Dextrose by IV/IM Thiamine  100 
mg IV, then 50-100 mg IM until 
regains consciousness 
Paracetamol Start N-acetylcysteine  (as 
indicated below) and refer
IV continuous infusion:
Body weight > 20 kg: 
100 ml of Dextrose 5% given over 
15 min, Followed by 

— The Unconscious Patient —Chapter 9:  Disorders of the Central Nervous System
205Complaints Diagnosis Action
50 mg/kg in 250 ml of Dextrose 
5% over 4 hours. 
Then 
100 mg/kg in 500 ml of Dextrose 
5% over 16 hours.
Children < 20 kg:
150 mg/kg in 3 ml/kg of Dextrose 
5% given over 15 min. 
Followed by 50 mg/kg in 7 ml/
kg of Dextrose 5% given over 4 
hours. 
Then 100 mg/kg in 14 ml of 
Dextrose 5% over 16 hours.
Presence or absence 
of history of diabetes; 
polyuria, polydipsia.
Hyperventilation, 
gradual onset of illness, 
evidence of infection
Urine sugar and ketone 
positive 
Blood glucose > 18 
mmol/LDiabetic ketoacidosis * (See section on DKA)
High-grade fever, 
seizures, headache, 
neck stiffness, altered 
consciousness etc.Meningitis  * Treat with appropriate antibiotics 
and anti-malarial until either 
diagnosis confirmed. 
(See appropriate section). Cerebral Malaria
History of previous 
seizures, sudden onset 
of convulsions; with or 
without incontinence.Epilepsy * Give Diazepam , IV (slowly over 
2-3 minutes), to abort seizures 
and continue or start with 
anti-epileptic drug treatment. 
(See appropriate section)
Patient with sudden 
onset of paralysis of one 
side of body.Stroke  * Check blood pressure and blood 
glucose. (See appropriate section)
Patient with 
hypertension, 
headaches, seizuresHypertensive    
encephalopathy *Check blood pressure 
If > 180/110 mmHg, give oral or 
parenteral anti-hypertensive to 
reduce BP gradually
Sudden onset associated 
with cardiac arrhythmia 
or emotional crisis.Syncope Unconsciousness  is usually brief. 
Prompt awakening occurs.
Monitor vital signs, ECG
Reassure

— The Unconscious Patient —
Standard  Treatment Guidelines, 7th Edition, 2017
206Complaints Diagnosis Action
History of injury, or 
alcoholism, signs of 
traumaHead Injury Treat lacerations, Stabilise Cervical 
spine
X-ray skull for fractures, Head 
CT scan
History of heavy alcohol 
ingestion over many 
years.
History of jaundice 
and gradual onset of 
changes in sensoriumHepatic Failure * Manage as hepatic 
encephalopathy
Diaphoresis, cold 
clammy skin, weak 
pulsesShock
Hypovolaemic 
Haemorrhagic
Cardiogenic
Septic(See appropriate sections)
* (See appropriate section)
Referral Criteria 
Refer to a specialist for further definitive management if not 
responding to standard measures of resuscitation.

10Chapter
207Psychiatric Disorders
69� Attention Deficit Hyperactivity Disorder  (ADHD )
Attention Deficit Hyperactivity Disorder  is the most common 
neurobehavioural disorder affecting children. It may present in infancy 
and can continue into adulthood. It affects 5-8% of children and nearly 
three times as many boys as girls. Nearly half the children presenting with 
ADHD  may also have an associated learning problem. 
The term is commonly applied wrongly to the normal child who is 
always on the go and never sits still. Recognized causes of hyperactivity 
in children include normal variation, boredom or understimulation or 
excessive restraint, learning difficulties, autism, partial seizures and drugs 
like clonazepam, phenobarbitone and phenytoin .
ADHD  is also wrongly attributed to poor parenting, too much TV, 
poor schools, poor home environment, excess sugar or food allergies.
No specific tests confirm a diagnosis of ADHD . A full physical and 
neurological examination must be done in all cases. The behavioural 
deficits and excesses that constitute a diagnosis of ADHD must be present 
in multiple settings such as home and school.
Causes 
 y Unknown 
 y Related factors: 
 y Hereditary
 y Imbalance of neurotransmitters
Symptoms
 y Inattention 
 y child often fails to finish things he or she starts
 y often does not seem to listen
 y has difficulty concentrating on school work
 y Impulsivity 
 y child often acts before thinking 
 y hits others when upset 
 y inability to wait for his or her turn in a game
 y engages in dangerous activities without consideration of the 
consequences

— Attention Deficit Hyperactivity Disorder (ADHD) —
Standard  Treatment Guidelines, 7th Edition, 2017
208 y has difficulty organizing work (this not due to cognitive impair -
ment)  
 y Hyperactivity 
 y child tries to do several things at once
 y talks incessantly, 
 y struggles to sit still at a desk and fidgets
 y Distractibility is evidenced by 
 y not listening when spoken to 
 y an inclination to daydream
 y not being able to work independently 
 y disorganized
Signs
 y Similar to symptoms above
Investigations
 y Usually none 
Treatment 
Treatment objectives
 y To reduce hyperactivity
 y To improve attention 
 y To improve compliance to instruction
Non-pharmacological treatment
Behaviour management techniques - Evidence Rating: [A]
 y A class helper in class to sit with child and focus attention to school 
work
 y Parenting class to help parents cope
 y Desist from punitive physical interventions e.g. caning 
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [A]
 y Methylphenidate , oral,
Adult s
10 mg 8-12 hourly (max. 60 mg)
Then
Increase weekly by 5-10 mg, if necessary, to max. of 30 mg 12 hourly
Children  
6-18 years;    2.5-5 mg 12 hourly
Increase weekly by 5-10 mg, if necessary, to max. of 30 mg 12 hourly
4-6 years;   2.5 mg 12 hourly
Increase weekly by 2.5 mg daily to max. of 1.4 mg/kg if necessary in 
2 to 3 divided doses. 
< 4 years;   not recommended
Or
 y Atomoxetine , oral,
Adult s

— The Acutely Disturbed Patient —Chapter 10:  Psychiatric Disorders
20940 mg once daily for 7 days
Then 
Increase according to response to a max. of 100 mg 
Children  
> 6 years (weight > 70 kg);   40 mg once daily for 7days
Then
Increase according to response to a max. of 80 mg
> 6 years (weight < 70 kg); 500 micrograms/kg daily for 7 days
Then
Increase according to response to a max. of 1.2 mg/kg daily
< 6 years;    not recommended
2nd Line Treatment
Evidence Rating: [B]
 y Imipramine , oral,
Adult s
75 mg daily
Then
Increase to 150 mg daily if necessary (max. 200 mg per day)
Children  
6-18 years;   10-30 mg 12 hourly 
Referral Criteria 
Refer to a clinical psychologist for behaviour management. An 
occupational therapist, remedial teacher, speech therapist following a 
needs assessment.
Refer to a specialist if there is no clinical improvement after a month 
of the above recommended therapy. 
70� The Acutely Disturbed Patient
The acutely disturbed patient presents in an excited, agitated or 
aggressive state. There may be delusions and perceptual changes like 
hallucinations that overwhelm the patient. Disorientation and alteration 
in consciousness are often prominent when the cause is organic.  The 
patients are usually brought in restrained by more than one person or by 
the police. The condition must be regarded as an emergency since a few 
cases are potentially fatal.
Causes 
Acute (Functional) Psychiatric Disorders
 y Mania or hypomania
 y Schizophrenia  and like states
 y Other psychotic disorders
 y Agitated depression
 y Acute psychosis
Acute (Organic) Psychiatric Disorders

— The Acutely Disturbed Patient —
Standard  Treatment Guidelines, 7th Edition, 2017
210 y Toxic psychosis secondary to drug intoxication (amphetamines, 
cocaine , marijuana , heroin etc.)
 y Abnormal reaction to alcoholic Intoxication
 y Acute Alcoholic Withdrawal Syndrome  (delirium tremens)
 y Infective causes e.g. typhoid, malaria, meningitis , HIV , encephalitis, 
hepatitis
Acute Metabolic Disorders
 y Hypoglycaemia
 y Thyroid disease
 y Porphyria
Others
 y Head trauma 
 y Subdural hematoma
Symptoms
(See relevant sections for symptoms of specific disorders)
 y Sleeplessness
 y Restlessness - agitated or even combative patient
 y Talking excessively and loudly, or low toned, reduced speech, even 
mute in some cases
 y Disinhibited behaviour or speech
 y Hearing or seeing “imaginary” people or objects. 
 y Expression of fear, undue suspicion, inappropriate guilt or bizarre 
beliefs
 y Destructiveness
Signs
(See relevant sections for signs of specific disorders)
 y Elated, irritable, angry or depressed mood
 y Physical aggression, agitation or restlessness
 y Lack of insight
 y Pressured or retarded speech
 y Hyperactivity or reduced motor activity  
 y Disinhibition - social and sexual 
 y Delusions  of grandeur, guilt or paranoia
 y Auditory hallucinations
 y Visual hallucinations (especially in toxic, infectious and withdrawal 
states)
 y Fever  (infective conditions)
 y Drowsiness, altered consciousness (mainly in alcohol withdrawal)
 y Disorientation and confusion (mainly in alcohol withdrawal)
 y Sweating
 y Tremors (mainly in alcohol withdrawal)
Investigations
 y Usually none
 y Urine screen (for substances like amphetamines, cocaine , heroin, 
cannabis)

— The Acutely Disturbed Patient —Chapter 10:  Psychiatric Disorders
211 y FBC, Rapid Diagnostic Test  for malaria parasites (when there is fever 
and suspected infections)
 y Random Blood Sugar
 y Blood culture
Treatment 
Treatment objectives
 y Rapid tranquilisation - to calm down the patient as quickly as possible 
using the safest drugs available without necessarily inducing sleep
 y To treat underlying cause
Non-pharmacological treatment
 y Restrain patient when necessary without causing injuries
 y Talk to the patient in a firm but reassuring manner
 y Avoid long periods of silence especially in paranoid patients
 y Remove and store away any offensive weapons on or around patient.
Pharmacological treatment 
Evidence Rating: [C]
 y Lorazepam , IV/IM,
Adult s
2-4 mg stat.
Repeated once after 10 minutes if necessary.
Children
> 12 years;   500 microgram-2 mg (max. 4 mg)
< 12 years;   500 microgram-1 mg (max. 2 mg)
Or
 y Haloperidol , IM,
Adult s
2-5 mg stat. may repeat in 4-8 hours (max. 20 mg per day)
Children
13-18 years;   2-5 mg 4-8 hourly as required 
6-12 years;   1-3 mg 4-8 hourly as required (max. 0.15 
mg/kg per day)
< 5 years;   not recommended
Note 10-1
Patient should be switched to oral as soon as possible 
Then
 y Haloperidol , oral,
Adult s
3-5 mg 8-12 hourly (max. 30 mg per day)
Children
> 12 years;   3-5 mg 8-12 hourly as required (max. 30 mg 
per day)
3-12 years (15-40 kg);  0.25-0.5 mg per day (max. 0.5 mg per day)
< 3 years;   not recommended
Or

— The Acutely Disturbed Patient —
Standard  Treatment Guidelines, 7th Edition, 2017
212 y Chlorpromazine , IM, (for very agitated patients) 
Adult s
50-150 mg stat. repeated after 30-40 minutes if necessary
Children
12-18 years;  25-50 mg 6-8 hourly
6-12 years;  500 microgram/kg 6-8 hourly (max. 75 mg 
per day)
1-6 years;  500 microgram/kg 6-8 hourly (max. 40 mg 
per day)
Note 10-2
Never give chlorpromazine intravenously! It may lead to severe hypotension.
Or
 y Olanzapine , IM,
Adult s
10-20 mg stat. subsequent doses of 10 mg may be given 2 hours 
after initial dose, if necessary and 4 hours after 2nd dose (max. 30 
mg per day)
Children  
Not recommended
Or
 y Chloral hydrate , oral or rectal,
Adult s
500 mg-1g 
Children  
12-18 years;   500 mg-1 g 
1 month-12 years;  30-50 mg/kg (max. 1g)
Neonate ;   30-50 mg/kg
Or
 y Diazepam , IV,
Adult s
10 mg slowly over 2-3 minutes (approximately 2.5 mg every 30 sec -
onds) 
Children
200-300 microgram/kg slowly over 2-3 minutes.
This may be repeated after 10 minutes if necessary (max 10 mg)
Or
 y Diazepam , rectal,
Children
> 12 years;  0.2 mg /kg 
6-12 years;  0.3 mg/kg 
2-6 years;  0.5 mg/kg 
1 month-2 years;  2.5 mg 
Neonate s;   1.25-2.5 mg
This may be repeated after 10 minutes (max 10 mg)
Note 10-3

— Psychogenic Seizures —Chapter 10:  Psychiatric Disorders
213If a rectal formulation is not immediately available, draw up the injectable form 
directly into a syringe and administer it into the rectum (after removing the 
needle). 
Diazepam  IV must be administered with care if the cause of the acute distur -
bance is thought to be organic.
 
Referral Criteria 
Refer all acutely disturbed patients to a specialist.
71� Psychogenic Seizures
Psychogenic seizures  or pseudo seizures  are non-epileptic seizures, 
which mimic epilepsy  but actually have an underlying psychological cause. 
In patients with this form of disorder, there may be a history of physical, 
sexual or psychological abuse.  The symptoms may be precipitated by 
stress and the signs are often variable and may include resistance to 
eye opening upon examination. The diagnosis requires a high level of 
suspicion since it is often difficult to separate from epileptic seizures and 
may, in fact co-exist with epilepsy.
Symptoms
 y Recurrent tonic clonic-like seizures
 y Attacks usually occur only when attention of other people can be 
attracted
 y Patients hardly ever get injured, even when they fall (unlike in true 
seizures)
 y Thrusting pelvic movements are common during “seizure” attacks
 y Tongue biting, if it occurs is usually at the tip of the tongue instead of 
the sides as in true seizures
 y May have urinary incontinence as in normal seizures
Investigations
 y Serum prolactin
 y EEG
Treatment
Treatment objectives
 y To stop seizures 
 y To restore normalcy  
Non-pharmacological treatment
 y Reassure parents, guardians etc. 
 y Counselling 
 y Psychotherapy
Pharmacological treatment
 y Anti-epileptic medicines do not appear to have any beneficial effect 
on frequency of attacks

— Insomnia —
Standard  Treatment Guidelines, 7th Edition, 2017
214Referral Criteria 
Refer all cases for evaluation by psychologist or psychiatrist.
72� Insomnia
Insomnia  is defined as a subjective report of difficulty with sleep 
initiation, duration, consolidation, or quality that occurs despite 
adequate opportunity for sleep, and that results in some form of daytime 
impairment. Insomnia symptoms occur quite commonly in the general 
population. Risk factors for insomnia include increasing age, female sex, 
co-morbid disorders such as medical, psychiatric, substance use, and shift 
work. Patients with psychiatric and chronic pain disorders have relatively 
high rates of insomnia. 
Causes 
 y Behavioural - spending more time in bed in an effort to “catch up” 
on sleep
 y Stress 
 y Learned habits which do not enhance sleep
 y Cognitive distortions (e.g. if one does not sleep throughout the night, 
one has not slept at all)
 y Medicines (e.g.for treatment of common cold, hypertension, asthma)
 y Caffeine-containing beverages (e.g. coffee, tea) 
 y Withdrawal from alcohol and other drugs of abuse (e.g. cocaine , 
marijuana , amphetamines)
 y Medical condition (e.g. sleep apnea, airway obstruction, liver 
disease, renal disease, thyroid disorders)
 y Psychological and environmental factors 
 y Other psychiatric disorders such as anxiety  and mood disorders
 y Travel (especially across time zones leading to jet lag) 
 y Shift work 
Symptoms
 y Prolonged average time for falling asleep - longer than 30 minutes 
 y Total sleep time less than 6.5 hours 
 y Difficulty falling asleep
 y Frequent awakenings
 y Difficulty returning to sleep
 y Awakening too early in the morning
 y Sleep that does not feel restful, refreshing or restorative
 y Anticipating poor sleep hours before bedtime, and becoming more 
alert and anxious as bedtime approaches
 y Daytime effects of poor sleep:
 y Fatigue and sleepiness
 y Mood disturbances and cognitive difficulties
 y Poor quality of life (worsened by interpersonal difficulties, or 

— Insomnia —Chapter 10:  Psychiatric Disorders
215avoidance of day activities)
 y Exacerbation of co-morbid conditions such as depression , high 
blood pressure, etc.  
 y Day-to-day variability
Box 10-1:  History taking and assessment of patients with Insomnia
 yCharacterization of the sleeping environment (couch/bed, light/dark, qui -
et/noisy, room temperature, alone/bed partner, TV on/off), patient’s state 
of mind (sleepy vs. wide awake, relaxed vs. anxious) 
 yIdentify perpetuating negative behaviours and cognitive processes 
 yAssess Sleep-Wake Schedule with sleep dairy:  time to fall asleep (sleep la -
tency), number of awakenings, Wake time After Sleep Onset (WASO), sleep 
duration
 yAssess   
 yBreathing-related sleep disorders (snoring, gasping, coughing)
 ySleep related movement disorders (kicking, restlessness)
 yParasomnias (behaviors or vocalization)
 yCo-morbid medical/neurological disorders (reflux, palpitations, seizures, 
headaches)
 yOther physical sensations and emotions associated with wakefulness (such 
as pain, restlessness, anxiety , frustration, sadness) 
Assess Daytime Activities and Daytime Function: 
 yNapping (frequency/day, times, voluntary/involuntary)
 yWork (work times, work type such as driving or with dangerous conse -
quences, disabled, caretaker responsibilities)
 yLifestyle (sedentary/active, homebound, light exposure, exercise) 
 yTravel (especially across time zones) 
 yQuality of life and exacerbation of co-morbid disorders
Investigations
 y FBC
 y BUE and creatinine
 y LFTs
 y Blood glucose
 y Thyroid function tests
Treatment 
Treatment objectives  
 y Reduction of waking symptoms
 y Improvement of daytime function
 y Reduction of distress
 y Treatment of co-morbid conditions
Non-pharmacological treatment
 y Stimulus control therapy  (avoid stimulating sleep environments such 
as leaving lights, TV and radio on) 
 y Relaxation training
 y Cognitive Behavior Therapy  
 y Avoidance of day-time sleep
 y Avoidance of excessive stimulant consumption pre-bed time (e.g. 

— Depression —
Standard  Treatment Guidelines, 7th Edition, 2017
216coffee, tea, alcohol etc.) 
Pharmacological treatment
1st Line Treatment 
Evidence Rating: [C]
 y Lorazepam , oral, 
Adult s
1-4 mg at bedtime
Children
Not recommended
Or
 y Triazolam , oral, 
Adult s
Elderly;   125-250 microgram at bedtime  
< 60 years;   125-500 microgram at bedtime  
Children
Not recommended 
2nd Line Treatment 
Evidence Rating: [B] 
 y Melatonin , oral, (particularly for children)
Adult s
3-5 mg daily, 1-2 hours before bedtime (max. 10 mg)
Children
1 month-18 years;  2-3 mg at bedtime
Increase if necessary after 1-2 weeks to 4-6 mg daily (max. 10 mg)
Or
Evidence Rating: [B]
 y Amitriptyline , oral,
Adult
25-50 mg at night for two weeks 
Children
Not recommended
Referral Criteria 
Refer to clinical psychologist for those patients who do not respond 
to the common non-pharmacological and pharmacological interventions 
for cognitive behaviour therapy. Refer patients with underlying physical 
causes to the appropriate specialists. 
73� Depression
Depression  is a mood disorder, which may occur in all age groups, 
although the symptoms may differ in children. It is a relatively common 
condition and has a tendency to recur. Some affected persons may turn 
out to have bipolar disorder, in which case, episodes of mania  occur. 
Clinically significant depression , also called major depression , is 

— Depression —Chapter 10:  Psychiatric Disorders
217twice as common in women as in men. Many affected individuals seek 
help from spiritual and traditional healers. For a good proportion of those 
who go to hospitals, their condition is not recognised.
Depression  is a significant cause of morbidity all over the world 
and most people who attempt or successfully complete suicide have 
depression . One should not dismiss or take for granted statements made 
by patients such as “I want to die”, “life is not worth living”, or “I am 
fed up with life”. All cases of attempted suicide should be referred to a 
psychiatrist after initial management of the presenting complication e.g. 
self-inflicted injuries or poisoning.
Recurrent depression  or unipolar depression is treated differently 
(with antidepressants) from bipolar depression, which responds more to 
mood stabilizers.
The diagnostic criteria for major depression  relies on the presence of 
at least five (5) of the symptoms listed in the section on symptoms below, 
experienced every day for at least two weeks.
In the treatment of depression , maximum tolerable doses of 
antidepressant medications must be given for at least 6 weeks before 
deciding a particular medication is not effective. 
After an episode of depression , treatment must be continued for at 
least 6 months, as there is a high risk of relapse within this period.
Antidepressants must be stopped immediately if a manic swing 
occurs. Patients with suicidal tendencies must be admitted and kept 
under close observation.
Causes 
 y Genetic
 y Familial
 y Environmental
 y Psychosocial factors
 y Endocrine disorders e.g. hypothyroidism , Cushing’s syndrome
Symptoms
 y Depressed mood, often reported as feeling ‘out of sorts’ 
 y Loss of interest or lack of pleasure in things previously of interest
 y Significant weight loss or weight gain
 y Insomnia  or sleeping too much
 y Psychomotor agitation or retardation
 y Fatigue or loss of energy
 y Feelings of worthlessness or excessive guilt
 y Impaired thinking
 y Poor concentration; 
 y indecisiveness; 
 y worrying excessively 
 y Multiple bodily complaints
 y Suicidal ideas or thoughts of death

— Depression —
Standard  Treatment Guidelines, 7th Edition, 2017
218 y Hallucinations  or delusions of morbid themes in severe cases
In children
 y Truancy or refusal to go to school
 y Poor school performance
 y Bedwetting in a previously ‘dry’ child
 y Odd behaviour, aggression or defiance
 y Irritability
 y Appetite changes
 y Some of the ‘adult’ symptoms listed above 
Signs
 y Depressed mood
 y Evidence of weight loss or weight gain
 y Agitation or retardation
 y Hallucinations  
Investigations
 y FBC
 y BUE and Creatinine
 y FBS
 y Thyroid function and cortisol levels if indicated
 y Administer a standardized scale of depression  such as the PHQ 
(patient health questionnaire 9 item scale)
Treatment 
Treatment objectives
 y To reduce symptoms
 y To prevent disruption to normal life at home, work or school
 y To prevent suicide
Non-pharmacological treatment
 y Counselling
 y Psychotherapy , specifically Cognitive Behaviour Therapy
 y Electroconvulsive therapy
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [A]
 y Fluoxetine , oral,
Adult s 
20 mg once daily for 2-4 weeks, 
Then
Increase if necessary to max. of 80 mg
Children
8-18 years;   10 mg once daily for 1-2 weeks 
Then
Increase if necessary to max. 20 mg once daily. 
< 8 years;   not recommended

— Depression —Chapter 10:  Psychiatric Disorders
219Note 10-4  
Use with caution in children with epilepsy . Stop if seizure occurs.
Or
 y Sertraline , oral,
Adult s
50 mg once daily, 
Then
Increase if necessary by increments of 50 mg at intervals of at least 1 
week, to max. of 200 mg daily.  
Children
13-18 years;  50 mg once daily 
Then
Increase if necessary by increments of 50 mg at intervals of at least 1 
week, to max. of 200 mg daily.  
6-12 years;   25 mg daily, 
Then
Increase if necessary to 50 mg daily after 1 week. 
Further increase if necessary in steps of 50 mg at intervals of at least 
one week to a max. of 200 mg daily
< 6 years;   not recommended
Or
 y Citalopram , oral, 
Adult s 
20 mg once daily, increase if necessary in steps of 20 mg daily, at 
intervals of 3-4 week, max. 40 mg.  
Children  
> 12 years;  10 mg once daily,
Then 
Increase if necessary to 20 mg once daily in the evening, over 2-4 
weeks (max. of 40 mg once daily)
< 12 years;   not recommended 
Or
 y Imipramine , oral, 
Adult s
25-50 mg once daily (early evening),
Then
Increase by 25 mg every 3-5 days up to max. of 150 mg.
Children
Not recommeded
Or
 y Amitriptyline , oral,
Adult s
25-50 mg once daily (early evening),
Then
Increase by 25 mg every 3-5 days up to a max. of 150 mg.
Children

— Schizophrenia —
Standard  Treatment Guidelines, 7th Edition, 2017
220> 16 years;   5-15 mg 12 hourly
< 16 years;   not recocommended
A.     Management of patients with depression  requiring night sedation 
 y Lorazepam , oral,
Adult s
2-3 mg 8-12 hourly, max. 10 mg daily
Children  
2-18 years;   0.05 mg/kg 8 hourly, max. 2 mg daily 
Or
 y Diazepam , oral,
Adult s
5-10 mg 6-12 hourly     
Children
12-18 years;   10 mg 12 hourly 
5-12 years;   5 mg 12 hourly 
Referral Criteria 
Refer patients with atypical or unusual symptoms, hysterical or phobic 
features, and those who do not respond to adequate anti-depressant 
treatment within 2 months, to a psychiatrist, as should children suspected 
to suffer from depression .
Patients requiring Cognitive Behaviour Therapy  should be referred 
to a psychologist.
74. Schizophrenia
Schizophrenia  is probably the most severe and potentially 
disabling form of mental illness in every community worldwide. It may 
present as an acute or chronic illness. The clinical features include 
characteristic ‘positive’ or ‘negative’ symptoms, deterioration in social, 
work or interpersonal relationships and continued evidence of disturbed 
behaviour for at least 6 months. 
The clinical features may be numerous and can change over time. 
Psychosis  associated with substance abuse and mood disorders with 
psychotic features may mimic schizophrenia. 
For this illness, a few people may recover completely after an 
episode or two. Treatment must be started once symptoms are present. A 
definitive diagnosis and establishment of a treatment plan is best carried 
out by a psychiatrist.  Treatment for acute episodes can be started by a 
psychiatrist and follow up treatment continued by most health care givers. 
Treatment must be for at least 18 months after remission of symptoms for 
a first episode. However, life long treatment is probably the best strategy 
to avoid recurrence. 
Side effects such as extra-pyramidal reactions  (slowness, drooling, 
stiffness, tremors, rigidity, muscle spasms including tongue sticking 

— Schizophrenia —Chapter 10:  Psychiatric Disorders
221out, neck bending, etc.) to antipsychotics may occur especially when 
administered at high doses.  These adverse reactions can be prevented 
or managed with anticholinergic agents, which must be used sparingly as 
they may contribute to the development of another adverse event, called 
tardive dyskinesia, in the long term. (See section on ‘Adjunct Treatment’ 
below)
Causes 
 y Largely unknown
 y Possible associations: 
 y Bio-Genetic (to do with dopamine and serotonin receptors)
 y Bio-Psycho social determinants; genetic predisposition coupled 
with stress (economic, disruptive family environments, etc.) 
Birth defects in brain associated with season of birth, possible 
viral infections, etc. 
 y Environmental triggers
 y Illicit drugs (marijuana , amphetamines etc.)
Symptoms/Signs
‘Positive’ symptoms 
 y Hallucinations  (e.g. hearing voices)
 y Delusions  (stated beliefs which cannot be substantiated)
 y Incoherent speech or illogicality
 y Odd or disorganised behaviour
 y Patient believes his or her thoughts are controlled by outside forces
‘Negative’ symptoms
 y Poverty of speech or content of speech (few words or with little 
substance)
 y Apathy
 y Reduced social contact or withdrawal
 y Flattened affect (showing little facial expressive responses)
 y Delusions  
 y May be persecutory, such as undue suspicion, or totally bizarre, 
like being controlled or being made to feel emotions or sensa -
tions
 y Grandiose delusions may also occur but without the elevated 
mood seen in manic patients
 y Hallucinations  
 y commonly auditory (but may involve any of the other senses)
 y Auditory hallucinations of multiple voices commenting on pa -
tients’ actions, arguing about the patient are almost diagnostic
 y Motor disorders like posturing, excitement or stupor may occur but 
are not essential for diagnosis
Investigations
 y Usually none required for diagnosis 
 y Tests to rule out organic causes of psychosis
 y Baseline full blood count, blood sugar, lipids, liver and kidney function 

— Schizophrenia —
Standard  Treatment Guidelines, 7th Edition, 2017
222tests, for purposes of guiding treatment
 y For Olanzapine  and Risperidone , ensure that fasting blood sug -
ar, lipid profiles, liver and kidney function test are carried out at 
least twice a year.
Treatment 
Treatment objectives
 y To abolish symptoms
 y To restore functioning to the maximum level possible
 y To reduce the chances of recurrence
 y To monitor blood glucose, lipid profiles, liver and kidney function at 
least twice a year for patients on olanzapine and risperidone 
Non-pharmacological treatment
 y Supportive psychotherapy  
 y Rehabilitation
 y Family therapy
 y Psychoeducation  about cause, course, treatment, side effects and 
relapse prevention
 y Behaviour Therapy e.g. social skills training, progressive muscle 
relaxation, coping skills, etc.
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [A]
A.     Management of acute attacks
 y Olanzapine , IM or oral, 
Adult s
5-10 mg stat. 
Then
5-10 mg daily, max. 20 mg daily
Children  
> 12 years;   5-10 mg stat. 
Then
5-10 mg daily, max. 20 mg daily
< 12 years;  not recommended
Or
 y Chlorpromazine , IM, 
Adult s
25-50 mg 6-8 hourly, adjusting to max. of 400 mg daily
Children
12-18 year;  25-50 mg 6-8 hourly, adjusting to max. of 400 mg daily
6-12 years;  500 microgram/kg 6-8 hourly to max. of 75 mg daily
1-6 year;  500 microgram/kg 6-8 hourly to max. of 40 mg daily
Or
 y Chlorpromazine , oral, 
Adult s 

— Schizophrenia —Chapter 10:  Psychiatric Disorders
22325 mg 8 hourly or 75 mg at night
Then 
Adjust according to response to 75-300 mg daily
Children  
> 12 years;  25 mg 8 hourly or 75 mg at night 
Then
Adjust according to response to max. of 75-300 mg daily
6-12 years;   10 mg 8 hourly 
Then
Adjust according to response to max. of 75 mg daily
1-6 years;  500 microgram/kg 4-6 hourly
Then
Adjust according to response to max. of 40 mg daily
Or
 y Haloperidol , IM, 
Adult s
2-5 mg stat.
Then 
Repeat 4-8 hourly according to response, to maximum of 20 mg daily
Children
6-12 years;   1-3 mg 4-8 hourly as required
< 6 years;   not recommended
Or
 y Haloperidol , oral, 
Adults
0.5-5 mg 8-12 hourly daily
Then 
5-10 mg 8-12 hourly (max. of 30 mg)
Children 
> 12 years;   0.5-5 mg 8-12 hourly daily
Then 
5-10 mg 8-12 hourly (max. of 30 mg)
3-12 years or body weight 15-40 kg; 0.25-0.5 mg daily
Then
Increase by 0.5 mg daily every 5-7 days
< 3 years;   not recommended
B�     Maintenance
 y Risperidone , oral,
Adult s
1-4 mg 12-24 hourly (start at low dose and adjust daily according to 
patient response)
Or
 y Olanzapine , oral,
Adult s 
5-10 mg, max. 20 mg daily

— Schizophrenia —
Standard  Treatment Guidelines, 7th Edition, 2017
224Children  
> 12 years;   5-10 mg, max. 20 mg daily
< 12 years;  not recommended
Or
 y Chlorpromazine , oral, 
Adults
25 mg 8 houly or 75 mg at night, adjust to max. of 200 mg 8 hourly
Children 
12-18 years; 25 mg 8 hourly or 75 mg at night, adjust to max. of 200 
mg 8 hourly
< 12 years;   not recommended
Or
 y Haloperidol , oral, 
Adult s
1-3 mg 8 hourly, adjusted to max. daily dose of 20 mg
Children  
12-18 years;   1-3 mg 8hourly, adjusted to max. daily dose 
of 20 mg
3-12 years;   500 micrograms 12 hourly, adjust up to a 
max. of 5 mg 12 hourly
C. Maintenance treatment for patients with recurrent or chronic 
illness (depot preparations)
 y Fluphenazine  decanoate , IM, 
Adult s
25 mg monthly
Children
Not recommended
Or
 y Flupenthixol  decanoate, IM, 
Adult s
Give test dose of 5-20 mg, and after at least 7 days, give 
40 mg monthly 
Children
Not recommended
D.     Adjunct treatment for management or prevention of antipsychotic 
drug side effects 
 y Trihexyphenidyl  (Benzhexol ), oral,
Adult s
2.5-5 mg 6-8 hourly max. 20 mg daily 
Children  
6-18 years;   0.5-1 mg 12-24 hourly, 
Then
Increase every 3-7 days by 1 mg daily according to response
Or
 y Benzatropine  (Benztropine ), oral,
Adult s

— Schizophrenia —Chapter 10:  Psychiatric Disorders
2251-2 mg 8-12 hourly
Children  
> 3 years;    20-50 microgram/kg 12-24 hourly
Or
 y Biperidine , oral,  
Adult s
1 mg 12 hourly, 
Then 
adjust to 2 mg 8 hourly up to 4 mg 8 hourly.
Children  
not recommended
Or
 y Biperidine , slow IV/IM,
Adult s
2.5-5 mg adjust to a max. of 20 mg in 24 hours    
Or
 y Benztropine , IV/IM,
Adult s
1-2 mg slowly over 2-4 minutes, repeat if symptoms persist after 
8-12 hours
Or
 y Diazepam , oral,
Adult s
5-10 mg 6-12 hourly     
Children
12 -18 years;   10 mg 12 hourly 
5 - 12 years;   5 mg 12 hourly 
Or
 y Diazepam , IV,
Adult s
5-10 mg slowly over 2-3 minutes (approximately 2.5 mg every 30 
seconds) 
Children
200-300 microgram/kg slowly over 2-3 minutes.
This may be repeated 10 minutes.
Or
 y Promethazine  hydrochloride, oral or IM, 
Adult s
12.5-25 mg initially, may repeat dose if symptoms persist after 6 
hours
Children  
> 6 years;  6.25-12.5 mg
Then 
Repeat dose after 6 hours
< 6 years;  not recommended
Referral Criteria 
Refer all patients to a psychiatrist after an acute episode if treatment 

— Bipolar Disorder —
Standard  Treatment Guidelines, 7th Edition, 2017
226was initiated without a psychiatrist’s supervision. 
Likewise refer all patients with recurrent episodes and those 
whose symptoms cannot be controlled to a psychiatrist for further drug 
treatment or Electroconvulsive Therapy. 
75� Bipolar Disorder
Bipolar disorder  is a form of mood disorder. The term refers to a 
condition in which patients experience mood swings between the two 
extremes of depression  and mania . Bipolar disorder is referred to in older 
literature as manic-depressive illness. It is important to note that the 
affected patient usually presents with one predominant mood state at a 
time, either depression or mania.
A single manic episode and a history of depression  qualify for 
classification as bipolar disorder. A current episode of depression without 
a past manic episode is not diagnosed as a bipolar disorder. Repeated 
depressive episodes are diagnosed as recurrent depression.
Causes 
 y Largely unknown
 y Possible associations:
 y Tendency to run in families
 y Genetic factors
Symptoms
 y Persistently elevated mood:- euphoria, expansiveness, feeling ‘high’ 
or irritable
 y Overactivity 
 y Talking fast and excessively
 y Grandiose claims
 y Reduced sleep
 y Reckless spending and being overly generous
 y Sexual and social disinhibition
 y Auditory hallucinations, in severe cases (patients may hear voices, 
often reinforcing their grandiose beliefs)
 y Undue suspicion (paranoia) may exist
 y Impaired judgement
Signs
 y None typical of bipolar disorder
 y Same as symptoms above
Investigations
 y Usually no specific investigations
 y Rarely, thyrotoxicosis  may mimic mania  and must be excluded

— Bipolar Disorder —Chapter 10:  Psychiatric Disorders
227Treatment
Treatment objectives
 y To treat symptoms of mania  or depression , whichever is present with 
current episode 
 y To reduce the level of activity in mania  to a manageable state 
 y To elevate mood to a normal state in depression
 y To abolish psychotic symptoms (delusions and hallucinations), if 
present
Non-pharmacological treatment
 y Psychotherapy
 y Psychoeducation
Pharmacological treatment 
A.     Management of the manic patient 
 y Risperidone , oral,
Adult s
1-4 mg 12-24 hourly, to a max. of 8 mg daily
Children  
>12 years;   500 micrograms stat.
Then
Adjust daily in steps of 500 micrograms - 1 mg daily to a max. of 6 
mg daily
< 12 years;   not recommended 
Or
 y Olanzapine , oral,
Adult s
5-15 mg 12-24 hourly to max. 20 mg daily 
Children  
12-18 years;   2.5 mg daily, up to max. of 20mg daily
<12 years;    not recommended
Or
 y Haloperidol , oral,
Adult s
5-10 mg 12 hourly up to a max. of 20 mg daily
Or
 y Chlorpromazine , oral,
Adult s
25 mg 8 houly or 75 mg at night, 
Then
Increase by 25 mg daily to 50-100 mg 8 hourly
Or
 y Sodium valproate , oral, 
Adult s
 250-750 mg 12 hourly (controlled release preferable)
Children  
< 18 years;   not recommended

— Bipolar Disorder —
Standard  Treatment Guidelines, 7th Edition, 2017
228Or 
 y Carbamazepine , oral, 
Adult s
200-800 mg 12 hourly (controlled release preferable)
Children  
< 18 years;   not recommended 
B.     Management of significantly aggressive patient 
(See section on ‘The Acutely Disturbed Patient ’).
C�     Management of the depressive phase
 y Lamotrigine , oral, 
Adult s
25 mg daily for 2 weeks 
Then
Increase by 25 mg every 2 weeks to a max. of 200 mg daily as re -
quired 
Children  
< 18 years;  not recommended 
And
 y Lorazepam , oral,
Adult s
2-3 mg 8-12 hourly, max. 10 mg daily
Children  
2-18 years;   0.05 mg/kg 8 hourly, max. 2 mg daily 
Or
 y Diazepam , oral,
Adult s
5-10 mg 6-12 hourly     
Children
12-18 years;   10 mg 12 hourly 
5-12 years;   5 mg 12 hourly 
Note 10-5
The benzodiazepines are withdrawn as soon as the patient is calm, but this 
should be done by slowly tapering the dose. 
D.     Maintenance management after control of the acute phase
 y Lithium , oral, 
Adult s
200-600 mg 6-8 hourly (max. 2400 mg daily)
Children  
12-18 years;  200-600 mg 8 hourly (max. 2400 mg daily)
6-12 years;   5-20 mg /kg 8 hourly
< 6 years;   not recommended

— Alcohol Withdrawal Syndromes   —Chapter 10:  Psychiatric Disorders
229Note 10-6
Lithium  levels should be monitored 12 hours after dose, twice weekly until con -
dition stabilises, then once every month.
Or
 y Sodium valproate , oral, 
Adult s
250-750 mg 12 hourly (controlled release preferable)
Children  
< 18 years;   not recommended
Or 
 y Carbamazepine , oral, 
Adult s
200-800 mg 12 hourly (controlled release preferable)
Children  
< 18 years;   not recommended 
Referral Criteria 
Refer all patients suffering a first episode, not responding to 
treatment after one month and all children to a psychiatrist.
76� Alcohol Withdrawal Syndromes   
These occur following sudden withdrawal from alcohol. They are 
often seen 12 to 18 hours after the last drink, but may be earlier and 
are worst between 24 to 48 hours after onset. This commonly occurs 
in patients admitted to hospital for other problems e.g. arising from 
accidents or physical illnesses, which keeps them from drinking. The 
presentation varies from minimal tremors to states of full-blown agitation 
and confusion, which are potentially fatal.
Causes
 y Abrupt cessation or significant reduction in alcohol intake in an 
individual with heavy drinking over many months or years 
Minor Withdrawal Alcoholic Hallucinosis Alcoholic Seizures
Onset 12 to 18 hours after 
last drink, but may 
be earlier. Peaks 
between 24-48 hours12-24 hrs after cessation 
of drinking and generally 
stops within 48 hours7-36 hours after the 
last drink but may 
be earlier. 
Symptoms Shaky hands
Headaches
Insomnia
Mild anxiety
Nausea ,
Vomiting
SweatingSensation of objects 
crawling on body
“Seeing” objects not really 
present
“Hearing” noises or voices 
nobody else can hear.sudden generalised 
seizures in a 
chronic alcoholic

— Alcohol Withdrawal Syndromes   —
Standard  Treatment Guidelines, 7th Edition, 2017
230Minor Withdrawal Alcoholic Hallucinosis Alcoholic Seizures
Signs Increased pulse rate
Raised blood pressureThe vivid hallucina -
tions occur in clear 
consciousness.
Pulse, Blood Pressure and 
respiration are within 
normal limitsgeneralised 
seizures
Treatment
Treatment objectives
 y To stabilise pulse and blood pressure
 y To prevent dehydration
 y To treat presenting conditions like malaria etc. 
 y To relieve pain, tremors and seizures
 y To stop hallucinations
Non-pharmacological treatment
 y Sit or lie in a quiet place
 y Physical restraints may be required temporarily for very agitated 
patients
 y Encourage intake of fluids as can be tolerated to prevent dehydration
Pharmacological treatment 
1st Line Treatment
Evidence Rating [A]
 y Haloperidol , oral/IM, 
Adult s
5 mg 8 hourly as required until hallucinations cease.
Children  
Refer to specialist
Or
 y Olanzapine , oral, 
Adult s
5-10 mg 24 hourly (max. of 10 mg 12 hourly)
Children  
> 12 years;   2.5-5 mg stat. 
Then
May be increased up to 10 mg (max. 5 mg 12 hourly)
Referral Criteria
Refer all patients with alcohol withdrawal syndromes to a psychologist 
or psychiatrist. Also refer all children to a paediatrician.

— Alcoholic Delirium Tremens  —Chapter 10:  Psychiatric Disorders
23177� Alcoholic Delirium Tremens  
This is the most dramatic withdrawal syndrome. It usually starts 2-3 
days after drinking stops. On average, the syndrome lasts 3 days but may 
continue for much longer. Without good supportive care and adequate 
treatment, Delirium Tremens (DT)  is associated with significant mortality.
Risk factors include long history of heavy alcohol use, previous history 
of DT, concurrent illness, significant alcohol level during withdrawal, long 
duration since last drink (over 48 hours) and age over 30 years.
Causes 
 y Sudden withdrawal of alcohol from a long-term chronic user of 
alcohol
Symptoms
 y Restlessness
 y Shaking of hands, whole limbs or body
 y Sweating
 y Confusion
 y Inappropriate behaviour
 y Unintelligible speech 
 y Misidentification
 y Seeing or talking to imaginary objects
Signs
 y Tremors
 y Psychomotor agitation or retardation
 y Sweating
 y Vomiting
 y Disorientation
 y Intermittent visual, tactile or auditory hallucinations or illusions 
(Visual hallucinations are frequently of small objects or frightening 
‘animals’ on walls etc.)
 y Fever  > 38°C.
 y Pulse > 100 beats/minute, Blood Pressure > 160/100mmHg
Investigations
 y Full Blood Count
 y Liver Function Tests 
 y Screen for malaria and common infections
Treatment
Treatment objectives
 y To relieve agitation and calm patient
 y To correct fluid and electrolyte imbalance
 y To prevent complications like seizures, development of amnesia and 
encephalopathy
 y To prevent or manage heart complications if present

— Alcoholic Delirium Tremens  —
Standard  Treatment Guidelines, 7th Edition, 2017
232  Non-pharmacological treatment
 y Seclusion of the patient
 y Application of restraints as necessary
 y Psychotherapy  and psychoeducation  
Pharmacological treatment
Evidence Rating: [A]
A.     For control of seizures 
 y Lorazepam , IV, IM or oral,
Adult s
Days 1 to 3:  2-4 mg once daily 
Days 4 and 5:   1-2 mg once daily
Or
 y Diazepam , IV, (administer slowly-over 2-3 minutes, approximately 
2.5 mg every 30 seconds)
Adult s
Day 1:  10-20 mg 6 hourly 
Day 2:  10-20 mg 8 hourly 
Day 3:  10-20 mg 12 hourly 
Day 4:  5-10 mg 8 hourly 
Day 5:  5-10 mg 12 hourly then stop
Note 10-7
It is best to give benzodiazepines as needed rather than on a fixed dose sched -
ule.
Withhold if patient is asleep or has slurred speech, ataxia , nystagmus  or over 
sedated. 
Or 
 y Chlordiazepoxide , oral,
Adult s 
50-100 mg 4 hourly as required (max. 300 mg)
And
 y Thiamine , oral, IM or IV, 
Adult s (oral, IM, IV)
100 mg daily for 3 days (before any IV Glucose load)
And
 y Folic Acid , oral, 
Adult s
1 mg daily as needed
And
 y Dextrose  saline  (5% glucose in 0.9% saline), IV, 
Adult s
As necessary 
B.     For patients with seizures not controlled by benzodiazepines alone
 y Lorazepam , IV, IM or oral,

— Anxiety Disorders   —Chapter 10:  Psychiatric Disorders
233Adult s
Days 1 to 3:  2-4 mg once daily 
Days 4 and 5:   1-2 mg once daily
Or
 y Diazepam , IV, (administer slowly-over 2-3 minutes, approximately 
2.5 mg every 30 seconds)
Adult s
Day 1:  10-20 mg 6 hourly 
Day 2:  10-20 mg 8 hourly 
Day 3:  10-20 mg 12 hourly 
Day 4:  5-10 mg 8 hourly 
Day 5:  5-10 mg 12 hourly then stop
And
 y Phenobarbitone , slow IV or IM,
Adult s
0.5-1.5 mg/kg 12 hourly 
Referral Criteria
Refer patients whose symptoms are difficult to control within 3 days 
or who remain agitated despite being given over 20 mg diazepam within 
4 hours to a specialist.
Refer patients to a psychiatrist or clinical psychologist for 
consideration of other treatment options to assist long-term abstinence 
and rehabilitation after acute phase is over.
78� Anxiety  Disorders   
Anxiety  is a common symptom that occurs in all psychiatric disorders 
including depressive illness and most psychoses. Physical diseases like 
hyperthyroidism , cardiac disease or hypertension may also present with 
anxiety  and therefore must be excluded. 
There are various forms of anxiety  disorders (e.g. generalized anxiety 
disorders, panic disorders, phobias, obsessive compulsive disorder, acute 
stress disorder, post traumatic stress disorder, etc.), but the common 
ones seen in general practice are generalized anxiety disorders and panic 
disorders. 
In all cases of suspected anxiety  disorders, it is important to assess 
the scope of the anxiety, including the antecedents, behaviour and 
consequences of anxiety for the patient through an indepth interview. It 
is also important to ask about the presence of obsessive thoughts and/
or compulsions as these are increasingly common and tend not to be 
reported out of embarrassment but which lead to much personal distress. 
In this case refer to a psychiatrist.
In generalized anxiety  disorders, there is excessive anxiety and 
worry about events or activities, such as performance at school or work, 

— Anxiety Disorders   —
Standard  Treatment Guidelines, 7th Edition, 2017
234occurring on most days, for at least 6 months.
A panic disorder refers to a pattern of recurrent unexpected 
attacks of intense fear or discomfort over a discrete period more than 
3 times a week. During attacks 4 or more of the symptoms listed below 
develop abruptly and reach a peak within 10 minutes. Panic disorders 
are accompanied by persistent concern about having another attack or 
worrying about implications of having an attack.  
In children especially, partial complex seizures may mimic panic 
attacks. Medications are required to treat panic disorders only if the 
attacks occur frequently enough to cause distress.
GENERALIZED ANXIETY DISORDERS
Causes 
 y Multiple negative life experiences
 y Environmental factors
 y Personality trait
 y Genetic predisposition
Symptoms
 y Excessive anxiety  and worry occurring on most days, for at least 6 
months
 y Anxiety  or worry associated with at least 3 of the following:
 y Muscle tension (often reported as pain in various parts like 
neck, trunk or headaches)
 y Crawling and burning sensation around the body
 y Restlessness or feeling on edge 
 y Being easily fatigued
 y Difficulty concentrating or mind going blank
 y Irritability
 y Sleep disturbance (difficulty falling asleep or frequent waken -
ing)
 y Palpitations 
Signs
 y Restlessness
 y Sweating 
 y Anxious mood
 y Tachycardia  
 y Tremors
Investigations
 y None to confirm the diagnosis. 
 y Tests to exclude probable differential diagnoses such as 
hyperthyroidism , phaeochromocytoma , cardiac arrhythmias etc.
Treatment 
Treatment objectives
 y To reduce anxiety

— Anxiety Disorders   —Chapter 10:  Psychiatric Disorders
235 y To attain relief of somatic symptoms
Non-pharmacological treatment
 y Reassurance about the absence of physical disease once they are 
ruled out
 y Teach relaxation methods 
 y Encourage regular physical exercise if possible
 y Encourage healthy social activities
 y Cognitive Behaviour Therapy
Pharmacological treatment 
A.     For anxiety  with somatic complaints
1st Line Treatment 
Evidence Rating: [B]
 y Sertraline , oral, 
Adult s
50 mg as a single oral evening dose; 
Then
Increase by 25 mg at 1 week intervals, if necessary, to a max. of 200 
mg
Children  
12-18 years;   50 mg daily 
6-12 years;   25 mg daily 
< 6 years;   not recommended
Or
 y Fluoxetine , oral,
Adult s
10 mg daily, 
Then
Increase up to 60 mg daily if necessary
Children  
7-18 years;   10 mg daily 
Then
Increase to 20 mg after 1-2 weeks if necessary
Or
 y Amitriptyline , oral, 
Adult s
25-50 mg daily (as a single evening dose) 
Children  
> 12 years;   10 mg daily (as a single evening dose) max. 
20 mg
Or
 y Imipramine , oral, 
Adult s
25-50 mg daily (as a single evening dose)
Children  
Not recommended for this indication 

— Anxiety Disorders   —
Standard  Treatment Guidelines, 7th Edition, 2017
236B�     For anxiety  with prominent somatic complaints
 y Propranolol , oral, 
Adult s
10-80 mg 12 hourly 
C.     Additional treatment for anxiety  with significant distress 
 y Diazepam , oral, 
Adult s
2-5 mg 12 hourly for 2 weeks and gradually tailed off over the next 
2 weeks. 
(Do not give for more than one month continuously)
Children  
1-12 years;  1.25-5 mg 6 hourly as needed
Referral Criteria 
Refer to a clinical psychologist for Cognitive Behaviour Therapy  and 
other non-pharmacological treatment modalities. Refer to a psychiatrist 
in severe cases not responsive to drug treatment.
PANIC DISORDERS
Causes 
 y Largely unknown
 y Misinterpretation of normal internal body stimuli (e.g. a quickened 
heart beat interpreted as a heart attack or serious illness, etc). 
 y Misinterpretation of external stimuli (crowds, enclosed spaces such 
as moving vehicles, lifts, etc.) as signalling danger
 y Contributing factors:
 y Stress
 y Genetic predisposition
Symptoms
 y Fear of dying or going ‘crazy’
 y Palpitations, pounding heart or rapid heart rate
 y Trembling or shaking
 y Sensation of shortness of breath
 y Feeling of choking
 y Chest pain or discomfort
 y Feeling dizzy, unsteady or faint
 y Numbness or tingling sensations
 y Chills or hot flushes
 y Derealisation (feeling of unreality) or depersonalisation (feeling 
detached from oneself)
 y Nausea  or abdominal distress
Signs
 y Tachycardia
 y Tremors 
 y Sweating

— Anxiety Disorders   —Chapter 10:  Psychiatric Disorders
237Investigations
 y None diagnostic
Treatment 
Treatment objectives
 y To stop the attacks of panic or at least reduce the frequency and 
intensity of symptoms to a minimum
 y To help return to normal activities of daily living
 y To prevent recurrence of symptoms
Non-pharmacological treatment
 y Rebreathing in and out of a paper bag closed around lips and nose 
(avoid polythene bags, try large paper envelopes)
 y Eliminate caffeine-containing foods e.g. coffee, tea, cola and 
chocolates, from their diet, as they tend to worsen anxiety
 y Relaxation training  
 y Cognitive Behaviour Therapy
Pharmacological treatment 
A.     Initial management for patients unresponsive to non-
pharmacological treatment 
1st Line Treatment 
Evidence Rating: [B] 
 y Fluoxetine , oral,
Adult s
10 mg daily (as a single morning dose) 
Then
Increase up to 60 mg daily if necessary
Children  
6-18 years;   10 mg daily
Then
Increase up to 20 mg after 1-2 weeks if necessary
Or
Sertraline , oral, 
Adults
25 mg daily (as a single evening dose) 
Then 
Increase to 50 mg after 1 week if necessary 
Then
50 mg weekly to a max. of 200 mg daily if necessary
Children 
Not recommended 
Or
 y Imipramine , oral, 
Adult s
25-50 mg daily (as a single evening dose) max. 150 mg daily
Children  

— Anxiety Disorders   —
Standard  Treatment Guidelines, 7th Edition, 2017
238Not recommended for this indication 
B.     For very frequent panic attacks
 y Lorazepam , oral,
Adult s
1-4 mg daily for 2 weeks
Children  
2-18 years;    0.05 mg/kg daily for 2 weeks
C.     For anticipated anxiety  attacks 
 y Lorazepam , oral,
Adult s
1-4 mg stat. 
Children
0.25-0.5 mg stat. 
D�  For Acute Symptomatic Control
 y Lorazepam , oral,
Adult s
1-4 mg 8-12 hourly as required (max. 10 mg daily) 
Children  
Not recommended for this indication 
Or 
 y Alprazolam , oral,
Adult s
0.25-0.5 mg 6-8 hourly 
Increase if necessary every 3-4 days, max. 4 mg daily
Children  
< 18 years;   not recommended
Or 
 y Diazepam , oral, 
Adult s
2-5 mg 12 hourly for 2 weeks and gradually taper off over the next 
2 weeks. 
(Do not give for more than one month continuously)
Children  
1-12 years;  1.25-5 mg 6 hourly as needed
Note 10-8
Duration of treatment for recurrent cases should be at least 6 weeks and should 
be continued for up to 6 months or more after attacks have remitted to prevent 
early relapse. Wean off slowly over a month or more.
Referral Criteria
Refer children with symptoms suggestive of a panic disorder to a 
paediatrician. Also refer patients to a psychologist for Cognitive Behaviour 
Therapy  and to a psychiatrist for additional drug therapy where indicated. 

— Substance Use Disorders —Chapter 10:  Psychiatric Disorders
23979� Substance Use Disorders
Abuse of substances such as marijuana , benzodiazepines, heroine , 
cocaine  etc. is prevalent in many communities around the country. 
Typically, individuals with such disorders request help only after they 
are forced to do so by family members. They may also begin to have 
withdrawal symptoms when on admission for serious physical illness. 
This is because they have no access to the substance being abused. This 
may complicate treatment of the primary disease for which they were 
admitted. 
Causes 
 y Social factors
 y Peer pressure (e.g. family members, friends)
 y Lack of coping skills (e.g. with life’s difficulties, aids to coping in 
times of trouble)
 y Addiction
 y Tolerance (increased requirement of substance to maintain the same 
feeling) 
 y Withdrawal effects (unpleasant effects lead to a return to drug use)
Symptoms 
Cannabis withdrawal
 y Insomnia  
 y Shakiness 
 y Irritability 
 y Restlessness 
 y Anxiety  
 y Anger
 y Onset: Within 24 hours of drug use
 y Duration: 1-2 weeks
Benzodiazepine withdrawal
 y Anxiety
 y Headache  
 y Insomnia
 y Muscle aching and twitching 
 y Perceptual changes 
 y Feelings of unreality
 y Depersonalization 
 y Seizures  
 y Onset: 1-10 days (depending on half-life of drug)
 y Duration: 3-6 weeks (may be longer)
Opioid withdrawal
 y Anxiety

— Substance Use Disorders —
Standard  Treatment Guidelines, 7th Edition, 2017
240 y Craving
 y Muscle tension 
 y Muscle and bone ache 
 y Muscle cramps and sustained contractions 
 y Sleep disturbance
 y Sweating 
 y Hot and cold flushes
 y Piloerection 
 y Yawning 
 y Lacrimation and rhinorrhoea 
 y Abdominal cramps
 y Nausea , vomiting  and diarrhoea
 y Palpitations
 y Elevated pulse and blood pressure 
 y Dilated pupils
 y Onset: 6-24 hours (may be later with longer-acting opioids)
 y Duration: peaks 2-4 days, ceases 5-10 days (more prolonged for 
longer-acting opioids)
Psychostimulant withdrawal
 y Crash   (fatigue, flat affect, increased sleep, reduced cravings) 
 y Withdrawal (fluctuating mood and energy levels, cravings, disturbed 
sleep, poor concentration)
 y Extinction (persistence of withdrawal features, gradually subsiding)
 y Onset: 6-12 hours (cocaine ); 12-24 hours (amphetamines)
 y Duration: Several weeks for withdrawal phase, then months for 
extinction
Signs
Cannabis withdrawal
 y Same as symptoms 
Benzodiazepine withdrawal
 y Same as symptoms 
Opioid withdrawal
 y Same as symptoms 
Psychostimulant withdrawal
 y Same as symptoms 
Investigations 
 y Toxicology screen for suspected substances

— Substance Use Disorders —Chapter 10:  Psychiatric Disorders
241Box 10-2:   Screening of patients suspected of substance abuse
Physical appearance 
 ySweating, tremor, agitation, problem with coordination, gait. Rate these ap -
pearances and reassess them at regular intervals to monitor the progress 
of symptoms. If symptoms are increasing in severity, notify a senior staff  
member, or if available, a doctor
Suicide risk assessment 
 yTo determine the level of risk at a given time and to provide appropriate 
clinical care and management. Possible suicidal behaviour includes thinking 
about suicide, harming oneself or attempting suicide. 
 yScreening questions of suicide risk: 
 yHave things been so bad lately that you have thought you would rather 
not be here?
 yHave you had any thoughts of harming yourself?
 yAre you thinking of suicide?
 yDo you have any plans to commit suicide?
 yHave you ever tried to harm yourself?
 yHave you made any current plans?
 yDo you have access to any thing with which to hurt yourself? 
Mental state examination
 yTo determine: 
 yThe need for other psychological therapies
 yConcomitant psychiatric conditions which place the patient or others at risk
 yThe patient’s capacity for informed consent and active participation in 
treatment planning
Assessment of psychosocial factors affecting withdrawal 
 yAsk patient about:
 yReasons for presenting for withdrawal management at this time
 yPast experiences, current knowledge and fears of withdrawal
 yPerceived ability to cope with withdrawal and its treatment.
 yFamily supports and social networks available for withdrawal treatment:
 yPotential barriers to successful withdrawal
 yCare of children (assess possible neglect or physical or sexual abuse of chil -
dren or exposure to such harm from others and intervene to protect as 
soon as possible or refer to appropriate agency)
 yDrug use of cohabitants
 yCurrent legal issues
 yFinancial problems
 yWork commitments
Treatment 
Treatment objectives
 y To provide supportive care (information, stress reduction, 
reassurance)
 y To teach coping skills (relaxation techniques, dietary guidelines, 
methods to reduce craving for the substance, sleep disturbance 
management)
 y To manage difficult behavior (anxiety , agitation, panic and aggression)

— Autistic Spectrum Disorder —
Standard  Treatment Guidelines, 7th Edition, 2017
242 y To manage confusion, disorientation and hallucinations
 y To plan an organised discharge, follow up and after-care to prevent 
relapse
Non-pharmacological treatment
 y Cognitive Behaviour Therapy   
 y Stress management to reduce craving 
Pharmacological treatment 
A.     Management of withdrawal symptoms - cannabis 
 y Requires no medical intervention 
B.     Management of withdrawal symptoms - stimulants
 y Requires observation but does not require a specific intervention
C�     Management of withdrawal symptoms - benzodiazapines
 y Substitute with equivalent dose of benzodiazapine for a few days, 
then taper off dose over 2-3 weeks 
D�     Management of withdrawal symptoms - opiates
 y Oral rehydration fluids or IV fluids may be required 
 y Long acting benzodiazapines e.g. diazepam, to control insomnia and 
muscle cramps (See drug doses under appropriate sections) 
 y Anti-emetics e.g. promethazine etc., for nausea and vomiting  (See 
drug doses under appropriate sections) 
 y Methadone , buprenorphine  and clonidine  may be used, where 
available and with caution, to reduce the severity of symptoms (See 
drug doses under appropriate sections) 
 y NSAIDs  e.g. ibuprofen , diclofenac  etc., for pain relief (See drug doses 
under appropriate sections) 
Referral Criteria 
Refer for specialist psychiatrist/clinical psychologist care and 
management if withdrawal symptoms are particularly distressful and do 
not respond to treatment or when there are repeated relapses.   
Refer for Cognitive Behaviour Therapy  to a clinical psychologist.
80� Autistic Spectrum Disorder
Autism is a neurodevelopmental disorder characterized by qualitative 
impairments occuring in a child before the age of 36 months, in three key 
areas; social interaction (often the earliest features of Autistic Spectrum 
Disorder -ASD ), communication, interests and activities. 
The clinical presentation is varied and may encompass children 
with severe manifestations of the above features or with more subtle 
behavioural deficits, hence the use of the term Autistic Spectrum 
Disorder . Learning disability in this condition is very common and the risk 
of epilepsy  is significant.

— Autistic Spectrum Disorder —Chapter 10:  Psychiatric Disorders
243ASD is increasingly being recognized in Ghana.
Causes 
 y No clear aetiology 
 y Genetic
Symptoms
 y Absence of joint attention (i.e. failure to show interest, follow gaze, 
lack of social smiling and limited use of gestures e.g. shaking head, 
waving or clapping)
 y Communication deficit 
 y Receptive: fails to acquire language or delays in understanding 
language 
 y Expressive: delays in use of language
 y Limited range of interests (limited play with toys and other objects)
 y Repetitive activities (e.g. spinning objects)
 y Global developmental delays (e.g. walking, speech etc.)
 y Learning difficulties
 y Attention deficit 
 y Sleeping difficulties
 y Feeding difficulties
Signs
 y Lack of pointing to objects by 24 months
 y No single words by 18 months
 y No two word spontaneous phrase by 24 months
 y Loss of language
 y Avoidance of eye contact
Investigations
 y Usually none required 
 y Electroencephalogram (EEG) if seizures suspected
 y Brain CT or MRI only in special circumstances e.g. abnormal physical 
features present
Treatment 
Treatment objectives
 y To correct social communication difficulties using a multidisciplinary 
behavioural and educational approach
Non-pharmacological treatment
 y Applied Behaviour Analysis (ABA ) - teaching based on teacher 
request, prompt assistance to child, child response and feedback 
Pharmacological treatment 
A.     For aggression, irritability or self-mutilation 
Evidence Rating: [B]
 y Risperidone , oral,
Children

— Autistic Spectrum Disorder —
Standard  Treatment Guidelines, 7th Edition, 2017
2445-18 years (body weight > 50 kg); 0.5 mg daily. May increase by 0.5 
mg on alternate days (max. 1 mg daily)
5-18 years (body weight < 50 kg); 0.25-0.5 mg daily. May increase 
by 0.25 mg on alternate days (max. 0.75 mg daily)
< 5 years;   not recommended
B�     For sleep problems
Evidence Rating: [B]
 y Melatonin , oral,
Children
1 month-18 years;  2-3 mg daily (before bedtime)
Then
Increase if necessary after 1-2 weeks to 4-6 mg (daily before bed -
time) max. 10 mg
C.     For significant hyperactivity-in children ≥ 4 years
Evidence Rating: [B]
 y Methylphenidate , oral, 
Children
6-18 years;  5 mg 12-24 hourly 
Then
Increase if necessary at weekly intervals by 5-10 mg 
(max. of 20 mg 8 hourly)
4-6 years;  2.5 mg 12 hourly 
Then
Increase if necessary by 2.5 mg at weekly intervals (max. 0.4-0.5 mg/
kg 8 hourly)
Note 10-9
Discontinue if there is no response after a month
 
Referral Criteria 
All suspected cases of autism should be referred to a Tertiary centre.

11Chapter
245Disorders of the Skin
Bacterial Skin Infections
81� Boils   
A boil or furuncle  is a deep bacterial infection of the hair follicles. A 
more superficial infection is termed folliculitis. Several boils grouped in 
an area and discharging pus from several points is termed a carbuncle. 
Patients with recurrent boils or carbuncles should be screened for 
diabetes mellitus and skin disorders such as scabies, pediculosis or 
eczema  while patients with repeated folliculitis in the shaving areas, e.g. 
face and armpits should be educated on shaving techniques.
Causes 
 y Staphylococcus aureus
Symptoms
 y Single or multiple painful swellings on the skin which may discharge 
pus
 y Fever
Signs
 y Swellings - purulent, warm, fluctuant and/or tender (in single or 
multiple areas of skin) 
Investigations
 y FBC
 y Fasting blood glucose (if diabetes suspected)
 y Swabs for culture and sensitivity in persistent or recurrent infection
Treatment 
Treatment objectives
 y To treat infection
 y To relieve pain
 y To identify and treat any predisposing condition
 y To prevent scars and keloids

— Impetigo  —
Standard  Treatment Guidelines, 7th Edition, 2017
246Non-pharmacological treatment
 y Incision and drainage - if boil becomes fluctuant and large
 y Wound dressing
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [B]
A.     For boils or furunculosis  in patients without penicillin allergy
 y Flucloxacillin , oral,
Adult s
250-500 mg 6 hourly for 7 days
Children
5-12 years;  250 mg 6 hourly for 7 days 
1-5 years;  125 mg 6 hourly for 7 days
<1 year;  62.5 mg 6 hourly for 7 days
B�     For boils or furunculosis  in patients with penicillin allergy
 y Erythromycin , oral,
Adult s
500 mg 6 hourly for 7 days    
Children
6-12 years;  250 mg 6 hourly for 7 days
1-5 years;  125 mg 6 hourly for 7 days
< 1 year;  62.5 mg 6 hourly for 7 days
And  
 y Paracetamol , oral, 
Adults
500 mg -1 g 6 to 8 hourly for 3-5 days
Children
6-12 years;   250-500 mg 6 to 8 hourly for 3-5 days
1-5 years;   120-250 mg 6 to 8 hourly for 3-5 days
3 months-1 year;  60-120 mg 6 to 8 hourly for 3-5 days
C.     For Folliculitis  
 y Mupirocin  ointment, topical, 
Adult s and children
12 hourly for 7 days 
Referral Criteria 
Refer to a specialist if the underlying condition requires further 
management.
82� Impetigo  
Impetigo  is a highly contagious superficial bacterial skin infection. It is 
common in neonates and children and may be associated with conditions 
such as scabies, eczema , lice infestation and herpes simplex infection as 

— Impetigo  —Chapter 11:  Disorders of the Skin
247secondary infection. The condition does not cause any symptoms until 
four to 10 days after initial exposure. It usually improves within a week 
of treatment. 
There are two types of impetigo. The non-bullous type typically 
affects the skin around the nose and mouth, causing lesions to develop, 
that quickly burst to leave a yellow-brown crust. The other type, bullous 
impetigo, typically affects the trunk causing fluid-filled blisters (bullae) to 
develop that burst after a few days to leave a yellow crust.
Both types of impetigo may leave behind marks when the crusts have 
cleared up, but these usually improve over the following days or weeks.
Its prevention involves good hygiene, regular hand-washing, 
trimming of fingernails to reduce breaking of the skin through scratching, 
and discouraging the sharing of towels and clothing.
Causes 
 y Staphylococcus aureus  
 y Streptococcus  pyogenes
Symptoms
 y Pus-filled blisters and sores on the body or scalp
Signs
 y Superficial, fragile fluid-filled blisters
 y Irregular spreading ulcers with yellow crusts
Investigations
 y Often no test required 
 y Microscopy and culture of the exudate from the blisters (except in 
recurrent or severe cases)
Treatment 
Treatment objectives
 y To eradicate infection
 y To prevent transmission
 y To reduce the risk of developing complications (e.g. cellulitis, 
septicaemia )
 y To identify and treat any predisposing condition
Non-pharmacological treatment
 y Antiseptic baths for all cases
Pharmacological treatment 
A.     Mild cases (few pustules without fever or systemic manifestations)
Evidence Rating: [B]
 y Mupirocin  ointment, topical,
Adult s and children
Apply 12 hourly for 7 days

— Impetigo  —
Standard  Treatment Guidelines, 7th Edition, 2017
248B.     Moderate to severe or extensive cases in patients without 
penicillin allergy
1st Line Treatment
 y Cloxacillin , IV,
Adults
500 mg 6 hourly for 3 - 5 days 
Children
10-18 years;  250-500 mg 6 hourly for 3-5 days
2-10 years;  125-250 mg 6 hourly for 3-5 days
< 2 years;  62.5-125 mg 6 hourly for 3-5 days
Then
 y Flucloxacillin , oral,
Adult s 
500 mg 6 hourly for 5-7 days 
Children
10-18 years;   250-500 mg 6 hourly for 5-7 days
2-10 years;   125-250 mg 6 hourly for 5-7 days 
< 2 years;   62.5-125 mg 6 hourly for 5-7 days
Or
 y Amoxicillin + Clavulanic Acid , oral,
Adult s 
625 mg 12 hourly for 5 7 days 
Children
11-18 years;  625 mg 12 hourly for 5-7 days
6-10 years;  457 mg 12 hourly for 5-7 days
1-5 years;  228 mg 12 hourly for 5-7 days
< 1 year;  114 mg 12 hourly for 5-7 days
2nd line treatment
Evidence Rating: [B]
 y Cefuroxime  IV, 
Adult s
750 mg 8 hourly for 3-5 days 
Children
1 month-18 years; 20 mg/kg 8 hourly for 3-5 days 
Then 
 y Cefuroxime , oral,
Adult s
250 mg 12 hourly 
Children
12-18 years;  250 mg 12 hourly
2-12 years;  15 mg/kg 12 hourly, max. 250 mg 12 hourly
3 months-2 years; 10 mg/kg max. 125 mg 12 hourly
C.     Moderate to severe or extensive cases in patients with penicillin 
allergy :
 y Azithromycin , oral,

—   Cellulitis and Erysipelas —Chapter 11:  Disorders of the Skin
249Adult
500 mg daily for 3-5 days
Children
10 mg/kg body weight daily for 3 days 
< 6 months;   not recommended because of a risk of py -
loric stenosis  
Referral Criteria 
Refer for hospital care and treatment if spreading rapidly or cellulitis, 
osteomyelitis or septicaemia  develops.
83�   Cellulitis  and Erysipelas
(See section on ‘Cellulitis’ in Disorders of the Musculoskeletal system)
84. Buruli Ulcer
This is a chronic painless necrotising ulcer with undermined edges, 
which can lead to debilitating skin and soft tissue infection and permanent 
disfigurement. While it is known that this ulcer is caused by a bacterium, 
the mode of transmission remains unclear. However, trauma, insect bite 
and inhalation have been suggested. 
When detected early, the majority can be cured with a combination 
of antibiotics. Thus, early identification and appropriate management 
reduce morbidity and disability from this condition. 
Causes 
 y Mycobacterium ulcerans  
Symptoms 
 y Painless subcutaneous nodule 
 y Painless swelling of the legs, arms or face 
 y Extensive skin ulceration 
Signs 
 y Nodule: Painless firm lesion 1-2 cm in diameter situated in the 
subcutaneous tissue and attached to the skin 
 y Diffuse painless swelling of the legs, arms or face 
 y Large painless area of induration 
 y Extensive skin ulceration 
Investigations 
 y Wound swab for AFBs, bacterial cultures and sensitivity
 y Skin biopsy for histopathology
Treatment
Treatment objectives 
 y To limit the extent of tissue destruction

— Yaws  —
Standard  Treatment Guidelines, 7th Edition, 2017
250 y To prevent disability
 y To treat both primary and secondary bacterial infection
Non-pharmacological treatment
 y Complete excision of nodules, preferably with primary closure if 
possible
 y Skin grafting of ulcers if facilities are available 
Pharmacological treatment 
1st Line Treatment 
Evidence Rating: [A]
 y Rifampicin , oral, 10 mg/kg daily for 8 weeks 
And 
 y Streptomycin , IM, 15 mg/kg daily for 8 weeks 
2nd Line Treatment 
Evidence Rating: [C]
 y Rifampicin , oral, 10 mg/kg daily for 8 weeks 
And 
 y Clarithromycin , oral, 7.5 mg/kg 12 hourly for 8 weeks 
Referral Criteria 
Refer to centres with expertise for managing buruli ulcer . 
85� Yaws  
Yaws  is a chronic infection by a bacterium that affects mainly the 
skin, bone and cartilage. Most people affected are children under 15 years 
of age but adults are not exempt. It is transmitted mainly through skin 
contact with an infected person. A single skin lesion develops at the point 
of entry of the bacterium after 24 weeks. Without treatment, multiple 
lesions appear all over the body. The disease is rarely fatal, however it 
can lead to chronic disfigurement and disability in about 10% of affected 
individuals if left untreated. Treatment with antibiotics is curative and 
relapse is rare.
        Overcrowding, poor personal hygiene and poor sanitation 
facilitate the spread of the disease.
Causes 
 y Treponema pertenue  
Symptoms 
 y Raised skin lesions
 y Painless skin ulcer
 y Bone pain
Signs 
 y Papular skin lesions
 y Painless skin ulcer with scab
 y Deformities of the nose, bones

— Yaws  —Chapter 11:  Disorders of the Skin
251 y Palmar or plantar skin thickening
Inve stigations
 y VDRL
Treatment 
Treatment objectiv es
 y To eradicate the organism and ensure cure
 y To prevent spread of the infection
 y To prevent long term complications
Non-pharmacological treatment
 y None
Pharmacological treatment
Evidence Rating: [A]
A.     Single Dose Treatment for Yaws
 y Azithromycin , oral,
Adult s
30 mg/kg body weight (max. 2 g) as a single dose  
Children
> 15 years;   2 g
10-15 years;   1.5 g 
6-9 years;   1 g 
6 months-6 years;   500 mg (syrup preferable)
< 6 months;  not recommended 
B.     For Non-response or Non-availability of Azithromycin   
 y Benzathine Penicillin , IM,
Adult s
1.2 million units stat.
Children
> 10 years;  1.2 MU stat.
< 10 years;  600 000 units stat.
Referral Criteria 
Refer intractable cases to the dermatologist.
Fungal Skin Infections

— Superficial Fungal Skin Infections —
Standard  Treatment Guidelines, 7th Edition, 2017
25286� Superficial Fungal Skin Infections
These are fungal infections that affect the outer layers of the skin, the 
nails and hair. When florid, it may be associated with immunosuppression 
such as in diabetes and retroviral infection and corticosteroid abuse.
Causes 
 y Dermatophytes (tinea) i.e. microsporum , epidermophyton , 
trichophyton
 y Yeasts i.e. candida , malassezia
Symptoms
 y Itchy scaly ring shaped rash on the skin
 y Scaly bald patches of the scalp
 y Distorted, discoloured finger or toe nails
 y Itchy and sore skin folds
 y Scaly patches of skin with altered pigmentation
Signs
 y Round scaly patches with thickened edges and clear centre on the 
skin 
 y Scaly bald patches of the scalp
 y Distorted discoloured nails
 y Altered pigmentation of skin (hypopigmented or brownish 
appearance) 
 y Pustular rash in the flexures
Investigations
 y Skin scrapings for microscopy and culture (mycology)
 y Nail and/or hair clippings for microscopy and culture
 y FBS and HIV  status (if infection is florid and/or oral candidiasis 
present)  
Treatment 
Treatment/management objectives
 y To eradicate infection
 y To prevent transmission
 y To identify and treat any predisposing conditions
Non-pharmacological treatment
 y Good personal hygiene
 y Use of loose clothing
 y Open footwear
Pharmacological treatment 
A.     Dermatophyte infection of scalp (tinea capitis  ) 
Evidence Rating: [C]
1st Line Treatment
 y Griseofulvin , oral, 

— Superficial Fungal Skin Infections —Chapter 11:  Disorders of the Skin
253Adult s
500 mg daily (double in severe infection) for 4 weeks
Children
1 month-12 years;  10 mg/kg (max. 500 mg) once daily or in 
two divided doses for 4 weeks
12-18 years;   500 mg once daily or in two divided doses 
(may be doubled in severe infections) for 4 weeks
2nd Line Treatment
 y Terbinafine , oral,
Adult s
Not recommended 
Children
Children  over 1 year; 
Body weight > 40 kg; 250 mg once daily for 4 weeks 
Body weight 20-40 kg; 125 mg once daily for 4 weeks
Body weight 10-20 kg; 62.5 mg once daily for 4 weeks
B.     Dermatophyte infection of body (tinea corporis ), perineum (tinea 
cruris ), hands (tinea manuum ) and feet (tinea pedis )           
Evidence Rating: [C]
1st Line Treatment
 y Benzoic Acid compound ointment  (Whitfield’s ointment ), topical, 
Adult s and children
Apply twice daily to patches up to one or two weeks after the last 
visible rash has cleared
Or
 y Clotrimazole  1%, topical, 
Adult s and children
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared
Or 
 y Miconazole  2%, topical, 
Adult s and children
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared
Or
 y Ciclopirox  olamine  1%, topical, 
Adult s and children
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared
2nd Line Treatment
 y Griseofulvin , oral, 
Adult s
500 mg daily (double in severe infection) for 4 weeks
Children
12-18 years;     500 mg once daily or in two divided doses 

— Superficial Fungal Skin Infections —
Standard  Treatment Guidelines, 7th Edition, 2017
254(may be doubled in severe infections) for 4 weeks
1 month-12 years;      10 mg/kg (max. 500 mg) once daily or in 
two divided doses for 4 weeks
Or
 y Itraconazole , oral,
Adult s
200 mg once daily or 12 hourly for 7 days
Children
12 years-18 years;        200 mg daily for 7 days 
1 month-12 years;         3-5 mg/kg (max. 100 mg) once daily for 15 
days or 30 days (for tinea pedis  and manuum)
Or
 y Terbinafine , oral,
Adult s
250 mg daily for 2-6 weeks  
Children
Children  over 1 year; 
Bodyweight > 40 kg; 250 mg once daily for 4 weeks, 
6 weeks-3 months in nail infections
Body weight 20-40 kg; 125 mg once daily for 4 weeks
Body weight 10-20 kg; 62.5 mg once daily for 4 weeks
C.     Dermatophyte infection of nails (onychomycosis )
Evidence Rating: [C]
1st Line Treatment
 y Itraconazole , oral,
Adult s
200 mg 12-24 hourly for 7 days, repeated courses after 21 days in -
terval (max.of 2 courses for finger nails and 3 courses for toe nails)
Children
12 years-18 years; 200 mg 12 hourly for 7 days, repeated 
courses after 21 days interval (finger nails 2 courses, toe nails 3 
courses)
1 year-12 years; 5 mg/kg (max 200 mg) daily for 7 days, re -
peated courses after 21 days interval (finger nails 2 courses and toe 
nails 3 courses)
Or
 y Terbinafine , oral,
Adult s
200 mg daily for 6 weeks-3 months
Children
Children  over 1 year; 
Bodyweight over 40 kg; 250 mg once daily for 6 weeks – 3 months
Body weight 20-40 kg; 125 mg once daily for 6 weeks – 3 months
Body weight 10-20 kg; 62.5 mg once daily for 6 weeks – 3 months
2nd Line Treatment
 y Griseofulvin , oral, 

— Pityriasis Versicolor —Chapter 11:  Disorders of the Skin
255Adult s
500 mg daily (double in severe infection) for 4 weeks
Children
12-18 years;  500 mg once daily or in two divided doses 
(may be doubled in severe infections) for 4 weeks
1 month-12 years; 10 mg/kg (max. 500 mg) once daily or in 
two divided doses for 4 weeks
D�     For  Candida  intertrigo
Evidence Rating: [C]
 y Benzoic Acid compound ointment  (Whitfield’s ointment ), topical, 
Apply twice daily to patches up to one or two weeks after the last 
visible rash has cleared. 
Or
 y Clotrimazole  1%, topical, 
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared
Or 
 y Miconazole  2%, topical, 
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared
Or
 y Ciclopirox  olamine  1%, topical, 
Apply twice daily to patches up to one or two weeks after last visible 
rash has cleared. 
E�     For Oral candidiasis  and Pityriasis  versicolor
Please refer to section on oral candidiasis and pityriasis versicolor
Referral Criteria 
Refer to a dermatologist if patient fails to respond to treatment.
87� Pityriasis Versicolor
Pityriasis versicolor  is a common yeast infection of the skin, in which 
flaky discoloured patches appear on the chest and back. It is sometimes 
called tinea versicolor. It  is more common in hot climates, and often affects 
people that perspire heavily. It is a disorder of the healthy but florid cases 
are seen in the immunosuppressed such as those with diabetes mellitus, 
HIV/AIDS  and topical steroid abuse.
Causes 
 y Pityrosporum orbiculare
 yPityrosporum	ovale  (malassezia  furfur )
Symptoms
 y Asymptomatic
 y Mildly Itchy

— Pityriasis Versicolor —
Standard  Treatment Guidelines, 7th Edition, 2017
256 y Pale or dark skin patches
Signs
 y Hypopigmented macules and/or patches 
 y White scaly patches
Investigations
 y Skin scraping for microscopy
 y Fasting blood glucose (for florid cases)
 y Retroscreen (for florid cases) 
Treatment 
Treatment Objectives
 y To eradicate infection
 y To prevent transmission
 y To address predisposing factors
Non-Pharmacological Treatment
 y Good personal hygiene
 y Avoid sharing bath towels, sponges and clothing
Pharmacological Treatment 
A.     For Mild Tinea  Versicolor
Evidence Rating: [C]
 y Miconazole , 2%, topical,
Adult s
12 hourly for 4 weeks
Children
> 2 years;  12 hourly for 4 weeks 
< 2 years;   12 hourly for 4 weeks
Or 
 y Clotrimazole , 1%, 
Adult s
12 hourly for 4 weeks
Children
> 2 years;  12 hourly for 4 weeks
Or
 y Whitfield’s ointment , topical,
Adult s
12 hourly for 4 weeks
Children  
Not recommended
Or
 y Selenium sulphide , shampoo 2.5%, topical,
Adult s
Once daily for 5-7 days (washed off after 30 minutes to prevent ir -
ritation)
Children
Once daily for 5-7 days 

— Herpes Simplex Infections  —Chapter 11:  Disorders of the Skin
257< 5 years;   not recommended
B�     For Severe Tinea  Versicolor
Evidence Rating: [B]
 y Itraconazole , oral,
Adult s
200 mg daily for 7 days 
Children
> 12 years;   200 mg daily for 7 days
1 month-12 years;  3-5 mg /kg daily for 7 days
Caution 11-1.   
Use of itraconazole is associated with potentially life-threathening liver-toxicity. 
Monitor liver function while on long term therapy.
Referral Criteria 
Refer intractable cases to a dermatologist.
Viral Skin Infections  
88� Herpes Simplex Infections  
These are acute self-limiting viral infections of the skin and mucous 
membranes resulting in blistering eruptions usually seen on the face 
(called “cold sores ”) or the genitalia.  Recurrence is common on previously 
affected skin areas and is due to proliferation of virus within the epidermis 
of the affected dermatome. Extensive lesions may be associated with an 
immunocompromised state or atopy.
Causes 
 y Herpes simplex virus  type 1
 y Herpes simplex virus  type 2
Symptoms
 y Fever
 y Tingling, discomfort, or painful sensation over affected skin area
 y Grouped small blisters
 y General malaise 
Signs
 y Fever
 y Tender grouped vesicles
 y Regional lymphadenopathy
 y Genital ulcers
 y Oral ulcers 
Investigations
 y Usually none 

— Herpes Simplex Infections  —
Standard  Treatment Guidelines, 7th Edition, 2017
258 y Diagnosis is mainly clinical
 y HSV serology (if necessary) 
Treatment 
Treatment objectives
 y To relieve pain and discomfort
 y To limit extent of disease spread in the immunocompromised and 
atopic eczema  patients
 y To prevent secondary infection
Non-pharmacological treatment
 y No specific measures 
Pharmacological treatment 
A.     Perioral or genital lesions
Evidence Rating: [B]
 y Aciclovir  cream 5%, topical, 
Adult s
4 hourly (five times daily) for 4-5 days
Children
4 hourly (five times daily) for 4-5 days
Note 11-1
Start immediately the premonitory symptoms are felt or within 48 hours of on -
set.
B.     For severe primary infections, disseminated herpes simplex, 
frequent recurrences and immunosuppressed patients
 y Aciclovir , oral, 
Adult s
400 mg 4 hourly (five times daily) for 5-7 days
Children
> 2 years;   200 mg 4 hourly (five times daily) for 5-7 
days
1 month-2 years;  100 mg 4 hourly (five times daily) for 5-7 
days
And
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly for 3-5 days
Children
6-12 years;   250-500 mg 6-8 hourly for 3-5 days
1-5 years;   120-250 mg 6-8 hourly for 3-5 days
3 months-1 year;  60-120 mg 6-8 hourly for 3-5 days
Referral Criteria 
Refer complicated cases to a dermatologist.

— Herpes Zoster Infections  —Chapter 11:  Disorders of the Skin
25989� Herpes Zoster  Infections 
This is an acute painful blistering viral infection of the skin. It can 
occur in childhood but is much more common in adults, especially the 
elderly, sick or immunosuppressed.  The primary infection presents as 
chickenpox  (varicella ), usually during childhood. Like herpes simplex, the 
virus persists usually in the anterior horn cells before it is reactivated. Post-
herpetic neuralgia  is a common complication and defined as persistence 
or recurrence of pain more than a month after the onset of shingles.
Causes 
 y Varicella -zoster virus
Symptoms
 y Fever
 y Severe pain over areas involved
 y Headache
 y Blisters 
Signs
 y Fever
 y Tender vesicles spread within one or more dermatomes unilaterally
 y Regional lymphadenopathy
Investigations
 y Usually none
 y HIV screen (for recurrence and/or multi-dermatomal cases) 
Treatment 
Treatment objectives
 y To provide adequate pain relief
 y To prevent secondary bacterial infection
 y To limit extent of disease spread in immuno-compromised patients
 y To prevent complications 
Non-pharmacological treatment
 y Bed rest 
Pharmacological treatment 
Evidence Rating: [B]
A.     Mild Herpes Zoster  Infection 
 y Aciclovir  cream 5%, topical, 
Adult s
4 hourly (five times daily) for 4-5 days
Children
4 hourly (five times daily) for 4-5 days
Note 11-2
Start immediately the premonitory symptoms are felt or within 48 hours of on -
set.

— Herpes Zoster Infections  —
Standard  Treatment Guidelines, 7th Edition, 2017
260And
 y Diclofenac , oral, 
Adult
50 mg 8 hourly for 7 days
Or
 y Ibuprofen , oral, 
Children
5-10 mg/kg 6 hourly for 7 days
And
 y Povidone iodine  10%, topical,
Adult s 
Apply to blisters daily till lesions resolve
Children  
Apply to blisters daily till lesions resolve
B�     Severe Herpes Zoster  Infection
Evidence Rating: [B]
 y Aciclovir , oral, 
Adult s
800 mg 4 hourly (five times daily) for 5-7 days
Children
> 12 years;  800 mg 4 hourly (five times daily) for 5-7 days
6-12 years;  800 mg 6 hourly for 5-7 days
2-6 years;  400 mg 6 hourly for 5-7 days 
< 2 years;  200 mg 6 hourly for 5-7 days
And
 y Diclofenac , oral,
Adult s
50 mg 8 hourly for 7 days
Or
 y Ibuprofen , oral, 
Children
5-10 mg/kg 6-8 hourly for 7 days
And
 y Povidone iodine  10%, topical,
Adult s 
Apply to blisters daily till lesions resolve
Children  
Apply to blisters daily till lesions resolve
C.     Post Herpetic Neuralgia
 y Amitriptyline , oral,
Adult s
25-50 mg daily till resolution 
Children
Not indicated for this condition 

— Chicken pox  —Chapter 11:  Disorders of the Skin
261Or
 y Carbamazepine , oral, 
Adult s
50-150 mg 12 hourly till resolution (maximum 600 mg 12 hourly)
Children
12-18 years;  50-100 mg 12 hourly  
Then  
Increase to 600 mg 12 hourly if necessary 
 
1 month-12 years;  2.5 mg/kg 12 hourly 
Then
Increase slowly to 5 mg/kg 12 hourly  
Or
 y Pregabalin , oral,
Adult s
75 mg 12 hourly till resolution 
Children
Not recommended
Referral Criteria
Refer complicated cases to a specialist.
90� Chicken pox  
Chicken pox  and shingles are caused by the same virus (Varicella  
or Herpes Zoster ). Humans are the only source of infection for chicken 
pox and shingles. Person-to-person transmission occurs by direct contact 
with vesicular fluid from patients with either condition. Chicken pox may 
additionally be transmitted by airborne spread from respiratory tract 
secretions. There is a risk of infection up to 21 days after contact.  
Chicken pox  is a highly contagious viral illness usually occurring 
in epidemics. It is generally a benign, self-limiting disease in immuno-
competent children but tends to be more severe in adolescents 
and adults and also in immunosuppressed patients e.g. patients on 
steroids. Complications include bacterial super-infection of skin lesions, 
pneumonia, central nervous system involvement (acute cerebellar ataxia , 
encephalitis), thrombocytopenia , and other rare complications such as 
glomerulonephritis, arthritis, and hepatitis. 
Exposure to the virus during the second 20 weeks of pregnancy can 
result in congenital varicella  syndrome characterised by skin scarring, 
abnormalities of limbs, brain, eyes and low birth weight. Varicella  
infection can be fatal for an infant if the mother develops varicella from 5 
days before to 2 days after delivery.
Shingles presents with skin lesions in a dermatomal distribution 
and in immunocompromised individuals, can be very extensive. It may 
be complicated by pain persisting for weeks to years after the infection 

— Chicken pox  —
Standard  Treatment Guidelines, 7th Edition, 2017
262(postherpetic neuralgia). 
Causes 
 y Varicella -Zoster (or Herpes Zoster ) virus
Symptoms
Chicken pox
 y Fever
 y Malaise
 y Anorexia
 y Headache  
 y Itchy skin rash
Shingles
 y Painful rash
 y Fever
Signs
Chickenpox
 y Vesicular rash eventually becoming crusted
 y Rash in different stages (papules, vesicles,  crusted lesions)
 y Appear first on face, scalp or trunk and spreads to rest of body, 
more concentrated on trunk
 y Persists for 5-7 days
 y Presence of pus in lesions suggests secondary bacterial infec -
tion
Shingles
 y Vesicular rash
 y Along a dermatome 
 y Rash eventually crusts
Investigations
 y Usually none (diagnosis is mainly clinical)
 y Polymerase Chain Reaction (PCR)  or cell culture from vesicular fluid, 
crusts, saliva, cerebrospinal fluid or other specimens (if diagnosis in 
doubt)
Treatment 
Treatment objectives
 y To relieve the intense itching or pain  
 y To prevent or treat secondary infection
 y To prevent dehydration  in children 
Non-pharmacological treatment
 y Avoid scratching  
 y Regular bathing with soap and water 
 y Avoid intentionally breaking up vesicles
Pharmacological treatment 
A.     To relieve pain and fever
1st Line Treatment

— Chicken pox  —Chapter 11:  Disorders of the Skin
263Evidence Rating: [C]
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly for 3-5 days 
Children
6-12 years;   250-500 mg 6-8 hourly for 3-5 days
1-5 years;   120-250 mg 6-8 hourly for 3-5 days
3 months-1 year; 60-120 mg 6-8 hourly for 3-5 days
B�     To soothe the skin and relieve pruritus
 y Calamine lotion /cream, topical, apply liberally to the skin 
And 
 y Cetirizine  oral,  
Adults
10 mg daily 
Children
12-18 years;                10 mg daily
6-12 years;                5 mg 12 hourly 
1-6 years;                2.5 mg 12 hourly 
Or 
 y Promethazine  hydrochloride, oral, (sedating)
Adult s
25 mg daily or 8 hourly daily
Or
 y Chlorpheniramine  maleate, oral, 
Adult
4 mg daily or 12 hourly daily
Children
6-12 years;   2 mg 6-12 hourly daily (max. 12 mg daily)
2-6 years;   1 mg 6-8 hourly (max 6 mg daily)
1-2 years;   1 mg 12 hourly 
C.     Antiviral therapy in immunocompetent individuals for Post 
exposure prophylaxis 
 y Aciclovir , oral,
Adult s
800 mg 4-6 hourly for 5 days
Children
20 mg/kg 6 hourly (max 800 mg 6 hourly) 
D.     Antiviral therapy in Immuno-compromised patients (e.g. HIV )
And 
 y Aciclovir , oral,
Adult s
800 mg 4 hourly (5 times daily) for 7 days or until 2 days after crust -
ing of lesions
Children
12-18 years;  800 mg 4 hourly (5 times daily) daily for 7 

— Chicken pox  —
Standard  Treatment Guidelines, 7th Edition, 2017
264days (continue for 2 more days after crusting of lesions
6-12 years;  800 mg 4 hourly (5 times daily) for 7 days 
(continue for 2 more days after crusting of lesions
2-6 years;  400 mg 4 hourly (5 times daily) for 5 days 
(continue for 2 more days after crusting of lesions)
1 month-2 years;  200 mg 4 hourly (5 times daily) for 5 days 
(continue for 2 more days after crusting of lesions
E.     Superimposed bacterial skin infection in individuals not allergic to 
penicillins
Evidence Rating: [C]
 y Flucloxacillin , oral,
Adult s
250-500 mg 6 hourly for 5-7 days 
Children
10-18 years;               250-500 mg 6 hourly 5-7 days
2-10 years;               125-250 mg 6 hourly 5-7 days
< 2 years;            62.5-125 mg 6 hourly 5-7 days
Or
 y Amoxicillin + Clavulanic Acid , oral, 
Adult s
625 mg 12 hourly for 5-7 days 
Children
10-18 years;               625 mg 12 hourly for 5 days
6-10 years;               457 mg 12 hourly for 5 days
1-5 years;           228 mg 12 hourly for 5 days
F.     Superimposed bacterial skin infection in individuals allergic to 
penicillin 
 y Azithromycin , oral,
Adult
500 mg daily for 3 days
Children
10 mg/kg body weight daily for 3 days
Not recommended for children less than 6 months because of a risk 
of pyloric stenosis
Referral Criteria 
Refer when severe complications set in. Also refer patients who are 
at risk of developing a disseminated rash e.g. patients on steroid therapy, 
other immunocompromised states and the newborn  whose mother has 
had a recent infection.
Non-Specific Skin Infections  

— Large Chronic Ulcers —Chapter 11:  Disorders of the Skin
26591� Large Chronic Ulcers
An ulcer or sore is a breach in the continuity of the skin and the 
underlying tissue. Large ulcers can cause a lot of morbidity and lead to 
serious complications. Predisposing and underlying disease needs to 
be investigated. Complications include deformity, ankylosis of joints, 
osteomyelitis, cellulitis and malignant transformation of ulcers. Surgical 
treatment may be needed.
Causes 
 y Infections and infestations e.g. Buruli ulcers, yaws ulcers, tuberculous 
ulcers, guinea worm ulcers
 y Non-specific ulcers e.g. pressure (decubitus), traumatic, venous, 
diabetic, sickle cell ulcers, ischaemic 
 y Malignant ulcers e.g. squamous cell carcinoma, melanoma, Kaposi’s 
sarcoma
Symptoms
 y Pain 
 y Loss of sensation at site of ulcer
 y Discharge, which may be offensive
 y Severe disfigurement 
 y Disability
Signs
 y Sloping edges (non-specific ulcers)
 y Undermined edges (buruli and tuberculous ulcers)
 y Punched out edges (yaws ulcers) 
 y Raised everted edges (malignant ulcers)
 y Loss of sensation in affected part (diabetes, leprosy, yaws or syphilis 
ulcers)
 y Deformity of affected part
 y Wound discharge (purulent or offensive) 
 y Gangrene of affected part (diabetes, peripheral vascular disease)
 y Darkening of affected area (peripheral vascular disease, venous 
insufficiency)
 y Pink granulation tissue without slough (healthy wound) 
Investigations
 y FBC, ESR
 y Sickling test
 y Fasting blood glucose
 y Wound swab for culture and sensitivity, Ziehl Nielsen staining
 y VDRL /RPR  test 
 y X-ray of underlying bone
 y Biopsy of ulcer 

— Large Chronic Ulcers —
Standard  Treatment Guidelines, 7th Edition, 2017
266Treatment 
Treatment objectives
 y To deslough the ulcer and promote healthy granulation tissue 
formation
 y To promote healing
 y To identify and manage any underlying cause
 y To prevent complications 
Non-pharmacological treatment
 y Change dressing daily
 y Use absorbent dressing for wounds that have profuse discharge
 y Deslough wounds that have adherent slough
 y Elevate lower limb on sitting
 y Adequate nutrition
Pharmacological treatment 
Evidence Rating: [C]
A.     For non-antiseptic wound cleansing 
 y Normal saline  solution (Do not use Eusol )
B.     For antiseptic wound cleansing
Evidence Rating: [C]
 y Chlorhexidine  solution  4%, topical, 
Or 
 y Cetrimide  15%, topical,
Or
 y Povidone iodine  solution 10%, topical,
C.     Systemic antibiotic treatment for secondary bacterial infections
Specific antimicrobial treatment is guided by culture and sensitivity 
results.
Empiric antibiotic treatment may be initiated while awaiting culture 
and sensitivity results based on suspected or likely organisms.
Note 11-3
Avoid topical antibiotics as there is insufficient evidence for their effectiveness
Referral Criteria 
Refer patients with ulcers failing to show signs of healing with 
above treatment, and patients who would require surgery either for skin 
grafting, wound excision or limb amputation to a surgical specialist. All 
ulcers suspected to be malignant should also be referred to a surgical 
specialist.

— Pruritus —Chapter 11:  Disorders of the Skin
26792� Pruritus
Pruritus  or itching is an unpleasant sensation on the skin that 
provokes the desire to rub or scratch the area. Itching can cause discomfort 
and frustration. In severe cases it can lead to disturbed sleep, anxiety  
and depression . Constant scratching to obtain relief can damage the skin 
and reduce its effectiveness as a major protective barrier. Treatment of 
pruritus  must address the underlying condition. Diagnosis therefore 
needs to be made for effective treatment. 
Causes 
Localised pruritus  (confined to a certain part of the body)
 y Seborrhoiec dermatitis
 y Pruritus  vulvae
 y Anogenital pruritus
 y Tinea  infections
 y Gravitational eczema
 y Lichen simplex chronicus
Pruritic skin disorders (due to a primary skin disease)
 y Atopic eczema
 y Dry skin 
 y Allergic contact dermatitis  
 y Urticaria  
 y Scabies
 y Prurigo
 y Miliaria  (heat rash)
 y Pediculosis  
 y Insect bites
 y Dermatitis herpetiformis
 y Lichen planus
 y Bullous pemphigoid
Generalised pruritus  (usually due to a systemic disease)
 y Haematological e.g. iron deficiency anaemia, polycythaemia rubra 
vera, lymphomas, leukaemias
 y Liver disease e.g. intrahepatic or extrahepatic cholestasis, primary 
biliary cirrhosis, hepatitis
 y Chronic kidney disease
 y Thyroid disease
 y Pregnancy
 y Diabetes mellitus
 y Carcinomas 
 y Drug reaction
 y Onchocerciasis  
 y Psychogenic 
Symptoms
 y Itching 

— Pruritus —
Standard  Treatment Guidelines, 7th Edition, 2017
268 y Scratching 
Signs
 y Excoriation
 y Lichenification
 y Scars
 y Features of underlying conditions
Investigations
 y FBC, film comment
 y BUE, Creatinine
 y LFTS
 y FBS
 y Thyroid function test
 y Skin snip and skin scrapings
 y Stool RE
Treatment 
Treatment objectives
 y To relieve symptoms
 y To identify and treat underlying disorder
Non-pharmacological treatment
 y Avoid or minimize exposure to any identifiable causative agents e.g. 
soaps, detergents, drugs, clothes or fabric, foods etc.
 y Good personal hygiene
 y Counselling (for psychogenic pruritus ) 
Pharmacological treatment 
A.     Symptomatic treatment
Evidence Rating: [C]
 y Hydrocortisone  1%, topical, apply 12 hourly for 14 days 
And
 y Cetirizine , oral,
Adult s 
10 mg daily for 7 days
Children
7-18 years;          10 mg daily for 7 days
2-6 years;            5 mg daily for 7 days
< 2 years;   safety not established 
Or
 y Chlorpheniramine , oral,
Children
< 2 years;             1 mg 12 hourly for 5 days
B�     For treatment of Scabies  
Evidence Rating: [A]
 y Permethrin  lotion 1%, topical,  

— Pruritus —Chapter 11:  Disorders of the Skin
269Adult
Apply to whole body and wash off after 8-12 hours 
Repeat after 7 days
Children
Apply to whole body and wash off after 8-12 hours
Repeat after 7 days
< 2 months;    not recommended
Note 11-4
Avoid contact with the mouth.
Refer patient to the clinical pharmacist for counselling on the use of permethrin 
lotion in children and for breastfeeding mothers. 
Evidence Rating: [C]
 y Benzyl benzoate  25% lotion, topical, 
Adult s
Apply over the whole body after a bath at night (except the face and 
head) for 3 nights [and wash off the next morning] 
Children  (> 2 years) (25% - half strength dilution) 
Apply over the whole body after a bath at night (except the face and 
head) for 3 nights [and wash off the next morning] 
Note 11-5
Treat all contact cases in same manner simultaneously. 
Consult the clinical pharmacist for appropriate dilution and counselling on the 
use of benzylbenzoate in children. 
Or 
 y Malathion  0.5%, topical,
Adult s
Apply to whole body. Leave on for 24 hours and wash off. Repeat 
application after 7 days
Children  
Apply to whole body. Leave on for 24 hours and wash off. Repeat 
application after 7 days
< 6 months;   not recommended 
Note 11-6
Clothing and bed linen must be changed and washed daily with a strong disin -
fectant and should be well dried and ironed or dry-cleaned.
Sexual and household contacts should also be treated.
C�     For treatment of Candidiasis
 y Clotrimazole  1%, topical,
Adult s
Apply to affected area 12 hourly for 14 days
Children
Apply to affected area 12 hourly for 14 days

— Pruritus —
Standard  Treatment Guidelines, 7th Edition, 2017
270Or
 y Miconazole  2%, topical
Adult s
Apply to affected area 12 hourly for 14 days
Children
Apply to affected area 12 hourly for 14 days
D�     For treatment of Miliaria  (Prickly Heat, Heat Rash)
 y Calamine lotion , topical,
Adult s
Apply 12 hourly for 7 days
Children
Apply 12 hourly for 7 days
Or
 y Zinc oxide  cream, topical,
Adult s
Apply 12 hourly for 7 days
Children
Apply 12 hourly for 7 days
E.     For treatment of Atopic Eczema
 y Aqueous cream , topical,
Adult s and children
Apply as often as possible 
Or
 y Aqueous soap , topical,
Adult s and children
Use as soap for bathing 12 hourly before applying cream
Or
 y Salicylic Acid  ointment, topical, 
Adult s and children
Apply as needed
F.     For treatment of Atopic Eczema  with acute flare-ups (see section 
on dermatitis )
 y Topical steroids may be used in addition to the above for Atopic Ec -
zema
And
 y Hydrocortisone  cream, 1% topical,
Adult s and children 
Apply 2-4 times daily
G.     For treatment of Urticaria
 y Cetirizine , oral,
Adults 
10 mg daily for 7 days
Children
7-18 years;          10 mg daily for 7 days
2-6 years;            5 mg daily for 7 days

— Urticaria —Chapter 11:  Disorders of the Skin
271< 2 years;       not recommended
Or 
 y Chlorpheniramine , oral,
Children
< 2 years;              1 mg 12 hourly for 5 days
(See section on ‘Urticaria ’)
H.     For treatment of Contact Dermatitis  
 y Hydrocortisone  1%, topical, 
Adult s and children
Apply 12 hourly for 14 days 
I.      For Insect Bites (e.g. Fleas, Bed Bugs)
Note 11-7
Sources of infestation such as combs, hat, clothing or bedding should be decon -
taminated by thorough washing, ironing or fumigation.
 y Cetirizine , oral,
Adults 
10 mg daily for 7 days
Children
7-18 years;          10 mg daily for 7 days
2-6 years;            5 mg daily for 7 days
< 2 years;      2.5 mg daily for 7 days
Or 
 y Chlorpheniramine , oral,
Children
< 2 years;             1 mg 12 hourly for 5 days
J.      For treatment of Pediculosis  (lice)
 y Malathion  0.5%, topical,
Adult s
Apply to whole body. Leave on for 24 hours and wash off. Repeat 
application after 7 days
Children  
Apply to whole body. Leave on for 24 hours and wash off. Repeat 
application after 7 days
< 6 months;   not recommended 
Referral Criteria 
Refer to a dermatologist as soon as possible if diagnosis is unclear.
93� Urticaria
Urticaria  or wheal is a transient, itchy swelling of the skin secondary 
to the release of histamine. Each episode of wheal may last a few minutes 
or several hours and may change shape. Wheals may be round, or form 

— Urticaria —
Standard  Treatment Guidelines, 7th Edition, 2017
272rings, a map-like pattern or giant patches. The surface wheals  may be 
accompanied by deeper swelling of mucous membrane such as the 
eyelids, lips, hands and other parts of the body. The deeper swelling is 
called angioedema.
Urticaria  is classified as acute urticaria if the condition lasts less 
than six (6) weeks and chronic urticaria if it lasts more than six (6) weeks.  
Causes of acute urticarias can easily be identified as against those for 
chronic urticaria.  
Causes 
 y Medicines e.g. penicillins, cephalosporins, aspirin , NSAIDS, toxoids, 
animal sera, morphine , radiocontrast media, ACE inhibitors
 y Foods e.g. fish, nuts, eggs, chocolate, shellfish, pork, spices, milk, 
cheese, food dyes, additives
 y Infections e.g. sepsis, hepatitis (viral)
 y Latex e.g. gloves, medical equipment
 y Medical conditions e.g. lupus erythematosus, lymphoma, 
polycythaemia
 y Plants
 y Idiopathic 
 y Environmental and physical factors
 y Pressure urticaria: wheals  appear on the area of skin experienc -
ing any form of pressure e.g. soles of feet after prolong standing
 y Solar, cold and heat urticaria: wheals  appear when exposed to 
these environments
 y Aquagenic urticaria: exposure to water leads to itchy wheals
 y Cholinergic urticaria: intense pruritic wheals  are seen in re -
sponse to sweating, exercise, emotions, and hot foods
 y Dermographism: linear wheals  noticed as a result of scratching 
or pressure
Symptoms
 y Itching
 y Wheals
Signs
 y Wheals
 y Demographism
 y Angioedema  
Investigations
 y Usually none
 y Full blood count (may show eosinophilia related to allergy or 
parasitic infestation or low white blood count from systemic lupus 
erythematosus)
 y Stool RE
 y Thyroid antibodies and function (in chronic urticaria if autoimmune 
origin is considered likely)

— Reactive Erythema and Bullous Reaction   —Chapter 11:  Disorders of the Skin
273 y Skin biopsy (if wheals  are prolonged, to identify vasculitis)
Treatment 
Treatment Objectives
 y To provide immediate relief
 y To prevent complications such as anaphylaxis , shock or asphyxiation
 y To identify possible underlying cause and address it.
Non-Pharmacological Treatment
 y Avoid contact with or further use of the suspected allergen or 
causative agent
Pharmacological Treatment 
A.     Control of wheals  and itching
Evidence Rating: [C]
 y Cetirizine , oral,
Adult s 
10 mg daily for 7 days
Children
7-18 years;          10 mg daily for 7 days
2-6 years;            5 mg daily for 7 days
< 2 years;      2.5 mg daily for 7 days
Or
 y Chlorphenamine , oral,
Adult s
4 mg 4-6 hourly 
Children  
6-12 years;           2 mg 4-6 hourly
2-6 years;             1 mg 4-6 hourly
1-2 years;             1 mg 12 hourly 
Or
 y Promethazine , oral, 
Adult s
25-50 mg 8-12 hourly 
Children
10-18 years;   12.5-25 mg 8-12 hourly or 25 mg at night
5-10 years;   6.25-12.5 mg 12 hourly or 10-25 mg at night
2-5 years;   6.25 mg 12 hourly or 5-15 mg at night
< 2 years;   not recommended
Referral Criteria 
Refer cases of chronic urticaria to a dermatologist.
94. Reactive Erythema  and Bullous Reaction   
These are immunologic reactions characterized by reddening with 
or without blistering of the skin and/or mucosa. The common types are 
erythema multiforme , Stevens-Johnson syndrome  and toxic epidermal 

— Reactive Erythema and Bullous Reaction   —
Standard  Treatment Guidelines, 7th Edition, 2017
274necrolysis (TEN) .  With all these conditions, there could be accompanying 
extensive denudation of skin with consequent fluid and electrolyte loss 
and a risk of secondary bacterial infection. All three conditions should be 
considered as emergencies requiring intensive care.
Erythema multiforme presents as itchy, target-like, non-scaly lesions 
of the palms, soles, forearms and legs.
Stevens-Johnson syndrome  is characterized by erythema and 
blister formation, which additionally involves the mucous membranes 
(conjunctiva, mouth, genitals etc.). 
Toxic epidermal necrolysis (TEN)  is a generalized scalded type of skin 
reaction, often due to an allergic reaction to drugs. A similar reaction 
occurs in children termed staphylococcal scalded skin syndrome, which is 
caused by Staphylococcus aureus .
Causes 
 y Viral infections e.g. herpes simplex virus , retrovirus , cytomegalovirus
 y Mycoplasma pnuemoniae  infection
 y Adverse drug reaction e.g. to sulphonamides, penicillin, NSAIDS, 
anticonvulsants etc.
 y Malignancy
Symptoms
 y Fever
 y Blisters
 y Itchy rash
 y Sore throat
 y General malaise
 y Discharging painful eyes
 y Asymptomatic  
Signs
 y Fever
 y Flaccid bullae 
 y Genital and/or oral ulcerations
 y Denuded area of skin 
Investigations
 y FBC
 y BUE & creatinine
 y HIV screen 
 y Blood and wound cultures (if indicated) 
Treatment 
Treatment objectives
 y To maintain adequate hydration
 y To maintain adequate nutrition
 y To correct electrolyte imbalance

— Reactive Erythema and Bullous Reaction   —Chapter 11:  Disorders of the Skin
275 y To maintain normal body temperature
 y To prevent secondary infection
 y To identify and eliminate underlying cause 
 y To prevent further exposure to the causative agent or drug
Non-pharmacological treatment
 y Withdrawal of identifiable causative agent or drug
 y Maintenance of adequate input and output of fluid
 y Adequate oral fluids 
 y Prevent contact of ulcerated skin with contaminated linen using a 
nursing cradle
 y Early ophthalmological consultation
 y Nutritious diet
Pharmacological treatment 
A.     For adequate rehydration 
 y Normal saline , IV, 
B�     For Pain and Fever
Evidence Rating: [A]
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly 
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
C.     For Control of the Immune Process in patients who can swallow
Evidence Rating: [C]
 y Prednisolone , oral, (at onset of condition)
Adult s 
0.5-1 mg/kg daily and taper off over 7-10 days
Children
0.5 mg/kg daily and taper off over 7-10 days
D.     For Control of the Immune Process in patients who cannot 
swallow
 y Hydrocortisone , IV,  
Adult s
100 mg 6 hourly until able to swallow 
Then 
 y Prednisolone , oral, as above 
Children
4 mg/kg 6 hourly until able to swallow 
Then 
 y Prednisolone , oral, as above 

— Acne Vulgaris  —
Standard  Treatment Guidelines, 7th Edition, 2017
276E.     To treat Secondary Bacterial Skin Infection or Mycoplasma 
Pneumonia  
Evidence Rating: [B]
 y Azithromycin , oral,
Adult s
500 mg daily for 5 days
Children
10 mg/kg once daily for 5 days
< 6 months;   not recommended
Or
 y Erythromycin , oral,
Adult s
500 mg 6 hourly for 7 days 
Children
6-12 years;   250 mg 6 hourly for 7 days
1-5 years;   125 mg 6 hourly for 7 days
< 1 year;   62.5 mg 6 hourly for 7 days
F.     For prevention of skin infections
Evidence Rating: [C]
 y Chlorhexidine  solution  4%, topical, 
Or 
 y Cetrimide  15%, topical,
Or
 y Povidone iodine  solution 10%, topical,
Note 11-8
Do not use silver sulfadiazine as it is a  sulfa drug  for skin care.
G�     For oral ulcers
 y Povidone iodine  1% mouthwash, 12 hourly 
Or
 y Chlorhexidine  0.12% mouthwash, 12 hourly 
Referral Criteria 
Refer all patients to appropriate specialist. 
95� Acne Vulgaris  
Acne vulgaris (pimples  or spots ) is a common chronic inflammatory 
skin disorder involving the hair follicle and sebaceous gland which 
presents mainly in adolescence. A variety of spots appear mostly on the 
face and other parts of the body. Severe acne may require evaluation 
to exclude an underlying hormonal disorder. This condition may induce 
some psychological disturbances. The choice of treatment depends on 
age, severity, and whether the acne is predominantly inflammatory or 

— Acne Vulgaris  —Chapter 11:  Disorders of the Skin
277comedonal.
Causes 
 y Increased sebum secretion
 y Abnormal keratinisation of the hair follicles (hereditary)
 y Increased sensitivity of the sebaceous glands to male hormones 
 y Propionibacterium acne s
 y Prolonged use of systemic and topical steroids e.g. Anabolic steroids 
such as danazol, stanozolol and nandrolone 
 y Use of pomades, especially products that contain lanolin, petrolatum, 
vegetable oils, butyl stearate, lauryl alcohol and oleic acid
 y Contraceptive agents: medroxyprogesterone injection, implanted or 
intrauterine progesterone, and oral contraceptives
 y Pregnancy 
 y Polycystic ovarian syndrome
 y Adrenal disorders
Symptoms
 y Pimples  (on the face and occasionally on the trunk, chest and 
shoulders)
 y Greasy skin
 y Facial disfigurement 
Signs
 y Comedones (blackheads and whiteheads)
 y Papules 
 y Cysts
 y Scars
 y Nodules
 y Pustules
 y Hirsutism (suggest excess androgens)  
Investigations
 y Usually none 
 y Serum testosterone (in females with accompanying hirsutism and 
virilising features)
 y Pelvic ultrasound (in females to exclude polycystic ovaries if hirsutism 
present) 
Treatment 
Treatment objectives
 y To improve cosmetic appearance
 y To prevent complications particularly scarring
 y To reassure patient
 y To identify and avoid any causative or contributing factors
Non-pharmacological treatment
 y Counselling of patients

— Acne Vulgaris  —
Standard  Treatment Guidelines, 7th Edition, 2017
278Pharmacological treatment 
A.     For mild to moderate acne
Evidence Rating: [A]
 y Benzoyl peroxide  5% lotion, topical, apply daily (avoiding mouth, 
eyes and the mucous membranes) 
And
 y Clindamycin , 1% lotion or gel, topical, apply daily
Or
 y Tretinoin  0.01% gel, topical, apply nocte (avoiding the sun, eyes, nos -
trils, mouth, mucous membrane and broken skin)
Caution 11-2.
Topical retinoids (Tretinoin ) are contraindicated in pregnancy 
Or
 y Adapalene  0.1% cream or gel, topical, apply thinly once daily (at 
night before sleep) 
B�     For moderate to severe acne (or where topical therapy is 
ineffective or not tolerated)
Evidence Rating: [B]
Topical treatment from above (A)
And
 y Doxycycline , oral,
Adult s
100 mg daily for 6 weeks-6 months (depending on response to treat -
ment)
Children
Not recommended
Or
 y Tetracycline , oral, 
Adult s
250-500 mg 12 hourly for 6 weeks-6 months (depending on response 
to treatment)
Change medication to erythromycin after 4 months if response is 
poor  
Children
> 12 years;   same dose as for adults above
< 12 years;  not recommended
Or
 y Erythromycin , oral,
Adult
500 mg 12 hourly for 6 weeks-6 months
Children
> 12 years;   500 mg 12 hourly for 6 weeks - 6 months 
1-12 years;   125 mg 12 hourly Or 250 mg once daily for 

— Eczema  —Chapter 11:  Disorders of the Skin
2796 weeks-6 months
Referral Criteria 
Refer patients not responding to treatment to a dermatologist. 
Suspected underlying endocrine conditions should be referred to an 
endocrinologist.
96� Eczema  
Eczema  or dermatitis  is an acute or chronic inflammatory reaction in 
the skin often due to an external (exogenous) or internal (endogenous) 
factor. Exogenous eczema  (contact eczema) includes primary irritant 
dermatitis and allergic contact dermatitis . Endogenous eczema includes 
atopic eczema , seborrhoiec eczema , discoid eczema , asteatotic eczema , 
varicose eczema  and endogenous hand and soles dermatitis.
Contact dermatitis  may be an irritant (concentration dependent) or 
allergic (delayed hypersensitivity) reaction to specific external substance 
such as metals, rubber, chemicals etc. In contrast to the endogenous 
types, the skin reaction is confined to the areas directly in contact with 
the offending substance or allergen. 
Atopic eczema  is a common chronic but self-limiting pruritic skin 
disorder mainly of childhood but sometimes persists into adult life. The 
rash usually appears within the first year of life, mostly between ages 
2 and 4 months. In older children the rash characteristically involves 
the flexural areas. A familial background of atopy (asthma, hay fever, 
eosinophilia, allergic rhinitis  and similar skin problem) is often present. 
The condition is characterised by relapses and remissions.
Seborrhoiec eczema  presents as a scaly, flaking, dry and reddened 
rash of the scalp, eyebrows, nasolabial folds, perioral, periorbital and 
periauricular skins. Sometimes it presents as hypopigmented macules. 
It may be associated with Pityrosporum	 ovale  infection. Extensive forms 
are associated with immunosuppressive states, particularly HIV /AIDS  and 
diabetes mellitus.
Causes 
 y Genetic
 y Irritants (e.g. acids, alkalis, detergents, petroleum products)
 y Allergens (e.g. nickel, rubber, additives, chromates, hair dyes, topical 
medicaments, plants, nail varnish, cosmetics etc.) 
 y Fungal infections (e.g. Pityrosporum	ovale , dermatophytosis) 
 y Venous stasis (e.g. varicose veins, heart failure, lymphoedema) 
Symptoms
 y Itchy skin
 y Dry skin
 y Weeping, reddened rash
 y Relapses and remissions pattern

— Eczema  —
Standard  Treatment Guidelines, 7th Edition, 2017
280Signs
 y Dry skin
 y Scaly skin
 y Erythema 
 y Excoriations
 y Lichenification
 y Post inflammatory hyperpigmentation or hypopigmentation
 y Papules
 y Vesicles
 y Fissuring   
Investigations
 y Patch testing for contact dermatitis
 y Skin scraping for fungal elements
 y HIV screen (seborrhoiec eczema  in adults)
 y Fasting blood sugar (seborrhoiec eczema  in adults) 
Treatment 
Treatment objectives
 y To relieve or control symptoms 
 y To identify and avoid any causative or prediposing factors
Non-pharmacological treatment
 y Counselling of patients
 y Avoidance of identifiable precipitating factors
Pharmacological treatment 
Evidence Rating: [C]
A.     For Atopic Eczema  
 y E45 cream , topical, 
Adult s
Apply 12 hourly 
Children
Apply 12 hourly
Or
 y Aqueous cream , topical, 
Adult s 
Apply 12 hourly
Children
Apply 12 hourly
Or
 y Shea butter , topical, 
Adult s 
Apply 12 hourly
Children
Apply 12 hourly
Or
 y Salicylic Acid  ointment 2%, topical, 

— Eczema  —Chapter 11:  Disorders of the Skin
281Adult s
Apply 12 hourly 
Children  
Apply 12 hourly 
And
 y Oilatum soap  (or bath gel), topical, 
Adult s 
Apply 8-12 hourly
Children  
Apply 8-12 hourly
And
 y Hydrocortisone  cream/ointment 1-2.5%, topical,
Adult s 
Apply 8-12 hourly
Children  (1% cream)
3 months-12 years; apply thinly 12 to 24 hourly in area of rash 
Or
 y Mometasone  lotion/ointment 0.1% 
Adult s 
Apply thinly once daily 
Children  
Apply thinly once daily 
Or
 y Betamethasone  cream/ointment 0.05-0.1%, topical,
Adult s 
Apply thinly 12-24 hours 
Children  (0.05%)
1-18 years;  apply thinly 12 to 24 hours 
And
 y Chlorphenamine , oral, 
Adult s
4 mg 4-6 hourly or 4 mg once at night for 7 days
Children  
6-12 years;  2 mg 4-6 hourly or 2 mg once at night for 7 days
2-6 years;  1 mg 4-6 hourly or 1 mg once at night for 7 days
1-2 years;  1 mg 12 hourly or 1 mg once at night for 7 days
B�     Seborrhoiec Eczema
Evidence Rating: [C]
 y Miconazole , 2% plus hydrocortisone  1% cream, topical,
Adult s 
Apply 12 hourly till rash resolves 
Children  
Apply 12 hourly till rash resolves
Or
 y Clotrimazole , 1% plus hydrocortisone  1% cream, topical,

— Eczema  —
Standard  Treatment Guidelines, 7th Edition, 2017
282Adult s 
Apply 12 hourly till rash resolves 
Children  
Apply 12 hourly till rash resolves
Or
 y Ketoconazole shampoo , topical, 
Adult s
Apply twice weekly for 4 weeks with at least 3 days between each 
application 
Children  
12 -18 years (shampoo); Apply twice weekly for 4 weeks with at least 
3 days between each application 
< 12 years; safety and efficacy not establised 
Or
 y Selenium sulphide  shampoo 
Adult s 
Apply whole body 2 times per week for 2 weeks initially 
Then
Once every 1-2 weeks to control symptoms.
Allow to remain on the scalp for 2-3 minutes then rinse thoroughly 
Children
5-18 years;   same as adult dose
< 5 years;   not recommended
Or
 y Itraconazole , oral,
Adult s
100 mg daily for 3 weeks 
Children
> 12 years;   100 mg daily for 3 weeks
1 month-12 years;  3-5 mg /kg daily for 3 weeks
Caution 11-3.
Use of itraconazole is associated with potentially life-threathening liver-toxicity. 
Monitor liver function while on long-term therapy.
C.     For Contact Dermatitis  
 y Betamethasone  cream/ointment, topical,
Adult s (0.05-0.1%)
Apply thinly 12 - 24 hourly for 7 days
Children  (0.05%)
1-18 years; apply thinly 12 - 24 hourly for 7 days
Or
 y Mometasone  lotion/ointment 0.1% 
Adult s 
Apply thinly once daily for 7 days
Children
Apply thinly once daily for 7 days

— Intertrigo —Chapter 11:  Disorders of the Skin
283D�     For facial contact Eczema
 y Hydrocortisone  cream, 1% topical,
Adult s and children 
Apply 12 hourly 
Referral Criteria 
Refer patients not responding to treatment and those needing 
further investigations such as patch testing to a dermatologist. 
97� Intertrigo
Intertrigo  is the term used to describe a rash in body folds or 
apposing skin surfaces such as axillae, groin, submammary regions, 
beneath an abdominal apron of fat, finger or toe web spaces.  Affected 
skin is reddened and uncomfortable. Intertrigo is particularly common in 
those who are overweight and patients with diabetes mellitus.
Body folds (flexures) are prone to inflammatory rashes because of 
relatively high skin temperature and moisture from insensible water loss. 
Sweating that is not easy to evaporate and friction from movement of 
adjacent skin, results in the sore skin.
Causes 
 y Candida  albicans  (monilia )
 y Tinea  infection
 y Eczema  (e.g. seborrhoiec, atopic, contact) 
 y Psoriasis  (flexural)
 y Erythrasma
Symptoms
 y Itchy, scaly rash
 y Dry skin
 y Weeping, reddened rash
 y Discharging lesions
Signs
 y Dry, scaly skin
 y Erythema 
 y Excoriations
 y Papules
 y Vesicles
 y Creamy satellite pustules at the margins of affected area 
 y Persistent brown patches  
 y Well-demarcated patches 
 y Plaques 
Investigations
 y Patch testing for contact dermatitis
 y Skin scraping for fungal elements

— Intertrigo —
Standard  Treatment Guidelines, 7th Edition, 2017
284 y Fasting blood glucose 
 y Swab for culture and sensitivity 
Treatment 
Treatment objectives
 y To relieve symptoms and/or associated discomfort 
 y To identify and treat any predisposing factors
Non-pharmacological treatment
 y Wear loose cotton clothing and open footwear for aeration of folds
 y Weight loss
 y Avoid precipitating factors if any
Pharmacological treatment 
A.     For candida  intertrigo , seborrhoeic eczema  or tinea infection 
Evidence Rating: [C]
 y Miconazole  2% plus 1% hydrocortisone  cream, topical,
Adult s
Apply 12 hourly for 14 days
Children  
Apply 12 hourly for 7 days
Then
 y Miconazole  2% cream, topical, 
Adult s 
Apply 12-24 hourly till rash resolves
Children
Apply 12-24 hourly till rash resolves
Or
 y Clotrimazole  1% cream, topical
Adult s 
Apply 12-24 hourly till rash resolves
Children
Apply 12-24 hourly till rash resolves
Or
 y Miconazole , 2% powder, topical, 
Adult s 
Apply 12-24 hourly till rash resolves
Children
Apply 12-24 hourly till rash resolves
Or
 y Clotrimazole , 1% powder, topical,
Adult s 
Apply 12-24 hourly till rash resolves
Children
Apply 12-24 hourly till rash resolves
Evidence Rating: [B]
 y Itraconazole , oral,

— Intertrigo —Chapter 11:  Disorders of the Skin
285Adult s
200 mg daily for 7 days 
Children
> 12 years;   200 mg daily for 7 days
1 month-12 years;  3-5 mg /kg daily for 7 days
Caution 11-4.
Use of itraconazole is associated with potentially life-threathening liver-toxicity. 
Monitor liver function while on long-term therapy.
B�     For Erythrasma
 y Fusidic Acid , 2% cream, topical,
Adult s
Apply 6-8 hourly to affected parts
Children
Apply 6-8 hourly to affected parts
Or 
 y Clarithromycin , oral,
Adult s
1g stat. 
Children
250-500 mg stat.  
Or 
 y Erythromycin , oral, 
Adult s
500 mg 12 hourly for 5 days
Children  
8-18 years;  250-500 mg 12 hourly for 5 days
2-8 years;  250 mg of syrup 12 hourly for 5 days 
Or
 y Miconazole  2% cream, topical, 
Adult s 
Apply 12-24 hourly till rash resolves
Children
Apply 12-24 hourly till rash resolves
Or
 y Whitfield’s ointment , topical,
Adult s
Apply 12 hourly till rash resolves
Children
Apply 12 hourly till rash resolves
C.     For Contact dermatitis , Atopic eczema  or Flexural psoriasis
 y Hydrocortisone  cream, 1% topical,
Adult s (1-2.5% cream/ointment)
Apply 2-3 times daily
Children  (1% cream)
> 10 years;   apply thinly 12-24 hourly in area of rash for 

— Intertrigo —
Standard  Treatment Guidelines, 7th Edition, 2017
2867 days
Or
 y Mometasone  lotion/ointment 0.1% 
Adult s 
Apply thinly once daily for 7 days
Children
Apply thinly once daily for 7 days
Or
 y Betamethasone  cream/ointment, topical,
Adult s (0.05-0.1%)
Apply thinly 12-24 hourly for 7 days
Children  (0.05%)
1-18 years;   apply thinly 12-24 hourly for 7 days
Referral Criteria 
Refer patients not responding to treatment to a dermatologist. 

12Chapter
287Endocrine and Metabolic 
Disorders
98� Diabetes Mellitus
Diabetes mellitus  is characterised by persistently elevated blood 
glucose levels. If left untreated or improperly treated for long periods this 
will result in widespread blood vessel damage and complications relating 
to the eyes, kidneys, heart, brain and nerves. There is an increased risk 
of lower limb amputations, poor fertility and pregnancy outcomes with 
improper glucose control.
Although children and adolescents often present with acute 
symptoms, many adults with diabetes are asymptomatic. It is therefore 
necessary to exclude diabetes in all persons, especially adults, attending 
health facilities for routine medical examinations, first out-patient review, 
ante-natal care, elective and emergency admissions or undergoing 
surgical procedures. 
The non-pharmacological and pharmacological interventions in 
diabetes management are usually life-long.
Individuals found to have venous or capillary plasma glucose levels 
in the pre-diabetes or diabetes ranges, as shown in the table below, will 
need further assessment to confirm the diagnosis.
Fasting plasma 
glucose2-hr post prandial 
plasma glucose HbA1cStatus
< 5.6 mmol/L < 7.8 mmol/L <5.7% Normal
< 5.6 mmol/L 7.8 – 11.1 mmol/L 5.7 – 6.4 % IGT (Pre-diabetes)
5.7-6.9 mmol/L < 7.8 mmol/L 5.7 – 6.4 % IFG (Pre-diabetes)
> 7.0 mmol/L > 11.1 mmol/L > 6.5 % Diabetes
HbA1c – Glycated Haemoglobin
IGT – Impaired Glucose Tolerance
IFG – Impaired Fasting Glycaemia

— Diabetes Mellitus —
Standard  Treatment Guidelines, 7th Edition, 2017
288Four forms of diabetes are encountered in practice:
 y Type 1 diabetes 
 y Type 2 diabetes 
 y Gestational diabetes  (See section on ‘Diabetes in Pregnancy’) 
 y Secondary diabetes (related to medication use, endocrine or 
pancreatic disease etc.)
Causes 
 y Autoimmune disorder (Type 1 diabetes)
 y Idiopathic (Type 1 diabetes)
 y Genetic factors causing a defect in the action or secretion of insulin 
(Type 2 diabetes)
 y Environmental factors e.g. excessive calorie intake and lack of 
physical activity (Type 2 diabetes)
 y Pregnancy (Gestational diabetes )
 y Secondary diabetes:
 y Medication e.g. corticosteroid use or abuse 
 y Pancreatic disease or pancreatectomy
 y Endocrine disorders e.g. Cushing’s syndrome , acromegaly etc. 
Symptoms
 y Usually none in many adults
 y Polyuria and nocturia
 y Polydipsia 
 y Unexplained weight loss
 y Blurred vision
 y Recurrent boils
 y Recurrent pruritus  vulvae
 y Erectile dysfunction  
 y Symptoms related to chronic complications (e.g. ‘pins and needles’ 
sensation or numbness in the hands or feet, foot gangrene , poor 
vision etc.) 
 y Delivery of large babies (> 4 kg)
Signs
 y Usually none in most patients
 y Lack of sensation in the feet or hands
 y Foot gangrene
 y Pedal oedema
 y Impaired visual acuity
 y Cataract
 y Retinal changes on fundoscopy
Investigations
Newly diagnosed patient
 y Fasting or random blood glucose
 y Oral glucose tolerance test (if required to confirm diagnosis)
 y Blood urea, electrolytes and creatinine

— Diabetes Mellitus —Chapter 12:  Endocrine and Metabolic Disorders
289 y Fasting blood lipid profile (adults) 
 y Glycated haemoglobin (HbA1c) 
 y FBC
 y ECG (adults)
 y Urinalysis
 y Urine ketones (with high initial glucose levels)
During routine follow ups
 y Blood glucose
 y Recorded results of regular self-monitoring of fasting and ran -
dom tests at home by the patient using a glucose meter
 y Periodic fasting or random tests during clinic reviews
 y Glycated haemoglobin (HbA1c) (at least twice a year)
 y Blood lipid tests (annually, but more frequently if levels abnormal or 
on lipid lowering medication)
 y Blood urea, electrolytes and creatinine (annually, but more frequently 
if levels abnormal)
 y Urine microalbumin (annually)
Treatment 
Treatment objectives
 y To relieve symptoms
 y To prevent acute hyperglycaemic complications (i.e. ketoacidosis and 
the hyperosmolar state)
 y To prevent treatment-related hypoglycaemia
 y To achieve and maintain appropriate glycaemic targets
 y Fasting blood glucose between 4-7 mmol/L (less intensive gly -
caemic targets in elderly patients)
 y 2-hour post-meal blood glucose between 5-9 mmol/L (less in -
tensive glycaemic targets in elderly patients)
 y Glycated haemoglobin 7 % or less (less intensive glycaemic tar -
gets in elderly patients)
 y To ensure weight reduction in overweight and obese individuals
 y To prevent chronic complications of diabetes by maintaining
 y The glycaemic targets noted above
 y Blood pressure less than 130/80 mmHg
 y LDL-cholesterol less than 2.5 mmol/L

— Diabetes Mellitus —
Standard  Treatment Guidelines, 7th Edition, 2017
290Non-pharmacological treatment
Box 12-1:   Therapeutic lifestyle modification
Diet:
 yComplex carbohydrates (e.g. kenkey, yam, plantain etc.) are preferred 
 yAvoid refined sugars as in soft drinks, or adding sugar to beverages. Artifi -
cial sweeteners and ‘diet’ soft drinks, which do not contain glucose, may 
however be used 
 yA day’s diet must generally consist of;
 yCarbohydrates (60%), protein (15%) and fat (20%) mostly of plant-origin 
and low in animal fat
 ySalt (sodium chloride) < 5 g/day
 yFruits and vegetables ≥ 400 g/day 
 ySoluble fibre (e.g. as found in oats, beans, apples, nuts etc.)
 yA reduced total caloric content (portions) of food and an increase in the 
amount of fibre e.g. vegetables, fruits and cereals
 yOwing to the special needs of children for a diet that will ensure optimal 
growth, their diet must be determined by a dietician in consultation with 
a paediatrician 
Alcohol: 
 yIntake of alcohol is prohibited for individuals less than 18 years of age. 
While low consumption is permissible in adult patients, moderate to heavy 
drinking of alcohol increases the total caloric intake and may worsen over -
weight and obesity. It may also increase the risk of hypoglycaemia
Exercise: 
 yRegular, simple exercise e.g. 30 minutes brisk walking at least 3 days a week 
in ambulant patients 
 yAll advice on exercise must give consideration to the patient’s age and the 
presence of complications and other medical conditions
Pharmacological treatment 
A.     Type 1 diabetes patients and Type 2 patients on insulin 
monotherapy
Note 12-1
Insulin dose requirements vary from patient to patient irrespective of age and 
body weight.
The total daily insulin requirement for most adults and pre-pubertal children 
is about 0.6-0.8 units/kg, which should be given in divided doses. However, it 
is prudent to begin with lower doses and build this up with time to prevent 
hypoglycaemia. 
Insulin requirements increase during infections, puberty, periods of stress, acci -
dental or surgical trauma, pregnancy etc.  
The usual route for insulin injections for outpatient diabetes treatment is sub -
cutaneous, administered 30 minutes before a meal for regular/soluble insulin, 
premix insulin, or NPH insulin and immediately before the meal for rapid acting 
analogue insulins (e.g. aspart, lispro) according to the following regimens: 
 yTwice daily pre-mixed insulin (soluble + intermediate acting insulin) before 
breakfast and supper (preferred) 
Or 

— Diabetes Mellitus —Chapter 12:  Endocrine and Metabolic Disorders
291 yTwice daily injections of Soluble PLUS NPH 30 minutes before breakfast and 
Soluble PLUS NPH 30 minutes before supper. The Soluble and NPH insulins 
must be given in separate syringes.
Evidence Rating: [A]
 y Insulin Premix, SC,  (30% soluble insulin and 70% NPH insulin), 
⅔ of total daily insulin requirement 30 minutes before breakfast 
And
⅓ of total daily insulin requirement 30 minutes before evening meal 
(supper)
Or
 y Soluble insulin, SC,
⅓ of total daily insulin requirement in 2 divided doses 30 minutes 
before breakfast and supper
And
 y Insulin NPH, SC, 
⅔ of total daily insulin requirement (⅔ of which would be given 30 
minutes before breakfast and ⅓ 30 minutes before supper)
B.     Type 2 diabetes patients on oral medications; initial management 
(Monotherapy)  
1st Line Treatment
Evidence Rating: [A]
 y Metformin , oral,
Adult s
500 mg-1 g daily 
Then  
Increase every 3 months to a maximum of 1 g 12 hourly if necessary 
Children  
Refer to specialist 
C.     Type 2 diabetes patients on oral medications; patients not 
achieving glycaemic targets with Metformin  monotherapy after 
approximately 3 months (Dual Therapy)  
 y Metformin , oral,
Adult s
1 g 12 hourly 
Children  
Refer to specialist 
And
 y Glibenclamide , oral, 
Adult s
2.5-10 mg daily 
(If required, not more than 5 mg of Glibenclamide  could additionally 
be given in the evening maximum total dose 15 mg daily) 
Children  
Not recommended 

— Diabetes Mellitus —
Standard  Treatment Guidelines, 7th Edition, 2017
292Or
 y Gliclazide , oral, 
Adult s
40-160 mg 12 hourly 
Children  
Not recommended 
Or
 y Glimepiride , oral, 
Adult s
2-6 mg daily (as a single dose in the morning)
Children  
Not recommended 
Or
 y Tolbutamide , oral, 
Adult s
250-1000 mg 8-12 hourly 
Children  
Not recommended 
Note 12-2
Tolbutamide  is preferred in individuals with impaired renal function and in the 
elderly 
D.     Type 2 diabetes patients on oral medications; patients not 
achieving glycaemic targets with combination of Metformin  and 
Sulphonylurea e.g. Glibenclamide etc. after apoximately 3 months 
(Triple Therapy)  
1st Line Treatment 
Evidence Rating: [A]
 y Metformin  and Glibenclamide  (or alternative), oral, as in section C 
above 
And 
 y Saxagliptin , oral,
Adult s
2.5-5 mg daily
Children  
Not recommended 
Or
 y Sitagliptin , oral, 
Adult s
50-100 mg daily
Children  
Not recommended 
Or
 y Vildagliptin , oral,
Adult s
25-50 mg 12-24 hourly

— Diabetic Ketoacidosis —Chapter 12:  Endocrine and Metabolic Disorders
293Children  
Not recommended 
Or
 y Pioglitazone , oral, 
Adult s
15-45 mg daily 
Children  
Not recommended 
E.     Type 2 diabetes patients on oral medications; not achieving 
glycaemic targets with Triple Therapy
 y Triple Therapy 
And
 y Insulin NPH , SC,
Adult s
2-20 units before bedtime 
Children  
Refer to specialist
Note 12-3
Refer to a diabetologist or physician specialist for insulin and oral medication 
combination therapy in type 2 diabetes 
Referral Criteria 
All individuals with diabetes must be referred to a dietician for 
dietary advice. All children with diabetes must be seen by a specialist 
(paediatrician or endocrinologist). All patients in whom glycaemic targets 
cannot be achieved as well as those with diabetes complications must be 
referred to the appropriate specialist.
All type 2 diabetics at diagnosis and type 1 diabetics 5 years after 
diagnosis should be referred to an eye specialist for screening for Diabetic 
Retinopathy. 
99� Diabetic Ketoacidosis
Diabetic ketoacidosis  (DKA ) is a condition associated with high blood 
glucose (usually > 18 mmol/L), which nonetheless, is unavailable to the 
body tissues as a source of energy. Fat is therefore broken down as an 
alternative source of energy, releasing toxic chemicals called ketones as 
a by-product. Additionally, there is severe dehydration  and electrolyte 
imbalance in DKA, especially low potassium. It is a common cause of 
death among diabetes patients in Ghana. It often occurs in type 1 diabetes 
patients but may also occur in type 2 diabetes.
In contrast, the Hyperosmolar Non-Ketotic state (HONK) in diabetes 
occurs primarily in Type 2 patients, and is similar in its clinical presentation 
to diabetic ketoacidosis in many respects. A major difference, however, is 

— Diabetic Ketoacidosis —
Standard  Treatment Guidelines, 7th Edition, 2017
294the absence of a significant amount of ketones in the urine (usually trace 
or 1+) and the presence of severe dehydration. The management of this 
condition is similar to that of DKA.
Causes 
 y Severe deficiency of insulin
 y Interruption of anti-hyperglycaemic therapy (usually for financial 
reasons or for alternative treatment)
 y Stress of intercurrent illness (e.g. infection, myocardial infarction, 
stroke , surgery, complicated pregnancy etc.)
Symptoms
 y Polyuria
 y Polydipsia 
 y Nausea , vomiting  
 y Abdominal pain 
 y Alteration in sensorium or collapse
 y Symptoms of infection or other underlying condition 
Signs
 y Dehydration  (dry skin, reduced skin turgor or sunken eyes)
 y Deep and fast breathing 
 y Low blood pressure 
 y Fast and weak pulse 
 y ‘Fruity’ breath (smell of acetone)
 y Confusion, stupor or unconsciousness 
 y Evidence of infection, recent surgery, stroke  etc.
 
Investigations
 y Random blood glucose (usually >18 mmol/L)
 y Urine glucose (usually >3+)
 y Urine ketones (usually >2+)
 y Blood urea and electrolytes (usually low potassium, however if in 
renal failure urea and potassium may be high)
 y Blood film for malaria parasites
 y Full blood count (raised white cell count would suggest bacterial 
infection)
 y Urine culture
 y Blood culture
 y Chest X-ray (for pneumonia)
 y Arterial blood gases 
 y Electrocardiogram (to identify hypokalaemia, and in adult patients to 
exclude acute myocardial infarction as a precipitating factor)
Treatment 
Treatment objectives
 y To replace the fluid losses
 y To replace the electrolyte losses, especially potassium 

— Diabetic Ketoacidosis —Chapter 12:  Endocrine and Metabolic Disorders
295 y To replace deficient insulin
 y To seek the underlying cause and treat appropriately
Pharmacological treatment 
A. Management of Diabetic Ketoacidosis (DKA) 
Table 12-1:   Regime for managing Diabetic Ketoacidosis in Adults
ADULTS
Blood Glucose
& 
Urine
Ketone
Test ResultsIntravenous Fluids
Soluble/ Regu -
lar InsulinPotassium 
Chloride (KCl) 
InfusionType of Fluid Rate of IV Fluid 
Infusion Initiating
Management
↓
Monitor blood 
glucose hourly
Monitor urine 
ketones twice 
dailyBlood glucose
>18 mmol/L 
Or
Urine ketones
>2+Sodium
Chloride
0.45%1st litre over 
first 30 mins
2nd litre over 
next 1hour
3rd litre over 
next 4 hours
4th litre over 
next 4 hours
Subsequently,
1 litre every 6
hours or as 
required Soluble/ 
regular insulin, 
IV or IM, 10-20 
units stat.
Thereafter, 
administer
Soluble/regular 
insulin, IV 
Infusion 
0.1 units/kg 
hourly 
Or 
5-10 units IM 
hourly until 
blood glucose
< 11 mmol/LStart 2 hours 
after initiat -
ing insulin 
and Sodium 
Chloride 
Infusion
Check ade -
quate urine 
output (>30 
ml/hour)
Place 10-20 
mmol KCl in 
500 ml Sodi -
um chloride 
0.9%
Run the IV 
infusion over 
at least one 
hour Maintaining
Management
↓
Monitor blood 
glucose every 4 
Hours
Monitor urine 
ketones twice 
dailyBlood glucose
< 13 mmol/LGlucose 5%
This measure 
is necessary 
to prevent 
subsequent
hypoglycae -
miaContinue
Glucose 5%
1 litre every 
6 hours or to 
meet require -
mentsSoluble/ 
regular insulin 
subcutaneously 
by ‘sliding 
scale’
(see example 
of ‘sliding scale’ 
in the table 
below)Repeat Potas -
sium Infusion 
after
2 hours if 
necessary
Check blood 
Potassium 
level twice 
Daily
Withhold KCl 
if blood level
of potassium
> 6 mmol/LRegular
Management
↓
Monitor blood 
glucose twice dai -
ly (pre-breakfast
and pre-supper)Blood glucose 
maintained 
between
6 -11 mmol/L
Urine ketones 
negative or 
tracePatient eating normally
(recommended diet)Change from
‘sliding scale’ 
to twice daily 
subcutaneous 
intermedi -
ate- acting 
or premixed 
insulinPotassium 
chloride, oral, 
if required

— Diabetic Ketoacidosis —
Standard  Treatment Guidelines, 7th Edition, 2017
296Table 12-2:   Regime for managing Diabetic Ketoacidosis in Children
CHILDREN
Blood Glucose
& 
Urine
Ketone
Test ResultsIntravenous Fluids
Soluble/ Regu -
lar InsulinPotassium 
Chloride (KCl) 
InfusionType of 
FluidRate of IV Fluid 
Infusion Initiating
Management
↓
Monitor blood 
glucose hourly
Monitor urine 
ketones twice 
dailyBlood glucose
>18 mmol/L 
Or
Urine ketones
>2+Sodium
Chloride
0.9%1st hour 
15 ml/kg
2nd hour
15 ml/kg
3rd Hour 
7.5 ml/kg
4th hour and
subsequently, 
adjust fluid 
rate to meet 
requirementsSoluble/ regu -
lar insulin, IV or 
IM, 0.15 unit/
kg stat
Thereafter, 
administer
Soluble/regular 
insulin, IV Infu -
sion or IM
0.1 units/kg 
hourly until 
Blood glucose
< 11 mmol/LStart 2 hours 
after initiating 
insulin and So -
dium Chloride 
Infusion
Check ade -
quate urine 
output (>30 
ml/hour)
Add KCl 0.2 
-0.4 mmol/
kg (max. 10 
mmol) in IV 
fluids. Run 
infusion over 
at least one 
hourMaintaining
Management
↓
Monitor blood 
glucose every 4 
Hours
Monitor urine 
ketones twice 
dailyBlood glucose
< 13 mmol/LSodium
Chloride in
4.3% 
Glucose
This 
measure is 
necessary 
to prevent 
subsequent
hypoglycae -
miaSet Infusion 
rate to meet
requirementsSoluble/ 
regular insulin 
subcutaneously 
by ‘sliding 
scale’
(see example 
of ‘sliding scale’ 
in the table 
below)Repeat Potas -
sium Infusion 
after
2 hours if 
necessary
Check blood 
Potassium 
level twice 
Daily
Withhold KCl 
if blood level
of potassium
> 6 mmol/LRegular
Management
↓
Monitor blood 
glucose twice dai -
ly (pre-breakfast
and pre-supper)Blood glucose 
maintained 
between
6 -11 mmol/L
Urine ketones 
negative or 
tracePatient eating normally
(recommended diet)Change from
‘sliding scale’ 
to twice daily 
subcutaneous 
intermediate- 
acting or 
premixed 
insulinPotassium 
chloride, oral, 
if required
Box 12-2:   Sample Sliding Scale Chart
Blood Glucose Result
(following 4-hourly testing)Corresponding Dose of Regular Insulin to administer 
Subcutaneously
mmol/L ADULTS CHILDREN

— Diabetes in Pregnancy  —Chapter 12:  Endocrine and Metabolic Disorders
297Box 12-2:   Sample Sliding Scale Chart
< 6.0 No Insulin No Insulin
6.1 -  9.0     4 units 0.06 units/kg
9.1  - 12.0  6 units 0.09 units/kg
12.1 - 15.0     8 units 0.12 units/kg
15.1 - 18.0    10 units 0.15 units/kg
Note 12-4
The example of the sliding scale given above is not a fixed standard. The require -
ment of insulin for each level of blood glucose measured differs from patient to 
patient.  The corresponding insulin doses may therefore need to be adjusted up 
or down to suit each patient.
For both adults and children, continue the sliding scale, making appropriate ad -
justments to the doses of insulin, until the patient is eating normally and the 
urine is free of ketones before changing to twice-daily intermediate or premixed 
insulin. This may take on average 12–72 hours.
B. Management of Hyperosmolar Non-Ketotic state (HONK) 
(See ‘Management of DKA’ above)
C. Adjunct Treatment for DKA and HONK 
 y Broad-spectrum   antibiotics   for   suspected   infections (See 
appropriate section)
 y Treat malaria if suspected or confirmed (See appropriate section)
Referral Criteria 
If there are inadequate resources for managing the patient, start 
0.9% Sodium Chloride, IV, and give initial dose of soluble or regular insulin 
IV or IM after confirming blood glucose and urine ketone levels and refer 
to a nearby regional or teaching hospital.
If the patient remains comatose or fails to pass adequate amounts 
of urine despite management, refer to a regional or teaching hospital for 
further care.
100� Diabetes in Pregnancy 
(See section on ‘Diabetes in Pregnancy’ under ‘Obstetric care and 
Obstetric Disorders’) 

— Treatment-Induced Hypoglycaemia —
Standard  Treatment Guidelines, 7th Edition, 2017
298101� Treatment-Induced Hypoglycaemia
Hypoglycaemia  refers to a blood glucose level below 3.6 mmol/L. 
It is more common in elderly diabetics and those with kidney function 
impairment as well as those on long-acting oral anti-hyperglycaemic 
medications or insulin. Severe hypoglycaemia (blood glucose < 2.2 
mmol/L) may result in alteration of consciousness, fits, self-injury and 
various degrees of irreversible brain damage. 
Following successful treatment of hypoglycaemia, its cause must be 
determined and measures, including patient education and revision of 
anti-hyperglycaemic drug doses, should be taken to prevent its recurrence. 
Causes 
 y Overdose of any anti-hyperglycaemic medication i.e. insulin or oral 
agent
 y Antihyperglycaemic medication use in renal impairment and the 
elderly
 y Omitted or inadequate amount of food
 y Unaccustomed physical over-activity
 y Excessive alcohol intake
Symptoms
 y Dizziness
 y Blurred vision
 y Headaches
 y Palpitation
 y Sweating
 y Shaking of the hands and body
 y Unconsciousness
 y Convulsions
 y Irritability and abnormal behaviour especially in children
Signs
 y Sweating
 y Tremors
 y Tachycardia  and bounding pulse
 y Confusion
 y Unconsciousness
 y Convulsions
Investigations
 y Random blood glucose (urgently done using a glucose meter)
 y Blood urea and electrolytes
 y Liver function tests
Treatment 
Treatment objectives
 y To rapidly restore blood glucose levels to normal

— Treatment-Induced Hypoglycaemia —Chapter 12:  Endocrine and Metabolic Disorders
299 y To maintain the level of blood glucose within the normal range until 
the patient can begin eating normally
 y To identify and address the cause
Non-pharmacological treatment
 y Mild hypoglycaemia
 y 2-3 teaspoons of granulated sugar or 3 cubes of sugar or ½ a 
bottle of soft drink (sugar-containing, not ‘diet’ drinks) to indi -
viduals who are conscious. 
 y A glass of milk or fruit drink and a tablespoonful of honey are 
useful alternatives
 y The above measures should be followed immediately by a meal 
or snack
 y Moderate hypoglycaemia
 y Same as for mild hypoglycaemia, but repeat after 10 minutes. If 
no improvement is observed, treat as for severe hypoglycaemia
Pharmacological treatment 
A.     Severe hypoglycaemia
1st Line Treatment
Evidence Rating: [A]
 y Dextrose , IV, 
Adult s
50% solution 
25-50 ml over 1-3 minutes through a large vein
Then
5-10% solution  
500 ml 4 hourly until the patient is able to eat normally
Children
10% solution
4 ml/kg body weight over 1-3 minutes through a large vein
Then
5% solution
According to total daily fluid requirement until blood glucose levels 
normalise
2nd Line Treatment
Evidence Rating: [A]
 y Glucagon , IV, IM or subcutaneous, 
Adult s
1 mg stat. 
Children
8-18 years (bodyweight > 25 kg);  1 mg stat.
8-18 years (bodyweight < 25 kg);  500 micrograms stat.
1 month-8 years;   500 micrograms stat.
Neonate ;   20 microgram/kg stat.

— Dyslipidaemia —
Standard  Treatment Guidelines, 7th Edition, 2017
300Referral Criteria 
If the patient does not respond to the above treatment 
recommendations, refer to a specialist. 
102� Dyslipidaemia
There is ample evidence linking high blood cholesterol levels to 
Cardiovascular Disease (CVD) events, including myocardial infarction, 
strokes, and peripheral vascular disease. On the other hand, there is also 
evidence for significant reduction in morbidity and mortality from CVDs 
by reducing blood cholesterol levels in those at risk (primary prevention) 
and those who have suffered a CVD event (secondary prevention). 
The commonly assessed blood lipid parameters are total cholesterol, 
HDL cholesterol, LDL cholesterol and triglycerides. However, the primary 
target for intervention is the LDL-cholesterol level. As treatment may 
be for long periods or lifelong, periodic monitoring of liver and muscle 
enzymes (transaminases and creatine kinase) and blood glucose are 
advisable to forestall medication-related side effects. 
Causes 
 y High dietary intake of saturated fats (animal fat)
 y Lack of physical activity
 y Metabolic syndrome (a combination of several of the following; 
obesity, hypertension, type 2 diabetes, dyslipidaemia, gout  etc.)
 y Hereditary factors
 y Excessive alcohol intake
 y Hypothyroidism
 y Nephrotic syndrome
Symptoms
 y Usually none
 y Abdominal pain from pancreatitis related to hypertriglyceridaemia 
Signs
 y Usually none
 y Occasionally
 y Whitish ring around the cornea (corneal arcus)
 y Yellowish skin eruptions around the eyes (xanthelasmata)
 y Whitish blood sample (lipaemic blood)
Investigations
 y Fasting blood lipid profile 
 y Thyroid function test (if lipid levels very high)
 y Plasma protein (if lipid levels very high, to exclude nephrotic 
syndrome)
 y Urine protein (if lipid levels very high, to exclude nephrotic syndrome)

— Dyslipidaemia —Chapter 12:  Endocrine and Metabolic Disorders
301Treatment objectives
 y To reduce the risk of clinical atherosclerotic cardiovascular events 
and related deaths in: 
 y Healthy individuals at risk (primary prevention) 
 y Individuals who have suffered a CVD event (secondary preven -
tion)
 y To reduce the LDL-C level to the following targets:
 y At least a 50 % LDL-C reduction for primary prevention (in the 
general population i.e. individuals ≥ 21 years of age with an un -
treated LDL-C ≥ 4.9 mmol/L)   
 y 30-49 % LDL-C reduction for primary prevention (in individuals 
40 to 75 years of age with diabetes with an untreated LDL-C 
1.8-4.9 mmol/L)   
 y LDL-C < 1.8 mmol/L for secondary prevention  (in adults who 
have previously suffered a heart attack, stroke or peripheral 
vascular disease)
Non-pharmacological treatment
 y Dietary measures - a low calorie, low saturated fat (animal fat), 
high polyunsaturated fat (plant fat) diet is recommended under the 
supervision of a dietician
 y Weight reduction in patients who are overweight or obese
 y Reduction in alcohol consumption, where this is excessive
 y Regular physical activity or exercise tailored to the individual patient
Pharmacological treatment 
A.     Low CVD risk - primary prevention
1st Line Treatment
Evidence Rating: [A]
 y Simvastatin , oral, 
Adult s
10-20 mg at night
B�     Moderate CVD risk - Diabetes and CVD risk equivalents
Evidence Rating: [A]
 y Atorvastatin , oral, 
Adult s 
10-20 mg daily
Or 
 y Rosuvastatin , oral, 
Adult s 
5-10 mg daily
Or 
 y Simvastatin , oral, 
Adult s
20-40 mg at night

— Goitre   —
Standard  Treatment Guidelines, 7th Edition, 2017
302C.     High CVD risk – Secondary prevention
 y Atorvastatin , oral, 
Adult s 
40-80 mg daily
Or 
 y Rosuvastatin , oral, 
Adult s 
20-40 mg daily
Referral Criteria 
Refer all patients who remain outside the target values despite 
adequate dietary, exercise and medication therapy to a specialist.
103� Goitre   
A goitre  is a swelling of the front of the neck due to enlargement of 
the thyroid gland. It may affect persons of any age. Not all neck swellings 
are goitres. Goitres are usually benign but may occasionally be malignant. 
They could be associated with normal, reduced or excessive function 
of the thyroid gland. A reduction in production of thyroid hormones 
results in hypothyroidism  while an excess results in hyperthyroidism  or 
thyrotoxicosis .  Abnormalities of thyroid hormone production may also 
occur in the absence of goitre.
Proper diagnosis and selection of appropriate surgical or non-surgical 
treatment of benign and malignant goitres is by full clinical assessment 
and investigations. Treatment is not necessarily by increasing iodine 
intake e.g. in iodated salt. Excess iodine intake may actually be harmful 
in some cases.
Causes 
 y Simple non-toxic goitre  or endemic goitre
 y Hypothyroidism  (See section on ‘Hypothyroidism’)
 y Hyperthyroidism  or Thyrotoxicosis  (See section on ‘Hyperthyroidism’)
 y Thyroid neoplasm - benign or malignant
Symptoms
 y Swelling in the neck  
 y Breathing and swallowing difficulty, if large
 y Symptoms of hypothyroidism  (See section on ‘Hypothyroidism ’) 
 y Symptoms of hyperthyroidism  (See section on ‘Hyperthyroidism ’)
Signs
 y Diffuse (smooth) or nodular (irregular) thyroid swelling
 y Signs of hypothyroidism  (See section on ‘Hypothyroidism ’) 
 y Signs of hyperthyroidism  (See section on ‘Hyperthyroidism ’)
Investigations
 y Thyroid function tests – free T3, free T4, TSH

— Hypothyroidism   —Chapter 12:  Endocrine and Metabolic Disorders
303 y Thyroid ultrasound scan
 y Thyroid autoantibodies (if necessary)
 y Radioisotope scan of thyroid (if necessary)
 y Fine needle aspiration cytology (if necessary)
 y X-ray of the neck including thoracic inlet view for large goitres
Treatment 
Treatment objectives
 y To assess and correct level of thyroid hormone production
 y To reduce symptoms associated with thyrotoxicosis
 y To reduce or prevent obstructive symptoms
 y To identify thyroid neoplasms and manage appropriately 
Non-pharmacological treatment
 y Subtotal thyroidectomy where indicated
Pharmacological treatment 
 y Appropriate treatment of hypothyroidism  or hyperthyroidism  (See 
sections on ‘Hypothyroidism ’ and ‘Hyperthyroidism ’)
Referral Criteria 
Refer patients to a physician or surgical specialist where complications 
(e.g. hypothyroidism , hyperthyroidism , breathing difficulty etc.) or 
malignancy are suspected or if full clinical assessment and investigations 
are not possible.
104. Hypothyroidism   
Hypothyroidism  is a condition associated with reduction in thyroid 
hormone production. Thyroid hormone is required for normal metabolism 
and growth. Its deficiency has major consequences on foetal development 
as well as intellectual and physical development in infants and children 
(cause of cretinism ).
In adults, it may be the cause of several problems including heart 
disease, menstrual irregularity and infertility, mental health conditions and 
dementia. Iodine replacement is not the treatment for hypothyroidism . 
Screening for hypothyroidism  in all new borns, and every 5 years in 
adults after age 35 years, especially females, by measuring TSH (thyroid 
stimulating hormone) levels in blood where this is possible, should be 
encouraged. 
Causes 
 y Antibody-related thyroid gland destruction 
 y Subtotal thyroidectomy
 y Pituitary surgery or lesions 
 y Congenital
 y Severe iodine deficiency
 y Drug induced (e.g. radioiodine therapy, amiodarone  etc.)

— Hypothyroidism   —
Standard  Treatment Guidelines, 7th Edition, 2017
304Symptoms
 y General weakness and tiredness
 y Intolerance to cold environments
 y Constipation
 y Weight gain
 y Hair loss
 y Dry skin
 y Hoarse voice
 y Memory loss
 y Goitre  may be present
 y Abnormal menstrual periods and sub-fertility (in adult females)
 y Poor growth, development and poor school performance in children 
Signs
Neonate
 y Prolonged neonatal jaundice
 y Excessive sleep
 y Feeding problems 
Children
 y Cretinism (mental subnormality, short stature, large tongue, dry 
skin, sparse hair, protuberant abdomen, umbilical hernia, abnormal 
facies) 
Adults
 y Slow pulse (usually <60 per minute)
 y Dry coarse skin
 y Puffy face 
 y Pallor
 y Hoarse voice
 y Slow reflexes
 y Dementia
 y Goitre  may be present
Investigations
 y Thyroid function tests - free T3, free T4, TSH
 y Fasting blood lipids (for elevated cholesterol level)
Treatment 
Treatment objectives
 y To correct blood level of thyroid hormones 
 y To maintain lifelong normal levels of thyroid hormones 
Non-pharmacological treatment
 y Surgical intervention for pituitary lesions where necessary
Pharmacological treatment 
A.     Initiation of Treatment and Maintenance
Note 12-5
Start treatment with a low dose of levothyroxine, especially in the elderly and 

— Hyperthyroidism  —Chapter 12:  Endocrine and Metabolic Disorders
305children as well as individuals with heart disease (e.g. 25-50 microgram), and 
adjust dose as appropriate every 6-8 weeks until TSH levels are within normal 
reference range. Treatment is often life-long.
Evidence Rating: [A]
 y Levothyroxine , oral, 
Adult s
25-200 microgram daily 
Children  
> 12 years; 25 microgram daily (max. 200 micrograms)   
2-12 years; 25 microgram daily (max. 100 micrograms) 
< 2 years; 25-75 micrograms daily
Referral Criteria 
Refer diagnosed or suspected cases of all ages, especially children 
with intellectual impairment, and individuals with pituitary disease to a 
specialist.
105� Hyperthyroidism  
Excess thyroid hormone in the blood results in hyperthyroidism  
(thyrotoxicosis ). If left untreated, significant weight loss, eye and cardiac 
complications, may occur. Addition of extra iodine to the diet (e.g. as in 
iodated salt) is not the recommended treatment and may, in fact, worsen 
the condition. 
Causes 
 y Grave’s disease
 y Toxic multi-nodular goitre
Symptoms
 y Weight loss despite increased appetite
 y Excessive sweating
 y Heat intolerance
 y Tremors of the hands
 y Nervousness and irritability
 y Menstrual irregularity and sub-fertility 
Signs
 y Staring gaze or protruding eyes
 y Tremors of the hands
 y Moist palms
 y Rapid pulse rate (which may be irregular)
 y Wide pulse pressure (High systolic BP with low diastolic BP e.g. 
170/50 mmHg)
 y Heart failure
 y Goitre  (often present but not always)
 y Smooth and diffuse in Grave’s disease  

— Hyperthyroidism  —
Standard  Treatment Guidelines, 7th Edition, 2017
306 y Irregular in toxic multi-nodular goitre  
Investigations
 y Thyroid function tests - free T3, free T4, TSH
 y Thyroid ultrasound scan 
Treatment 
Treatment objectives
 y To reduce thyroid hormone levels in the blood to normal
 y To reduce symptoms associated with thyrotoxicosis
 y To prevent or treat complications e.g. heart failure, ophthalmopathy 
Non-pharmacological treatment
 y Subtotal thyroidectomy 
Pharmacological treatment 
A.     Initiation of Treatment and Maintenance
1st Line Treatment
Evidence Rating: [A]
 y Carbimazole , oral, 
Adult s                  
20-40 mg daily 
Children  
3-18 years; Initial dose 15 mg daily (adjusted according to thyroid 
hormone level) 
< 2 years;  not recommended
Note 12-6
Decrease dose of carbimazole when thyroid hormone levels are within the 
normal range and adjust doses subsequently according to two-monthly thyroid 
function tests
2nd Line Treatment
Evidence Rating: [A]
 y Propylthiouracil , oral, 
Adult s
100 mg 8 hourly 
Children
12-18 years;  50-100 mg 8 hourly
5-12 years;  50 mg 8 hourly
1-5 years;  25 mg 8 hourly
1 month-1 year; initially 5-10mg/kg 8 hourly, 
Then   
2.5-5 mg/kg 8 hourly based on thyroid hormone levels
< 1 month;  2.5-5 mg/kg 12 hourly
Note 12-7
Propylthiouracil  is preferred in pregnancy and in those who do not tolerate 
Carbimazole .  Decrease the dose when thyroid hormone levels are within the 

— Adrenal Insufficiency   —Chapter 12:  Endocrine and Metabolic Disorders
307normal range and adjust doses subsequently according to two-monthly thyroid 
function tests.
B.     Adjunct treatment (to reduce symptoms of thyrotoxicosis )
 y Propranolol , oral, 
Adult s
10-40 mg 8 hourly (adjust dose till thyroid function normalises - 
avoid in asthmatics) 
Children
> 1 year; 1 mg/kg (max. 40 mg) 8 hourly 
Neonate s;  1 mg/kg 12 hourly 
Referral Criteria 
Refer all cases not responding to conventional treatment to 
specialists in a secondary or tertiary hospital for further investigations 
and management.
106� Adrenal Insufficiency   
Adrenal insufficiency  arises when the adrenal gland is destroyed by 
disease, or atrophies following pituitary failure or chronic corticosteroid 
use or abuse. In these situations, the amount of cortisol produced from 
the adrenal gland is insufficient to meet the body’s needs during periods 
of physical and psychological stress or severe illness. The condition is 
associated with severe fluid and electrolyte imbalance and results in 
acute circulatory collapse.  
Causes 
 y Sudden cessation of prolonged corticosteroid use or abuse. 
 y Stress (e.g. infection, severe trauma, surgery, and dental procedures) 
in a patient with undiagnosed adrenal insufficiency or patients on 
prolonged corticosteroid treatment.
 y Pituitary failure  
 y Auto-immune disease of the adrenal gland (Addison’s disease ) 
 y Severe infections affecting the adrenal gland (e.g. meningococcus, 
tuberculosis, HIV )
 y Congenital adrenal hyperplasia in children
Symptoms
 y Nausea
 y Vomiting
 y Weakness
 y Collapse
 y Abdominal pain
 y Diarrhoea  
Signs
 y Dehydration  
 y Low or unrecordable blood pressure

— Adrenal Insufficiency   —
Standard  Treatment Guidelines, 7th Edition, 2017
308 y Darkening of oral mucosa, gums, skin, palms and soles in some 
individuals
 y Evidence of corticosteroid abuse e.g. skin bleaching, Cushingoid 
appearance
 y Ambiguous genitalia, short stature and failure to thrive in children
 y Variable states of consciousness
Investigations
 y FBC (may show anaemia and eosinophilia)
 y Blood urea and electrolytes (may show high potassium)
 y Blood glucose (may be low)
 y Plasma cortisol (low)
 y Blood film for malaria parasites, if indicated 
 y Urine and blood cultures, if indicated 
Treatment 
Treatment objectives
 y To correct the fluid and electrolyte imbalance
 y To correct hypoglycaemia
 y To replace corticosteroids
 y To identify cause and treat any precipitating factor
Non-pharmacological treatment
 y None
Pharmacological treatment 
A.      Acute treatment
1st Line Treatment
Evidence Rating: [B]
 y Intravenous fluid replacement 
Adult s
0.9% Sodium Chloride  in 5% Glucose (Dextrose  Saline), IV, 
1 litre 4-6 hourly, until condition is stable
Children
0.45% Sodium Chloride  in 5% Glucose, IV, according to total fluid re -
quirement
And
 y Hydrocortisone , IV, 
Adult s
200 mg stat. followed by 100 mg 6 hourly until condition is stable 
Children  
6-12 years;  100 mg 6 hourly
1-5 years;  50 mg 6 hourly
< 1 year;  25 mg 6 hourly
Note 12-8  
The IV hydrocortisone  therapy may be required for several days. Do not rush 
to change to maintenance therapy. When the patient’s condition is stable (i.e. 

— Adrenal Insufficiency   —Chapter 12:  Endocrine and Metabolic Disorders
309normal BP , cessation of vomiting  etc.) go on to maintenance therapy.
B.     Adjunct treatment in acute cases
Treat infection (e.g. malaria, pneumonia, UTI ) or stress-inducing 
condition, if present or suspected, with appropriate medication.
C.     Maintenance - for patients not previously on corticosteriods
1st Line Treatment
Evidence Rating: [A]
 y Prednisolone , oral, life-long
Adult s
5 mg morning and 2.5 mg evening each day
Children
70 micrograms/kg 12 hourly 
2nd Line Treatment
Evidence Rating: [A] 
 y Hydrocortisone , oral, life-long
Adult s
10-20 mg morning and 5-10 mg evening each day
Children
280 micrograms/kg 12 hourly 
D.     Maintenance - For patients on long term corticosteroid therapy 
who go into adrenocortical crisis (e.g. asthma, nephrotic 
syndrome) 
Adults and Children
 y Restart the previous doses of oral corticosteroids given for the con -
dition.
E.     Maintenance - For patients who abuse corticosteroids 
Adults 
Restart oral corticosteroids, or replace topical corticosteroids with  
 oral corticosteroids
 y Prednisolone , oral, 20-40 mg daily 
Gradually taper off the dose over several months (e.g. reducing by 
2.5 mg per month) and eventually discontinue.
Caution 12-1.
 yLong-term corticosteroid therapy requires specialist supervision. Healthcare 
practitioners should inform patients of the following;
 yPatients on corticosteroids should report to a hospital if they become ill 
and should tell their doctor, dentist, nurse or pharmacist that they are 
on corticosteroids
 yPatients SHOULD NOT stop treatment if they become ill, have an infec -
tion or are undergoing a dental procedure. Rather a doubling of the reg -
ular doses of corticosteroids is needed
 yRevert to hydrocortisone , IV for even minor surgical procedures including 
labour and delivery
 yThe dose of corticosteroids must be reduced gradually if treatment has 

— Cushing’s Syndrome   —
Standard  Treatment Guidelines, 7th Edition, 2017
310been for longer than 3 weeks and is to be stopped
 yDiscourage the abuse of oral or topical corticosteroids
Referral Criteria 
All patients suspected to have adrenal insufficiency should be 
referred, after resuscitation, to a regional or teaching hospital for 
assessment and long-term management.
107� Cushing’s Syndrome   
This condition results from high levels of cortisol in the blood and is 
associated with various changes in the body including the development 
of obesity, hypertension, diabetes and osteoporosis. The prolonged use 
or abuse (especially by women for cosmetic reasons) of oral or topical 
corticosteroids such as prednisolone, dexamethasone , hydrocortisone  or 
cortisone, or preparations containing any of these drugs, is also a cause.
Causes 
 y Pituitary tumour
 y Adrenal tumour
 y Prolonged and excessive intake (for asthma, nephrotic syndrome 
etc.) or abuse of corticosteroids
Symptoms
 y Weight gain
 y Excess body hair and acne (pimples )
 y Easy bruising of skin
 y Stretch marks (reddish or purplish)
 y Menstrual irregularity and sub-fertility
 y Weakness of the thigh muscles
 y Lightening of the skin
Signs
 y Rounded or ‘moon’ face
 y Prominent supraclavicular fat pads
 y Truncal obesity
 y Excess facial and body hair 
 y Acne
 y Striae (reddish or purplish stretch marks)
 y Thin skin 
 y Easy bruising and bleeding into the skin after venepuncture
 y Hypertension  
 y Inability to rise from the squatting position 
Investigations
 y Plasma cortisol (commonly elevated in pituitary and adrenal 
tumours, but low in corticosteroid use or abuse) 

— Overweight and Obesity  —Chapter 12:  Endocrine and Metabolic Disorders
311 y Blood electrolytes (may show low potassium)
 y Blood glucose (commonly elevated)
 y Abdominal ultrasound scan (may show an adrenal tumour) 
 y CT scan (may show evidence of a pituitary or adrenal tumour) 
Treatment 
Treatment objectives
 y To normalise plasma level of cortisol
 y To correct electrolyte imbalance
 y To correct plasma glucose
 y To correct blood pressure
 y To prevent complications of excess plasma cortisol 
Non-pharmacological treatment
 y Pituitary or adrenal surgery where tumours in the respective glands 
have been diagnosed
Pharmacological treatment 
Treatment is dependent on the cause and requires specialized 
investigations. Manage hypertension and diabetes along standard lines 
(See appropriate sections) and refer patient for definitive treatment.
Note 12-9
Do not withdraw corticosteroids suddenly in patients with Cushing’s syndrome  
due to corticosteroid abuse or prolonged use. Instead, the dose must be ta -
pered off slowly over several weeks and months to prevent acute adrenal insuf -
ficiency ( See section on ‘Adrenal Insufficiency ’).
Referral Criteria 
Refer all suspected cases to an endocrinologist or specialist physician 
in a regional or teaching hospital for the appropriate investigations and 
management.
108� Overweight  and Obesity  
Overweight  and obesity are associated with conditions that cause 
premature ill-health and death, such as type 2 diabetes, high blood 
pressure (hypertension), heart disease and stroke .  Other conditions 
such as gout , obstructive sleep apnoea, gallstones, heartburn, arthritis, 
skin infections as well as various cancers have been linked to excess body 
weight. They also increase the risk of developing deep vein thrombosis 
and pulmonary embolism as well as elevated blood cholesterol, which 
increases the risk for heart attacks and strokes.   
Weight reduction often corrects, or helps to control, these associated 
conditions. Occasionally rapid weight gain may be associated with an 
underlying endocrine condition such as hypothyroidism and Cushing’s 
syndrome. 

— Overweight and Obesity  —
Standard  Treatment Guidelines, 7th Edition, 2017
312Causes 
 y Excess intake of calories
 y Lack of regular physical activity
 y Secondary causes e.g. hypothyroidism, Cushing’s syndrome
Symptoms
 y Usually none 
Signs
 y Body Mass Index (BMI) increased 
 y 18.5-24.9 kg/m2  -  Ideal weight
 y 25.0-29.9 kg/m2  -  Overweight
 y 30.0-34.9 kg/m2  -  Obese
 y > 35.0 kg/m2        - Severely obese
 y Mid-abdominal (waist) girth, taken roughly at the level of the 
umbilicus, increased
Adult females:
< 80 cm or 32 inches Ideal abdominal girth
80 - 88 cm or 32-35 inches Overweight
> 88 cm or 35 inches Obese
Adult males:
< 94 cm or 37 inches Ideal abdominal girth
94 - 102 cm or 37 - 40 inches Overweight
> 102 cm or 40 inches Obese
 
Investigations
 y Blood glucose
 y Blood lipid profile
 y Blood uric acid
 y ECG
Treatment 
Treatment objectives
 y To ensure a loss of 10% of the initial body weight, within 6 months, 
at a rate of no more than 2-4 kg per month
 y To attain the ideal BMI and/or abdominal girth
 y To sustain the weight reduction achieved 
Non-pharmacological treatment
 y Weight reduction diet, preferably under the supervision of a dietician 
 y Regular physical activity comprising 30 minutes brisk walking, or 
equivalent activity, for a minimum of 3 days per week if there are no 

— Overweight and Obesity  —Chapter 12:  Endocrine and Metabolic Disorders
313contraindications 
 y Appropriate management of associated co-morbid disorders 
Pharmacological treatment 
 y Approved anti-obesity treatments are available but should only be 
given under specialist guidance 
Referral Criteria 
Individuals with severe and morbid obesity may require referral to a 
physician specialist and occasionally may need psychological counselling.  
Individuals who gain weight rapidly over a short period may have an 
underlying hormonal disorder and will require referral to a physician or 
endocrinologist.

13Chapter
314Obstetric Care and 
Obstetric Disorders
109� Antenatal Care  
Antenatal care  refers to the comprehensive care given to a pregnant 
woman to ensure that she goes through pregnancy, labour and the 
puerperium  safely with the delivery of a healthy baby.
The recommended approach to antenatal care is known as Focused 
Antenatal Care . It has the following principles: emphasizes quality of 
care rather than quantity of care (four comprehensive antenatal visits 
recommended for women with normal pregnancy); individualized care 
that meets each woman’s own medical and psychosocial needs; and 
disease detection instead of risk categorization based on the simple 
principle that all pregnant women are at risk of complications. 
Pregnant woman should be carefully assessed at booking and at all 
subsequent visits to identify problems that are likely to have an adverse 
effect on the pregnancy. Pregnancies with risk conditions (one or more 
risk factors) should be seen more frequently and also referred to a hospital 
and/or obstetrician for management.
Another important component of antenatal care is the health 
education and counselling that is given to clients. These promote healthy 
behaviour and lifestyle during the pregnancy and also enable the woman 
to recognize danger signs in pregnancy and prepare adequately for 
emergencies and safe delivery. Findings at each visit should be accurately 
documented. 
Antenatal Visits Schedule for a Normal Healthy Woman
Women who are healthy at booking and who remain healthy at 
subsequent visits and do not have any identified potential risk conditions 
may have four comprehensive visits as follows: 
Table 13-1:   Recommended schedule for Antenatal Visits for a Normal 
Healthy Woman
Visit Recommended schedule
Booking visit As soon as woman suspects she is pregnant; (preferably 
before 14 weeks) 

— Antenatal Care  —Chapter 13:  Obstetric Care and Obstetric Disorders
315Visit Recommended schedule
1st scheduled visit At 16–20 weeks
2nd scheduled visit In sixth month (about 24–28 weeks)
3rd scheduled visit In eighth month (28–32 weeks)
4th scheduled visit In ninth month (about 36 weeks) 
During the last visit, the woman should be asked to return 
if she does not give birth within 2 weeks after her expected 
date of birth 
More frequent visits or follow up schedules are implemented to 
meet the client’s individual needs. 
In Ghana, many clients come for their first visit during their second 
trimester of pregnancy. In this case, the visit schedule must be modified 
to ensure that the client receives all the essential components of care 
before childbirth. 
Assessment of the mother at the booking visit
 y Take detailed history (present health, past medical and surgical 
history, past obstetric history, family and social history)
 y Confirm the last menstrual period and established gestational age
 y Examine from head to toe and all body systems including a check for 
anaemia, blood pressure, pulse, general health status and manage 
appropriately
 y Conduct obstetric examination to confirm pregnancy, measure 
uterine size (SFH) and assess foetal wellbeing (FHR).
 y Request for/ conduct screening test as per national protocol (See list 
of investigations)
Assessment of the mother at follow-up visits:
 y Ask about mother’s health status since last visit and ask about health 
concerns
 y Enquire about foetal activity (gestation > 20 weeks)
 y Test urine for albumin and sugar
 y Examine mother for weight gain, anaemia, and for complications 
such as pre-eclampsia and manage appropriately 
 y Check blood pressure (the upper limit of normal is 140 mmHg for the 
systolic pressure and 90 mmHg for the diastolic pressure). 
 y Obstetric examination:
 y Measure Uterine size: measure symphysio-fundal height in cen -
timetres between 20 and 36 weeks gestation.
 y Check the lie, presentation and position of the baby and the 
descent of the presenting part (3rd trimester). Check the foetal 
heart sounds. Normal rate is 120-160 beats per minute

— Antenatal Care  —
Standard  Treatment Guidelines, 7th Edition, 2017
316Investigations
 y Full blood count (at booking, 28 and 36 weeks or more frequently if 
indicated)
 y Fasting blood glucose must be done on all pregnant women (at 
booking, 28 and 32 weeks) See note below
 y Haemoglobin level (at booking, 28 and 36 weeks or more frequently 
if indicated)
 y Blood film for malaria parasites
 y Sickling (if necessary Hb electrophoresis)
 y G6PD  activity
 y Urine analysis at each visit (proteinuria, glucosuria)
 y Stool analysis at booking
 y Blood group and antibody screen 
 y VDRL /TPHA /RPR  test
 y HBsAg test
 y HIV antibody testing (counselling required before testing)
 y Ultrasound scan  
 y Early ultrasound scan for foetal age estimation and to exclude 
ectopic pregnancy 
 y Foetal anomaly scanning at 18-24 weeks is beneficial 
 y Late screening at 36 weeks (placenta position, foetal well being 
etc.)
Box 13-1:   Screening tests for diabetes in pregnancy
Fasting blood glucose test must be done on all pregnant women at booking and 
also at 28-32 weeks 
Test for urine glucose at each antenatal visit
 yUrine glucose of 1+/2+ on 2 occasions or 3+/4+ on one occasion warrants a 
full oral glucose tolerance test (OGTT)
Those found to have a normal curve can be tested again later in pregnancy after 
28-32 weeks
Those with impaired glucose tolerance or frankly diabetic curves should have 
treatment
Treatment 
Treatment objectives
 y To ensure good health throughout pregnancy, labour/delivery and 
the puerperium
 y To detect and treat adequately any existing or potential health 
problems
 y To prevent anaemia and malaria
 y To ensure delivery of a healthy baby
Non-pharmacological treatment
 y Encourage use of insecticide treated nets
 y Counselling and education on the following topics: 
 y Healthy balanced diet 
 y Avoid smoking and alcohol intake

— Antenatal Care  —Chapter 13:  Obstetric Care and Obstetric Disorders
317 y Avoid non-prescribed medications and herbs
 y Pregnancy discomforts and management
 y Malaria  prevention 
 y Family planning 
 y Breast feeding and new born care 
 y Immunisation
 y Danger signs and symptoms in pregnancy
 y Exercise: Mild to moderate exercise, preferably non-weight 
bearing, at least 3 times per week is to be encouraged. Avoid 
exercise in the supine position after the first trimester. Discon -
tinue exercise when there are danger signs such as any of the 
following: bloody vaginal discharge, persistent headaches and 
or visual disturbances, faintness or dizziness, chest pain  and un -
explained abdominal pain 
 y Exercise is contraindicated in: 
 y Pregnancy-induced hypertension
 y Preterm rupture of membranes 
 y Preterm labour in women with incompetent cervix sec -
ond/third trimester bleeding 
 y Unexplained Intra uterine growth retardation
 y Develop a birth preparedness and complication readiness plan 
with the woman
Pharmacological treatment 
A.     Anaemia  prevention 
1st Line Treatment
Evidence Rating: [A]
 y Ferrous sulphate  (dried or anhydrous), oral, 200 mg (65 mg elemen -
tal iron) daily
Or
 y Ferrous fumarate , oral, 200 mg (65 mg elemental iron) daily
Or 
 y Iron (III) hydroxide Polymaltose complex , oral, 100 mg elemental iron 
daily 
And 
 y Folic Acid , oral, 5 mg once daily
Where combination pre-natal drug formulations of Iron, folate and 
other micronutrients are preferred, ensure that the iron content 
meets the minimum requirement dose of 65 mg/dayNte 
B�     Malaria  prophylaxis  
(See section on ‘Malaria  in Pregnancy’)
 y Sulphamethoxazole-Pyrimethamine  (SP) , oral,
5 doses, one month apart starting from week 16 or 1st quickening 
(prophylactic treatment should not exceed week 36).

— Antenatal Care  —
Standard  Treatment Guidelines, 7th Edition, 2017
318C�     Tetanus  prophylaxis 
 y Tetanol , IM, 0.5 ml: 
1st dose from 20th week gestation; 2nd dose 1 (one) month after 
initial dose, if patient has not previously had anti-tetanus Immuni -
sation
A course of tetanus toxoid vaccinations should be given to all women 
according to the following schedule:
 y TT1-Give the 1st dose (0.5 ml, SC or IM) at any contact with a 
pregnant woman including the 1st antenatal visit 
 y TT2-Give the 2nd dose at least 4 weeks after TT1  
 y TT3-Give the 3rd dose at least 6 months after TT2 or during a 
subsequent pregnancy
 y TT4 & TT5-One dose in each of 2 subsequent pregnancies to make up 
a total of five doses. No further doses will be necessary in subsequent 
pregnancies.
Box 13-2:    High-risk pregnancies
High-risk pregnancies include: 
 yBleeding  at any time in the pregnancy before labour
 yYoung (<18 years) and older (>35 years) mothers in their first pregnancy
 yPresence of medical conditions such as: 
 ySevere anaemia 
 ySickle-cell disease
 yHypertension
 yDiabetes mellitus
 yHeart disease 
 yAsthma , chronic cough such as pulmonary tuberculosis and
 yThyrotoxicosis
 yHIV positivity
 yWomen with more than 5 children (the grand multiparous mother)
 yPast history of bleeding after delivery or retained placenta
 yAbnormal presentation and position of the baby in the womb at term 
transverse lie or breech presentation
 yMultiple pregnancies
 yProlonged pregnancy (when the pregnancy lasts longer than 42 weeks)
 yContracted pelvis (pelvis too small for the baby to be delivered safely per 
vaginam). This may be obvious when the mother is short (< 154 cm) or 
has small feet (shoe size < 4½ UK)
 yBig baby at term when the symphysio-fundal height is more than 39-40 
cm at term or when the estimated foetal weight is 4 kg or higher
 yPast history of stillbirths or babies who die within the first week of life, 
especially if they die of the same problem
 yPast pregnancy history of miscarriages around the same gestational age

— Antenatal Care  —Chapter 13:  Obstetric Care and Obstetric Disorders
319 yDecrease in growth of the baby (foetal growth restriction) - uterine size 
smaller than the gestational age.
 yUterine size much bigger than the gestational age with one foetus present
 yPrevious instrumental delivery (vacuum extraction or forceps delivery)
 yPrevious operation on the womb such as Caesarean section, myomectomy 
or when the uterus is repaired after perforation during D&C
 yPreterm labour  (labour before 37 completed weeks)
 yRhesus  Negative mothers with Rhesus positive husbands and/or with other 
antibodies
 yWomen who are at risk for sensitization must be given Anti-D Immunoglob -
ulin (500 IU) at 28 week and repeated within 72 hours of delivery
Referral Criteria 
High-risk pregnancies (See note above) should be referred to a 
hospital or obstetrician for management and delivery.
 

— Antenatal Care  —
Standard  Treatment Guidelines, 7th Edition, 2017
320Table 13-2:   Antenatal Care Protocol Chart
VISIT TIMING 
OF VISITGOALS HISTORY 
TAKINGEXAMINATION LABORATORY 
INVESTIGATIONSHEALTH PROMOTION ACTIONS
BOOKING
VISITAnytime 
before 16
weeks 
gestation• Patient assess -
ment
• Plan for ANC
• Develop birth 
and emergency 
plan
• Give health 
education
• Check foetal 
growth and 
maternal 
wellbeing
• Start preven -
tive interven -
tions • Medical
• Surgical
• Obstetric
• LMP
• Confirm 
period of 
gestation
• Contra -
ceptive 
(type, 
duration)
• STI
• Social: 
smoking,   
alcohol/
drugs
• Social 
supports• General exam. 
including BP
• Vulval exam. 
(use speculum if  
indicated)
• SFH (symphysio- 
fundal height) 
• Abdominal exam.     
• Vital observa -
tions
*Mood
*Evidence of 
trauma• Syphilis test 
(RPR )
• VCT
• Check urine 
for protein, 
glucose
• Check Hb
• Determine 
blood group
• Check for sick -
ling, G6PD• Educate on ANC visits 
• Address any observed or 
volunteered problems
• Involve husband in ANC
• Develop birth and emergency 
plan
• Teach danger signs during 
pregnancy 
• Discuss STI /HIV/AIDS
• Provide VCT. If HIV- positive, 
ask to come back at 14 weeks 
to begin ARV for PMTCT 
• Discuss pregnancy discomforts, 
sexual relations 
• Counsel on nutrition and 
self-care
• Counsel on ITN use
• Advise on common discom -
forts of pregnancy• Give TT1
• Give iron/folic acid
• HIV counselling, testing and 
post-test counselling
• If HIV -positive, begin 
PMTCT at 14 weeks 
gestation
• Treat any problems
• Counsel  woman 
• Start IPT with SP after 16 
weeks gestationFIRST
VISITAt 16-20 
weeks
2ND
VISIT24–28
weeks• Give TT
• Exclude 
multiple    
pregnancy
• Check for preg -
nancy induced 
hypertension 
• Check foetal 
growth
• Exclude 
anaemia • Ask for 
problems
• Ask date 
of first 
foetal 
move -
ments 
• Ask if any 
vaginal 
bleeding• Measure BP 
• Measure SFH 
• Abdominal exam: 
rule out multiple 
pregnancy
• Check foetal 
heartbeat • If BP > 140/90, 
check urine for 
protein
• Check Hb• Address problems
• Update birth and emergency 
plan
• Review danger signs in 
pregnancy
• If HIV- positive, counsel on 
PMTCT
• Counsel on ITN use
• Advise on common discom -
forts of pregnancy• Give TT2
• Refill iron/folic acid
• IPT/SP dose 2
• Mebendazole
• If HIV -positive, PMTCT
• Treat any problems
• Counsel woman

— Antenatal Care  —Chapter 13:  Obstetric Care and Obstetric Disorders
321VISIT TIMING 
OF VISITGOALS HISTORY 
TAKINGEXAMINATION LABORATORY 
INVESTIGATIONSHEALTH PROMOTION ACTIONS
3RD
VISIT30−32 
weeks• Check foetal 
growth
• Exclude 
anaemia
• Check for PIH
• Update birth 
and emergency 
plan• Ask for 
problems
• Ask if any 
vaginal 
bleeding• Measure BP
• Check for pallor
• Measure SFH 
• Abdominal exam
• Check foetal 
heartbeat • If BP > 140/90, 
check urine for 
protein
• Check Hb• Address problems
• Teach danger signs in pregnan -
cy/labour
• Discuss labour
• Update birth and emergency 
plan
• Discuss family planning
• If HIV- positive, counsel on 
PMTCT
• Counsel on ITN use
• Teach about postpartum care
• Teach care of the new-born : 
Early exclusive breastfeeding, 
thermal care, cord care, 
danger signs• Refill iron/folic acid
• IPT/SP dose 3
• Treat any problems
• If HIV -positive, PMTCT
• Use dual protection for 
FP/HIV
• Counsel woman
4TH
VISIT>36 weeks • Check foetal 
growth
• Check for PIH
• Check for 
preeclampsia
• Exclude 
cephalo-pelvic 
disproportion, 
abnormal      
presentation/
lie
• Update birth 
and emergency 
plan• Ask for 
problems
• Ask if 
there is 
vaginal 
bleeding• Measure BP
• Measure SFH
• Count foetal 
heart rate       
• Abdominal exam
• Check lie
• Check presen -
tation• If BP >140/90, 
check urine for 
protein
• Check Hb• Early exclusive breastfeeding, 
thermal care, cord care, 
danger signs 
• Address problems
• Discuss labour
• Update birth and emergency 
plan
• Teach PMTCT in labour, birth, 
postpartum
• Counsel on ITN use
• Re-discuss FP and HIV  
prevention
• Teach about postpartum care 
• Teach care of the new-born : 
danger signs in new-born, early 
and exclusive breastfeeding, 
thermal care, cord care• Refill iron/folic acid
• Treat any problems
• If HIV -positive, PMTCT
• Dual protection for FP/HIV  
prevention
• Counsel woman

— Hyperemesis Gravidarum —
Standard  Treatment Guidelines, 7th Edition, 2017
322110� Hyperemesis Gravidarum
This refers to excessive vomiting  usually during the early part 
of pregnancy, and is usually common. It is a diagnosis of exclusion 
and therefore important to rule out other causes of vomiting such as 
malaria, urinary tract infection, gastritis, peptic ulcer disease, hepatitis 
and hypoglycaemia. Surgical conditions such as acute appendicitis, 
bowel obstruction, cholecystitis and twisted ovarian cyst, should also 
be excluded. Hyperemesis gravidarum may be associated with multiple 
pregnancy or molar pregnancy.
Causes 
 y Pregnancy
Symptoms
 y Excessive vomiting  (sometimes with inability to keep anything down 
throughout the day)
 y Inability to eat or drink (due to fear of vomiting )
 y Weight loss
Signs
 y The patient looks unwell
 y Dehydration  (dry skin, dry tongue, sunken eyes in extreme cases)
 y The pulse is rapid and thready in extreme cases
 y The BP may be low 
 y Deep and fast breathing in extreme cases 
Investigations
 y FBC
 y Blood film for malaria parasites
 y Urinalysis and culture
 y Blood urea and electrolytes
 y Abdominopelvic ultrasound 
Treatment 
Treatment objectives
 y To stop the vomiting  
 y To rehydrate the patient 
 y To treat shock if present
 y To treat associated conditions e.g. UTI , malaria etc.
Non-pharmacological treatment
 y Mild cases can have treatment at home with frequent small meals
 y Dry foods such as biscuits may be very helpful 
 y Drink fluids in sips or small volumes, if able to

— Hypertension in Pregnancy —Chapter 13:  Obstetric Care and Obstetric Disorders
323Pharmacological treatment 
A.     Mild cases
1st Line Treatment
Evidence Rating: [A]
 y Metoclopramide , oral, 10 mg 8-12 hourly 
2nd Line Treatment
Evidence Rating: [A]
 y Promethazine  theoclate, oral, 25 mg 8-12 hourly 
Or
 y Promethazine  hydrochloride, oral, 25 mg 8-12 hourly 
B�     Severe Cases
 y Normal saline , IV, (alternate with 5% Dextrose  to meet requirements)
Or
 y Ringers lactate , IV, (alternate with 5% Dextrose  to meet require -
ments)
And
         1st Line Treatment
Evidence Rating: [A]
 y Metoclopramide , IM or IV, 5-10 mg 8 hourly 
If body weight < 60 kg, give 5 mg 8 hourly. Do not exceed 500 micro -
gram/kg in a day   
2nd Line Treatment
Evidence Rating: [A]
 y Ondansetron , oral, IM, IV, 4-8 mg 8 hourly as needed
3rd Line Treatment
Evidence Rating: [A]
 y Promethazine  hydrochloride, IM or IV, 25 mg 8-12 hourly
(max. daily dose, 100 mg)
Referral Criteria 
Refer severe cases with dehydration  and/or shock and metabolic 
disturbances to a hospital for intravenous fluid replacement and 
antiemetic therapy.
111� Hypertension  in Pregnancy
Hypertension  in pregnancy  denotes a systolic blood pressure of 
140 mmHg or higher and/or diastolic pressure of 90 mmHg or higher 
on 2 occasions at least 5 minutes apart using an appropriate-sized cuff  
especially in obese patients. It is severe when systolic blood pressure 
is 160 mmHg or higher and diastolic blood pressure is 110 mmHg or 
higher. This includes women whose hypertension was diagnosed prior to 

— Hypertension in Pregnancy —
Standard  Treatment Guidelines, 7th Edition, 2017
324pregnancy as well as during pregnancy. 
Known hypertensives on ACE inhibitors, ARBs and alpha-blockers 
should be switched to medications considered safe during preganancy. 
Causes 
 y Pregnancy-induced hypertension (no proteinuria)
 y Pre-eclampsia (hypertension with proteinuria)
 y Eclampsia  (hypertension with proteinuria and fits)
 y Chronic hypertension (existing before pregnancy)
 y Chronic hypertension with super-imposed pre-eclampsia or 
eclampsia
(See sections on ‘Hypertension ’, ‘Pre-eclampsia’ and ‘Eclampsia ’)
Symptoms
(See section on ‘Hypertension ’)
Signs 
(See section on ‘Hypertension ’) 
Investigations
 y FBC 
 y Clotting profile
 y Serum Uric Acid 
 y BUE and Creatinine 
 y Urinalysis and culture 
 y Liver function tests
 y Random blood glucose 
 y Daily assessment of urine proteins (if patient on admission)
 y Repeated ultrasound scans for close foetal growth monitoring
Treatment 
Treatment objectives
 y To control blood pressure 
 y To detect or treat any complications that may arise especially super 
imposed pre-eclampsia
 y To prevent foetal complications
 y To deliver a healthy baby
Non-pharmacological treatment
(See section on ‘Antenatal Care ’ and on ‘Hypertension ’)
Pharmacological treatment
A. Hypertension  in Pregnancy not associated with pre-eclampsia or 
eclampsia
1st Line Treatment
Evidence Rating: [A]
 y Methyldopa , oral, 250-500 mg 8-12 hourly (max. 2g daily) 
2nd Line Treatment
Evidence Rating: [A]

— Pre-eclampsia —Chapter 13:  Obstetric Care and Obstetric Disorders
325 y Nifedipine  sustained release, oral, 10-40 mg 12 hourly
B�     Hypertension  in Pregnancy associated with pre-eclampsia and 
eclampsia
(See sections on ‘Hypertension ’, ‘Pre-eclampsia’ and ‘Eclampsia ’)
Referral Criteria 
Refer all cases of super-imposed pre-eclampsia or other obstetric 
complication promptly to a hospital or obstetrician after initiation of 
treatment.
112� Pre-eclampsia
Pre-eclampsia is a disease specifically associated with pregnancy. It 
usually occurs in the second half of pregnancy and it is characterized by 
hypertension and proteinuria. The presence of pedal oedema or excessive 
weight gain may also be a feature of pre-eclampsia.  
Blood pressure monitoring every 4 hours together with daily 
weighing of the patient are essential in the management of pre-eclampsia 
alongside the recommended investigations.
While blood pressure reduction is essential, lowering the blood 
pressure below 140/90mmHg may cause foetal distress and should be 
avoided.
Causes
The cause is unknown but the disease is more commonly associated 
with the following:
 y Primigravidae 
 y Maternal age (women < 18 or > 35 years)
 y Multiple pregnancies
 y Hydatidiform mole
 y Medical disorders e.g. polycystic ovaries, chronic hypertension, 
diabetes mellitus, kidney disorders
 y First pregnancy with a new partner
 y Previous history of pre-eclampsia
 y Family history of pre-eclampsia
Symptoms 
 y Patients with pre-eclampsia are often asymptomatic
 y Swollen feet
Signs 
Mild cases
Systolic blood pressure between 140 and 159 mmHg Diastolic blood 
pressure between 90 and 109 mmHg Proteinuria of 1+ or 2+
 y Pedal oedema
Severe cases

— Severe Pre-Eclampsia and Imminent Eclampsia —
Standard  Treatment Guidelines, 7th Edition, 2017
326 y Systolic blood pressure 160 mmHg or higher
 y Diastolic blood pressure 110 mmHg or higher
 y Proteinuria of 3+ or 4+
 y Pedal or generalised oedema
Investigations
 y FBC 
 y Serum Uric Acid
 y BUE and Creatinine 
 y Urinalysis and culture 
 y Liver function tests
 y Random blood glucose 
 y Daily assessment of urine proteins
 y Ultrasound scan for close foetal growth monitoring
Treatment
Treatment objectives
 y To reduce elevated blood pressure, but not less than 140/90 mmHg
 y To prolong the pregnancy as much as possible to allow the foetus to 
grow and mature for delivery
 y To prevent foetal distress
 y To prevent or treat any complications that may arise
 y To prevent eclampsia
Non-pharmacological treatment
 y Admit for rest if possible
 y Encourage patients to lie on their sides to avoid supine hypotension
Pharmacological treatment
A.      Mild pre-eclampsia
There is no need for drug treatment of the hypertension unless the 
BP rises above 150 mmHg systolic or 100 mmHg diastolic or the patient 
becomes symptomatic of imminent eclampsia (see below). 
Evidence Rating: [B]
 y Methyldopa, oral, 250-500 mg 8-12 hourly (max. 2 g/day)
Or
 y Nifedipine retard, oral, 10-40 mg 12 hourly
Or
 y Nifedipine slow release, oral, 30-60 mg daily
113� Severe Pre-Eclampsia and Imminent Eclampsia
This is an obstetric emergency and must be treated urgently. 
Treatment is the same as that of eclampsia (see below).  These cases are 
best managed in hospital under the supervision of an obstetrician.
While blood pressure reduction is essential, lowering the blood 

— Severe Pre-Eclampsia and Imminent Eclampsia —Chapter 13:  Obstetric Care and Obstetric Disorders
327pressure below 140/90mmHg may cause foetal distress and should be 
avoided. BP monitoring must be carried out every 15-30 minutes until the 
BP is reduced and the patient is stable. Thereafter monitoring can be done 
by 2-4 hourly. Daily weighing of the patient is essential.
Symptoms 
 y Frontal headaches
 y Vomiting
 y Visual disturbances such as double vision (diplopia), blurred vision, 
flashes of light 
 y Epigastric pain
 y Decrease in urine production (oliguria) 
Signs
 y Elevated blood pressure
 y Liver tenderness 
 y Urine production of < 30 ml/hour or < 400 ml/24 hours
 y Increased tendon reflexes 
 y Presence of ankle clonus (occasionally)
Investigations
 y FBC
 y Blood clotting profile (bedside clotting time, prothrombin time, INR, 
APTT)
 y Serum uric acid
 y BUE and Creatinine
 y Urinalysis and culture
 y Liver function tests 
 y Random blood glucose
 y Daily assessment of urine proteins
 y Ultrasound scan for close foetal growth monitoring
Treatment
Treatment objectives
 y To reduce the blood pressure, but not lower than 140/90 mmHg
 y To prevent the mother from suffering from complications of the 
hypertension such as a stroke
 y To prevent fits/eclampsia
 y To stabilise the patient and deliver her if eclampsia is imminent
Non-pharmacological treatment
 y Early delivery of mother if eclampsia is imminent
 y If the patient is not symptomatic and the pregnancy is less than 34 
weeks allow pregnancy to continue if the foetal condition would 
allow
 y If the pregnancy is 34 weeks or more consider delivery after 
stabilisation

— Eclampsia —
Standard  Treatment Guidelines, 7th Edition, 2017
328Pharmacological treatment
Evidence Rating: [C]
A.     BP management in severe pre-eclampsia and imminent eclampsia
 y Hydralazine, IV, 5-10 mg slowly over 20-30 minutes 
Or
 y Nifedipine, sublingual, 10 mg stat.
Or
 y Labetalol, IV, 20 mg stat. over at least 1 minute
Repeat at 10-minute intervals if the BP remains > 160/110 mm Hg 
as follows: 40 mg; 80 mg; 80 mg boluses to a cumulative dose of 
220 mg
When the BP < 160/110 mmHg commence an infusion of 40 mg per 
hour. 
Double the infusion rate at 30-minute intervals until satisfactory re -
sponse or a dose of 160 mg per hour is attained. 
Then
 y Nifedipine retard, oral, 20-40 mg daily
Or
 y Methyldopa, oral, 250-500 mg 8-12 hourly 
B.     Management or prevention of seizures in severe pre-eclampsia 
and imminent eclampsia
 y Magnesium sulphate, IV, 20 ml of the 20% solution (4 g)
And 
 y Magnesium sulphate, IM, 10 ml of the 50% solution, (5 g) into each 
buttock (total of 10 g)
Referral Criteria 
Refer all cases of severe pre-eclampsia and imminent eclampsia 
promptly to a hospital or obstetrician after initiation of treatment.
When the “obstetrician” considers that the foetus is immature, the 
patient should be transferred to a hospital capable of looking after the 
immature baby.
114. Eclampsia
Eclampsia  occurs as a complication of worsening pre-eclampsia. 
The blood pressure is high with associated proteinuria and convulsion  
or eclamptic fit, which is similar to an epileptic fit with tonic and clonic 
phases followed by coma . The fits are often repetitive and of short 
duration (60-90 seconds).
Causes 
 y As for pre-eclampsia

— Eclampsia —Chapter 13:  Obstetric Care and Obstetric Disorders
329Symptoms
 y Fits
 y Unconsciousness
Signs
 y Convulsions
 y Coma
 y Elevated blood pressure
 y Proteinuria
Investigations
 y FBC
 y Blood film for malaria parasites
 y Urinalysis and culture
 y Blood urea and electrolytes
 y Ultrasound examination of the uterus to exclude multiple pregnancy 
and/or molar pregnancy
Treatment 
Treatment objectives
 y To protect the patient from injury
 y To prevent further fits 
 y To lower the blood pressure
 y To monitor for organ failures (e.g. renal) as well as obstetric 
complications e.g. placental abruption and foetal distress
 y To prevent maternal mortality
 y To deliver the baby when the mother is stable
Non-pharmacological treatment
 y Lay patient in the recovery position
 y Prevent patient from falling
 y Avoid restricting patient to prevent limb fractures and joint 
dislocations
 y Do not put anything in patient’s mouth to prevent tongue biting
 y Maintain the airway by either holding up the chin or if possible, 
inserting a mechanical airway to hold down the tongue
 y If postpartum and patient remains unconscious for a long period, 
consider turning them every hour to prevent sores from developing
 y Artificial respiration may be required following general anaesthesia
After the fits
 y Obtain IV access
 y Catheterise the patient
 y If no further fits and after patient is stabilized, deliver the foetus by 
the most appropriate method to ensure safety of both mother and 
baby
 y Mode of delivery will depend on the patient’s clinical condition, the 
status of the foetus and her preference

— Eclampsia —
Standard  Treatment Guidelines, 7th Edition, 2017
330Pharmacological treatment 
Evidence Rating: [A]
A.     Fluid replacement 
 y Sodium Chloride  0.9%, IV,
Or 
 y Ringer’s lactate , IV, (Maximum 1 Litre in 6 hours or 4 Litres in 24 
hours)
B�     Treatment of convulsions  
 y Magnesium sulphate , IV, 20 ml of the 20% solution (4 g) 
Administer slowly over 5 to 15 minutes
Then 
 y Magnesium sulphate , IM, 10 ml of the 50% solution, (5 g) into each 
buttock (total of 10 g)
C�     Treatment of recurrent convulsions  
If fits recur within 20 minutes, do not repeat Magnesium sulphate .   
(See other treatment options below)
If fits recur after 20 minutes, repeat Magnesium Sulphate, IV,
> 70kg;  20 ml of the 20% solution (4g) 
< 70kg;  10 ml of the 20% solution (2 g) once 
D�     Maintenance 
 y Magnesium sulphate , IM, 5 g in alternating buttocks every 4 hours till 
24 hours after last seizure or delivery, whichever is later
Note 13-1
Toxicity to Magnesium Sulphate  presents as slowing or arrest of the heartbeat 
and the respiration and loss of the deep tendon reflexes. Before giving a dose 
ensure that the following parameters are normal:
 yRespiratory rate > 12-16 per minute
 yUrine output 100 ml or more over the previous 4 hours
 yPresence of knee jerk or other deep tendon reflexes
In case of toxicity to Magnesium Sulphate
 yGive assisted respiration
 yAdminister 10 ml of 10% Calcium  Gluconate, IV, slowly in suspected magne -
sium sulphate toxicity
E�     Treatment of convulsions not responding to Magnesium sulphate    
And
Evidence Rating: [A]
 y Diazepam , IV, 10 mg slowly over 2-3 minutes (not exceeding 2.5 mg 
every 30 seconds, 
Then
> 60kg;   5-10 mg 8 hourly
< 60kg;   5 mg 8 hourly

— Malaria in Pregnancy  —Chapter 13:  Obstetric Care and Obstetric Disorders
331(Do not exceed 500 microgram/kg in a day or 30 mg in 24 hours)
F�     Treatment of Hypertension  in Eclampsia   
 y Hydralazine , IV, 5-10 mg stat. (over 5-10 mins)
Boluses can be repeated every 20-30 mins. BP should not fall below 
140/90 mmHg
Then
 y Hydralazine , IV infusion, 
20-40 mg in 500 ml of Sodium Chloride  0.9% 
Rate of infusion to be titrated against the blood pressure readings.
Note 13-2
If the Hydralazine  infusion runs unattended, profound hypotension may ensue. 
Hydralazine, IV, is best given as multiple bolus doses at 20-30 minute intervals 
till the BP is reduced. The diastolic pressure should not go below 90 mmHg as 
placental perfusion may be impaired with resultant foetal distress.
Or
 y Labetalol , IV, 20 mg stat. over at least 1 minute
Then 
Repeat at 10-minute intervals if the BP remains >160/110mmHg as 
follows:  40 mg; 80 mg; 80 mg boluses to a cumulative dose of 220 
mg
When the BP < 160/110 mmHg start an infusion of 40 mg per hour. 
Double the infusion rate at 30-minute intervals until satisfactory re -
sponse or a dose of 160mg per hour is attained.
Referral Criteria 
 Transfer all cases of eclampsia immediately to a hospital or 
obstetrician in a facility with operative capacity.
 As much as possible set up an IV line of Sodium Chloride  0.9% or 
Ringer’s lactate  and administer the IV dose of Magnesium Sulphate slowly 
at the health facility. Follow this with the IM dose and accompany the 
patient to a referral facility.
If the IV dose cannot be given, simply give the IM dose of 5 g into 
each buttock and transfer.
115� Malaria  in Pregnancy  
(See section on ‘Malaria ’) 
116� Anaemia  in Pregnancy  
Anaemia  in pregnancy is a haemoglobin concentration of < 11 g/
dL (World Health Organisation).  It is described as severe if the Hb is < 
7 g/dL. Anaemia has adverse effects on the health of the woman and 
the outcome of the pregnancy. It is associated with an increased rate of 

— Anaemia in Pregnancy  —
Standard  Treatment Guidelines, 7th Edition, 2017
332miscarriage, preterm delivery, foetal growth restriction, foetal death and 
increased perinatal loss. It is also associated with ante- and post-partum 
haemorrhage and an increased maternal mortality rate.
Ideally no woman should go into labour with anaemia. Appropriate 
measures including blood transfusion may be required to correct the 
anaemia especially if a woman is close to her expected delivery date.
Causes 
 y Physiological (due to blood volume expansion in pregnancy)
 y Poor dietary intake of iron, folate and vitamin B12
 y Haemolytic disorders (e.g. sickle cell disease, G6PD  defect)
 y Malaria
 y Infestations with hookworm, ascaris, schistosomes 
 y Chronic infections e.g. TB, UTI , HIV  
 y Bleeding  complications in pregnancy e.g. APH
Symptoms
 y Dizziness
 y Swelling of the feet
 y General weakness
 y Easy fatiguability 
Signs
 y Mucosal pallor
 y Jaundice  (may or may not be present)
 y Hepato-splenomegaly (may or may not be present)
 y Heart failure in severe cases
Investigations
 y FBC 
 y Peripheral blood film comment
 y Blood film for malaria parasites
 y Sickling and Hb electrophoresis
 y G6PD  activity
 y Serum iron, total iron binding capacity, ferritin 
 y Stool analysis for hookworm ova
 y Urinalysis for schistosoma ova and urobilinogen
Treatment 
Treatment objectives
 y To relieve symptoms
 y To correct haemoglobin level before patient reaches term or goes 
into labour
 y To identify and treat underlying cause 
 y To recognize and manage the associated complications in mother 
e.g. cardiac failure, and baby e.g. intrauterine growth restriction
Non-pharmacological treatment
 y Encourage intake of foods such as red meat, poultry, fish, dark 

— Anaemia in Pregnancy  —Chapter 13:  Obstetric Care and Obstetric Disorders
333leafy vegetables, shell fish, dried fruits which are rich in iron, folate, 
Vitamins B and C
 y Avoid tea, coffee, bran, cola and unhealthy habits such as eating of 
clay, which inhibits iron absorption 
 y Encourage intake of folate and vitamin rich foods including beans, 
avocado, citrus fruits, spinach and mangoes
 y Protein rich foods must also be included in the diet
 y Ensure these anaemic patients are seen more frequently in the 
antenatal clinic and their response to treatment monitored with 
haemoglobin level checks.
Pharmacological treatment 
Evidence Rating: [A]
 y Ferrous sulphate , oral, 325 mg 8 hourly 
Or
 y Ferrous gluconate , oral, 300 mg 8-12 hourly. Evaluate after 4-6 weeks 
And
 y Folic Acid , oral, 5 mg daily
 y Blood transfusion  
Note 13-3
In severe anaemia (Hb < 7 g/dL), blood transfusion may be necessary. 
In labour severe anaemia is best treated by blood transfusion
When there is heart failure preferably transfuse packed cells . 
Add 
 y Furosemide  IV, 20-40 mg if giving whole blood  
Referral Criteria 
Refer patients with anaemia to a dietician or diet nurse for counselling 
and support. Treatment for severe anaemia (Hb < 7g/dL) is best given in 
health facilities with blood transfusion capability.
All women who do not respond satisfactorily to oral treatment 
should be referred for further evaluation.
Those with associated conditions like HIV  and Haemogobinopathies 
should be managed in the hospital. HIV patients on antiretroviral 
medication may need modification of their drug combinations to exclude 
those that aggravate anaemia e.g. zidovudine.
Flowchart

— Sickle Cell Disease in Pregnancy  —
Standard  Treatment Guidelines, 7th Edition, 2017
334
Fig 13-3:  Flowchart: management of anaemia in pregnancy
117� Sickle Cell Disease  in Pregnancy  
Pregnancy in the Sickle Cell Disease  (SCD ) patient is associated 
with poor obstetric outcomes for both the mother and her baby. Data 
from referral centres in Ghana show that sickle cell complications during 
pregnancy leads to high maternal and perinatal mortality. 
Common pregnancy complications of the mother with SCD  include 
miscarriages, frequent vaso-occlusive crises, severe anaemia, recurrent 
urinary tract infections, acute chest syndrome , preterm labour and 

— Sickle Cell Disease in Pregnancy  —Chapter 13:  Obstetric Care and Obstetric Disorders
335pulmonary embolism. In the foetus, complications include intrauterine 
growth restriction, prematurity and intrauterine foetal death.
Care by a multidisciplinary team consisting of the Obstetricican, 
Physician specialist, Haematologist, Clinical Pharmacist, Anaesthetist, 
Nurse and Midwife ensures good health outcomes for these patients.
Causes 
(See section on ‘Sickle Cell Disease ’)
Symptoms
 y Recurrent Jaundice
 y Bone and joint pain (recurrent episodes)
 y Delayed puberty
 y Sub-fertility
 y Anaemic complications (easy fatiguability, palpitations)
Signs
(See section on ‘Sickle Cell Disease ’)
Investigations
 y Sickling test and Haemoglobin electrophoresis
 y Full blood count including reticulocyte count
 y RDT or blood film for malaria parasites
 y Midstream urine for Culture and sensitivity at booking and whenever 
indicated
 y Renal function test (BUN, Creatinine, electrolytes)
 y Liver function tests
 y Serum iron, TIBC  and Ferritin  (if possible)
 y All other antenatal screening test
Treatment 
Treatment objectives
 y To identify patients with condition early during pregnancy for closer 
monitoring
 y To correct anaemia
 y To prevent known crises triggers
 y To detect and manage promptly all associated complications and 
crises
 y To deliver client safely as soon as baby is viable 
Non-pharmacological treatment
 Pre-pregnancy Care
 y Provide genetic counselling
 y Assist patient to plan pregnancy in a status of optimum health
 y Educate on potential risk and health problems of SCD  in Pregnancy

— Sickle Cell Disease in Pregnancy  —
Standard  Treatment Guidelines, 7th Edition, 2017
336 Care during Pregnancy
At booking 
 y Assess patient carefully for risk of frequent crises, and previous 
obstetric complications
 y Examine for nutritional status, anaemia, jaundice, and 
hepatosplenomegally
 y Perform ultrasound to date pregnancy and exclude foetal abnormality 
and growth retardation 
 y Perform the above listed investigations to screen for and detect 
complications 
 y Manage identified problems at booking  (e.g. urinary tract infection, 
malaria etc.) appropriately and promptly
Follow up visits
 y If low risk, schedule follow up visits monthly until 2nd trimester, then 
2 weekly until 28th week and thereafter weekly
 y If high-risk, schedule visits 2 weekly until third trimester, then weekly 
until term
 y At review visits, enquire about maternal well-being, symptoms of 
crises, infection and foetal activity. Examine for pallor, jaundice, fever 
and proteinuria. Check for foetal growth and compare to gestational 
age
 Labour and delivery
 y Stress and pain of labour and delivery can trigger crisis. Risks of crisis 
is increased if dehydration , fever, infection, hypothermia develop 
during labour. Care during labour/delivery is targeted at preventing 
these triggers
 y All women with Sickle cell Disease must deliver in hospital, and the 
most experienced midwife and obstetrician should be involved in 
their care 
 y In uncomplicated pregnancies, spontaneous vaginal delivery must be 
aimed at until 40 weeks (term). Induction must be undertaken only if 
the woman has not delivered after this time.
 y For the high risk women with recurrent complications deliver as soon 
as baby is viable 
 y At admission in labour;  
 y Labour should be monitored closely with partograph
 y Check for haemoglobin level 
 y Group and cross-match a unit of blood on standby 
 y Maintain good hydration with IV fluids 
 y Provide adequate pain relief (See section on ‘Analgesia in La -
bour ’)
 y Provide prophylactic antibiotics (See section on ‘Antibiotic pro -
phylaxis  in labour and puerperium ’ below) 
 y Vaginal delivery should be the aim unless there are obstetric reasons 
for cesarean section 

— Sickle Cell Disease in Pregnancy  —Chapter 13:  Obstetric Care and Obstetric Disorders
337 y Prolonged second stage labour should be avoided by offering assisted 
delivery (vacuum) 
 y Active Management of Third Stage of Labour (AMTSL) is 
recommended to prevent PPH  
 Postpartum care
 y All Sickle Cell Disease  patients must be hospitalized and monitored 
closely for at least 72 hours postpartum 
 y Check for pallor, puerperal sepsis, acute chest syndrome , vaso-
occlusive crises and urinary tract infection 
 y Continue with prophylactic antibiotics for at least 72 hours 
postpartum
 y Counsel women and their support persons to avoid crises triggers 
such as stress, pain, lack of sleep, fatigue etc.
 y Encourage early ambulation (especially after operative delivery) 
 y Review client at 7 days postpartum and thereafter weekly until 6 
weeks
 y Refer patient to physician for continuing care
 y Counsel on family planning and offer contraception
 Baby
 y The baby should be screened for sickle cell disease
 y Closely monitor the babies with associated complications e.g. IUGR, 
prematurity etc.
 Sickling crises in pregnancy 
 y Admit all sickle cell patients with sickling and/or obstetric 
complications during pregnancy to a hospital
 y Avoid NSAIDs  e.g. Diclofenac  in the 3rd trimester
 y Opiods like pethidine and morphine  for pain management should be 
used with care during labour due to respiration depression  effects on 
baby (See section on Analgesia in Labour )
 y Identify and treat underlying triggers e.g UTI , malaria, dehydration  
etc. (See appropriate sections)
 y Blood transfusion  is recommended if haemogloblin level is less than 
7g/dl at 36 weeks and/or during crises (See section on ‘Sickle Cell 
Disease ’)
 y If in vaso-oclusive crises maintain hydration with IV fluids (crystalloids) 
2-4 litres in 24 hours, and provide analgesia (See section on ‘Sickle 
Cell Disease ’)
 y Acute chest syndrome (ACS)- foetal monitoring is essential during 
this crisis (See section on ‘Acute Chest Syndrome’)
Pharmacological treatment 
A.     Antenatal treatments 
(See section on Pharmacological treatments under ‘Antenatal Care ’)

— Diabetes Mellitus in Pregnancy —
Standard  Treatment Guidelines, 7th Edition, 2017
338And
 y Multivitamin , oral, once daily
B.     Antibiotic prophylaxis  in labour and puerperium
 y Ceftriaxone , IV/IM, 1 g daily for 72 hours 
Or
 y Amoxicillin + Clavulanic Acid , IV, 1.2 g stat.
Then 
 y Amoxicillin + Clavulanic Acid , oral, 625 mg 12 hourly for 72 hours
Referral Criteria 
All patients with sickle cell disease with obstetric complications 
should be referred to a specialist for continuing care.  
118� Diabetes Mellitus  in Pregnancy
Diabetes Mellitus  in pregnancy  includes individuals known to be 
diabetic prior to pregnancy and those who develop impaired glucose 
tolerance during pregnancy. Gestational diabetes  refers to impaired 
glucose tolerance of any degree that develops or is first recognized during 
the current pregnancy, irrespective of whether it resolves after delivery 
or not.  Diabetes is associated with poor health outcomes for a mother 
and her baby if not properly managed.  Many patients with gestational 
diabetes are asymptomatic making screening for all pregnant women 
mandatory to identify those at risk. A fasting blood glucose test must be 
done on all pregnant women at booking and also at 28-32 weeks (See 
section on ‘Antenatal Care ’).
The management of diabetes mellitus in pregnancy and the 
puerperium  involves close monitoring of the woman by a multidisciplinary 
approach comprising a team of obstetricians, midwives, nurses, dieticians, 
physicians, anaesthetists and paediatricians.
Labour (induced or spontaneous) and Caesarean section are best 
supervised in hospital under specialist care.
Anti-diabetic treatment requirements reduce dramatically after 
delivery hence, post delivery treatment doses must be tailored to each 
individual patient’s needs.  
The newborn  baby of a diabetic mother needs special care and 
is best managed by a paediatrician/ neonatologist. Hypoglycaemia  
in the baby in the first few hours of birth is a major problem. It can be 
prevented by initiating early (within 1 hour) breastfeeding. They may 
also require management for respiratory distress syndrome, electrolyte 
imbalances (e.g. hypercalcaemia , hypokalaemia, hypomagnesaemia) and 
hyperbilirubinaemia .  
 All diabetic mothers must be counselled on family planning.  

— Diabetes Mellitus in Pregnancy —Chapter 13:  Obstetric Care and Obstetric Disorders
339Causes 
 y Pre-existing Type 1 diabetes mellitus
 y Pre-existing Type 2 diabetes mellitus 
 y Gestational diabetes  mellitus
Symptoms
 y Usually asymptomatic
 y Previous history of large babies ( > 4 kg)
 y Previous poor obstetric history (foetal deaths, miscarriages etc.)
 y Other features of diabetes (See section on ‘Diabetes Mellitus ’)
Signs
 y Foetus larger than gestational age (as assessed by serial symphysio-
fundal height or by ultrasound scan)
 y Foetus smaller than gestational age (IUGR)
 y Presence of polyhydramnios
 y Other signs of diabetic complications (See section on ‘Diabetes 
Mellitus ’)
Investigations
 y All basic Antenatal Care  Investigations 
 y Ultrasound scan 
 y Foetal anomaly scan at 16-22 weeks  
 y Serial scans for growth assessment in third trimester
 y Urine culture and sensitivity (monthly)
 y High vaginal swab for candidiasis
 y Blood urea, electrolytes and creatinine
 y Blood glucose profile (Fasting blood glucose and 2-hour post-
prandial blood glucose monthly in the lab; more frequently by self-
monitoring) 
 y Glycated haemoglobin (HbA1C) every 6-8 weeks
Note 13-4  
There is no place for urine glucose estimation in the management of diabetes in 
pregnancy except for screening. 
Self-monitoring of blood sugar should be encouraged for those who can afford 
a glucose meter.  
Treatment 
Treatment objectives
 y To achieve normal blood glucose and glycated haemoglobin levels 
throughout pregnancy, labour, delivery and puerperium
 y To prevent maternal and foetal complications
 y To prevent neonatal morbidity and mortality 
 y To detect and manage other associated complications e.g. pre-
eclampsia

— Diabetes Mellitus in Pregnancy —
Standard  Treatment Guidelines, 7th Edition, 2017
340Non-pharmacological treatment
 y General measures (dietary modification, exercise, patient counselling 
and education, blood glucose monitoring must be discussed with a 
dietician, obstetrician or midwife, respectively)
 y Frequent ANC visits are required
 y Delivery 
 y by 40 weeks gestation: in well controlled patients with no com -
plications
 y by 38 weeks gestation; in Insulin treated patients and those 
with complications
 y Caesarean section; for patients with either of the following; 
 y severe pre-eclampsia, previous caesarean section, 
 y advanced maternal age, malpresentation or foetal 
 y macrosomia
 y If elective preterm delivery is necessary, mature the foetal lungs 
with corticosteroids under specialist care
 y Puerperium
 y Close blood glucose monitoring in the first 48 hours after de -
livery  
Pharmacological treatment 
Box 13-4:   Notes on glycaemic control of diabetes in pregnancy
Before planned pregnancy 
Optimise glycaemic control in known diabetics before pregnancy. 
During pregnancy
If diet alone cannot control the blood glucose level consider hypoglycaemic 
agents: metformin, glibenclamide and insulin
 yDiabetic patients on oral medication who become pregnant can be main -
tained on their oral medication if sugar control is satisfactory (fasting glu -
cose levels between 4-6 mmol/L and 2-hour postprandial glucose between 
4-7 mmol/L; glycated Hb [HbA1c] less than 6.5%)
Indications for oral antidiabetic agents use:
 yGestational Diabetics who fail to achieve satisfactory control with diet and 
exercise alone (FBS > 6.1mmmol/l)
 yPoor compliance to insulin e.g. poor administration skills
 yPoor glycaemic self monitoring
 yInsulin therapy poses financial burden or is not readily available
Absolute Indications for Insulin use
 ySignifiant diabetic related morbidity exists e.g. nephropathy, retininopathy, 
neuropathy
 yPersistently high Haemoglobin A1c
 yPersistent ketonuria
 ySignificant obstetric morbidities e.g. foetal macrosomia, polyhydraminios, 
IUGR
 yDuring antenatal corticosteroid therapy with expected deterioration of gly -
caemic control
 yPoor glycaemic control with oral antidiabetic agents
Evidence Rating: [B]
 y Metformin, oral, 500 mg 8-12 hourly. (max. dose 2g per day)
And/Or 

— Cardiac Disease in Pregnancy —Chapter 13:  Obstetric Care and Obstetric Disorders
341 y Glibenclamide, oral, 2.5-5 mg 12-24 hourly. Increase dose by 5 mg if 
necessary until max. dose of 15 mg/day
Note 13-5
Metformin can be given as monotherapy or in combination with insulin and/
or Sulphonylurea 
The use of sulphonylureas (e.g. glibenclamide) in pregnancy should generally be 
avoided because of the risk of neonatal hypoglycaemia. However, glibenclamide 
can be used in the 2nd and 3rd trimester in women with gestational diabetes.
 
And/Or 
 y Insulin   
Evidence Rating: [A]
(See section on Insulin Therapy in ‘Diabetes Mellitus’)
 y Start with small doses (e.g. total daily dose of 6-10 units) of NPH 
insulin or premixed insulin (which has 30% of regular and 70% of 
NPH insulin), subcutaneously.
 y Give approximately two-thirds of the total daily dose before breakfast 
and one-third before dinner.
 y Adjust the insulin doses before breakfast and/or dinner by plus or 
minus 2 units according to results of blood glucose tests.
 y Monitor insulin therapy with 2-4 weekly FBS (and 2-hour post-
prandial blood glucose where possible) up to 34 weeks then weekly 
till delivery.
 y Keep fasting glucose levels between 4-6 mmol/L and 2-hour 
postprandial glucose between 4-7 mmol/L.
 y This is often achievable on an out-patient basis. However, some 
patients would need to be admitted to hospital for short periods to 
ensure good glycaemic control. 
 y Insulin requirements during labour should be given according to a 
sliding scale (See section on ‘Diabetic ketoacidosis’ and Sliding scale)
 y Insulin requirements during caesarean section and other operative 
procedures (using a sliding scale or Glucose-Potassium-Insulin 
infusion or GKI) should be discussed with the anaesthetist
Referral Criteria 
Refer to hospital for specialist care. For the convenience of patients 
shared care between specialist and medical officer may be appropriate.
119� Cardiac Disease in Pregnancy
Cardiac diseases are associated with high maternal and foetal 
mortality and morbidity. They may be present before the pregnancy 
or develop during the pregnancy or puerperium (e.g. peripartum 
cardiomyopathy).  Pregnancy places additional burden on the heart and 
makes pre-existing cardiac disease worse. 

— Cardiac Disease in Pregnancy —
Standard  Treatment Guidelines, 7th Edition, 2017
342Some of the signs of pregnancy may mimic cardiac disease. Careful 
assessment of all patients must be undertaken to determine if they have 
cardiac disease or not.
Management requires a multi-disciplinary team including the 
obstetrician, neonatologist, anaesthetist and physician specialist or 
cardiologist.  
Patients with known cardiac disease must plan their pregnancies 
carefully in full consultation with their cardiologist and obstetrician.  They 
must book early as soon as they become pregnant for antenatal care in 
hospital.
All patients needing pharmacological treatment must be managed 
by a physician specialist or cardiologist and obstetrician. 
Causes 
 y Rheumatic heart disease e.g. mitral incompetence and stenosis
 y Hypertension
 y Cardiomyopathy
 y Anaemia
 y Congenital heart diseases  
 y Thyrotoxicosis
Symptoms
 y Asymptomatic
 y Palpitations
 y Easy fatiguability
 y Chest pain
 y Dyspnoea - orthopnoea, paroxysmal nocturnal dyspnoea
 y Cough
 y Leg swelling
Signs
 y Cardiac murmurs
 y Other signs of cardiac disease depending on the type of lesion (See 
section on ‘Disorders of the cardiovascular system’)
 y Presence of heart failure (See section on ‘Heart failure’)
Investigations
 y FBC
 y Blood urea and electrolytes
 y Thyroid function test, if indicated
 y Electrocardiogram
 y Echocardiogram
 y Chest X-ray (with protection of foetus)
 y All other antenatal investigations 
Treatment 
Treatment objectives
 y To maintain good cardiac function throughout the pregnancy, labour, 

— Jaundice in Pregnancy  —Chapter 13:  Obstetric Care and Obstetric Disorders
343delivery and puerperium
 y To prevent maternal and foetal complications  
 y To prevent maternal death 
Non-pharmacological treatment
(See appropriate cardiac disease)
Pharmacological treatment 
(See appropriate cardiac disease)
Referral Criteria 
All patients with cardiac disease must be referred to a specialist 
physician or cardiologist and an obstetrician.
120� Jaundice in Pregnancy 
Jaundice occurring in pregnancy may be a symptom or sign of a 
severe disease and should not be underestimated.
Causes 
Obstetric
 y Severe pre-eclampsia/eclampsia/HELLP Syndrome (Haemolysis, 
Elevated Liver enzymes, Low Platelets syndrome)
 y Severe hyperemesis gravidarum
 y Cholestatic jaundice of pregnancy
 y Acute Fatty Liver of pregnancy 
Non-obstetric
 y Viral hepatitis
 y Haemolytic: malaria, sickle cell disease, G6PD defect, septicaemia, 
drugs and herbal medications
 y Surgical: acute cholecystitis, cholelithiasis, obstructive jaundice
Symptoms
 y Yellowish discoloration of eyes
 y Deep yellow or dark urine
 y Generalized itching
 y Other symptoms relating to the cause (e.g. general malaise, dizziness, 
fever etc.)
Signs
 y Yellow discoloration of mucous membranes and skin
 y Delirium and coma (if severe)
 y Liver enlargement (If associated with liver disease)
 y Other signs relating to the cause (e.g. fever, elevated blood pressure)
Investigations
 y FBC, blood film for malaria parasites, RDT 
 y Sickling status
 y G6PD status

— Post-Partum Haemorrhage  —
Standard  Treatment Guidelines, 7th Edition, 2017
344 y Blood group and cross matching 
 y Blood urea, electrolytes, and creatinine
 y Liver function tests
 y Hepatitis B surface antigen
 y Abdominal ultrasound scan with emphasis on the hepato-biliary 
system and pancreas
Treatment 
Treatment objectives
 y To identify and treat cause
 y To prevent related maternal and foetal complications
Non-pharmacological treatment
 y Depends on the underlying cause (See appropriate sections)
Pharmacological treatment 
 y Depends on the underlying cause (See appropriate sections) 
Referral Criteria 
Severe cases of jaundice and those associated with abdominal pain 
must be referred for specialist care.
121� Post-Partum Haemorrhage 
Post-partum haemorrhage may be primary or secondary. Primary 
postpartum haemorrhage refers to bleeding of more than 500 ml from the 
genital tract within the first twenty-four hours of delivery or any amount 
of blood loss that result in haemodynamic compromise of the patient. It 
usually occurs during or immediately after the third stage of labour.
Secondary post-partum haemorrhage is defined as excessive vaginal 
bleeding occurring from twenty-four hours to six weeks after delivery.
The bleeding may occur with the placenta retained or after its 
expulsion from the uterus. Postpartum haemorrhage becomes life 
threatening if the mother is already anaemic.  Blood loss of more than 
500 ml may lead to shock.
Causes 
 y Uterine atony (70-90% of cases)
 y Retention of all or part of placental tissue within the uterine cavity
 y Infection within the uterine cavity (endo-myometritis)
 y Genital tract trauma
 y Clotting disorders
Symptoms
 y Excessive or prolonged vaginal bleeding after delivery
 y Lower abdominal pains 
Signs
 y Active bleeding from the genital tract

— Post-Partum Haemorrhage  —Chapter 13:  Obstetric Care and Obstetric Disorders
345 y Conjunctival pallor
 y Rapid pulse
 y Blood pressure may be low or normal
 y Deterioration of maternal levels of consciousness
 y Flabby poorly contracted uterus
 y Obvious tears in birth canal and/or perineum
 y Obvious retained placenta
 y Suprapubic tenderness 
Investigations
 y FBC, sickling status 
 y Bedside clotting test
 y Blood grouping and cross-matching
 y Ultrasound scan (if patient is stable to check for retained placenta 
tissue) 
Treatment 
Treatment objectives
 y To identify the cause and stop bleeding as quickly as possible
 y To correct hypotension
 y To correct resulting anaemia
Non-pharmacological treatment
Due to uterine atony (70-90% of cases), with no placental retention 
 y Massage fundus of uterus to stimulate contraction
 y Encourage woman to empty bladder or pass a urethral catheter to 
empty the bladder and monitor urine output
 y Bimanual compression of the uterus and balloon tamponade if 
uterus fails to contract with massage 
Due to retained placenta
 y Attempt removal of the placenta by controlled cord traction as soon 
as a contraction is felt. If not successful await the next contraction 
and repeat the procedure
 y If the placenta cannot be expelled in this fashion, manual removal 
under anaesthesia is indicated 
 y If the placenta has been delivered and is incomplete, exploration the 
uterus and manual removal under anaesthesia is indicated
 y If the facilities for manual removal of placenta under anaesthesia are 
not immediately available refer to hospital
Bleeding with uterus well contracted and placenta completely 
delivered 
 y Examine the patient in the lithotomy position with adequate 
analgesia and/or anaesthesia, good lighting to identify and suture 
perineal, vaginal and cervical tears
 y If the tear(s) extends into the uterine body, effective suturing cannot 

— Post-Partum Haemorrhage  —
Standard  Treatment Guidelines, 7th Edition, 2017
346be performed and repair will involve a laparotomy
 y For ruptured uterus, repair or hysterectomy is required
Bleeding associated with coagulopathy 
 y Bedside clotting test - 5 ml of blood placed in a 10 ml round bottomed 
glass tube should clot in 6 minutes
Pharmacological treatment 
A.     If the uterus is poorly contracted (Atony)
1st Line Treatment
Evidence Rating: [A]
 y Oxytocin, IM, 10 units stat. 
Then
 y Oxytocin, IV, infusion, 10-40 units in 500 ml Dextrose saline or 0.9% 
or Normal saline
Note 13-6
Dose not to exceed 40 units
If intravenous oxytocin is unavailable, or if the bleeding does not respond to 
oxytocin, the following second line drugs are recommended.
2nd Line Treatment
Evidence Rating: [B]
 y Misoprostol, sublingual, 600 microgram (for PPH prophylaxis within 
1 minute of delivery)
 y Misoprostol, sublingual, 800 microgram stat if patient is conscious 
(for PPH treatment)
Or 
3rd Line Treatment
Evidence Rating: [B]
 y Ergometrine, IV, 500 microgram stat.
Or
Evidence Rating: [B]
 y Oxytocin-ergometrine, IM, (Oxytocin 10 units and Ergometrine 500 
microgram) stat.
Or
Evidence Rating: [B]
 y Oxytocin-misoprostol, (Oxytocin, IV, 10 units and Misoprostol, rectal, 
600 micrograms) stat.
Note 13-7
High rates of adverse effects (nausea, vomiting, and high blood pressure) occur 
in women treated with ergometrine. 
They should not be given to women with hypertension in pregnancy or heart 
disease.

— Post-Partum Haemorrhage  —Chapter 13:  Obstetric Care and Obstetric Disorders
347B�     Protracted bleeding uncontrolled by Oxytocin and other 
Uterotonics or if bleeding is due partly to trauma
Evidence Rating: [B]
 y Tranexamic Acid, slow IV (not to exceed 100 mg per minute), 
 1 g stat. 
Then
 1 g 8 hourly (Maximum 3 g in 24 hours)
C�     Hypovolaemia
 y Sodium Chloride 0.9% or Ringers lactate, IV, and blood transfusion as 
clinically indicated 
(See section on ‘Shock’)
D.     Anaesthesia for manual removal of placenta
 y Morphine, IV, 2.5 - 5 mg stat. as required (if no anaesthetist is avail -
able)
Or
 y Pethidine, IV slowly or IM, 1 mg/kg 6 - 8 hourly as required (max. 100 
mg per dose) 
And 
 y Diazepam, slow IV, 5-10 mg 8 hourly as required (NOT more than 2.5 
mg per minute) 
Note 13-8
Do not mix pethidine and diazepam in the same syringe. Monitor respiratory 
rate of patient closely. Stop drugs if respiratory rate is less than 12 per minute.
Or
 y Ketamine, IM, 5-10 mg/kg stat.
Or 
 y Ketamine, IV, 0.5-2 mg/kg stat.
Note 13-9
Ketamine must be used only by trained Medical Officer/anaesthetist
Provide antibiotics prophylaxis after manual removal of placenta or exploration 
of uterus or repair of birth canal tears.
E�     Secondary Postpartum Haemorrhage
 y Oxytocin, IV infusion, 20 units in 1 L of Normal Saline
Or
 y Ergometrine, oral, 500 microgram 8 hourly for 3 days
F.      Antibiotic prophylaxis 
 y Amoxycillin, oral, 500 mg 8 hourly for 7 days 
And 
 y Metronidazole, oral, 400 mg 8 hourly for 7 days

— Post-Partum Haemorrhage  —
Standard  Treatment Guidelines, 7th Edition, 2017
348Referral Criteria 
Refer patients who do not respond to the treatments above 
to a specialist. Also refer promptly to a hospital with theatre and 
blood transfusion facilities for examination under anaesthesia and/or 
laparotomy if these are not immediately available. 
Fig 13-5:  Flowchart: Post partum haemorrhage

— Post-Partum Pyrexia  —Chapter 13:  Obstetric Care and Obstetric Disorders
349122� Post-Partum Pyrexia 
Post-partum pyrexia refers to body temperature of 38°C or more on 
2 or more occasions during the first 10 days of the puerperium excluding 
the first day. Risk Factors include prolonged labour, prolonged premature 
rupture of membranes, retained placental tissue, instrumental deliveries 
and birth canal injuries.
Causes 
 y Malaria
 y Uterine infection (endo-myometritis)
 y Perineal Infections (e.g. infected episiotomy)
 y Breast problems (engorgement, mastitis, abscess formation)
 y Urinary tract infection
 y Respiratory tract infection
Symptoms
 y Fever
 y Other symptoms as related to cause 
Signs
 y Fever
 y Other signs as related to cause
Investigations
 y FBC
 y RDT
 y Blood film for malaria parasites
 y Blood for culture and sensitivity 
 y Urine for culture and sensitivity 
 y High vaginal swab 
 y Fasting or Random Blood Glucose
 y Pelvic scan to exclude retained products of conception or pelvic 
abscess
Treatment 
Treatment objectives
 y To identify and treat the underlying cause 
Non-pharmacological treatment
 y Examination under anaesthesia with possible uterine curettage for 
retained products of conception
 y Encourage frequent emptying of breasts if cause is due to 
engorgement
 y Incision and drainage for breast and perianal abscess 

— Post-Partum Pyrexia  —
Standard  Treatment Guidelines, 7th Edition, 2017
350Pharmacological treatment 
A.     Breast problems - engorgement
Evidence Rating: [B]
 y Paracetamol, oral, 1 g 6-8 hourly as required
B.     Breast problems - mastitis/abscess
Evidence Rating: [A]
 y Flucloxacillin, oral, 500 mg 6 hourly for 5-7 days
C.     Endo-myometritis and perineal infections 
Evidence Rating: [B]
 y Amoxicillin + Clavulanic Acid, IV, 600 mg-1.2 g 8 hourly for 72 hours 
And
 y Metronidazole, IV, 500 mg 8 hourly for 72 hours 
Then
 y Amoxicillin + Clavulanic Acid, oral, 625 mg-1 g 12 hourly for 7 days
And
 y Metronidazole, oral, 400 mg 8 hourly for 7 days 
Referral Criteria 
Refer all cases of severe sepsis to hospital for management.

— Post-Partum Pyrexia  —Chapter 13:  Obstetric Care and Obstetric Disorders
351Flowchart 
Fig 13-6:  Flowchart: Management of Postpartum pyrexia

— Analgesia in Labour —
Standard  Treatment Guidelines, 7th Edition, 2017
352123� Analgesia in Labour
The pain threshold may be low during labour on account of fear, 
anxiety and uncertainty. Adequate pain relief during labour results in less 
anxiety and good progress.
In the first stage of labour pain relief may be required for painful 
uterine contractions, whereas in the second stage of labour, analgesia is 
required for instrumental delivery and when an episiotomy is given.
Pharmacological treatment
A.  During the first stage of labour - parenteral 
Evidence Rating: [C]
 y Morphine, IV, 2.5-5 mg 4 hourly as required 
And
 y Metoclopramide, IV, 5-10 mg 8 hourly as required for vomiting
Or
 y Pethidine hydrochloride, IM, 50-100 mg stat. repeated as required 
3-4 hours later (Maximum 400 mg in 24 hours)
And
 y Promethazine, IV/IM, 25 mg as required (Maximum 25 mg 6 hourly) 
as required to reduce the chances of vomiting and to potentiate the 
analgesic effect of Pethidine
Box 13-7: 
 yGiven IM, the maximum analgesic effect of Pethidine is obtained after 45 
minutes and lasts for 3-4 hours. It is therefore best not to give it when deliv -
ery is anticipated within 4 hours i.e. up to 6-7 cm dilatation 
 yIf the baby is born within 6 hours of Pethidine administration it may have 
respiratory depression requiring narcotic antagonists such as Naloxone IM, 
100 microgram/kg stat. (If no response, give subsequent dose of 100 micro -
gram after 3-8 minutes). Continue resuscitation with oxygen via a facemask 
or through an endotracheal tube and self inflating (Ambu) bag until the de -
pression is reversed.
 yHowever, Pethidine should not be withheld from patients who need anal -
gesia when the cervix is already 6-7 cm dilated in which case 50-75 mg IM 
Pethidine with 12.5-25 mg. Promethazine may be given intravenously. 
B.  During the first stage of labour – inhalational 
 y Nitrous oxide and Oxygen mixture, 50:50 
Note 13-10
To be used in the late first stage when delivery is expected within 1 hour.  

— Analgesia in Labour —Chapter 13:  Obstetric Care and Obstetric Disorders
353C.  During the first stage of labour - epidural 
Note 13-11
This procedure is best carried out by an anaesthetist.   
D�     During the second stage of labour 
 y Local Anaesthetics for episiotomy and pudendal block anaesthesia to 
facilitate instrumental delivery.
 y Lidocaine hydrochloride (Xylocaine/Lignocaine) 1%, with or without 
adrenaline, infiltrated in the perineum before an episiotomy. If not 
given before delivery it can be given before the repair of the episi -
otomy
E.     Anaesthesia for short obstetric procedures e.g. manual removal of 
placenta, repair of large vaginal and cervical tears
 y Pethidine, IM or IV, 1 mg/kg slowly (max. 100 mg) if no anaesthetist 
is available
And
 y Promethazine hydrochloride, IM, 25 mg stat. (if vomiting occurs)
Or 
 y Metoclopramide, IV, 5-10 mg 8 hourly as required  
And
 y Diazepam , slow IV, 5-10 mg (at a rate of 2.5 mg per minute)
Note 13-12
Monitor respiratory rate closely. Stop Diazepam  if respiratory rate is less than 
10 /minute).
Do not mix the two drugs in the same syringe.
2nd Line Treatment 
 y Ketamine , IM, 5-10 mg/kg stat.
Or
 y Ketamine , IV slowly, 1-2 mg/kg
Or
 y Ketamine , IV infusion, (For longer procedures) 1 mg per ml of ket -
amine in dextrose 5% or normal saline (maintenance dose 10-45 mi -
crogram per kg per minute adjusted according to response. 
And
 y Diazepam , slow IV, 5-10 mg, administered over 2-3 minutes (approx -
imately 2.5 mg per minute) to prevent Hallucinations
F.      Premedication before Ketamine  administration
 y Atropine , IM, 600 microgram stat. 
And
 y Oxygen , by face mask, 6-8 L/minute

— Preterm Labour in Premature Delivery  —
Standard  Treatment Guidelines, 7th Edition, 2017
354Note 13-13
Ketamine  is contraindicated in patients with high blood pressure (Hypertension ) 
and heart disease.
124. Preterm Labour in Premature Delivery  
Preterm labour  refers to labour occurring after 28 weeks but before 
37 completed weeks resulting in premature delivery. The preterm 
newborn  is at risk of death because all its body systems such as lungs, 
brain, digestive and immune systems are not fully developed. There is 
increased susceptibility to infection and impaired clotting mechanisms. 
The baby is also at risk of birth injuries such as cerebral haemorrhage 
because the fragile cranial bones do not provide sufficient protection 
for the brain. Some risk factors for preterm labour include young age of 
mothers, poor socio-economic class and smoking.
Causes 
 y Maternal infections e.g. pyelonephritis , malaria
 y Incompetent cervix
 y Premature rupture of membranes
 y Multiple pregnancies
 y Abruptio placentae
 y Diabetes mellitus
 y Pre-eclampsia/eclampsia
Symptoms
 y Regular and painful uterine contractions or abdominal pains
 y There may be a show
Signs
 y Small maturity
 y Palpable regular uterine contractions 
 y Progressive effacement and dilatation of the cervix
 y Ruptured membranes 
Investigations
 y FBC
 y Fasting or Random Blood Glucose 
 y Ultrasound scan (for those not in established labour) for 
 y Gestational age
 y Foetal lie
 y Presentation
 y Amniotic fluid volume
 y Placental site 
 y Estimation of the foetal weight

— Preterm Labour in Premature Delivery  —Chapter 13:  Obstetric Care and Obstetric Disorders
355Treatment 
Treatment objectives
 y To stop uterine contractions if labour is not fully established
 y To allow foetal growth and maturation in utero if feasible
 y To promote foetal lung maturity (gestations 28-34 weeks)
 y To allow labour to progress if it is already well established
 y To treat any underlying cause (e.g. malaria, pyelonephritis ) 
Non-pharmacological treatment
 y Avoid sexual intercourse
 y Avoid strenuous physical activity
 y Bed rest
 y Cervical cerclage suture for cases diagnosed as due to cervical 
incompetence 
Pharmacological treatment 
A.     Tocolysis
Evidence Rating: [B]
 y Salbutamol , IV infusion, 2.5 mg in 500 ml of Dextrose  5%; 
Start infusion at 10 micrograms per minute (i.e. 2 ml per minute) and 
increase rate gradually according to response at 10 min intervals un -
til contractions dimish, then increase rate slowly until contractions 
cease (Maximum rate 45 micrograms per minute); 
Maintain rate for one hour after contraction has stoped, then grad -
ually reduce by 50% every 6 hours; (Maximum duration 48 hours.)
Or
Evidence Rating: [A]
 y Nifedipine , oral, 20 mg initially, 
Then 
20 mg after 90 minutes
If contractions persist therapy can be continued with 20 mg every 
3-8 hours for 48-72 hours as tolerated by patient (max. 160 mg per 
day)
Note 13-14 4
Monitor blood pressure 
 y Magnesium sulphate , IV, 6 g intravenous load initial over 20 minutes
Then
2 g infusion per hour 
After
Infusion rate is based on response
B.  Foetal lung Maturation with Antenatal corticosteroids Gestations 
between 28-34 weeks 
Evidence Rating: [A]
 y Betamethasone , oral, 0.6-7 mg every 24 hours (2 doses)
Or 

— Premature Rupture of the Membranes  —
Standard  Treatment Guidelines, 7th Edition, 2017
356 y Dexamethasone , 6 mg 12 hourly for (4 doses)  
Note 13-15
Treatment is most effective if delivery occurs at least 24 hours after the first 
dose of the medicine has been given and less than 7 days after the last dose of 
the medicine. 
Caution 13-1.
AVOID Dexamethasone /Bethamethsone  use when infection is present.
Dangers of steroid use include susceptibility to infection, fluid retention and 
pulmonary oedema and maternal postpartum collapse.
Referral Criteria 
Treatment is best done in a hospital where the facilities can support 
the adequate care of the preterm neonate . Therefore, refer the mother if 
the clinic cannot adequately care for the immature neonate. It is better to 
transfer the foetus in-utero to the referral centre.
125� Premature Rupture of the Membranes  
This is the rupture of the membranes before the onset of labour. The 
two types are preterm (before 37 completed weeks) and term (after 37 
weeks, but ≥ 1 hour before onset of labour).
Causes 
 y Cervical Incompetence
 y Genital tract infection
 y Trauma
Symptoms
 y Gush or leakage of copious fluid from the vagina 
Signs
 y Speculum examination reveals clear fluid from the cervical os or pool 
of fluid in the posterior vaginal fornix
 y Smaller uterine size for the gestational age
 y If complicated by infection (chorioamnionitis)
 y Fever
 y Purulent vaginal discharge
 y Foetal tachycardia or bradycardia 
 y Maternal tachycardia
 y Uterine tenderness
Investigations
 y FBC
 y Sterile speculum examination including swab for culture
 y Ultrasound scan (if available) for the gestational age, foetal lie and 

— Premature Rupture of the Membranes  —Chapter 13:  Obstetric Care and Obstetric Disorders
357presentation, amniotic fluid volume (normal or reduced), and the 
placental site. Estimate the foetal weight.
 y Urinalysis and culture 
Treatment 
Treatment objectives
 y To prevent and/or treat infection
 y To prevent labour if preterm and baby is very immature
 y To improve foetal survival through improved foetal lung maturity 
Non-pharmacological treatment
 y Bed rest
Pharmacological treatment 
A. Infection Prevention
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin (Amoxycillin) , oral, 500 mg 8 hourly for 7 days 
And 
 y Metronidazole , oral, 400 mg 8 hourly for 7 days 
2nd Line Treatment
Evidence Rating: [C]
 y Amoxicillin  + Clavulanic Acid , oral, 625 mg - 1 g 12 hourly for 7 days 
B. Infection Prevention – patients with penicillin allergy
 y Erythromycin , oral, 500 mg 6 hourly for 7 days
And 
 y Metronidazole , oral, 400 mg 8 hourly for 7 days 
C.      Foetal lung maturation – for babies 28-34 weeks 
Evidence Rating: [A]
 y Betamethasone , oral, 0.6-7 mg every 24 hours (2 doses)
Or 
 y Dexamethasone , oral, 6 mg 12 hourly for (4 doses)  
Note 13-16
Treatment is most effective if delivery occurs at least 24 hours after the first 
dose of the medicine has been given and less than 7 days after the last dose of 
the medicine. They also benefit the premature newborn  by lowering the risk of 
intraventricular hemorrhage and death. 
Referral Criteria 
If at sub-district level refer patients to hospital or specialist for 
further management if signs of maternal infection, pregnancy is less than 
37 weeks and or premature labour occurs.

14Chapter
358Gynaecological Disorders  
126� Dysmenorrhoea  
Dysmenorrhea  refers to cyclical lower abdominal pain associated 
with menstruation. The pain is thought to result from uterine contractions. 
It may be primary when there is no identifiable cause or secondary when 
associated with an underlying cause.
Causes 
 y Often no underlying cause (primary) 
 y Uterine fibroids
 y Chronic pelvic infections e.g. Chlamydial infections
 y Endometriosis
Symptoms
 y Lower abdominal pain that is cramping or colicky in nature but may 
be dull and constant
 y Pain may radiate to the lower back or legs
 y Nausea , vomiting , headaches and dizziness may sometimes be 
associated with the pain
Signs
 y No typical physical signs
Investigations
 y FBC
 y Sickling
 y Pelvic ultrasound scan to rule out pelvic lesions such as fibroids 
Treatment 
Treatment objectives
 y To relieve pain
 y To treat underlying cause 
Non-pharmacological treatment
 y Bed rest
 y Warm pads applied to the lower abdomen 

— Abortion —Chapter 14:  Gynaecological Disorders 
359Pharmacological treatment 
A.     Mild Cases
1st Line Treatment
Evidence Rating: [A]
 y Paracetamol , oral, 1 g 6-8 hourly
B�     Severe cases
 y Ibuprofen , oral, 200-400 mg 8 hourly 
Or
 y Mefenamic Acid , oral, 500 mg 8 hourly
Referral Criteria 
Refer to a gynaecologist if pain interferes with normal activity 
especially if treatment is ineffective or an underlying cause is identified.
127� Abortion
Abortion  refers to the expulsion of the foetus and other products 
of conception before the 28th week of pregnancy.  It may occur 
spontaneously (threatened, inevitable, incomplete, complete or missed) 
or be induced (therapeutic, criminal). Both spontaneous and induced 
abortion may become complicated by infection (sepsis) and/or profuse 
bleeding.
After appropriate treatment and discharge from hospital, it is 
recommended that patients report back to hospital if there is lower 
abdominal pain, fever, vaginal bleeding and malodorous discharge. A 
follow up review should also be done in two weeks. 
Causes 
 y Spontaneous Abortions
 y Infections e.g. malaria, UTI , bacterial vaginosis  etc.
 y Foetal abnormalities
 y Incompetent cervix
 y Chronic illness e.g. diabetes, thyroid disorders, sickle cell dis -
ease etc.
 y Trauma
 y Unsafe Abortions
 y Interference of the pregnancy with medications (oral, parenter -
al or douches) or instrumentation
THREATENED ABORTION
Symptoms
 y Scanty to moderate painless vaginal bleeding 
 y Mild pelvic discomfort
Signs
 y The uterine size is compatible with the gestational age

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
360 y There is no cervical effacement or dilatation 
Investigations
 y FBC and sickling
 y Ultrasound scan (to confirm viable foetus in utero with closed cervix) 
 y Other investigations for potential underlying causes e.g. malaria
Treatment 
Treatment objectives
 y To maintain a viable pregnancy to term if possible 
Non-pharmacological treatment
 y Bed rest at home or hospital
 y To abstain from sexual intercourse
 y To report back if bleeding or pain increases
Pharmacological treatment  
 y No specific treatment required
 y Treat any underlying illnesses e.g. malaria 
INEVITABLE ABORTION
Symptoms
 y Lower abdominal pain 
 y Heavy vaginal bleeding
 y No foetus or products of conception passed per vagina
 y Painless loss of liquor per vaginam
Signs
 y The cervix is dilated with the membranes bulging
 y There may be loss of liquor
 y The uterine size is compatible with the gestational age
 y There may be signs of shock pallor, collapsed peripheral vessels, 
rising pulse with reducing volume, falling BP and cold clammy skin 
Investigations
 y FBC and sickling
 y Blood grouping and cross matching
 y Ultrasound scan (shows the foetus dead or alive)
 y Cervix may be dilated with membranes bulging through it 
 y In instances associated with loss of liquor there may be 
oligohydraminios
 y Ultrasound is necessary only if the diagnosis is in doubt
Treatment 
Treatment objectives
 y To resuscitate patient and/or prevent shock
 y To relieve pain
 y To allow the patient to abort (assist uterine contractions if weak) 
 y To evacuate the retained products of conception from the uterus

— Abortion —Chapter 14:  Gynaecological Disorders 
361 y To determine cause of abortion if recurrent
 y To prevent infection with antibiotic prophylaxis
 y To prevent risk of Rhesus  incompatibility in future pregnancies 
Non-pharmacological treatment
 y Evacuation of the uterus is done by either of the following techniques 
after the expulsion of the foetus or before the expulsion of the foetus 
if it is less than 12-14 weeks size 
 y Manual Vacuum Aspiration (MVA) with or without paracervical 
block anaesthesia 
Or
 y Uterine curettage under paracervical block or general anaes -
thesia (Gestations 12 weeks or less
 y Uterine evacuation under anaesthesia especially when the 
uterine size is larger than 12 weeks size 
Pharmacological treatment 
A.     If patient is in shock or bleeding is severe 
 y IV fluids and blood transfusion as necessary
B�     To relieve severe pain
Evidence Rating: [C]
 y Morphine , IV, 2.5-5 mg 4 hourly as required 
And
 y Metoclopramide , IV, 5-10 mg 8 hourly as required for vomiting
Or
 y Pethidine , IM, 75-100 mg stat. 
Then
50-100 mg 6-8 hourly if required
And
 y Promethazine , IV/IM, 25 mg as required (max. 25 mg 6 hourly) as 
required to reduce the chances of vomiting  and to potentiate the 
analgesic effect of Pethidine
C�     Evacuate uterus
If uterine size  > 12-14 weeks
Evidence Rating: [A] 
 y Oxytocin , IV, 10-20 units per litre of Normal saline
Or
Uterine size <12 weeks
Evidence Rating: [C]
 y Misoprostol , oral/SL, 600 microgram stat.
D.     To Prevent Infection
 y Amoxicillin , oral, 500 mg 8 hourly for 5-7days 
And 
 y Metronidazole , oral, 400 mg 8 hourly for 5-7days

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
362E.  To prevent Rhesus  Isommunization in Rhesus negative women  
Evidence Rating: [A]
 y Anti D Rh Immune Globulin , IM, 300 microgram (1,500 Units), stat. 
within 72 hours of abortion 
INCOMPLETE ABORTION
Symptoms
 y Passage of large blood clots and/or the foetus and some products 
per vaginam
 y Severe lower abdominal pain
Signs
 y If bleeding is severe: Pallor and/or Shock (collapsed peripheral 
vessels, fast pulse, falling BP and cold clammy skin)
 y Uterine size is smaller than the dates
 y Cervix is dilated with the foetus already aborted
 y Whole placenta or parts thereof may be present within the uterine 
cavity 
Investigations
 y FBC and sickling
 y Blood grouping and cross matching
 y Ultrasound scan (to be requested if doubt exists in the diagnosis 
especially in early pregnancies)
Treatment 
Treatment objectives
 y To resuscitate patient 
 y To evacuate the retained products of conception from the uterus 
 y To prevent infection with antibiotic prophylaxis
 y To determine cause of abortion, if recurrent
 y To prevent risk of Rhesus  incompatibility in future pregnancies 
Non-pharmacological treatment
 y Digital curettage during vaginal examination to remove as much of 
the retained tissues as possible  
 y Surgical evacuation of retained products of conception e.g. manual 
vacuum aspiration (MVA) with or without anaesthesia
 y Post abortion abstention from sexual intercourse for at least 2 weeks
 y Post abortion counselling and psychological support (including 
Family Planning)
Pharmacological treatment 
A. If in shock and/or severe bleeding
 y IV fluids and blood transfusion as necessary
B. Abortion  with uterine size < 12 weeks
Evidence Rating: [A]
 y Ergometrine , IM/IV, 500 microgram stat.

— Abortion —Chapter 14:  Gynaecological Disorders 
363Or 
 y Misoprostol, oral, 600 microgram stat.
Or 
 y Misoprostol, sublingual, 400 microgram stat. 
C. Abortion  with uterine size > 12 weeks and ≤ 24 weeks
Evidence Rating: [A]
 y Misoprostol , oral, 600 micrograms stat.
Or
 y Misoprostol , sublingual, 400 micrograms stat.
D. Abortion  with uterine size > 24 weeks
Evidence Rating: [B] 
 y Oxytocin , IV, 20 units into 1 L of Sodium Chloride  0.9% and infuse at 
30-60 drops per minute 
Or
 y Misoprostol , oral, 600 micrograms stat.
Or
 y Misoprostol , sublingual, 400 micrograms stat.
E.  To prevent infection
 y Amoxicillin , oral, 500 mg 8 hourly for 5-7days 
And 
 y Metronidazole , oral, 400 mg 8 hourly for 5-7days
F.  To prevent infection – in patients with penicllin allergy 
 y Erythromycin , oral, 500 mg 8 hourly for 5-7days 
And 
 y Metronidazole , oral, 400 mg 8 hourly for 5-7days
G.     To prevent Rhesus  Isommunization  
Evidence Rating: [A]
(See section under ‘Inevitable Abortion ’ above)
COMPLETE ABORTION
Symptoms
 y Cessation or reduction of vaginal bleeding following heavy bleeding 
with passage of clots and/or the foetus and placenta.
 y Resolution or abatement of pain
Signs
 y The uterus is smaller than the gestational age
 y The cervix is closed and firm
 y No pelvic tenderness
Investigations
 y FBC 
 y Blood grouping and cross matching
 y Ultrasound scan: to confirm empty uterine cavity

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
364Treatment 
Treatment objectives
 y To confirm abortion is complete
 y To assess for and manage anaemia if present
 y To assess for and manage pelvic infection if present
 y To prevent risk of Rhesus  incompatibility in future pregnancies
Non-pharmacological treatment
 y Counselling and psychological support (including family Planning) 
Pharmacological treatment 
 y Treat anaemia if present (See section on ‘Anaemia  in Pregnancy’)
 y Provide antibiotics if needed (See section on treatment of 
‘Incomplete Abortion ’)
 y Provide Anti D Immune globulin if Indicated (See section under ‘Inev -
itable Abortion ’ above)
SEPTIC ABORTION
This is a life threatening complication of abortion. Most often 
there is a history of criminal interference with the pregnancy.  It may 
lead to complications such as septic shock, uterine damage, peritonitis, 
haemorrhage, disseminated intravascular coagulation (DIC ), acute renal 
failure, adult respiratory distress syndrome, tetanus or gas gangrene .
Causes
 y Infected retained products of conception
Symptoms
 y Severe lower abdominal pain
 y Fever  
 y Vomiting  
 y Headache  
 y Offensive, bloody vaginal discharge
Signs
 y Fever  (but temperature may be normal)
 y Tachycardia
 y If in septic shock: low blood pressure
 y Peritonism
 y Bulky tender uterus
 y Cervix may be opened or closed
 y Retained offensive products of conception 
Investigations
 y FBC and sickling test
 y Clotting screen
 y Blood grouping and cross matching
 y Blood culture and sensitivity
 y Urine culture and sensitivity

— Abortion —Chapter 14:  Gynaecological Disorders 
365 y Endo-cervical swab for culture and sensitivity
 y Blood urea and electrolytes
 y Chest and abdominal X-ray (to exclude foreign body, gas under the 
diaphragm suggesting uterine perforation)
 y Abdomino-pelvic ultrasonography (for intra-abdominal and pelvic 
abscesses, presence of products in uterus, fluids and gas in the pelvis)
Treatment 
Treatment objectives
 y To resuscitate patient
 y To treat infection
 y To evacuate uterus 
 y To provide post-abortion counselling 
Non-pharmacological treatment
 y Evacuate the retained products of conception (careful evacuation of 
the uterus must be done as risk of uterine perforation is high)
 y Gentle digital curettage followed by the instrumental curettage 
under general anaesthesia within 6 hours of initiation of antibiotic 
therapy 
 y Examine to confirm if uterus is perforated and determine if surgery 
is required
 y Psychological support and family planning counselling
Pharmacological treatment 
A.  Resuscitation for shock 
Evidence Rating: [A]
 y IV fluids and blood transfusion as necessary
B.     Treatment of Sepsis 
 y Amoxicillin  + Clavulanic Acid , IV, 1.2 g 8 hourly for 24-72 hours 
And 
 y Gentamicin , IV, 80 mg 8 hourly for 5 days 
And
 y Metronidazole , IV, 500 mg 8 hourly for 24-72 hours
Note 14-1
Culture and sensitivity test results will direct further antibiotic therapy.
IV antibiotic therapy should be continued until the patient is afebrile for at least 
24 hours. Oral therapy should be continued for at least seven days. If Gentami -
cin is to be continued give 80 mg IM or IV 8 hourly for at least 5 days.
C�     Evacuate uterus
Note 14-2
To abort foetus if still in utero and/or if surgical evacuation of products is not 
immediately possible.

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
366 y Oxytocin , IV infusion 
(See section on ‘Inevitable Abortion ’)
Or
 y Misoprostol , sublingual oral or vaginal, 600 microgram stat. 
(See section on ‘Incomplete Abortion ’ above)
D�     Severe Pain management
Evidence Rating: [C]
 y Morphine , IV, 2.5-5 mg 4 hourly as required 
And
 y Metoclopramide , IV, 5-10 mg 8 hourly as required for vomiting
Or
 y Pethidine , IM, 50-100 mg 4-6 hourly (Maximum 400 mg in 24 hours)
And
 y Promethazine , IV/IM, 25 mg 8-12 hourly as required (max. 25 mg 
6 hourly) to reduce the chances of vomiting  and to potentiate the 
analgesic effect of Pethidine
E.      Tetanus  Prophylaxis  
 y Tetanol , IM, 0.5 ml stat.  
And
 y Human Immune Tetanus  Globulin , IM, 250-500 units stat.
MISSED ABORTION 
This refers to foetal death in-utero before 28 weeks gestation.
Symptoms
 y There is reversal of the symptoms of pregnancy
 y There may be recurrent bloody vaginal discharge
 y Absent maternal perception of foetal movements (if quickening has 
already occurred) 
Signs
 y Uterus is smaller than gestational age / dates
 y Foetal heart tones are not heard either with the Pinards stethoscope 
or with a foetal Doppler device such as Sonicaid 
Investigations
 y FBC and sickling test
 y Blood grouping and cross matching
 y Blood film for malaria parasites if necessary  
 y Blood clotting profile for the larger pregnancies
 y Pregnancy test 
 y Ultrasound scan 
 y Fasting blood sugar 

— Abortion —Chapter 14:  Gynaecological Disorders 
367Treatment 
Treatment objectives
 y To make patient fit for uterine evacuation
 y To ensure safe uterine evacuation
 y To establish cause of foetal death if possible 
Non-pharmacological treatment
 y Evacuation of the uterus by suction curettage (manual or with 
machine); < 12 weeks gestation 
 y Surgical evacuation of uterus (D&E) after cervical ripening with 
medication; second trimester
Pharmacological treatment 
A.     Ripening of cervix to facilitate surgical evacuation 
Evidence Rating: [A]
 y Misoprostol , oral or vaginal, 400 micrograms stat. at least 3 hours 
prior to surgical evacuation 
B.  Emptying uterus with Medication in Missed Abortion   
(See section on Misoprostol  treatment under ‘Induced Abortion ’ 
below)
Or 
Evidence Rating: [B]
 y Oxytocin  drip may be used for induction where other cervical ripen -
ing methods (e.g. Foleys catheter balloon) are used.  
Note 14-3
Oxytocin  should not be used concurrently together with Misoprostol  for uterine 
sizes geater than 20 weeks. A 4 to 6 hour time interval must be given between 
use of the two drugs. If both must be used this must be done with extreme 
caution as risk for uterine rupture is great.
INDUCED (SAFE) ABORTION
This refers to the deliberate termination of pregnancy. Termination 
of pregnancy is requested for and done for reasons permissible by law 
either through a surgical procedure or by pharmacological means. Under 
the current provisions for Ghana, an induced abortion may be carried out 
legally only under the following conditions: in case of rape, defilement or 
incest; threat to the physical and mental health of the mother; presence 
of foetal abnormality and mental retardation of the mother. 
Patients given a pharmacological option for abortion will need to be 
monitored closely for completeness of the abortion process. They should 
be informed to report back immediately in cases of profuse or heavy 
vaginal bleeding, fever or offensive vaginal discharge.
Investigations
 y FBC
 y Blood group and Rhesus  factor

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
368 y Special Investigations for medico-legal indications e.g. rape (DNA, 
HIV status etc.) 
Treatment 
Treatment objectives
 y To ensure that legal requirements for termination are met
 y To ensure safe abortion
 y To provide family planning counselling and services as needed 
 y To prevent risk of Rhesus  incompatibility in future pregnancies
Non-pharmacological treatment
 y Manual Vacuum Aspiration (4-12 week gestation)
 y Dilatation and curettage (4-12 week gestation)
 y Cervical ripening followed by Dilatation and Evacuation (D&E) 
 y (> 12 weeks gestation)
Pharmacological treatment 
A.     Medication Abortion
Evidence Rating: [A]
 y Mifepristone
Then 
 y Misoprostol  
(See Table below for dosage regimes for the various gestational ages.)
Table 14-1:   Dosage regimes for Mifepristone and Misoprostol for various 
gestational ages
Gestational 
agesMifepristone  and Misoprostol  
(Evidence Rating A)Misoprostol  Only 
(Evidence Rating A)
4-8 weeks Mifepristone  200 mg stat. PLUS 
followed 24-48 hours later by
Misoprostol , 800 micrograms (oral, 
vaginally) stat followed if needed by 
2 repeat doses of 800 micrograms 
vaginally or sublingually every 3-12 
hourly (max. 3 doses)Misoprostol  only: 800 
microgram stat. vaginally 
followed by 2 repeat doses of 
800 microgram vaginally or 
sublingually if needed every 
3-12 hourly (max. 3 doses)
9-12 weeks Mifepristone 200 mg orally, PLUS 36 
-48 hours later:  
Misoprostol  800 microgram vaginally, 
follow with up to 2 additional doses 
of Misoprostol 400 microgram 
sublingually or vaginally at 3 -12 hour 
intervals (max. 3 doses)Misoprostol  800 microgram 
vaginally stat., 
Followed by 2 repeat doses 
of 800 microgram every 3-12 
hours if needed (max. 3 doses)

— Abortion —Chapter 14:  Gynaecological Disorders 
369Gestational 
agesMifepristone  and Misoprostol  
(Evidence Rating A)Misoprostol  Only 
(Evidence Rating A)
13-24* weeks Mifepristone 200 mg orally, PLUS 
36-48 hours later
Misoprostol  800 microgram 
vaginally, Follow by repeated dose 
of Misoprostol 400 microgram every 
3-4 hourly vaginally (or sublingually 
if there is significant bleeding from 
earlier vaginal misoprostol adminis -
tration) until expulsion. 
(max. 5 doses)Misoprostol  800 microgram 
vaginally followed by 400 
microgram vaginally (or 
sublingually if there is 
significant bleeding) at 3-6 
hourly intervals. 
Repeat dosing until expulsion 
(max. 5 doses)
24 -28*
weeksMifepristone 200 mg orally, PLUS 
36-48 hours later
Misoprostol  100- 200 microgram 
vaginally or orally every 4 hours
Repeat dosing until expulsion (max. 5 
doses. Decrease dose of misoprostol 
with increasing gestational age. Misoprostol  100-200 
microgram vaginally or orally 
every 4 hours
Repeat dosing until expulsion 
(max. 5 doses.
Decrease dose of misoprostol 
with increasing gestational 
age. 
Note 14-4
 yUterine sensitivity to Misoprostol  increases with gestational age. Lower dos -
es of misoprostol are therefore used for older gestations
 y*Medication Abortions in second trimester should only be done by doctors 
Referral Criteria 
For all types of abortion, refer early for specialist care if the uterus is 
suspected or found to be perforated or if complications e.g. infection or 
profuse bleeding are severe.
Table 14-2:   Misoprostol Uses and Dosage in Management of Pregnancy 
Complications
Indication Dosage Notes
Induced abortion 
(0-8 weeks)Misoprostol  800 microgram 
vaginally or orally or 
sublingually 3-12 hourly 
(max. 3 dosesIdeally used 24-48 hours after 
Mifepristone, oral, 200 mg. 
Induced abortion 
(9-12 weeks)Misoprostol  800 microgram 
vaginally followed by 
Misoprostol 400 microgram 
vaginally or sublingually 
every 3 hours hourly (max. 
3 dosesIdeally used 24-48 hours after 
Mifepristone, oral, 200 mg

— Abortion —
Standard  Treatment Guidelines, 7th Edition, 2017
370Missed abortion 
(0-12 weeks)Misoprostol  800 microgram 
vaginally if needed repeat 
dose in 24 to 72 hours 
OR
Misoprostol  600 microgram 
sublingually followed by two 
additional doses if needed 
3 hourlyGive 2 doses and leave to work 
for 1-2 days (unless heavy 
bleeding or infection)
Incomplete abortion 
(0-12 weeks)600 microgram orally stat Leave to work for 2 days (unless 
heavy bleeding or infection).
Induced abortion 
(13-24 weeks)400 microgram vaginally 3-4 
hourly (max. 5 doses)Ideally used 48 hours after 
Mifepristone, oral, 200 mg. 
A lower Misoprostol  dose of 
<200 microgram may be used 
with caution in women with 
caesarean scar only under 
specialist supervision
Intrauterine foetal 
death (<28 weeks)13-17 weeks: Misoprostol  
200 microgram 6 hourly
18-28 weeks: Misoprostol  
100 microgram 6 hourly Misoprostol  should be used 
with caution in women with 
caesarean scar and only under  
specialist supervision 
Intrauterine foetal 
death (>28 weeks)28-42 weeks: Misoprostol  
25-50 microgram 4 hourly Do not administer to women 
with previous caesarean section 
or other uterine scar
Induction of labour
(live fetus > 28 
weeks) 25 microgram vaginally 4 
hourly Or 
50 microgram orally 4 hourly 
Or 
20 microgram oral solution 
2 hourlyDo not use if previous 
caesarean section. 
PPH treatment 600 microgram orally or 
sublingually stat.Use as second line drug if 
oxytocin is not available or is 
ineffective. 
Cervical 
ripening prior to 
instrumentation400 microgram vaginally 3 
hours before procedureUse for insertion of intrauterine 
device, surgical termination 
of pregnancy, dilatation and 
curettage, hysteroscopy
stat = single dose taken immediately, PPH  = postpartum haemorrhage
Note: Misoprostol  is associated with an increase in shivering, diarrhoea, and temperature high -
er than 38°C.

— Abnormal Vaginal Bleeding —Chapter 14:  Gynaecological Disorders 
371128� Abnormal Vaginal Bleeding
This refers to bleeding which deviates from the normal menstrual 
pattern (in terms of the amount, duration or interval). Abnormal menstrual 
patterns and bleeding are common in young adolescents and women 
within the ages of 45-50 years. No cause may be found on investigation in 
these age groups as it is mostly due to immaturity or ageing of the ovaries 
and its pituitary controls. 
Bleeding  may be mild or severe and life threatening.
In other age groups, the causes are multiple and may be associated 
with the identifiable disorders. Postmenopausal bleeding is said to occur 
when a woman who has stopped having menstruation for 6-12 or more 
months begins to bleed per vagina. Occasionally bleeding from the rectum 
and urethra may be confused with genital tract bleeding. 
Treatment is directed at the cause found.
Causes 
Pre-pubertal girls
 y Urethral mucosal prolapse
 y Coital lacerations due to rape and defilement
 y Trauma 
Young Adolescents
 y Dysfunctional uterine bleeding
 y Complications of pregnancy
 y Coital lacerations due to rape and defilement 
 y Accidental traumatic lesions of vulva and vagina
Women of Child Bearing Age
 y Complications of pregnancy, including ectopic pregnancy, abortion 
and choriocarcinoma
 y Coital lacerations
 y Use of hormonal methods of contraception or intrauterine 
contraceptive device (IUCD )
 y Cervical cancer
 y Fibroids
 y Dysfunctional bleeding
Peri-menopausal Women
 y Dysfunctional uterine bleeding 
 y All other causes listed for women of childbearing age also apply
Post-menopausal Women
 y Pelvic cancers such as cervical cancer, endometrial cancer, vaginal or 
vulva cancer and ovarian tumours
 y Withdrawal from oestrogen therapy
 y Atrophic vaginitis
 y Endometritis
 y Coital tears
 y Urethral caruncle

— Abnormal Vaginal Bleeding —
Standard  Treatment Guidelines, 7th Edition, 2017
372Symptoms
 y Vaginal bleeding which deviates from normal menstrual pattern 
 y May be associated lower abdominal pain or dysmenorrhoea
 y Symptoms of anaemia (dizziness, palpitations, easy fatigue etc.)
Signs
 y Signs of anaemia (if heavy bleeding)
 y Other signs related to cause
Investigations
 y FBC 
 y Sickling test
 y Blood clotting screen e.g. Prothrombin time , INR
 y Pelvic ultrasound scan (to rule out pelvic lesions)
 y Urinalysis
 y Diagnostic Dilatation and Curettage (DD & C) for women of child 
bearing age and postmenopausal women
Treatment 
Treatment objectives
 y To resuscitate patient where necessary
 y To find the cause of bleeding
 y To treat and stop the bleeding 
Non-pharmacological treatment
 y Vaginal coital tear - suturing in theatre
 y Inevitable or incomplete abortion - uterine evacuation
 y Surgery (myomectomy, hysterectomy, oophorectomy etc.)
 y Radiation therapy for cancers
Pharmacological treatment 
A. Dysfunctional uterine bleeding – mild bleeding
1st Line Treatment
Evidence Rating: [B]
 y Norethisterone  acetate , oral, 5 mg 8 hourly for 10-12 days (to stop 
bleeding)
Then 
5 mg 12 hourly (days 19 to 26 of cycle to prevent bleeding) 
2nd Line Treatment
Evidence Rating: [B]  
 y Mefenamic Acid , oral, 500 mg 8 hourly on days 1 to 5 of cycle
(Especially if associated with dysmenorrhoea)
B�     Life threatening bleeding
1st Line Treatment 
Evidence Rating: [A]
 y IV fluids and blood transfusion as required 

— Abnormal Vaginal Discharge —Chapter 14:  Gynaecological Disorders 
373And
Evidence Rating: [A]
 y Tranexamic Acid , oral or IV, 1 g 6-8 hourly for 4-7 days
2nd Line Treatment
Evidence Rating: [B]
 y Mefenamic Acid , slow IV injection, 500 mg 8 hourly (days 1 to 5 of 
cycle)
C�     For recurrent or protracted abnormal bleeding 
1st Line Treatment 
Evidence Rating [A]
Low dose oral contraceptive pill daily for 3-6 cycles or longer
 y Ethinylestradiol + levonorgestrel
Or
 y Ethinylestradiol + norethisterone
2nd Line Treatment 
Evidence Rating: [C]
 y Conjugated oestrogen , oral, 1.25-2.5 mg daily for 10-12 days
And
Evidence Rating: [A]
 y Norethisterone , oral, 5-10 mg 8 hourly for 21 days (days 5-25) 
Or
Evidence Rating: [B]
 y Medroxyprogesterone acetate , oral, 5-10 mg daily for 5-10 days 
(days 19 to 26 of cycle)
Referral Criteria 
Refer all women with heavy menstrual bleeding and/or abnormal 
vaginal bleeding not responding to therapy to a gynaecologist for 
comprehensive assessment and management.
129� Abnormal Vaginal Discharge
While a vaginal discharge is a notable clinical feature of a Sexually 
Transmitted Infection (STI ), not all forms of vaginal discharge are abnormal 
or indicative of an STI. Vaginal discharge may be associated with normal 
physiological changes such as the menstrual cycle or pregnancy. Increased 
discharge may also occur with the presence or use of foreign substances 
such as the Intra Uterine Contraceptive Device (IUCD ). 
Careful history taking should reveal whether a vaginal discharge 
is abnormal and if it is associated with use of chemical substances e.g. 
topical self-medication, repeated douching with abrasive substances or 
indeed due to STI . Changes in the characteristics of a woman’s vaginal 
discharge either in colour, odour, amount and presence of additional 

— Abnormal Vaginal Discharge —
Standard  Treatment Guidelines, 7th Edition, 2017
374symptoms and signs such as soreness and itchiness indicate a need for 
medical attention.
 Abnormal vaginal discharge due to STIs may result in serious pelvic 
inflammation with sequelae such as ectopic pregnancy and infertility.  
Careful risk assessment is therefore required (see note below) of women 
presenting with a vaginal discharge in order to identify the possible causes 
and provide appropriate treatment regimens based on the most likely 
aetiology of the vaginal discharge. Factors that must also be considered 
when selecting treatment for patients include pregnancy status and 
patient discomfort. 
Additionally, the syndromic approach must be used to assess the 
patient, identify risk factors and treat the likely cause of infection. 
Causes 
 y STI-related 
 y Neisseria gonorrhoea
 yChlamydia	trachomatis
 yTrichomonas	 vaginalis  (green or yellow, smelly, bubbly or frothy 
discharge associated with itching)
 y Herpes simplex virus  (following extensive first episode of infec -
tion) 
 y Non STI -related 
 y Candidiasis  (white, lumpy or thick discharge associated with 
itching)
 y Bacterial vaginosis (grey or white, fishy smelling discharge, es -
pecially after sexual intercourse)
 yGardnerella	vaginalis  
 y Foreign bodies 
 y Herbal preparations
Symptoms
 y Abnormal vaginal discharge - change in colour, odour, consistency 
or amount 
 y Vulval itching
 y Vulval swelling
 y Pain on urination
 y Lower abdominal or back pain
Signs
 y Abnormal vaginal discharge
 y Vulval swelling
 y Vulval erythema
 y Lower abdominal tenderness
 y Cervical excitation tenderness
 y Cervical mucopus or erosions (on speculum examination)
Investigations
 y High vaginal swab for microscopy, culture and sensitivity (if available)

— Abnormal Vaginal Discharge —Chapter 14:  Gynaecological Disorders 
375Treatment 
Treatment objectives
 y To identify and treat non-STI  vaginitis 
 y To assess STI  risk and treat STI-related infections appropriately
 y To prevent complications and sequelae
 y To treat both partners simultaneously as much as possible
Non-pharmacological treatment
 y Promote good peri-anal and genital hygiene 
 y Encourage use of loose cotton underwear 
 y Dry underwear out in the sun
 y Keep underwear dry
 y Avoid douching with herbal or chemical preparations 
 y Avoid use of medicated soaps
Pharmacological treatment 
Box 14-1:   Risk assessment
Parameters used in the risk assessment for cervicitis are: 
i.   Patient’s partner is symptomatic (i.e. partner has a urethral discharge)                                
ii.  Patient is less than 21 years old   
iii. Patient is single  
iv. Patient has more than one sexual partner 
v.  Patient has had a new sexual partner in the last 3 months 
The risk assessment is said to be positive and treatment for cervicitis is recom -
mended if 
The answer to (i) is yes or 
The answer to any 2 of items (ii) - (v) is yes. 
If a woman has a vaginal discharge with no positive risk factor, treat for vaginitis 
alone.  
If she has a vaginal discharge, and a positive risk factor, treat for both vaginitis 
and cervicitis.
A. Treatment for Vaginitis  due to trichomoniasis  and bacterial 
vaginosis  
Evidence Rating: [B]
 y Metronidazole , oral, 400 mg 8 hourly for 5 days (contraindicated 
during the 1st trimester of pregnancy)
Or 
 y Metronidazole , oral, 2 g stat. (contraindicated during the 1st trimes -
ter of pregnancy)
Or
 y Secnidazole , oral, 2 g stat. (contraindicated during the 1st trimester 
of pregnancy)
B. Treatment for Vaginitis  due to trichomoniasis  and bacterial 
vaginosis  for pregnant women in the 1st trimester
 y Clindamycin  cream, 2%, vaginal, One applicator full at bedtime for 
7 days  

— Abnormal Vaginal Discharge —
Standard  Treatment Guidelines, 7th Edition, 2017
376C. Treatment for Vaginitis  due to Candidiasis  
 y Fluconazole , oral,
Uncomplicated: 150 mg stat. as a single dose
Complicated: 150 mg 72 hourly for 3 doses
Recurrent: 150 mg daily for 10 to 14 days followed by 150 mg once 
weekly for 6 months
Or
 y Clotrimazole , vaginal tablets, 200 mg inserted into vagina at night 
for 3 days 
Or 
 y Miconazole  vaginal tablets, 200 mg inserted into vagina at night for 
3 days  
And
 y Clotrimazole  cream, vaginal, 1% or 2%, Apply twice daily for 3 to 7 
days (for vulval irritation) 
D.     Treatment for Cervicitis  due to gonorrhoea
1st Line Treatment 
Evidence Rating: [B]
 y Cefixime , oral, 400 mg stat.
And
 y Azithromycin , oral, 1 g stat.
         2nd Line Treatment 
Evidence Rating: [B]
 y Ceftriaxone , IM, 250 mg stat. 
And
 y Azithromycin , oral, 1 g stat.
E.     Treatment for Cervicitis  due to Chlamydia
1st Line Treatment
Evidence Rating: [A] 
 y Doxycycline , oral, 100 mg 12 hourly for 7 days (avoid in pregnant and 
nursing mothers)
Or 
 y Erythromycin , oral, 500 mg 6 hourly for 7 days
Or
 y Azithromycin , oral, 1 g stat. (recommended in pregnancy)
Referral Criteria 
Refer all cases of recurrent vaginal discharge and/or treatment 
failures to a health facility where speculum examination can be carried 
out and microbiological culture and antimicrobial sensitivity tests can be 
done on the vaginal discharge.

— Abnormal Vaginal Discharge —Chapter 14:  Gynaecological Disorders 
377Flowchart
Fig 14-2:  Flowchart: Abnormal Vaginal Discharge (Without Speculum)

— Abnormal Vaginal Discharge —
Standard  Treatment Guidelines, 7th Edition, 2017
378Flowchart
Fig 14-3:  Flowchart: Vaginal Discharge with Speculum And Bimanual 
Examination

— Acute Lower Abdominal Pain —Chapter 14:  Gynaecological Disorders 
379130� Acute Lower Abdominal Pain
Acute lower abdominal pain in a woman may have several causes. 
These include Pelvic Inflammatory Disease (PID ), ruptured ectopic 
pregnancy and septic abortion. The latter two are surgical emergencies, 
which require extreme urgency in their management (See sections on 
‘Ectopic Pregnancy’ and ‘Abortions’). 
PID is caused by organisms which may be Sexually Transmitted 
Infection (STI )-related or other bacteria that ascend from the lower 
genital tract and produce inflammation of the uterus, fallopian tubes and 
other structures in the pelvis. However, after excluding ectopic pregnancy, 
STI-related organisms are the most likely cause of lower abdominal pain in 
a sexually active woman who has not recently delivered a baby, or has no 
past or recent history of uterine instrumentation.
The presence of intrauterine contraceptive devices (IUCD ) favours 
the development of PID  particularly in the month following insertion.
Causes 
 y Ectopic pregnancy
 y Appendicitis 
 y Ovarian torsion
 y STI-related 
 y Non STI -related (e.g urinary tract infection)
 y Septic abortion
 y Post partum sepsis
 y Foreign body including IUCD
Symptoms
 y Fever  
 y Lower abdominal pain 
 y Pain with sexual intercourse (dyspareunia) 
 y Offensive vaginal discharge 
 y Dysuria or urethral discomfort
Signs
 y Abnormal vaginal discharge
 y Tenderness on moving the cervix (cervical excitation) on bimanual 
vaginal examination
 y Lower abdominal tenderness
 y Adnexal tenderness
 y Adnexal masses
Investigations
 y Pelvic ultrasound
 y Pregnancy test (if sexually active and amenorrhoea present)
 y High vaginal swab culture and sensitivity

— Acute Lower Abdominal Pain —
Standard  Treatment Guidelines, 7th Edition, 2017
380Treatment 
Treatment objectives
 y To identify and manage potential life threatening causes e.g. ectopic
 y To treat any underlying bacterial infection
 y To relieve pain and inflammation
Non-pharmacological treatment
 y Surgery where indicated
 y Remove IUD, if present, 3 days after initiation of drug therapy
Pharmacological treatment 
A.     For Pelvic inflammatory Disease  (mild cases)  
1st Line Treatment
Evidence Rating: [B]
 y Ciprofloxacin , oral, 500 mg 12 hourly for 3 days
And
 y Doxycycline , oral, 100 mg 12 hourly for 14 days
And 
 y Metronidazole , oral, 400 mg 12 hourly for 14 days 
Box 14-4: 
Consider hospitalization or referral in the following cases:
 yWhere surgical emergencies e.g. ectopic, appendicitis cannot be excluded.
 yThe patient is pregnant (PID  is uncommon in pregnancy, especially after 
the first trimester).
 yThe patient does not respond clinically to oral antimicrobial therapy.
 yThe patient is unable to follow or tolerate an outpatient oral regimen.
 yThe patient has severe illness, associated with nausea and vomiting , or high 
fever.
 yThe patient has a tubo-ovarian abscess.
 yHIV infection
 yYouth/adolescents (particularly if compliance is an issue)
B.     For Pelvic inflammatory Disease  (severe cases) 
 y Ceftriaxone , IM, 250 mg daily for 3 days 
And
 y Doxycycline , oral, 100 mg 12 hourly for 3 days 
And
 y Metronidazole , IV, 500 mg 8 hourly for 3 days 
Then
 y Doxycycline , oral, 100 mg 12 hourly for 14 days 
And 
 y Metronidazole , oral, 400 mg 12 hourly for 14 days 
Note 14-5
The use of ciprofloxacin and doxycycline is contraindicated in pregnant and lac -
tating women.

— Acute Lower Abdominal Pain —Chapter 14:  Gynaecological Disorders 
381C�     Pain relief
 y Diclofenac , rectal, oral, IM, 50-100 mg 8 to 12 hourly (max. 100 mg 
twice daily)
Or
 y Mefenamic Acid , oral, 500 mg 8 hourly 
Referral Criteria 
Refer to a gynaecologist or general surgeon if there is no improvement 
or if a pelvic abscess is suspected.
Flowchart
Fig 14-5:  Flowchart: Acute Lower Abdominal Pain

— Female Infertility —
Standard  Treatment Guidelines, 7th Edition, 2017
382131� Female Infertility
Primary infertility  is said to occur when a couple has never achieved 
a pregnancy despite at least one year of uninterrupted and adequate 
unprotected sexual intercourse. Secondary infertility implies that there 
has been a previous pregnancy. It is often necessary to evaluate both 
partners simultaneously and to elicit sexual, menstrual and obstetric 
history, a past history of Pelvic Inflammatory Disease (PID ) and Sexually 
Transmitted Infections (STIs), contraception use and other significant past 
medical history.
Causes 
Female factors
 y Ovulation failure
 y Polycystic ovarian syndrome (PCOS)
 y Hyperprolactinaemia
 y Pelvic factors
 y Congenital malformations of uterus etc.
 y Tubal disease
 y Pelvic adhesions
 y Uterine fibroids
 y Endometriosis
 y Cervical factors 
Male factors
 y Oligospermia
 y Azoospermia
 y Penile and testicular abnormalities 
 y Erectile dysfunction  
Symptoms
 y Inability to achieve pregnancy despite regular unprotected sex at 
least 2-3 times weekly
 y Amenorrhoea  (females)
 y Impotence  (males)
Signs
Female
 y Absence of secondary sexual characteristics 
 y Virilisation changes (hirsutism, clitoromegaly, deepening of voice 
etc.) 
 y Galactorrhoea
 y Abdominal masses due to uterine or ovarian enlargement
 y Abnormal vaginal discharge indicative of infection
Male
 y Abnormal penile discharge indicative of infection
 y Absence of secondary sexual characteristics 
 y Testicular abnormalities e.g. varicocoeles, small or absent testes

— Female Infertility —Chapter 14:  Gynaecological Disorders 
383Investigations
 y FBC, Sickling
 y High vaginal swab
 y Blood glucose
 y Hystero-Salpingogram (best done under fluoroscopic guidance).
 y Semen analysis 
 y Serum progesterone level in mid-luteal phase (day 21-23 of menstrual 
cycle) to check for ovulation
 y Thyroid function tests 
 y Further hormonal studies e.g. Serum LH, FSH, Serum Testosterone, 
Prolactin to be done by specialist
Treatment 
Treatment objectives
 y To treat the underlying cause of the infertility if possible
 y To achieve pregnancy within the shortest possible time
Non-pharmacological treatment
 y Counselling
 y Uterine, Tubal and Testicular surgery where needed
 y Assisted Reproduction Technologies e.g. Artificial insemination, In-
vitro-fertilization with embryo transfer where indicated
Pharmacological treatment 
A. Failure of ovulation 
1st Line Treatment
Evidence Rating: [A]  
 y Clomifene citrate , oral, 50 mg daily for 5 days, starting between the 
2nd and 5th day of the menstrual cycle.
B. Hyperprolactinaemia
1st Line Treatment
Evidence Rating: [A]
 y Bromocriptine , oral, 1.25 mg nocte for 7 days (with the evening meal 
or at bedtime). Increase weekly to a max. of 2.5 mg 8 hourly 
Referral Criteria 
Early referral of all patients with infertility to a specialist is preferred, 
particularly women with uterine, ovarian or tubal disease requiring 
surgery or who require ovulation induction not responsive to clomifene 
citrate. Also refer male partners for review by a urologist.

— Menopause —
Standard  Treatment Guidelines, 7th Edition, 2017
384132� Menopause
Menopause  refers to the point in time when permanent cessation 
of menstruation occurs due to loss of ovarian function. The cessation 
of menses is preceded by a peri-menopausal phase during which there 
may be menstrual irregularity. The age at onset is usually between 45 
and 55 years. A woman is considered to be menopausal if there has not 
been menstruation for a period of at least 12 months in the absence 
of pregnancy. Menopause may be associated with physical, emotional, 
and psychological upheaval of varying intensity in some women. Sixty 
percent of menopausal women however have mild symptoms or are 
asymptomatic. The risk of osteoporosis and cardiovascular disease 
increase after the menopause.
Causes 
 y A natural life event due to the ageing of the individual
 y Surgical removal of the ovaries (bilateral oophorectomy)
 y Pelvic irradiation
 y Premature ovarian failure 
 y Pituitary damage from primary post-partum haemorrhage (Sheehan’s 
syndrome)
 y Cytotoxic (anticancer) therapy
Symptoms
 y Hot flushes (heat or burning in the face, neck and chest with resultant 
sweating) 
 y The flushes may be associated with 
 y Palpitations 
 y Faintness
 y Dizziness
 y Fatigue
 y Weakness
 y Emotional and psychological problems include:
 y Mood changes
 y Depression
 y Anxiety
 y Nervousness
 y Irritability
 y Loss of libido
 y Vaginal dryness and dyspareunia
 y Symptoms due to atrophic changes in the genital tract: 
 y Increased frequency of micturition and dysuria.
 y Stress incontinence (urinary incontinence with coughing or 
straining)
Signs
 y Usually none 

— Menopause —Chapter 14:  Gynaecological Disorders 
385Investigations
 y Serum LH, FSH, Oestradiol
 y Routine investigations e.g. FBC, blood glucose, lipid profile
 y Urine or blood pregnancy tests (to exclude pregnancy)
Treatment 
Treatment objectives
 y To control bothersome symptoms e.g. severe hot flushes, atrophic 
vaginitis and recurrent cystitis
 y To prevent cardiovascular morbidity
 y To prevent osteoporosis especially in individuals with premature 
menopause
Non-pharmacological treatment
 y Counselling and reassurance
 y Encourage active lifestyles, healthy diet, exercise and regular physical 
checkups for common medical problems
Pharmacological treatment 
A.     Hormone Replacement Therapy (HRT ) for women with intact 
uterus 
1st Line Treatment 
Evidence Rating: [A]
 y Combined conjugated oestrogens and progestogen,  oral,
(28 tablets each containing conjugated oestrogens-625 micrograms 
including 12 tablets containing norgestrel-150 micrograms)
One tablet daily
Or 
 y Conjugated oestrogen  and norgestrel tablet, oral, 
(625 microgram and 150 microgram)
1 tablet daily on days 17-28 of each 28-day treatment cycle; 
B.     Hormone Replacement Therapy (HRT ) for women with previous 
hysterectomy 
Evidence Rating: [A]
 y Conjugated oestrogens , oral, 625 microgram daily 
C. For relief of vaginal symptoms only
Evidence Rating: [A]
 y Oestrogen cream , vaginal, apply topically once daily 
Note 14-6
Women with intact uterus should never be given oestrogens alone.  
Current evidence suggests that hormone replacement therapy in the meno -
pause does not prevent coronary heart disease or strokes.
HRT increases the risk of venous thrombo-embolic phenomena, breast cancer 
and endometrial cancer after prolonged use and should therefore be given for 
the shortest possible time whenever indicated

— Carcinoma of the Cervix  —
Standard  Treatment Guidelines, 7th Edition, 2017
386Referral Criteria 
Refer cases with osteoporosis or severe unremitting symptoms to 
the specialist.
133� Carcinoma of the Cervix  
Carcinoma of the cervix  is the commonest form of female genital 
cancer seen in Ghana. While the disease is preventable, in Ghana, the 
absence of an effective screening system has resulted in most cases 
presenting late with advanced disease. In developed countries, the 
incidence of cervical cancer has fallen considerably due to regular 
screening procedures (e.g. Pap smear , visual inspection with acetic acid, 
Human Papilloma Virus  [HPV ] test). 
Vaccination against cancer-causing HPV  infection is the ideal method 
for primary prevention of cervical cancer. Treatment of cervical cancer 
requires the services of a gynaecological oncologist and radiotherapist. 
Treatment includes surgery and/or radiation and/or chemotherapy. 
Surgery involves removal of the central tumour as well as the lymphatics 
draining the area (Wertheim’s hysterectomy ).  This extensive surgery 
should be carried out only by trained specialists. Radiation treatment 
often involves localized pelvic irradiation.
Causes 
 y Human papilloma virus  (accounts for 80% of cases)
 y Associated risk factors include:
 y Sexual promiscuity
 y Multiple child births
 y Infections with Herpes Simplex Hominis type II, HIV
 y Smoking
 y Low socio-economic status
 y Family history
Symptoms
 y Asymptomatic (diagnosed on routine cervical screening)
 y Symptomatic  (advanced disease)
 y Abnormal vaginal bleeding 
 y In between regular menstrual periods
 y After sexual intercourse
 y Post menopausal bleeding
 y Abnormal vaginal discharge
 y Lower abdominal pain 
 y Pain during sexual intercourse
 y Weight loss
 y Urinary symptoms e.g. dysuria, frequency, incontinence
 y Rectal pain

— Carcinoma of the Cervix  —Chapter 14:  Gynaecological Disorders 
387Signs
 y Early disease:  Erosion of cervix or changes of chronic cervicitis
 y Late/advanced disease: Ulcerative or fungating cervical lesion on 
speculum examination
Investigations
 y Cervical biopsy
 y FBC and sickling status
 y Blood urea and electrolytes
 y Serum Creatinine
 y Serum uric acid
 y Chest X-ray
 y Ultrasound of Kidneys
 y CT Scan and or Magnetic Resonance Imaging (to detect aortic nodes 
and metastases to the lungs and liver)
 y Pelvic examination under anaesthesia
 y Cystoscopy and proctoscopy with or without biopsy to allow 
visualisation of vesical or rectal mucosa
Treatment 
Treatment objectives
 y To treat central tumour 
 y To treat areas of tumour spread with the aim of eradicating the 
disease
Non-pharmacological treatment
 y Surgery
 y Radiotherapy 
 y A combination of surgery, and radiotherapy 
Pharmacological treatment 
Evidence Rating: [A]
 y Adjuvant chemotherapy  (See section on referral below)
Referral Criteria 
All patients must be referred to a specialist for evaluation to decide 
on stage of disease and best mode of treatment. Treatment of carcinoma 
of the cervix is best done in hospital under specialist team care. 

14Chapter
388Disorders of the Kidney and 
Genitourinary System
134. Acute Glomerulonephritis
This is a disease characterised by damage to the glomerular filtration 
apparatus, which causes protein and blood to leak into the urine. 
Mechanisms for the glomerular damage may be immune-mediated. This 
condition may be associated with hypertension and fluid retention.
Causes 
 y Post streptococcal infections (pharyngeal or skin infections)
 y Infected scabies
 y Other bacterial Infections e.g. salmonella 
 y Hepatitis  B virus, Hepatitis C virus, HIV
 y Parasitic e.g. Schistosoma, Malaria
 y Systemic lupus erythematosus  and other vasculitides
Symptoms
 y A history of preceding infection
 y Generalized oedema most marked around the eyes
 y Breathlessness
 y Anorexia  (sometimes associated with vomiting  and abdominal pain)
 y Fever
 y Seizures
 y Scanty urine 
 y Haematuria
Signs
 y Oedema
 y Oliguria (urine volumes < 400 ml/day)
 y Hypertension
 y Haematuria
 y Dark coloured urine
 y Acute heart failure
 y Coma  
Investigations
 y Urinalysis

— Acute Glomerulonephritis —Chapter 14:  Disorders of the Kidney and Genitourinary System
389 y Sediment shows erythrocytes, leukocytes and a variety of casts 
including erythrocyte casts
 y Proteinuria usually less than 2 g/24 hours but may be in the nephrotic 
range
 y FBC
 y BUE and Creatinine
 y Throat cultures (in children may be useful)
 y Chest X-ray (may show pulmonary oedema)
 y ECG
 y Immunology (e.g. ANA , AntiDsDNA)
 y ASO (antistreptolysin O) titres
 y Ultrasound of kidneys
Treatment 
Treatment objectives
 y To identify and stop the cause of renal injury
 y To prevent and control complications
Non-pharmacological treatment
 y Bed rest
 y Salt restriction in diet
 y Control fluid balance:
Adults
Control fluid retention by restricting daily fluid intake to 800 ml plus 
previous day’s urine output. 
Children
Restrict fluids to 400 ml/m2 of body surface area and previous day’s 
urine output.
Pharmacological treatment 
A.  For fluid retention in Post-infectious Glomerulonephritis 
Evidence Rating: [B]
 y Furosemide , oral or IV, 
Adult
40 mg daily, increasing to 80 mg daily
Children
1 month-12 years; 1-2 mg/kg/day initially. Increase by 1-2 mg/kg 8 
hourly to a max. of 6 mg/kg per day, not to exceed 80 mg per day.
Neonate s
0.5-1 mg/kg 8 to 24 hourly; max. 2 mg/kg.
B.  For hypertension in Post-infectious Glomerulonephritis
 y Treat blood pressure (See section on ‘Hypertension ’) 
Referral Criteria 
Refer all patients with complications of renal failure, severe cardiac 
failure and hypertensive encephalopathy  that arise following post 
infectious glomerulonephritis to a physician specialist or a nephrologist. 

— Nephrotic Syndrome —
Standard  Treatment Guidelines, 7th Edition, 2017
390Patients with other causes such as lupus nephritis or systemic 
vasculitis, should also be referred to a physician specialist or a nephrologist.
135� Nephrotic Syndrome
This condition is associated with proteinuria in excess of 3-3.5 g/1.73 
m2 daily accompanied by hypoalbuminaemia , oedema, hyperlipidaemia 
and hypercoagulable state. Diuretics should be used with caution and not 
given as a routine in children with nephrotic syndrome.
Causes 
 y Primary Glomerular Disease
 y Minimal change disease  - common in children 
 y Focal and segmental glomerulosclerosis
 y Membranous nephropathy
 y Membranous proliferative glomerulonephritis
 y Infections
 y Bacterial (Post streptococcal infection)
 y Viral-Hepatitis  B and C, HIV  
 y Parasitic ( Plasmodium malariae , Schistosoma mansoni , Filaria -
sis)
 y Systemic Diseases
 y Diabetes mellitus
 y Systemic Lupus Erythematosus
 y Amyloidosis
 y Drug-related
 y Non steroidal anti-inflammatory drugs
Symptoms
 y Early morning facial puffiness
 y Generalized body swelling
 y Foamy appearance of urine
 y Weight gain (unintentional)
 y Poor appetite
Signs
 y Periorbital, peripheral, genital oedema
 y Ascites
 y Pleural effusion
 y Protein malnutrition particularly in children with long standing 
disease
Investigations
 y Urinalysis
 y BUE and creatinine
 y Serum albumin
 y Serum lipids
 y Fasting blood glucose

— Nephrotic Syndrome —Chapter 14:  Disorders of the Kidney and Genitourinary System
391 y Serology - Hepatitis  B, C, HIV
 y Hb electrophoresis
 y Antinuclear antibody (ANA )
 y Ultrasound of kidneys 
Treatment 
Treatment objectives
 y To relieve symptoms
 y To treat underlying condition
 y To prevent and manage complications
 y To delay progressive kidney damage
Non-pharmacological treatment
 y Restrict salt intake
 y Adequate protein diet; 0.6-0.8 g/kg body weight of 1st class protein 
(eggs, meat, fish, dairy products) per day for adult and 2-4 g/kg per 
day for children
Pharmacological treatment 
A.     For control of oedema 
1st Line Treatment
Evidence Rating: [C]
 y Furosemide , IV,
Adult
40-80 mg 8-12 hourly (max. 160 mg daily)
Children
Refer to specialist.
Note 14-1
In children, furosemide is used in conjunction with albumin infusion only in ser -
vere oedema. 
Or 
 y Furosemide , oral,
Adult
40 mg daily, increasing to 80 mg daily; max. 240 mg daily
Children
Refer to specialist.
B�     For control of resistant oedema 
 y Furosemide , IV or oral. (as above for adults and children) 
And
 y Metolazone , oral, 
Adult s
 2.5-10 mg once daily
Children  
Refer to specialist.

— Acute Kidney Injury —
Standard  Treatment Guidelines, 7th Edition, 2017
392Note 14-2
Diuretics should be used with caution and not given as a routine in nephrotic 
syndrome in children.
C�     For control of proteinuria 
 y Lisinopril , oral,
Adult
5-20 mg daily  
And
 y Prednisolone, oral,
Adult s 
1 mg/kg daily 
Children
60 mg/m2 or 2 mg/kg daily (max. 80 mg). For long-term manage -
ment, refer to a paediatrician.
Note 14-3  
Corticosteroids should be given to children and selected adults with minimal 
change nephrotic syndrome by specialists only.
Referral Criteria 
Refer all patients to a physician specialist, paediatrician or 
nephrologist immediately after diagnosis and stabilisation.
136� Acute Kidney Injury
Acute Kidney Injury  (AKI ) is a term that has now replaced the term 
Acute Renal Failure (ARF). It describes a sudden decrease in renal function 
occurring over a period of hours to days resulting in accumulation of 
nitrogenous waste products and disruption of blood volume, electrolyte 
and acid-base balance. 
The differential diagnosis of AKI  includes prerenal azotaemia, renal 
(intrinsic) and post renal (obstructive nephropathy) forms of AKI. The 
most important risk factor for the development of AKI is the presence 
of pre-existing chronic kidney disease. Other than good medical care 
with avoidance of volume contraction, prevention of hypotension 
and avoidance of nephrotoxic agents, no specific interventions have 
been reliably demonstrated to prevent the development of AKI. During 
management, a strict fluid input and output chart should be maintained.
AKI has been staged by the Kidney Disease: Improving Global 
Outcomes (KDIGO ), AKI working group for severity according to the 
criteria below: 
KDIGO  AKI DEFINITION
Injury, based on the AKIN Criteria

— Acute Kidney Injury —Chapter 14:  Disorders of the Kidney and Genitourinary System
393Stage Serum creatinine criteria Urine output criteria
1 1.5-1.9 times baseline or increase of > 
26.4 micromol< 0.5 ml/kg/hour for 6-12 hours
2 2.0-2.9 times baseline < 0.5 ml/kg/hour for 
> 12 hours
3 3.0 times baseline or increase in serum 
creatinine to > 353.6 micromol/L Or 
initiation of dialysis< 0.3 ml/kg/hour for > 24 hours  
Or anuria for > 12 hours
Causes 
Obstetric 
 y Septic abortion
 y Post-caesarean section
 y Severe pre-eclampsia/Eclampsia
 y Postpartum Haemorrhage (PPH )
 y HELLP (Haemolysis  Elevated Liver Enzymes Low Platelet) Syndrome  
Gynaecological
 y Bilateral ligation of ureters following abdominal hysterectomy
Medical 
 y Acute Glomerulonephritis
 y Haemolysis  due to:
 y Malaria
 y Infection
 y Herbal medicines
 y Typhoid fever
 y G6PD  deficiency
 y Diarrhoea , vomiting  and dehydration
Surgical 
 y Haemorrhage
 y Peritonitis
 y Acute Pancreatitis
 y Obstructive uropathy
 y Burns
Symptoms
 y Nausea  and vomiting
 y Oliguria
 y Anuria
 y Oedema
 y Decreased appetite
 y Metallic taste in mouth
 y Hiccups
 y Change in mood
 y Flank pain 
 y Fatigue

— Acute Kidney Injury —
Standard  Treatment Guidelines, 7th Edition, 2017
394 y Diarrhoea
Signs
 y Usually no specific signs
Investigations
 y Urinalysis
 y FBC
 y BUE and creatinine 
 y Serum uric acid
 y Blood culture
 y Urine culture
 y Abdomino-pelvic ultrasound scan  
 y Plain X-ray of abdomen
Treatment 
Treatment objectives
 y To recognise and correct reversible causes 
 y To prevent further renal injury
 y To maintain a normal electrolyte and fluid volume milieu
 y To remove toxic waste from the body (dialysis)
Non-pharmacological treatment
 y Nutrition: Give protein of high biological value at 40 g protein/day in 
adults. In children 0.8-1 g/kg of 1st class protein/day
 y Daily weighing
 y Maintain fluid balance
 y Beware of hyperkalaemia - avoid potassium containing foods e.g. 
bananas, coconut
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
A.     Treatment of hypovolaemia
 y Sodium Chloride , 0.9%, IV,
Or
 y Ringers lactate  (if there is no hyperkalaemia) in cases of diarrhoea 
and vomiting
Or
 y Blood transfusion  (in severe bleeding)
Or
 y Plasma replacement  (in cases of severe burns).
Note 14-4  
In children, give 10-20 ml/kg fluid boluses. 
B.     To re-establish diuresis after adequate fluid replacement
 y Furosemide , IV, 

— Acute Kidney Injury —Chapter 14:  Disorders of the Kidney and Genitourinary System
395Adult
40-80 mg stat.  
Children
2-4 mg/kg stat.  Do not repeat.
C�      Control of hyperkalaemia
Adult
 y Calcium  gluconate  10%, IV, 10-20 ml, slow IV, over 2-5 minutes  
And
 y Soluble Insulin , IV, 10 units in 50-100 ml Dextrose  50%  
And
 y Sodium bicarbonate , IV, 8.4% (50 mEq in 50ml) 1-2 ml/kg over 5 min -
utes 
Note 14-5
Do not mix calcium gluconate and bicarbonate in the same delivery system.
Children
 y Salbutamol, nebulised, (preferred)
> 25 kg; 5 mg
< 25 kg; 2.5 mg
Or 
 y Calcium  gluconate  10%, IV, 0.5-1 ml/kg, slow IV, over 5-10 minutes  
And
 y Soluble Insulin , IV, 0.2 units in 5 ml Dextrose  20%, give 2.5-5 ml/kg/
hour. Keep blood glucose at 10-15 mmol/L.  
And
 y Sodium bicarbonate , IV, 8.4% (50 mEq in 50ml) 1-2 ml/kg over 5 min -
utes 
Note 14-6
Do not mix calcium gluconate and bicarbonate in the same delivery system.
D�     Treatment of hypertension crises/encephalopathy  
(See section on ‘Hypertension ’)
Note 14-7
Indications for dialysis
 yCongestive heart failure
 yPulmonary Oedema
 yElectrolyte abnormalities especially hyperkalaemia not controlled by con -
servative means
 yMetabolic acidosis 
 yUraemic symptoms (seizures, pericarditis)
 yHypertensive Crises/Encephalopathy

— Chronic Kidney Disease  —
Standard  Treatment Guidelines, 7th Edition, 2017
396Referral Criteria 
All patients with clinical indications for dialysis must be referred 
promptly to a centre with facilities for dialysis. 
137� Chronic Kidney Disease  
Chronic Kidney Disease  (CKD ) refers to kidney damage of more 
than 3 months duration. The early stage of CKD is usually asymptomatic 
but can be detected through laboratory tests of serum creatinine and 
estimation of Glomerular Filtration Rate (eGFR) , measurement of urine 
albumin creatinine ratio and screening of individuals at increased risk 
such as those with hypertension, diabetes mellitus or a past history of 
glomerulonephritis.
CKD may manifest either as urine abnormalities (e.g. persistent 
microalbuminuria, proteinuria, haematuria), blood abnormalities (e.g. 
elevated urea and creatinine and estimated GFR < 90 ml/minute/1.73 m2) 
and structural kidney changes on ultrasonography.  
For all stages of CKD , patients should be encouraged to cease 
smoking, reduce weight if obese, check lipids and treat, and avoid NSAIDs  
and other nephrotoxic drugs.
Table 14-1:   Stages of Chronic Kidney Disease
Stage Description eGFR 
(ml/min/1.73 m2)
1 Kidney damage with normal or increased GFR > 90
2 Kidney damage with mild reduction in GFR 60-89
3 Moderate reduction in GFR 30-59
4 Severe reduction in GFR 15-29
5 Kidney failure < 15
Causes 
 y Chronic hypertension
 y Chronic glomerulonephritis
 y Diabetes mellitus
 y Obstructive uropathy
 y Renal calculi
 y Polycystic kidney disease
 y Toxins (drugs, herbs, heavy metals, etc.)
 y Connective tissue disease
Symptoms
 y None in the early stages
 y Reduced attention and concentration
 y Anorexia , nausea, vomiting

— Chronic Kidney Disease  —Chapter 14:  Disorders of the Kidney and Genitourinary System
397 y Gastrointestinal bleeding
 y Hiccups
 y Breathlessness on exertion
 y Thirst
 y Nocturia, polyuria
 y Muscle Cramps
 y Paraesthesia
 y Pruritus
 y Insomnia
Signs
 y Lethargy
 y Bleeding  tendency
 y Pallor
 y Hypertension
 y Pericarditis
 y Peripheral neuropathy
 y Peripheral oedema
 y Asterixis  (flapping tremor)
 y Increased skin pigmentation and/or excoriation 
Investigations
 y FBC, Sickling, Blood film comment
 y Urinalysis
 y Blood Urea, Electrolytes, Serum Creatinine
 y Calcium , Phosphate
 y Fasting blood glucose
 y Lipids
 y Chest X-ray
 y Ultrasound of kidneys 
Treatment 
Treatment objectives
 y To detect chronic kidney disease early in susceptible individuals
 y To control hypertension 
 y To control blood glucose
 y To manage underlying causes
 y To prevent complications and further worsening of kidney function
Non-pharmacological treatment
 y Avoid nephrotoxins e.g. NSAIDs , herbal medication
 y Daily intake of fluid of 600 ml over previous day’s urine output for 
adults (400 ml/m2 body surface area in children)  
 y Restrict salt intake
 y Restrict dietary protein to 1 gram/kg/day
 y Avoid potassium containing foods e.g. bananas
 y Dialysis (refer to a nephrologist)

— Chronic Kidney Disease  —
Standard  Treatment Guidelines, 7th Edition, 2017
398Pharmacological treatment 
A.     To control fluid overload
1st Line Treatment
Evidence Rating: [C]
 y Furosemide , oral or IV, 40-120 mg daily
B�     Treatment of hypertension 
(See section on ‘Hypertension ’)
C�     Treatment of renal anaemia 
(See section on ‘Anaemia  in Chronic Kidney Disease ’)
D�     Control of hyperkalaemia 
Adult
 y Calcium  gluconate  10%, IV, 10-20 ml, slow IV, over 2-5 minutes  
And
 y Soluble Insulin , IV, 10 units in 50-100 ml Dextrose  50%  
And
 y Sodium bicarbonate , IV, 8.4% (50 mEq in 50ml) 1-2 ml/kg over 5 min -
utes 
Note 14-8
Do not mix calcium gluconate and bicarbonate in the same delivery system.
Children
 y Salbutamol, nebulised, (preferred)
> 25 kg; 5 mg
< 25 kg; 2.5 mg
Or 
 y Calcium  gluconate  10%, IV, 0.5-1 ml/kg, slow IV, over 5-10 minutes  
And
 y Soluble Insulin , IV, 0.2 units in 5 ml Dextrose  20%, give 2.5-5 ml/kg/
hour. Keep blood glucose at 10-15 mmol/L.  
And
 y Sodium bicarbonate , IV, 8.4% (45 mEq) over 5 minutes, 1-2 mmol/
kg (1-2 ml/kg) 
Note 14-9
Do not mix calcium gluconate and bicarbonate in the same delivery system.
Referral Criteria 
Refer all patients with predisposing factors and complications to a 
physician specialist or nephrologist for further definitive management 
of chronic kidney disease. Refer all patients requiring dialysis to a 
nephrologist.

—  Anaemia in Chronic Kidney Disease —Chapter 14:  Disorders of the Kidney and Genitourinary System
399Table 14-2:   Summary of management of various stages of CKD
CKD STAGE DESCRIPTION ACTION 
1 Kidney damage with 
normal or reduced GFRDiagnosis and treatment: Slow progression 
by meticulous BP control, Annual follow 
up, eGFR, Urinalysis and Urine Protein 
creatinine ratio measurements
2 Kidney damage with 
mildly decreased GFREstimate progression and manage as 
stage 1
3 Moderately decreased 
GFREstimate and treat complications: If Hb <11 
g/dL check Ferritin , B12 and folate. Annual 
check of serum calcium, phosphate and 
PTH. Refer if eGFR ≤30 ml/min/1.73 m2
4 Severely decreased GFR Prepare for kidney replacement therapy: 
Refer
5 Kidney Failure Kidney replacement therapy: Dialysis or 
transplantation: Refer
138�  Anaemia  in Chronic Kidney Disease
Anaemia  develops early in the course of Chronic Kidney Disease  
(CKD ) and is nearly universal in patients with CKD stage 5 (End-stage 
kidney disease). The prevalence of anaemia at higher levels of glomerular 
filtration rate (GFR)  (i.e. CKD stage 1-2) is relatively low in individuals from 
the general population. Anaemia of CKD is primarily caused by deficiency 
of erythropoietin. The kidneys are the major source of erythropoietin 
and, as renal function declines, production of erythropoietin declines 
proportionately. 
Though erythropoietin deficiency is common among patients with 
anaemia in CKD, other potential causes and contributing disorders should 
be identified or excluded if initial evaluation yields evidence for disorders 
other than iron deficiency or erythropoietin deficiency. Correction of 
anaemia in CKD patients improves survival and quality of life. 
Causes 
 y Deficiency of erythropoietin 
 y Red cell destruction from microvascular disease from diabetes or 
hypertension
 y Increased gastrointestinal bleeding  
 y Increased oxidative stress leading to shortened red cell survival
Symptoms
(See section on ‘Anaemia ’)

—  Anaemia in Chronic Kidney Disease —
Standard  Treatment Guidelines, 7th Edition, 2017
400Signs
(See section on ‘Anaemia ’)
Investigations
 y FBC 
 y Reticulocyte count
 y Transferrin saturation
 y Serum ferritin 
 y Stool occult blood 
Treatment 
Treatment objectives
 y To achieve and maintain a target-range Hb level of 11-12 g/dL
Non-pharmacological treatment
(See section on ‘Anaemia ’)
Pharmacological treatment 
A. CKD  Stages 1-2
1st Line Treatment
Evidence Rating: [A]
 y Ferrous sulphate , oral, 325 mg 8 hourly for 4 weeks
B.     CKD  Stages 3-4
Iron replacement: Target Hb should be 11-12 g/dL
 y Ferrous sulphate , oral, 325 mg 8 hourly 
Or
 y Ferrous gluconate , oral, 300 mg 8-12 hourly. Evaluate after 4-6 weeks 
Or 
 y Iron sucrose , IV, consult specialist
Or  
 y Ferric sodium gluconate complex , consult specialist
And
 y Epoietin beta , SC, consult specialist
Or
 y Methoxy polyethylene glycol epoietin beta  (pegylated form of Epo), 
SC, consult specialist
Or
 y Darbepoietin alfa , SC, consult specialist
Referral Criteria 
Refer all (adults and children) patients with CKD  and anaemia to a 
specialist or nephrologist.

— Urinary Tract Infection —Chapter 14:  Disorders of the Kidney and Genitourinary System
401139� Urinary Tract Infection
Urinary tract infection  (UTI ) is the presence of micro-organisms in the 
urine or tissues of the normally sterile genitourinary tract. Infection may 
be localized to the bladder alone or the kidneys or, in men the prostate. 
Acute uncomplicated UTI occurs in women with a normal 
genitourinary tract and usually manifests as acute cystitis  (bladder 
infection or lower tract infection). Complicated UTI occurs in individuals 
with structural or functional abnormalities of the genitourinary tract, 
including those with indwelling devices such as urethral catheters.
Congenital abnormalities of the genito-urinary tract predispose 
children to UTI .  Proven UTI in a child or recurrent UTI requires further 
urogenital evaluation.
Definitive treatment of UTI  depends on culture and sensitivity 
reports. However, empirical treatment may be initiated while awaiting 
the report.
Causes 
 y Bacteraemia or septicaemia
 y Urinary tract obstruction e.g. enlarged prostate in adult males, 
posterior urethral valves in infants/children
Symptoms
 y Frequent painful urination
 y Haematuria  
 y Cloudy/foul smelling urine
 y Vomiting
 y Suprapubic pain
 y Fever  - may be persistent and unexplained (in children)
 y There may be feeding problems, diarrhoea, and failure to thrive as 
well (in children)
Note 14-10
UTI symptoms can be non-specific in young children.
Signs
 y Fever
 y Loin tenderness
 y Suprapubic tenderness
 y Foul smelling urine
Investigations
 y FBC
 y Mid-stream specimen of urine for microscopy, culture and sensitivity 
(re-culture urine after treatment)
 y Abdominal ultrasound scan in children if indicated

— Urinary Tract Infection —
Standard  Treatment Guidelines, 7th Edition, 2017
402Treatment 
Treatment objectives
 y To relieve symptoms such as fever and pain (See section on ‘Fever’ 
and ‘Pain Management’)
 y To eradicate causative agent
 y To prevent complications
 y To identify patients with abnormalities of the genito-urinary tract
Non-pharmacological treatment
 y Liberal oral fluids to encourage good urinary output
 y Personal hygiene and proper cleaning after defaecation
Pharmacological treatment 
A. Treatment of Uncomplicated UTI
1st Line Treatment
Evidence Rating: [C]
 y Ciprofloxacin , oral,
Adult s 
500 mg 12 hourly for 7 days (female); 10-14 days (male)
Children
15-20 mg/kg 12 hourly; (max. of 750 mg daily in two divided doses)
Or
 y Cefuroxime , oral,
Adult s
250-500 mg 12 hourly for 5-7 days (female); 10-14 days (male)
Children
12-18 years; 250 mg 12 hourly for 5-7 days
2-12 years; 15 mg/ kg 12 hourly (max. 250 mg) for 5-7 days
3 months-2 years; 10 mg/kg 12 hourly (max. 125 mg) for 5-7 days
B.     Treatment of Complicated UTI  (including catheter-related, stones, 
prostate enlargement, urologic abnormalities and pregnancy)
1st Line Treatment
Evidence Rating: [C]
 y Ciprofloxacin , IV,
Adult s
400 mg 8-12 hourly for 7 days (to be administered over 60 minutes)
Or
 y Gentamicin , IV, (if kidney function is normal)
Adult s
40-80 mg 8 hourly for 7 days
Children  
12-18 years;    2 mg/kg 8 hourly for 7 days
1 month-12 years;  2.5 mg/kg 8 hourly for 7 days
Or 
 y Ceftriaxone , IV,
Adult s
1-2 g daily for 7 days

— Medicines and the Kidney —Chapter 14:  Disorders of the Kidney and Genitourinary System
403Children
All ages 25 mg/kg 12 hourly (max. 75 mg/kg daily)
Or
 y Amoxicillin + Clavulanic Acid , IV, 
Children
1 month-18 years; 20-30 mg/kg 8 hourly (max. 500 mg) for 5-7 
days 
Neonate s (dose doubled in severe infection)
7-28 days;    30 mg/kg 8 hourly for 5-7days
< 7 days;     30 mg/kg 12 hourly for 5-7days
And
 y Gentamicin , IV, (slow intravenous injection over at least 3 minutes)
Children
12-18 years;   2 mg/kg 8 hourly
1 month-12 years; 2.5 mg/kg 8 hourly
Or 
 y Cefuroxime , IV, 
Children
1 month-18 years;  20 mg/kg 8 hourly max. 750 mg, (increase 
to 40-50 mg/kg max. 1.5g 6-8 hourly in severe infections)
Neonate s (double the dose in severe infections, IV route only)
21-28 days;   25 mg/kg 6 hourly 
7-12 days;   25 mg/kg 8 hourly 
< 7 days;   25 mg/kg 12 hourly 
Referral Criteria 
Refer patients who are very ill, with recurrent UTI , persistent 
haematuria and congenital abnormalities to the appropriate specialist. 
140. Medicines and the Kidney
Medicines can lead to renal damage in a number of different ways 
and examples are given below. In the wrong circumstances life-saving 
medicines can do more harm than good. Doctors, pharmacists and nurses 
can help their patients by checking their treatment charts in hospital or at 
the outpatients department. The medicines listed below may cause renal 
impairment and must therefore be stopped or not prescribed in patients 
with deteriorating renal function. All medicines in this table should be 
dosed based on kidney function (estimated GFR). Avoid concomitant use 
of nephrotoxic medications and diuretics. Monitor renal function before 
and during treatment. Patient-related risk factors for all these medicines 
include age, pre-existing chronic kidney disease, volume depletion, and 
concurrent use of nephrotoxic medicines. 

— Medicines and the Kidney —
Standard  Treatment Guidelines, 7th Edition, 2017
404Medication Risk Factor Pathophysiology Prevention
Aciclovir High dose, IV 
bolus doseDeposition of Aciclovir  
crystal
-intratubular obstruction 
and foci of interstitial 
inflammation 
–crystal nephropathy 
proximal tubulopathyAvoid bolus dose, 
Prior hydration  
(maintain urine 
output > 75 ml/hour
Slow drug infusion 
over 1-2 hours
Aminoglycosides
(e.g. 
gentamicin)Dose, duration 
and frequency of 
administration. 
Concurrent renal 
ischaemia or 
administration 
of nephrotoxins. 
Liver disease 
plasma 
concentration 
>10mg/dl peak  In proximal tubule 
aminoglycoside bound 
to anionic phospholipid, 
delivered to megalin, 
endocytic uptake into 
the cell. Within cell, 
accumulates –direct 
toxicity- AKIMaintain therapeutic 
range. Give once 
daily dose if 
necessary
Angiotensin 
Converting 
Enzyme 
inhibitors/
Angiote-nsin 
Receptor 
blockers
(e.g. Lisinopril /
Losartan )Vasoconstriction 
– pre-renal ARFAvoid in bilateral renal 
artery stenosis
Non Steroidal 
Anti-inflam -
matory drugs 
(NSAIDs ) e.g. 
IbuprofenVolume 
and sodium 
depletion. 
Diuretic use. 
Large dose and 
long therapy. 
Severe liver 
diseaseHaemodynamically 
induced AKI  due to 
vasoconstriction via 
reduced prostaglandin 
production
Acute and chronic 
tubulointertitial 
nephritis, with or 
without nephrotic 
syndrome.
Direct toxicity- chronic 
interstitial nephritis and 
papillary necrosisAvoid coprescription 
of diuretics
Avoid large dose
Radiocontrast Dose and 
frequency 
Osmolarity of 
contrast mediaHigh osmolarity, 
medullary vasoconstric -
tion , active transport 
in thick ascending loop 
of Henle – increased 
oxygen demandHydration before and 
after administration 
Acetylcysteine  
unproven

— Medicines and the Kidney —Chapter 14:  Disorders of the Kidney and Genitourinary System
405Medication Risk Factor Pathophysiology Prevention
Methotrexate Acidic urine 
High dosePrecipitates in the urine 
and induces tubular 
injuryPrior hydration
Alkaline urine to 
pH>7.0 (3L of 5% 
Dextrose  in water 
+ 44-66 mmol of 
NaHCO3 per day
Cisplatin Low chloride, 
high doseChloride in cis- position 
replaced by H2O
- highly reactive hydroxyl 
radical via CYP450 
–DNA injury tubular cell 
death
Nephrogenic diabetes 
insipidus, Hypomag -
nesaemia (may be 
persistent)Mesna
Cyclosporin  /
TacrolimusDose 
Age
Postoperative 
AKI
Diabetes
HypertensionDecreased PG, and 
increased 20-HETE acid 
production
 – vasoconstriction 
generation of H2O2 
resulting in depleted 
glutathione 
– decreased GFR, 
ischaemic collapse 
or scarring of the 
glomeruli, vacuolization 
of the tubules, and focal 
areas of  tubular atrophy 
and interstitial fibrosisMaintain in 
therapeutic range
Avoid drugs that 
raise (CYP 3A4 
inhibitors)
Calcium  channel 
blockers
Interferon Pre-renal AKI  
Tubulointerstitial 
nephritis
Thrombotic 
microangiopathy
Membranoproliferative 
glomerulonephritis
Tenofovir Dose , Duration Tubular cell 
karyomegaly, 
degeneration and 
necrosis 
– interstitial nephritis, 
AKI, Fanconi syndrome

— Acute Cystitis  —
Standard  Treatment Guidelines, 7th Edition, 2017
406Medication Risk Factor Pathophysiology Prevention
Lithium Renal 
impairment
Dehydration
Hyponatremia
Diuretic use 
especially 
thiazideImpairment of collecting 
duct concentrating 
ability
 – diabetes insipidus
Chronic tubulointersti -
tial nephropathyTherapeutic range 
(0.6-1.2 mmol/L)
Prevent dehydration  
Avoid low-sodium 
diet
Avoid thiazide
AKI – Acute Kidney Injury
ACE – Angiotensin converting enzyme 
HETE – Hydroxyeisosatetraenoic acid
PG – Prostaglandin
141. Acute Cystitis  
 Acute cystitis  is an acute inflammation of the bladder. Women are 
affected 10 times more than men due to the shortness of their urethra 
compared to that of men. 40%-50% of all women will develop cystitis  in 
their lifetime. 
The ascending faecal-perineal-urethral route is the primary mode of 
infection. Occasionally sexually transmitted organisms are involved. Risk 
factors include urethral catheterization and diabetes.
Causes 
 y E. coli  (about 80%)
 yStaphylococcus	saprophyticus
 y Klebsiella
 y Proteus mirabilis
 y Gonococcus
 y Enterococci  
Symptoms
 y Low grade fever
 y Frequency 
 y Nocturia
 y Urgency 
 y Dysuria
 y Haematuria
 y Cloudy and foul smelling urine
 y Low back and suprapubic pain
Signs
 y Low grade fever
 y Suprapubic tenderness
 y Haematuria  
Investigations
 y Urinalysis

— Acute Cystitis  —Chapter 14:  Disorders of the Kidney and Genitourinary System
407 y Mid-stream urine for culture and sensitivity
 y FBC
 y FBS 
 y Imaging of urinary tract in recurrent or persistent cases to exclude 
anatomical abnormalities, lower urinary tract obstruction etc. 
 y Urethrocystoscopy in selected cases 
Treatment objectives
 y To eradicate infection
 y To prevent recurrence and complications 
 y To relieve pain 
Non-pharmacological treatment
 y Liberal oral fluids to encourage good urinary output
 y Pre-coital and post-coital emptying of the bladder
 y Personal hygiene and proper cleaning after defaecation especially in 
females
Pharmacological treatment 
A.     Acute uncomplicated cystitis  (absence of fever and flank pain)
1st Line Treatment
Evidence Rating: [A]
 y Nitrofurantoin , oral,
Adult s
100 mg 6 hourly for 5-7 days
Children  
12-18 years;   50 mg 6 hourly for 7 days
3 months-12 years;  750 micrograms/kg 6 hourly for 7 days
2nd Line Treatment
Evidence Rating: [A]
 y Ciprofloxacin , oral,
Adult s 
500 mg 12 hourly for 5-7 days
Children  
12-18 years;   250-750 mg 12 hourly 
1 month-12 years;  7.5 mg /kg 12 hourly (dose doubled in se -
vere cases) 
Neonate s
7.5 mg/kg 12 hourly
Or  
 y Cefuroxime , oral, 
Adult s
500 mg 12 hourly for 5-7days
Children  
12-18 years;   250 mg 12 hourly (dose reduced to 125 mg 
12 hourly in lower urinary tract infections)
2-12 years;   15 mg/kg 12 hourly (max. 250 mg 12 hour -

— Benign Prostatic Hyperplasia   —
Standard  Treatment Guidelines, 7th Edition, 2017
408ly)
3 months-2 years;  10 mg/kg 12 hourly (max. 125 mg 12 hour -
ly)
And
Evidence Rating: [C]
 y Mist Potassium citrate , oral,
10 ml 8 hourly if urine is acidic (pH of 6 or below). To reduce bladder 
pain and dysuria. 
Note 14-11
Monitor potassium levels and avoid in hyperkalaemia. Do not give with cipro -
floxacin.
Or
 y Paracetamol , oral, 500 mg-1g 6-8 hourly when required
B.      For symptomatic cystitis  and UTI  in pregnancy
 y Cefuroxime , oral, 
Adult s
500 mg 12 hourly for 5-7days
And
Evidence Rating: [C]
 y Mist Potassium citrate , oral,
10 ml 8 hourly if urine is acidic (pH of 6 or below). To reduce bladder 
pain and dysuria. 
Note 14-12
Monitor potassium levels and avoid in hyperkalaemia. Do not give with cipro -
floxacin.
Referral Criteria 
Refer all cases, which require cystoscopy and all cases of persistent 
haematuria, recurrent cystitis  or bacterial resistance to the specialist.
142. Benign Prostatic Hyperplasia   
Benign Prostatic Hyperplasia  (BPH ) refers to non-cancerous 
enlargement of the prostate gland which results in obstruction of urine 
flow from the bladder. BPH is the commonest cause of male urinary 
symptoms in Ghana. The average age at which lower urinary tract 
symptoms (LUTS ) related to BPH occurs is about 50 years. Men may seek 
treatment for LUTS either because the symptoms are bothersome or they 
feel that it may lead to acute urinary retention or out of fear that it may 
be an indication of prostate cancer.
It is important to establish what the patient wants from the 
consultation. In some patients, once reassured that the likelihood of 
urinary retention and prostate cancer is low, they may not wish treatment 

— Benign Prostatic Hyperplasia   —Chapter 14:  Disorders of the Kidney and Genitourinary System
409for the symptoms. 
Currently available medicines can either relax prostatic smooth 
muscles or cause reduction in the prostate size and therefore ease the 
symptoms of BPH . A combination of available medications, especially in 
patients with a prostate size more than 40 ml, produce better responses 
than monotherapy. 
BPH may lead to complications such as recurrent urinary tract 
infection, acute urine retention with painful distension of the bladder, 
chronic urine retention with painless gross distension of the bladder, 
haematuria, and renal failure.
Causes 
 y Increase in number of prostate cells due to stimulation by 
testosterone
Symptoms
 y Lower Urinary Tract Symptoms  (previously referred to as prostatism )
 y Hesitancy - delay in initiating urination
 y Poor or weak urinary stream
 y Straining
 y Terminal dribbling
 y Sensation of incomplete bladder emptying
 y Urinary incontinence (overflow) or bedwetting
 y Frequent passage of urine especially at night (Nocturia)
 y Urgency and urge incontinence
Signs
 y Enlarged prostate gland on rectal examination 
 y Tender palpable bladder (acute urinary retention)
 y Non-tender palpable bladder (chronic retention) 
 y Uraemic signs (e.g. drowsiness, confusion etc.)
 y Palpable kidneys in hydronephrosis
Investigations
 y Serum creatinine  
 y Prostate specific antigen (PSA ) - to exclude prostate cancer
 y Urine for culture and sensitivity
 y Abdominal and pelvic ultrasound – to exclude hydronephrosis if 
serum creatinine is elevated
Treatment 
Treatment objectives
 y To exclude prostate cancer and reassure patients accordingly 
 y To relieve symptoms and prevent development of complications
 y To identify and treat any associated complications 
Non-pharmacological treatment
 y Programme of monitoring and watchful waiting through regular 
check-ups for mild symptoms

— Bacterial Prostatitis —
Standard  Treatment Guidelines, 7th Edition, 2017
410 y Urethral catheterization for acute retention of urine or suprapubic 
cystostomy if urethral catheterization fails 
 y Suprapubic needle puncture and aspiration/drainage of urine to 
partially decompress the bladder and relieve pain, when suprapubic 
cystostomy is delayed.
Pharmacological treatment 
A. Patients with bothersome symptoms and prostate size less than 
40 ml (small prostate)
1st Line Treatment
Evidence Rating: [A]
 y Terazosin , oral, 2-10 mg at night, (start with 2 mg at night; double 
dose at weekly intervals) max. 10 mg.
Or
 y Tamsulosin , oral, 400 microgram once daily 
Or
 y Alfuzosin , oral, 10 mg daily 
B.     Patients with bothersome symptoms and prostate size more than 
40 ml (big prostate)
Evidence Rating: [A]
 y Finasteride , 5 mg daily
And
 y Terazosin , oral, 2-10 mg at night, (start with 2 mg at night; double 
dose at weekly intervals) max. 10 mg.
Or
 y Tamsulosin , oral, 400 microgram daily 
Or
 y Alfuzosin , oral, 10 mg daily 
Referral Criteria 
Refer patients who don’t respond to pharmacological treatment, 
or have complications (urine retention, haematuria, renal failure and 
recurrent urinary tract infection) to a Urologist or Surgical specialist.
143. Bacterial Prostatitis
Prostatitis is inflammation of the prostate gland, which may be 
bacterial or abacterial.  Bacterial prostatitis is more common than 
abacterial prostatitis. It may present as an acute condition which may 
either be sexually transmitted or result from urethral reflux of infected 
urine into the prostatic ducts. Other potential sources may be bacteria 
spread from rectum or bloodstream.
If inadequately treated this may progress to chronic prostatitis. It is 
more common in men below below 50 years.

— Bacterial Prostatitis —Chapter 14:  Disorders of the Kidney and Genitourinary System
411Causes
 y Gram-negative bacterial infections e.g. from E. coli , Pseudomonas, 
Streptococcus faecalis , Proteus, Klebsiella, Serratia and 
Enterobacteria.
 y Sexually transmitted infections e.g. from Gonococcus and Chlamydia. 
Symptoms
Acute
 y Fever
 y Chills and malaise
 y Low back and waist pain
 y Myalgia and arthralgia
 y Rectal /perineal pain
 y Urinary urgency and frequency
 y Nocturia
 y Dysuria
 y Difficulty in urination/retention of urine 
 y Haematuria
 y Haemospermia and loss of libido
Chronic
 y Insiduous onset
 y Relapsing UTI
 y Persistence of bacteria in seminal fluid despite antibiotic treatment
 y Low back and waist pain
 y Urinary urgency and frequency
 y Nocturia
 y Difficulty in urination
 y Haematuria
 y Haemospermia
Signs
Acute
 y Swollen and tender prostate on Digital Rectal Examination (DRE). 
(Avoid prostatic massage as this could lead to septicaemia).
 y The rectum feels “hot” from the inflammation. 
Chronic
 y Findings on DRE may be normal or a tender prostate occasionally 
for longstanding disease it may feel very firm or hard as in prostate 
cancer.
Investigations
 y Urinalysis and culture
 y FBC, ESR
 y PSA
 y Blood culture 
 y Expressed prostatic secretions for culture and sensitivity through 
DRE. Voided specimen before and after prostate massage compared 

— Bacterial Prostatitis —
Standard  Treatment Guidelines, 7th Edition, 2017
412(in chronic prostatitis only). 
Treatment
Treatment objectives
 y To relieve pain and fever
 y To control infection
 y To relieve lower urinary tract obstruction
 y To prevent chronic prostatitis
Non-pharmacological treatment
 y Bed rest
 y Hydration
 y Hospitalisation may be required in severe cases or when the condition 
is complicated by acute urinary retention and significant haematuria.
 y Suprapubic cystostomy for acute urinary retention. (Urethral 
catheterization should be avoided.)
Pharmacological treatment
A. Mild to Moderate infections 
1st Line Treatment 
Evidence Rating: [B]
 y Ciprofloxacin, oral, 500 mg 12 hourly for 4-6 weeks
And
 y Doxycycline, oral, 100 mg 12 hourly for 4-6 weeks
 2nd Line Treatment 
 y Levofloxacin, oral, 500 mg daily for 4-6 weeks
And
 y Doxycycline, oral, 100 mg 12 hourly for 4-6 weeks
B. Severe infections
 y Ciprofloxacin, IV, 400 mg 8-12 hourly (to be administered over 60 
minutes)
Or
 y Levofloxacin, IV, 500 mg 12 hourly 
Or
 y Ceftriaxone, IV, 1-2g Daily 
And
 y Gentamicin, IV, 80 mg 12 Hourly
Note 14-13
Initial therapy with parenteral antibiotics is indicated in severe cases. Follow up 
should be for at least 4 months
C. For improvement of urinary flow 
 y Tamsulosin, 400 micrograms daily (at night)
Or
 y Alfuzosin, 10 mg daily
Or

— Scrotal Masses —Chapter 14:  Disorders of the Kidney and Genitourinary System
413 y Terazosin, 2-5 mg daily (at night)
D. Adjunct treatment in severe presentations  
Evidence Rating: [C]
 y Sodium chloride 0.9%, IV, as required in severe systemic infections.
And
 y Ibuprofen, oral, 400 mg 8 hourly when required
Or 
 y Diclofenac, oral, 75 mg 12 hourly when required
And
 y Lactulose, oral, 10-15 ml 12 hourly and adjust dose accordingly
Referral Criteria  
Refer all cases of severe infections or chronic prostatitis for specialist 
care.
144. Scrotal Masses
These are swellings found in the scrotum.
Causes
Painless Swellings
 y Testicular tumour
 y Inguinoscrotal hernia
 y Hydrocoele
 y Hydrocoele of spermatic cord
 y Spermatocoele/epididymal cysts
 y Varicocoele
 y Epididymal tumours
 y Chronic epididymo-orchitis
Painful Swellings
 y Testicular torsion
 y Acute epididymitis (STI or non-STI related)
 y Acute epididymo-orchitis
 y Strangulated inguinoscrotal hernia
 y Testicular tumour (usually painless except rapidly growing type or 
tumour necrosis)
 y Varicocoeles are occasionally accompanied by pain/discomfort
Symptoms
 y Swelling and/or pain of scrotum or its contents
 y Sudden onset e.g. torsion of testis
 y Gradual onset e.g. spermatocoele, hydrocoeles
 y Gradual onset becoming suddenly painful e.g. obstructed hernia
 y Fever, may be present in infections e.g. Acute epididymitis and acute 
epididymo-orchitis

— The Empty Scrotum —
Standard  Treatment Guidelines, 7th Edition, 2017
414Signs
 y Tender or non-tender swelling restricted to the scrotum (except a 
hernia which may extend into the inguinal area)
 y Fever may be present in infections
 y Transillumination for cystic swellings e.g. hydrocoeles and 
spermatoceles
 y Hard swelling e.g. Tumour 
Investigations
 y Ultrasound scan with or without colour doppler
 y Laboratory investigations are tailored towards cause and specific 
treatment 
Treatment
Treatment objectives
 y To make an accurate diagnosis to ensure appropriate treatment
 y To relieve pain
 y To prevent complications
 y To expedite emergency intervention eg Testicular Torsion
Non-pharmacological treatment
 y Surgery: elective or emergency
 y Emergency surgery within 6 hours is required for testicular torsion to 
salvage the testis 
Pharmacological treatment
A. For sexually transmitted infection 
Evidence Rating: [B]
 y Ciprofloxacin, oral, 500 mg single dose
And
 y Doxycycline, oral, 100 mg 12 hourly for 10 days
Or 
 y Ceftriaxone, IM, 250 mg single dose
And
 y Doxycycline, oral, 100 mg 12 hourly for 10 days
Referral Criteria 
Refer all emergency cases and those suspected to be tumours to a 
urologist or surgical specialist.
145. The Empty Scrotum
This refers to the absence of testis(es) in the scrotum/hemiscrotum. 
Ten percent of cases are bilateral. Seventy-five percent of full term infants 
with undescended testes and 90% of premature infants would have 
spontaneous descent of testes from the intra-abdominal site by the age of 
one year. Persistent undescent of the testis is associated with an increased 

— The Empty Scrotum —Chapter 14:  Disorders of the Kidney and Genitourinary System
415risk of malignancy, subfertility, atrophy of the testis and torsion. All health 
workers who see neonates and children should do routine examination of 
the scrotum and testis to prevent late presentations and complications.
Causes
 y Undescended testes
 y Unknown/idiopathic; most cases are congenital      
 y Premature birth
 y Genetically inherited diseases
 y Associated with anomalies like Prune Belly syndrome and 
hypospadias
 y Ectopic testis
 y Retractile testis
 y Severe atrophy
 y Orchidectomy
 y Agenesis of the testes (rarely)
Symptoms
 y Absence of one or both testes 
 y In children, parents or the health worker may notice this at birth
Signs
 y Absent testis in both supine and upright positions
Investigations
 y Ultrasound scan of abdomen, pelvis and inguinal canal
Treatment
Treatment objectives
 y To decrease potential for cancer
 y To improve fertility
 y To repair hernia
 y To decrease risk of torsion
 y To avoid social and psychological complications
Non-pharmacological treatment
 y Surgical intervention before two years of age. (All ectopic testes 
should be operated because they will not descend)
Pharmacological treatment 
None
Referral Criteria 
Refer patients aged over one year with no evidence of testicular 
descent to a urologist or surgical specialist.

— Priapism  —
Standard  Treatment Guidelines, 7th Edition, 2017
416146. Priapism 
This refers to a spontaneous, prolonged, persistent, usually painful 
erection, which is unwanted and not associated with sexual desire and 
not relieved by coitus. Priapism is classified into three types namely: 
Low-flow or ischaemic (commonest), High-flow (non-ischaemic) and 
Stuttering Priapism. It is commonly seen as a prolongation of Nocturnal 
Penile Tumescence (NPT) or early morning erection. This is a well-known 
complication of sickle cell disease. 
Patients are usually shy and reluctant to come to the hospital due 
to stigmatisation. Late presentation is therefore common and herbal 
medicine applications and spiritual remedies may have been tried to 
relieve symptoms prior to being seen in hospital. Early reversal within 
24-48 hours may reduce the high impotence complication rate of 50%. 
Although the occurrence is usually in adults, it may periodically occur in 
older children.
Causes
 y Idiopathic or unknown in 60% of cases
 y Drugs e.g. marijuana and herbal concoctions
 y Other causes:
 y Leukaemia
 y Sickle cell disease and thalassaemia
 y Penile trauma
 y Spinal cord injury
 y Pelvic infections
 y Pelvic tumour
 y Iatrogenic e.g. Intracavernosal prostaglandin E1 for impotence, 
sildenafil citrate, psychotropics e.g. chlorpromazine
Symptoms
 y Painful persistent erection
Signs
 y Erect, tender penis
 y Clinical signs of sickle cell disease
Investigations
 y FBC, blood film comment
 y Sickling status - Hb electrophoresis
 y Urinalysis
Treatment
Treatment objectives
 y To relieve pain
 y To ensure early relief of penile congestion
 y To prevent complications

— Posterior Urethral Valves  —Chapter 14:  Disorders of the Kidney and Genitourinary System
417Non-pharmacological treatment 
Evidence Rating: [A]
 y Maintain adequate hydration
 y Winter’s Procedure
 y Corpora Irrigation
 y Surgery: Shunts 
Pharmacological treatment
A. Conservative management 
Evidence Rating: [C]
 y Sodium Chloride 0.9%, IV, 
Adult s
1 L 6 hourly and liberal oral fluids
Children
500 ml 6 hourly and liberal oral fluids
And
 y Pethidine, IM, 
Adult s
100 mg 8 hourly if required
Children
1 mg/kg (max. 50 mg) 8 hourly if required
And 
 y Diazepam, IV, 
Adult
10 mg stat. (given slowly over 2-3 minutes, approximately 2.5 mg 
every 30 seconds) then refer 
Children
0.3 mg/kg stat. (given slowly over 2-3 minutes) then refer
B� Specialist management 
 y Intracavernosal injections (see referral criteria) 
Referral Criteria   
Patients not responding to conservative management should be 
promptly referred to a urologist or surgical specialist.
147. Posterior Urethral Valves 
These valves or folds of tissue are congenital obstructing membranes 
within the lumen of the urethra. It affects between 1 in 5,000 – 8,000 
males. It is the commonest cause of congenital bladder outlet obstruction. 
They obstruct urinary outflow from the bladder but permit easy urethral 
catheterisation. Because the obstruction starts in-utero, secondary 
changes in the bladder and upper urinary tract are advanced at birth. 
Some patients may be born with severe renal impairment or this may 
develop soon after birth if recognition is delayed. Most patients present 
as neonates or infants. Occasionally presentation is late in childhood. All 

— Posterior Urethral Valves  —
Standard  Treatment Guidelines, 7th Edition, 2017
418male newborn babies should be closely watched to ensure good stream 
of urine. Prenatal diagnosis is possible using ultrasound.
Causes 
 y Congenital valves or folds within the lumen of the posterior urethra
Symptoms
 y Poor urinary stream
 y Crying while voiding
 y Straining to void with dribbling of urine
 y Intermittent stream
 y Failure to thrive
 y Fever
 y Poor feeding
 y Abdominal distension
Signs
 y Voiding dysfunction
 y Palpable bladder and kidneys
 y Respiratory distress
 y Signs of sepsis e.g. Fever
 y Azotaemia/uraemia
 y Poor physical growth/growth retardation
Investigations
 y FBC
 y Blood urea, electrolytes and creatinine
 y Urinalysis
 y Urine culture
 y Abdominal ultrasound
 y Micturating cysto-urethrogram
Treatment
Treatment objectives
 y To prevent and treat renal failure
 y To remove obstructing valves
Non-pharmacological treatment 
 y Prompt bladder decompression and continuous drainage to protect 
the upper tract from back pressure damage. This is preferably done by 
vesicostomy in most infants. Indwelling catheters should be avoided 
in most cases due to complications and death from septicaemia
 y Surgical removal or destruction of the valve
Pharmacological treatment
Evidence Rating: [A]
 y Treatment of urinary tract infections (See appropriate section)
Referral Criteria 
Refer immediately after diagnosis for specialist evaluation and 

— Urinary Tract Calculi —Chapter 14:  Disorders of the Kidney and Genitourinary System
419treatment.
148. Urinary Tract Calculi
These are crystal-like objects, which form in various parts of the 
urinary tract. They consist mainly of mineral salts i.e. crystal-forming 
ions. Some of the common stone-types include calcium oxalate, calcium 
phosphate, magnesium ammonium phosphate and uric acid. Some 
risk factors in developing stones include crystalluria, affluence, diet, 
occupation, climate (dehydration), family history and medications. 
Majority of stones less than 5 mm in diameter will pass spontaneously.
Causes
 y Hypercalcaemia
 y Hyperuricaemia
 y Hyperoxaluria
 y Urinary stasis and obstruction
 y Urinary tract infection: struvite (infection) stones
 y Foreign body including urinary catheter and suture material
 y Idiopathic hypercalciuria
 y Dehydration
 y Immobilisation especially in the elderly
 y Inborn errors of metabolism e.g. Cystinuria
Symptoms and signs
LOCATION OF 
CALCULISYMPTOMS SIGNS
Kidney/Ureter • Loin Pain
• Ureteric colic: sudden acute 
agonizing paroxysmal pain, 
which begins in the loin, 
then radiates around the 
flank towards the bladder 
and scrotum/testis in the 
male and labium majus 
in the female. May be 
associated with nausea, 
vomiting and sweating
• Haematuria• Signs may be few but 
tenderness in the loin and 
abdomen would be felt 
during a painful attack
• Sometimes there may 
be associated abdominal 
distension and fever if there 
is super-added infection
• A hydronephrotic kidney 
may be palpable

— Urinary Tract Calculi —
Standard  Treatment Guidelines, 7th Edition, 2017
420LOCATION OF 
CALCULISYMPTOMS SIGNS
Bladder/Urethra • Suprapubic pain
• Frequency
• Urgency
• Haematuria
• Strangury: an uncontrollable 
and often painful desire to 
pass urine, which results in 
little urine (may be blood-
stained) or no urine being 
voided
• Retention of urine• Suprapubic tenderness
• Palpable bladder (from 
retention or a large stone)
• Hard urethral lump 
(impacted stone)
• Haematuria
Investigations
 y Urinalysis
 y Urine culture
 y Blood urea, electrolytes and creatinine
 y Serum uric acid, calcium, phosphate, magnesium
 y Plain X-ray of abdomen
 y Ultrasound scan of abdomen
 y Intravenous urogram
 y Retrograde ureteropyelogram
 y CT scan
 y Stone analysis
Treatment 
Treatment objectives
 y To control pain during acute attack
 y To aid passage of the calculus or ensure complete removal of calculus
 y To remove large stones
 y To prevent recurrence if the cause is known
 y To treat associated infections
Non-pharmacological treatment
 y Encourage oral fluid intake (2-3 L daily in an adult) and avoid 
dehydration
 y Avoid low calcium diet (it encourages increased oxalate excretion)
 y Diet-therapy
 y Manage acute urinary retention due to bladder or urethral stones by 
urethral catheterisation or suprapubic cystostomy respectively
Pharmacological treatment
Evidence Rating: [B]
 y Pethidine, IM, 100 mg 4 hourly as required 
Or
 y Diclofenac, IM, 75 mg 12 hourly 
Or
 y Diclofenac, rectal, 100 mg 12 hourly

— Urethral Stricture —Chapter 14:  Disorders of the Kidney and Genitourinary System
421And
 y Hyoscine butylbromide, IV, 20 mg 8 hourly 
Or 
 y Mebeverine, oral, 135 mg 8 hourly may be useful
Caution 14-1.
Avoid morphine as it may cause further ureteric spasm and worsening of symp -
toms
 y Give antibiotics if urinary tract infection is present. (See section on 
‘Urinary Tract Infection’)
Referral Criteria 
Refer to a urologist or surgical specialist for definitive treatment after 
initial management.
149. Urethral Stricture
This refers to a narrowing or complete obstruction of the urethral 
lumen due to fibrosis (scarring). It is the second commonest cause of 
retention of urine in Ghana and the most common in young males usually 
resulting from previous inadequately treated STI. The commonest site is 
the anterior urethra i.e. bulbar and penile urethra in males. It may be 
complicated by periurethral abscess, superficial extravasation of urine 
and urethrocutaneous fistulae, retention of urine and post-renal renal 
failure.
Causes
 y Gonococcal or non-gonococcal urethritis
 y External trauma e.g. road traffic injuries, falls, straddle or astride 
injury and pelvic fractures
 y Iatrogenic: Urethral instrumentation e.g. catheterisation, endoscopy
 y Postoperative e.g. prostatectomy
 y Congenital strictures (rare)
Symptoms
 y Lower Urinary Tract Symptoms (LUTS) e.g. poor urinary stream, split 
or splayed stream, reduced caliber of stream improved by straining, 
frequency and dysuria, post-void dribbling, incomplete emptying of 
bladder
 y Urinary (overflow) incontinence
 y Urinary retention (acute or chronic)
Signs
 y There may be none in uncomplicated cases
 y Palpable induration of urethra 
 y Periurethral abscesses
 y Extravasation of urine into scrotum and superficial tissue
 y Urethrocutaneous fistulas/watering-can scrotum

— Vasectomy (Male Sterilisation)  —
Standard  Treatment Guidelines, 7th Edition, 2017
422 y Bladder may be palpable if there is retention
 y Kidney may be palpable in hydronephrosess
 y Localized induration may be felt along the urethra
 y Failure of catheterisation - this heightens the suspicion of a stricture
Investigations
 y Urinalysis
 y Urine culture and sensitivity
 y Blood urea, electrolytes and creatinine
 y Ultrasound Scan of kidneys, bladder, postvoid residual urine and 
spongiofibrosis
 y Retrograde urethrogram 
 y Antegrade urethrogram/Micturating Cysto-uretrogram (MCUG) 
provided a suprapubic catheter is in place
 y Uroflowmetry
 y Urethrocystoscopy
Treatment
Treatment objectives
 y To relieve symptoms and prevent complication
 y To treat underlying cause
Non-pharmacological treatment
 y Try catheterisation -  a gentle attempt is made to pass a urethral 
catheter, which will be held up, at the site of stricture in patients who 
present with retention of urine. Confirmation of site of obstruction is 
still needed by urethrography or urethroscopy.
 y If catherization fails and patient is in acute retention
 y Suprapubic cystostomy or suprapubic needle puncture and aspiration 
(try this procedure if facilities for suprapubic cystostomy are lacking). 
Aspirate as much urine as possible to decompress the bladder and 
relieve pain before referral
 y Definitive treatment is surgical. In most cases referral to a specialist 
centre will be necessary
Pharmacological treatment 
 y None except for Urinary Tract Infection (See appropriate section)
Referral Criteria 
Refer to specialist for further investigations prior to definitive 
treatment.
150� Vasectomy (Male Sterilisation) 
Vasectomy is a permanent male contraceptive method, which is 
a simple, short and safe surgical procedure. It is carried out by trained 
surgeons usually under local anaesthesia after careful counselling and 
informed consent. 

— Acute Epididymo-orchitis —Chapter 14:  Disorders of the Kidney and Genitourinary System
423Vasectomy is the most effective male family planning method. 
Involving males in issues of reproductive health and family planning has 
several benefits with a positive impact on society. 
Vasectomy should be encouraged for appropriate clients. It is less 
invasive and simpler than female sterilisation. Reversal of vasectomy is a 
difficult surgery using loupes/microscope with success rate of 60-80% if 
done in less than 3 years after vasectomy.
Box 14-1: 
Misconceptions
 yVasectomy is ligation of the vas deferens and NOT CASTRATION
 yVasectomy does not affect erection
 yVasectomy does not affect ejaculation and orgasm. There would be normal 
ejaculation but the semen does not contain spermatozoa 
 yVasectomy does not work immediately. A back-up method of contraception 
is necessary for up to 20 ejaculations, 3 months after the procedure or until 
examination of semen shows no sperm
 yAfter vasectomy males will still require the use of condoms to prevent sexu -
ally transmitted infections including HIV-AIDS
Box 14-2: 
Effectiveness rates of various male contraceptive methods:
Evidence Rating: [B]
 yVasectomy - 99.85%
 yMale condom - 86%
 yWithdrawal method - 81% 
Preoperative requirements
 yDetailed counselling (ideally both partners must be present) and informed 
consent
 yCounselling should mention irreversibility of procedure, possible recanaliza -
tion and risk of chronic scrotal pain postoperative.
 yMedical history
 yPhysical examination
 yLaboratory investigations e.g. Hb, sickling, urinalysis
 yHistopathology confirmation of the removed segment of vas deferens may 
be necessary for medicolegal reasons.
Referral Criteria 
Clients should be referred to a Family Planning Unit or Urologist for 
the procedure.
151� Acute Epididymo-orchitis
This is an acute inflammation of the epididymis and testis usually due 
to a bacterial infection. It may follow ascending infection from the urethra 
(including STIs), instrumentation/catheterization, untreated lower urinary 

— Acute Epididymo-orchitis —
Standard  Treatment Guidelines, 7th Edition, 2017
424tract obstruction and genito-urinary surgery. It is a known complication of 
mumps. Poorly managed acute epididymo-orchitis may be complicated 
by septicaemia, abscess formation, chronic epididymo-orchitis, secondary 
hydrocoele, infertility and Fournier’s gangrene. 
Before managing as acute epidymoorchitis make sure testicular 
torsion has been conclusively excluded.
Causes
 y Mumps virus (orchitis)
 y Escherichia coli
 y Chlamydia
 y Gonococcus
 y Staphylococcus
 y Streptococcus
 y Pseudomonas
 y Mycobacterium tuberculosis
Symptoms
 y Fever
 y Scrotal/testicular pain
 y Scrotal swelling  
 y Urethral discharge
 y Dysuria 
 y Malaise
Signs
 y Fever 
 y Tender and swollen hemiscrotum 
 y Inflamed epididymis and testis
 y Secondary hydrocoele 
 y Positive Prehn’s sign (lifting of scrotum towards pubic symphysis in 
the palm relieves pain) 
Investigations
 y Urinalysis
 y Urine culture and sensitivity - first catch of urine preferred to 
midstream urine
 y FBC and ESR 
 y Blood culture and sensitivity
 y Scrotal ultrasound/MRI
Treatment
Treatment objectives
 y To relieve symptoms
 y To eradicate the infection
 y To prevent recurrence
 y To prevent complications e.g. abscess and sterility 
Non-pharmacological treatment
 y Bed rest

— Testicular Torsion (Torsion of Spermatic Cord) —Chapter 14:  Disorders of the Kidney and Genitourinary System
425 y Scrotal support 
 y Surgical drainage of abscess
 y Avoid unprotected sex until treatment has been completed 
successfully and follow up counseling.
 y Trace and treat sexual contacts
Pharmacological treatment
1st Line Treatment 
 y Ciprofloxacin, oral,
Adult
500 mg 12 hourly for 14 days
Children
5-15 mg/kg 12 hourly for 14 days 
And 
 y Doxycycline, oral, 100 mg 12 hourly for 4 weeks in cases of sexually 
transmitted infections 
Or 
 y Azithromycin, oral,
Adult
500 mg daily for 3 days
Children
10 mg/kg daily for 3 days  
2nd Line treatment
 y Norfloxacin, oral, 400 mg 12 hourly for 14 days
And
Doxycycline or Azithromycin (as above in 1st Line Treatment). 
Or
 y Levofloxacin, 500 mg daily for 14 days
And 
Doxycycline or Azithromycin (as above in 1st Line Treatment)
And 
 y Diclofenac sodium, oral, 50 mg 8 hourly
Or
 y Ibuprofen, oral, 400 mg 8 hourly
Referral Criteria 
Refer all cases of persistent fever and complications to the surgical 
specialist or urologist.
152� Testicular Torsion (Torsion of Spermatic Cord)
This is cessation of blood supply to the testis due to twisting of the 
spermatic cord. This is a medical emergency that needs to be recognized 
before the cardinal signs and symptoms are fully manifest as prompt 

— Testicular Torsion (Torsion of Spermatic Cord) —
Standard  Treatment Guidelines, 7th Edition, 2017
426surgery saves the testes. 
Delay in treatment could result in testicular atrophy, abnormal sperm 
count leading to infertility/sterility.
It can be classified into intravaginal torsion, which constitute more 
than 95% and extra-vaginal torsion, which is usually found in infants.  
About 50% of torsion occurs during sleep and early in the morning.  It is 
rare in older children and adults but common in children under 15 years.  
Causes
 y Undescended testis
 y Bell-clapper malformation
 y Horizontal lie of testis/inversion of testis 
 y Long mesorchium 
 y Trauma
 y Spasm of cremaster muscles
Symptoms
 y Sudden onset of acute severe pain in one testicle or recurrent pain 
which resolves spontaneously (recurrent torsion and detorsion) 
 y Pain may occur typically early in the morning
 y Lower abdominal pain on affected side
 y Nausea and vomiting
 y No urinary symptoms 
 y No fever
Signs
 y Swollen, tender and abnormal position of testis and epididymis. 
 y Shortened & twisted cord.
 y Oedema/reddening of scrotal wall
 y Right testis - twisted clockwise
 y Left testis - twisted anticlockwise
 y Prehn’s sign is absent (elevation of scrotum in the palm towards the 
Pubic symphysis does not relieve pain)
Table 14-3:   Distinguishing between Torsion and Epididymo-orchitis
Parameter Torsion Epididymo-orchitis 
Age < 15 years > 15 years/sexually active
Onset of pain Sudden/early morning Gradual
History of coitus Usually absent Usually present
Fever Absent Present
Urinary symptoms Absent Present
Urethral discharge Absent Present in STIs
Position of testis Changed Unchanged

— Fournier’s Gangrene  —Chapter 14:  Disorders of the Kidney and Genitourinary System
427Parameter Torsion Epididymo-orchitis 
Swelling Testis Epididymis and testis
Prehn’s sign Absent/negative Present/positive
Blood supply: doppler 
testReduced Normal or increased
Treatment Surgical Non surgical
Investigations
 y Urinalysis
 y FBC
 y Doppler stethoscope
 y Colour Doppler Ultrasound Scan
 y 99mTc-pertechnetate scintillation scan (90-100% accurate)
Treatment
Treatment objectives
 y To have surgical intervention within 6 hours of onset
 y To surgically explore all doubtful cases
 y To prevent testicular loss
Non-pharmacological treatment
 y Emergency surgery is the standard treatment
 y If surgery is delayed then manual detorsion should be carried out 
carefully to prevent loss of testis.
 y Manual detorsion procedure-under local anaesthesia (see below) 
and standing at the foot of bed untwist: Right testis anticlockwise, 
Left testis - clockwise
 y Emergency surgery should follow this procedure as soon as possible
Pharmacological treatment
Evidence Rating: [C]
 y Lignocaine 1%, into the spermatic cord on both sides - for cord block 
anaesthesia 10-20 ml 
Referral Criteria 
Refer as soon as possible (if surgical intervention is not available) to a 
surgeon or urologist. Beware testicular torsion has potential medico-legal 
implications.
153� Fournier’s Gangrene 
It is an acute fulminant polymicrobial necrotising fascitis or gangrene 
affecting the scrotum and sometimes extending to the perineum, penis 
and lower abdomen. It is also called idiopathic gangrene of the scrotum. 
The synergistic infections of anaerobic and aerobic bacteria coupled 
with obliterative arteritis results in the extensive gangrene. The risk factors 

— Fournier’s Gangrene  —
Standard  Treatment Guidelines, 7th Edition, 2017
428include diabetes mellitus, HIV/Immunosuppression, perineal abscess/
infection of scrotum and contents, trauma, extravasation of urine, 
periurethral abscess and urethral stricture/calculi. The complications of 
Fournier’s gangrene include septicaemia, extravasation of urine, exposure 
of testes and fistula formation.
Causes
 y Staphylococcus spp
 y Microaerophilic Streptococcus
 y E. coli  
 y Fusibacteria
 y Clostridium welchii
 y Bacteroides
Symptoms
 y Acute onset of painful anterior scrotal swelling in previously healthy 
tissue
 y Fever
 y Pain in affected scrotum
 y General malaise
Signs
 y Fever
 y Prostration
 y Rapidly progressing gangrene
 y Foetid odour 
 y Sharp demarcation between ‘dead’ tissue and healthy tissue
 y Crepitus on palpation of affected tissue
 y Testis is usually spared
 y Urinary extravasation 
 y Presence of risk or predisposing factors
Investigations
 y Wound culture and sensitivity
 y Serum culture and sensitivity
 y Urinalysis
 y FBC and ESR
 y Grouping and cross-matching 
 y Fasting blood glucose
 y HIV screening
 y Plain X-ray of pelvis will reveal gas in affected tissue
Treatment
Treatment objectives
 y To resuscitate patient
 y To treat the infection 
 y To manage concomitant risk factors
 y To salvage the testes 

— Bladder Cancer —Chapter 14:  Disorders of the Kidney and Genitourinary System
429 y To prevent/treat complications
Non-pharmacological treatment
 y Surgical intervention
 y Radical debridement 
 y Reconstructive surgery:
 y Testis buried in upper thigh temporarily to prevent dessication 
 y Skin grafting and reconstruction of scrotum (scrotoplasty)
 y Myocutaneous flaps
 y Nutrition supplement
 y Wound care
 y Management of diabetes mellitus if present
 y Management of HIV/AIDS if present  
Pharmacological treatment
Evidence Rating:  [C]
A. IV fluids, haemotransfusion and hyperbaric oxygen
As required for patients clinical state
B. Antibiotics
 y Gentamicin, IV, 80 mg 8 hourly
And 
 y Ampicillin, IV, 500 mg 6 hourly 
And 
 y Metronidazole, IV, 500 mg 8 hourly
Or
 y Amoxicillin + Clavulanic Acid, IV, 1 g 12 hourly 
And
 y Metronidazole, IV, 500 mg 8 hourly
Or
 y Cefuroxime, IV, 750 mg 8 hourly 
And
 y Metronidazole, IV, 500 mg 8 hourly
Referral Criteria 
Refer all cases with septic shock after resuscitation and all those who 
require reconstructive surgery to a urologist or surgical specialist.
154. Bladder Cancer
Bladder cancer is the second commonest urological cancer after 
prostate cancer. It is the commonest of all the cancers, which affect the 
urinary tract lining (urothelium). Males are more affected than females 
in a ratio of about 3:1. It is more common in the white race compared 
to the black race in a ratio of 4:1. More than 80% of clients with bladder 
cancer are above 50 years. The commonest pathological types are 

— Bladder Cancer —
Standard  Treatment Guidelines, 7th Edition, 2017
430transitional cell carcinoma TCC (90%), Squamous cell carcinoma (8%) and 
adenocarcinoma and carcinoma in-situ (2%).
Causes
 y Chronic Infections of the bladder like Schistosoma haematobium  
(Bilharzia) and chronic bacterial infections
 y Smoking of cigarettes: cancer usually develops 10-20 years after 
smoking and 20 sticks a day/a packet carries a high risk of cancer 
development. Passive smoking may also carry the risk of cancer
 y Occupational risks; environmental exposure to cancer-causing 
chemicals used in industries e.g. dye, textile, rubber, cable, printing 
etc.
 y Genetic and familial factors
Symptoms
 y May be asymptomatic in early disease (25%)
 y Haematuria (usually painless). Painful only in advanced disease and 
infection/UTI
 y Irritative symptoms: frequency, urgency, dysuria
 y Flank pain (hydronephrosis)
 y Pelvic pain from cancer invasion
 y Oedema of lower limbs from advanced disease
Signs
 y Pallor
 y Wasting
 y Palpable bladder mass
 y Palpable kidney from ureteric obstruction and hydronephrosis
 y Lymphoedema of lower limb/limbs
 y Secondary UTI in 30% of cases
Investigations
 y FBC and ESR
 y Urine analysis and culture
 y Urine cytology
 y Urea, creatinine, electrolytes
 y Ultrasound scan: Abdominopelvic
 y CT Scan /MRI for staging (By specialist)
 y Special Investigations: Abdominopelvic IVU
 y Urethrocystoscopy and biopsies (By specialist)
 y Examination under anaesthesia (Bimanual palpation of bladder 
through DRE and Pelvic examinations).
Treatment
Treatment objectives
 y Surgical cure for early disease
 y Prevention of recurrence, progression and metastases
 y Management of complications

— Carcinoma of Prostate —Chapter 14:  Disorders of the Kidney and Genitourinary System
431 y Additional treatment with cancer drugs and radiotherapy where 
necessary (Neoadjuvant and adjuvant therapy)
Non-pharmacological treatment 
 y Cystectomy: Partial or radical with or without bladder replacement.
 y Radiotherapy
Pharmacological treatment
Evidence Rating: [C]
A. Early Stage
 y BCG or Thiotepa bladder instillation for superficial tumours after 
Trans-Urethral Resection of Bladder Tumour (TURBT)  
B. Advanced Disease
 y Chemotherapeutic agents recommended for advanced stage include 
Methotrexate, Vinblastine, Adriamycin and Cisplatin. 
Referral Criteria 
Refer all cases of bladder cancer for specialist evaluation and 
treatment. All cases of chronic cystitis should be referred to specialist to 
exclude bladder cancer.
155� Carcinoma of Prostate
Ninety-five per cent of these tumours are adenocarcinomas. 
The majority of men affected are aged between 65 and 85 years. The 
incidence increases with age. It is recommended that every male, 40 years 
and above, should have annual screening by Prostate Specific Antigen 
(PSA) tests and Digital Rectal Examination (DRE) since early detection is 
associated with better prognosis. The benefit or otherwise of screening 
should be discussed with patients. 
Patients with a family history of prostate cancer and should consider 
annual screening from 40 years and above with PSA and DRE. It is worth 
noting that not every hard prostate on DRE is malignant. Likewise a 
normal-feeling prostate does not exclude a malignancy. A prostatic biopsy 
is therefore necessary to establish a diagnosis.
Causes 
 y Ageing 
 y Functional testes
 y Family history of prostate cancer, breast cancer, ovarian cancer 
 y Race (more common in blacks) 
 y High dietary fat intake 
Symptoms
 y Asymptomatic: prostate cancer may be present without symptoms 
in the early stage
 y Lower Urinary Tract Symptoms (LUTS) and IPSS

— Carcinoma of Prostate —
Standard  Treatment Guidelines, 7th Edition, 2017
432 y Retention of urine 
 y Haematuria 
 y General debility anorexia, weight loss, listlessness 
 y Bone pain (commonly in the waist or limbs) 
 y Paralysis in the lower limbs or inability to walk 
 y Pathological Fracture
 y Impotence
 y Haemospermia
 y Tenesmus
Signs 
On DRE clinical signs include; 
 y Hard prostate gland with an irregular surface and edges 
 y Obliterated median sulcus 
 y Adherent rectal mucosa 
Advanced or metastatic disease: 
 y Anaemia 
 y Uraemia 
 y Wasting 
 y Bone tenderness 
 y Paraplegia 
 y Pathological fracture 
Investigations 
 y FBC 
 y Blood urea, electrolytes and creatinine 
 y Prostate Specific Antigen (PSA) 
 y Liver function tests 
 y Abdominal and pelvic ultrasound 
 y Transrectal Ultrasound (TRUS) of the prostate, if available 
 y Transrectal needle biopsy of the prostate 
 y TRUS-guided or finger-guided
Treatment 
Treatment objectives 
 y To relieve symptoms 
 y To control complications 
 y To achieve cure for early disease 
 y To prevent local progression and metastases 
Non-pharmacological treatment 
 y Urethral catheterisation to relieve urinary retention where needed
 y Radical prostatectomy or radiotherapy, under specialist care, for 
early disease
 y Surgical castration (bilateral orchidectomy) for advanced disease
Pharmacological treatment 
Evidence Rating: [A]
 y Pharmacological treatment of carcinoma of the prostate, which 

— Erectile Dysfunction —Chapter 14:  Disorders of the Kidney and Genitourinary System
433involves hormonal manipulation, which inhibits growth of the tumour 
by depriving it of androgens, is best carried out under specialist care.
 y The common drugs used in advanced prostate cancer therapy are:
A. Antiandrogens 
 y Bicalutamide, oral, 50 mg daily (refer to specialist)
Or
 y Flutamide, oral, 250 mg 8 hourly (refer to specialist)
B� Oestrogen
 y Stilboestrol, oral, 2-5 mg daily (Avoid in clients with cardiovascular 
diseases), (refer to specialist)
C. LHRH Analogues
 y Goserelin, SC, preferably in the abdominal wall (refer to specialist)
Or
 y Leuprolide acetate, IM, (refer to specialist)
And 
 y Biphosphonates and Fentanyl patches (refer to specialist)
Referral Criteria 
Refer all cases to a specialist centre for evaluation and management.
156� Erectile Dysfunction
It means the persistent inability of a man to achieve an erection, 
which is adequate in terms of hardness and duration for satisfactory 
sexual intercourse.  So long as a man can achieve a hard enough erection 
to permit vaginal penetration, with a long enough “staying power” 
to perform the sexual act till ejaculation is attained, he is judged to be 
potent. The number of “rounds” per session is irrelevant.
The condition may be classified as organic, psychogenic or mixed in 
terms of aetiology; primary (never been able to attain and/or maintain 
an erection for satisfactory sexual intercourse) or secondary, where 
impotence occurs in men who have previously had a satisfactory sexual 
performance.
Causes 
Psychogenic
 y Anxiety
 y Depression
 y Stress
 y Marital conflict
Organic
 y Vasculogenic: arterial insufficiency/occlusion; venous incompetence
 y Neurogenic: peripheral neuropathy; spinal cord lesions
 y Traumatic: penectomy; pelvic fracture (with urethral rupture); 

— Erectile Dysfunction —
Standard  Treatment Guidelines, 7th Edition, 2017
434perineal trauma
 y Endocrine: diabetes mellitus, hypogonadism; hyperprolactinaemia; 
pituitary, adrenal and thyroid disorders
 y Drugs: e.g. antihypertensives, antidepressants
 y Post-operative: Cystectomy, Radical Prostatectomy; 
Abdominoperineal resection
 y Inflammation; urethritis; prostatitis
 y Mechanical: congenital penile abnormalities; Peyronies disease
 y Endurance related: heart/renal/liver failure; pulmonary insufficiency 
 y Post-priapism 
Symptoms
 y Inability to achieve erection
 y Inability to sustain erection
 y Reduced sexual desire
Signs
 y Features related to underlying causes
 y Hypogonadal features e.g. gynaecomastia, lack of male sexual 
characteristics
 y Penile plaques and curvature (Peyronies disease)
Investigations
 y FBC and sickling status
 y Lipid profile
 y Urinalysis
 y Fasting blood glucose
 y Serum prolactin 
 y Serum LH, FSH and testosterone
Treatment
Treatment objectives
 y To determine causative factors and treat appropriately
 y To restore sexual potency
Note 14-14
Erectile dysfunction may be the first warning sign of underlying cardiovascular 
disease like Myocardial Infarction
Non-pharmacological treatment
 y Patients should avoid excessive alcohol consumption, cigarette 
smoking, recreational drug abuse and excessive weight gain
 y Psychosexual counseling
Pharmacological treatment
Box 14-3: 
 yTreatment should be directed at underlying cause e.g. change or discontin -
ue medication, if found to be the cause, in consultation with the patient’s 
physician

— Male Infertility  —Chapter 14:  Disorders of the Kidney and Genitourinary System
435 yDrugs for erectile dysfunction e.g. sildenafil, tadalafil or vardenafil (PDE5 in -
hibitors) can be prescribed as first line treatment after careful cardiovascular 
evaluation. They are contraindicated in ischaemic heart disease and those 
on nitrates
 y Sildenafil citrate, 50 or 100 mg 30 minutes to 1 hour before coitus
Or
 y Tadalafil, 20 mg 30-60 minutes before coitus
Or
 y Verdanafil, 10 or 20 mg 30-60 minutes before coitus
Note 14-15
These medications require sexual stimulation for optimal results
 y Prostaglandin E1 must only be used under specialist care. 
Referral Criteria
Referral to a specialist centre is necessary for proper evaluation and 
management in most cases.
157� Male Infertility 
Infertility is the failure of a couple to achieve conception within 
12 months of adequate unprotected coitus. About one third of cases of 
infertility result from pathologic factors in men, one third from factors in 
both men and women and one third from factors in females. Male causes 
therefore account for 50% of infertility. About 15% of all married couples 
experience reproductive difficulties. Components of infertility history 
include medical, surgical, fertility, sexual, family, medication, social and 
occupational history.
Causes
For practical purposes the main causes can be divided into three:
 y Treatable causes
 y Potentially treatable causes
 y Untreatable causes
The causes can also be classified under three categories: Pre-
testicular, Testicular and Post-testicular.
Table 14-4:   Causes of Male Infertility
Treatable causes Potentially treatable 
causesUntreatable causes
Varicocoele  Idiopathic Congenital abnormalities 
e.g. absence of both 
testis and chromosomal 
abnormalities

— Male Infertility  —
Standard  Treatment Guidelines, 7th Edition, 2017
436Treatable causes Potentially treatable 
causesUntreatable causes
Infections of testis, 
epididymis, urethra, 
prostateUndescended 
TestisBilateral testicular atrophy
Ejaculatory dysfunction Gonadotoxins  (drugs, 
radiation)
Erectile dysfunction Blockage of vas deferens
Hyperprolactinaemia
Hypogonadotropic 
hypogonadism 
Symptoms
 y Patients usually complain of their wives’ inability to give them a 
child. Such patients are quite often very apprehensive, frustrated 
and reluctant to undergo investigations
 y Symptoms suggestive of history of STI, UTI, mumps, genital, pelvic or 
inguinoscrotal surgery and injuries
Signs
 y Absence of male secondary sexual characteristics
 y Gynaecomastia
 y Examine external genitalia to assess:
 y Testes: presence or absence, size and consistency
 y Epididymis: thickening
 y Vas deferens: absence, thickening
 y Varicocoeles
 y Inguinoscrotal region: scar from previous herniorrhaphy
 y Penis: size, curvature, hypospadias, epispadias
 y Urethra: discharge, meatal stenosis, stricture
Investigations
 y FBC and sickling
 y Semen analysis
 y Urinalysis
 y Fasting blood glucose
 y Specific investigations relating to various causes e.g. scrotal 
ultrasound 
 y Specialised investigations e.g. hormonal profile done by specialists
 y Evaluation of female partner by gynaecologist
Treatment
Treatment objectives
 y To improve fertility potential
 y To achieve pregnancy with partner

— Haematuria  —Chapter 14:  Disorders of the Kidney and Genitourinary System
437Non-pharmacological treatment
 y Sexual counselling
 y Smoking cessation
 y Reduction in alcohol intake
 y Avoid local (scrotal) exposure to excessive heat, cold and chemicals
 y Avoid tight underwear. Use of boxer shorts and cotton briefs (not 
silk/nylon) is recommended. (This reduces heat around the testes to 
promote spermatogenesis)
Pharmacological treatment
 y This is best provided under specialist care.
Referral Criteria 
Refer all cases that require special investigation, pharmacological or 
surgical treatment to specialist.
158� Haematuria 
This is the passage of blood in the urine. It may be microscopic or 
macroscopic, intermittent or continuous. The pattern of blood in the urine 
may be initial, terminal or frank/total. Blood in urine is a serious symptom 
and must always be fully investigated especially to exclude cancer. 
Certain drugs and food products may colour urine red resulting in false 
haematuria and these should be differentiated from true haematuria, 
which is detected by microscopic examination of the urine. Examples 
of such substances are rifampicin and rhodamine B food colouring used 
in cakes, cookies and soft drinks. Occasionally vaginal bleeding may be 
mistaken for haematuria.
Definitive treatment depends on the cause. 
Causes
Glomerular 
 y Glomerulonephritis usually presents with dysmorphic red blood cells 
in the urine or red blood cellcasts with proteinuria
Non-Glomerular 
 y Urethra: Trauma, Infection
 y Bladder: Infection, stone, bladder cancer, varices, BPH, prostate 
cancer drug reaction (cyclophosphamide) radiation cystititis, parasite 
infestation ( S. haematobium )
 y Ureter: Infection, stone, tumour
 y Kidney: Infection (pyelonephritis), stone, anatomic anomalies 
(Polycystic Kidney Disease, A-V Fistula) renal vein or artery 
thrombosis,
 y Neoplasms: Renal cell carcinoma (Wilms Tumour) 
 y Trauma
 y Sickle cell disease
 y Benign Prostatic Hyperplasia (BPH)

— Haematuria  —
Standard  Treatment Guidelines, 7th Edition, 2017
438 y Carcinoma of prostate, bladder and kidney
 y Urinary tract infection
 y Urinary calculi
 y Medical causes e.g. sickle cell disease, acute glomerulonephritis and 
anticoagulant therapy
Symptoms
 y Fever suggests infection e.g. pyelonephritis, cystitis and prostatitis
 y Colicky flank pain suggests urinary stones
 y Associated lower urinary tract symptoms suggest bladder or prostatic 
cause 
 y Blood in the urine (on initiation, mixed with the urine, or at the end 
of passing urine)
 y Pain/discomfort on passing urine usually associated with infection, 
calculi or trauma
 y Painless intermittent haematuria associated with cancers eg bladder 
and kidney cancers
 y Lower Urinary Tract Symptoms (LUTS)
 y Loin pain
Signs
 y Pallor
 y Abdominal masses e.g. kidney, bladder
 y Low or suprapubic tenderness from urinary tract infection or calculus
Investigations
 y FBC and sickling status (Hb electrophoresis if sickling test is positive)
 y Blood urea, electrolyte and creatinine
 y Urinalysis
 y Urine culture and sensitivity
 y Abdominal and pelvic ultrasound
Treatment
Treatment objectives
 y To treat underlying cause
 y To arrest bleeding
Non-pharmacological treatment
 y High fluid intake is advised in order to prevent clot formation in the 
urinary bladder
 y If patient presents with clot retention, then catheterise and refer
Pharmacological treatment
A.     For Urinary Schistosomiasis
Evidence Rating: [A]
 y Praziquantel, oral, 
(See section on ‘Urinary Schistosomiasis’)

— Urinary Schistosomiasis —Chapter 14:  Disorders of the Kidney and Genitourinary System
439B.     For Urinary Tract Infection
 y Give appropriate antibiotics (See section on ‘Urinary Tract Infection’)
Referral Criteria 
Refer all other cases as well as those with persistent haematuria for 
appropriate investigations and treatment.
159� Urinary Schistosomiasis
This is a water-borne disease caused by penetration of the skin 
or mucous membranes by the early stages of the causative organism 
(Schistosoma haematobium ), which in the adult form settles in the blood 
vessels of the urinary bladder resulting in the common presentation of 
haematuria.  
This disease is common in Ghana with several endemic areas along 
the lakes, slow-flowing rivers and irrigation systems.  The commonest 
body sites affected are the bladder, ureters and pelvic organs. Prevention 
entails avoiding contact with infested water.
Chronic infestation may lead to severe anaemia, ureteric stricture 
and hydronephrosis as well as carcinoma of the bladder.
Cause
 y Schistosoma haematobium
Symptoms
Initial
 y Itching and redness of skin at site of penetration of parasite
 y Fatigue, low grade fever, malaise, lassitude, excessive sweating, 
headache and backache
Later
 y Terminal haematuria
 y Painful urination (dysuria)
 y Lower abdominal pain (bladder pain)
Signs
 y Pallor
 y Palpable kidney from hydronephrosis due to ureteric stricture
 y Palpable bladder from bladder cancer or retention of urine due to 
clots or bladder neck stenosis
 y DRE may reveal a fibrosed prostate, enlarged seminal vesicle or 
thickened bladder base
Investigations
 y FBC
 y Urine for red blood cells, pus cells, and schistosoma ova (mid-day 
urine specimen preferably taken after physical exercise is ideal)
 y Midstream urine for culture in associated urinary tract infections
 y Imaging: Ultrasound scan; Intravenous Urogram (IVU) may show 

— Persistent or Recurrent Urethral Discharge  —
Standard  Treatment Guidelines, 7th Edition, 2017
440calcification of bladder, ureters, hydronephrosis and hydroureters
Treatment
Treatment objectives
 y To eliminate the causative organism
 y To manage the complications
Non-pharmacological treatment
 y Avoid repeated exposure to infested water bodies if possible
Pharmacological treatment
Evidence Rating: [A]
 y Praziquantel, oral, 
Adult s and Children
40 mg/kg as a single dose
 y Treat anaemia if present (See section on ‘Anaemia’)
Referral Criteria 
Refer patient after adequate treatment if: haematuria and/
or symptoms of urinary infection persist or if complications like 
hydronephrosis, bladder mass, retention of urine, severe wasting and 
severe anaemia are present.
160� Persistent or Recurrent Urethral Discharge 
(See section on ‘STI-related persistent or recurrent urethral 
discharge’). 
161� Retention of Urine
Retention of urine is inability to empty a full bladder. It is the 
commonest urological emergency in Ghana and worldwide. Adult males 
are more commonly affected. It is rare in children and in females. The 
causes differ in different age groups as well as in males and females. A 
family history of retention of urine in Benign Prostatic Hyperplasia (BPH), 
prostate cancer, breast cancer and ovarian cancer are risk factors.
Retention of urine can be classified into three:
1. Acute retention of Urine is of sudden onset with a palpable tender 
bladder.
2. Chronic Retention of Urine is of insidious onset and presents with a 
palpable non-tender bladder and overflow incontinence resulting in more 
damage to the bladder, ureters and kidneys. Post-renal renal failure may 
complicate this type of retention with hydronephroses and hydroureters.
3. Acute-on-chronic retention of urine is when a chronic retention of 
urine is suddenly complicated by acute retention of urine. 

— Retention of Urine —Chapter 14:  Disorders of the Kidney and Genitourinary System
441Causes
 y Adult males - (above 50 years): BPH, urethral strictures, bladder neck 
stenosis
 y Adult males - (below 50 years/young males): urethral strictures, 
urethral injuries, bladder neck stenosis, neurogenic bladder/spinal 
injury, paraphimosis, urethral caculi, acute prostatitis
 y Male children - posterior urethral valves, meatal stenosis, phimosis, 
urethral calculi, congenital strictures
 y Adult females - retroverted gravid uterus, uterine fibroids/myomas, 
impacted ovarian cysts, neurogenic (postoperative and pelvic 
inflammatory disease), carcinoma of cervix with infiltration into the 
urethra
Symptoms
 y Retention of urine in BPH precipitated by postponement of 
micturition, alcohol abuse and infection
 y Sudden inability to pass urine with painful bulge in lower abdomen 
for acute retention of urine
 y Gradual onset of inability to pass urine with painless bulge in lower 
abdomen for chronic retention of urine
 y History of urethritis, urethral instrumentation (e.g. catheterisation) 
or perineal injury, pelvic fracture or surgery in urethral strictures
 y International Prostate Symptom Score (IPSS)
Signs
 y Palpable tender bladder in acute retention of urine
 y Palpable non-tender bladder for chronic retention of urine
 y Uraemia/Azotaemia in renal failure
 y Fever in infections: UTI and prostatitis
 y Palpable kidneys in hydronephrosis
 y Haematuria in BPH, prostate cancer and urethral strictures
Referral Criteria 
Patients with hydronephroses on ultrasound scan and renal failure 
should be referred to specialist.

16Chapter
442Sexually Transmitted 
Infections  
162� Sexually Transmitted Infections in Adults 
Sexually Transmitted Infections (STIs) result in several clinical 
syndromes caused by organisms that can be acquired and transmitted 
through sexual activity. 
They cause acute morbidity in adults and may result in long-term 
complications such as urethral stricture, infertility, ectopic pregnancy, 
anal fistula, cervical cancer, foetal wastage, prematurity, low birth 
weight, ophthalmia neonatorum and congenital syphilis. Their control is 
the cornerstone in improving reproductive health and reducing Human 
Immunodeficiency Virus (HIV) infections.
Comprehensive management of STI is important and comprises 
prompt and effective case detection and treatment. However, owing to 
the lack of laboratory equipment and manpower in primary care facilities 
where most patients first present, an accurate diagnosis is often not 
possible. Also with most STIs, one cannot usually tell which organism is 
causing the infection from the history and physical examination alone. 
Multiple infections also occur, with each needing to be treated. Failure to 
treat one infection adequately may result in the development of serious 
complications.
It is therefore more practical in managing STIs to base treatment on a 
‘syndromic diagnosis’, which identifies all STIs that could cause a particular 
symptom or sign and provide treatment for each of them simultaneously.
The common clinical syndromes associated with STIs include urethral 
discharge in males, persistent/recurrent urethral discharge, vaginal   
discharge,   lower   abdominal   pain,  genital ulcer, scrotal swellings, 
inguinal lymphadenopathy (buboes), ano-rectal syndromes (ano-rectal 
discharge, ulcers and vesicles), and genital warts. Scabies and pediculosis 
pubis may also be transmitted by sexual contact. 
In dealing with patients with STI, privacy and confidentiality, 
especially with the history taking and examination, are paramount.
Education and counselling of STI patients and concurrent 
management of their partners provide additional opportunities to reduce 
the risk of STI in the community.

— STI-related Urethral Discharge in Males  —Chapter 16:  Sexually Transmitted Infections 
443(See section on ‘Sexually Transmitted Diseases in Children’ for STIs 
in children)
163� STI-related Urethral Discharge in Males 
Causes
 y Neisseria gonorrhoea  (Gonococcal urethrits)
 yChlamydia	trachomatis  (Non-gonococcal urethritis)
164. Mycoplasma genitalum
Sympt oms
 y Urethral discharge
 y Dysuria or discomfort on urination
Signs
 y Urethral discharge
Note 16-1
Gentle milking of the urethra may reveal the discharge if it is not initially visible.
In uncircumcised males, check that the discharge is coming from the urethral 
opening and not from the glans penis.
Inve stigations
 y Urethral swab culture and sensitivity (if available)
Treatment
Treatment objectiv es
 y To treat gonorrhoea and chlamydia urethritis simultaneously
 y To prevent further transmission to sexual partners.
 y To treat both partners simultaneously as much as possible
 y To prevent development of complications and sequelae
 y To reduce risk of HIV infection
Non-pharmacological treatment
 y None
Pharmacological Treatment
Evidence Rating: [C]
A.     For Gonorrhoea
 y Ceftriaxone, IM, 250 mg stat
Or
 y Cefixime, oral, 400 mg stat
Or
 y Ciprofloxacin, oral, 500 mg stat
And

— STI-related Persistent or Recurrent Urethral Discharge —
Standard  Treatment Guidelines, 7th Edition, 2017
444B�     For Chlamydia and Mycoplasma:
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
Or
 y Azithromycin, oral, 1 g stat. 
165� STI-related Persistent or Recurrent Urethral Discharge
This may occur due to drug resistance, poor treatment compliance 
or re-infection following treatment for an STI. In some cases persistence 
of urethral discharge may be due to infection with Trichomonas	 vaginalis .
Causes
 y Neisseria gonorrhoeae , Chlamydia 	trachomatis  or Mycoplasma 
genitalum  following drug resistance, poor compliance or re-infection 
after treatment
 yTrichomonas	vaginalis
Treatment
Treatment objectiv es
 y To re-treat for gonococcal or non-gonococcal urethritis if suspected 
to be due to previous poor treatment compliance or re-infection
 y To treat infection with Trichomonas	vaginalis
 y To prevent transmission to sexual partners
 y To treat both partners simultaneously as much as possible
 y To prevent development of complications and sequelae
 y To reduce risk of HIV infection
Non-pharmacological treatment
 y None
Pharmacological Treatment
Evidence Rating: [C]
A.     For Gonorrhoea, Chlamydia,  Mycoplasma
Repeat treatment for urethral discharge 
B�     For Trichomonas	vaginalis
 y Metronidazole, oral, 400 mg 12 hourly for 7 days
Or
 y Metronidazole, oral, 2 g stat.
Or
 y T inidazole, oral, 2 g stat.
Or 
 y Secnidazole, oral, 2 g stat. 

— STI-related Vaginal Discharge  —Chapter 16:  Sexually Transmitted Infections 
445Referral Criteria
Refer all cases of treatment failure to a health facility where 
microbiological culture and antimicrobial sensitivity tests can be done on 
the urethral discharge. 
166� STI-related Vaginal Discharge 
While a vaginal discharge is a notable clinical feature of an STI, not all 
forms of vaginal discharge are abnormal or indicative of an STI. A vaginal 
discharge may be associated with a physiological state such as menses 
or pregnancy, or with the presence or use of foreign substances and 
chemicals in the vagina.
A careful risk assessment (See note below) of women with a 
vaginal discharge may help identify STIs and non-STIs and selection of 
appropriate treatment regimens based on the most likely aetiology of the 
vaginal discharge. Other considerations for selecting treatment include 
pregnancy status and patient discomfort.
Causes 
 y Neisseria gonorrhoea
 yChlamydia	trachomatis
 yTrichomonas	 vaginalis  (green or yellow, smelly, bubbly or frothy 
discharge associated with itching)
 y Herpes simplex virus (following first episode of infection)
Sympt oms
 y Vaginal discharge - change in colour, odour, consistency or amount
 y Vulval swelling
 y Pain on urination
 y Lower abdominal or back pain
Signs
 y Vaginal discharge
 y Vulval swelling
 y Vulval erythema
 y Lower abdominal tenderness
 y Cervical excitation tenderness
 y Cervical mucopus or erosions (on speculum examination)
Inve stigations
 y High vaginal swab for microscopy, culture and sensitivity (if available)
Treatment
Treatment objectiv es
 y To identify and treat non-STI vaginitis (especially candidiasis, which is 
frequently diagnosed in women being evaluated for STIs)
 y To assess STI risk and treat STI-related infections appropriately
 y To prevent complications and sequelae

— STI-related Vaginal Discharge  —
Standard  Treatment Guidelines, 7th Edition, 2017
446 y To treat both partners simultaneously as much as possible
Non-pharmacological treatment
 y None for STI-related discharge 
Pharmacological Treatment
Evidence Rating: [C]
Note 16-2
Risk Assessment
Parameters used in the risk assessment for cervicitis are:
i. Patient’s partner is symptomatic (i.e. partner has a urethral discharge)
ii.   Patient is less than 21 years old 
iii.  Patient is single
iv.  Patient has more than one sexual partner
v.    Patient has had a new sexual partner in the last 3 months
The risk assessment is  said  to  be  positive  and  treatment  for  cervicitis  is 
recommended if
-The answer to (i) is yes or
-The answer to any 2 of items (ii) - (v) is yes.
If a woman has a vaginal discharge with no positive risk factor, treat for vaginitis 
alone. If she has a vaginal discharge, and a positive risk factor, treat for both 
vaginitis and cervicitis
A.     Treatment for trichomoniasis and bacterial vaginosis
 y Metronidazole, oral, 2 g stat. (contraindicated during the 1st trimes -
ter of pregnancy)
Or 
 y Metronidazole, oral, 400 mg 8 hourly for 5 days  (contraindicated 
during the 1st trimester of pregnancy)
Or
 y Secnidazole, oral, 2 g stat. (contraindicated during the 1st trimester 
of pregnancy)
Or
 y Tinidazole, oral, 2 g stat. (contraindicated during the 1st trimester of 
pregnancy) 
Or
 y Clindamycin cream (2%), topical (preferred in pregnancy)
And 
B�     Treatment for candidiasis
 y Miconazole vaginal tablets, 200 mg inserted into vagina at night for 
3 days
 y Or
 y Clotrimazole, vaginal tablets, 200 mg inserted into vagina at night 
for 3 days
 y And
 y Clotrimazole cream, apply 12 hourly (for vulval irritation)
C�      Treatment for gonorrhoea
 y Ceftriaxone, IM, 250 mg stat.

— STI-related Lower Abdominal Pain in Women —Chapter 16:  Sexually Transmitted Infections 
447Or
 y Cefixime, oral, 400 mg stat
Or
 y Ciprofloxacin, oral, 500 mg stat. (avoid in pregnant and lactating 
mothers)
And 
D�     Treatment for chlamydia
 y Doxycycline, oral, 100 mg 12 hourly for 7 days (avoid in pregnant and 
lactating mothers)
Or
 y Tetracycline, oral, 500 mg 6 hourly for 7 days (avoid in pregnant and 
lactating mothers)
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
Or
 y Azithromycin, oral, 2 g stat.
Referral Criteria 
Refer all cases of recurrent vaginal discharge and/or treatment 
failures to a health facility where speculum examination can be carried 
out and microbiological culture and antimicrobial sensitivity tests can be 
done on the vaginal discharge.
167� STI-related Lower Abdominal Pain in Women
Causes
 y Neisseria gonorrhoea
 yChlamydia	trachomatis
 y Anaerobic bacteria (often relating to recurrent infections)
Sympt oms
 y Lower abdominal pain
 y Pain with sexual intercourse (dyspareunia)
 y Vaginal discharge
 y Dysuria or urethral discomfort
 y Fever
Signs
 y Lower abdominal tenderness
 y Vaginal discharge
 y Tenderness on moving the cervix (cervical excitation) on bimanual 
vaginal examination
 y Adnexal tenderness
 y Adnexal masses
Inve stigations
 y High vaginal swab culture and sensitivity

— STI-related Genital Ulcer —
Standard  Treatment Guidelines, 7th Edition, 2017
448 y Pelvic ultrasound
Treatment
Treatment objectiv es
 y To treat for gonorrhoea, chlamydia and anaerobic bacterial infection
 y To relieve pain and inflammation
Non-pharmacological treatment
 y Remove IUD, if present, 3 days after initiation of drug therapy
Pharmacological Treatment
Evidence Rating: [C]
A. Out-Patients
 y Cefixime, oral, 400 mg stat.
Or
 y Ciprofloxacin, oral, 500 mg 12 hourly for 3 days
And
 y Doxycycline, oral, 100 mg 12 hourly for 14 days
And
 y Metronidazole, oral, 400 mg 12 hourly for 14 days
B� In- Patients
 y Ceftriaxone, IM, 250 mg daily for 3 days
And
 y Doxycycline, oral, 100 mg 12 hourly for 17 days
And
 y Metronidazole, oral, 400 mg 12 hourly for 17 days
168� STI-related Genital Ulcer
Causes
 y Herpes simplex
 y Treponema pallidum  (syphilis)
 y Haemophilus ducreyi  (chancroid)
 yCalymmatobacterium	granulomatis  (granuloma inguinale)
Sympt oms
 y Genital ulcer (painful or painless)
 y Urethral discharge
 y Inguinal swelling (lymphadenopathy)
Signs
 y Inguinal lymphadenopathy 
 y Herpes simplex
 y Multiple, recurrent vesicular lesions (Herpes simplex)
 y Syphilitic ulcers
 y Often single, painless and indurated lesions with a clear base 
and well-defined edges

— STI-related Genital Ulcer —Chapter 16:  Sexually Transmitted Infections 
449 y Occasionally multiple, painful, non-indurated or have a puru -
lent base
 y Discrete, firm, painless, inguinal lymphadenopathy a week after 
the primary lesion
 y Primary ulcer usually heals within six weeks, usually without 
leaving a scar.
 y Chancroid
 y Painful with undermined ragged edges
 y The base is covered with a purulent exudate and easily bleeds 
to touch
 y Several ulcers may coalesce to form serpiginous lesions
 y Lymphadenopathy is usually unilateral and may become fluc -
tuant
 y Granuloma inguinale
 y Begins with a small papule that progresses into an enlarging 
granulomatous ulcer with trauma
 y Edges are well defined
 y Healing is not spontaneous and is accompanied by extensive 
scarring
Inve stigations
 y VDRL (if available)
 y TPHA (if available)
Treatment
Treatment objectiv es
 y To treat small ulcers and vesicles, especially if recurrent for Herpes 
simplex
 y To direct initial management of all ulcers at herpes simplex, syphilis 
and chancroid concurrently
Non-pharmacological Treatment
 y Keep lesions dry and clean
Pharmacological Treatment
Evidence Rating: [C]
A.        For Herpes simplex
 y Aciclovir, oral, 200 mg 4-6 hourly for 7-10 days (5 doses daily)
Or
 y Aciclovir, oral, 400 mg 8 hourly for 7-10 days
For individuals with herpes and HIV co-infection
 y Aciclovir, oral, 400 mg 8 hourly for 7-10 days 
Or
 y Aciclovir, oral, 800 mg 12 hourly for 7-10 days
Episodic therapy for recurrent episodes 
 y Aciclovir, oral, 400 mg 8 hourly for 5 days 
Or
 y Aciclovir, oral, 800 mg 12 hourly for 5 days
Or

— STI-related Scrotal Swelling —
Standard  Treatment Guidelines, 7th Edition, 2017
450 y Aciclovir, oral, 800 mg 8 hourly for 2 days
Suppressive therapy in HIV infected individuals 
 y Aciclovir, oral, 400-800 mg 8-12 hourly for 2-6 years
B�        For Syph ilis
 y Benzathine Penicillin G, IM, 1.2 MU in each buttock (total dose 2.4 
MU) stat.
Or 
 y Procaine Penicillin Aqueous, IM (by deep injection), 1.2 MU daily for 
10 days
For persons allergic to penicillin
 y Doxycycline, oral, 100 mg 12 hourly for 14 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 14 days
For pregnant women allergic to penicillin
 y Erythromycin, oral, 500 mg 6 hourly for 14 days
Or
 y Azithromycin, oral, 500 mg daily for 10 days
C�      For Chancroid
 y Ceftriaxone, IM, 250 mg stat.
Or
 y Azithromycin, oral, 1 g stat.
Or
 y Ciprofloxacin, oral, 500 mg 12 hourly for 3 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
169� STI-related Scrotal Swelling
Causes
 yChlamydia	trachomatis
 y Neisseria gonorrhoea
 y Treponema pallidum  (very rarely)
Sympt oms
 y Scrotal swelling
 y Scrotal pain
 y Urethral discharge
 y Dysuria
 y Frequency of micturition
 y Fever
Signs
 y Scrotal swelling, oedema and/or erythema
 y Scrotal tenderness
 y Urethral discharge

— STI-related Inguinal Bubo   —Chapter 16:  Sexually Transmitted Infections 
451 y Fever
Inve stigations
 y Urethral swab for culture
 y Urine culture and sensitivity
 y Ultrasound scan of the scrotum
Treatment
Treatment objectiv es
 y To provide pain relief
 y To identify and treat STI and non-STI related causes appropriately
 y To treat for gonorrhea and chlamydia simultaneously 
Non-pharmacological treatment
 y Bed rest
 y Scrotal support until inflammation and fever subside
Pharmacological Treatment
Evidence Rating: [C]
A.  For Gonorrhoea
 y Ceftriaxone, IM, 250 mg stat.
Or
 y Cefixime, oral, 400 mg stat.
Or
 y Ciprofloxacin, oral, 500 mg stat.
And
B�  For Chlamydia
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 7 days
Or
 y Azithromycin, oral, 1 g stat.
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
170� STI-related Inguinal Bubo  
Causes
 yChlamydia	trachomatis  (Lymphogranuloma venereum)
 y Haemophilus ducreyi  (Chancroid)
Sympt oms
 y Painful or painless inguinal swelling(s)
Signs
 y Inguinal swellings:
 y unilateral or bilateral
 y tender or non-tender

— STI-related Genital Warts  —
Standard  Treatment Guidelines, 7th Edition, 2017
452 y fluctuant
 y suppurating
 y Genital ulcer
Inve stigations
 y No investigations required, in view of the syndromic approach
 y Recommended in managing STIs
Treatment
Treatment objectiv es
 y To relieve pain
 y To relieve the swelling
 y To treat the infection of lymphogranuloma venereum and chancroid 
concurrently 
Non-pharmacological treatment
 y Aspiration of fluctuant buboes using a wide bore needle through 
adjacent healthy skin every second or third day. An incision and 
drainage should not be attempted. If buboes persist, the patient 
should be referred.
 y Sequelae such as strictures and/or fistula may require surgery.
Pharmacological treatment
A. For Lymphogranuloma Venereum (LGV) and Chancroid
Evidence Rating: [C]
 y Doxycycline, oral, 100 mg 12 hourly for 21 days
Or
 y Azithromycin, oral, 1 g stat.
Or
 y Erythromycin, oral, 500 mg 6 hourly for 14 days
171� STI-related Genital Warts 
Causes
 y Human papilloma virus
Symptoms
 y Usually no symptoms
 y Small painless swellings in the ano-genital region
 y Itching or discomfort in the genital area
 y May cause increased vaginal discharge 
 y Anal or vaginal bleeding during or after sex
Signs
 y Small, flat, papular, pedunculated, flesh-coloured swellings on the 
skin and mucous membranes of the genitals (penis, vulva, vagina, 
cervix, urethra, perianal region)

— STI-related Ano-rectal Related Syndromes  —Chapter 16:  Sexually Transmitted Infections 
453Inve stigations
 y Acetic acid solution (vinegar) test
Treatment
Treatment objectiv es
 y To eliminate the warts
Non-pharmacological treatment
 y Protect normal skin with vaseline (paraffin) while applying 
Podophyllin
 y External genital and perianal warts should be washed thoroughly 
1- 4 hours after application of Podophyllin and 6-10 hours after 
application of Imiquimod.
 y Cryotherapy with liquid nitrogen, solid carbon dioxide, or a 
cryoprobe. Repeat applications every 1-2 weeks
 y Electrosurgery
 y Surgical removal
Pharmacological treatment
Evidence Rating: [C]
 y Podophyllin 10-25% tincture of benzoin, topical, apply directly to the 
warts avoiding normal skin tissue. 
 y Protect normal skin with vaseline (paraffin). 
Repeat treatment at weekly intervals until complete resolution.
Or
 y Trichloroacetic Acid (TCA) (80-90%), topical, 
apply carefully to the warts avoiding normal tissue, followed by 
powdering of the treated area with talcum powder to remove unreacted 
acid.
Repeat treatment at weekly intervals until complete resolution.
Or
 y Podophyllotoxin, 0.5%, topical, apply 12 hourly three times a week 
for 4 weeks  
Or
 y Imiquimod, 5% cream, topical, apply three times a week for 16 
weeks. Should be washed 6-10 hours after application.
Note 16-3
Do not use TCA during pregnancy and lactation. 
Do not use Podophyllin or TCA on cervical warts.
172� STI-related Ano-rectal Related Syndromes 
Causes
 yC.	Trachomatis
 y Herpes Simplex Virus-2 (HSV-2)
 y N. Gonorrhoea 

— STI-related Ano-rectal Related Syndromes  —
Standard  Treatment Guidelines, 7th Edition, 2017
454 y Treponema pallidum  
Symptoms 
 y Anal discharge 
 y Rectal Bleeding 
 y Pruritus 
 y Rectal pain, 
 y Tenesmus
 y Constipation 
Signs
 y Anal ulcers or blisters
 y Anal growth 
 y Tenderness on rectal examination 
 y Anal discharge or bleeding 
Treatment 
Treatment objectives
 y To relive pain
 y To treat for the major causes simultaneously 
Non-pharmacological treatment 
 y Keep lesions dry and clean 
Pharmacological treatment 
A.     For anorectal discharge, treat for gonorrhea and chlamydia
(See sections above)
B�     For anorectal ulcers or vesicles
For 1st episode of vesicular lesions treat for herpes simplex virus 
 y Aciclovir, 200 mg, 4-6 hourly for 7 days (5 doses per day)
Or 
 y Aciclovir, 400 mg, 8 hourly for 7 days 
Episodic treatment for recurrent HSV vesicular lesions to be started 
on first day of appearance of lesions
 y Aciclovir, 400 mg, 8 hourly for 5 days 
Or
 y Aciclovir, 800 mg, 12 hourly for 5 days
Or
 y Aciclovir, 800 mg, 8 hourly for 2 days
And 
C�    For Syph ilis
 y Benzathine Penicillin G, IM, 1.2 MU in each buttock (total dose 2.4 
MU) stat.
Or 
 y Procaine Penicillin Aqueous, IM (by deep injection), 1.2 MU daily for 
10 days
Or

— Sexually Transmitted Infections in Children  —Chapter 16:  Sexually Transmitted Infections 
455D�     For persons allergic to penicillins 
 y Doxycycline, oral, 100 mg 12 hourly for 14 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 14 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 14 days
And
E�      For Chlamydia 
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
And
F�      For Chanchroid
 y Ceftriaxone, IM, 250 mg stat.
Or
 y Azithromycin, oral, 1g stat.
Or
 y Ciprofloxacin, oral, 500 mg 12 hourly for 3 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
Referral Criteria
If the symptoms or lesions do not improve after treatment refer to 
a health facility with microbiology support for appropriate treatment and 
exclusion of other causes to exclude other causes.
173� Sexually Transmitted Infections in Children 
Neonates, pre-pubertal and pubertal children are also at risk of 
contracting STIs. The modes of transmission in these children are mostly 
through maternal infections, sexual abuse or exploitation and voluntary 
sexual activity in older children. The STls   in this age group include 
neonatal conjunctivitis (ophthalmia neonatorum), and other STI-related 
syndromes similar to that in adults. 
Some of these STls (e.g., gonorrhea, syphilis, and chlamydia), if 
acquired after the neonatal period, are indicative of sexual contact. For 
other STls, (e.g. HPV infections and vaginitis), the association with sexual 
contact is not clear.
174. STI-related Neonatal Conjunctivitis (Opthalmia Neonatorum)
(See section on ‘Neonatal Conjunctivitis’ under Neonatal Disorders)

— STI-related Urethral Discharge Syndrome in Children —
Standard  Treatment Guidelines, 7th Edition, 2017
456Management of specific STI and STI syndromes in children
175� STI-related Urethral Discharge Syndrome in Children
A.     For Gonorrhea
Children  < 12 years (or child < 45 kg)
 y Ceftriaxone, IM, 125 mg stat.
Children  > 12 years (or child > 45 kg)
 y Cefixime, oral, 400 mg stat. 
Or
 y Ceftriaxone, IM,250 mg stat. 
And
B�     For Chlamydia 
Children  < 12 years 
 y Erythromycin, oral, 12.5 mg/kg  6 hourly for 14 days
Children  > 12 years
 y Azithromycin, oral, 1g stat.
Or
 y Doxycycline, oral,  100 mg 12 hourly  for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
176� STI-related Vaginal Discharge Syndromes in Children
Note 16-4
Examination should be carried out without a speculum. Intravaginal treatment 
is not recommended for younger girls.  Oral treatment may be more appropri -
ate.
Non-pharmacological treatment
 y Ensure good genital hygiene 
 y Encourage use of loose underwear
 y Dry underwear in the sun or iron with hot plate
 y Ensure good peri-anal hygiene
 y Avoid douching with herbal or chemical preparations
 y Avoid medicated soaps
Pharmacological treatment
A.     For Vaginitis (Trichomoniasis and B a c t e r i a l  vaginosis)
Children  < 12 years (or < 45 kg)
 y Metronidazole, oral, 7.5 mg/kg 12 hourly for 7days
Children  > 12years (or > 45 kg)
 y Metronidazole, oral, 400 mg 12 hourly for 7days 

— STI-related Lower Abdominal Pain or Pelvic Inflammatory Disease Syndrome in Children —Chapter 16:  Sexually Transmitted Infections 
457Or
 y Metronidazole, oral, 2 g stat.
And
B� For Candidiasis
 y Clotrimazole 2% cream, topical (vaginal), apply 8-12 hourly for 7   
days 
Or
 y Fluconazole, oral, 3-6 mg/kg stat.
Note 16-5
Intravaginal treatment is not recommended for younger girls.  Oral treatment 
may be more appropriate. 
And
C�     For Cervicitis
For Gonorrhea
Children  < 12 years (or < 45 kg)
 y Ceftriaxone, IM, 125 mg stat.
Children  > 12 years (or  > 45 kg)
 y Cefixime, oral, 400 mg stat.
Or
 y Ceftriaxone, IM, 250 mg stat.
And
For Chlamydia
Children  < 12 years
 y Erythromycin, oral, 12.5 mg/kg 6 hourly for 14 days
Children  > 12years
 y Azithromycin, oral, 1 g stat.
Or
 y Doxycycline, oral, 100 mg 12 hourly for 7 days 
Or
 y Erythromycin, oral, 500 mg  6 hourly for 7 days
177� STI-related Lower Abdominal Pain or Pelvic Inflammatory Disease 
Syndrome in Children
Children < 12 years (or < 45 kg)
 y Ceftriaxone, IM, 125 mg stat.
And
 y Erythromycin, oral, 12.5 mg/kg 6 hourly for 14 days
And
 y Metronidazole, oral, 7.5 mg/kg 12 hourly for 14 days
Children > 12 years
 y Ceftriaxone, IM, 250 mg stat. 
And

— STI-related Genital Ulcer Syndrome in Children —
Standard  Treatment Guidelines, 7th Edition, 2017
458 y Doxycycline, oral, 100 mg 12 hourly for 14 days 
And
 y Metronidazole, oral, 400 mg 12 hourly for 14 days
178� STI-related Genital Ulcer Syndrome in Children
A.     For Syphilis
 y Benzyl penicillin, IV,
Children  
> 12 years; 50,000 units/kg 4-6 hourly for 10 days
< 12 years; 50,000 units/kg 4-6 hourly for 10 days
Or
 y Procaine penicillin, IM (deep), 
Children
> 12 years;  1.2 MU daily for 10 days
< 12 years; 50,000 IU/kg daily for 10 days (max. daily dose 
750,000 units)
Or
 y Benzathine Penicillin, IM,
> 12 years;       1.2 MU into each buttock during one clinic visit (total 
2.4 MU)
For persons allergic to penicillin:
 y Doxycycline, oral, 100 mg 12 hourly for 14 days
Or
 y Tetracycline, oral, 500 mg 6 hourly for 14 days
And
B�     For Chancroid
Children   > 12 years
 y Cefixime, oral, 400 mg stat.
Or
 y Azithromycin, oral, 1 g stat.
Or
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 days
Children  < 12 years (or < 45 kg)
 y Ceftriaxone, IM, 250 mg stat.
Or
 y Erythromycin, oral, 12.5 mg/kg 6 hourly for 7 days
And
C�      For Genital Herpes Simplex
 y Aciclovir, oral, 
Children  

— STI-related Ano-Rectal Related Syndromes in Children —Chapter 16:  Sexually Transmitted Infections 
459> 2 years;  200 mg 4-6 hourly for 5 days
1 month-2 years; 100 mg 4-6 hourly for 5 days
For Infants with Known or Suspected Neonatal Herpes 
 y Aciclovir, IV, 
Children   <  1 month 
20 mg/kg every 8 hours for 14 days ( for disease limited to the skin 
and mucous membranes) 
Or
20 mg/kg every 8 hours for 21 days (for disseminated and CNS dis -
ease)
179� STI-related Ano-Rectal Related Syndromes in Children
Ano-rectal Discharge
A.      For Gonorrhea
Children  > 12 years (or  > 45 kg)
 y Cefixime, oral, 400 mg stat.
Or
 y Ceftriaxone, IM, 250 mg stat.
Children  < 12 years (or  < 45 kg)
 y Ceftriaxone, IM, 125 mg stat.
And
B�     For Chlamydia
Children  > 12 years
 y Azithromycin, oral, 1 g stat.
Or
 y Doxycycline, oral, 100 mg 12 hourly for 7 days
Or
 y Erythromycin, oral, 500 mg 6 hourly for 7 day
Children  < 12 years
 y Erythromycin, oral, 12.5 mg/kg 6 hourly for 14 days
Anorectal ulcers / vesicles 
A.      For Syphilis 
(See sections above under ‘Genital Ulcer Syndrome in Children’ for 
treatment of Syphilis’)
B�      For Chancroid 
(See sections above under ‘Genital Ulcer Syndrome in Children’ for 
treatment of Chancroid’)
C�      For Genital Herpes 
(See sections above under ‘Genital Ulcer Syndrome in Children’ for 

— STI-related Ano-Rectal Related Syndromes in Children —
Standard  Treatment Guidelines, 7th Edition, 2017
460treatment of Genital Herpes’)
Genital Warts in Children 
(See section on treatment of ‘Genital Warts’ in adults. Podophyllotoxin 
and Imiquimod are not used in children)
Scabies 
(See section on ‘Pruritus’)
Pubic Lice
 y Malathion liquid 0.5% in aqueous base 
Apply over whole body and allow to dry naturally. Wash off after 12 
hours or overnight. Repeat after 1 week
Referral Criteria 
If the symptoms or lesions do not improve after treatment refer to 
a health facility with microbiology support for appropriate treatment and 
exclusion of other causes to exclude other causes.

17Chapter
461HIV Infections and AIDS
180� HIV Infection and AIDS
Acquired Immune Deficiency Syndrome  (AIDS ) is a late stage of 
infection with the Human Immune Deficiency Virus  (HIV ). It can affect 
both adults and children often predisposing them to opportunistic 
infections and certain malignancies. Co-infection with tuberculosis (TB) 
and Hepatitis  B are particularly frequent in HIV infected individuals and 
must be screened for in all cases. 
The main risk factors for HIV /AIDS  remain transmission by exchange 
of body fluids and blood products through sexual contact, transfusion, 
needle-stick injury, non-sterile surgical practices and mother to child 
transfer.
HIV infection is currently not curable. However, for persons living 
with HIV infection (PLHIV) , effective anti-retroviral therapy (ART) is 
available country-wide at accredited centres at the regional and district 
level in both public and private health care facilities to which all diagnosed 
patients must be referred. 
Prevention of infection remains the key to reducing its spread.  
Causes 
 y Human Immunodeficiency Virus 
Symptoms 
 y Persistent cough 
 y Persistent or recurrent diarrhoea 
 y Weight loss 
 y Skin rashes 
 y Persistent or recurrent fever 
 y Mouth ulcers 
Signs
 y Weight loss 
 y Chronic diarrhoea
 y Prolonged fever
 y Generalised lymphadenopathy

— HIV Infection and AIDS —
Standard  Treatment Guidelines, 7th Edition, 2017
462 y Oropharyngeal candidiasis 
 y Persistent cough 
 y Generalised dermatitis  
 y Recurrent herpes zoster (adults)
 y Chronic progressive and disseminated herpes simplex infections 
(adults)
 y Finger nail changes e.g. blue discoloration of the nails (adults)
 y Failure to thrive or slow growth (infants and children)
 y Recurrent common infections e.g. otitis media , pharyngitis (infants 
and children)
Investigations
 y Confirmatory HIV  test (HIV1, HIV2, HIV1 and 2)
 y HIV Viral load
 y CD4 count
 y Other tests asOther tests asOther tests as required (See Table 17-1 
on page )d (See Table 17-1 on page )d (See Table 17-1 on page 462)
Table 17-1:   Other baseline tests for HIV  
Haematological test Full blood count
Biochemical test Blood Urea
Electrolytes and Creatinine
Liver Function tests
Fasting Blood Sugar
Cholesterol and lipid profile
Routine examinations Urinalysis (Urine R/E)
Stool R/E
Respiratory examinations TB screening
Chest X-ray
Serological Test Serological Test Hepatitis  B Surface antigen
Supplementary tests
These tests are performed
depending on signs and
symptomsHistology on skin and lymph node biopsy
Kidney biopsy
Screening for STIs
Pregnancy test
Pap smear , HPV  DNA
Treatment
Treatment objectives
 y To suppress HIV  replication to as low as possible and for as long as 
possible
 y To preserve and enhance the immune function (CD4 restoration)
 y To improve quality of life
 y To reduce morbidity and mortality related to HIV  
 y To promote growth and neurological development in children  

— HIV Infection and AIDS —Chapter 17:  HIV Infections and AIDS
463Pharmacological treatment
A.     Standard Treatment 
1st Line Treatment 
Table 17-2:  Standard Treatment (1st Line Treatment) for HIV-AIDS
Medicines Caution Comment
Preferred Regimen
Tenofovir  (TDF) + 
Lamivudine  (3TC) 
(or Emtricitabine ) + 
Efavirenz  (EFV)Caution with 
Tenofovir  in renal 
dysfunctionMonitor renal function including 
urinalysis
Alternative Regimen
Tenofovir  + Lamivudine  
(or Emtricitabine  (FTC)) 
+ Nevirapine  (NVP)Caution with 
Tenofovir  in renal 
dysfunction
Nevirapine  is 
contraindicated in 
liver dysfunction and 
NVP hypersensitivityMonitor renal function including 
urinalysis
Stop NVP if client develops jaundice 
or severe rashes and refer to ART 
centre for further management.
Zidovudine  (AZT) + 
Lamivudine  (3TC) + 
Nevirapine  (NVP) Zidovudine  is 
contraindicated in 
severe anaemia
Nevirapine  is 
contraindicated in 
liver dysfunction and 
NVP hypersensitivityTDF to be used where Hb is < 8 g/
dL or drops >25% from the baseline 
value in a client on AZT.
Stop NVP if client develops jaundice 
or severe rashes and refer to ART 
centre for further management
Zidovudine  (AZT) + 
Lamivudine  (3TC) + 
Efavirenz  (EFV)Zidovudine  is 
contraindicated in 
severe anaemiaTDF to be used where Hb is < 8 g/
dL or drops >25% from the baseline 
value in a client on AZT.
2nd Line Treatment 
Table 17-3:  Standard Treatment (2nd Line Treatment) for HIV-AIDS
Medicines Comments
First Alternative Zidovudine  + 
Lamivudine  (or 
Emtricitabine ) + 
Lopinavir /r (or 
Atazanavir /r)If TDF based first line.
If LPV/r was used for HIV2 in first 
line, use ATV/r
Second Alternative Tenofovir  + 
Lamivudine  (or 
Emtricitabine ) + 
Lopinavir /r (or 
Atazanavir /r)If ZDV based first line.
Consider Abacavir if patient 
has used both Tenofovir  and 
Zidovudine

— HIV Post Exposure Prophylaxis (PEP) for exposed healthcare personel  —
Standard  Treatment Guidelines, 7th Edition, 2017
464B.     Special conditions
Table 17-4:   Standard Treatment in special conditions for HIV-AIDS
Condition Recommendation Comments
HIV co-infection with 
Hepatitis  B. (See section 
on ‘Hepatitis B’)The recommended regimen 
shall be: Lamivudine  + 
Tenofovir  + EfavirenzLamivudine  and Tenofovir  
are active against both HBV 
and HIV  
Dual HIV -1 and HIV-2 or 
HIV-2 infectionsDue to the ineffectiveness 
of non-nucleoside drugs 
(Nevirapine  and Efavirenz ) in 
HIV-2 infection combination 
of nucleosides and protease 
inhibitors such as LPVr or 
ATV/r should be used. 
Referral criteria 
Refer all HIV  positive patients to an accredited treatment centre in 
Ghana.
181� HIV Post Exposure Prophylaxis (PEP) for exposed healthcare 
personel  
Post-exposure prophylaxis (PEP) is short-term antiretroviral 
treatment to reduce the likelihood of HIV infection after potential 
exposure by preventing the establishment of infection or preventing new 
infection. PEP reduces staff exposure to HIV infections at work and also 
clears possible HIV infection from infected dendritic cells. Workplace 
accidents or injury expose health workers to body fluids of patients. Risk 
of exposure to blood and blood borne pathogens is slightly higher for 
healthcare personnel. The risk of infection for HIV from a percutaneous 
injury is approximately 0-3% and that of mucous membranes or non-
intact skin are much lower. PEP is particularly effective within 1-2 hours 
and not more than 72 hours after exposure.
Causes 
 y An exposure considered as possible risk is defined as “an exposure 
from possibly infected blood, tissue or other body fluids through:
 y A percutaneous injury (e.g. a needle stick or cut with a sharp 
object) or
 y A mucocutaneous membrane or non-intact (chapped, abraded 
skin) contact
 y The risk of infection appears to be higher after:
 y Exposure to a large quantity of blood or to other infectious flu -
ids
 y Exposure to the blood of a patient in an advanced HIV disease 

— HIV Post Exposure Prophylaxis (PEP) for exposed healthcare personel  —Chapter 17:  HIV Infections and AIDS
465stage
 y A deep percutaneous injury or an injury with a hollow bore, 
blood filled needle.
Signs 
 y None 
Symptoms
 y None
Box 17-1:   Steps to prevent occupational transmission of HIV
In the event of possible exposure to HIV the following actions should be taken:
 yThe wound site should be cleaned with soap and water
 yFor mucous membranes, the exposed area should be flushed with plenty of 
water (e.g. eyes with water or saline)
 yAssess the level of risk: the risk of possible infection from the exposure 
should be assessed and classified based on the categories below:
 yVery Low Exposure: 
 yExposure of potentially infectious material to intact skin)
 yLow Risk Exposure: 
 yExposure to a small volume of blood or body fluids contaminated with 
blood from asymptomatic HIV-positive patient  
 yInjury with a solid needle or any superficial injury or mucocutaneous ex -
posure
 yHigh Risk Exposure: 
 yExposure to a large volume of blood or potentially infectious fluids
 yExposure to blood or body fluids contaminated with blood from an HIV 
positive patient with high viral load
 yInjury with a hollow bore needle/deep and extensive injury from a con -
taminated sharp instrument
 yExposure to blood from an HIV drug resistant patient
Investigations 
 y Full blood count
 y Liver and renal function tests 
 y Hepatitis B Surface Antigen
 y HIV serology or PCR if available
Treatment 
Treatment Objectives 
 y To prevent establishment of HIV infection
Non-pharmacological treatment 
 y Counselling and Testing:
 y Exposed health workers must receive counselling and testing 
immediately from a trained counsellor. The session is to continue 
throughout the PEP period and thereafter if necessary. Refusal of HIV 
test by any exposed worker should be documented
 y Counsellor must emphasize safe sex including condom use.
 y All known source-patients shall also be counselled and tested 

— HIV Post Exposure Prophylaxis (PEP) for exposed healthcare personel  —
Standard  Treatment Guidelines, 7th Edition, 2017
466for HIV infection if this is not known.  
Pharmacological treatment 
Note 17-1  
Timing: If PEP is necessary, it should be initiated promptly, preferably within 1-2 
hours post–exposure and not more than 72 hours after exposure.
Evidence Rating: [A]
A. Very Low Risk 
 y Wash exposed area immediately with soap and water
B. Low Risk 
 y Tenofovir 300 mg daily for 28 days 
And
 y Emtricitabine  200 mg daily for 28 days
Or
 y Zidovudine  300 mg 12 hourly for 28 days 
And
 y Lamivudine  150 mg 12 hourly for 28 days
C. High Risk 
 y Tenofovir  300 mg daily for 28 days 
And
 y Emtricitabine  200 mg daily for 28 days 
And
 y Lopinavir /r 400 mg/100 mg 12 hourly for 28 days
Or
 y Zidovudine  300 mg 12 hourly for 28 days 
And
 y Lamivudine  150 mg 12 hourly for 28 days 
And
 y Lopinavir /r 400 mg/100 mg 12 hourly for 28 days
Note 17-2
If the source patient is HIV/HBV co-infected then a Tenofovir  containing regimen 
should be used.
Follow up
During the period of prophylaxis a number of baseline and follow-
up investigations need to be done to determine HIV sero-status, and to 
monitor the level of drug toxicity. 

— HIV Post Exposure Prophylaxis (PEP) for exposed healthcare personel  —Chapter 17:  HIV Infections and AIDS
467Table 17-5:   Recommended Monitoring of Drug Toxicity & HIV Serology of 
Exposed Health Care Personnel
Baseline tests: Full blood count
Liver and renal function tests, Hepatitis B Surface Antigen
HIV serology or PCR if available
Two weeks: Full blood count 
Liver and renal function tests
Six weeks: HIV serology
Three months: HIV serology
Six months: HIV serology
Individuals who sero-convert should have access to comprehensive care 
and ART services.
Box 17-2:   Reporting and Documentation
All occupational exposures should be reported immediately to the supervisor; 
circumstances of the exposure and PEP management should be recorded. 
Details should include:
 yDate and time of exposure
 yWhere and how the exposure occurred, exposure site on the body and type 
of sharp device. Type and estimated amount of exposure fluid, severity 
(depth/extent) of the exposure
 ySource of exposure and whether the source material contained HIV or 
blood.
 yClinical status of source patient.
 yRelevant information about exposed health care worker (medical condi -
tions, vaccination including Hepatitis B, and medications, pregnancy or 
breast-feeding)
 yDocument counselling, post exposure management and follow ups

18Chapter
468Infectious Diseases and 
Infestations 
182� Fever   
Fever  is a common complaint, which is usually related to an infection 
of viral, bacterial or parasitic origin. It may be a valuable guide to the 
diagnosis and severity of infections.
Fever  is defined as an axillary temperature above 37.5 °C (read after 
keeping the thermometer in place for 3 minutes).  Fever above 38 °C in 
children and adults often needs urgent attention, especially if the patient 
is restless or delirious. Not every fever is due to malaria or typhoid. 
Every fever should be investigated and treated appropriately. A thorough 
history, physical examination and appropriate investigation would usually 
reveal the cause of the fever.
In neonates and the elderly, severe infections may not be accompanied 
by a fever. In infants and young children, fever may be associated with 
convulsions, collapse or coma . (See table below for possible differential 
diagnoses and appropriate action) 
Causes 
 y Viral infection
 y Bacterial infection 
 y Fungal infections
 y Parasitic infestations
 y Haematological malignancies e.g. lymphoma, leukaemia
 y Connective tissue disease
 y Medicine-related 
Symptoms
 y Chills, rigors
 y Body aches
Signs
 y Temperature > 37.5 oC
 y Evidence of dehydration  e.g. sunken eyes
 y Evidence of underlying conditions (refer guidelines below)
 y Tachypnoea
 y Tachycardia

— Fever   —Chapter 18:  Infectious Diseases and Infestations 
469Investigations
 y FBC
 y Blood film for malaria parasites
 y Rapid diagnostic test for malaria 
 y Cultures of urine, blood, sputum, ear discharge, throat swab, wound 
swab, cerebrospinal fluid depending on presentation 
Treatment 
Treatment objectives
 y To reduce body temperature to normal 
 y To relieve symptoms
 y To identify and treat the underlying cause of the fever (see guidelines 
below)
Non-pharmacological treatment
 y Keep the patient well hydrated with fluids e.g. water, fruit juices, 
light porridge, “rice-water” or coconut milk
 y Maintain nutrition, continue breast-feeding in babies
 y Tepid sponge the child. (Wet a towel with lukewarm water and apply 
to the body starting from the extremities and gradually work your 
way upwards to the head. Leave a film of water on the body to dry 
on the skin. Repeat the process as often as needed)
Pharmacological treatment 
Evidence Rating: [A]
 y Paracetamol , oral, 
Adult s
1 g 6-8 hourly
Children
10-15 mg/kg/dose. May repeat dose 6-8 hourly as necessary 
Or
 y Paracetamol , rectal suppository,
Adult s
1 g 6-8 hourly
Children  
125-250 mg 6-8 hourly
Or 
 y Ibuprofen , oral,
Adult s
200-400 mg 6-8 hourly
Children
7-18 years;   200 mg 6-8 hourly 
2-7 years;   100 mg 8 hourly  
6 months-2 years;  50 mg 8 hourly 
1-6 months;   5 mg/kg 6-8 hourly  
Treat the cause of the fever appropriately (See appropriate section) 

— Fever   —
Standard  Treatment Guidelines, 7th Edition, 2017
470Note 18-1
DO NOT give Aspirin  to children under the age of 16 years. Control convulsions 
with diazepam ( See section on ‘Seizure Disorders’)
Referral Criteria 
Fever  persisting for more than 10 days in spite of treatment should 
be considered as pyrexia of unknown origin (PUO) and should be referred 
for further investigation.
Table 18-1:   Guidelines for the treatment of the patient with fever
Complaints Diagnosis Action
(See appropriate 
section)(See appropriate section)
Rigors, fever (occasionally 
periodic), sweating, general 
malaise, joint painsMalaria Take a blood film or perform 
rapid diagnostic test for 
malaria parasites and treat 
appropriately
Rigors, fever, sweating, general 
malaise, altered sensoriumCerebral Malaria Take a blood film or perform 
rapid diagnostic test for 
malaria parasites and treat 
appropriately
Headache , vomiting , 
drowsiness, stiff neck, seizuresMeningitis Do not delay treatment while 
awaiting results of lumbar 
puncture
Cough , brown sputum, rapid 
breathing, pain on deep 
breathing Pneumonia  Give appropriate antibiotic
Increased frequency of 
urination and/or painful 
micturition, loin painUrinary tract 
infectionDo urine examination plus 
culture and sensitivity; Give 
appropriate antibiotic
Fever , constipation or 
diarrhoea (may be with blood), 
headache, abdominal pain, 
general malaiseTyphoid Start appropriate treatment
Warm, swollen, painful, 
reddish looking limbCellulitis , Erysipelas  
or impetigoGive appropriate antibiotic
Fever  in a child with cough, 
sore throat and red ear drumsOtitis media Give appropriate antibiotic

— Tuberculosis  —Chapter 18:  Infectious Diseases and Infestations 
471Complaints Diagnosis Action
Fever  during pregnancy with 
loin painPyelonephritis Take sample for urine culture 
and sensitivity and give 
appropriate antibiotic
Pain in a bone (usually a limb 
bone), painful to touchOsteomyelitis X-ray the affected part; treat as 
for osteomyelitis
Jaundice  preceded by feeling 
unwell, anorexia, low grade 
FeverViral hepatitis Do liver function tests, Hepatitis  
B surface antigen; treat 
conservatively, bed rest
Headache , body ache, runny 
nose, sneezingCommon cold or 
influenzaGive Paracetamol  if required
Long standing fever, weight 
loss, chronic diarrhoea, 
lymphadenopathyAcquired 
immunodeficiency 
syndromeManage as appropriate 
Sore throat or pain on 
swallowingTonsillitis  and 
pharyngitis Manage as appropriate
Abrupt fever, chills and 
malaise; weakness, muscle 
pain, rash, diarrhoea, bleedingViral haemorrhagic 
fever e.g. Ebola 
virus diseaseManage according to standard 
protocol
183� Tuberculosis  
Tuberculosis  (TB) may affect any part of the body, but the commonest 
site is the lung (Pulmonary TB). Other sites affected include the spine, 
bone and joints, brain, urinary tract, abdomen and lymph nodes etc.  
Pulmonary TB patients who have acid-fast bacilli (AFB) in their sputum 
(bacteriologically positive TB) are most infectious and spread the disease 
through airborne droplets when they cough, spit or sneeze.  Drinking 
unpasteurized milk may cause bovine TB, which manifests as abdominal 
TB. Persons with lowered resistance to infection, such as HIV /AIDS  and 
diabetes, are especially at risk of developing TB.  Such individuals tend 
not to have the typical symptoms and signs of TB. They may have features 
such as fever, weight loss and diarrhoea, which could also be attributed 
to the condition.
In children with severe malnutrition who show poor response to 
dietary treatment, TB must be considered and excluded.

— Tuberculosis  —
Standard  Treatment Guidelines, 7th Edition, 2017
472Causes 
 y Mycobacterium tuberculosis
 yMycobacterium	bovis  (bovine TB)
 y Mycobacterium africanum  I and II 
 yM.	microti , M. kansasii  and M. malmoensi  (rarer causes)
Symptoms
Adults
 y Cough  often for 2 weeks or more 
 y Chest pain
 y Loss of weight
 y Loss of appetite
 y Blood stained sputum
 y Fever
 y Drenching night sweats
Children
 y All adult symptoms and the following
 y Malnourished and chronically ill looking (cachexia)
 y Persistent low grade fever (lasting ≥ 2-3 weeks)
 y Failure to thrive
 y Fatigue, malaise, poor appetite
 y Back pain  and/or lower limb weakness
 y Irritability
 y Vomiting  and impaired consciousness (due to TB meningitis )
Signs
 y Signs of malnutrition 
 y Cachexia
 y Pallor
 y Signs of pneumonia or pleural effusion
 y Lymphadenopathy
 y Neck stiffness, altered level of consciousness in TB meningitis  
 y Spinal tenderness, gibbus, paraplegia/paresis in Pott’s disease
 y Signs of extrapulmonary disease
Investigations
 y Sputum smear microscopy  
 y Chest X-ray
 y Mantoux  test
 y Gene Xpert (Xpert MTB/Rif) 
 y Line Probe Assay 
 y Mycobacterial culture 
 y Full blood count 
 y ESR
 y Liver function test (for monitoring medication side effects)
 y HIV screening

— Tuberculosis  —Chapter 18:  Infectious Diseases and Infestations 
473Treatment 
Treatment objectives
 y To cure the disease
 y To prevent further transmission
 y To prevent the development of drug resistance
 y To manage drug side effects
 y To offer psychosocial support
 y To investigate close contacts. Where a child is affected, always check 
adult contacts with productive cough
Non-pharmacological treatment
 y Counselling
 y Encourage good nutrition (some food supplementation is provided 
by National TB Programme)
 y Encourage adequate rest
 y Admit severely ill patients
 y Assign a treatment supporter
Pharmacological treatment 
Note 18-2
For the purposes of TB management, consider the following definitions:
 yAdults – All persons aged 15 years and above 
 yChildren – All persons aged below 15 years  
 yNew Patients – All persons who have never had TB treatment or have taken 
TB treatment for less than one month.
 yPreviously Treated Patients – All patients who have previously received TB 
treatment for one month or more.   
Refer to the TB Client Card (TB 01) for guidance on formulations and dosing 
by weight� 
A.     Standard treatment 
1st Line Treatment 
TB 
Treatment 
CategoryTB Patient Type Treatment Regimen Comments
Adults Initial PhaseContinuation 
Phase
New 
Patients
Cat I + IIIAll New Cases 
(including): New 
smear-positive 
PTB; 
New smear 
negative PTB;
Concomitant HIV  
disease;
Extra-pulmonary 
TB2 months 
of HRZE  = 
56 doses of 
HRZE 4 months 
of HR = 112 
doses of HR 
 Treatment is once 
daily 
In HIV  disease, 
treatment can 
be extended to 8 
months

— Tuberculosis  —
Standard  Treatment Guidelines, 7th Edition, 2017
474TB 
Treatment 
CategoryTB Patient Type Treatment Regimen Comments
Previously 
Treated 
Patients
Cat IIPreviously 
treated sputum 
smear-positive 
PTB:
- Relapse
- Treatment after 
interruption  
- Treatment failure2 months of 
S + 3 months 
of HRZE
= 56 doses 
of S and 84 
doses of 
HRZE5 months of 
HRE 
= 140 doses 
of HRERequest Drug 
susceptibility 
testing (DST)  
before start of 
treatment
Treatment is once 
daily
TB 
Meningitis * 
& Osteo-ar -
ticular TBAll cases 2 months 
of HRZE  = 
56 doses of 
HRZE10 months 
of HR
= 280 doses 
of HR Treatment is once 
daily 
Children Initial PhaseContinuation 
PhaseComments
New 
PatientsAll New Cases 
(including): New 
smear-positive 
PTB; 
New smear 
negative PTB;
Concomitant HIV  
disease;
Extra-pulmonary 
TB2 months 
of HRZE  = 
56 doses of 
HRZE4 months 
of HR 
= 112 doses 
of HRTreatment is once 
daily 
In HIV  disease, 
treatment can 
be extended to 8 
months
Previously 
Treated 
PatientsPreviously 
treated sputum 
smear-positive 
PTB:
- Relapse
- Treatment after 
interruption
- Treatment failure2 months of 
S + 3 months 
of HRZE
= 56 doses 
of S and 84 
doses of 
HRZE5 months of 
HRE 
= 140 doses 
of HRERequest DST 
before start of 
treatment
Treatment is one 
daily 
TB 
Meningitis * 
& Osteo-ar -
ticular TBAll cases 2(HRZE ) = 
56 doses of 
HRZE10(HR) = 280 
doses of HRTreatment is daily
Isoniazid  (H), Rifampicin  (R), Pyrazinamide  (Z), Ethambutol  (E), Streptomycin  (S)
Note 18-3
Treatment month is 28 days.  
All patients taking Isoniazid  (H) should take 25 mg of Pyridoxine  (Vitamin B6 ) to 
prevent peripheral neuropathy. 
Dose of Pyridoxine  should be doubled in HIV  patients

— Tuberculosis  —Chapter 18:  Infectious Diseases and Infestations 
475* Indications for steroid use in childhood TB include Endobronchial TB , Large 
Pleural Effusions, Pericardial Effusion and TB Meningitis . The duration of steroid 
use should not exceed one month.    
All children under 5 years and all HIV  positive children who are contacts of a 
TB patient should be given prophylactic Isoniazid  at a dose of 10 mg/kg body 
weight for at least 6 months.
Table 18-2:   Dosing for TB Medicines
Anti-TB Drug (Ab -
breviation)Recommended Daily Dosage (Maximum Dose)
Adult Dosing Children Dosing
Isoniazid  (H) 4-6 mg/kg (375mg) 10 – 15 mg/kg (300 mg)
Rifampicin  (R) 8-12 mg/kg (750 mg) 10 – 20 mg/kg (600 mg)
Pyrazinamide  (Z) 20-30 mg/kg (2000 mg) 30 – 40 mg/kg (2000 mg)
Ethambutol  (E) 15-20 mg/kg (1375 mg) 15 – 25 mg/kg (1200 mg)
Streptomycin  (S) 12-18 mg/kg (1000mg) 20 – 40 mg/kg (1000mg)
B.     Adjunctive treatment 
 y Pyridoxine  (Vitamin B6 ), oral, 
Adult s
50-100 mg daily for 3- 8 months
Children
25-50 mg daily for 8 months
And 
 y Prednisolone , oral, (in cases of TB meningitis  and TB pericarditis)
Adult s
40-60 mg daily, 2-4 weeks then taper off on improvement over 2-4 
weeks and discontinue
Children
1-2 mg/kg daily, 2-4 weeks then taper off on improvement over 2-4 
weeks and discontinue
C.     Treatment in Special Situations
Chronic kidney disease
New cases (Adults and children)
Owing to a high risk of uveitis, give the following   
 y Intensive phase  - HRZ for 2 months
 y Continuation phase  - HR for 4 months
Pregnancy and breastfeeding
 y Give standard treatment. 
 y Do not use streptomycin (ototoxic to foetus)
Note 18-4
Prevention of drug resistance
 yTo prevent the development of drug resistance to Rifampicin  it is recom -

— Drug resistant tuberculosis (DR-TB)  —
Standard  Treatment Guidelines, 7th Edition, 2017
476mended that Isoniazid  + Rifampicin combination tablet is used instead. Pre -
scribing Rifampicin alone is not approved and must be discouraged
 yDuring treatment the patient must swallow all the oral drugs preferably on 
an empty stomach under direct observation
 yThe patient needs to be under close supervision by a health worker or a 
responsible person or member of the community with support from health 
staff during the full duration of treatment
Monitoring
During the course of treatment, all smear positive pulmonary TB patients should 
have repeat sputum smears examined after 2 (or 3 months if retreatment), at 
5 months and at the end of treatment. If result is smear positive, request for 
mycobacterial culture and drug sensitivity testing. 
184. Drug resistant tuberculosis (DR-TB ) 
Drug resistant tuberculosis (DR-TB) must be presumed (suspected) 
in persons who remain bacteriologically positive (either smear positive, 
culture positive or Gene Xpert positive) after intensive phase of standard 
first-line TB treatment with or without clinical improvement. Persons who 
test rifampicin resistance positive at initial diagnosis with Gene Xpert 
must also be treated as cases of DR-TB. These persons must be further 
evaluated using TB culture and Drug Susceptibility Testing (DST) or newer 
molecular diagnostic tests such as Line Probe Assays (LPA). 
Persons at high risk of drug resistance are TB patients failing Category 
I+III or Category II treatment, contacts of confirmed DR-TB patients and 
TB/HIV co-infected patients not improving on treatment. 
Persons at medium risk of drug resistance are relapsed TB patients, 
return after lost-to-follow up and health care workers newly diagnosed 
with TB. Patients are classified according to the pattern of documented 
drug resistance profile. 
The drug regimen for treatment is selected based on the following 
principles: 
 y History of drugs used to treat TB patients, profile of drug resistance 
in Ghana and/or DST profile of the patient
 y A minimum of four new core medicines that are known to be effective
 y Kanamycin/Capreomycin an injectable medicine, is the backbone of 
the four core medicines and should be used in the intensive phase
 y An effective fluoroquinolone should be used due to the extensive 
use of earlier generation fluoroquinolones
 y May include a first line drug to which the strain is susceptible.
 y Cross-resistance may occur between drugs of the same group and 
this is taken into consideration.
 y Drugs are administered daily under strict DOT throughout the 
injectable and continuation phases.
Treatment of Multi Drug Resistant-TB (MDR-TB) and Rifampicin 
Resistant-TB (RR-TB) patients is prioritised. Treatment duration is 20-24 

— Drug resistant tuberculosis (DR-TB)  —Chapter 18:  Infectious Diseases and Infestations 
477months and is determined by sputum smear and culture (bacteriological) 
conversion (Treatment lasts 16-18 months after bacteriological 
conversion). Progression from initial to continuation phase is dependent 
on at least four (4) consecutive months of negative sputum cultures. 
Community-based care is promoted in Ghana over facility-based care 
except in situations requiring admission for management of complications. 
The practice of infection prevention and control should be maintained at 
all times during treatment of these patients. 
Treatment adherence is critical in the treatment of DR-TB due to 
limited number of available, effective medicines. Treatment is challenging 
due to long duration, drug toxicities and side effects. Clinical teams must 
use a patient-centred care approach and support patients throughout 
treatment until cured. Psychosocial and economic support is required 
from treatment supporters, patient families and clinical teams throughout 
treatment. Early detection and prompt management of drug side effects 
ensures successful outcomes.
Treatment 
Pharmacological treatment 
Note 18-5
Treatment of Multi Drug Resistant-TB (MDR-TB ) and Rifampicin  Resistant-TB 
(RR-TB) patients is prioritised. Treatment duration is 20-24 months and is de -
termined by sputum smear and culture (bacteriological) conversion (Treatment 
lasts 16-18 months after bacteriological conversion). Progression from initial to 
continuation phase is dependent on at least four (4) consecutive months of neg -
ative sputum cultures. 
2nd Line Treatment 
B.     Multi Drug Resistant-TB (MDR-TB ) 
TB Treatment 
CategoryTB Patient 
TypeTreatment Regimen Comments
Adults and Children Initial 
PhaseContinuation 
Phase
Multi Drug 
Resistant 
Tuberculosis 
(MDR-TB)All Newly 
Diagnosed 
MDR-TB with or 
without HIV  &
Symptomatic 
contacts of 
Confirmed 
MDR-TB with or 
without HIV8 months 
of Z-Cm-
Lfx-Pto-
Cs#(PAS*)12 months 
Z-Lfx-Pto-Cs# 
(PAS*)Treatment is 
daily (Treatment 
month is 28 
days). 
Modify 
treatment 
according to 
culture results.  
# For every 250mg of Cycloserine give 50mg of Pyridoxine (Vitamin B6) to prevent Peripheral 
Neuropathy. Dose of Pyridoxine should be doubled in HIV patients. 
* PAS is an alternative to Cs   

— Drug resistant tuberculosis (DR-TB)  —
Standard  Treatment Guidelines, 7th Edition, 2017
478C.     Treatment Protocol for Other Resistant Types
Table 18-3:   Treatment Protocol for Other Resistant Types
Resistance Pat -
ternTB Patient 
TypeTreatment Regimen Comments
Adults and Children Initial Phase Continuation 
Phase
Streptomycin 
resistant (S)Mono-Resis -
tant2 months of 
HRZE4 months of HR
Ethambutol 
resistant (E) Mono-Resis -
tant 3 months of 
HRZ6 months of HR
Isoniazid resis -
tant (H) Mono-Resis -
tant 9 months of HRZE Add extra dose of 
Isoniazid up to a 
maximum of 300 
mg daily for treat -
ment duration 
Streptomycin 
and Isoniazid 
resistant (S-H) Poly-Resistant 
TB9 months of HRZE Add extra dose of 
Isoniazid up to a 
maximum of 300 
mg daily for treat -
ment duration 
Isoniazid and Eth -
ambutol resistant 
(H-E)  Poly-Resistant 
TB9 months of R-Z-Lfx Extend treatment 
to 12 months if 
extensive lung 
destruction from 
x-ray image
H, E, and S (±Z) Poly-Resistant 
TB3 months of 
Km-Pto-Lfx-R-Z15 months of 
Pto-Lfx-R-ZModified MDR 
regimen plus R
R mono- or poly- 
resistance Rifampicin-Re -
sistant TB8 months of 
H-Z-Cm-Lfx-Pto-
Cs (PAS*)12 months of 
H-Z-Lfx-Pto-Cs 
(PAS*)Full MDR regimen 
plus H
 * PAS is alternative to Cs   
Note 18-6
Definitions 
Mono-resistant TB: 
TB bacilli have resistance to only one from the first line anti-tuberculosis medi -
cines: streptomycin, isoniazid, rifampicin, pyrazinamide or ethambutol.
Poly-Resistant: 
TB bacilli have resistance to at least two medicines but not to both isoniazid 
and rifampicin. 
Rifampicin-Resistant (RR-TB): 
TB bacilli have resistance to rifampicin, with or without resistance to other first 
line anti-tuberculosis medicines. This may be mono, poly, multi or extensively 
drug resistant TB. 

— Typhoid Fever   —Chapter 18:  Infectious Diseases and Infestations 
479Multi-Drug Resistant (MDR-TB): 
TB bacilli have resistance to at least both rifampicin and isoniazid. 
Extensively Drug Resistant (XDR-TB): TB bacilli have resistance to one of the 
fluoroquinolones and at least one of the three injectable second-line drugs (ka -
namycin, capreomycin or amikacin), in addition to MDR  TB.
Table 18-4:   Dosing of Second-Line Medicines
Anti-TB Drug 
(Abbreviation)Recommended Daily Dosage (Maximum Dose)
Adult Dosing Children Dosing
Pyrazinamide (Z) 20-30 mg/kg once daily (2000 mg) 30-40 mg/kg once daily (2000 
mg)
Kanamycin (Km) 15-20 mg/kg once daily (1000 mg) 15-30 mg/kg once daily (1000 
mg)
Capreomycin (Cm) 15-20 mg/kg once daily (1000 mg) 15-30 mg/kg once daily (1000 
mg)
Levofloxacin (Lfx) 750-1000 mg once daily (1000 
mg)15-20 mg/kg/day in 2 divided 
doses (1000 mg)
Ethionamide (Eto) 500-750 mg daily in 2 divided 
doses (1000 mg)15-20 mg/kg/day in 2 divided 
doses (1000 mg)
Prothionamide 
(Pto) 500-750 mg daily in 2 divided 
doses (1000 mg)15-20 mg/kg/day in 2 divided 
doses (1000 mg)
Cycloserine (Cs) 500-750 mg daily in 2 divided 
doses (1000 mg)10-20 mg/kg/day in 2 divided 
doses (1000 mg)
Para-aminosalicylic 
acid (PAS)8g once daily or in 2 divided doses 
(12g) 200-300 mg/kg/day in 2-3 divid -
ed doses (8g)  
Note 18-7
Ghana will be adopting a shorter treatment regime (9-12 months) for manage -
ment of DR-TB.  Please keep checking with the National TB Control programme.
Referral Criteria 
Refer all patients to a DOTS treatment centre for management and 
monitoring under Ghana National Tuberculosis Programme.
185� Typhoid Fever   
Typhoid fever  (enteric fever ) is a severe bacterial illness, which 
occurs where sanitary conditions are poor permitting contamination of 
food or water with faeces. The bacteria which are spread by the faeco-oral 
route invade the intestinal wall and spread through the bloodstream to 
all organs. They are passed into the stool and urine of infected patients. 
Organisms may continue to be present in the stool of healthy carriers, i.e. 

— Typhoid Fever   —
Standard  Treatment Guidelines, 7th Edition, 2017
480patients with positive stool cultures, 12 months after treatment or those 
with long-term subclinical disease.
If improperly treated typhoid fever  may result in complications such 
as intestinal perforation with peritonitis, bloody stools, acute psychosis 
and severe intravascular haemolysis leading to acute kidney injury 
(especially in G6PD  deficiency).
Public education on good personal hygiene, hand washing and 
appropriate disposal of solid waste would often prevent the disease.  
Screening of food handlers by carrying out stool cultures to exclude 
carrier status and safe handling of food, fruits and vegetables are also 
helpful preventive measures.
Causes 
 y Salmonella  typhi  and paratyphi
Symptoms
 y Fever  which increases gradually to a high fever and persists for weeks 
(fever does not respond to antimalarials)
 y Constipation  in the early stages
 y Abdominal pain and diarrhoea in the second week of illness
 y Severe headache 
 y Dry cough
 y Psychosis  and confusion may occur
Signs
 y High fever with a relatively slow pulse rate (occasionally pulse is fast 
especially with myocarditis or intestinal perforation) 
 y Abdominal tenderness 
 y Hepato-splenomegaly (tender)
 y Confusion
 y Signs of chest infection (pneumonitis)     
Investigations
 y FBC, differential, 
 y RDT / blood film for malaria parasite (to exclude malaria)
 y Blood culture
 y Stool culture
 y Urine culture
Note 18-8
Notes on Diagnosis
 yDiagnosis of typhoid fever  is based on a strong clinical suspicion backed by 
 yBlood cultures, positive during first 10 days of fever
 yStool cultures, positive after 10th day up to 4th or 5th week
 yUrine cultures, positive during 2nd and 3rd week 
 yThe above tests are superior to the Widal test, which is unreliable and rarely 
useful in confirming a diagnosis of typhoid fever

— Typhoid Fever   —Chapter 18:  Infectious Diseases and Infestations 
481Treatment 
Treatment objectives
 y To eradicate the infection
 y To detect and manage complications
 y To prevent transmission of infection to other people
Non-pharmacological treatment
 y Tepid sponging to reduce body temperature if required
Pharmacological treatment 
Evidence Rating: [B]
 y Ciprofloxacin , oral,
Adult s
500 mg 12 hourly for 10-14 days
Children
10 mg/kg 12 hourly for 10-14 days
Or 
 y Ciprofloxacin , IV, (to be administered over 60 minutes)
Adult s
400 mg 8-12 hourly for 10-14 days
Children
10 mg/kg (max. 400 mg) 12 hourly for 10-14 days
Note 18-9
Ciprofloxacin  should be used with  in children. Ciprofloxacin may rarely cause 
tendinitis. At the first sign of pain or inflammation, patients must discontinue 
treatment and alternative treatment (e.g. Azithromycin /Ceftriaxone ) started.
2nd Line Treatment 
Evidence Rating: [B]
 y Ceftriaxone , IV, 
Adult s
2-4 g daily for 7-10 days 
Children
100 mg/kg daily for 7-10 days
Or 
 y Azithromycin , oral,
Adult s    
500 mg daily for 7 days
Children  
10-20 mg/kg for 7 days
Referral Criteria 
Refer very ill patients and those with complications such as intestinal 
perforation, intravascular haemolysis and peritonitis to the appropriate 
specialist. Healthy carriers should also be referred for specialist 
management.

— Malaria —
Standard  Treatment Guidelines, 7th Edition, 2017
482186� Malaria
Malaria  is a very common infection in Ghana. It follows the 
introduction of protozoan malaria parasites into the bloodstream by 
the bite of an infected female Anopheles mosquito. Malaria is a major 
cause of significant morbidity and mortality especially among vulnerable 
individuals, such as children under 5 years of age, pregnant women 
(sometimes with adverse foetal and maternal outcomes), patients with 
sickle cell disease and visiting non-resident Ghanaians and expatriates.  
Based on the clinical severity, cases of malaria are categorized as 
either ‘uncomplicated’ or ‘severe’. A diagnosis of malaria can be suspected 
based on the patient’s symptoms and the physical findings at examination. 
However, for a definitive diagnosis to be made laboratory tests (blood film 
and/or Rapid Diagnostic Test ) must demonstrate the malaria parasites or 
their components since the clinical presentation of the condition can be 
similar to other common diseases such as typhoid fever , urinary tract 
infection, septicaemia , pneumonia and meningitis  in both adults and 
children and measles, otitis media , tonsillitis, etc. in children.
In Ghana, diagnosis is progressively being shifted from clinical to 
laboratory confirmation as the basis for treatment. Rapid Diagnostic Test 
(RDT ) may be used to confirm a diagnosis if microscopy (blood film) is not 
available.
Preventive measures in the community mainly target elimination 
of the insect vector or prevention of mosquito bites while additional 
chemoprophylaxis is required for vulnerable individuals.  
The development of resistance of malaria parasites to anti-malarial 
medications is a matter of major public health concern. This phenomenon 
is largely the result of ‘over-diagnosis’ and wrong diagnosis of malaria 
by healthcare practitioners and patients alike, with its attendant over-
treatment and sometimes partial or incomplete treatment, leading to 
over-exposure of the parasites to the anti-malarial drug (drug pressure).   
Additionally, Artemisinin Combination Therapy (ACT ), rather than 
monotherapy with artemisinin derivatives, is currently recommended for 
the treatment of uncomplicated malaria to prevent the development of 
drug resistance.
It is therefore necessary to obtain laboratory confirmation of 
a diagnosis of malaria before starting treatment.  Exceptions to this 
principle are children under 5 years and cases of suspected severe 
malaria where laboratory confirmation is not immediately possible. In 
such circumstances, a complete course of the appropriate anti-malarial 
medication(s) must be given.
Causes 
 y Plasmodium falciparum  (commonest and responsible for most of the 
deaths and morbidity associated with malaria in Ghana)

— Uncomplicated Malaria —Chapter 18:  Infectious Diseases and Infestations 
483 y Plasmodium malariae
 yPlasmodium	ovale
187� Uncomplicated Malaria
Symptoms
 y Fever  
 y Chills 
 y Rigors 
 y Sweating
 y Headache
 y Generalized body and joint pain
 y Nausea  and/or vomiting
 y Loss of appetite
 y Abdominal pain (especially in children)
 y Irritability and refusal to feed (in infants)
Signs
 y Fever
 y Mild pallor
 y Mild jaundice 
 y Splenomegaly
Investigations
 y Microscopy - thick and thin blood films for malaria parasites
 y Rapid Diagnostic Test (RDT ) 
 y FBC
 y Other tests as indicated
Treatment 
Treatment objectives
 y To avoid progression to severe malaria 
 y To limit the duration of the illness
 y To minimize the development of drug resistant parasites
Non-pharmacological treatment
 y In children, tepid sponging to reduce body temperature 
Pharmacological treatment 
1st Line Treatment 
Evidence Rating: [A]
 y Artesunate + Amodiaquine , oral, (See Table 18-5 on page 484, Table 
18-6 on page 484, Table 18-7 on page 484 )
Or
 y Artemether + Lumefantrine , oral, (See Table 18-8 on page 485) 
Or
 y Dihydroartemisinin + Piperaquine , oral, (See Table 18-9 on page 
485) 

— Uncomplicated Malaria —
Standard  Treatment Guidelines, 7th Edition, 2017
484Table 18-5:   Artesunate  + Amodiaquine  co-blistered formulation (Regimen 
for ONCE DAILY DOSING)
Weight Age Artesunate  (50 mg tablets) Num -
ber of Tablets To Be GivenAmodiaquine (150 mg base 
tablets) Number of Tablets To 
Be Given
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
5-10 kg < 1 yr ½ ½ ½ ½ ½ ½
11-24 kg 1-6 yr 1 1 1 1 1 1
24-50 kg 7-13 yr 2 2 2 2 2 2
50-70 kg 14-18 
yr3 3 3 3 3 3
>70 kg > 18 yr 4 4 4 4 4 4
The dose in mg/body weight is: Amodiaquine 10 mg/kg + Artesunate  4 mg/ kg, taken as a single 
dose daily for three (3) days, after meals.
Table 18-6:   Artesunate  + Amodiaquine  co-blistered formulation (Regimen 
for TWICE DAILY DOSING)
Weight Age Artesunate  (50 mg tablets) Num -
ber of Tablets To Be GivenAmodiaquine (150 mg base 
tablets) Number of Tablets To 
Be Given
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
AM PM AM PM AM PM AM PM AM PM AM PM
5-10 kg < 1 yr ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ 
11-24 kg 1-6 yr ½ ½ ½ ½ ½ ½ ½ ½ ½ ½ ½ ½
24-50 kg 7-13 yr 1 1 1 1 1 1 1 1 1 1 1 1
50-70 kg 14-18 yr 1½ 1½ 1½ 1½ 1½ 1½ 1½ 1½ 1½ 1½ 1½ 1½ 
>70 kg > 18 yr 2 2 2 2 2 2 2 2 2 2 2 2
 The dose in mg/body weight is: Amodiaquine 10 mg/kg + Artesunate  4 mg/kg, taken as two 
divided doses daily for three (3) days, after meals.
Table 18-7:  Artesunate  and Amodiaquine Fixed Dose Combination 
(Standard Regimen, using the 3 available dosing strengths)
Artesunate  (AS) + Amodiaquine (AQ) 
Number of Fixed Dose Combination Tablets to be given
Weight Age Tablet Dosing 
StrengthDay 1 Day 2 Day 3
<8 kg 2-11 mo. AS: 25 mg AQ: 
67.5 mg1 1 1

— Uncomplicated Malaria —Chapter 18:  Infectious Diseases and Infestations 
485Table 18-7:  Artesunate  and Amodiaquine Fixed Dose Combination 
(Standard Regimen, using the 3 available dosing strengths)
9-17 kg 1-5 yrs AS: 50 mg AQ: 
135 mg1 1 1
18-35 kg 6-13 yrs AS: 100 mg 
AQ: 270  mg1 1 1
> 36 kg > 13 yrs AS: 100 mg 
AQ: 270 mg2 2 2
Each Fixed Dose Combination tablet contains both Artesunate  (AS) and Amodiaquine (AQ), at 
the dosages indicated.  The product packaging clearly indicates which dosing strength applies 
to which age group. The  maximum daily dose of Artesunate/Amodiaquine is 200 mg/600 m g
Table 18-8:   Artemether  and Lumefantrine (Dosing Regimen)
Artemether  (20 mg) + Lumefantrine (120 mg) Number of Tablets 
To Be Given
Weight Age Day 1 Day 2 Day 3
First
DoseSecond
Dose
(after
8hrs)AM PM AM PM
< 5 kg < 6 mo Not recommended for patients under 5 kg
5-15 kg 6mo-3 yr 1 1 1 1 1 1
15-25 kg 3-8 yr 2 2 2 2 2 2
25-35 kg 8-12 yr 3 3 3 3 3 3
>35 kg >12 yr 4 4 4 4 4 4
  
Table 18-9:  Dihydroartemisinin and Piperaquine (Dosing Regimen)
Weight Age Dihydroartemisinin (40 mg) / Piperaquine (320 mg base) 
Number of Tablets To Be Given
Day 1 Day 2 Day 3
5-10 kg < 1 yr ¼ ¼ ¼
11-15 kg 1-3 yr ½ ½ ½
16-24 kg 4-6 yr 1 1 1
24-35 kg 7-10 yr 1¼ 1¼ 1 ¼
36-50 kg 11-13 yr 1½ 1½ 1 ½
50-70 kg 14-18 yr 2 2 2
>70 kg > 18 yr 3 3 2

— Severe Malaria —
Standard  Treatment Guidelines, 7th Edition, 2017
486188� Severe Malaria
Severe or ‘complicated malaria’ can arise from delay in diagnosis 
or inappropriate treatment of uncomplicated malaria. It mostly occurs 
in children under 5 years of age, pregnant women and non-immune 
individuals.  The events causing most deaths in severe malaria are 
related to cerebral involvement (cerebral malaria), severe anaemia, 
hypoglycaemia, severe dehydration , renal failure and respiratory acidosis.
The diagnosis of severe malaria is based on clinical features and 
confirmed with laboratory testing. Not all cases of severe malaria have 
high parasitaemia and initial blood film examination may be negative. 
Where the diagnosis is suspected, treatment must be started without 
delay while awaiting confirmation. 
Symptoms
 y Poor oral intake  (e.g. breast milk in children)
 y Repeated profuse vomiting
 y Dark or ‘cola-coloured’ urine
 y Passing of very little urine 
 y Difficulty in breathing 
 y Generalised weakness, inability to walk or sit without assistance
 y Altered consciousness (change of behaviour, confusion, delirium, 
coma )
 y Repeated generalized convulsions 
Signs
 y Hyperpyrexia  (axillary temperature > 38.5°C)
 y Extreme pallor (severe anaemia; Hb < 5 g/dl)
 y Marked jaundice 
 y Circulatory collapse or shock (cold limbs, weak rapid pulse) 
 y Tachypnoea  (Rapid breathing)
 y Crepitations on chest examination
 y Sweating (due to hypoglycaemia)
 y Haemoglobinuria (dark or ‘cola-coloured’ urine)
 y Oliguria
 y Spontaneous unexplained heavy bleeding (disseminated 
intravascular coagulation)
 y Altered consciousness (change of behaviour, confusion, delirium, 
coma )
Investigations
 y Rapid diagnostic test
 y Blood film for malaria parasites - thick and thin blood films (should 
be done where available)
 y FBC
 y Sickling test

— Severe Malaria —Chapter 18:  Infectious Diseases and Infestations 
487 y Random blood glucose 
 y BUE and creatinine
 y Blood grouping and cross-matching
 y Lumbar puncture in the convulsing or comatose patient to exclude 
meningitis  or encephalitis 
Treatment
Treatment objectives
 y To ensure rapid clearance of parasitaemia
 y To provide urgent treatment for life threatening complications or 
conditions e.g. convulsions, hypoglycaemia, dehydration , renal 
impairment
 y To provide appropriate supportive care
Non-pharmacological treatment
 y Place patients who are unconscious or having seizures in an 
appropriate position to prevent aspiration
Pharmacological treatment
 Evidence Rating: [A] 
A.      Pre-referral treatment 
 y Artesunate , IM, 
Adult s and Children  > 20 kg
2.4 mg/kg
Children  < 20 kg 
3 mg/kg
Or 
 y Artemether , IM, 
Adult s and Children  
3.2 mg/kg 
Or 
 y Quinine , IM, 10Artesunate, rectal, 10 mg/kg (preferred in children 
under 6 years;ee Table 110) 
Or
 y Artesunate , rectal, 10 mg/kg (preferred in children under 6 years; 
Table 18-10:  Dosing Regimen for Quinine  IM Injection in young Children
Weight Volume of Quinine  Dihydrochloride 
Injection  (50 mg/ml dilution)
< 5 kg 1.0 ml
5.1-7.5 kg 1.5 ml
7.6-10.0 kg 2.0 ml
10.1-12.5 kg 2.5 ml
12.6-15.0 kg 3.0 ml
15.1-17.5 kg 3.5 ml - half to each thigh

— Severe Malaria —
Standard  Treatment Guidelines, 7th Edition, 2017
488Table 18-10:  Dosing Regimen for Quinine  IM Injection in young Children
17.6-20.0 kg 4.0 ml - half to each thigh
20.1-22.5 kg 4.5 ml - half to each thigh
22.6-25.0 kg 5.0 ml - half to each thigh
25.1-27.5 kg 5.5 ml - half to each thigh
27.6-30.0 kg 6.0 ml -  half to each thigh
The dosage for IM Quinine  is 10 mg (0.2 ml) per kg of bodyweight every 8 hours.
Note 18-10
How to give Intramuscular Quinine
Intramuscular Quinine  in Young Children:
 yWeigh the child
 yPrepare a Quinine  dilution of 50 mg/ml:  Use a 10 ml sterile syringe and 
needle to draw up 5 mls of sterile water for injection or saline (not dextrose). 
Then into the same syringe draw up 300 mg (1ml) from an ampoule of Qui -
nine. The syringe now contains 50 mg Quinine per ml. 
 yThe dosage is 10 mg (0.2 ml) per kg or body weight every 8 hours. Calculate 
the volume to give based on body weight.  (For examples of body weights 
and doses in children < 30 kg, sArtesunate, rectal, 10 mg/kg (preferred in 
children under 6 years;110).
 yAdminister by intramuscular injection to the thigh. If the diluted volume ex -
ceeds 3 ml, inject half the dose into each thigh.
Intramuscular Quinine  in Adults:
 yUse a Quinine  dilution of 100 mg/ml. To prepare this, draw 2 mls of Quinine 
600 mg and add 4 mls of sterile water or saline (not dextrose)
 yThe dosage is 10 mg/kg body weight of Quinine  given 8 hourly by deep IM 
injection, to a maximum dose of 600 mg
 ySmall adults (weighing less than 60 kg) should be weighed to calculate the 
correct dose.  Larger adults will simply receive the maximum dose (600 mg)
 yIf the required volume is more than 5 ml, divide it into two and inject at 
separate sites
Table 18-11:  Rectal Artesunate  (Pre-Referral Treatment in Children)
Weight Age Artesunate
DoseRegimen
5 - 8 kg < 1 yr 50 One 50 mg suppository
9 - 19 kg 1 - 1½ yrs 100 Two 50 mg suppositories
20 - 29 kg 1½ - 5 yrs 200 One 200 mg suppository
30 - 39 kg 6 - 13 yrs 300 Two 50 mg and one 200 mg 
suppositories
> 40 kg > 14 yrs 400 Two 200 mg suppositories

— Severe Malaria —Chapter 18:  Infectious Diseases and Infestations 
489B.      Treatment in Referral Centre 
Note 18-11
Parenteral antimalarials and follow-on treatment.
The current recommendation is to give parenteral antimalarials in the treat -
ment of severe malaria for a minimum of 24 hours (irrespective of the patient’s 
ability to tolerate oral medication) until the patient is able to tolerate oral med -
ication as follow-on treatment. Recommended follow-on treatments include 
ACTs and Quinine + clindamycin. 
 y Artesunate , IV or IM, 
Adult s and Children  > 20 kg 
2.4 mg/kg 12 hourly 
Given at time 0 hour (i.e. on admission), at 12 hours and 24 hours
Then 
2.4 mg/kg daily until patient can swallow (max. 7 days)
Then
A full 3-day course of recommended oral artemisinin combination 
therapy (ACT ) 
Children  < 20 kg
3 mg/kg 12 hourly 
Given at time 0 hour (i.e. on admission), at 12 hours and 24 hours
Then 
3.0 mg/kg daily until patient can swallow (max. 7 days)
Then
A full 3-day course of recommended oral ACT
Note 18-12
Artesunate  reconstitution for parenteral injection
Reconstitution: 
Use a syringe to draw and inject the solvent (sodium bicarbonate 50mg/ml 
solution) into the vial of artesunate powder. Shake the vial until the powder is 
completely dissolved and the solution is clear.
For intravenous injection: Add either glucose 50 mg/ml (i.e. 5% Dextrose  solu -
tion) or sodium chloride 9 mg/ml (i.e. 0.9% Normal saline  solution) to the re -
constituted artesunate solution to create a 10 mg/ml solution of artesunate. 
Draw required volume and give slowly by IV at about 3-4 ml/minAdd either 
glucose 50 mg/ml (i.e. 5% Dextrose solution) or sodium chloride 9 mg/ml (i.e. 
0.9% Normal saline solution) to the reconstituted artesunate solution to create 
a 20 mg/ml solution of artesunate. Draw required volume and give slowly by IM 
anterior thigh. If the required volume is more than 5 ml, divide it into two and 
inject at separate sitAdd either glucose 50 mg/ml (i.e. 5% Dextrose solution) or 
sodium chloride 9 mg/ml (i.e. 0.9% Normal saline solution) to the reconstituted 
artesunate solution to create a 20 mg/ml solution of artesunate. Draw required 
volume and give slowly by IM anterior thigh. If the required volume is more 
than 5 ml, divide it into two and inject at separate sitAdd either glucose 50 mg/
ml (i.e. 5% Dextrose solution) or sodium chloride 9 mg/ml (i.e. 0.9% Normal 

— Severe Malaria —
Standard  Treatment Guidelines, 7th Edition, 2017
490saline solution) to the reconstituted artesunate solution to create a 20 mg/ml 
solution of artesunate. Draw required volume and give slowly by IM anterior 
thigh. If the required volume is more than 5 ml, divide it into two and inject at 
separate sites. (See Table 112)Table 112)Table 112)ble 112).
For intramuscular injection: 
Add either glucose 50 mg/ml (i.e. 5% Dextrose  solution) or sodium chloride 9 
mg/ml (i.e. 0.9% Normal saline  solution) to the reconstituted artesunate solu -
tion to create a 20 mg/ml solution of artesunate. Draw required volume and 
give slowly by IM anterior thigh. If the required volume is more than 5 ml, divide 
it into two and inject at separate sitAdd either glucose 50 mg/ml (i.e. 5% Dex -
trose solution) or sodium chloride 9 mg/ml (i.e. 0.9% Normal saline solution) to 
the reconstituted artesunate solution to create a 20 mg/ml solution of artesu -
nate. Draw required volume and give slowly by IM anterior thigh. If the required 
volume is more than 5 ml, divide it into two and inject at separate sitAdd either 
glucose 50 mg/ml (i.e. 5% Dextrose solution) or sodium chloride 9 mg/ml (i.e. 
0.9% Normal saline solution) to the reconstituted artesunate solution to create 
a 20 mg/ml solution of artesunate. Draw required volume and give slowly by IM 
anterior thigh. If the required volume is more than 5 ml, divide it into two and 
inject at separate sites. (See Table 112)Table 112)Table 112)
Table 18-12:  Approximate quantities for dilution 
Route IV Injection IM Injection
Strength of medicine 30 mg 60 mg 120 mg 30 mg 60 mg 120 mg
Sodium bicarbonate  
50 mg/ml solution for 
reconstitution (ml)0.5 1 2 0.5 1 2
Glucose 50 mg/ml 
solution for injection 
Or
Sodium chloride 9 
mg/ml for injection 
(ml)2.5 5 10 1 2 4
Total diluent needed 
(ml)3 6 12 1.5 3 6
Artesunate  
concentration (mg/
ml)10 10 10 20 20 20
Note 18-13
Calculation of dose of Artesunate  needed (ml):
Adults:
For IV route:          
2.4 mg x body weight (kg)
IV Artesunate  solution concentration 10 mg/ml

— Severe Malaria —Chapter 18:  Infectious Diseases and Infestations 
491For IM route:            
2.4 mg x body weight (kg)
IM Artesunate  solution concentration 20 mg/ml
Children < 20kg:
For IV route:          
3 mg x body weight (kg)
IV Artesunate  solution concentration 10 mg/ml
For IM route:            
3 mg x body weight (kg)
IM Artesunate  solution concentration 20 mg/ml
Precautions:
 yInject immediately after reconstitution and discard if not used within 1 hour
 yDiscard if solution is not clear
 yDo not use in IV drip, Give slowly by direct IV injection at about 3-4 ml/min
Or 
 y Artemether , IM, 
Adult s and Children
3.2 mg/kg stat.
Then (8 hours later)  
1.6 mg/kg
Then (24 hours after initiation of treatment)
1.6 mg/kg once daily until patient can swallow (up to 5 days)
Then
A full 3-day course of recommended oral artemisinin combination 
therapy (ACT ) 
Or
 y Quinine , IV, (in Dextrose  saline  or in 5% Dextrose [5-10 ml/kg])
Adults and Children
10 mg/kg (max. dose 600 mg) infused over 4-8 hours. 
Repeat infusion 8 hourly until patient can swallow. 
Then
 y Quinine , oral, 10 mg/kg 8 hourly to complete 7 days of treatment      
And
 y Clindamycin , oral, 10 mg/kg, 12 hourly for 7 days 
Note 18-14
Clindamycin  should be administered with food and copious amounts of water.
Quinine , IV, should always be given by a slow infusion, never by bolus intrave -
nous injection as this may cause severe hypotension.
Or
 y Quinine , IM,
Adult s and Children
10 mg/kg (max. dose 600 mg), 8 hourly until patient can swallow
Then
 y Quinine , oral, 10 mg/kg 8 hourly to complete 7 days of treatment 

— Malaria in Pregnancy —
Standard  Treatment Guidelines, 7th Edition, 2017
492     
And
 y Clindamycin , oral, 10 mg/kg, 12 hourly for 7 days 
Referral Criteria
Patients diagnosed as having severe malaria or who fail to respond to 
the recommended antimalarial medications must be referred. Appropriate 
treatment as indicated above must be initiated prior to transferring the 
patient. If referral is not possible immediately, continue the treatment 
regimen as shown above for severe malaria until referral is possible.
189� Malaria in Pregnancy
Pregnancy makes women more likely to get malaria or die from 
malaria. Malaria  infection is more severe during pregnancy while 
pregnancy and its outcomes can become complicated by it. The effects 
of malaria on the pregnant mother include a severe form of the illness, 
anaemia, miscarriage, pre-term labour, and post-partum haemorrhage. 
Risks to the foetus include foetal anaemia, pre-maturity, intra-uterine 
growth restriction, low birth weight, stillbirth, congenital malaria, and 
increased perinatal mortality. Preventive measures must be emphasised 
(i.e. Insecticide-treated Nets [ITNs] and Intermittent Preventive Treatment 
in pregnancy [IPTp ] under direct observation) while confirmed cases must 
be treated promptly.  
Treatment objectives
 y To ensure prompt and effective case management
Non-pharmacological treatment 
 y None 
Pharmacological treatment 
A.     Treatment of Uncomplicated Malaria  in the First Trimester  
 y Quinine , oral, (may be given as monotherapy if Clindamycin  is not 
available)
10 mg/kg (max. 600 mg) 8 hourly for 7 days
And
 y Clindamycin , oral, 10 mg/kg, twice daily for 7 days
Note 18-15
The drug of choice for uncomplicated malaria for pregnant women in the first 
trimester is oral Quinine .  ACTs are not recommended for use in the first tri -
mester. However, their use should not be withheld in cases where they are 
considered to be life-saving, or where other antimalarials are considered to be 
unsuitable.

— Malaria in Pregnancy —Chapter 18:  Infectious Diseases and Infestations 
493B.     Treatment of Uncomplicated Malaria  in the Second and Third 
Trimesters  
 y Artesunate + AmodiArtesunate + Amodiaquine co-blistered formu -
lation (Regimen for TWICE DAILY DOSING)orThe dose in mg/body 
weight is: Amodiaquine 10 mg/kg + Artesunate 4 mg/kg, taken as 
two divided doses daily for three (3) days, after meals. Table 15, Ta -
ble 16, Table 17) 
Or
 y Artemet efantrine , oral, (See Table 18)
Or
 y Quinine , oral, (See section Treatment of Uncomplicated Malaria  in 
the First Trimester)
C�     Treatment of Severe Malaria  in Pregnancy (All trimesters and 
puerperium )
Evidence Rating: [A]
 y Artesunate , IV or IM, 
Then
 y ACT, oral, for 3 days
(See section on Treatment of ‘Severe Malaria’  above)
Or 
 y Quinine , IV or IM,
Then
 y Quinine + clindamycin combination, oral,
(See section on Treatment of ‘Severe Malaria’  above)
D�     Treatment of Severe Malaria  in Pregnancy (Second and Third 
trimesters and Puerperium)
 y Artemether , IM, 
Then
 y 3 days of oral ACT
(See section on Treatment of ‘Severe Malaria’  above) 
E.     Intermittent Preventive Treatment in Pregnancy (IPTp )
IPTp  consists of giving the fixed-dose combination medication 
Sulphadoxine  Pyrimethamine  (SP) in treatment doses at predefined 
intervals after quickening (16 gestational weeks). Current recommendation 
is that IPTp with sulfadoxine-pyrimethamine (IPTp-SP ) be given to all 
pregnant women at each scheduled antenatal care visit except during the 
first trimester. WHO recommends a schedule of four focused antenatal 
care visits for normal pregnancy. In Ghana, the national malaria control 
strategy reserves SP for the purpose of intermittent preventive treatment 
only. 
To prevent the development of drug resistance, SP is not to be used 
for other purposes such as treatment of acute attacks of malaria. 
 y Sulphadoxine  (500 mg)-Pyrimethamine  (25 mg), oral, 

— Seasonal Malaria Chemoprevention (SMC) —
Standard  Treatment Guidelines, 7th Edition, 2017
494Note 18-16
Co-administered as Directly Observed Therapy (DOT) during antenatal visits on 
at least 3 occasions and at most on 7 occasions
Dose of 
IPTp Antenatal visit Recommended 
gestational 
weeksHealth worker to 
administer
IPTp1 First ANC visit after 
quickening 16 Midwives, Medical 
officers, Family 
physicians, Obstetricians
IPTp2 At least one month 
after the first dose.20 Midwives, Medical 
officers, Family 
physicians, Obstetricians
Physician assistants, 
Community Health 
Officers, Community 
Health NursesIPTp3 At least one month 
after the second dose.24
IPTp4-7 At least one month 
after each dose.28, 32, 36, 40
Note 18-17
Pregnant women with the following conditions shall be exempted from using 
SP:
 yFirst trimester of pregnancy (< 13 weeks gestation)
 yG6PD  enzyme deficiency
 ySevere liver disease or unexplained recurrent jaundice
 yKnown allergy to any sulpha drugs or allergy to pyrimethamine
 yHistory of previous reaction to SP
 yRecent treatment with a sulpha drug such as co-trimoxazole (within 4 weeks)
 yPost-dates pregnancy (gestation beyond 36 weeks)
 yBreastfeeding
 yAcute case of malaria (treat as above)
Owing to antagonism between folic acid and SP , folic acid supplementation 
should be delayed and started one week after SP administration. For additional 
information on IPTp  and malaria in pregnancy, refer to the latest Ghana Health 
Service training manuals and guidelines on the subject.
190� Seasonal Malaria Chemoprevention (SMC )
This is the intermittent administration of full treatment courses 
using the recommended anti-malarial medicine during peak malaria 
transmission seasons to prevent malaria illness. A complete treatment 
course is given to children aged between 3 and 59 months at monthly 
intervals to a maximum of 4 doses during the malaria transmission 
season. In Ghana, SMC  has been implemented in the Northern Savannah 
using Sulphadoxine -Pyrimethamine and Amodiaquine (SP + AQ)

— Meningitis —Chapter 18:  Infectious Diseases and Infestations 
495 y Sulphadoxine -Pyrimethamine, oral,
And 
 y Amodiaquine, oral, 
191� Meningitis
This is an infection of the coverings of the brain, and is most 
commonly caused by bacteria, viruses, fungi and protozoa. One type, 
Cerebrospinal Meningitis  (CSM ), caused by Neisseria	 meningitides , is 
common in the Northern and Upper Regions of Ghana, and usually 
occurs in epidemics during the harmattan season. The presentation may 
sometimes be confused with cerebral malaria. Meningitis  is a medical 
emergency. Failure to recognise and adequately manage meningitis 
results in serious complications.
Inform regional or district health authorities immediately in epidemic 
meningitis .
Causes 
 y Bacterial
 yNeisseria	meningitides  
 y Streptococcus  pneumoniae
 yHaemophilus	influenza
 y Mycobacterium tuberculosis
 y Staphylococcus aureus
 y Escherichia coli  (neonates)
 y Viruses e.g. Herpes viruses
 y Protozoa e.g. Toxoplasma  in HIV -AIDS
 y Fungi e.g. Cryptococcus neoformans
Symptoms
For Adults and Children > 5 years
 y Fever
 y Neck pains
 y Severe headaches
 y Photophobia
 y Change in behaviour
 y Convulsions
 y Vomiting
Children < 1 year 
 y Fever
 y Irritability
 y Refusal to eat
 y Poor sucking
 y Vomiting
 y Drowsiness and weak cry

— Meningitis —
Standard  Treatment Guidelines, 7th Edition, 2017
496 y Focal or generalized convulsions after which the child is sleepy
 y Lethargy
 y Bulging fontanelle
Signs
For Adults and Children > 5 years
 y Fever
 y Neck stiffness
 y Positive Kernig’s sign
 y Altered consciousness
 y Coma
Children < 1 year
 y Neck retraction  
 y Presence or absence of neck stiffness 
 y Presence or absence of fever
 y Bulging fontanelle
 y Coma
 y Hypotonia or hypertonia
 y Convulsion
Investigations
 y FBC
 y Rapid diagnostic test (to exclude cerebral malaria)
 y Blood film for malarial parasites (to exclude cerebral malaria)
 y Lumbar puncture (only after excluding raised intracranial pressure)
 y Blood culture and sensitivity
Treatment 
Treatment objectives
 y To identify and eradicate the causative organisms 
 y To prevent complications
 y To prevent spread to contacts 
 y To maintain good nutrition
Non-pharmacological treatment
 y Tepid sponging
 y Keep the airway clear 
 y Nasogastric tube feeding if applicable
Pharmacological treatment 
A.     Bacterial Meningitis
1st Line Treatment
Evidence Rating: [A]
 y Ceftriaxone , IV/deep IM, 
Adult s 
2-4 g daily for 7-10 days 
Children
> 12 years;     2-4 g daily for 7-10 days

— Meningitis —Chapter 18:  Infectious Diseases and Infestations 
497< 12 years;   50-80 mg/kg for 10-14 days
Neonate s;   20-50 mg/kg once daily for 21 days
And
 y Vancomycin , IV, 
Adult s 
15 mg/kg 12 hourly for 7-10 days 
Children
> 12 years;     15 mg/kg 12 hourly for 7-10 days 
2-12 years;   15 mg/kg 12 hourly for 7-10 days
1 month-2 years;    15 mg/kg 8 hourly for 10-14 days
< 1 month;    not recommended 
Or
Evidence Rating: [B]
 y Benzylpenicillin , IV,
Adult s
4 MU 4 hourly for 14 days
Children
0.2 MU/kg 6 hourly for 14 days 
And
 y Chloramphenicol , IV, 
Adult s
1 g 6 hourly for 14 days
Children
25 mg/kg 6 hourly for 14 days
This may be subsequently changed to oral therapy with significant 
clinical improvement
Or
 y Chloramphenicol , IM, (oily preparation)
Adult s 
100 mg/kg as a single dose
Children  
100 mg/kg as a single dose
Note 18-18
Not recommended for children below 2 months, and also for pregnant and lac -
tating mothers.
C�     For penicillin allergy  
 y Clindamycin , IV, 
Adult s
600-900 mg 8 hourly for 14 days
Children
13 mg/kg 8 hourly for for 14 days
And
 y Chloramphenicol , IV, 
Adult s
1 g 6 hourly for 14 days

— Meningitis —
Standard  Treatment Guidelines, 7th Edition, 2017
498Children
25 mg/kg 6 hourly for 14 days
2nd Line Treatment
Evidence Rating: [B]
 y Cefotaxime , IV, 
Adult s
2g 6 hourly for 7 days
Children  
> 12 years or body weight > 50kg; 2 g 6 hourly
< 12 years or body weight < 50kg; 50 mg/kg 6 hourly 
And
 y Vancomycin , IV, 
Adult s 
15 mg/kg 12 hourly for 7-10 days 
Children
> 12 years;     15 mg/kg 12 hourly for 7-10 days 
2-12 years;   15 mg/kg 12 hourly for 7-10 days
1 month-2 years;      15 mg/kg 8 hourly for 10-14days
< 1 month;   not recommended 
D�     Prophylaxis for CSM
Prophylactic treatment is recommended for patients 2 days prior to 
discharge and also for their close contacts
 y Ciprofloxacin , oral,
Adult s 
500 mg as a single dose (Avoid in Pregnancy)
Children
5-12 years;  250 mg as a single dose
Or
 y Ceftriaxone , IM,
Adult s 
250 mg as a single dose
Children
< 12 years;  125 mg as a single dose
Note 18-19
Role of steroids: Dexamethasone  started together with the first dose of the ap -
propriate antibiotic has been found to lead to major reduction in hearing loss 
and death in both children and adults. 
 y Dexamethasone , IV, 4-10 mg 6 hourly for 5-7 days 
Referral Criteria 
Refer all patients not responding to treatment within the first 48 
hours for specialist care.

— Worm Infestation (Intestinal)   —Chapter 18:  Infectious Diseases and Infestations 
499Table 18-13:  Summary of treatment options for Bacterial Meningitis
Age Pathogens 1st line Empirical 
treatmentAlternatives
 (Specialist care)
< 50 years Meningococcus, 
Pneumococcus ,
Haemophilus
InfluenzaCeftriaxone  
And
VancomycinCefotaxime
Meropenem  
Fluoroquinolones
> 50 years Pneumococcus , 
Listeria ,
Gram-negative bacilliCeftriaxone  
Or
Ampicillin  
And 
VancomycinFluoroquinolone
Hospital 
AcquiredStaphylococci ,
Gram-negative bacilli,
Pneumococcus
PseudomonasCeftazidime
+/- GentamycinMeropenem
Vancomycin
192� Worm Infestation (Intestinal)   
Infestation with worms  is very common. Poor hygiene or contact 
of bare skin with soil in which the worm or its eggs live predisposes 
individuals to infestation.
Causes 
 y Hookworm  
 y Ascaris 
 y Strongyloides  
 y Tape worm 
 y Thread worm 
 y Whip worm 
Symptoms
 y Generalised Itching 
 y Perianal itching (threadworm)
 y Dry cough (when the larvae pass through the lungs)
 y Wheeze (when the larvae pass through the lungs)
 y Abdominal discomfort and or pain
 y Easy fatiguability
 y Passage of worm(s) in the stool
 y Altered bowel habit
 y Vomiting  of worms
Signs
 y Pallor
 y Features of malnutrition

— Worm Infestation (Intestinal)   —
Standard  Treatment Guidelines, 7th Edition, 2017
500 y Poor physical growth in children
 y Large distended abdomen in children
 y Wheezing
Investigations
 y Stool for routine examination
 y FBC
Treatment 
Treatment objectives
 y To eliminate the worms
 y To treat the complications of infestation e.g. anaemia, malnutrition
 y To ensure proper sanitation 
Non-pharmacological treatment
 y Ensure proper nutrition
 y Proper hand washing with soap and running water
Pharmacological treatment 
(See table below on ‘Pharmacological treatment of Worm 
Infestations’)
Referral Criteria 
Refer patients with intestinal obstruction from a heavy load of 
suspected worm infestation to a surgical specialist. 
Pharmacological treatment of Worm Infestations
Worm Treatment Note Evidence 
Rating
Hookworm Mebendazole , oral, 
Adults
500 mg as single dose
Or
100 mg 12 hourly for 3 days  
Children > 12 months
100 mg 12 hourly for 3 days Not recommended 
for children below 
12 months and in 
pregnant womenB
Or
Albendazole , oral,
Adults and children > 12 
months
400 mg as a single dose
Children below 12 months
200 mg as a single dose Not recommended 
during pregnancyB

— Worm Infestation (Intestinal)   —Chapter 18:  Infectious Diseases and Infestations 
501Pharmacological treatment of Worm Infestations
Worm Treatment Note Evidence 
Rating
Ascaris Mebendazole , oral, 
Adults and children above 12    
months;
100 mg 12 hourly for 3 days  
Or
500 mg as single doseNot recommended 
for children below 
12 months and in 
pregnant womenA
Or
Albendazole , oral, 
Adults and children above 12 
months
400 mg as a single dose
Children below 12 months
200 mg as a single dose Not recommended 
during pregnancyA
Whipworm Mebendazole , oral, 
Adults and children above 12 
months;
100 mg 12 hourly for 3 days  
Or
500 mg as single doseNot recommended 
for children below 
12 months and in 
pregnant womenB
Or
Albendazole , oral, 
Adults and Children above 12 
months 
400 mg as a single dose
Children below 12 months
200 mg as a single dose Not recommended 
during pregnancyB
Threadworm Mebendazole , oral,
Adults and children above 12 
months;
100 mg 12 hourly for 3 days  
Or
500 mg as single doseNot recommended 
for children below 
12 months and in 
pregnant women
Repeat treatment 
after 3 weeksC
Or
Albendazole , oral, 
Adults and Children above 12 
months
400 mg as a single dose
Children below 12 months
200 mg as a single dose Not recommended 
during pregnancy
Repeat treatment 
after 3 weeksC

— Worm Infestation (Intestinal)   —
Standard  Treatment Guidelines, 7th Edition, 2017
502Pharmacological treatment of Worm Infestations
Worm Treatment Note Evidence 
Rating
Strongyloides Albendazole , oral, 
Adults and Children above 12 
months
400 mg 12 hourly for 3days
Children below 12 months
200 mg 12 hourly for 3 days            
Or 
Tiabendazole  (Thiabendazole), 
oral,
Adults
1.5 g 12 hourly for 3 days   
Children
25 mg/kg 12 hourly for 3 daysNot recommended 
during pregnancy
Repeat treatment 
after three weeks. 
Alternatively, a 
7-days treatment 
without repeat is 
acceptable.
Ivermectin is the 
drug of choice but 
has the danger 
of precipitating 
life-threatening 
encephalopathy in 
microfilaria endemic 
areas.B
Tapeworm Praziquantel , oral,
Adults and children;
5-10 mg/kg as a single dose.
(25 mg/kg as a single dose for 
Hymenolepis nana ; repeated in 
10 days)  
Or
Niclosamide , oral,
Adults and children above 6 
years;
2g as a single doseTaken after a light 
breakfastC
Children < 2 years;     
500 mg as a single dose
2-6 years;
1 g as a single dose
Chew tablets 2 hours before 
a meal C

19Chapter
503Eye Disorders
193� Neonatal Conjunctivitis   
(See section on ‘Neonatal Conjunctivitis’ under Neonatal Disorders) 
194. Xerophthalmia  
This condition is common in children. It is associated with inadequate 
intake of foods that contain Vitamin A . It is a common cause of blindness 
in children. It is important to prevent this condition by examining the eyes 
of all sick and malnourished children. The diet of children should include 
foods that contain Vitamin A (dark green leafy vegetables e.g. nkontomire, 
yellow fruits and vegetables, palm oil, milk, eggs). 
Parents and other caregivers should be discouraged from putting 
any traditional preparations such as herbs, sea water, saliva, urine, etc. or 
drugs into the eye unless prescribed by a physician.
Causes 
 y Vitamin A  deficiency resulting from
 y Protein calorie malnutrition
 y Measles
 y Malabsorption states
Symptoms
 y Poor night vision (in the early stages) 
Signs
 y Dry conjunctiva
 y Grey sclera
 y Conjunctival folding (wrinkling)
 y Keratomalacia  (cloudy cornea, soft and easy ulceration)
Investigations
 y Nil

— Foreign body in the eye —
Standard  Treatment Guidelines, 7th Edition, 2017
504Treatment 
Treatment objectives
 y To recognize and correct vitamin A deficiency
 y To prevent complications e.g. blindness 
Non-pharmacological treatment
 y High vitamin A containing foods should be encouraged
Pharmacological treatment 
Give Vitamin A  to children as soon as the illness is diagnosed and also 
in patients with measles and malnutrition
Evidence Rating: [A]
 y Vitamin A , oral,
Children
Immediately after diagnosis 
1-6 years;   200,000 Units
6-11 months;    100,000 Units
Then (after 24 hours)
1-6 years;   200,000 Units
6-11 months;    100,000 Units
Then (after 1 week)
1-6 years;   200,000 Units
6-11 months;    100,000 Units
Referral Criteria 
Refer all established cases of xerophthalmia to an eye specialist if the 
condition is severe with an uneven or bulging cornea.
195� Foreign body in the eye
Foreign bodies refer to specks of dust, small insects or other tiny 
objects that get into the eyes. The foreign body may be either in the 
conjunctival sac, on the cornea or inside the eyeball (intraocular). A 
history of the likely nature of the foreign body aids in its detection and 
removal. The foreign body may be seen by careful inspection of the 
cornea or conjunctival sac. Adequate lighting is needed to detect corneal 
foreign bodies.
Causes 
 y Specks of dust
 y Small insects
 y Ferrous metallic specs (such as occurs with metal grinders)
 y Other tiny objects
Symptoms
 y Feeling of something in the eye which may be irritating
 y Sudden discomfort or severe pain
 y Watering of the eye
 y Red eye(s)

— Foreign body in the eye —Chapter 19:  Eye Disorders
505 y Photophobia  i.e. intolerance to light
 y Inability to open the eye
Signs
 y Evidence of foreign body
 y Conjunctivitis
 y Tearing of the eyes
 y Photophobia
 y Chemosis  
 y Sub-conjunctival haemorrhage
 y Irregular pupil in penetrating eye injury with retained intraocular 
foreign body
 y Blood in the anterior chamber (hyphaema)
Investigations
 y X-ray of the orbit (suspected metallic foreign body)
Treatment 
Treatment objectives
 y To remove superficial foreign bodies
 y To treat associated injury
 y To prevent complications
Non-pharmacological treatment
 y Where the foreign body is under the upper eyelid, evert the eyelid 
and remove the foreign body.
 y If the foreign body cannot be removed, apply topical antibiotic, pad 
the eye and REFER to an eye specialist clinic.
Pharmacological treatment 
A.     Foreign body identification
 y Tetracaine hydrochloride , 0.5% eye drop, Instill one or two drops pri -
or to evaluation 
B.     For eye irrigation  
 y Normal Saline , 0.9%,
C.     Prevention of infection
1st Line Treatment
Evidence Rating: [C]
 y Chloramphenicol  eye ointment, 1% topical, (After removal of foreign 
body)
D�     Pain control
 y Paracetamol , oral,
Adult s
500 mg-1 g 6 -8 hourly as required 
Children
6-12 years;   250-500 mg 6-8 hourly as required
1-5 years;   120-250 mg 6-8 hourly as required 
3 months-1 year;  60-120 mg 6-8 hourly as required

— Red Eye —
Standard  Treatment Guidelines, 7th Edition, 2017
506Referral Criteria 
Refer patients with corneal foreign bodies, intraocular foreign 
bodies, persistent pain and redness of the eye to the eye specialist.
196� Red Eye
Red eyes are either the result of inflammation of ocular tissue or 
bleeding into the sub conjunctival space. The pattern of the redness, 
nature of the discharge, associated pain and its intensity, vision loss and 
appearance of the cornea are helpful in characterising the red eye.  Red 
eye is a potentially very serious condition especially in situations where 
the redness is around the cornea. 
Causes 
 y Conjunctivitis
 y Corneal ulcer or keratitis
 y Acute anterior uveitis (inflammation of the uveal tract)
 y Acute angle closure glaucoma
 y Episcleritis
 y Scleritis
 y Subconjunctival haemorrhage
Table 19-1:   Characterising Acute Red Eye  with no history of injury
Diagnosis Predominant 
Pattern of 
RednessNature of 
DischargeVision Loss Corneal 
AppearanceAssociated Pain
Conjuncti -
vitisPalpebral (inner 
lining of the 
eyelids)Watery, mucoid, 
mucopurulent or 
purulentNil except 
when cornea 
is involvedClear, may 
show punctate 
epithelial 
stains with 
fluorescein in 
keratoconjunc -
tivitisNil to mild pain
Corneal 
UlcerAround the 
corneaWatery or muco -
purulentVariable Grey or greyish 
white patch 
when bacterial 
or fungal or 
dendritic when 
Herpes Simplex Severe pain
Acute anteri -
or UveitisAround the 
corneaWatery Variable Clear to hazy Moderately 
severe
Acute Angle 
Closure 
GlaucomaAround the 
corneaWatery Profound Uniformly hazy Very severe
Episcleritis Sectorial Nil or watery Nil Clear Mild to severe
Scleritis Sectorial Nil or watery Nil except 
when asso -
ciated with 
uveitisClear Very severe

— Red Eye —Chapter 19:  Eye Disorders
507Diagnosis Predominant 
Pattern of 
RednessNature of 
DischargeVision Loss Corneal 
AppearanceAssociated Pain
Subconjunc -
tival Haem -
orrhageSectorial Nil Nil Clear Nil
Table 19-2:   Summary of the common types of Conjunctivitis and their 
management
Age and Background 
of PatientsType of 
DischargePredominant 
type of ocular 
discomfortDuration Treatment
Bacterial All ages Purulent Nil to mild 
itching or pain1-2 weeks Antibiotic eye 
drops 
Viral All ages Watery to Mu -
copurulentNil to mild 
itching or pain1-8 weeks Symptomatic
Allergic Children and ado -
lescentsStringy mucoid Itching Chronic in -
termittentMast cell 
stabilizing 
agents, sodium 
chromoglycate 
2 % 
Trachoma* All ages, associated 
with dirty, dry, 
dusty and poor 
environmentMucopurulent Nil to mild 
itching or pain1 month to 
1 year or 
moreTetracycline  
eye ointment 
Azithromycin  
tablets
*WHO Grading of Trachoma
1) TF - at least five follicles in the upper tarsal conjunctiva. Indicates active disease and need 
for treatment
2) TI - intense inflammation. Need for urgent treatment
3) TS - scarring stage. Old infection, now inactive
4) TT- trachoma trichiasis. Need surgical treatment
5) CO - corneal opacities. Visual loss from previous infection
Investigations
 y Conjunctival swab for culture and sensitivity (purulent or 
mucopurulent discharge)
Treatment 
Treatment objectives
 y To treat the infection in the case of acute conjunctivitis 
 y To relieve pain and refer immediately to the specialist for urgent 
management to prevent blindness in the case of corneal ulcers, 
acute anterior uveitis, acute angle closure glaucoma, episcleritis and 
scleritis.
Non-pharmacological treatment
  Acute conjunctivitis
 y Wipe discharges with tissue, discard it and wash hands after each 
wipe
 y Don’t share towels with others
 y Adults and children should avoid close contact with others e.g. from 

— Glaucoma —
Standard  Treatment Guidelines, 7th Edition, 2017
508school, work, camp and swimming
Pharmacological treatment 
A.     For treatment of Acute conjunctivitis
1st Line Treatment
Evidence Rating: [C]
 y Tetracycline , 1% ointment, apply at night for 7 days
And
 y Chloramphenicol , 0.5% eye drops, 
 1 drop 2 hourly for 48 hours
Then
 1 drop 6-8 hourly for 7 days
Or
 y Ciprofloxacin , 0.3% eye drops, 1-2 drops 6-12 hourly 
Referral Criteria 
Refer corneal ulcers, acute anterior uveitis, acute angle closure 
glaucoma, episceritis and scleritis immediately to the eye specialist. Also 
refer acute conjunctivitis, which shows no improvement after 48 hours of 
treatment.
197� Glaucoma
Glaucoma  is an optic neuropathy usually but not always associated 
with raised intraocular pressure. It is the second leading cause of 
preventable blindness in the world. Chronic Glaucoma may produce 
severe loss of vision and blindness without prior warning symptoms 
and must therefore be screened for in all adults beyond the age of 40 
years. Acute glaucoma is however associated with very high intraocular 
pressures and very severe pain and inflammation of the eye and can lead 
to blindness quickly if not treated. When congenital, glaucoma causes 
enlargement of the eyeball associated with increased sensitivity to light 
and watering.
Pharmacological treatment may vary from patient to patient 
according to local availability, affordability, and individual response to 
treatment. 
Causes 
 y Acute closure of the drainage angle (due to pupil block in primary 
angle closure glaucoma)
 y Inadequate drainage of aqueous from the anterior chamber (despite 
open drainage angles in chronic open angle glaucoma)
 y Neovascular membrane in the drainage angle in ischaemic eye 
diseases such as proliferative diabetic retinopathy
 y Displaced lens in secondary angle closure glaucoma
 y Malformation of the drainage angle in congenital glaucoma

— Glaucoma —Chapter 19:  Eye Disorders
509Symptoms and signs
Table 19-3:   Characteristics of the various types of the common types of 
Glaucoma
Symptoms 
and signsChronic open angle Acute angle closure Congenital
Onset Usually 40 years and 
aboveElderly Infants and toddlers
Symptoms Nil till late then 
progressive visual lossSudden visual loss, 
Severe eye pain, very 
inflamed eye, watery 
discharge, headache 
and vomiting  
sometimesPhotophobia , 
watering,
Intraocular 
pressureUsually high, may be 
normalVery high High
Cornea Normal Hazy Enlarged and hazy 
with linear breaks
Investigations
 y Gonioscopy
 y Central retinal thickness measurement
 y Visual field analysis
 y Optic Disc photography
 y Retinal Nerve Fibre Thickness Analysis
 y Examination of children under anaesthesia
Treatment 
Treatment objectives
 y To prevent progression of the disease and halt further deterioration 
of vision
 y To normalise intraocular pressure
Non-pharmacological treatment
 y Drainage Surgery
 y Laser Surgery
 y Glaucoma  Drainage device
 y Various other implants
Pharmacological treatment 
Note 19-1
Consult an ophthalmologist on the treatment of glaucoma.
1st Line Treatment
Evidence Rating: [B]
Treatment is with one medication from one or more of the following 
groups:
 y Latanoprost, eye drops, 50 microgram/ml

— Cataract —
Standard  Treatment Guidelines, 7th Edition, 2017
510 y Bimatoprost, eye drops, 300 microgram/ml
 y Travoprost, eye drops, 40 microgram/ml 
And/Or 
 y Timolol 0.5% eye drops 
 y Levobunolol 0.5% eye drops 
 y Betaxolol 0.5% eye drops
And /Or
 y Brimornidine, 1 mg/ml or 1.5 mg/ml
And/Or
 y Acetazolamide, oral, 250 mg 
 y Brinzolamide, eye drops, 10 mg/ml 
 y Dorzolamide, eye drops, 20 mg/ml 
And/Or
 y Pilocarpine 1-4%, eye drops
Referral Criteria 
Refer all suspected cases of glaucoma to the ophthalmologist for 
assessment and initial treatment.
198� Cataract
It is the opacity of the crystalline lens of the eye. It is the leading 
cause of blindness worldwide.
Causes 
 y Old age
 y Trauma to the eye
 y Inflammation within the eye
 y Metabolic conditions such as diabetes mellitus
 y Congenital
Symptoms
 y Variable disturbance of vision (sometimes worse when sunny or 
reading)
 y Glare especially at night during driving
 y Monocular double vision in the affected eye 
 y Change in refractive status:
 y more short sighted (myopic shift)
 y more long sighted (hypermetropic shift)
 y White spot in the eye (children)
Signs
 y Lens opacity
 y Reduced visual acuity
 y Reduced contrast sensitivity

— Exposure Keratopathy —Chapter 19:  Eye Disorders
511Investigations
 y Fasting blood sugar
 y FBC
Treatment 
Treatment objectives
 y To improve vision
 y To prevent the development of amblyopia  in the child
Non-pharmacological treatment
 y Use of spectacles
 y Surgical removal of cataract
Pharmacological treatment 
 y Nil
Referral Criteria 
Refer all cases to the eye specialist.
199� Exposure Keratopathy
Exposure keratopathy  is the drying of the cornea as a result of inability 
to close the eyelids or blink adequately. If not detected and treated can 
result in corneal ulceration and perforation leading to blindness.
Causes 
 y Facial nerve palsy e.g. Bell’s palsy or leprosy
 y Scarring of the eyelids
 y Coma
 y Thyroid eye disease
 y Parkinson’s disease
 y Proptosis
 y Steven Johnson’s Syndrome
Symptoms
 y Feeling of drying of the eye
 y Foreign body sensations in the eye
 y Photophobia
 y Blurring of vision
Signs
 y Lagophthalmos  (inability to close the eyes)
 y Incomplete blink (the upper eyelid does not cover the whole cornea 
during blink)
 y Infrequent blink 
 y Superficial punctate stains on the cornea 
 y Large coalescent corneal epithelial defect
 y Corneal ulceration 
 y Corneal perforation

— Strabismus —
Standard  Treatment Guidelines, 7th Edition, 2017
512Investigations
 y Nil
Treatment 
Treatment objectives
 y To moisten the cornea artificially
 y To prevent the complications of dry eyes 
Non-pharmacological treatment
 y Taping the eyelids closed in the comatose patient 
 y Partial tarsorrhaphy 
 y Education of patients with Parkinson’s or thyroid eye disease to to 
blink frequently voluntarily rather than rely on reflex blink
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
 y Hydroxymethyl cellulose , 0.3% eye drops, 1-2 hourly during waking 
time 
2nd Line Treatment
Evidence Rating: [C]
 y Polyvinyl alcohol , 1.4-2% eye drops, 1-2 hourly during waking time 
And  
 y Chloramphenicol , 1% eye ointment, at night before bedtime
Or
 y Tetracycline , 1% eye ointment, at bedtime
Referral Criteria 
Refer patients whose exposure keratopathy  is not improving to the 
eye specialist.
200� Strabismus
Strabismus  is misalignment usually of one eye preventing 
simultaneous viewing of an object by both eyes. Onset in children under 
7 years interferes with the development of the visual system of the 
deviating eye in the brain leading to amblyopia . Acute onset at an older 
age causes double vision. Diplopia  does not occur in children because of 
the ability to suppress the second image or development of amblyopia. 
Amblyopia does not occur if the deviation alternated from one eye to the 
other. The more frequent types are horizontal misalignment. Esotropia  is 
convergent deviation and exotropia  is divergent deviation. 
Causes 
 y Congenital misalignment
 y Acquired deviation 
 y Paralysis of the cranial nerve VI, III or IV

— Sickle Cell Disease – Retinopathy  —Chapter 19:  Eye Disorders
513 y Fibrosis in an extraocular muscle 
 y Myasthenia gravis
 y Intraocular lesion e.g. retinoblastoma and macular scar
Symptoms
 y Misalignment of the eye
 y Impaired judgement of depth or distance
 y Diplopia  or double vision  
Signs
 y Deviation of the corneal light reflex in one eye from a central position
 y Movement of the deviating eye to take up fixation when the fixing 
eye is covered
 y Normal extraocular eye movement (in non-paralytic strabismus )
 y Limitation of eye movement (in paralytic or restrictive strabismus )
 y Hypermetropia  on refraction in children 
 y Retinal lesion e.g. retinoblastoma
Investigations
 y Cycloplegic refraction in children
 y Other specific tests for suspected causes e.g. myasthenia gravis or 
retinoblastoma 
Treatment 
Treatment objectives
 y To identify and correct any significant refractive error
 y To treat any amblyopia
 y To relieve any diplopia
 y To correct the misalignment
 y To treat any underlying condition
Non-pharmacological treatment
 y Spectacle correction of any refractive error
 y Treatment of amblyopia  in the deviating eye by patching the non-
deviating eye
 y Use of prisms to correct small deviations
 y Patching of the deviating eye to relieve diplopia in older patients
Pharmacological treatment 
 y Nil
Referral Criteria 
All patients diagnosed with strabismus  must be referred to the eye 
specialist for further management.
201� Sickle Cell Disease  – Retinopathy  
Symptoms
 y Sudden loss of vision especially in sickle cell “SC” patients

— Endocrine and metabolic disorders with eye complications —
Standard  Treatment Guidelines, 7th Edition, 2017
514Referral Criteria 
All Sickle Cell “SC” patients 12 years and above should be referred 
to the eye specialist for screening for proliferative sickle cell retinopathy. 
Refer all sickle cell patients with eye complications to the eye specialist.
202� Endocrine and metabolic disorders with eye complications
Referral Criteria 
Patients with persistently poor blood glucose control, poor 
blood pressure control, frequent diabetes-related admissions, visual 
impairment, cataract or any retinal changes, foot ulcers or gangrene , 
persistent proteinuria, or other chronic complications of diabetes should 
be referred to the eye specialist.

20Chapter
515Ear, Nose and Throat 
Disorders
203� Stridor
Stridor  is an emergency condition. It has a characteristic noise in the 
inspiratory phase of breathing. This occurs when there is an obstruction 
of the upper airway from the nasopharnyx down to the trachea and main 
bronchi. The obstruction is usually in the subglottic area. 
It is commonly a viral illness, and may be preceded usually 
by the common cold. Measles  may also be complicated by 
Laryngotracheobronchitis (LTB) . Two important causes of stridor  in 
children are viral croup (LTB) and acute epiglottitis.
In the management of stridor , steroids are most useful when given 
within 6 hours of onset of symptoms. Cough  syrups containing opiates 
and atropine  are contraindicated.
STRIDOR IN CHILDREN
Causes 
 y Viral (laryngotracheobronchitis)
 y Bacterial infection 
 y Acute epiglottitis 
 y Inflammatory obstruction 
 y Inhalation of hot fumes e.g. in fire outbreaks
 y Angioneurotic oedema
 y Retropharyngeal abscess
 y Inhalation of a foreign body
 y Congenital malformation of the larynx e.g. laryngomalacia
Symptoms
 y Low grade fever
 y Hoarse voice
 y Barking cough
 y Breathing difficulty
 y Restlessness  
Signs
 y Stridor

— Stridor —
Standard  Treatment Guidelines, 7th Edition, 2017
516 y Low grade fever
 y Restless apprehensive child when obstruction is severe
 y Hoarse voice
 y Barking cough
 y Laboured breathing e.g. suprasternal, supraclavicular, substernal and 
intercostals retractions 
 y Tachypnoea
 y Cyanosis  in severe obstruction 
 y Reddened throat
Investigations
 y Sputum culture
 y Lateral soft tissue X-ray of neck 
 y Chest X-ray
Treatment 
Treatment objectives
 y To avoid aggravation of the obstruction with thick or crusted 
secretions
 y To ensure early and timely relief of obstruction
Non-pharmacological treatment
 y Ensuring good hydration including liberal oral fluids 
 y Ensure maximum rest for the child
 y Establish the airway by intubation or tracheostomy in severe 
obstruction 
Pharmacological treatment 
A.     For hydration of very sick patients who cannot drink
1st Line Treatment
Evidence Rating: [C]
 y Dextrose  saline , IV, 5%
B�     For restless and distressed children who require oxygen
 y Oxygen , 1-6 L as required (based on oxygen saturation level)
C�     For steroid therapy
 y Dexamethasone , oral/IM/IV, 
Children  
0.6 mg/kg stat.
Or
 y Budesonide , nebulised, 
Children  
2 mg stat.
Or
 y Prednisolone , oral, 
Children  
1-2 mg/kg stat.
Or

— Stridor —Chapter 20:  Ear, Nose and Throat Disorders
517 y Hydrocortisone , IV, 
Children
4 mg/kg 6 hourly for 2-3 days 
Note 20-1
Steroids are most useful when given within 6 hours of onset of symptoms. Anti -
biotics should be given in suspected secondary bacterial infection.
Cough  syrups containing opiates and atropine  are contraindicated 
D. In superimposed bacterial infection
1st Line Treatment 
Evidence Rating: [C]
 y Cloxacillin , IV, 
Children  
5-12 years;   250 mg 6 hourly for 7 days
1-5 years;   125 mg 6 hourly for 7 days
< 1 year;   62.5 mg 6 hourly for 7 days
And
 y Gentamicin , IV, 
Children  
1-12 years;   2.5 mg/kg 8 hourly for 7 days
< 1 year;   2.5 mg/kg 12 hourly for 7 days
And
 y Metronidazole , IV, 
Children  
7.5 mg/kg 8 hourly for 7 days 
2nd Line Treatment 
Evidence Rating: [C]
 y Cefuroxime , IV,
Children  
20 mg/kg 8 hourly
And
 y Metronidazole , IV, 
Children  
7.5 mg/kg 8 hourly for 7 days
E�      For severe Croup
 y Adrenaline , 1:1000 solution, nebulised, 2 ml stat.
Then
Repeat hourly if effective
STRIDOR IN ADULTS
Causes 
 y Inflammatory obstruction 
 y Acute epiglottitis
 y Laryngeal tumour
 y Vocal cord paralysis

— Stridor —
Standard  Treatment Guidelines, 7th Edition, 2017
518 y Retropharyngeal abscess
 y Inhalation of a foreign body
Symptoms
 y Hoarse voice
 y Breathing difficulty
 y Restlessness  
Signs
 y Stridor
 y Laboured breathing
 y Tachypnoea
 y Cyanosis  in severe obstruction 
Investigations
 y Lateral soft tissue X ray of neck
 y Chest X-ray 
Treatment 
Treatment objectives
 y To ensure early and timely relief of obstruction
Non-pharmacological treatment
 y Establish the airway by intubation or tracheostomy in severe 
obstruction 
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
A.     For oxygen therapy 
 y Oxygen , 1-6 L as required (based on oxygen saturation level)
B�     For steroid therapy 
 y Hydrocortisone , IV, 
Adult s
100 mg 6 hourly for 2-3 days 
C.      For superimposed bacterial infection 
1st Line Treatment 
Evidence Rating: [C]
 y Amoxicillin + Clavulanic Acid , IV, 
Adult s
600 mg 8 hourly
Or
1.2 g 12 hourly
And
 y Metronidazole , IV, 
Adult s
500 mg 8 hourly for 7 days 

— Acute Epiglottitis —Chapter 20:  Ear, Nose and Throat Disorders
5192nd Line Treatment 
Evidence Rating: [C]
 y Cefuroxime , IV,
Adult s
750 mg 8 hourly
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7 days
Referral Criteria 
Refer cases with severe obstruction and complications in children to 
a Paediatrician or ENT specialist.  Also refer all cases of stridor  if there is 
no expertise to intubate or perform tracheostomy to a specialist.
204. Acute Epiglottitis
This is an acute and life-threatening infection in which the epiglottis 
and surrounding tissue become acutely inflamed and oedematous 
causing severe obstruction of the upper airways. The disease tends to run 
an extremely rapid course (4-6 hours) to respiratory failure and death.
It is more common in children. However, the incidence has 
reduced significantly due to the current immunisation schedule with the 
pentavalent vaccine.
Examination of the throat in patients with this condition must be 
done only in the presence of a doctor capable and ready to intubate. 
Causes
 yHaemophilus	influenzae  type B
 y Streptococcus  pyogenes  
 y Streptococcus  pneumoniae
 y Staphylococcus aureus
Symptoms
 y Sudden onset of high fever
 y Drooling of saliva 
 y Dysphagia
 y Breathing difficulty
Signs
 y Extremely ill and toxic child
 y Fever
 y Head is held forward to extend the neck
 y Breathing difficulty  
 y Weak voice (not hoarse) 
 y Reduced air entry on auscultation
 y Stridor

— Acute Epiglottitis —
Standard  Treatment Guidelines, 7th Edition, 2017
520 y Cyanosis  in very sick children
 y Swollen and reddened epiglottis
Investigations
 y FBC
 y Blood culture
 y Lateral soft tissue X-ray of the neck
Treatment
Treatment objectives
 y To relieve obstruction 
 y To treat bacteraemia
Non-pharmacological treatment
 y Establishment of airway if necessary by intubation or tracheostomy 
Pharmacological treatment
A.      For treatment of bacterial infection
1st Line Treatment
Evidence Rating: [B]
 y Cefuroxime , IV,
Adult s
750 mg-1.5 g 8 hourly for 7 days
Children
25 mg/kg 8 hourly for 7 days
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7 days
Children
7.5 mg/kg 6 hourly for 7 days
2nd Line Treatment 
Evidence Rating: [B]
 y Cefotaxime , IV, 
Adult s 
1-2 g IV or IM 8 hourly for 7 days
Children
50 mg/kg 8 hourly for 7 days
Or 
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly for 7 days in severe infections 
Children
12-18 years;   600 mg to 1.2 g 12 hourly, 
Increased to 1.2g 8 hourly for 7 days in severe infections
3 months-12 years;  30 mg/kg 12 hourly, 
Increased to 30 mg/kg 8 hourly for 7 days in severe infections

— Retropharyngeal Abscess —Chapter 20:  Ear, Nose and Throat Disorders
5217 days-3 months;   30 mg/kg 8 hourly for 7 days
Preterm and < 7 days; 30 mg/kg 12 hourly for 7 days
Note 20-2
Treatment should be changed to oral antibiotics when appropriate and contin -
ued for a total of 7 days
Referral Criteria
Refer all patients immediately to a specialist if there is no expertise 
available for intubation or tracheostomy.
205� Retropharyngeal Abscess
This emergency condition refers to collection of pus in the 
retropharyngeal space. Early diagnosis and treatment will prevent 
mortality.
Causes 
 y Group A - haemolytic	Streptococcus  
 y Staphylococcus aureus  
 y Osteomyelitis of cervical vertebrae from tuberculosis
Symptoms
 y Fever
 y Sore throat
 y Difficulty in swallowing
 y Hyperextension of neck
 y Laboured and noisy breathing
Signs
 y Fever
 y Reddened throat, large and inflammed tonsils 
 y Laboured respiration with intercostal retractions
 y Stridor
 y Bulge in the posterior pharyngeal wall
Investigations
 y FBC
 y Throat swab for culture and sentivity testing 
 y Ziehl-Neelsen stain  to exclude tuberculosis 
 y Lateral soft tissue X-ray of neck
 y Chest X-ray to exclude tuberculosis 
Treatment 
Treatment objectives
 y To treat infection 
 y To relieve the obstruction by draining the abscess
 y To relieve pain

— Retropharyngeal Abscess —
Standard  Treatment Guidelines, 7th Edition, 2017
522Non-pharmacological treatment
 y Incision and drainage of pus under general anaesthesia  
Pharmacological treatment 
A.      For pain relief 
1st Line Treatment
Evidence Rating: [B]
 y Paracetamol , oral, 
Adult s
500 mg-1 g 4-6 hourly
Children
6-12 years;  250-500 mg 4-6 hourly
1-5 years;   120-250 mg 4-6 hourly
3 months-1 year;  60-120 mg 4-6 hourly
B.      For treatment of infection  
1st Line Treatment 
Evidence Rating: [B]
 y Cefuroxime , IV,
Adult s
750 mg-1.5 g 8 hourly for 72 hours 
Children  
25 mg/kg 8 hourly for 72 hours
And
 y Metronidazole , IV,
Adult s  
500 mg 8 hourly for 72 hours 
Children
7.5 mg/kg 8 hourly for 72 hours
Then
 y Cefuroxime , oral,
Adult s
500 mg 12 hourly for 7 days
Children
12-18 years;   250 mg 12 hourly for 7 days
2-12 years;   15 mg/kg (max. 250 mg) 12 hourly for 7 
days
3 months-2 years;  10 mg/kg (max. 125 mg) 12 hourly for 7 
days
And
 y Metronidazole , oral,
Adult s
400 mg 8 hourly for 7 days
Children
7.5 mg/kg 8 hourly for 7 days
2nd Line Treatment 
Evidence Rating: [B]

— Pharyngitis and Tonsillitis  —Chapter 20:  Ear, Nose and Throat Disorders
523 y Flucloxacillin , IV,
Adult s   
500 mg 6 hourly for 72 hours
Children
50-100 mg/kg 6 hourly for 72 hours 
And
 y Metronidazole , IV,
Adult s  
500 mg 8 hourly for 72 hours 
Children
7.5 mg/kg 8 hourly for 72 hours
Then
 y Metronidazole , oral,
Adult s
400 mg 8 hourly for 7 days
Children
7.5 mg/kg 8 hourly for 7 days
And
 y Flucloxacillin , oral,
Adult s   
500 mg 6 hourly for 7 days if patient is able to swallow
Children
50 mg/kg 6 hourly for 7 days if patient is able to swallow  
Referral Criteria 
Refer all cases to the ENT specialist.
206� Pharyngitis  and Tonsillitis  
This is an infection of the throat and tonsils. Most sore throats are 
due to viral infections and should NOT be treated with antibiotics as 
they subside within 3 to 5 days. However, it is important to diagnose 
streptococcal pharyngitis since it may give rise to abscesses in the throat 
(retropharyngeal and peritonsillar abscess) as well as complications 
that involve organs like the kidneys and the heart. Streptococcal throat 
infections require treatment with antibiotics in order to reduce the 
complications noted above.
Causes 
 y Viruses
 y Heamolytic streptococcus
 yHaemophilus	influenza
 y Other gram positive bacteria 
Symptoms
 y Fever
 y Difficulty in swallowing
 y Sore throat

— Pharyngitis and Tonsillitis  —
Standard  Treatment Guidelines, 7th Edition, 2017
524 y Runny nose 
 y Cough
Signs
 y Reddened throat
 y Enlarged and reddened tonsils 
 y Sustained high grade fever
 y Palpable tonsillar lymph glands (streptococcal pharyngitis) 
 y Runny nose (suggests viral)
 y Cough  (suggests viral)
 y Red eyes (suggests viral)
 y Whitish exudate at the back of the throat as well as whitish tonsillar 
exudate
 y Scarlet fever rash
Investigations
 y FBC 
 y Monospot test 
 y Throat swab for culture and sensitivity
Treatment 
Treatment objectives
 y To relieve symptoms
 y To recognise and treat streptococcal throat infection 
 y To relieve pain
Non-pharmacological treatment
 y Warm, salty water gargles
Pharmacological treatment 
A.      For pain relief 
1st Line Treatment
Evidence Rating: [A]
 y Paracetamol , oral, 
Adult s 
500 mg-1 g 6-8 hourly 
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or
 y Ibuprofen , oral,
Adult s 
200-400 mg 8 hourly
Children
7-12 year; 7.5-10 mg/kg 6-8 hourly (max. 30 mg/kg or 600 mg per 
day)
4-7 years; 7.5-10 mg/kg 8 hourly (max. 30 mg/kg or 450 mg per day)

— Pharyngitis and Tonsillitis  —Chapter 20:  Ear, Nose and Throat Disorders
525B.     For treating the infection
1st Line Treatment 
Evidence Rating: [A]
 y Amoxicillin , oral, 
Adult s 
500 mg 8 hourly for 10 days 
Children
6-12 years;   250 mg 8 hourly for 10 days
1-5 years;   125 mg 8 hourly for 10 days
< 1 year;   62.5 mg 8 hourly for 10 days
Or
 y Amoxicillin + Clavulanic Acid , oral,
Adult s 
1 gram 12 hourly for 10 days 
Children
> 12 years; One 500/125 mg strength tablet, 12 hourly for 10 
days
6-12 years;   5 ml of 400/57 mg suspension 12 hourly (5 ml of 
250/62 mg suspension 8 hourly for 10 days; dose doubled in severe 
infection)  
1-6 years; 5 ml of 200/28.5 mg suspension 12 hourly for 10 days; 
dose doubled in severe infection
1 month-1 year; 2.5 ml of 200/28.5 mg suspension 12 hourly for 10 
days; dose doubled in severe infection
Neonate ;      2.5 ml of 200/28.5 mg suspension 12 hourly for 10 
days; dose doubled in severe infection
Or
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
600 mg-1.2 g 12 hourly for 10 days
Children  
1-12 years;  15 mg/kg 12 hourly for 10 days 
Or
 y Crystalline Penicillin, IV,
Adult s
2-4 MU 6 hourly for 10 days
Children  
> 12 years;   2-4 MU 6 hourly for 10 days
1-12 years; 0.6-1.2 MU (25 mg/kg) 6 hourly for 10 days
Note 20-3
Do not give co-trimoxazole for acute streptococcal throat infections

— Acute Sinusitis —
Standard  Treatment Guidelines, 7th Edition, 2017
5262nd Line Treatment
Evidence Rating: [B]
 y Cefuroxime , oral,
Adult  
250 mg 12 hourly for 10 days
Children  
> 12 years;  250 mg 12 hourly for 10 days
3 months-12 years; 10 mg/kg 12 hourly for 10 days 
Or
 y Cefuroxime , IV,
Adult  
750 mg 8 hourly for 10 days
Children  
> 12 years;  750 mg 8 hourly for 10 days
3 months-12 years; 25-50 mg/kg 8 hourly for 10 days 
C.     For treating the infection in patients allergic to penicillin 
 y Erythromycin , oral,
Adult s
500 mg 6 hourly for 10 days 
Children
2-8 years;  250 mg 6 hourly for 10 days
1 month-2 years; 125 mg 6 hourly for 10 days
Neonate s;   12.5 mg/kg 6 hourly
Or
 y Azithromycin , oral,
Adult s 
500 mg daily for 3 days
Children
> 6 months;  10 mg/kg daily for 3 days
Referral Criteria 
Refer patients with recurrent tonsillitis, retropharyngeal and 
peritonsillar abcess to an ENT specialist.
207� Acute Sinusitis
This is an acute infection of the para-nasal sinuses. It may lead to 
complications with attendant morbidity and mortality. Early recognition 
of this clinical condition is mandatory.  
Swimming in dirty waters, dental infection or dental extraction, 
fractures involving the sinuses, nasal obstruction from polyps and allergic 
rhinitis  are predisposing factors to developing acute sinusitis.
Causes 
 y Viral (common cold)
 y Bacterial 
 y Group A haemolytic Streptococci  

— Acute Sinusitis —Chapter 20:  Ear, Nose and Throat Disorders
527 y S. pneumonia
 y S. aureus
 yH.	influenzae
 y M. catarrhalis  
 y Allergy
Symptoms
 y Cough
 y Nasal congestion
 y Pressure in the face and head
 y Frontal headaches
 y Postnasal drip 
Signs
 y Yellow or green thick nasal discharge, which may be foul smelling
 y Halitosis
 y Persistent fever
 y Tenderness above and below the eyes, when patient bends over or 
when these areas are tapped lightly
Investigations
 y FBC 
 y X-ray of paranasal sinuses   
Treatment 
Treatment objectives
 y To reduce symptoms of pain and fever
 y To eradicate infection
 y To encourage drainage of sinuses
Non-pharmacological treatment
 y Adequate hydration 
 y Steam inhalation  
 y Tooth extraction under antibiotic cover (if dental focus of infection 
is present) 
Pharmacological treatment 
A.      For treatment of bacterial infection 
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin , oral, 
Adult s
500 mg 8 hourly for 10 days
Children
6-12 years; 250 mg 8 hourly for 10 days
1-5 years; 125 mg 8 hourly for 10 days
< 1 year; 62.5 mg 8 hourly for 10 days
Or
 y Amoxicillin + Clavulanic Acid , oral,

— Acute Sinusitis —
Standard  Treatment Guidelines, 7th Edition, 2017
528Adult s
1g 12 hourly for 7 days
Children
>12 years;  One 500/125 mg tablet 12 hourly for 10 days
6-12 years;  5 ml of 400/57 mg suspension 12 hourly for 10 days
1-6 years;  5 ml of 200/28.5 mg suspension 12 hourly for 10 days
1 month-1 year; 2.5 ml of 200/28.5 mg suspension 12 hourly; dose 
doubled in severe infection
2 weeks-1 month;  1.25 ml of 200/28.5 mg suspension 12 
hourly; dose doubled in severe infection
2nd Line Treatment
Evidence Rating: [B]
 y Cefuroxime , oral, 
Adult s 
250-500 mg 12 hourly for 5 - 7 days
Children
3 months-12 years;   125 mg 12 hourly, double in severe infec -
tion
B.     For treatment of bacterial infection in patients with penicillin 
allergy
 y Erythromycin , oral,
Adult s
500 mg 6 hourly for 10 days
Children
2-8 years;  250 mg 6 hourly for 10 days
1 month-2 years; 125 mg 6 hourly for 10 days
Neonate ;   12.5 mg/kg 6 hourly
Or
 y Azithromycin , oral,
Adult s
500 mg daily for 5 days
Children
10 mg/kg daily for 5 days
C�      For pain relief 
 y Paracetamol , oral, (to relieve pain if present)
Adult s
500 mg-1 g 6-8 hourly 
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1year;  60-120 mg 6-8 hourly
D.     For nasal decongestion 
 y Ephedrine  nasal drops 
Adult s (1%) 

— Acute Otitis Media —Chapter 20:  Ear, Nose and Throat Disorders
5291-2 drops into each nostril up to 4 times daily when required
Children  (0.5%)
1-2 drops into each nostril up to 4 times daily when required
Or
 y Neomycin  0.5%/Hydrocortisone  1.5% nasal drops,
Adult s
2 drops 12 hourly
Children  
1 drop 12 hourly 
Referral Criteria 
Refer all cases, which do not improve after 1 week of treatment to 
the ENT Specialist
208� Acute Otitis Media
This is an infection of the middle ear, which communicates with the 
throat. It is important in a febrile child to look for it and treat it. Untreated 
or poorly managed cases may lead to complications such as mastoiditis, 
chronic otitis media , deafness, meningitis  and brain abscess.
Precursors to the bacteria infections are viral upper respiratory tract 
infections.
Causes 
 yHaemophilus	influenzae
 yHaemolytic	streptococcus
 y Streptococcus  pneumoniae
 y Staphylococcus aureus
Symptoms
 y Fever
 y Sudden and persistent ear ache
 y Purulent discharge from the ear 
 y Vomiting
 y Diarrhoea
 y Crying and agitation
 y Impaired hearing
Signs
 y Red eardrum 
 y Discharging ear
 y Occasionally inflamed throat 
 y Perforated eardrum
Investigations
 y FBC 
 y Ear swab for culture and sensitivity 

— Acute Otitis Media —
Standard  Treatment Guidelines, 7th Edition, 2017
530Treatment 
Treatment objectives
 y To relieve symptoms
 y To ensure prompt and adequate antibiotic therapy 
 y To prevent chronicity and other complications 
Non-pharmacological treatment
 y Adequate hydration 
 y Surgical repair and drainage of abscess 
Pharmacological treatment 
A.      For pain relief 
1st Line Treatment
Evidence Rating: [B]
 y Paracetamol , oral, 
Adult s
500 mg-1 g 6-8 hourly
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
B.     For treatment of infection 
1st Line Treatment 
Evidence Rating: [B]
 y Amoxicillin , oral,
Adult s
500 mg 8 hourly for 10 days 
Children
6-12 years;   250 mg 8 hourly for 10 days
1-5 years;   125 mg 8 hourly for 10 days
< 1 year;   62.5 mg 8hourly for 10 days
Or
 y Amoxicillin + Clavulanic Acid , oral,
Adult s
1 g 12 hourly for 7 days
Children
> 12 years;   One 500/125 mg tablet 12 hourly for 10 
days
6-12 years;   5 ml of 400/57mg suspension 12 hourly for 
10 days
1-6 years;   5 ml of 200/28.5 mg suspension 12 hourly 
for 10 days
1 month-1 year;  2.5 ml of 200/28.5 mg suspension 12 hour -
ly; dose doubled in severe infection
2 weeks-1 month;  1.25 ml of 200/28.5 mg suspension 12 
hourly; dose doubled in severe infections

— Chronic Otitis Media —Chapter 20:  Ear, Nose and Throat Disorders
5312nd Line Treatment 
Evidence Rating: [B]
 y Cefuroxime , oral,
Adult s
250 mg 12 hourly for 5 days 
Children
125 mg 12 hourly for 5 days 
C.      For treatment of infection in patients with penicillin allergy   
 y Erythromycin , oral,
Adult s
250-500mg 6 hourly for 10 days
Children  
2-8 years;  250 mg 6 hourly for 10 days
1 month-2 years; 125 mg 6 hourly for 10 days
Neonate ;   12.5 mg/kg 6 hourly
Or
 y Azithromycin , oral,
Adult s
500 mg once daily for 5 days
Children
10 mg/kg once daily for 5 days
Referral Criteria 
Refer patient to ENT specialist if there is no response after 10 days 
of treatment.
209� Chronic Otitis Media
This is a chronic infection of the middle ear with perforation of the 
tympanic membrane and pus discharging from the ear for more than 2 
weeks. 
Causes 
 y Secondary bacterial infections:
 y Pseudomonas aeruginosa  
 yProteus	vulgaris    
 y Pnuemococci
Symptoms
 y Chronic ear discharge (otorrhoea)
 y Hearing loss 
Signs
 y Perforation of tympanic membrane 
 y Conductive hearing loss
 y Ear discharge 

— Epistaxis —
Standard  Treatment Guidelines, 7th Edition, 2017
532Investigations
 y Ear swab for culture and sensitivity
Treatment 
Treatment objectives
 y To keep the ear dry
 y To treat any acute exacerbations and complications e.g. mastoiditis
Non-pharmacological treatment
 y Roll a piece of clean absorbent gauze into a wick and insert carefully 
into the ear. Leave for one minute then remove and replace with a 
clean wick. Do frequently (at least 4 times a day)
 y If bleeding occurs, drying the ear should be stopped temporarily
 y Nothing should be left in the ear between wicking 
 y Avoid swimming or getting the inside of the ear wet
 y Re-assess weekly to ensure that the mother is drying the ear correctly
Pharmacological treatment 
A.      For acute exacebations 
(See section on Treatment for ‘Acute Otitis Media ’)
B.      For topical antibiotic therapy
Evidence Rating: [B]
 y Gentamicin  ear drops, 0.3%, 2-3 drops 6-8 hourly and at night
Or
 y Ciprofloxacin  eye/ear drops, 0.3%, 1 drop 6 hourly daily
Referral Criteria 
Refer all chronically discharging ears to the ENT Specialist.
210� Epistaxis
Epistaxis  also called nosebleed is a common medical emergency, 
which requires prompt management to avoid morbidity and mortality.
Causes 
 y Picking of the nose, especially when there is an upper respiratory 
tract infection
 y Trauma
 y Sinonasal and nasopharyngeal neoplasms 
 y Hypertension
 y Bleeding  disorders
 y Atrophic rhinitis
Symptoms
 y Nose bleed 
Signs
 y Nose bleed 

— Epistaxis —Chapter 20:  Ear, Nose and Throat Disorders
533 y Signs related to underlying cause 
 y Signs of shock (if severe) 
Investigations
 y FBC 
 y Sickling test
 y Coagulation screen
 y Liver function test
 y Retroviral screen, if indicated 
Treatment 
Treatment objectives
 y To stop epistaxis 
 y To prevent recurrence
 y To detect shock and replace blood if necessary
Non-pharmacological treatment
 y Sit patient up and flex head to prevent blood running down throat 
and airway
 y Pinch soft part of nose for 10 minutes (patient must breathe through 
mouth)
 y Apply ice-pack to nasal bridge
Pharmacological treatment 
A.     For haemostasis 
1st Line Treatment
 y Oxymetazoline , nasal spray, 2-3 sprays per nostril 12 hourly 
Or 
 y Adrenaline , topical, (as nose pack, on cotton wool) 1:1000 solutions
Referral Criteria 
Refer patients with recurrent or severe epistaxis to the ENT specialist.

21Chapter
534Oral and Dental Conditions  
211� Dental Caries  
Dental caries is a tooth surface cavity caused by acid demineralization 
of tooth hard tissue. It occurs as a result bacterial conversion of refined 
carbohydrates to acids, which in prolonged contact with tooth surface 
leads to the demineralisation. This process is entirely preventable but can 
progress to severe decay and tooth loss or complicated by infection.
Causes
 y Acid demineralisation of hard tooth surface
Symptoms
 y Usually asymptomatic
 y Toothache precipitated by hot, cold or sweet foods or drinks
 y Pain may be intermittent or severe, sharp and constant if the nerve 
endings are exposed
Signs
 y A hole or black spot may be visible on any surface of a tooth
 y Tenderness on percussion of the affected tooth
Treatment
Treatment objectives
 y To relieve pain
 y To arrest process by excavation and filling of cavities
 y To educate on good dental habits
 y To prevent complications
Non-pharmacological treatment
 y Regular mouth rinse after refined carbohydrate intake
 y Brushing of teeth before bedtime
Pharmacological treatment
A.     For pain relief
Evidence Rating: [C]
 y Paracetamol , oral, 

—  Oral Candidiasis  —Chapter 21:  Oral and Dental Conditions 
535Adult s
500 mg-1 g 6-8 hourly 
Children
6-12 years;  250-500 mg 6-8 hourly
1-5 years;  120-250 mg 6-8 hourly
Or
 y Ibuprofen , oral,
Adult s
200-400 mg 8 hourly 
Children
4-7 years;   150 mg 8 hourly (max. 7.5-10 mg/kg daily 
6-8 hourly)
7-12 year;   200 mg 8 hourly (max. 7.5-10 mg/kg daily 
6-8 hourly)
Referral Criteria 
Refer patient to a dentist for definitive treatment.
212�  Oral Candidiasis  
Oral candidiasis  (oral thrush) is an infection of the mouth by yeast. 
It mainly affects the very young, the very old or those whose immunity is 
impaired. It occurs more frequently in HIV /AIDS  patients, the malnourished, 
diabetics, patients on long-term antibiotics and corticosteroids and those 
with poor oral hygiene.
Causes 
Candida  albicans  (monilia )
Symptoms
 y White patches in the mouth
 y Burning sensation in the mouth
 y Difficulty in swallowing
 y Breast fed babies may refuse to suck
 y Sore mouth
Signs
 y Well defined white or cream–coloured pustules and patches in the 
mouth   
Investigations
 y Buccal mucosal scraping for fungal elements
 y FBS 
 y Retroscreen  
Treatment 
Treatment objectives
 y To eradicate infection
 y To identify and treat any underlying condition

— Acute Necrotising Ulcerative Gingivitis —
Standard  Treatment Guidelines, 7th Edition, 2017
536Non-pharmacological treatment
 y Proper oral hygiene and toileting
Pharmacological treatment 
A.     For treatment of uncomplicated oral candidiasis
1st Line Treatment
Evidence Rating: [B]
 y Nystatin  suspension, oral,
Adult s
100,000 units 6 hourly after food for 14 days
Children
100,000 units 6 hourly after each feed for at least 10 days. Make sure 
it is spread well in the mouth.
2nd Line Treatment
 y Miconazole , oral gel, 
Adult s and Children
2.5 ml smeared on the oral mucosa twice daily for 7-10 days
B.     For immunocompromised patients with oral candidiasis
Evidence Rating: [B]
 y Fluconazole , oral,
Adult s
50-100 mg daily for 7-14 days
Children
12-18 years;                 50-100 mg daily for 7-14 days
14 days-12 years;         3-6 mg/kg on first day, 
Then 
3 mg/kg (max. 100 mg) daily for 14 days
7-14 days;                   3-6 mg/kg on first day 
Then 
3 mg/kg every 48 hours for 14 days
< 7 days;                         3-6 mg/kg on first day 
Then 
3 mg/kg every 72 hours for 14 days
Referral Criteria 
Refer patients not responding to above treatment or if there 
is the presence of an underlying illness e.g. diabetes mellitus, 
immunosuppression to appropriate specialist.
213� Acute Necrotising Ulcerative Gingivitis
It is a specific gum disease affecting mainly the interdental papillae 
and gum margin. It affects usually healthy young adults with poor oral 
hygiene.

— Acute Necrotising Ulcerative Gingivitis —Chapter 21:  Oral and Dental Conditions 
537Causes 
 y Spirochaetes  
 y Gram-negative fusiforms
 y Host factors of poor oral hygiene, cigarette smoking and immune-
suppression
Symptoms
 y Gum margin soreness or pain of sudden onset
 y Bleeding
 y Malaise
 y Bad taste and foul breath 
Signs
 y Crater-like ulcers and necrosis mainly limited to gum margin and 
inter-dental gingiva
 y Poor oral hygiene
 y Fever  
 y Lymph node enlargement 
Investigations
 y Swab for culture and sensitivity 
Treatment 
Treatment objectives
 y To eradicate bacterial overgrowth
 y To establish good oral hygiene
 y To control fever and pain
Non-pharmacological treatment
 y Improve oral hygiene habits e.g. brushing at least two times daily, 
frequent antiseptic oral rinse 
Pharmacological treatment 
A.     For treatment of infection 
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin (Amoxycillin) , oral,
Adult
1 g stat.
Then
500 mg 6 hourly for 7 days
Children
7-10 years;              250 mg   6 hourly for 7 days
3-7 years;               125 mg   6 hourly for 7 days
1-3 years;               62.5 mg 6 hourly for 7 days
B�      For Individuals with penicillin allergy
Evidence Rating: [C]
 y Clindamycin , oral,

— Bacterial Endocarditis and Prophylaxis in Dentistry  —
Standard  Treatment Guidelines, 7th Edition, 2017
538Adult s
150-300 mg 6-8 hourly for 7 days
Children
12-18 years;   150-300 mg 6 hourly for 7 days
1 month-11 years;  3-6 mg/kg 6 hourly for 7 days
C�     For pain and fever control
 y Paracetamol , oral, 
Adult s
500 mg-1 g 6 hourly as required 
Children
6-12 years;  250-500 mg 6 hourly as required
1-5 years;  125-250 mg 6 hourly as required
3 months-1 year;  62.5-125 mg 6 hourly as required
Referral Criteria 
Refer all patients after initiating therapy to a dentist.  
214. Bacterial Endocarditis and Prophylaxis in Dentistry  
Antibiotic prophylaxis  is an established requirement in the 
management of patients with cardiac related diseases at risk of bacterial 
endocarditis in the course of dental manipulation.
Predisposing risk factors include previous history of bacterial 
endocarditis, history of heart valve disease and a history of heart valve 
replacement.
Causes
 y Streptococcus  sanguis  
 y Streptococcus 	mitis  
 y Streptococcus  mutans
 y Streptococcus 	salivarius  
 y Other oral bacterial flora
Treatment 
Treatment objectives
 y To prevent seeding of oral bacteria during the transient bacteraemic 
phase during dental manipulation unto intra-cardiac defects and 
valvular lesions 
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin (Amoxycillin ), oral,
Adult s
2 g stat. (2 hours before procedure)
Children
50 mg/kg stat. (2 hours before procedure) 

— Acute Bacterial Sialoadenitis   —Chapter 21:  Oral and Dental Conditions 
539Or
 y Clindamycin , oral,
Adult s   
600 mg stat. (1 hour before procedure)
Children
20 mg/kg stat. (1 hour before procedure)
Referral Criteria 
Refer to a cardiologist if cardiac status cannot be ascertained or 
history is not clear.
215� Acute Bacterial Sialoadenitis   
Bacterial infection usually of the parotid glands. It is mostly unilateral. 
Seen exclusively in debilitated, elderly, dehydrated patients or who have 
drug or disease-induced xerostomia.   
Causes 
 y Staphylococcus aureus
 y Anaerobes
 y Streptococcus  (occasionally)
Symptoms
 y Painful parotid swelling of sudden onset
 y Fever
 y Chills 
Signs
 y Erythematous swelling
 y Tense and shiny overlying skin
 y Purulent discharge from duct 
Investigations
 y FBC
 y Culture and sensitivity of discharge
Treatment 
Treatment objectives
 y To treat infection 
 y To provide pain relief 
Non-pharmacological treatment 
 y Encourage bed-rest
 y Adequate fluid intake 
 y Discontinue medications that can cause xerostomia
 y Surgical drainage if indicated

— Ludwig’s Angina/Cervico-Facial Abscess   —
Standard  Treatment Guidelines, 7th Edition, 2017
540Pharmacological treatment 
A.     For treatment of infection 
1st Line Treatment
Evidence Rating: [B]
 y Flucloxacillin , oral, 
Adult s
500 mg 6 hourly for 7-10 days
Children  
5-12 years;   250 mg 6 hourly for 7-10 days
1-5 years;   125 mg 6 hourly for 7-10 days
< 1 year;   62.5 mg 6 hourly for 7-10 days
B.     For treatment of infection in patients with penicillin allergy  
Evidence Rating: [C]
 y Clindamycin , oral,
Adult s
150-300 mg 6-8 hourly for 7 days
Children
12-18 years;   150-300 mg 6 hourly for 7 days
1 month-11 years;   3-6 mg/kg 6 hourly for 7 days
C�     For pain relief 
 y Paracetamol , oral, 
Adult s
500 mg-1 g 6 hourly as required 
Children
6-12 years;  250-500 mg 6 hourly as required
1-5 years;  125-250 mg 6 hourly as required
3 months-1 year;  62.5-125 mg 6 hourly as required
Referral Criteria 
Refer to a dentist after initiation of treatment.
216� Ludwig’s Angina /Cervico-Facial Abscess   
It is a spreading infection originating usually from a molar tooth into 
the fascial spaces of the sub-lingual, sub-mandibular and para-pharynx. 
This happens when a periapical abscess erodes through the lingual 
cortical plate of the mandible and gains access to these neck fascial 
spaces. The infection can then track down and enter the thorax. Another 
source of infection is the tonsillar crypt abscess. The initial presentation 
with swelling of the floor of the mouth and spread, with upper neck 
involvement is termed Ludwig’s angina. As it spreads down the neck, the 
term cervico-facial abscess is used. This condition is an emergency and 
must be treated as such. 

— Ludwig’s Angina/Cervico-Facial Abscess   —Chapter 21:  Oral and Dental Conditions 
541Causes 
 y Odontogenic infection 
 y α-haemolytic Streptococci  
 y Staphylococci
 y Bacteriodes  
 y Tonsillar crypt abscess
Symptoms
 y Facial swelling with floor of the mouth elevated with oedema 
 y Protruding tongue
 y Drooling of saliva
 y Fever  
 y Chills 
Signs
 y Tense and tender jaw swelling 
 y Board-like firmness of jaw swelling 
 y Severe systemic upset
 y Raised floor of the mouth with limitation of mouth-closing and saliva 
drooling
 y Dehydration
Investigations
 y FBC
 y BUE/CR
 y X-ray of jaw
Treatment 
Treatment objectives
 y To treat the infection 
 y To prevent dehydration
 y To control fever and pain
Non-pharmacological treatment
 y Adequate hydration 
 y Intubation if airway obstruction present  
 y Incision and drainage as appropriate
 y Extraction of tooth if it is the source of infection
Pharmacological treatment 
A.     For treatment of infection in patients unable to swallow and 
toxaemic         
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 8 hourly for 7-10 days
Children
3 months-18 years; 30 mg/kg 8 hourly (max. 1.2 g 8 hourly for 

— Ludwig’s Angina/Cervico-Facial Abscess   —
Standard  Treatment Guidelines, 7th Edition, 2017
5427-10 days)
< 3 months;   30 mg/kg 12 hourly for 7-10 days
And
 y Ceftriaxone , IV,
Adult
2 g daily for 7-10 days, 
Children
All ages 25 mg/kg 12 hourly (max. 75 mg/kg daily)
2nd Line Treatment 
Evidence Rating: [B]
 y Clindamycin , IV,
Adult s
300-600 mg 6 hourly for 7-10 days
Children
3-6 mg/kg 6 hourly for 7-10 days
And 
 y Ceftriaxone , IV,
Adult
2 g daily for 7-10 days 
Children
All ages 25 mg/kg 12 hourly (max. 75 mg/kg daily)
3rd Line Treatment 
Evidence Rating: [C]
 y Procaine Penicillin , IM, 
Adult
600,000-1,000,000 units daily
Children
> 27 kg;  600,000 units daily
< 27 kg;  25,000-50,000 units/kg daily
Neonate s;   not recommended
And
 y Gentamicin , IV,
Adult s
40-80 mg 8 hourly for 7-10 days
Children
1-12 years;  2.5 mg/kg 8 hourly for 7-10 days
< 1 year;  2.5 mg/kg 12 hourly for 7-10 days
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7-10 days
Children
7.5 mg/kg 8 hourly for 7-10 days
Referral Criteria 
Refer to the specialist as soon as possible. 

— Chronic Periodontal Infections    —Chapter 21:  Oral and Dental Conditions 
543217� Chronic Periodontal Infections    
Chronic periodontal infections are due to prolonged bacterial 
infection around the teeth, which leads to destruction of periodontal 
and bony supporting tissue of the tooth. This usually leads to pocket 
formation, gum recession, tooth mobility and or loss.
Causes 
 y Bacteria
Symptoms
 y Recurrent painful chewing
 y Mobility of teeth
 y Bleeding  gum margin
Signs
 y Gum recession
 y Pocket formation
 y Loss of supporting bony tissue 
Investigations
 y X-ray of involved teeth and supporting tissues
Treatment 
Treatment objectives
 y To restore tooth function 
 y To treat infection 
 y To relieve pain
Non-pharmacological management 
 y Debridement
 y Reconstructive surgery
Pharmacological treatment
A.     Adjunctive Antimicrobial therapy
 y Clindamycin , oral,
Adult s
300-450 mg 6-8 hourly for 7 days
Children
12-18 years;   150-300 mg 6 hourly for 7 days
1 month-11 years;   3-6 mg/kg 6 hourly for 7 days
Or
 y Amoxicillin + Clavulanic Acid , oral,  
Adult s
1 g 12 hourly for 14-21 days
Children
>12 years;   One 500/125 tablet 12 hourly
6-12 years;   5 ml of 400/57 suspension 12 hourly 

— Mouth Ulcers —
Standard  Treatment Guidelines, 7th Edition, 2017
5441-6 years;   2.5 ml of 400/57 suspension 12 hourly 
1 month-1 year;  0.25 ml/kg body weight of 125/31
suspension 8 hourly 
< 1 month;   0.25 ml/kg body weight of 125/31
suspension 8 hourly 
B�     For pain relief 
 y Paracetamol , oral, 
Adult s
500 mg-1 g 6 hourly as required 
Children
6-12 years;  250-500 mg 6 hourly as required
1-5 years;  125-250 mg 6 hourly as required
3 months-1 year;  62.5-125 mg 6 hourly as required
Referral Criteria 
Refer all patients to the dental specialist.
218� Mouth Ulcers
Mouth ulcers are generally due to infection (bacterial, viral or 
fungal), neutropaenia, malignancy-related or trauma. The common ones 
are apthous and viral ulcers.
APTHOUS ULCERS
Apthous ulcer  is a recurrent ulcer of non-viral origin that occurs on 
the movable surfaces of the oral cavity. Size is variable but may have a rim 
of erythema with yellowish base, and later becoming a greyish hue. They 
are classified into minor, major or herpetiform on clinical presentation. 
The minor is < 1 cm, and the major 1-3 cm in diameter. The herpetiform 
comes in multiple crops of 1-3 cm. Though the cause is unknown, systemic 
conditions associated with apthous ulcer include Behcet’s syndrome , HIV , 
Vitamin deficiency states (vitamin B group, folic acid). 
Herpetiform ulcers  are a crop of oral apthous ulcers resembling oral 
viral ulcers.
Behcet’s disease  is a more severe and generalised form involving the 
eye, skin and genitalia.
Causes 
 y Unknown
Symptoms
 y Tingling on the oral mucosa (prodromal phase)
 y Painful ulcer
SIGNS 
 y Crater-like soft tissue ulcer with a yellowish-grey floor  
 y Tenderness 

— Odontogenic Infections   —Chapter 21:  Oral and Dental Conditions 
545Investigations
 y Nil 
Treatment 
Treatment objectives
 y To control pain
 y To treat ulcer
 y To control stress
 y To prevent secondary infection
Non-pharmacological treatment
 y Proper oral hygeine
 y Relaxation 
Pharmacological treatment 
A.     To control pain
1st Line Treatment
Evidence Rating: [C]
 y Local anaesthetic gel, oral, applied with a cotton tip locally to the 
ulcer base
Adult s
Applied not less than every 3 hours as needed and not more than 6 
applications daily
Children
Applied not less than every 3 hours as needed and not more than 6 
applications daily.
And
 y Ibuprofen , oral,
Adult s
400 mg 6-8 hourly as needed
Children
6-12 years;   200-400 mg 6-8 hourly as needed
1-5 years;   100-200 mg 6-8 hourly as needed
3 months-1 year;  not recommended
Referral Criteria 
Refer to a dentist if the ulcer does not heal within 2 weeks.
219� Odontogenic Infections   
Odontogenic infections are infections arising primarily from the 
tooth. This occurs as the result of intraoral bacteria gaining access to pulp 
via a dental cavity such as a carious lesion. The pulp undergoes necrosis 
and an abscess collects at the tooth apex over time. 
Causes 
 y Streptococci

— Odontogenic Infections   —
Standard  Treatment Guidelines, 7th Edition, 2017
546Symptoms
 y Pain on chewing
 y Jaw swelling with persistent gnawing pain
 y Fever  
 y Chills
Signs
 y Tooth tenderness to percussion
 y Lymphadenopathy  
Investigations
 y X-ray of affected tooth
Treatment 
Treatment objectives
 y To control infection
 y To control pain
 y To remove source of infection 
 y To restore tooth integrity and function 
Non-pharmacological treatment
 y Root canal therapy with drainage, debridement, epicectomy etc.
 y Restoration of structure and function 
Pharmacological treatment 
A.     For treatment of mild infection 
1st Line Treatment: 
Evidence Rating: [B]
 y Amoxicillin , oral,
Adult s
500 mg 8 hourly for 7 days
Children
5-18 years;   500 mg 8 hourly for 7 days
1-5 years;   250 mg 8 hourly for 7 days
1 month-1 year;  125 mg 8 hourly for 7 days
B.     For treatment of mild infection-in patients allergic to penicillins 
Evidence Rating: [B]
 y Doxycycline , oral,
Adult s
100 mg 12 hourly for 7 days 
Note 21-1
Not recommended in pregnancy, lactating mothers and in children < 8 years 
of age.
C.     For treatment of severe infection 
1st Line Treatment
Evidence Rating: [B]
 y Amoxicillin + Clavulanic Acid , oral, 

— Odontogenic Infections   —Chapter 21:  Oral and Dental Conditions 
547Adult s
625 mg 8 hourly for 7 days
Children
> 12 years;   One 500/125 tablet 12 hourly for 7-10 days
4-12 years;   5 ml of 400/57 suspension 12 hourly for 
7-10 days
1-4 years;   5 ml of 200/28 suspension 12 hourly for 
7-10 days
3 months - 1 year;  20 mg/kg (of amoxicillin) 12 hourly for 7-10 
days 
< 3 months;  15 mg/kg (of amoxicillin) 12 hourly for 7-10 
days
Or
 y Azithromycin , oral,  
Adult s
500 mg daily for 5 days
Children  
10 mg/kg body weight daily for 5 days. 
Not recommended for children less than 6 months because of a risk 
of pyloric stenosis .
D.     For treatment of severe infection-in patients allergic to penicillins 
Evidence Rating: [B]
 y Azithromycin , oral,  
Adult s
500 mg daily for 5 days
Children  
10 mg/kg body weight daily for 5 days 
Not recommended for children less than 6 months because of a risk 
of pyloric stenosis .
Or 
 y Clindamycin , oral,
Adult s
150-300 mg 6-8 hourly for 7 days
Children
12-18 years;   150-300 mg 6 hourly for 7 days
1 month-11 years;   3-6 mg / kg 6 hourly for 7 days
E�     For pain relief 
Evidence Rating: [B]
 y Paracetamol , oral, 
Adult s
500 mg-1 g 6 hourly as required 
Children
6-12 years;  250-500 mg 6 hourly as required
1-5 years;  125-250 mg 6 hourly as required
3 months-1 year;  62.5-125 mg 6 hourly as required

— Oral Squamous Cell Carcinoma   —
Standard  Treatment Guidelines, 7th Edition, 2017
548Referral Criteria 
Refer all patients with odontogenic infections to a dental specialist 
after initiation of treatment. 
220� Oral Squamous Cell Carcinoma   
This condition presents as a non-healing ulcer of more than two weeks 
in the mouth. There may be a genetic predisposition but environmental 
causes have been identified. For an oral ulcer, 2 weeks observation for 
healing is usually adequate. If suspected to be due to an infection, an 
appropriate antimicrobial is given. 
Causes 
 y Usually unknown 
 y Associations: 
 y Tobacco/betel nut chewing
 y Alcohol 
 y Smoking 
 y HPV  infections 
Symptoms
 y Non-healing ulcer in the mouth
 y Pain
 y Jaw swelling and deformity 
Signs
 y Intra-oral mass ulcer
 y White mucosal patch
 y Neck mass 
Investigations
 y Incisional biopsy for histopathology
Treatment 
Treatment objectives
 y To eradicate tumour mass/cells 
 y To control pain
 y To carry out definitive treatment
Non-Pharmacological treatment
 y Surgery +/- radiotherapy 
Pharmacological treatment 
 y Chemotherapy (+/- surgery +/- radiotherapy) 
Referral Criteria 
Refer immediately to the oncologist for further management.

— Temporo-mandibular Joint dysfunction and masticatory muscle dysfunction —Chapter 21:  Oral and Dental Conditions 
549221� Temporo-mandibular Joint  dysfunction  and masticatory muscle 
dysfunction
Temporo-mandibular Joint  (TMJ ) dysfunction and or masticatory 
muscle dysfunction  is a complex of derangements affecting only the joint, 
the muscles of mastication or both. The pathological process may be due 
to joint arthropathy, disc disease or tension in tendons and masticatory 
muscles from abnormal movement behaviour or occlusal disharmony.
Causes 
 y Behavioural induced bruxism
 y Arthropathy
 y Trauma (physical) 
 y Occlusal disharmony
Symptoms
 y Pre-auricular pain associated with opening and closing the mouth
 y Clicking noise on opening and closing
 y Dull, persistent pain in masticatory muscles 
Signs
 y Tenderness in the TMJ  associated with mouth opening
 y Clicking in TMJ  on mouth opening and closing
 y Tenderness in muscles of mastication on contraction 
 y Occlusal abnormalities
Investigations
 y X-ray-TMJ  views
 y ESR 
Treatment 
Treatment objectives
 y To control pain 
 y To relax muscles of mastication
 y To correct any stress inducing imbalance 
Non-pharmacological treatment
 y Occlusal splints
 y On-lays
 y Reduce stress and encourage relaxation in masticatory apparatus
Pharmacological treatment 
A.     For muscle relaxation 
1st Line Treatment
Evidence Rating: [C]
 y Diazepam , oral,
Adult s
5 mg 12 hourly     

— Trigerminal Neuralgia   —
Standard  Treatment Guidelines, 7th Edition, 2017
550Children
12-18 years;   5 mg 12 hourly 
5-12 years;   2.5 mg 12 hourly 
B�     For pain relief 
 y Ibuprofen , oral,
Adult s
400 mg 12 hourly as required 
Children
6-12 years;   200-400 mg 6-8 hourly as required
1-5 years;   100-200 mg 6-8 hourly as required
3 months-1 year;  not recommended
Referral Criteria 
Refer all cases to the dentist for further management.
222� Trigerminal Neuralgia   
Trigerminal neuralgia  is a condition characterised by unilateral facial 
pain that follows the distribution of the trigerminal nerve. It presents with 
recurrent, sudden onset sharp-shooting pain in the face and may have 
a trigger-point.  The patient may present with marked anxiety  and may 
mimic a psychiatric disorder.
Causes 
 y Degenerative  
 y Inflammatory 
 y Pressure-induced
Symptoms
 y Sudden sharp-shooting pain in the face
 y Severe anxiety  
Signs
 y Anxiety
 y Hypesthesia of affected area (transient)
Investigations
 y X-ray to rule out a fractured tooth
 y MRI to rule out intracranial pathology 
Treatment 
Treatment objectives
 y To reassure patient 
 y To allay anxiety
 y To manage the neuropathy 
Non-pharmacological treatment 
 y Reassurance and counseling 

— Trigerminal Neuralgia   —Chapter 21:  Oral and Dental Conditions 
551Pharmacological treatment 
A.     For the control of anxiety
1st Line Treatment
Evidence Rating: [C]
 y Diazepam , oral,
Adult s
5 mg at night      
Children
12-18 years;   2.5-5 mg at night      
5-12 years;   2.5 mg at night   
B�     For treatment of neuropathic pain 
1st Line Treatment 
Evidence Rating: [A]
 y Carbamazepine , oral, 
Adult s
50-150 mg 12 hourly till resolution (max. 600 mg 12 hourly)
Children
12-18 years;  50-100 mg 12 hourly  
Then 
Increase to 600 mg 12 hourly if necessary 
1 month-12 years;  2.5 mg/kg 12 hourly 
Then
Increase slowly to 5 mg/kg 12 hourly 
Or
 y Pregabalin , oral,
Adult s
75 mg 12 hourly till resolution 
Children
Not recommended
C.     For additional pain relief 
 y Ibuprofen , oral,
Adult s
400 mg 8 hourly as required 
Children
6-12 years;   200-400 mg 8 hourly as required
1-5 years;   100-200 mg 8 hourly as required
3 months-1 year;  not recommended
Referral Criteria 
Refer to the neurologist for further management.

22Chapter
552Disorders Of The 
Musculoskeletal System
223� Osteoarthritis
This is a degenerative articular cartilage disease of varied aetiology. It 
can affect all joints, but mostly the hips and knees. Important differentials 
include, rheumatoid arthritis and tuberculosis affecting the joints. 
Primary osteoarthritis is usually age-related (old age), whiles 
secondary osteoarthritis may be due to other causes. 
Causes 
 y Trauma 
 y Infections
 y Inflammatory arthritides
Symptoms
 y Pain on activity and relieved by rest initially
 y Joint stiffness
 y Joint swelling
 y Limping 
Signs
 y Limping
 y Joint swelling
 y Joint effusion 
 y Deformities
 y Leg length discrepancy 
Investigations
 y X-ray of affected joint
Treatment 
Treatment objectives
 y Relieve pain
 y Prevent progression
 y Improve function of joint
 y Prevent deformities or complications

— Osteoarthritis —Chapter 22:  Disorders Of The Musculoskeletal System
553Non-pharmacological treatment
 y Physiotherapy
 y Weight loss
 y Walking aid
 y Braces
 y Surgery
 y Aspiration of excessive synovial fluid
 y Osteotomies
 y Arthroplasties  
 y Arthrodesis
Pharmacological treatment 
A.     For pain relief
1st Line Treatment
Evidence Rating: [A]
 y Naproxen  EC, oral,
Adult s
250-500 mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
Not indicated 
Or 
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;   50 mg 12 hourly
< 12 years;   not recommended
Or
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2.4 g daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg per kg daily)
And
 y Diclofenac  gel, topical, 
Adult s and Children  
Apply 12 hourly as necessary 
Or

— Rheumatoid arthritis —
Standard  Treatment Guidelines, 7th Edition, 2017
554 y Diclofenac  spray, topical,
Adult s and Children  
Apply 12 hourly as necessary
2nd Line Treatment
Evidence Rating: [C]
For any of the following therapy, consult a specialist 
 y Methyl prednisolone acetate , Intra-articular
 y Triamcinolone , Intra-articular
 y Betamethasone , Intra-articular
Referral Criteria 
Refer complicated cases to the orthopaedic specialist.
224. Rheumatoid arthritis
Rheumatoid arthritis  (RA) is a chronic systemic inflammatory disease 
of unknown cause. An external trigger (e.g. cigarette smoking, infection, or 
trauma) triggers an autoimmune reaction, leading to synovial hypertrophy 
and chronic joint inflammation along with the prospect for extra-articular 
manifestations. It is believed to occur in genetically susceptible individuals 
and more common in middle aged women. 
Causes 
 y Unknown
 y Autoimmune disorder
 y Likely a combination of genetic and environmental factors
Symptoms
 y Joint stiffness
 y Painful joints
 y Swelling of affected joints
 y Deformity of affected joints
 y Limitation of motion
 y Skin nodules
 y Difficulty in breathing 
 y Easy fatiguability 
Signs
 y Persistent symmetric polyarthritis  (synovitis) of hands and feet
 y Joint stiffness
 y Joint tenderness
 y Joint swelling
 y Joint deformity
 y Limitation of joint movement 
 y Rheumatoid nodules
 y Signs relating to extra-articular involvement e.g. lung disease, uveitis, 
pericardial or pleural effusions

— Rheumatoid arthritis —Chapter 22:  Disorders Of The Musculoskeletal System
555Investigations
 y FBC, ESR
 y C-reactive protein  level
 y Rheumatoid Factor  assay
 y Antinuclear Antibody (ANA ) assay 
 y Anti−Cyclic Citrullinated Peptide (Anti-CCP)
 y Joint aspiration and analysis of synovial fluid
 y Hepatitis  B and C tests 
 y HIV test
 y X-rays of hands and feet 
 y MRI of cervical spine (to detect subluxation)
 y Ultrasonography of joints  
Treatment 
Treatment objectives
 y To reduce pain, swelling and stiffness
 y To prevent deformities
 y To delay disease progression and long-term complications
 y To reduce drug side effects
Non-pharmacological treatment
 y Heat and cold therapies
 y Orthotics and splints
 y Physiotherapy
 y Occupational therapy
 y Adaptive equipment
 y Joint-protection education 
 y Couselling and education
 y Synovectomy
 y Tenosynovectomy
 y Tendon realignment
 y Reconstructive surgery or arthroplasty
 y Arthrodesis
Pharmacological treatment 
A.     Symptoms present more than 6 weeks or antibody positive
1st Line Treatment
Evidence Rating: [B]
 y Prednisolone , oral, 0.5-1 mg/kg body weight 
Caution 22-1.
Take corticosteroids after food.
High-dose glucocorticoids may cause insomnia; immediate-release formulation 
is typically administered in morning to coincide with circadian rhythm.
And 
 y Omeprazole , oral,
Adult s 
20 mg daily 

— Rheumatoid arthritis —
Standard  Treatment Guidelines, 7th Edition, 2017
556Children
> 20 kg;   20 mg daily 
10-20 kg;   10 mg daily 
5-10 kg;   5 mg daily 
Or
 y Esomeprazole , oral,
Adult s
20-40 mg daily 
Children
12-18 years;  20-40 mg daily 
1-12 years;  10-20 mg daily 
< 1 year;  not recommended
And
 y Diclofenac , oral, 
Adult s
50 mg 8 hourly or 100 mg 12 hourly as required
Children
>12 years;   50 mg 12 hourly as required
<12 years;   not recommended
Or 
 y Diclofenac , rectal,
Adult s 
100 mg 12 hourly as required 
Children  
> 12 years;   75-100 mg daily as required 
< 12 years;   not recommended
Or
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
> 2 years (> 25 kg); 100 mg 12 hourly as required
> 2 years (and 10-25 kg);50 mg 12 hourly as required
< 2 years;  not recommended   
Or
 y Paracetamol , oral,
Adult s
500 mg-1 g 6 - 8 hourly as required
Children
6-12 years;   250-500 mg 6-8 hourly as required
1-5 years;   120-250 mg 6-8 hourly as required
3 months-1 year;  60-120 mg 6-8 hourly as required
And 
 y Calcium  supplements 

— Juvenile Idiopathic Arthritis    —Chapter 22:  Disorders Of The Musculoskeletal System
557Adult s and Children  
As required 
B�     Maintenance treatment for symptoms present more than 6 weeks 
or antibody positive
1st Line Treatment
Evidence Rating: [B]
 y Hydroxychloroquine, consult specialist
 y Sulfasalazine, consult specialist 
 y Methotrexate, consult specialist 
 y Leflunomide, consult specialist 
Or 
 y Etanercept, consult specialist 
 y Infliximab, consult specialist 
 y Adalimumab, consult specialist 
 y Certolizumab, consult specialist 
 y Golimumab, consult specialist 
Or 
 y Rituximab, consult specialist 
 y Anakinra, consult specialist 
 y Abatacept, consult specialist 
 y Tocilizumab, consult specialist 
 y Tofacitinib, consult specialist 
2nd Line Treatment
Evidence Rating: [C]
 y Cyclosporine, consult specialist 
 y Azathioprine, consult specialist 
 y Gold salts, consult specialist 
 y D-penicillamine, consult specialist 
 y Minocycline, consult specialist 
Referral Criteria 
Refer all cases to a physician specialist or rheumatologist. 
225� Juvenile Idiopathic Arthritis    
Juvenile idiopathic arthritis  results from abnormally regulated 
immune responses that lead to inflammation of joints, surrounding 
tissues and other organs. Often, non-rheumatic diseases that can cause 
similar features need to be excluded during evaluation. 
Rheumatoid arthritis  in children may present in one of three forms; 
a systemic onset arthritis (Still’s disease ), poly-articular onset arthritis (5 
or more joints usually of both large and small affected) or pauci-articular 
onset arthritis (fewer than 5 of mainly large joints affected) either of 
which may be rheumatoid factor positive or negative.  Those with positive 

— Juvenile Idiopathic Arthritis    —
Standard  Treatment Guidelines, 7th Edition, 2017
558Antinuclear Antibodies (ANA ) tests need regular eye checks for uveitis.
For this condition, it is mandatory for arthritis to be present for at 
least 6 weeks for the diagnosis to be made.
Causes 
 y Autoimmune disease 
Symptoms
 y Morning stiffness
 y Joint pain
 y Painful red eyes 
 y Rash
 y Joint swelling
 y Fever
Signs
 y Swollen warm joints 
 y Restricted range of joint movement
 y Systemic onset
 y Fever
 y Macular rash
 y Hepatosplenomegaly
 y Lymphadenopathy
 y Serositis e.g. pericardial effusion
 y Red eyes
Investigations
 y FBC
 y ESR
 y BUE and creatinine 
 y Liver function tests
 y C-reactive protein
 y Rheumatoid Factor  (RF) 
 y Anti-Cyclic Citrullinated Peptide (CCP) antibody
 y Antinuclear Antibodies (ANA )
 y X-Ray of affected joints
 y Slit lamp examination 
 y Other tests as determined by specialist 
Treatment 
Treatment objectives
 y To control pain and inflammation 
 y To prevent deformities and growth retardation 
 y To control extra articular complications  
 y To minimise drug side effects
 y To optimise chance for normal social development
Non-Pharmacological Treatment
 y Physiotherapy  

— Juvenile Idiopathic Arthritis    —Chapter 22:  Disorders Of The Musculoskeletal System
559 y Psychotherapy
 y Occupational therapy
 y Diet therapy
 y Patient counselling  
Pharmacological Treatment 
A.     To control pain and inflammation 
1st Line Treatment
Evidence Rating: [A]
 y Ibuprofen , oral,
Children
6-12 years;   200-400 mg 8 hourly as required
1-5 years;   100-200 mg 8 hourly as required
3 months - 1 year;  not recommended
Or
 y Indomethacin , oral,
Children
> 14 years;   25-50 mg 8-12 hourly (max. 200 mg per 
day)
2-14 years;   500 microgram-1 mg/kg 12 hourly (max. 
150 mg per day)
< 2 years;   not recommended 
Or
 y Naproxen , oral,
Children  
> 5 years;  5-7.5 mg/kg 12 hourly (max. 1 g per day)
< 5 years;  not recommended for this condition 
2nd Line Treatment
Evidence Rating: [A]
 y Celecoxib , oral, 
Children  
> 2 years ( > 25 kg);  100 mg 12 hourly  
> 2 years (and 10-25 kg);  50 mg 12 hourly  
< 2 years;   not recommended   
Caution 22-2.
The long-term use of NSAIDs  like diclofenac , naproxen , and ibuprofen  (i.e. for 
more than two weeks) may cause renal impairment and gastritis.
Refer after two weeks of NSAIDs use.
B.     Steroid therapy to control inflammation 
(See treatment ‘to control pain and inflammation’ in (A) above) 
And 
 y Prednisolone , oral,
Children
0.5-2 mg/kg daily or 12 hourly (max. 60 mg per day)

— Back pain —
Standard  Treatment Guidelines, 7th Edition, 2017
560Note 22-1
If symptoms do not improve after 6 weeks of steroid use, treat as a chronic case.
 
C�     For treatment of chronic symptoms
1st Line Treatment
Evidence Rating: [A]
 y Intra-articular corticosteroid injection, consult specialist
 y Methotrexate , consult specialist 
 y Etarnecept , consult specialist 
 y Infliximab , consult specialist 
 y Adalimumab , consult specialist 
 y Anakinra , consult specialist 
Referral Criteria 
Refer all suspected cases to a paediatrician or rheumatologist. 
226� Back pain
This is the commonest cause of reported pain to healthcare 
facilities. More than 80% of people will have at least one episode in their 
lifetime. Most are benign and will resolve. However, 33%-66% will have a 
recurrence within a year. It is important to identify red, and yellow flags. It 
may be acute if it is less than 3 months and chronic if it is more.
Box 22-1:   Notes of back pain
YELLOW flags
 yPessimistic attitude toward pain, excessive fear of movement and activity 
and little hope for improvement
 yWork-related problems (e.g. dissatisfaction, conflicts)
 yEmotional problems (e.g. depression , anxiety , worry)
 yGeneralized pain (e.g. headache, fatigue, dizziness)
 yDesire for passive treatment, little ability to be proactive
 yPrevious episodes of low back pain that were followed for an extended pe -
riod of time
RED flags
 yPatients < 20 years or > 55 years of age experiencing back pain for the  
first time
 yPatients experiencing pain significantly different from previous episodes
 yPain that is constant over time and does not disappear during sleep
 yGeneral malaise and poor general condition
 yTraumatic injuries, tumours, steroid use or improper use of immunosup -
pressants
 yNeurological compromise
 ySpinal deformity
 yPronounced morning stiffness lasting for longer than 1 hour and/or high 
erythrocyte sedimentation rate
Causes 
 y Mechanical (e.g. disc degeneration, fractured vertebrae, instability, 

— Back pain —Chapter 22:  Disorders Of The Musculoskeletal System
561unknown cause [most cases])
 y Neurogenic (e.g., herniated disc, spinal stenosis, osteophyte damage 
to nerve root)
 y Non-mechanical spinal conditions (e.g., neoplasm, infections, 
inflammatory arthritis, Paget’s disease)
 y Referred visceral pain (e.g., gastrointestinal disease, kidney disease, 
abdominal aortic aneurism)
 y Other (e.g., fibromyalgia , somatoform disorder, “faking” pain)
Symptoms
 y Pain
 y Nociceptive
 y Diffuse pain
 y Neuropathic 
 y Pricking, tingling, pins and needles
 y Electric shocks of shooting
 y Hot or burning
 y Numbness 
 y Altered sensation
 y Radicular pain
 y Incontinence of urine and faeces
Signs
 y Deformity of spine 
 y Tenderness in affected region
 y Weakness of the affected limb
 y Muscle wasting in the affected limb
 y Altered sensation in the affected limb
Investigations
Criteria - ACR Recommendation
Uncomplicated, acute low back pain Imaging usually not appropriate
Low-velocity trauma, osteoporosis or age > 
70 yearsMRI of lumbar spine without contrast 
usually appropriate
Low back pain and/or radiculopathy in 
surgical or interventional candidate
Suspicion of cancer, infection or 
immunosuppressionMRI of lumbar spine with and without 
contrast usually appropriate
Prior lumbar surgery
Cauda equina syndrome
 y FBC, ESR, 
 y Mantoux  
 y Chest X-ray (if TB is suspected)
 y Rheumatoid factor  

— Back pain —
Standard  Treatment Guidelines, 7th Edition, 2017
562 y HLA-B27  (if inflammatory arthritides is suspected)
 y CT scan of spine 
 y CT myelogram
 y Plain X-rays of spine
Treatment 
Treatment objectives
 y Pain relief
 y Prevention of recurrence
 y Identification of red and yellow flags
 y Treatment of underlying cause
 y Improvement of function
Non-pharmacological treatment
 y Splints
 y Physiotherapy
 y Weight loss and lifestyle adjustment
 y Acupuncture  
 y Sleep hygiene
 y Occupational therapy
Pharmacological treatment 
A.     For relief of acute back pain
1st Line Treatment
Evidence Rating: [B]
 y Paracetamol , oral, 500 mg-1 g 6-8 hourly  
And 
 y Naproxen  EC, oral,
250-500 mg 12 hourly as required 
Or 
 y Celecoxib , oral, 
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Or 
 y Diclofenac , oral, 50 mg 8 hourly or 100 mg 12 hourly 
Or
 y Ibuprofen , oral, 400 mg 6-8 hourly
And
 y Diazepam , oral, 5 mg 12 hourly     
Or
 y Methocarbamol , consult specialist
Or
 y Tizanidine , consult specialist
2nd Line Treatment

— Fibromyalgia —Chapter 22:  Disorders Of The Musculoskeletal System
563Evidence Rating: [B]
 y Amitriptyline , oral, (when there are neuropathic signs and symp -
toms), 25-50 mg daily 
Or 
 y Pregabalins , oral, consult specialist
And
 y Tramadol , oral,
25 mg stat.
Then
Increase by 25-50 mg daily up to 50-100 mg 6 hourly as necessary; 
(max. 400 mg per day)
Or
 y Codeine , oral, 15-60 mg 4-6 hourly as required 
Or 
 y Morphine  sulphate, oral, 5-10 mg 8-12 hourly 
B.      For Inflammatory Arthritides 
 y Prednisolone , oral, consult specialist 
 y Methotrexate , oral, consult specialist
 y Rituximab , IV, consult specialist
Referral Criteria 
Individuals may need to be referred to the orthopaedic specialist, 
neurosurgeon or rheumatologist based on the red and yellow flag criteria 
above.
227� Fibromyalgia
Fibromyalgia  is a disorder of chronic, widespread pain and 
tenderness. It typically presents in young women in the third decade or 
middle-aged women but can affect patients of either sex and at any age.
Fibromyalgia  is a diagnosis of exclusion and often occurs in patients 
with other conditions, such as autoimmune inflammatory arthritis and 
osteoarthritis. The clinical evaluation may reveal objective evidence for 
other co-morbid illness, such as hypothyroidism , rheumatoid arthritis, 
systemic lupus erythematosus, polymyalgia rheumatica and other 
inflammatory or autoimmune disorders.
  No clear pathophysiological mechanism for fibromyalgia  has 
been established, but evidence suggests that there is an abnormality in 
central pain processing.
Although there is no cure for fibromyalgia , treatment can relieve 
some of the symptoms. Since symptoms are numerous and vary among 
patients, treatment programs must be individualized for each patient. 
Treatment includes patient education, stress reduction, regular exercise 
and medications.  Always combine pharmacologic and non-pharmacologic 

— Fibromyalgia —
Standard  Treatment Guidelines, 7th Edition, 2017
564therapy in the treatment of fibromyalgia.
Causes
 y Usually unknown 
Symptoms  
 y Chronic widespread pain 
 y Unrefreshing sleep and tiredness
 y Anxiety
 y Depression
 y Migraine  or tension headaches 
 y Numbness or tingling of different parts of the body
 y Abdominal pain 
 y Constipation  or diarrhoea
 y Irritable bladder
Signs
 y Tender Points (commonly found around the elbows, shoulders, 
knees, hips, back of the head, and the sides of the breastbone)
 y Myalgia  (more than three months)
Investigations
 y FBC, ESR
 y BUE and creatinine
 y Urinalysis
 y Thyroid stimulating hormone level
 y 25-hydroxy vitamin D level
 y Vitamin B12  level
 y Iron studies
 y Magnesium level
Treatment 
Treatment objectives
 y To reduce pain
 y To aggressively treat co-morbid depression
 y To improve sleep
 y To reduce fatigue 
Non-pharmacological treatment
 y Stress management 
 y Exercise 
 y Balanced diet 
 y Sleep therapy 
 y Psychologic/behavioural therapy
Pharmacological treatment 
A.     For treatment of mild symptoms
1st Line Treatment
Evidence Rating: [B]

— Fibromyalgia —Chapter 22:  Disorders Of The Musculoskeletal System
565 y Paracetamol
Adult s
500 mg-1 g 6-8 hourly as required 
Children
6-12 years;  250-500 mg 6-8 hourly as required
1-5 years;  125-250 mg 6-8 hourly as required
3 months-1 year;  62.5 mg-125 mg 6-8 hourly as required
Or
 y Diclofenac , oral, 
Adult s
50 mg 8 hourly or 100 mg 12 hourly as required
Children
> 12 years;   50 mg 12 hourly as required
< 12 years;   not recommended
Or 
 y Diclofenac , rectal,
Adult s 
100 mg 12 hourly as required 
Children
> 12 years;   75-100 mg daily as required 
< 12 years;   not recommended
2nd Line Treatment 
Evidence Rating: [B]
 y Tramadol , oral,
25 mg stat.
Then
Increase by 25-50 mg daily up to 50-100 mg 6 hourly as necessary; 
(max. 400 mg per day)
And
 y Amitriptyline , oral, 
10 mg nocte
Then
Gradually increase to 75 mg daily as required 
B�     For treatment of chronic or severe symptoms with anxiety  
(See ‘treatment for mild symptoms’ as above) 
And
1st Line Treatment
Evidence Rating: [B]
 y Clonazepam , oral,
Adult s 
250 microgram 12 hourly (max. 1 mg 12 hourly) 
Children  
Not recommended for this condition 
C�     For treatment of chronic or severe symptoms with depression
(See ‘treatment for mild symptoms’ as above) 

— Fibromyalgia —
Standard  Treatment Guidelines, 7th Edition, 2017
566And
1st Line Treatment
Evidence Rating: [B]
 y Fluoxetine , oral,
Adult s 
20 mg daily (max. 80 mg per day)
Children  
8-18 years;   10 mg daily (max. 20 mg per day)
< 8 years;   not recommended
Or
 y Amitriptyline , oral,
Adult s
25-50 mg once daily (early evening),
Then
Increase by 25 mg every 3-5 days up to a max. of 150 mg
Children
> 16 years;   5-15 mg 12 hourly
< 16 years;   not recocommended
Or 
 y Duloxetine , oral,
Adult s 
20-30 mg 12-24 hourly (max. 60 mg per day)
Children  
7-17 years;   20-30 mg daily (max. 60 mg per day)
D�     For treatment of chronic or severe symptoms with myalgia
(See ‘treatment for mild symptoms’ as above) 
And
1st Line Treatment
Evidence Rating: [B]
 y Tizanidine , oral,
Adult s 
2 mg 8 hourly 
May increase to 4 mg 8 hourly after 7 days
Children  
Not recommended
Or
 y Cyclobenzaprine , oral,
Adult s 
5-10 mg 8 hourly as required
Children  
5 mg 8 hourly as required  
E�      For treatment of chronic or severe symptoms with neuropathic 
pain
(See ‘treatment for mild symptoms’ as above) 
And
1st Line Treatment

— Fibromyalgia —Chapter 22:  Disorders Of The Musculoskeletal System
567Evidence Rating: [B]
 y Pregabalin , oral,
Adult s
50-75 mg 12 hourly till resolution (max. 300 mg per day)
Children
Not recommended
Or
 y Gabapentin , oral,
Adult s 
300 mg daily 
Then
Increase by 300 mg daily to a max. of 600 mg 8 hourly 
Children  
Not recommended
F�      For treatment of chronic or severe symptoms with migraine 
(See ‘treatment for mild symptoms’ as above) 
And
 y Clonidine , oral,
 Adult s 
 50-75 microgram 12 hourly 
 Children  
 Not recommended 
Referral Criteria 
Refer patients not responding to treatment to the appropriate 
specialist.
Fig 22-2:  Fibromyalgia  tender points

— Idiopathic inflammatory myopathies —
Standard  Treatment Guidelines, 7th Edition, 2017
568228� Idiopathic inflammatory myopathies
The idiopathic inflammatory myopathies (IIM ) are systemic connective 
tissue diseases, which are characterized by symmetrical, proximal muscle 
weakness, reduced muscle strength and chronic inflammation in muscle 
tissue. These are rare disorders, and affects more women than men. 
Although the peak age of onset is in the 50s, the disorders can occur at 
any age. The word “juvenile” is used in the name when a child is affected 
by myositis.  
Adults with inflammatory myopathies, have an increased risk of 
cancer including cancer of the lung, breast, prostate, and ovaries etc.
Causes 
 y Unknown 
 y Autoimmune  
Symptoms
 y Muscle weakness (around the neck, shoulders and hips)
 y Trouble climbing stairs, getting up from a seat, or reaching for objects 
overhead
 y Pain in the muscles
 y Choking while eating 
 y Aspiration of food 
Signs
 y Proximal muscle weakness 
 y Aspiration pneumonia
 y Gottron’s sign  or Gottron’s papules  (rash over the back of the fingers, 
elbows or knees) 
 y Shawl sign (flat, reddened area that appears on the upper back, 
shoulders, and back of the neck) 
 y Photosensitive rash  
 y Heliotrope rash  
 y Nail bed abnormalities 
 y Mechanic’s hands 
 y Alopecia
 y Interstitial lung disease 
 y Calcium  deposits in the skin (calcinosis)
Investigations
 y Creatine kinase levels 
 y Antinuclear Antibodies (ANA )
 y Hepatitis  B and C screen
 y HIV Test
 y Muscle biopsy
 y MRI scan of the muscles  
 y Electromyogram (EMG)     

— Idiopathic inflammatory myopathies —Chapter 22:  Disorders Of The Musculoskeletal System
569Treatment 
Treatment objectives
 y To improve muscle strength  
 y To minimise long-term muscle damage
 y To prevent complications from muscle weakness
 y To reduce treatment side effects 
Non-pharmacological treatment
 y Physical therapy and rehabilitation to prevent contractures 
 y Avoidance of exposure to direct sunlight 
 y Appropriate feeding techniques to prevent aspiration 
Pharmacological treatment 
A.     For treatment of acute condition
1st Line Treatment
Evidence Rating: [B]
 y Prednisolone , oral, 0.5-1 mg/kg body weight 
And 
 y Omeprazole , oral,
Adult s 
20 mg daily 
Children
> 20 kg;   20 mg daily 
10-20 kg;   10 mg daily 
5-10 kg;   5 mg daily 
Or
 y Esomeprazole , oral,
Adult s
20-40 mg daily 
Children
12-18 years;  20-40 mg daily 
1-12 years;  10-20 mg daily 
< 1 year;  not recommended
And 
 y Calcium  supplements with vitamin D  
Adult s and Children  
As required 
Or
 y Bisphosphonates  
Adult s and Children  
Consult specialist 
B.     For treatment of rash in dermatomyositis  
(See treatment for acute condition in (A) above) 
And
 y Hydroxychloroquine , oral,
Adult s 

— Management of the Hot Swollen Joint —
Standard  Treatment Guidelines, 7th Edition, 2017
570200-400 mg daily 
Children  
5-6.5 mg/kg (max. 400 mg per day)
C.     For treatment of acute condition with steroid resistance
1st Line Treatment
Evidence Rating: [B]
 y Methotrexate , consult specialist 
Or
 y Azathioprine , consult specialist 
Or
 y Intravenous immunoglobulin , consult specialist 
Or
 y Mycophenolate  mofetil , consult specialist 
Or
 y Rituximab , consult specialist 
Referral Criteria 
Refer all patients to a physician specialist or rheumatologist. 
229� Management of the Hot Swollen Joint
The hot swollen joint is a common presentation and has extensive 
differential diagnosis. Some of the most serious causes are septic arthritis 
(with a case fatality of 11%) and acute leukemia in children. Late diagnosis 
and poor treatment leads to joint damage and death.  
The commonest affected joint is the big toe, typically due to gout  
and can be diagnosed on clinical grounds. Patients with a short history of 
a hot, swollen and tender joint (or joints) with restriction of movement 
should be regarded as having septic arthritis until proven otherwise. If 
clinical suspicion is high, then it is imperative to treat as septic arthritis 
even in the absence of fever.
Causes 
 y Septic arthritis
 y Reactive arthritis
 y Monoarticular presentation of polyarthritis
 y Inflammatory arthritis
 y Gout  or crystal arthritis
 y Haemarthrosis
 y Trauma
 y Bursitis /cellulitis 
 y Leukaemia  (in children)
 y Haemophilia 
Symptoms
 y Fever
 y Joint swelling (monoarthritis)

— Management of the Hot Swollen Joint —Chapter 22:  Disorders Of The Musculoskeletal System
571 y Joint pain
 y Limited mobility of affected joints
Signs
 y Hot swollen native joint
 y Fever
 y Joint tenderness 
Investigations
 y FBC, ESR
 y Blood culture
 y Blood film comment
 y C-reactive protein  (CRP)  
 y Serum uric acid  level  
 y BUE and creatinine
 y Liver function tests 
 y Synovial fluid aspirate for microscopy and culture
 y X-ray of affected joint  
 y MRI of the affected joint
 y Ultrasonography to aid diagnostic aspiration   
Treatment 
Treatment objectives
 y To reduce pain
 y To reduce swelling and stiffness
 y To prevent deformities
 y To delay disease progression and long-term complications 
Non-pharmacological treatment
 y Rest of affected joints using bedrest, splints
 y Physiotherapy
 y Joint aspiration 
Pharmacological treatment 
A.     For control of pain and inflammation 
1st Line Treatment
Evidence Rating: [B]
 y Diclofenac , oral, 
Adult s
50 mg 8 hourly or 100 mg 12 hourly as required
Children
> 12 years;   50 mg 12 hourly as required
< 12 years;   not recommended
Or 
 y Diclofenac , rectal,
Adult s 
100 mg 12 hourly as required 
Children  

— Gout —
Standard  Treatment Guidelines, 7th Edition, 2017
572> 12 years;  75-100 mg daily as required 
< 12 years;   not recommended
Caution 22-3.
The long-term use of NSAIDs  like diclofenac , naproxen , and ibuprofen  (i.e. for 
more than two weeks) may cause renal impairment and gastritis.
B.     For control of inflammation in the absence of infection  
 y Prednisolone , oral, 
Adult s 
0.5-2 mg/kg daily or 12 hourly (max. 80 mg per day)
Children
0.5 mg/kg daily or 12 hourly (max. 60 mg per day)
Or 
 y Intra-articular corticosteroid injection – consult specialist
C.     For treatment of infection in Septic arthritis 
(See section on ‘Septic Arthritis’) 
Referral Criteria 
Refer patients with an acutely swollen joint to the orthopedic 
surgeon or rheumatologist.  
230� Gout
This condition, which typically affects males with cardiovascular risk 
factors and women after menopause, results from the deposition of uric 
acid crystals in joints and periarticular tissues. Gout  is characterised by 
pain and inflammation of the affected joints. It is often, but not always, 
associated with raised blood uric acid levels and may be present even 
when the level of uric acid in the blood is normal, while patients with 
high levels of uric acid may not necessarily have attacks of gout . Individual 
gout flares are often triggered by acute increases or decreases in uric 
acid levels which may be associated with acute alcohol ingestion, acute 
overindulgence in foods high in purines, rapid weight loss, dehydration , 
or trauma. 
Causes 
 y Overproduction of uric acid  in disorders that cause high cell turnover 
with release of purines found in cell nuclei 
 y Myeloproliferative and lymphoproliferative disorders
 y Psoriasis
 y Haemolytic anemias
 y Cell lysis from chemotherapy, especially those of the haemato -
poietic or lymphatic systems
 y Excessive exercise 
 y Metabolic syndrome (obesity, diabetes, hypertension, elevated 
cholesterol etc.)
 y Impaired excretion of uric acid

— Gout —Chapter 22:  Disorders Of The Musculoskeletal System
573 y Renal impairment
 y Lead nephropathy
 y Starvation or dehydration
 y Drugs e.g. thiazide and loop diuretics, cytotoxic drugs, pyrazin -
amide
 y Alcohol ingestion  
 y Inherited purine metabolic disorders e.g. Lesch-Nyhan syndrome
Symptoms
 y Excruciating pain and swelling usually of a joint (classically the big toe 
but may affect the knee, ankles or wrists)
 y Multiple joint pain
 y Joint swelling
Signs
 y Inflamed, swollen and tender joint 
 y Migratory polyarthritis  
 y Tophi in soft tissues (helix of the ear, fingers, toes, prepatellar bursa, 
olecranon) 
 y Fever  
Investigations
 y FBC, ESR
 y BUE, creatinine
 y Serum uric acid
 y Blood glucose
 y Serum lipids
 y X-ray of affected joint
 y Joint aspirate for culture and polarised microscopy
Treatment 
Treatment objectives
 y To relieve acute pain 
 y To reduce joint inflammation
 y To prevent recurrent attacks and joint damage
 y To prevent uric acid  crystal deposition in soft tissues 
Non-pharmacological treatment
 y Optimize weight  
 y Reduce protein in diet e.g. liver, kidneys, shellfish and yeast extracts
 y Reduce alcohol intake to < 14 units/week (men and women)  
 y Avoid highly sweetened soft drinks and other beverages or foods 
 y Encourage to drink > 2 litres of water daily and avoid dehydration .
 y Affected joints should be elevated and exposed in a cool environment. 
‘Bed cages’ and ice packs can be effective adjuncts to therapy
 y Intense physical exercise should be avoided but moderate physical 
exercise encouraged
 y Identify and treat underlying cardiovascular (metabolic syndrome) 
risk factors

— Gout —
Standard  Treatment Guidelines, 7th Edition, 2017
574Pharmacological treatment
A.  Acute Gout
1st Line Treatment
Evidence Rating: [C]
 y Diclofenac , oral
Adult s
50 mg 8 hourly or 75 mg 12 hourly ORDERS ORY 
Children
> 12 years;  50 mg 8 hourly
< 12 years;  not recommended
Or
 y Diclofenac, rectal,  
Adult s 
100 mg daily
Children  
> 12 years;  75-100 mg daily 
< 12 years;  not recommended
Caution 22-4.
Long-term NSAIDs  for more than two weeks, e.g. diclofenac  may cause gastri -
tis and should therefore be given together with a proton pump inhibitor e.g. 
omeprazole.
2nd Line Treatment
 y Colchicine , oral,
500 microgram 6-12 hourly until symptoms relieved (max. 6 mg per 
course. Course should not to be repeated within 3 days) 
Or
 y Prednisolone , oral,
Adult s
10-40 mg for 1-3 days 
B�     Chronic Gout  – following treatment of acute gout
 Evidence Rating: [B]
 y Allopurinol , oral, 
100 mg daily
Then
Increase by 100 mg every 2-5 weeks, adjusted if necessary for renal 
function, until the therapeutic target (Serum Uric Acid [SUA] < 300 
micromol/L) is reached (max. dose 900 mg)
Caution 22-5.
Do not start Allopurinol  until 1-2 weeks after inflammation has settled to pre -
vent acute flare. But in patients already on allopurinol, it should be continued 
and the acute attack treated as usual.
Prescribe lower doses in renal or hepatic failure.

— Pseudo-gout (chondrocalcinosis) —Chapter 22:  Disorders Of The Musculoskeletal System
575Referral Criteria 
Refer patients to a dietician for dietary modification and a weight 
reducing diet in obese and overweight individuals.
Patients with co-morbid conditions such as Type 2 diabetes, 
hypertension, dyslipidaemia, renal impairment or not responding 
to Allupurinol etc. should be referred to a physician specialist or 
rheumatologist.
231� Pseudo-gout  (chondrocalcinosis )
This refers to attacks of synovitis induced by deposition of Calcium 
Pyrophosphate Dihydrate  (CPPD ) crystals. Most patients are old females.
It behaves like gout  in many respects, but unlike gout, attacks persist 
longer and affect the knee most commonly.
Common risk factors include trauma, surgery, severe illness, 
parathyroidectomy, pamidronate therapy. Co-morbidities for this 
condition are usually cardiovascular, renal and metabolic diseases e.g. 
diabetes mellitus. 
Cause
 y Deposition of Calcium Pyrophosphate Dihydrate  (CPPD ) crystals in 
and around joints
Symptoms
 y Joint pain
 y Swollen joint
Signs
 y Swollen joint
 y Tenderness
 y Joint effusion
Investigations
 y Serum uric acid  
 y X-ray of joint
 y Microscopic examination of joint or bursa fluid aspirate
Treatment 
Treatment objectives
 y Relieve pain
 y Prevent joint stiffness
 y Eradicate disease and correct underlying metabolic derangement
Non-pharmacological treatment
 y Physiotherapy  
Pharmacological treatment 
A.     For acute flare up
1st Line Treatment

— Pseudo-gout (chondrocalcinosis) —
Standard  Treatment Guidelines, 7th Edition, 2017
576Evidence Rating: [C]
 y Naproxen  EC, oral,
Adult s
250-500 mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
Not indicated 
Or 
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;   50 mg 12 hourly
< 12 years;   not recommended
Or
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2.4 g daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg per kg daily)
Or 
 y Colchicine, oral,
Adult
500 micrograms 6-12 hourly 
Children  
Not recommended 
2nd Line Treatment
Evidence Rating: [C]
 y Prednisolone , oral, consult specialist
 y Methyl prednisolone acetate , Intra-articular, consult specialist
 y Triamcinolone , Intra-articular, consult specialist
 y Betamethasone , Intra-articular, consult specialist
3rd Line Treatment
 y Probenecid , consult specialist
 y Methotrexate , consult specialist
 y Phosphocitrate , consult specialist
 y Anakinra , consult specialist 

— Systemic lupus erythematosus —Chapter 22:  Disorders Of The Musculoskeletal System
577Referral Criteria 
Start analgesia and refer to rheumatologist/orthopaedic surgeon.
232� Systemic lupus erythematosus
Systemic Lupus Erythematosus  (SLE ) is a chronic multisystem 
autoimmune inflammatory disease that has variable signs and follows a 
relapsing and remitting course. More than 90% of cases of SLE occur in 
women, commonly of childbearing age.
This condition can lead to complications such as acute or chronic 
renal failure, seizures, psychosis, pleurisy, pleural effusion, pneumonitis, 
pulmonary hypertension, pericarditis, myocarditis, leukopaenia, 
lymphopaenia, thrombocytopaenia and interstitial lung disease.
Management of SLE  often depends on the individual patient’s 
disease severity and disease manifestations. 
Causes 
 y Autoimmune 
 y Genetic and environmental factors
Symptoms
 y Fatigue 
 y Malaise
 y Fever  
 y Weight loss
 y Rash
 y Hair loss
 y Mouth sores
 y Joint pains
 y Sensitivity to sunlight
 y Seizures
 y Nausea
 y Dyspepsia
 y Abdominal pain
Signs
 y Lymphadenopathy
 y Fever  
 y Malar rash 
 y Discoid rash
 y Fatigue 
 y Arthralgia
 y Arthropathy  
 y Myalgia  
 y Arthritis 
 y Photosensitivity rash

— Systemic lupus erythematosus —
Standard  Treatment Guidelines, 7th Edition, 2017
578 y Anaemia
Investigations
 y FBC, ESR
 y BUE and Creatinine 
 y Urinalysis with microscopy
 y C - reactive protein
 y Antinuclear Antibodies (ANA )
 y Anti-Double stranded DNA  (dsDNA )
 y Complement levels
 y Liver function tests
 y Spot Urine protein/spot creatinine ratio
 y Other Autoantibody tests e.g. Extractable Nuclear Antigens (ENA) 
 y Hepatitis  B and C screen
 y HIV screen
 y Joint radiography
 y Chest radiography 
 y Echocardiography
 y Brain MRI/MRA 
Treatment 
Treatment objectives
 y To control symptoms 
 y To adequately control underlying disease 
 y To prevent and treat complications 
 y To avoid possible long-term side effects of the drugs 
Non-pharmacological treatment
 y Avoidance of excessive sunlight
 y Rest as appropriate
 y A low-fat diet with added fish oil
 y Avoidance of oestrogen-containing contraceptive pills 
 y Counselling and Education 
Note 22-2
Vaccinations: avoid ‘live’ vaccines in patients on greater than 10 mg predniso -
lone and/or immunosuppressives. In patients on immunosuppressives, there 
may be a reduction in vaccine efficacy but there is adequate humoral response 
to hepatitis B, influenza and pneumococcal vaccine.
Pharmacological treatment 
A.      Acute flare and maintenance therapy
1st Line Treatment
Evidence Rating: [B]
 y Methylprednisolone , IV infusion, (infuse over 1 hour)
Adult s 
1 g daily for 3-5 days 

— Systemic lupus erythematosus —Chapter 22:  Disorders Of The Musculoskeletal System
579Children  
1 month-18 years;   10-30 mg/kg every other day for 6 doses (max. 
1 g daily)
Then
 y Prednisolone , oral,
Adult s and Children  
0.5-1 mg/kg body weight 
Caution 22-6.
Take corticosteroids after food.
High-dose glucocorticoids may cause insomnia; immediate-release formulation 
is typically administered in morning to coincide with circadian rhythm.
And 
 y Omeprazole , oral,
Adult s 
20 mg daily 
Children
> 20 kg;   20 mg daily 
10-20 kg;   10 mg daily 
5-10 kg;   5 mg daily 
Or
 y Esomeprazole , oral,
Adult s
20-40 mg daily 
Children
12-18 years;  20-40 mg daily 
1-12 years;  10-20 mg daily 
< 1 year;  not recommended
And
 y Diclofenac , oral, 
Adult s
50 mg 8 hourly or 100 mg 12 hourly as required
Children
> 12 years;   50 mg 12 hourly as required
< 12 years;   not recommended
Or 
 y Diclofenac , rectal,
Adult s 
100 mg 12 hourly as required 
Children  
> 12 years;  50-100 mg daily as required 
< 12 years;   not recommended
Or
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then

— Systemic lupus erythematosus —
Standard  Treatment Guidelines, 7th Edition, 2017
580200 mg 12-24 hourly as required 
Children  
> 2 years (>25kg); 100 mg 12 hourly as required
> 2 years (and 10-25kg); 50 mg 12 hourly as required
< 2 years;  not recommended 
Or
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly as required
Children
6-12 years;   250-500 mg 6-8 hourly as required
1-5 years;   120-250 mg 6-8 hourly as required
3 months-1 year;  60-120 mg 6-8 hourly as required
And 
 y Calcium  with Vitamin D supplements  
Adult s and Children  
As required 
And 
The following medications will be used in addition to the treatments 
above under specialist care. 
Biologic DMARDs :
 y Belimumab, consult specialist 
 y Rituximab, consult specialist  
 y Intravenous immunoglobulin, consult specialist
Non-Biologic DMARDs :
 y Cyclophosphamide, consult specialist  
 y Methotrexate, consult specialist  
 y Azathioprine, consult specialist  
 y Mycophenolate, consult specialist  
 y Cyclosporine, consult specialist
Antimalarials:
 y Hydroxychloroquine, consult specialist 
Referral Criteria 
Refer all cases to a physician or rheumatologist.  
Table 22-1:   Recommendations for use of conventional immunosuppressive 
drugs in lupus
Symptom Medicines to try Dose and duration 
Arthralgia  Non-steroidal anti-inflammatory 
drugsAvoid in renal involvement
Use briefly
Myalgia Hydroxychloroquine Specialist care

— Systemic lupus erythematosus —Chapter 22:  Disorders Of The Musculoskeletal System
581Symptom Medicines to try Dose and duration 
Lethargy Annual retinal checks years
Baseline and frequent monitoring for 
those with baseline eye problems
Rash Hydroxychloroquine Specialist care
Topical steroids or Tacrolimus
Arthritis Prednisolone  Prednisolone : 20–40 mg per day initially 
for 2–4 weeks, reducing in 5–10 mg 
increments per week, if patient is 
responding; treatment is likely to be 
required for several months
Hydroxychloroquine Refer to Specialist
Methotrexate  in refractory cases
Pleuritis and pericarditis NSAIDs 20-30 mg prednisolone per day then ta -
pering doses, along the lines of arthritic 
treatment (above)
Antimalarials Refer to Specialist
Low dose corticosteroids
Refractory cases - azathioprine , 
Mycophenolate  mofetil  or cyclophos -
phamide.
Autoimmune haemolyt -
ic anaemia/thrombocy -
topaenia Corticosteroids often accompanied 
by azathioprine  or Cyclophosphamide60–80 mg prednisolone for 1–2 weeks 
reducing in 10 mg increments in 
response to the blood test results 
Rituximab Refer to Specialist
Renal Prednisolone  plus cyclophosphamide 
or mycophenolate mofetilRefer urgently to Specialist 
Azathioprine  or mycophenolate 
mofetil for maintenance 
Rituximab  for refractory cases
Central nervous system Corticosteroids plus an appropriate 
drug, e.g. an antidepressant, anticon -
vulsant, etc.Controversial— 20–60 mg prednisolone 
daily
Cyclophosphamide Refer urgently to Specialist
Rituximab

23Chapter
582Trauma And Injuries
233� Head Injuries   
These are injuries in which the scalp, skull, meninges, brain, or the 
blood vessels within the brain may be affected separately or together. 
They are a common cause of death and disability especially in young 
people. With the advent of increased use of motorbikes as public 
transport, the incidence has gone up.  Head injuries may be open or close, 
mild, moderate or severe. Symptoms and signs, as well as the treatment 
modality, will depend on the severity of the injury. 
Significant head injury is defined as a Glasgow Coma Scale (GCS) 
of less than 10. However, take even mild injuries seriously as these may 
evolve with time. Continuous monitoring of the patient is required as the 
situation can change quickly. 
Corticosteriods have demonstrated no benefits in the treatment 
of acute head injury and are no longer recommended for routine 
management. Sedatives must also not be given except in cases of 
transporting an aggressive patient.
Causes 
 y Road traffic accidents
 y Falls, especially from heights
 y Blows to the head (fights, including domestic violence, street fights)
 y Gunshot wounds
 y Stab wounds
 y Child abuse
Symptoms
 y Headaches
 y Drowsiness
 y Loss of consciousness
 y Vomiting
 y Seizures
 y Memory loss
 y Leakage of clear fluid or bleeding from the ears or nostrils
 y Intolerance to light (photophobia)

— Head Injuries   —Chapter 23:  Trauma And Injuries
583Signs
 y Level of consciousness - may vary from fully conscious to deeply 
unconscious (use the Glasgow Coma  Scale whenever possible) 
 y External signs of injuries - abrasions, contusions, lacerations, 
darkening around the eyes and the back of the ears
 y CSF or blood leakage from the ears/nostrils
 y Pupillary abnormalities - unequal size, pin point or dilated 
 y Focal neurological deficits - paralysis, loss of speech or vision
 y Signs of raised intracranial pressure such as deepening coma , a rising 
blood pressure, slowing of the pulse rate and irregular respiration
 y Other associated injuries
 y Alcoholic breath (in cases of intoxication)
Investigations
 y FBC
 y BUE, Creatinine
 y Blood glucose
 y X-ray (skull, cervical spine, chest, pelvis)
 y Head CT scan (also for children) 
Treatment 
Treatment objectives
 y To prevent further injury to the brain
 y To treat associated injuries
Note 23-1
Criteria for admission: 
 yLoss of consciousness ˃ 5 mins
 yPresence of a fracture on skull X-ray
 yPresence of focal/lateralizing signs
 yPersistent/ recurrent headaches, vomiting  or seizures
 yOpen injuries
 yCSF otorrhoea or rhinorrhoea
 yEspecially among Children, and the elderly, or in the 
 yAbsence of a reliable adult to look after patient at home, please admit
Non-pharmacological treatment
 y Assess level of consciousness and provide appropriate treatment 
 y Maintain a clear airway, suck out any secretions and assist ventilation 
if necessary
 y Maintain the blood pressure (if patient hypotensive or hypertensive)
 y Prevent hypoglycaemia 
 y Nurse with head end of bed elevated
 y Stabilize the neck with a collar till cervical spine injury has been 
excluded
 y If patient is unconscious, turn every 2 hours
 y Catheterize patient

— Head Injuries   —
Standard  Treatment Guidelines, 7th Edition, 2017
584 y Pass nasogastric tube for feeding if patient is unconscious. Do NOT 
pass nasogastric tube if there is suspected fracture of the skull base 
(i.e if there is fluid or blood coming from the nostrils, or ears) 
Pharmacological treatment 
A.     For lowering of raised intracranial pressure
Evidence Rating: [B]
 y Mannitol  20%, IV, (may be given over 30 to 60 minutes)
Adult s
2.5-10 ml/kg (0.5-2g/kg)
Children
2.5-5 ml/kg (0.5-1g/kg)
Or
 y Hypertonic saline  3%, IV (particularly for children)
Adult s and Children  
3-5 ml/kg over 10-20 minutes (max. 250 ml)
B�     For mild pain management 
Evidence Rating: [A]
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly as required 
Children
6-12 years;  250-500 mg 6-8 hourly as required 
1-5 years;  120-250 mg 6-8 hourly as required
3 months-1 year; 60-120 mg 6-8 hourly as required
C�     For fracture base of skull 
Evidence Rating: [A]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly 
Children  
5-12 years;   250 mg 6 hourly 
1-5 years;   125 mg 6 hourly 
< 1 year;   62.5 mg 6 hourly 
D�     For open skull fractures
 y Amoxicillin + Clavulanic Acid , IV, 
Adult s 
600 mg 8 hourly
Children
25 mg/kg 6 hourly
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly 
Children

— Acute Abdomen —Chapter 23:  Trauma And Injuries
5857.5 mg/kg 8 hourly 
And
Evidence Rating: [B]
 y Benzylpenicillin , IV, 
Adult s
1.2-2.4 g 6 hourly
Children
50 mg /kg 6 hourly 
E.     For aggressive patients requiring sedation 
1st Line Treatment 
 y Haloperidol , IM, 
Adult s 
2-5 mg 4-8 hourly as required (max. 20 mg in 24 hours) 
Children  
> 12 years;  2-5 mg 4-8 hourly as required 
(max. 20 mg in 24 hours)
6-12 years;  1-3 mg 4-8 hourly as required 
(max. 150 microgram per kg per day) 
< 6 years;  not recommended 
2nd Line Treatment 
 y Lorazepam , IV/IM,
Adult s
500 microgram-2 mg 6 hourly as needed (max. 10 mg per day)
Children  
>2years;  50 microgram 4-8 hourly as needed 
(max. 2 mg per dose)
Referral Criteria 
Refer all patients with significant head injuries immediately to a 
neurosurgeon.
234. Acute Abdomen
Acute abdomen  is sudden onset of severe abdominal pain, which 
may require surgical intervention. Some medical conditions may present 
as acute abdominal pain.
Causes 
 y Inflammatory conditions e.g. appendicitis, salpingitis, cholecystitis
 y Perforations e.g. typhoid, peptic ulcer, trauma 
 y Intestinal obstruction e.g. strangulated hernia, adhesions, volvulus
 y Haemorrhage e.g. ruptured ectopic pregnancy, ruptured spleen
 y Acute pancreatitis
 y Colics e.g. ureteric, biliary or intestinal 
 y Medical conditions e.g. diabetic ketoacidosis, gastro-enteritis, 
gastritis, malaria, pneumonia, UTI , sickle cell crises, adrenocortical 

— Acute Abdomen —
Standard  Treatment Guidelines, 7th Edition, 2017
586crises, porphyria, nephrotic syndrome
Symptoms
 y Abdominal pain
 y Anorexia , nausea and vomiting  
 y Dyspepsia  
 y Fever  
 y Headaches 
 y Joint pains 
 y Dizziness
 y Vaginal discharge 
 y Dysuria 
 y Watery mucoid blood-stained stools 
Signs
 y Dehydration  
 y Fever  
 y Hypotension
 y Rapid pulse 
 y Abdominal distension with fluid or gas  
 y Abdominal surgical scars  
 y Strangulated hernia (especially femoral hernia)
 y Tenderness, rebound tenderness and guarding 
 y Absent bowel sounds 
 y Increased bowel sounds 
 y Tenderness in the recto-vesical or recto-uterine pouch
 y Signs of basal pneumonia or myocardial infarction
 y Pallor, gnathopathy, frontal bossing in sickle cell disease
Investigations
 y FBC
 y Blood film for malaria parasites
 y Sickling test
 y Chest X-ray  
 y Plain abdominal X-ray (erect and supine) 
 y 4-quadrant abdominal tap  
 y Random blood glucose
 y Urine examination 
 y BUE and Creatinine
 y Ultrasound scan of abdomen  
Treatment 
Treatment objectives
 y To resuscitate patient
 y To relieve pain
 y To control infection if present
 y To treat the underlying cause

— Acute Abdomen —Chapter 23:  Trauma And Injuries
587Non-pharmacological treatment
 y Pass nasogastric tube and aspirate the stomach in suspected surgical 
cases
Pharmacological treatment 
A.     For resuscitation 
Evidence Rating: [C]
 y IV fluids 
Or 
 y Blood transfusion
B�     For pain management 
 y Paracetamol , IV,
Adult s
> 50 kg;    1 g 6 hourly as required 
< 50 kg;    1 g 8 hourly as required (max. 3 g daily) 
Children  
12-18 years (> 50 kg);  1g 8 hourly as required (max. 3 g daily)
12-18 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 750 mg 
per dose)
2-12 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 75 mg/ 
kg/day)
Or
 y Pethidine , IM, 
Adult s
50-100 mg 4 hourly as required (max. 400 mg/day)
Children
0.5-2 mg/kg repeated 4 hourly as required
Or
 y Morphine , IV/IM,
Adult s
2-5 mg 4 hourly as required
Children
50-200 microgram/kg 4 hourly as required 
C.     For infectious consitions, perforations and intestinal obstruction 
1st Line Treatment 
Evidence Rating: [B]
 y Gentamicin , IV/IM,  
Adult s
1-1.5 mg/kg 8 hourly
Children  
2.5 mg/kg 8 hourly  
Do not give if urine output is less than 30 ml/hour. Avoid in renal 
impairment.
And
 y Metronidazole , IV, 
Adults

— Abdominal Trauma —
Standard  Treatment Guidelines, 7th Edition, 2017
588500 mg 8 hourly 
Children 
7.5 mg/kg 8 hourly
2nd Line Treatment 
Evidence Rating: [B]
 y Ceftriaxone , IV, 
Adult s 
1-2 g daily
Children  
50 mg/kg daily
Further treatment will depend on the diagnosis.
And
 y Metronidazole , IV, 
Adult s
500 mg 8 hourly 
Children  
7.5 mg/kg 8 hourly
3rd Line Treatment 
Evidence Rating: [B]
 y Ciprofloxacin , IV,
Adult s 
400 mg 8-12 hourly infused over 30-60 minutes (may be added for 
typhoid perforation)
Children  (Use only when benefit outweighs the risk)
5-12 years;  10 mg/kg 12 hourly
1-5 years;  5 mg/kg 12 hourly
< 1 year;                    not recommended
And
 y Metronidazole , IV, 
Adult s
500 mg 8 hourly 
Children  
7.5 mg/kg 8 hourly
Referral Criteria 
Refer all cases to the appropriate specialist depending on the 
suspected diagnosis.
235� Abdominal Trauma
This may present as a blunt or penetrating injury to the abdomen.
Causes 
 y Road traffic accidents 
 y Gunshots
 y Violence

— Abdominal Trauma —Chapter 23:  Trauma And Injuries
589 y Trauma to the abdomen 
Symptoms
 y Pain 
 y Vomiting  
 y Distended abdomen
Signs
 y Distended abdomen
 y Tenderness and rebound tenderness
 y Guarding 
 y Tympanitic percussion sound 
 y Reduced or absent bowel sounds
 y Point of penetration
Investigations
 y Plain and erect abdominal X-ray
 y Abdominal CT scan
 y BUE and Creatinine 
 y Abdominal ultrasound scan
 y Diagnostic peritoneal lavage 
 y Blood grouping and cross matching
Treatment 
Treatment objectives
 y To correct fuid and electrolyte imbalance 
 y To decompress bowel
 y To repair damaged viscus
 y To prevent infection
 y To relieve pain
Non-pharmacological treatment
 y Insert an NG tube
 y Surgical repair of damaged viscus if necessary
Pharmacological treatment 
A.     For infection control
1st Line Treatment
Evidence Rating: [A]
 y Cefuroxime , IV,
Adult s
750 mg 8 hourly for 7-14 days
Children  
> 3 months           25 mg/kg body weight 12 hourly for 7-14 
days
And  
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7-14 days

— Closed Fractures —
Standard  Treatment Guidelines, 7th Edition, 2017
590Children  
7.5 mg/kg 8 hourly for 7-14 days
Referral Criteria 
Refer all cases to a general surgeon.
236� Closed Fractures
This is a break in the continuity of the bony cortex with associated 
soft tissue injury. As opposed to open fractures (See section on ‘Open 
fractures’), closed fractures do not communicate with an epithelial 
surface like skin, bowel mucosa, bladder mucosa etc.  
Resuscitation and stabilisation of the patient is paramount. Patients 
should never be sent for imaging unless haemodynamically stable.
Causes 
 y Road traffic accidents
 y Domestic violence
 y Work place injuries
 y Pathological fractures
 y Fall from a height
 y Assaults 
Symptoms
 y Pain
 y Swelling
 y Inability to move the part
Signs
 y Pain
 y Swelling
 y Deformity 
 y Inability to move the part
 y Crepitus
 y Shock if there has been significant blood loss
 y Confusion if there is shock or associated head injury
Investigations
 y Haemoglobin
 y Blood for grouping and cross matching
 y X-rays of suspected part to include joints above and below
 y Trauma series X-rays (Cervical spine, Chest and Pelvis) if injury is 
deemed severe or if patient is confused or unconscious
 y CT scan (for fractures involving the following areas):
 y Head
 y Spine 
 y Pelvis
 y Fractures  around joints

— Closed Fractures —Chapter 23:  Trauma And Injuries
591 y CT angiograms (if significant vascular injury is suspected)
 y MRI (to assess spinal cord and soft tissue injuries of the knee)
 y Abdominal USG (if intra-abdominal injury is suspected)
Treatment
Treatment objectives
 y To resuscitate the patient (save a life first) - ATLS protocol (ABCDE)
 y To save the affected limb(s) (save a limb next)
 y To restore function of the affected limb(s)
Non-pharmacological treatment
 y Splinting 
 y P .O.P . backslab
 y Prefabricated splints
 y Customized splint
 y Elevation of limb(s)
 y Nil per os until a final decision about surgical or non-surgical 
management has been made
 y Manipulation Under Anaesthesia (MUA) if possible
Pharmacological treatment 
A.     For pain relief 
Evidence Rating: [A]
Morphine , IV/IM,
Adult s
2-5 mg 4 hourly as required
Children
50-200 microgram/kg 4 hourly as required 
Or
 y Pethidine , IV/IM, 
Adult s 
50-100 mg 4 hourly as required (max. 400 mg/day)
Children   
0.5-2 mg/kg repeated 4 hourly as required
Or
 y Paracetamol , IV,
Adult s
> 50 kg;    1 g 6 hourly as required 
< 50 kg;    1 g 8 hourly as required (max. 3 g daily) 
Children  
12-18 years (> 50 kg);  1 g 8 hourly as required (max. 3 g daily)
12-18 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 750 mg 
per dose)
2-12 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 75 mg/
kg per day)
Or 
 y Diclofenac , IM, 
Adult s

— Open Fractures —
Standard  Treatment Guidelines, 7th Edition, 2017
59250-75 mg 8-12 hourly (max. 150 mg daily)
Children  
Not recommended 
2nd Line Treatment
Evidence Rating: [B]
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2400 mg daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg/kg daily)
Or 
 y Naproxen  EC, oral,
Adult s
250-500 mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
Not indicated 
Or 
 y Codeine , oral,  
Adult s
15-60 mg 4-6 hourly as required 
Children  
Not recommended 
Referral Criteria 
Refer individuals with the following conditions associated with 
closed fractures to an orthopaedic surgeon; difficult reduction, fractures 
with intra articular extension, fractures around growth plates and when 
there is neuro-vascular compromise.
237� Open Fractures
Open fractures imply communication of the fracture haematoma 
with an epithelial surface like skin, bowel mucosa, bladder mucosa etc. 
The main problem here is infection, and therefore, every effort should be 
made to prevent it. In some cases, the degree of bone loss may warrant 
amputation. Exclude a neurological deficit especially when the injury is 
extensive. It is prudent to take a photograph of the affected part(s) for 
documentation and medico-legal purposes.

— Open Fractures —Chapter 23:  Trauma And Injuries
593Patients should never be sent for imaging unless haemodynamically 
stable.
Causes 
 y Road traffic accidents
 y Domestic violence
 y Assaults 
 y Work place injuries
 y Fall from a height
Symptoms
 y Localised pain
 y Swelling
 y Bleeding
 y Exposed bone, muscle and fascia
 y Inability to move the part
Signs
 y Swelling
 y Deformity 
 y Blood
 y Laceration over the fracture
 y Crepitus
 y Shock if there has been significant blood loss
 y Confusion or unconsciousness if there is shock or associated head 
injury
Investigations
 y Haemoglobin
 y Blood for grouping and cross matching
 y X-rays of suspected part to include joints above and below
 y Trauma series X-rays (Cervical spine, Chest and Pelvis) if injury is 
deemed severe or if patient is confused or unconscious
 y CT scan (for fractures involving the following areas):
 y Head
 y Spine 
 y Pelvis
 y Fractures  around joints
 y CT angiograms (if significant vascular injury is suspected)
 y MRI (to assess spinal cord and soft tissue injuries of the knee)
 y Abdominal USG (if intra-abdominal injury is suspected)
Treatment 
Treatment objectives
 y To resuscitate the patient (save a life first) - ATLS protocol (ABCDE)
 y To save the affected limb(s) (save a limb next)
 y To prevent and eradicate infection
 y To restore function of the affected limb(s)

— Open Fractures —
Standard  Treatment Guidelines, 7th Edition, 2017
594Non-pharmacological treatment
 y Remove all foreign bodies
 y Cover with sterile dressing
 y Splinting of affected limb(s)
 y P .O.P . backslab
 y Prefabricated splints
 y Customized splint
 y Elevation of affected limb(s)
 y Early range of motion physiotherapy
 y Keep nil per os until final decision about management has been 
made.
 y Surgical - under general anaesthesia 
 y Irrigation 
 y Debridement
 y External fixation or backslab
Pharmacological treatment 
A.     For treatment of infection 
1st Line Treatment
Evidence Rating: [A]
 y Cefuroxime , IV,
Adult s
750 mg 8 hourly
Children  
25 mg/kg body weight 12 hourly 
Or 
 y Clindamycin , IV,
Adult s
300-600 mg 6 hourly for 4 weeks or until clinical improvement
Children
3-6 mg/kg 6 hourly for 2-4 weeks
B�     If the fracture is in perineal region
 y Above antibiotics in section A.
And 
 y Metronidazole , IV, 
Adult s
500 mg 8 hourly for 7 days
Children
7.5 mg/kg 8 hourly for 7 days
C�     Tetanus  prophylaxis 
All patients with open fractures must have tetanus prophylaxis. 
(See appropriate section).
Referral Criteria 
Refer complicated fractures e.g. pelvic and intra-articular, and 
multiple injuries to an orthopaedic surgeon.

— Dislocations —Chapter 23:  Trauma And Injuries
595238� Dislocations
This refers to the dissociation of articular surfaces. Since there are 
important neuro-vascular structures around most joints, it is important 
to assess and document the neuro-vascular status of the limb(s) involved 
after a dislocation.
Causes 
 y Road traffic accidents
 y Domestic violence
 y Assaults 
 y Work place injuries
 y Sports injuries
 y Falls
 y Convulsions  
Symptoms
 y Pain
 y Swelling
 y Inability to move the part
Signs
 y Tenderness
 y Swelling
 y Inability to move the part
Investigations
 y X-ray of affected part(s)
 y CT scan or MRI if available
 y CT angiogram or Doppler scan (if vascular status assessment is 
abnormal)
Treatment 
Treatment objectives
 y Save a life first - ATLS (advanced trauma life support)
 y Save a limb
 y Achieve a congruently reduced joint
 y Achieve a stable reduction of the dislocated joint
 y Prevent joint stiffness
Non-pharmacological treatment
 y Traction 
 y Splinting of affected part
 y Keep nil per os until reduction has been achieved
 y Early range of motion physiotherapy

— Dislocations —
Standard  Treatment Guidelines, 7th Edition, 2017
596Pharmacological treatment 
A.      Analgesia for dislocations 
Evidence Rating: [A]
 y Morphine , IV/IM,
Adult s
2-5 mg 4 hourly as required
Children
50-200 microgram/kg 4 hourly as required 
Or
 y Pethidine , IV/IM, 
Adult s
50-100 mg 4 hourly as required (max. 400 mg/day)
Children
0.5-2 mg/kg repeated 4 hourly as required
Or
 y Paracetamol , IV,
Adult s
> 50 kg;    1 g 6 hourly as required 
< 50 kg;    1 g 8 hourly as required (max. 3g daily) 
Children  
12-18 years (> 50 kg);  1 g 8 hourly as required (max. 3g daily)
12-18 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 750 mg 
per dose)
2-12 years (< 50 kg);  15 mg/kg 6 hourly as required (max. 75 mg 
per kg per day)
Or 
 y Diclofenac , IM, 
Adult s
50-75 mg 8-12 hourly (max. 150 mg daily)
Children  
Not recommended 
2nd Line Treatment
Evidence Rating: [B]
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2400 mg daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg/kg daily)
Or 
 y Naproxen  EC, oral,
Adult s
250-500 mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 

— Acute orthopaedic infections —Chapter 23:  Trauma And Injuries
597Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
Not indicated 
Or 
 y Codeine , oral,  
Adult s
15-60 mg 4-6 hourly as required 
Children  
  Not recommended 
Referral Criteria 
Refer all complicated dislocations to an orthopaedic specialist.
239� Acute orthopaedic infections
Acute orthopaedic infections , which often present as emergencies, 
include acute osteomyelitis , acute septic arthritis , acute pyomyositis, 
acute-on-chronic osteomyelitis , and acute-on-chronic septic arthritis .
Acute osteomyelitis  and septic arthritis can co-exist in the same 
individual. They are more common in children and in patients with sickle-
cell disease. When the diagnosis is made in an adult, it is important to 
exclude immune-suppression. Staph. aureus  and epidermidis  account for 
the majority of the above infections. The commonest route of infection is 
haematogenous and may originate from skin lesions and ENT infections. 
It is important to cover empirically with appropriate antibiotics 
without necessarily waiting for the culture and sensitivity report.
Causes 
 y Staph. aureus
 y Staph. epidermidis
 y Salmonella  (common in sickle-cell disease)
 yHaemophilus	influenza  
 y Strept. pyogenes
 y Strept. faecalis
 y E. coli
 y Open fractures
 y Iatrogenic
 y Implant surgery
 y Joint aspirations
 y Femoral vessel procedures
 y Intra-osseous infusions and transfusions
 y Umbilical vessel catheterization

— Acute orthopaedic infections —
Standard  Treatment Guidelines, 7th Edition, 2017
598Symptoms
 y Fever
 y Pain
 y Inability to move affected limb
 y Swelling
 y Lethargy  
 y Refusal to feed (children)
Signs
 y Febrile
 y Swelling 
 y Inability to use the limb
Investigations
 y FBC, ESR
 y Sickling
 y CRP
 y Blood culture 
 y X-ray of affected part
 y Ultrasound scan of affected part (may also be used for guided 
aspiration)
 y Gram stain and culture of aspirate
 y MRI (if available)
 y Radionuclide scans
Treatment 
Treatment objectives
 y Eradicate infection
 y Prevent development of chronicity
 y Prevent complications 
Non-pharmacological treatment
 y Splinting 
 y Ultrasound guided aspiration
 y Incision and drainage
Pharmacological treatment 
A. Anti-infective therapy
1st Line Treatment
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 2-4 weeks
Children  
5-12 years;  250 mg 6 hourly for 2-4 weeks
1-5 years;  125 mg 6 hourly for 2-4 weeks
< 1 year;  62.5 mg 6 hourly for 2-4 weeks 
And 

— Acute orthopaedic infections —Chapter 23:  Trauma And Injuries
599 y Ciprofloxacin , IV, (to be administered over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children
10 mg/kg (max. 400 mg) 12 houly for 14 days
Note 23-2
Monitor BUE and creatinine and perform auditory examinations weekly while 
on gentamicin
2nd Line Treatment
Evidence Rating: [B]
 y Clindamycin , IV,
Adult s
300 mg 6 hourly for 7 days
Children
3-6 mg/kg 6 hourly for 7 days
Or
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 12 hourly 
Increased to 1.2 g 8 hourly for 7 days in severe infections 
Children
12-18 years;   600 mg to 1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly for 7 days in severe infections
3 months-12 years;  30 mg/kg 12 hourly, 
Increased to 30 mg/kg 8 hourly for 7 days in severe infections
7 days-3 months;   30 mg/kg 8 hourly for 7 days
Preterm and < 7 days; 30 mg/kg 12 hourly for 7 days
B� For individuals with penicillin sensitivity 
1st Line Treatment
Evidence Rating: [B]
 y Clindamycin , IV,
Adult s
300 mg 6 hourly for 7 days
Children
3-6 mg/kg 6 hourly for 7 days
And
 y Gentamicin , IV,
Adult s
40-80 mg 8 hourly for 14 days
Children
1-12 years;   2.5 mg/kg 8 hourly for 14 days
< 1 year;   2.5 mg/kg 12 hourly for 14 days
C� For individuals with sickle cell anaemia 
Evidence Rating: [B]
 y Cloxacillin , IV, 

— Acute orthopaedic infections —
Standard  Treatment Guidelines, 7th Edition, 2017
600Adult s
500 mg 6 hourly for 2-4 weeks
Children  
5-12 years;   250 mg 6 hourly for 2-4 weeks
1-5 years;   125 mg 6 hourly for 2-4 weeks
<1 year;   62.5 mg 6 hourly for 2-4 weeks 
And 
 y Ciprofloxacin , IV, 
Adult s
200-400 mg 12 hourly for 2-4 weeks
Children
10 mg/kg 12 hourly for 2-4 weeks
D.      Analgesia
1st Line Treatment
 y Ibuprofen , oral,
Adult s
200-800 mg 6-8 hourly (max. 2400 mg daily)
Children
10-15 mg/kg 6-8 hourly (max. 40 mg/kg daily)
Or
 y Diclofenac , oral,
Adults
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;        50 mg 12 hourly
< 12 years;  not recommended
Or 
 y Diclofenac , IM, 
Adult s
50-75 mg 8-12 hourly (max. 150 mg daily)
Children  
Not recommended 
Or
 y Morphine , oral, 
Adult s 
15-30 mg 4-6 hourly as required 
Children  
200-500 micrograms/kg 4-6 hourly as required 
Or
 y Morphine , IV/IM, 
Adult s 
2-5 mg 4 hourly as required 
Children  
50-200 micrograms/kg 4 hourly as required
Or
 y Codeine , oral,  

— Chronic Osteomyelitis and Chronic Septic Arthritis —Chapter 23:  Trauma And Injuries
601Adult s
15-60 mg 4-6 hourly as required 
Children  
Not recommended 
E�      For control of fever
 y Paracetamol , oral, 
Adult s
500 mg-1g 6-8 hourly
Children
6-12 years;  250-500 mg 6-8 hourly 
1-5 years;  120-250 mg 6-8 hourly 
3 months-1 year; 60-120 mg 6-8 hourly
Or
 y Paracetamol , IV,
Adult s
> 50 kg;    1 g 6 hourly as required 
< 50 kg;    1 g 8 hourly as required (max. 3 g daily) 
Children  
12-18 years (>50kg);  1 g 8 hourly as required (max. 3g daily)
12-18 years (<50kg);  15 mg/kg 6 hourly as required (max. 750 mg 
per dose)
2-12 years (<50kg);  15 mg/kg 6 hourly as required (max. 75 mg 
per kg per day)
Referral Criteria
Refer to an orthopaedic specialist if there is collection of pus and no 
improvement in 36 hours.
240. Chronic Osteomyelitis  and Chronic Septic Arthritis
These are usually from inadequately treated acute episodes, which 
include acute osteomyelitis , acute septic arthritis , acute-on-chronic 
osteomyelitis , and acute-on-chronic septic arthritis . Some may arise from 
the onset as a chronic infection due to mycobacteria or fungi. 
The patient is usually not ill-looking unless there is an acute 
exacerbation.
Causes 
 y Acute bacterial infections of bone and joints
 y Mycobacterium tuberculosis  and fungal infections 
 y Infected orthopaedic implants
 y Iatrogenic
Symptoms
 y Chronic discharging sinuses
 y Pain 
 y Deformity 

— Chronic Osteomyelitis and Chronic Septic Arthritis —
Standard  Treatment Guidelines, 7th Edition, 2017
602Signs
 y Swelling
 y Tenderness 
 y Deformity
 y Scarring
 y Chronic discharging sinuses
 y Hyper-pigmentation of the involved part
Investigations
 y FBC, ESR
 y X-ray 
 y CT scan 
Treatment 
Treatment objectives
 y Eradicate infection
 y Restore function
 y Prevent and correct deformities
Non-pharmacological treatment
 y Wound dressing
 y Splinting
 y Surgery
 y Sequestrectomy
 y Implant removal
Pharmacological treatment 
A.     For acute flare up of infection
1st Line Treatment
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 2-4 weeks
Children  
5-12 years;   250 mg 6 hourly for 2-4 weeks
1-5 years;   125 mg 6 hourly for 2-4 weeks
< 1 year;   62.5 mg 6 hourly for 2-4 weeks 
And
 y Ciprofloxacin , IV, (to be infused over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children  
10 mg/kg 12 hourly for 14 days
B.     For acute flare up of infection in patients with penicillin sensitivity
1st Line Treatment
Evidence Rating: [B]

— Chronic Osteomyelitis and Chronic Septic Arthritis —Chapter 23:  Trauma And Injuries
603 y Clindamycin , IV,
Adult s
300 mg 6 hourly for 7 days
Children
3-6 mg/kg 6 hourly for 7 days
And
 y Ciprofloxacin , IV, (to be infused over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children  
10 mg/kg 12 hourly for 14 days
C.     For acute flare up of infection in patients with sickle cell disease
1st Line Treatment
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 2-4 weeks
Children  
5-12 years;   250 mg 6 hourly for 2-4 weeks
1-5 years;   125 mg 6 hourly for 2-4 weeks
< 1 year;   62.5 mg 6 hourly for 2-4 weeks 
And
 y Ciprofloxacin , IV, (to be infused over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children  
10 mg/kg 12 hourly for 14 days
2nd Line Treatment
Evidence Rating: [B]
 y Clindamycin , IV,
Adult s
300 mg 6 hourly for 4 weeks or until clinical improvement
Children
3-6 mg/kg 6 hourly for 2-4 weeks
And
 y Ciprofloxacin , IV, (to be infused over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children  
10 mg/kg 12 hourly for 14 days
Or
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly for 7 days in severe infections 
Children

— Cellulitis —
Standard  Treatment Guidelines, 7th Edition, 2017
60412-18 years;   600 mg to 1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly for 7 days in severe infections
3 months-12 years;  30 mg/kg 12 hourly, 
Increased to 30 mg/kg 8 hourly for 7 days in severe infections
7 days-3 months;   30 mg/kg 8 hourly for 7 days
Preterm and < 7 days; 30 mg/kg 12 hourly for 7 days
And
 y Ciprofloxacin , IV, (to be infused over 60 minutes)
Adult s
400 mg 8-12 hourly for 14 days
Children  
10 mg/kg 12 hourly for 14 days
D�  For pain relief
(See section on pain relief in ‘Acute Orthopaedic Infections’)
Referral Criteria 
All patients should be referred as soon as possible to an orthopaedic 
specialist.
241. Cellulitis
Cellulitis  is an infection of skin, specifically the dermis and 
subcutaneous tissues usually following a break in the skin such as infected 
wound or prick by a pin, nail, thorn, insect bite or cracks between the toes 
from athletes’s foot. 
It may affect any part of the body, but it affects the legs mostly. 
Obesity  and leg swelling are risk factors. It is important to rule out acute 
osteomyelitis , necrotizing fasciitis and Deep Vein Thrombosis (DVT ).
Causes 
 y Streptococcus  pyogenes  (the commonest cause)
 y Staphylococcus aureus
Symptoms
 y Pain over area affected
 y Swelling of the affected parts
 y Reddening or darkening of the overlying skin
 y Blistering 
 y Ulcers 
 y Fever  
 y Rigors
 y Malaise
 y Vomiting
 y Confusion
Signs
 y Swelling of affected part

— Cellulitis —Chapter 23:  Trauma And Injuries
605 y Blisters
 y Localised tenderness and skin colour change
 y Localised warmth
 y Ulcers including the web spaces  
 y Enlarged and tender regional lymph nodes 
 y Underlying pus
 y Offensive wound
 y Fever
Investigations
 y FBC, ESR 
 y CRP
 y Blood culture
 y Fasting blood glucose
 y Gram stain and culture of discharge
 y X-ray of affected part
Treatment 
Treatment objectives
 y To relieve pain  
 y To control and eradicate the infection
 y To treat predisposing conditions
 y To prevent complications like ulceration and osteomyelitis 
Non-pharmacological treatment
 y Rest and elevate the affected part if possible
 y Clean and dress any open wounds
 y Incision and drainage if pus forms
 y Debridement 
 y Split skin graft (if indicated)  
Pharmacological treatment 
A.     For pain relief 
 Evidence Rating: [B]
(See section for pain relief in ‘Closed fractures’ under Trauma and 
Injuries)
B.  Antibiotic therapy for individuals stable enough to be treated as 
outpatients 
1st Line Treatment
Evidence Rating: [C]
 y Amoxicillin , oral,
Adult s
500 mg-1 g 8 hourly for 7 days
Children
6-12 years;  250 mg 8 hourly for 7 days
1-5 years;  125 mg 8 hourly for 7 days
< 1 year;  62.5 mg 8 hourly for 7 days

— Cellulitis —
Standard  Treatment Guidelines, 7th Edition, 2017
606And
 y Flucloxacillin , oral,
Adult s
500 mg 6 hourly for 7 days 
Children
> 10 years;  250-500 mg 6 hourly for 7 days   
2-10 years;  125-250 mg 6 hourly for 7 days
< 2 years;   62.5-125 mg 6 hourly for 7 days 
2nd Line Treatment
Evidence Rating: [C]
 y Co-amoxyclav , oral,
Adult s 
625 mg 8-12 hourly for 5-7 days 
Children
11-18 years;   625 mg 8-12 hourly for 5-7 days
6-10 years;   457 mg 8-12 hourly for 5-7 days
1-5 years;   228 mg 8-12 hourly for 5-7 days
< 1 year;   114 mg 8-12 hourly for 5-7 days
For Individuals with penicillin allergy
Evidence Rating: [C]
 y Erythromycin , oral,
Adult s 
250-500 mg 6 hourly for 7 days
Children  
8-18 years;   250-500 mg 6 hourly for 7 days
2-7 years;   250 mg 6 hourly for 7 days
< 2 years;   125 mg 6 hourly for 7 days
Or
 y Clindamycin , oral,
Adult s
150-300 mg 6-8 hourly for 7 days
Children
12-18 years;   150-300 mg 6 hourly for 7 days
1 month-11 years;   3-6 mg/kg 6 hourly for 7 days
C.      Antibiotic therapy for patients who require admission
1st Line Treatment 
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly in severe infections
Children
12-18 years;   600 mg to 1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly in severe infections
3 months-12 years;  30 mg/kg 12 hourly, 
Increased to 30 mg/kg 8 hourly in severe infections
7 days-3 months;   30 mg/kg 8 hourly 

— Cellulitis —Chapter 23:  Trauma And Injuries
607Preterm and < 7 days; 30 mg/kg 12 hourly 
Then 
 y Amoxicillin + Clavulanic Acid , oral,
Adult s
1 g 12 hourly 
Children
> 12 years;  500/125 mg 12 hourly 
4-12 years;  5 ml of 400/57 mg suspension 12 hourly 
1-4 years;  5 ml of 200/28 mg suspension 12 hourly 
3 months-1 year; 20 mg/kg (of amoxicillin) 12 hourly 
< 3 months; 15 mg/kg (of amoxicillin) 12 hourly 
And
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly 
Children  
5-12 years;  250 mg 6 hourly 
1-5 years;  125 mg 6 hourly 
< 1 year;  62.5 mg 6 hourly 
Then
 y Flucloxacillin , oral, 
Adult s
500 mg 6 hourly 
Children  
5-12 years;  250 mg 6 hourly 
1-5 years;  125 mg 6 hourly 
< 1 year;  62.5 mg 6 hourly 
 2nd Line Treatment 
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly in severe infections
Children
12-18 years;   600 mg to 1.2 g 12 hourly, 
Increased to 1.2 g 8 hourly in severe infections
3 months-12 years;  30 mg/kg 12 hourly, 
Increased to 30 mg/kg 8 hourly in severe infections
7 days-3 months;   30 mg/kg 8 hourly 
Preterm and < 7 days; 30 mg/kg 12 hourly 
Then 
 y Amoxicillin + Clavulanic Acid , oral,
Adult s
1 g 12 hourly 
Children
> 12 years;  500/125 mg 12 hourly 

— Necrotizing Fasciitis —
Standard  Treatment Guidelines, 7th Edition, 2017
6084-12 years;  5 ml of 400/57 mg suspension 12 hourly 
1-4 years;  5 ml of 200/28 mg suspension 12 hourly 
3 months-1 year; 20 mg/kg (of amoxicillin) 12 hourly 
< 3 months; 15 mg/kg (of amoxicillin) 12 hourly 
And
 y Clindamycin , IV,
Adult s
300 mg 6 hourly or 600 mg 8 hourly 
Children
3-6 mg/kg 6 hourly 
Then 
 y Clindamycin , oral,
Adult s
150-300 mg 6-8 hourly 
Children
12-18 years;   150-300 mg 6 hourly 
1 month-11 years;    3-6 mg/kg 6 hourly 
D�     For methicillin resistant Staph. aureus   
Evidence Rating: [B]
 y Vancomycin , IV, 
Adult s
1 g 12 hourly by slow infusion over 1 hour (max. 2 g daily)
Children
1 month-12 years;  10 mg/kg per day in divided doses 6-12 
hourly (max. 1 g daily)
Referral Criteria 
Refer all cases with treatment failure, complications or ulceration 
requiring debridement and grafting to a plastic or general surgeon. 
242. Necrotizing Fasciitis
It is a rapidly progressive inflammatory infection of the fascia with 
progressive destruction of the skin and subcutaneous tissue (also known 
as ‘flesh-eating’ disease).
It is a life threathening condition and if not properly managed may 
be fatal. It must be managed as an emergency. It is commoner in the 
immune-compromised state e.g. diabetes, HIV , malignancies.  
Causes 
 y Mixed bacterial infections 
 y Strept. spp
 y Staph. spp  
 y Clostridium perfringens  
 y Bacteroides  

— Necrotizing Fasciitis —Chapter 23:  Trauma And Injuries
609Symptoms
 y Pain 
 y Fever
 y Swelling 
 y Discharge 
Signs
 y Fever  
 y Swelling 
 y Discharge which may be serosanguinous or purulent
 y Skin colour change
Investigations
 y FBC, ESR
 y CRP
 y Blood culture
 y Random blood sugar
 y HIV screening
 y Gram stain and culture of discharge
 y X-ray 
 y BUE and Creatinine 
Treatment 
 y Resuscitate (Save life first) 
 y Eradicate infection
 y Treat underlying cause
Non-pharmacological treatment
 y Surgery
 y Debridement
 y Grafting and or flap cover
Pharmacological treatment 
A.      For eradication of infection
1st Line Treatment
Evidence Rating: [B]
 y Clindamycin , IV,
Adult s
600 mg 8 hourly for 4 weeks or until clinical improvement
Children
3-6 mg/kg 6 hourly for 2-4 weeks 
And 
 y Amoxicillin + Clavulanic Acid , IV,
Adult s
1.2 g 8 hourly for 4 weeks or until clinical improvement
Children
12-18 years;   600 mg-1.2 g 8 hourly for 4 weeks or until 
clinical improvement
3 months-12 years;  30 mg/kg 8 hourly, for 4 weeks or until clin -

— Hand Infections —
Standard  Treatment Guidelines, 7th Edition, 2017
610ical improvement
7 days-3 months;   30 mg/kg 8 hourly for 4 weeks or until clini -
cal improvement
Preterm and < 7 days; 30 mg/kg 12 hourly for 4 weeks or until clin -
ical improvement
2nd Line Treatment
Evidence Rating: [B]
 y Vancomycin , IV, 
Adult s
1 g 12 hourly by slow infusion over 1 hour (max. 2 g daily)
Children
1 month-12 years;  10 mg/kg per day in divided doses 6-12 
hourly (max. 1 g daily)
Note 23-3
 yDosing Modifications
Renal impairment: 15 mg/kg initially; further doses are based on renal function, 
serum drug level, and institutional protocol; dosing intervals range from every 
24 to 96 hours, depending on severity of impairment.
 yDosing Considerations
General dosing recommendation: 2 g/day IV divided  6-12 hourly; may be in -
creased on basis of body weight or to achieve higher trough values; increased 
toxicity at dosage > 4 g/day
Peak values 18-26 mg/L; trough values 5-10 mg/L; however, Infectious Diseases 
Society of America and other guidelines urge troughs 15-20 mg/L
B�      For pain relief 
 Evidence Rating: [B]
(See section for pain relief in ‘Closed fractures’ under Trauma and 
Injuries)
Referral Criteria 
Refer all patients to the plastic, general or orthopaedic surgeons as 
soon as the patient has been resuscitated.
243. Hand Infections
These are emergencies and require early diagnosis and prompt 
treatment.  Staph. spp  are responsible for the majority of cases and it is 
commoner in manual workers, farmers and fishmongers. 
They can be classified as simple or severe infections.

— Hand Infections —Chapter 23:  Trauma And Injuries
611Simple infections Severe infections
 yInfections of distal phalangeal 
pulps Felons (also referred to as 
whitlow or pulp space infection)
 yParonychia (acute and chronic)
 ySub-epithelial blisters and ab -
scesses
 yHerpes
 ySeptic granulomas
 yCarbuncular infections (from se -
bum of hair follicles and sweat 
glands) ySuppurative tenosynovitis
 yFascial space abscesses
 yAcute osteomyelitis
 yAcute septic arthritis
 yAcute Lymphangitis and allied in -
fections
 yCombinations 
 yComplications of acute infections
Causes 
 y Staph. aureus  and epidermidis
 y Strept. pyogenes
 y Fungi
 y Viruses 
Symptoms
 y Pain
 y Swelling 
 y Blistering 
 y Fever  
 y Skin discoloration 
 y Loss of function
Note 23-4
In chronic types there may be no pain or fever.
Signs
 y Fever  
 y Swelling 
 y Tenderness 
 y Discharge 
 y Stiffness 
Investigations
 y FBC, ESR
 y CRP
 y Blood culture
 y Random blood sugar
 y Gram stain and culture of discharge
 y X-ray
 y Nail clippings for chronic paronychia

— Hand Infections —
Standard  Treatment Guidelines, 7th Edition, 2017
612Treatment 
Treatment objectives
 y Eradicate infection early and aggressively
 y Prevent complications such as stiffness of the joints and septicaemia
Non-pharmacological treatment
 y Elevation of the affected hand
 y Bandaging
 y Protective wear
 y Physiotherapy  
 y Surgical drainage of abscesses 
 y Fasciotomy in compartment syndrome 
Pharmacological treatment 
A.      For treatment of suspected simple Staph.infections
1st Line Treatment
Evidence Rating: [B]
 y Flucloxacillin , oral,
Adult s
250-500 mg 6 hourly for 7-14 days
Children
5-12 years; 250 mg 6 hourly for 7-14 days
1-5 years; 125 mg 6 hourly for 7-14 days 
<1 year; 62.5 mg 6 hourly for 7-14 days
2nd Line Treatment
Evidence Rating: [B]
 y Clindamycin , oral,
Adult s
150-300 mg 6-8 hourly for 7-14 days
Children
12-18 years;   150-300 mg 6 hourly for 7-14 days 
1 month-11 years;    3-6 mg/kg 6 hourly for 7-14 days
B�     For treatment of suspected severe Staph.	infections
1st Line Treatment
Evidence Rating: [B]
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 7-14 days
Children  
5-12 years;   250 mg 6 hourly for 7-14 days
1-5 years;   125 mg 6 hourly for 7-14 days
< 1 year;   62.5 mg 6 hourly for 7-14 days
2nd Line Treatment 
 y Clindamycin , IV/IM,
Adult s 

— Hand Infections —Chapter 23:  Trauma And Injuries
613300-600 mg 8 hourly for 14 days
Children
12 years-18 years;          150-675 mg 6 hourly for 14 days
1 month-12 years;          3.75-6.25 mg/kg 6 hourly for 14 days
C�     For treatment of chronic paronychia
1st Line Treatment
Evidence Rating: [B]
 y Itraconazole , oral,
Adult s
200 mg daily for 7 days 
Children
> 12 years;   200 mg daily for 7 days
1 month-12 years;  3-5 mg/kg daily for 7 days
Caution 23-1.
Use of itraconazole is associated with potentially life-threathening liver-toxicity. 
Monitor liver function while on long term therapy.
And 
 y Miconazole  tincture, topical,
Adult s and Children  > 2 years 
Apply 12 hourly to affected area
2nd Line Treatment 
Evidence Rating: [B]
 y Fluconazole , oral,
Adult
150-300 mg weekly
Children
12-18 years;                 50-100 mg weekly
14 days-12 years;         3-6 mg/kg weekly 
Or
 y Clotrimazole , topical,
Adult s and Children
Apply 8-12 hourly to affected area
Or
 y Nystatin  cream, topical,
Adult s and Chidren
Apply 8-12 hourly to affected area
Or
 y Econazole  cream, topical,
Adult s and Children  
Apply 8-12 hourly to affected area
Or 
 y Ciclopirox  cream, topical,
Adult s 
Apply 8-12 hourly to affected area 
Children
> 10 years;         apply 8-12 hourly to affected area

— Hand Infections —
Standard  Treatment Guidelines, 7th Edition, 2017
614< 10 years;    not recommended
3nd Line Treatment 
Evidence Rating: [C]
 y Griseofulvin , oral, 
Adult s
500 mg daily (double in severe infection) for 4 weeks
Children
12-18 years;          500 mg once daily or in two divided doses 
(may be doubled in severe infections) for 4 weeks
1 month-12 years; 10 mg/kg (max. 500 mg) once daily or in 
two divided doses for 4 weeks
And 
 y Miconazole  tincture, topical,
Adult s and Children
Apply 12 hourly to affected area
D.     For treatment of septic granuloma
1st Line Treatment 
 y Copper sulphate stone  (blue stone ), topical,
Adult s and Children
Apply to the affected site 12 hourly
Or
Evidence Rating: [B]
 y Hydrocortisone  cream, 0.5-2.5%, topical,
Adult s (0.5-2.5%)
Apply 8-12 hourly to affected area(s)
Children  (0.5-1%)
Apply 8-12 hourly to affected area(s)
Or
 y Clobetasol propionate  cream (0.05%), topical,
Adult s 
Apply 8-12 hourly to affected area(s)
Children
> 12 years;  apply 8-12 hourly to affected area(s)
< 12 years;  not recommended 
Or 
 y Betamethasone  dipropionate cream (0.05%), topical,
Adult s and Children  < 12 years
Apply 12 hourly to affected area(s)
Referral Criteria 
Refer to appropriate specialists if patient does not improve.

— Tuberculosis in orthopaedics —Chapter 23:  Trauma And Injuries
615244. Tuberculosis  in orthopaedics
Tuberculosis  can affect all bones and joints. The spine is affected in 
50% of all cases. It affects all ages but commoner in the extremes of age. 
May co-exist with pulmonary TB in some cases and also in HIV  positive 
patients.
There may be a positive history of contact with a TB infected patient.
Causes 
 y Mycobacterium tuberculosis  
 y Mycobacterium africanum  
 yMycobacterium	bovis
Symptoms
 y Pain especially at night
 y Swelling
 y Deformity
 y Night sweats
 y Low grade fever
 y Chronic cough
 y Weight loss
Signs
 y Swelling
 y Tenderness 
 y Deformities
 y Discharging sinuses
 y Cold abscesses
 y Muscle wasting
Investigations
 y Chest X-Ray to rule out pulmonary TB
 y X-ray of the suspected part
 y Sputum/gastric washings for AFBs
 y FBC, ESR
 y MRI of suspected parts (if available) 
 y Bone and soft tissue biopsy for culture and histology
 y Mantoux  test  
Treatment 
Treatment objectives
 y Eradicate infection
 y Prevent and correct deformity
 y Prevent stiffness
Non-pharmacological treatment
 y Physiotherapy
 y Splints/corsets/body jackets

— Rickets and Osteomalacia —
Standard  Treatment Guidelines, 7th Edition, 2017
616 y Draining of abscesses 
 y Debridement
 y Arthrodesis  
Pharmacological treatment 
A.     For bone and joint tuberculosis
(See section on ‘Tuberculosis’)
B�      For pain relief 
Evidence Rating: [B]
(See section for pain relief in ‘Closed fractures’ under Trauma and 
Injuries)
Referral Criteria 
Refer to appropriate specialist as soon as diagnosis is made.
245. Rickets  and Osteomalacia
Rickets  is caused by failure of osteoid to calcify in a growing person 
resulting in softening and weakening of bones, due to extreme or 
prolonged vitamin-D deficiency.
Osteomalacia  is essentially its equivalent in the skeletally mature.
Causes 
 y Vitamin-D  deficiency due to:
 y Reduced intake (nutritional is the commonest)
 y Malabsorption 
 y Reduced sunlight 
 y Vitamin-D  resistance
 y Vitamin-D  dependence
Symptoms
 y Usually none 
 y Pain in the wrists
Signs
 y Malnourished with discoloured hair
 y Deformities 
 y Small for age
 y Swelling of wrists
 y Rachitic rosary
Investigations
 y Serum vitamin-D level
 y Serum calcium
 y Serum and urine phosphate levels
 y X-ray of deformed bones

— Rickets and Osteomalacia —Chapter 23:  Trauma And Injuries
617Treatment 
Treatment objectives
 y Correct metabolic derangement
 y Prevent and treat deformities
Non-pharmacological treatment
 y Nutritional support and advice
 y Surgical correction 
Pharmacological treatment 
A. For rickets
1st Line Treatment
Evidence Rating: [A]
 y Vitamin-D , oral, 
Adult s and Children
125-250 microgram (5 000-10 000 Units) daily for 2-3 months until 
healing is well established
B� For rickets in patients with malabsorption 
 y Vitamin-D , IM, 
Adult s and Children
12-18 years;  10 000-40 000 Units daily 
1-12 years;  10 000-25 000 Units daily 
Or
 y Vitamin-D , oral, 
Adult s and Children
10 000-300 000 Units daily based on severity of condition
And
 y Calcium , oral, 
Adult s and Children  
1000-1500 mg daily 
C.      For patients with osteomalacia
1st Line Treatment 
 y Vitamin-D , oral, 
Adult s
2 000-5 000 Units daily for 2-3 months until healing is well estab -
lished
Or
 y Vitamin-D , lM, 
Adult s
10 000 Units daily for 2-3 months until healing is well established
Referral Criteria 
Refer to a paediatrician and orthopaedic surgeon once diagnosis is 
made.

— Scurvy —
Standard  Treatment Guidelines, 7th Edition, 2017
618246. Scurvy
Scurvy  is a multi-system disease, which may present with bony 
deformities and soft tissue scarring. It is caused by dietary deficiency of 
Vitamin-C  (ascorbic acid). It is rare globally but seen in the low-middle 
income countries. Presentation may be dramatic, but once the diagnosis 
is made, the treatment is effective and rewarding.
Causes 
 y Vitamin-C  deficiency  
Symptoms
 y Pain and swelling of long bones
Signs
 y Tenderness of the legs 
 y Bleeding  gums 
 y Swelling of long bones
Investigations
 y X-ray 
 y Vitamin-C  assay
Treatment 
Treatment objectives
 y Correct deficient states
 y Correct deformity
Non-pharmacological treatment
 y Fruits rich in Vitamin-C  e.g. oranges
 y Surgery to correct deformities
Pharmacological treatment 
A.     For scurvy
1st Line Treatment
Evidence Rating: [C]
 y Vitamin-C , oral,
Adult s
500 mg 12-24 hourly (max. 1 g daily)
Children  
12-18 years;       500 mg 12-24 hourly (max. 1 g daily)
4-12 years;       250 mg 12-24 hourly (max. 500 mg daily)
1 month-4 years; 125 mg daily 12-24 hourly (max. 250 mg daily)
Referral Criteria 
Refer all cases to paediatrician and orthopaedic specialist.

— Osteoporosis —Chapter 23:  Trauma And Injuries
619247. Osteoporosis
Osteoporosis  is a systemic skeletal disease characterized by low bone 
mass and small areas of deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture. Risk of fractures is 
higher in elderly individuals with poor walking balance and vision.
Some risk factors include parental hip fractures, advanced 
age - especially women after menopause, smoking, alcohol abuse, 
immobilization, inadequate intake of vitamin-D and calcium, prolonged 
steroid use, hyperthyroidism , hyperparathyroidism, type-I diabetes 
mellitus, rheumatoid arthritis, malabsorption syndromes, and low femoral 
neck Bone Mineral Density (BMD). 
Cause 
 y Imbalance between new bone formation and old bone breakdown 
 y Bone mineral loss
 y Low bone density 
Symptoms
 y Back pain
 y Inability to walk after a very trivial fall
Signs
 y Deformed limbs 
 y Fractures
 y Stooping stance
Investigations
 y X-rays of wrists/hips
 y Bone Mineral Density (BMD) scan
 y Quantitative CT scan
Treatment 
Treatment objectives
 y Management of underlying risk factors
 y Prevention of fractures
 y Early treatment of fractures
Non-pharmacological treatment
 y Dietary (adequate intake of calcium and vitamin-D containing foods) 
 y Therapeutic Lifestyle Changes (refer to risk factors in the preamble 
above)
Pharmacological treatment 
A.      For low fracture risk
1st Line Treatment
Evidence Rating: [A]
 y Calcium  with Vitamin-D , oral,
Adult s 

— Sickle-cell Vaso-occlusive Crisis —
Standard  Treatment Guidelines, 7th Edition, 2017
6201000-1300 mg daily of Calcium  and 200-800 IU vitamin-D daily 
B�     For moderate fracture risk
Evidence Rating: [A]
 y Calcium  with Vitamin-D , oral,
Adult s 
1000-1500 mg daily of Calcium  and 200-800 IU vitamin-D daily 
C�      For high fracture risk
Note 23-5
For any of the therapies below, consult a specialist 
 y Hormone replacement therapy (HRT ) 
 y Estrogen therapy  (ET)  
 y Bisphosphonates
 y Calcitonin
 y Selective estrogen receptor modulators  (SERMs )
 y Denosumab
 y Strontium
 y Teriparatide
Referral Criteria 
Refer all cases to a physician or orthopaedic specialist.
248. Sickle-cell Vaso-occlusive Crisis
This is a painful complication of sickle-cell disease, induced by 
obstruction of small blood vessels by crystallized sickle cells leading 
to ischaemic injury to several organs, including bone. The bone pain is 
usually difficult to distinguish from acute osteomyelitis . 
Causes 
 y Pyogenic infection
 y Malaria  
 y Dehydration  
 y Severe anaemia
 y Stress and anxiety  
Symptoms
 y Bone pain
 y Fever  
 y Sickle-cell anaemia
Signs
 y Bone tenderness
 y Fever  

— Avascular Necrosis —Chapter 23:  Trauma And Injuries
621Investigations
 y FBC, ESR
 y CRP
 y Sickling and Hb Electrophoresis (if not previously known)
 y Blood film or Rapid Diagnostic Test  (RDT ) for malaria parasites
 y Urinalysis and culture
 y BUE and Creatinine
 y Blood culture and sensitivity
Treatment 
Treatment objectives
(See section on ‘Sickle Cell Disease ’) 
Non-pharmacological treatment
Encourage adequate fluid intake 
(See section on ‘Sickle Cell Disease ’) 
Pharmacological treatment 
A.     Treatment of underlying Malaria  
(See section on ‘Malaria ’) 
B.     For treatment of other infections
(See appropriate section)
C.     For rehydration
(See section for pharmacological treatment in ‘Sickle Cell Disease ’) 
D�     For analgesia
(See section for pharmacological treatment in ‘Sickle Cell Disease ’)
Referral Criteria 
Refer all patients with complications to a paediatrician, physician 
specialist or haematologist.    
249. Avascular Necrosis
This is bone death caused by reduced blood supply.
Causes 
 y Non-traumatic
 y Sickle-cell anaemia
 y Infection – septic arthritis
 y Slipped capital femoral epiphyses / slipped upper femoral 
epiphyses
 y HIV
 y Prolonged steroid use
 y Alcohol abuse
 y Vasculitis 
 y Idiopathic

— Avascular Necrosis —
Standard  Treatment Guidelines, 7th Edition, 2017
622 y Developmental dysplasia of hip
 y Traumatic 
 y Displaced femoral neck fractures
 y Dislocations  of joints
Symptoms
 y Pain in the affected joint
 y Limping
Signs
 y Limping
 y Tenderness on joint movement
 y Deformity 
 y Leg length discrepancy
Investigations
 y X-ray
 y MRI
Treatment 
Treatment objectives
 y Treat underlying cause
 y Prevent progression
 y Encourage recovery
 y Pain relief
Non-pharmacological treatment
 y Physiotherapy  
 y Walking aid when lower limb is involved
 y Surgery 
 y Core decompression
 y Osteotomies
Pharmacological treatment 
A.     For pain relief
1st Line Treatment
Evidence Rating: [A]
 y Naproxen  EC, oral,
Adult s
250-500mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  

— Osteogenesis Imperfecta —Chapter 23:  Trauma And Injuries
623Not indicated 
Or 
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;   50 mg 12 hourly
< 12 years;   not recommended
Or
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2.4 g daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg per kg daily)
B.     For prevention of bone collapse
Pamidronate , consult specialist 
Alendronate , consult specialist 
Referral Criteria 
Refer once the diagnosis is made to orthopaedic specialist.
250� Osteogenesis Imperfecta
This is also known as brittle bone disease. It is a genetic disorder 
characterised by low bone mass, skeletal fragility and recurrent fractures.
Causes 
 y Gene mutation leading to defective collagen formation 
Symptoms
 y Incessant crying
Signs
 y Bluish sclera
 y Dentinogenesis imperfecta (blueish-grey or yellowish-brown 
colouration of teeth)
 y Multiple fractures with callus formation
 y Bone deformities
Investigations
 y X-ray – Baby-gram (multiple fractures at different stages)
Treatment 
Treatment objectives
 y Make child comfortable
 y Prevent recurrent fractures
 y Prevent deformities 

— Burns  —
Standard  Treatment Guidelines, 7th Edition, 2017
624Non-pharmacological treatment
 y Counsel parents
 y Splints 
 y Baby handling techniques 
 y Surgical prevention and correction of deformities
Pharmacological treatment 
A. For prevention of fractures
1st Line Treatment
Evidence Rating: [B]
 y Alendronate , IV,
Children
Consult specialist 
B�      For pain relief 
 y Paracetamol , oral or rectal,
Children  
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Referral Criteria 
Refer as soon as diagnosis is made to a paediatrician and orthopaedic 
specialist.
251� Burns  
A burn is basically destruction of the skin. In certain situations 
deeper tissues such as subcutaneous tissue, muscle and bone may be 
involved. The burn may be superficial or deep depending on the extent of 
the injury. This condition, which can have devastating effects on affected 
people, can be prevented most of the time. It affects young and fit people 
in most cases and they must be managed properly so that they can return 
to their normal life.
Causes 
 y Dry heat (fire)
 y Wet heat (scalds) from hot liquids, steam, soups etc.
 y Electrical (low or high voltage)
 y Chemical (acids and alkalis)
Symptoms
 y Pain (very severe in superficial type and less in deeper burns)
 y Swelling 
 y Difficulty in breathing 
 y Blisters  

— Burns  —Chapter 23:  Trauma And Injuries
625Signs
 y Shock 
 y Inhalational injury (burnt nasal hairs, soot in the throat, hoarseness 
of the voice and black particles in sputum)
 y Swelling 
 y Blister formation  
 y Charring of tissue (deep burns)
 y ECG changes (electrical burns)
Investigations
 y FBC and sickling
 y BUE and Creatinine 
 y Wound swab
 y Blood gases
 y Chest X-ray 
Treatment 
Treatment objectives
 y Prevent further injury from burns
 y Relieve pain 
 y Replace lost fluid
 y Prevent infection of burn wound 
 y Aid healing of the burn wound  
 y Avoid complications
Non-pharmacological treatment
 y Remove clothing from affected part
 y Put affected part under running water if available till pain goes away 
or it is reduced
 y If chemical is in powder form brush it off the affected part and put 
under running water 
 y Secure airway
 y Leave intact blisters alone
 y Do not apply any creams or ointment
 y Affected limbs should be elevated
 y Good nutrition 
 y Psychological therapy
 y Physiotherapy
 y Reassure patient 
Pharmacological treatment 
A.     For burns with Total Body Surface Area (TBSA) of less than 10% in 
children and 15% in adults
Note 23-6
 yUpdate tetanus prophylaxis
 y(See section on ‘Tetanus  prophylaxis’)

— Burns  —
Standard  Treatment Guidelines, 7th Edition, 2017
626 yLiberal oral fluids
 yDress burns with Silver Sulphadiazine
 yOral Analgesia
 y Paracetamol , oral,
Adult s
500 mg-1 g 6-8 hourly  
Children
6-12 years;   250-500 mg 6-8 hourly
1-5 years;   120-250 mg 6-8 hourly
3 months-1 year;  60-120 mg 6-8 hourly
Or
 y Naproxen  EC, oral,
Adult s
250-500 mg 12 hourly as required 
Children  
Not indicated 
Or 
 y Celecoxib , oral, 
Adult s
400 mg stat. 
Then
200 mg 12-24 hourly as required 
Children  
Not indicated 
Or 
 y Diclofenac , oral,
Adult s
50 mg 8 hourly or 100 mg 12 hourly 
Children
> 12 years;   50 mg 12 hourly
< 12 years;   not recommended
Or
 y Ibuprofen , oral,                                         
Adult s
200-800 mg 6-8 hourly as required (max. 2.4 g daily)
Children
10-15 mg/kg 6-8 hourly as required (max. 40 mg per kg daily)
And
 y Flucloxacillin , oral, 
Adult s
500 mg 6 hourly for 2 weeks
Children  
5-12 years;   250 mg 6 hourly for 2 weeks
1-5 years;   125 mg 6 hourly for 2 weeks
< 1 year;   62.5 mg 6 hourly for 2 weeks 

— Burns  —Chapter 23:  Trauma And Injuries
627B.     If the Patient has burns (TBSA) of more than 10% in children and 
15% in adults
Note 23-7
 yAdmit
 yUpdate tetanus prophylaxis
 y(See section on ‘Tetanus  prophylaxis’)
 yResuscitate by calculating IV fluids requirement using Parkland’s formula (4 x 
TBSA x Weight of Patient) given in the form of crystalloids 
 yIn adults give half of calculated total fluid in first 8 hours from the time of 
injury and the other half in 16 hours as Ringers lactate
 yIn children add daily fluid requirement to the calculated fluid for resuscita -
tion and administer as above as Ringers lactate and 4.3% dextrose in ⅕ saline
 yDress burns with silver sulphadiazine 
 yOpioid Analgesia
 y Morphine , IV,
Adult s 
2.5-5 mg 4 hourly
Children  
0.1 mg/kg (max. 5 mg) 4 hourly 
Or 
 y Pethidine , IV,
Adult s
25-50 mg 4 hourly.  Lower dose in the elderly.
Children  
1 mg/kg (max. 50 mg) 4 hourly
And
 y Cloxacillin , IV, 
Adult s
500 mg 6 hourly for 7 days
Children  
5-12 years;   250 mg 6 hourly for 7 days
1-5 years;   125 mg 6 hourly for 7 days
< 1 year;   62.5 mg 6 hourly for 7 days 
B.  If the Patient has burns (TBSA) of more than 10% in children and 
15% in adults – and allergic to penicillins
 y Clindamycin , IV, (if patient is allergic to penicillin)
Adult s
300-600 mg 6 hourly for 7 days
Children
3-6 mg/kg 6 hourly for 7 days
And 
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7 days

— Burns  —
Standard  Treatment Guidelines, 7th Edition, 2017
628Children
7.5 mg/kg 8 hourly for 7 days
C.     If the Patient has burns (TBSA) of more than 20% in children and 
30% in adults (considered as severe burns)
Note 23-8
 yAdmit 
 yUpdate tetanus prophylaxis
 y(See section on ‘Tetanus  prophylaxis’)
 yResuscitate by calculating IV fluids requirement using Parkland’s formula (4 x 
TBSA x Weight of Patient) given in the form of crystalloids 
 yIn adults give half of calculated total fluid in first 8 hours from the time of 
injury and the other half in 16 hours as Ringers lactate
 yIn children add daily fluid requirement to the calculated fluid for resuscita -
tion and administer as above as Ringers lactate and 4.3% dextrose in 1/5 
saline
 yDress burns with silver sulphadiazine
 y Cefuroxime , IV,
Adult s
750 mg-1.5 g 8 hourly for 7 days
Children
25 mg/kg 8 hourly for 7 days
And
 y Metronidazole , IV,
Adult s
500 mg 8 hourly for 7 days
Children
7.5 mg/kg 6 hourly for 7 days
And
 y Omeprazole , IV, 
Adult s 
40 mg 12 hourly 
Or
 y Esomeprazole , IV, 
Adult s 
40 mg daily
 For DVT prophylaxis  
 y Enoxaparin , SC, 
Adult s
40 mg daily
Children  
2 months-18 years; 1 mg/kg 12 hourly
1-2 months;  1.5 mg/kg 12 hourly 
Neonate s;  1.5-2 mg/kg 12 hourly 

— Burns  —Chapter 23:  Trauma And Injuries
629Or
 y Dalteparin , SC,
Adult s
5000 units daily
Children  
12-18 years;     2500-5000 units daily
1 month-12 years; 100 units/kg 12 hourly 
Neonate s;  100 units/kg 12 hourly 
D�     If a burn is clinically infected 
Note 23-9
 yAdmit 
 yUpdate tetanus prophylaxis
 y(See section on ‘Tetanus  prophylaxis’)
 yTake wound swabs and blood for culture and sensitivity testing
 yGive IV Fluids
 yGive IV Analgesics
 yStart IV Antibiotics
1st Line Treatment 
 y Gentamicin , IV,
Adult s
40-80 mg 8 hourly for 14 days
Children
1-12 years;   2.5 mg/kg 8 hourly for 14 days
< 1 year;   2.5 mg/kg 12 hourly for 14 days
Or 
 y Ceftazidime, IV, 
Adult s 
1-2 g 8 hourly 
Children  
1 month-18 years; 25 mg/kg 8 hourly  
Neonate s
21-28 days;  25 mg/kg 8 hourly 
7-21 days;  25 mg/kg 12 hourly 
< 7 days;  25 mg/kg daily 
And
 y Metronidazole , IV, (doses as indicated in section B. above)
And
 y Cloxacillin , IV, (doses as indicated in section B. above)
2nd Line Treatment
 y Meropenem , IV,
Adult s
0.5-1 g 8 hourly
Children
12-18 years;   0.5-1 g 8 hourly 

— Wounds —
Standard  Treatment Guidelines, 7th Edition, 2017
6301 month-12 years (> 50 kg); 0.5-1 g 8 hourly
1 month-12 years (< 50 kg); 10-20 mg/kg 8 hourly
Neonate
> 7 days;  20 mg/kg 8 hourly 
< 7 days;  20 mg/kg 12 hourly   
Or 
 y Amikacin, slow IV over 3-5 minutes, (monitor serum Amikacin levels)
Adult s 
7.5 mg/kg 12 hourly (max. 1.5 g daily and 15 g per course)
Children   
 y  12-18 years;  7.5 mg/kg every 12 hours (max. 500 mg 8 
hourly, and 15 g per course)  
Referral Criteria 
Refer all cases of burns with the following characteristics to a 
specialist. 
Partial-thickness burns more than 10% of TBSA 
Deep burns of any percentage.
Burns  involving face, hands, feet, genitalia, perineum, or major joints
Chemical burns 
Electrical burns 
Any burn with concomitant trauma in which burn poses greatest risk 
to patient 
Inhalation injury 
Infected burns 
Burns  with pre-existing diabetes, renal failure etc.
 
252� Wounds
A wound is a break in the continuity of tissues in the body. It may 
involve overlying epithelium like skin. Wounds are usually caused by injury. 
Tissues affected include subcutaneous tissue, muscles and even bones. It 
may be small or large and may be deep or superficial. It may bleed, may 
be contaminated with dirt and other foreign matter and become infected. 
Causes 
 y Mechanical agents e.g. cut from cutlass or knife, gunshot, accidents, 
contusion from blunt injury. Wounds may follow snake or insect 
bites, animal or human bites
 y Chemical agents e.g. strong acids or alkalis, other corrosive chemicals
 y Thermal injury resulting in burns
Symptoms
 y Local pain
 y Bleeding
 y Discharge of pus if infected

— Wounds —Chapter 23:  Trauma And Injuries
631Signs
 y Local swelling and tenderness
 y Look for other injuries e.g., head, chest, abdomen, bone, nerves
 y Determine the physical characteristics of the wound e.g. site, size, 
shape and depth
Investigations
 y Haemoglobin level if patient has bled
 y Group and cross-match blood if indicated
 y X-ray of injured part may be required to rule out osteomyelitis and 
bone fractures
 y Wound swab for culture and sensitivity if wound is infected
Treatment  
Treatment objectives
 y To control bleeding
 y To relieve pain 
 y To prevent or treat infection
 y To protect against tetanus
 y To promote wound healing 
Non-pharmacological treatment
 y Apply sterile pressure dressing to bleeding site and raise the injured 
part to control bleeding.
 y  If a bleeding vessel can be identified, it should be ligated. (the use of 
tourniquet to stop bleeding is discouraged)
 y Bleeding from a tooth socket - put a small piece of sterile gauze in the 
socket and ask the patient to bite on it.
Box 23-1:   Wound management
 yImmediate closure of wounds is good, but this is not advisable if the wound 
is dirty or likely to become infected e.g. gunshot wounds, animal and human 
bites and wounds over 6 hours old. They should not be sewn up.
 yWash hands well and wear sterile gloves. Clean the wound with antiseptic 
solution. Scrub dirty wounds with antiseptic solution and irrigate with dilute 
hydrogen peroxide and saline.
 yIf there are bits of gravel, glass or dirt in the wound, remove them gently. Lift 
up all flaps of skin, clean under them, excise all dead tissue and cover the 
wound with sterile gauze. 
 yAnaesthesia may be required.
 yDo not use Eusol, which is both irritant and exposes patient to unnecessary 
borate levels Dress infected wound as often as needed with normal saline 
or povidone iodine lotion. Take wound swab for culture and sensitivity test 
if possible and start Amoxicillin (Amoxycillin) while waiting for results of 
wound culture
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]

— Bites and Stings  —
Standard  Treatment Guidelines, 7th Edition, 2017
632 y Tetanus prophylaxis for all potentially contaminated wounds, fol -
lowed by booster doses of tetanus toxoid as appropriate (See section 
on ‘Immunisation’)
And
 y Paracetamol, oral,
Adult s
500 mg-1 g 6-8 hourly
Children
6-12 years;  250-500mg 6-8 hourly
1-5 years;  120-250 mg 6-8 hourly 
3 month-1 year; 60-120 mg 6-8 hourly
And 
 y IV fluids and blood transfusion as required.
And 
 y Amoxicillin (Amoxycillin), oral,
Adult s
500 mg 8 hourly
Children  
6 -12 years; 250 mg 8 hourly 
1-5 years; 125 mg 8 hourly 
1 year; 62.5 mg 8 hourly 
Referral Criteria 
Complicated wounds (e.g. wounds associated with fractures, division 
of tendons, blood vessels and nerves).
253� Bites and Stings 
SNAKE BITE
Most snake bites are non-poisonous. Vipers are the commonest 
cause of poisonous snake bites in tropical Africa. Others are the cobras and 
water snakes. All cases of snake bites (venomous/non-venomous) should 
be observed for at least 6 hours. Identify the type of snake if possible. 
Don’t rely too much on fang marks; however multiple fang marks usually 
indicate a non-poisonous bite whereas one or two fang marks suggest a 
poisonous bite. It is important to determine whether envenomation has 
occurred. The role of tourniquets and incision over the site of the bite are 
controversial issues and are to be avoided.
Causes 
 y Snakes
Symptoms
 y Pain 
 y Bleeding
 y Swelling

— Bites and Stings  —Chapter 23:  Trauma And Injuries
633 y Fainting
 y Dark-coloured urine
 y Headache
 y Muscle ache
 y Fear
 y Loss of consciousness
Signs
(Poisonous snake bites) 
Cardiovascular:
 y Hypotension, shock, cardiac arrhythmias
 y Spontaneous systemic bleeding, from bite site, mucosa and old 
wounds, haematuria
 y Dark urine from myoglobinuria and intravascular haemolysis  
Neuromuscular:
 y Cranial nerve paralysis - ptosis, opthalmoplegia, slurred speech
 y Bulbar respiratory paralysis - drooling, and inability to breath 
properly
 y Impaired consciousness, seizures
 y Meningism 
 y Tender and stiff muscles
Local effects:
 y Rapid progression of swelling to more than half of bitten limb
 y Blistering, necrosis and bruising
 y Fascial compartmentalisation on bitten digits
Investigations
 y Full blood count
 y Renal function test
 y 20 minutes whole blood clotting test (leave 2-5 ml of blood in dried 
test tube. Failure to clot after 20 minutes implies incoagulable blood)
 y Liver function test
Treatment 
Treatment objectives
 y To relieve pain and anxiety
 y To support the respiration or circulation if indicated
 y To counteract the spread and effect of the snake venom
 y To prevent secondary infection
Non-pharmacological treatment
First Aid  
 y Immobilization/splinting of the affected limb. Do not move the limb 
that has been bitten - the more it is moved, the faster the poison 
spreads.  Carry the person on a stretcher and tie the limb to a straight 
piece of wood. If ice is available, wrap pieces in cloth and place it 

— Bites and Stings  —
Standard  Treatment Guidelines, 7th Edition, 2017
634around the bite. 
 y Clean the wound and reassure the patient. 
At the hospital
 y Bed rest, reassure, keep warm
 y Assess patient’s airway, breathing and circulation (ABC of 
resuscitation) 
For probable venomous bites:
 y Clean site of bite with antiseptic lotion or soap and water
 y Do not attempt to suck or make any incisions at the site of the bite
 y Leave wound open; punctured wounds are especially likely to be 
infected. 
 y If the snake is identified as non-poisonous or there is absence of 
swelling or systemic signs after 6 hours reassure the patient
 y Surgical debridement when required
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [B]
A. Indication for anti-venom treatment 
Presence of symptoms and signs of local and systemic effects of 
envenomation. 
 y Anti-snake serum (ASS) - polyvalent
Have resuscitation tray ready (adrenalin 1: 1000)
Test dose - 0.2 ml, subcutaneous, to test for anaphylaxis
ASS 50-100 ml (5-10 ampoules) depending on severity by IV drip in 
0.9% N/S or 5% Dextrose over 2-4 hours. Monitor signs and repeat 
as required
Note 23-10
Never inject anti-venom into toe/finger
Monitor patient and correct:
 y Hypovolaemic shock - crystalloids/colloids/blood
 y Defects of haemostasis - clotting factors/fresh frozen Plasma/plate -
lets
 y Respiratory distress - oxygen /intubate/ventilate
 y Anti-tetanus therapy,
 y Tetanol, IM, 0.5 ml stat. 
And
 y Diazepam, oral, 5-10 mg stat.
B�      For Pain relief
 y Paracetamol, oral, 
Adult s
500 mg-1 g 6-8 hourly 
Children

— Bites and Stings  —Chapter 23:  Trauma And Injuries
6356-12 years;  250-500 mg 6-8hourly
1-5 years;  120-250 mg 6-8hourly 
3 months-1 year;    60-120 mg 6-8hourly
Or 
 y Morphine, IV, IM, SC, 
Adult s
10 mg stat.
Children
> 2 years;    200 micrograms/kg 
< 2 years;    100-200 micrograms/kg  
C.     Prevention of secondary infection
 y Amoxicillin (Amoxycillin), oral, 
Adult s
500mg 8 hourly for 5 days
Children  
6-12 years;    250 mg 8 hourly for 5 days 
1-5 years;     125 mg 8 hourly for 5 days 
1 year;     62.5 mg 8 hourly for 5 days N
Note 23-11  
Corticosteriods are of little or no value during poisoning except in treating ana -
phylactic crisis. Avoid venopuncture in sites of generalized bleeding.
Referral Criteria 
Refer all patients with respiratory failure, heart failure, renal failure, 
muscle paralysis, muscle necrosis, bleeding or intravascular haemolysis to 
a regional hospital for specialist care.
SNAKE SPIT IN THE EYES
The black-necked cobra or the spitting cobra sprays its venom into 
the eyes of its victim. 
It causes irritation of the eyes and may cause conjunctivitis and even 
blindness if not washed away immediately.
Treatment
 y Irrigate the eye with any liquid available (water, milk, saline etc).
 y Instil diluted anti-venom (one part to five parts of Sodium Chloride 
0.9%).
 y Treat as corneal abrasion with topical antibiotics (See section on ‘Eye 
Injuries’)
SCORPION STING
Scorpion stings leave a single mark, and the stings are extremely 
painful.
Symptoms
 y Pain at the site of bite

— Bites and Stings  —
Standard  Treatment Guidelines, 7th Edition, 2017
636 y Localized swelling
 y Vomiting
 y Abdominal pain
Signs
 y Excessive salivation
 y Sweating 
 y Rapid respiration
 y Single-puncture wound
Treatment 
Treatment objectives
 y To relieve pain
 y To maintain hydration
 y To reassure patient
Non-pharmacological treatment
 y Detain for observation.
 y Put ice compresses on the area. 
 y Give the patient plenty of fluids to drink
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
 y Paracetamol, Aspirin, Ibuprofen or Diclofenac, oral,
And
 y 1% Lidocaine (Lignocaine), 2-5 ml for local infiltration to relieve pain 
BEE AND WASP STINGS
Majority of bee and wasp stings only produce localized pain. They 
may occasionally cause allergic reactions, which may lead to anaphylaxis 
with local pain, generalized urticaria, hypotension, and difficulty in 
breathing as a result of bronchospasm and oedema of the glottis. Death 
may occur.
Symptoms 
 y Localized pain at the site of sting
Signs
 y Swelling at site
 y Urticuria
 y Hypotension
 y Difficulty in breathing
 y Bronchospasm
Treatment 
Treatment objectives
 y To relieve pain
 y To manage anaphylaxis if necessary

— Bites and Stings  —Chapter 23:  Trauma And Injuries
637Non-pharmacological treatment
 y Detain for observation
 y Put ice compresses on the area
 y Give the patient plenty of fluids to drink
 y In the case of bee sting remove stinger from skin by scraping. Do not 
pull it out
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
 y Adrenaline, SC, (1:1000) 0.5-1 ml stat.
 y Promethazine, IM,
Adult s
50 mg stat.
Children
12.5-25 mg stat.
 y Hydrocortisone, IV, 100-200 mg repeated 6 hours later if necessary 
 For shock
 y IV fluids
 For pain
 y Paracetamol, oral,  
Adult s
500 mg-1 g 6 - 8 hourly
Children
6-12 years;  250-500 mg 6-8hourly
1-5 years;  120-250 mg 6-8hourly 
3 months-1 year;     60-120 mg 6-8hourly
Referral Criteria 
Refer all patients with anaphylaxis who are not responding to 
treatment
HUMAN BITES
Human bites (which usually occur during fights) lead to infections, 
which if neglected, almost invariably produce a highly destructive, 
necrotizing lesion contaminated by a mixture of aerobic and anaerobic 
organisms. A deliberately inflicted bite on the hand or elsewhere should 
be considered as contaminated.
Symptoms
 y Pain
 y Swelling
 y Bleeding
 y Fever, if bites get infected
Signs
 y Teeth impression on bitten site

— Bites and Stings  —
Standard  Treatment Guidelines, 7th Edition, 2017
638 y Wound
Treatment 
Treatment objectives
 y To relieve pain
 y To treat any secondary infection
Non-pharmacological treatment
 y Clean wound thoroughly 
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [C]
 y Tetanus prophylaxis (See section on ‘Tetanus prophylaxis’)
 y Flucloxacillin, oral,
Adult s
500 mg 6 hourly for 7 days
Children
5-12 years;  250 mg 6 hourly for 7 days
1-5 years;  125 mg 6 hourly for 7 days
> 1 year;   62.5 mg 6 hourly for 7 days
And
 y Amoxicillin (Amoxycillin), oral, 
Adult s
500 mg 8 hourly for 7 days
Children
6-12 years;  250 mg 8 hourly for 7 days
1-5 years;  125 mg 8 hourly for 7 days
< 1 year;  62.5 mg 8 hourly for 7 days
And
 y Paracetamol, oral,
Adult s
500mg-1g 6-8 hourly
Children
6-12 years;  250-500 mg 6-8 hourly
1-5 years;  120-250 mg 6-8 hourly
3 months-1 year; 60-120 mg 6-8 hourly
Note 23-12
As a general rule, do not suture wounds from human bite. 
Referral Criteria 
Refer if there is necrotising fasciitis.
DOG AND OTHER ANIMAL BITES
Mammals, including dogs, may carry the rabies virus. Saliva from 
an infected animal contains large numbers of the rabies virus which is 
inoculated through a bite, laceration, or a break in the skin. There is also 

— Bites and Stings  —Chapter 23:  Trauma And Injuries
639risk of tetanus and other bacterial infection following the bites of any 
mammal.
Symptoms
 y Pain
 y Swelling
 y Bleeding
 y Fever, if bites get infected
Signs
 y Teeth impression on bitten site
 y Wound
Treatment 
Treatment objectives
 y To treat laceration
 y To prevent rabies infection
 y To prevent other infections
 y To treat any secondary infection
Non-pharmacological treatment
 Immediate local care
 y Wash site with soap and water
 y All injuries-abraded skin: minor bites and scratches, major bites and 
scratches are treated in the same way by thorough irrigation with 
copious amounts of saline solution or cleansing with cetrimide plus 
chlorhexidine solution
Pharmacological treatment 
1st Line Treatment
Evidence Rating: [A]
 y Flucloxacillin, oral,
Adult s
500 mg 6 hourly for 7 days  
Children
5-12 years;  250 mg 6 hourly for 7 days
1-5 years;  125 mg 6 hourly for 7 days
> 1 year;   62.5 mg 6 hourly for 7 days
And
 y Amoxicillin (Amoxycillin), oral, 
Adult s
500 mg 8 hourly for 7 days  
Children
6-12 years;  250 mg 8 hourly for 7 days
1-5 years;  125 mg 8 hourly for 7 days
< 1 year;  62.5 mg 8 hourly for 7 days
Update or provide (if not previously immunised) tetanus 
Immunisation (See section on ‘Tetanus Immunisation’)

— Bites and Stings  —
Standard  Treatment Guidelines, 7th Edition, 2017
640Indication for use of Rabies Immunoglobulin and Rabies vaccine
It should be remembered that not every animal carries rabies, 
although the possibility should be borne in mind for every animal bite. The 
treatment provided is dependent on both the certainty of the presence of 
the rabies virus in the animal and the Immunisation state of the patient.
Table 23-1:   Indication for use of Rabies Immunoglobulin and Rabies vaccine
Condition of Animal Treatment
At time of attack During  observation Vaccination 
procedureImmunoglobulin 
administration
Normal No change after 
10 daysDo not vaccinate  Give first dose
Normal Confirmed signs of 
rabies after 10 days 
unconfirmed sign in 
animal
Rabies confirmedInitiate vaccination 
in patient upon first 
sign of rabies in 
animal 
initiate vaccination 
stop if animal is 
normal on day 5
  
continue 
vaccination regime
immediate 
vaccinationGive according to 
guidelines below 
give according to 
guidelines  
give according to 
guidelines
give according to 
guidelinesStrong suspicion of 
rabies
Rabies 
Rabies Immunisation post exposure
 Patients vaccinated within last three years
Day 0
Infiltrate wound and around wound with 
 y Rabies immunoglobulin (10 IU/kg body weight); 
And
Rabies Immunoglobulin (10 IU/kg body weight) by IM injection;
1 ml Rabies vaccine by IM injection* 
Day 3 (or any day up to  day 7)
1 ml Rabies vaccine by IM injection*
 Patients with no vaccination or more than 3 years since 
vaccination
Day 0
Infiltrate wound and around wound with 
 y Rabies immunoglobulin (10 IU/kg body weight); 

— Shock —Chapter 23:  Trauma And Injuries
641And
 y Rabies Immunoglobulin (10 IU/kg body weight) by IM injection;
1 ml Rabies vaccine by IM injection* Days 3, 7, 14, 30 
Note 23-13
Evidence shows that when this vaccine is injected into the gluteal region there 
is a poor response. Always use the deltoid muscle, or in small children the an -
terolateral thigh, to give the IM injection of rabies vaccine. 
Always complete the rabies vaccine monitoring form. Check availability of treat -
ment for the next patient
First dose of anti-rabies vaccine may be given whilst observing for presence or 
absence of rabies in the dog
These guidelines are prepared with respect to the use of Rabies Immunoglobu -
lin of human origin and human diploid cell rabies vaccine.
For the use of other products seek advice and guidance from the Pharmacist or 
SMO Public Health at either Regional or District level.
RABIES IMMUNISATION
Prophylactic immunisation should be offered to those at high risk 
(eg. laboratory staff working with rabies virus, animal handlers, veterinary 
surgeons, and wildlife officers likely to be exposed to bites of possibly 
infected wild animals). 
 y Rabies vaccine, IM, 1 ml on each of days 0, 7 and 28 Booster doses 
should be given every 2-3 years
Referral Criteria 
Refer to a tertiary centre when symptoms of rabies set in.
254. Shock
Shock is a clinical state of cellular dysfunction as a result of decreased 
circulating blood volume leading to reduction in delivery of oxygen and 
other nutrients to vital organs which if prolonged leads to irreversible 
multiple organ failure.
Causes
 y Hypovolemia e.g. haemorrhage, vomiting, diarrhoea, acute intestinal 
obstruction
 y Cardiogenic e.g. myocardial infarction, Massive pulmonary embolus
 y Obstructive e.g. Pericardial tamponade, tension pneumothorax
 y Severe sepsis 
 Symptoms
 y Thirst 
 y Feeling faint
 y Palpitations
 y Sweating
 y Restlessness

— Shock —
Standard  Treatment Guidelines, 7th Edition, 2017
642 y Clouding of consciousness, confusion
Signs
 y Altered sensorium
 y Pallor
 y Cold extremities
 y Collapsed peripheral veins
 y Tachycardia, pulse > 90 bpm 
 y Hypotension, Systolic BP < 90 mmHg
Investigations
 y Septic screen if sepsis is suspected
 y CXR, ECG and Echocardiogram if cardiogenic shock suspected
 y Supportive tests like FBC, BUE, Creatinine and LFT is done to detect 
any derangement and correct them 
Treatment 
Treatment objectives
 y To reverse shock
 y To secure airway, breathing and circulation
 y To prevent complications and multiple organ failure
 y To prevent death
Non-pharmacological treatment
 y Raise foot end of bed
Pharmacological treatment
Evidence Rating: [C]
A. Hypovolaemic shock
Insert the largest bore cannula (size 14 or 16) in the largest vein 
visible. Two cannulae may be inserted at separate sites for rapid IV infusion
Raise drip stand or squeeze bag to increase infusion rate
 y Give colloids 
 y In haemorrhagic states cross-matched blood is preferred but in the 
meantime resuscitate with crystalloids e.g. normal saline. 
 y Ringers lactate, IV, 
Adult s 
70 ml/kg body weight
Children
(See section on ‘Management of severe dehydration’)
 y Normal saline should be given quickly and slowed only when BP rises 
and urine flow is adequate. 
Adult s and older children 
0.5-1 ml/kg per hour of urine
Smaller children 
1 ml/kg per hour of urine
 y Catheterise the bladder to monitor the urine output.
 y Oxygen, nasally or by facial masks, 6 L/minute

— Shock —Chapter 23:  Trauma And Injuries
643 y Continue to monitor BP , pulse and urine output
MULTIPLE ORGAN DYSFUNCTION SYNDROME
This is a life-threatening complication of shock. Different organs may 
be affected moderately or severely in the process as follows:
 y CNS - Encephalopathy
 y Heart - Tachyarrhythmias
 y Pulmonary - Acute Respiratory Failure 
  - ARDS
 y Kidney - Acute Tubular Necrosis
 y Gastrointestinal - Ileus, Pancreatitis
 y Liver - Ischemic hepatitis
 y Blood - Disseminated Intravascular Coagulation
 y Metabolic - Hyperglycemia, Hypoglycemia
 y Immune system - Immune depression
Referral Criteria 
Refer all patients to the appropriate physician specialist.

24Chapter
644General Emergencies
255� Acute Allergic Reaction (Anaphylaxis ) 
An acute allergic reaction  or anaphylaxis  is a life-threatening 
but rapidly reversible condition if treated promptly. Anaphylaxis  can 
develop within minutes of injection or ingestion of medicines or contact 
with allergen. Persons who are aware of the risk of anaphylaxis are to 
be informed of avoidance measures, and may be taught the use of an 
epinephrine (adrenaline) pen.   
Causes 
 y Bee or other insect stings
 y Drugs e.g. penicillins, sulphonamides
 y Vaccines
 y Antisera e.g. snake serum, anti-tetanus serum
 y Intravenous contrast media
 y Foods like seafood, groundnuts, fruit etc.
Symptoms
 y Severe itching
 y Urticarial rash
 y Facial and peri-oral swelling
 y Difficulty in breathing 
 y Wheeze
 y Collapse 
 y Syncope
Signs
 y Angio-oedema  
 y Difficulty in breathing
 y Bronchospasm with wheeze
 y Tachycardia
 y Hypotension 
 y Cold clammy extremities
 y Facial oedema
 y Urticaria
 y Cyanosis

— Acute Allergic Reaction (Anaphylaxis)  —Chapter 24:  General Emergencies
645Investigations
 y FBC (eosinophilia)
 y Skin prick test for specific allergens 
 y Serum specific IgE 
Treatment 
Treatment objectives
 y Secure airways, breathing and circulation
 y Reverse symptoms
 y Remove the offending cause if possible
 y Rapidly intervene and correct abnormal vital signs
Non-pharmacological treatment
 y Avoid the allergen
 y Resuscitation 
Pharmacological treatment 
A. Acute Anaphylactic Reaction
1st Line Treatment
Evidence Rating: [B]
 y Oxygen  
By nasal prongs  2-6 L/min
Or 
Face mask  4-8 L/min
Or 
Non-rebreather mask,  10-15 L/min
And
 y Adrenaline  (Epinephrine), IM,
Adult s
0.3-0.5 ml of 1:1000 solution (i.e. 300-500 micrograms) repeated if 
necessary every 10 minutes and while monitoring blood pressure 
and pulse
Children
0.3 ml of 1:1000 solution (i.e. 300 micrograms)
Repeat as for adults.
And
 y Hydrocortisone , IV,
Adult s
100-200 mg 6-8 hourly, to control any late allergic reaction that may 
occur
Children
All ages;  2 mg/kg 6 hourly for 4 doses, not to exceed   
250 mg/day
Then
 y Prednisolone , oral, 
Adult s

— Acute Allergic Reaction (Anaphylaxis)  —
Standard  Treatment Guidelines, 7th Edition, 2017
64640 mg daily for 14 days and taper off 
Children
2 mg/kg daily for 14 days and taper off 
And
 y Promethazine  hydrochloride, IM,
Adult s
25 mg repeat after 2 hours if necessary, 
Then 12 hourly for 24 hours
Children
2 years-12 years;  6.25-12.5 mg 8-12 hourly for 24 hours
< 2 years;   not recommended  
Or
 y Chlorpheniramine , IM,
Adult s
5-10 mg 6 hourly (max. of 40 mg daily) 
Children
6-12 years;   5mg up to a max. of 4 doses in 24 hours
6 months-6 years;  2.5 mg, 
< 6 month;   250 microgram/kg (max. 1.5 mg)
B.     Acute Anaphylactic Reaction with severe airway obstruction 
And
 y Salbutamol , nebulised,
Adult s
5 mg 4-6 hourly until resolved
Children
2.5 mg 4-6 hourly until resolved
Or
 y Aminophylline , IV,
Adult s
250 mg over 20 minutes, then continuous infusion by perfusor at 0.5 
mg/kg/hour for 24 hours if necessary 
Children
3-5 mg/kg over 20 minutes as a slow bolus injection or by infusion in 
500 ml Sodium Chloride  0.9%, IV, 4-6 hourly for 24 hours
C.     Acute Anaphylactic Reaction with severe hypotension  
And
 y Normal saline , 0.9%, IV, 1 L- 4 L, rate determined by clinical assess -
ment
Referral Criteria 
Refer to district or regional hospital if symptoms of anaphylaxis  
persist after stabilizing the patient and giving initial treatment.

25Chapter
647Antibiotic Prophylaxis In 
Surgery 
256� Antibiotic Prophylaxis in Surgery  
Antibiotic prophylaxis  refers to the administration of antibiotics in 
patients to reduce the risk of perioperative sepsis. The main cause of 
morbidity and mortality in surgery is infectious complications.
Antibiotic prophylaxis  is indicated in cases where sepsis is expected 
and could have disastrous local or generalised effects.
For prophylaxis to be effective, antibiotics must be given before 
contamination takes place or at the earliest possible time before infection 
is established. For surgery, therefore, it must be given IV about the time of 
induction of anaesthesia, so that tissues are saturated with the antibiotic 
before contamination occurs. 
Causes  
 y Staphylococcus aureus
 y Streptococcus  spp.
 y Enterobacteriaceae  (GI)
 y Anaerobes  (GI)
 y Coagulase negative staphylococci  (especially cardiac surgery, and 
implantation surgery), etc.
Objectives
 y Prevent infections 
 y Prevent complications
Indications
Proven Indications
 y Acute appendicitis and intestinal obstruction
 y Surgery on the colon and rectum
 y Surgery on the biliary tract
 y Gastro-oesophageal and oro-pharyngeal surgery for carcinoma
 y Hysterectomy
 y Surgery in the presence of pus
 y Patients with rheumatic heart disease
 y Patients with congenital heart disease

— Antibiotic Prophylaxis in Surgery  —
Standard  Treatment Guidelines, 7th Edition, 2017
648Accepted Indications
 y Implant surgery where prosthesis and device implants are used
 y Cardiovascular surgery
 y Caesarean section
Possible Indications  
 y Thoracic surgery
 y Neurosurgery
 y Surgery on the genito-urinary tract
 y Trauma surgery
Choice of Antibiotics
The antibiotic chosen must:
 y Have antibacterial activity against the anticipated pathogens
 y Not easily induce antimicrobial resistance
 y Have a high concentration at the site of infection
 y Be safely metabolised and excreted
 y Have few toxic or adverse reactions
 y Be affordable
Table 25-1:   Choice of Antibiotics for prophylaxis
SURGICAL PROCEDURE REGIMEN
Appendicectomy/ 
Uncomplicated 
appendicitisAmpicillin , IV, 
Adults
1g 
Children
6-12 years;   500 mg 
< 5 years;      250 mg 
   
And
Metronidazole , IV,
Adults
500 mg single dose at induction of anaesthesia
Children
7.5 mg/kg single dose at induction of anaesthesia
Or
Metronidazole , rectally,
Adults  
1 g one hour before surgery
Children
125-250 mg one hour before surgery
Resection of the colon 
or rectum or obstructed 
bowelGentamicin§, IV, 
5 mg/kg 
And
Metronidazole§, IV,
Adults
500 mg
Children
7.5 mg/kg 
Or

— Antibiotic Prophylaxis in Surgery  —Chapter 25:  Antibiotic Prophylaxis In Surgery 
649SURGICAL PROCEDURE REGIMEN
Metronidazole , IV, (doses same as above) 
And 
Cefuroxime§, IV,
Adults   
1.5  g
Children  
60 mg/kg as a single dose.
Or 
Ciprofloxacin , IV, (to be administered over 60 minutes)
Adults
400 mg 8-12 hourly    
Children
10 mg/kg 12 hourly (max. 400 mg)
And 
Metronidazole, IV,  
Adults
500 mg stat. 
Children
7.5 mg/kg stat.
Biliary tract surgery Single dose of Gentamicin , IV, (same as above)
And 
Cefuroxime , IV, (same as above)
HysterectomySingle dose of Metronidazole , IV, 
500 mg
Dental procedures for 
patients with heart valve 
prostheses, rheumatic 
heart disease, septal 
defect and patent ductus 
arteriosusUnder Local Anaesthesia:
Amoxicillin (Amoxycillin ), oral,
Adults  
3 g one hour before procedure
Children
6-12 years; 1.5 g
5 years;        750 mg 
Patients with Penicillin allergy or who have received more 
than one dose Penicillin in the previous month; 
Clindamycin , oral,
Adults
600  mg
Children
5-10 years;   300  mg
< 5 years;      150  mg
Patients who have had previous Endocarditis
Adults
Ampicillin , IV, 1g 
And
Gentamicin , IV, 
120 mg at induction
Then
Amoxicillin , oral, 
500 mg 6 hours later.

— Antibiotic Prophylaxis in Surgery  —
Standard  Treatment Guidelines, 7th Edition, 2017
650SURGICAL PROCEDURE REGIMEN
Children
Ampicillin ,IV,
6-12 years;   500 mg 
< 5 years;      250 mg    
And
Gentamicin , IV, 2 mg/kg
Then (6 hours later)
Amoxicillin , oral,
6-12 years;  250  mg
< 5 years;  125  mg
Under General Anaesthesia:
Amoxicillin + Clavulanic Acid , IV, 
Adults
1.2 g at induction 
Then 
Amoxicillin , oral, 
500 mg 6 hours later.
Children
5-10 years; ½ of adult dose
< 5 years; ¼ of adult dose
If patient has a prosthetic valve or previously had 
endocarditis, Ampicillin , IV and Gentamicin , IV.
Patients who are allergic to penicillin or who have had 
more than a single dose of Penicillin In previous month: 
Clindamycin , IV,
Adults
300 mg over at least 10 minutes at induction or 15 minutes 
before procedure, then 
Clindamycin , oral or IV, 150 mg 6 hours later
Children
6 mg/kg stat. 3 mg/kg 6 hours later

26Chapter
651Management of Acute Pain
257� Management of Acute Pain
Pain is an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage. Many factors influence the feeling 
and emotion of pain and these factors vary from person to person. Pain is 
what the patient says it is.
Acute pain (as opposed to chronic pain) is defined as lasting for less 
than three months and is due to noxious stimuli from identifiable causes 
such as trauma, surgery, or acute illness.
Management of acute pain must be individualized to each patient 
and should include analgesia as well as treatment of the underlying 
condition. Special attention must be given, and precautions taken in 
providing pain relief in children, the elderly, pregnant women, as well as 
those with concurrent hepatic or renal disease, and those who are opiate 
tolerant or have a history of substance abuse. 
Causes 
 y Traumatic musculoskeletal injury
 y Surgery
 y Burns
 y Labour and delivery
 y Headache
 y Sickle-cell crisis
 y Myocardial infarction
 y Acute abdomen  e.g. acute pancreatitis
 y Joint inflammation
 y Others
Symptoms
 y Depend on the underlying cause
Signs
 y Depend on the underlying cause
Investigations
 y Depend on the underlying cause

— Management of Acute Pain —
Standard  Treatment Guidelines, 7th Edition, 2017
652Treatment 
Treatment objectives
 y Resuscitate the patient if necessary
 y Relieve pain
 y Treat any underlying disorder
Non-pharmacological treatment
 y Place affected part in most comfortable position where appropriate
 y Elevation of affected part where indicated
 y Splinting when indicated
 y Cold or warm compresses where indicated
 y Reassurance
Pharmacological treatment 
 y Paracetamol
 y Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
 y Opioids
 y Nerve blocks with local anaesthetics
 y Multimodal treatment
A.     Paracetamol  (Acetaminophen )
Adult s
Oral :
0.5-1 g 6 hourly (max. 4 g/24 hours)
For adults body weight < 60 kg, dose is 15 mg/kg 6 hourly (max. 60 
mg/kg/24 hours)
Rectal:
1 g 6 hourly (max. 4 g/24 hours)
For adults body weight < 60kg, dose is 15 mg/kg 6 hourly (max. 60 
mg/kg/24 hours) 
IV (Intravenous):
Should be given slowly over 15 minutes
1 g 6 hourly (max. 4 g/24 hours)
For adults body weight < 60 kg, dose is 15 mg/kg 6 hourly (max. 60 
mg/kg/day)
Paediatric doses
Oral:
Children :  15 mg/kg 6 hourly (max. 60 mg/kg/24 hours)
Neonate s:  10-15 mg/kg 8-12 hourly (max. 30 mg/kg/24  
hours)
Rectal:
Same as oral dose above but a loading dose is given (First dose  
only) 
Loading dose for children and Full term neonates is 30 mg/kg.
IV (Intravenous):
Should be given slowly over 15 minutes
Children  body weight > 10 kg weight:
15 mg/kg 6 hourly (max. 60 mg/kg/24 hours)

— Management of Acute Pain —Chapter 26:  Management of Acute Pain
653Children  body weight < 10 kg and above the age of 2 months:
7.5 mg/kg 6 hourly (max. 30 mg/kg/24 hours)
B.     Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Note 26-1
NSAIDs  should be used with caution. Before starting any patient on NSAIDs, 
one must make sure the patient is not likely be affected by the adverse effects 
of the NSAIDS.
Some of the adverse effects of NSAIDS are:-
 yExcacerbates peptic ulcer disease
 yCauses platelet dysfunction
 yAffects renal function – decreases renal blood flow
 yTriggers bronchospasm in some asthmatic patients
 yCauses fluid retention
Thus NSAIDS should not be given to several groups of patients, including the 
following:-
 yPatients with peptic ulcer disease 
 yPatients with coagulation or bleeding problems
 yPatients who are at risk of postoperative bleeding eg tonsillectomies
 yPatients with impaired renal function or patients who are at risk of going into 
renal failure (eg septic patients)
 yPatients with heart failure.
 yPregnant women, particularly in the third trimester, as it causes early closure 
of the patent ductus arteriolosis
 yShould be used with increased caution in elderly patients.
There have been concerns about the cardiovascular safety of the COX-2 selec -
tive inhibitor group of NSAIDS. The recommendations are that this group of 
drugs should not be given to patients with ischaemic heart disease or cerebro -
vascular disease.
Adult
 y Diclofenac , oral, 25-50 mg 8 hourly or 75 mg 12 hourly
Or
Rectal, 50 mg 12 hourly or 100 mg 18 hourly
Or
IM, 25-50 mg 8 hourly or 75 mg 12 hourly (max. 150 mg/day)
 y Ibuprofen , oral,
Adult
400 mg 6-8 hourly
Children
20-30 mg/kg daily in 3 divided doses (max. 1.2 g per day)
C�     Opioids
These are used for severe pain.
 y Tramadol
Adult s 

— Management of Acute Pain —
Standard  Treatment Guidelines, 7th Edition, 2017
654Oral, 50-100 mg 4-6 hourly (max. 400 mg daily)
 y Pethidine , IM,
Adult s 
25-50 mg (approx. 1 mg/kg) 4 hourly.  Lower dose in the elderly
Children  
1 mg/kg (max. 50 mg) 4 hourly
 y Pethidine , IV,
Adult s 
25 mg repeated if necessary with caution
 y Morphine , IV,
Adult  
1-2 mg boluses repeated if necessary with caution
 y Morphine , IM,
Adult s
5-10 mg 4 hourly
Children
0.1 mg/kg (max. 5 mg) 4 hourly 
D.     Nerve blocks with local anaesthetic agents
 y Lidocaine  
 y Bupivacaine  
E.      Multimodal Treatment
Note 26-2
Different groups of drugs can be used together to treat pain. This increases the 
effectiveness of pain relief as there is a limit to the dosage of each drug that can 
be given. This limits its effectiveness when used alone.
 y Paracetamol  And Opioid
Or
 y Paracetamol  And NSAID
Or
 y Paracetamol  And NSAID And Opioid
Referral Criteria 
If underlying condition does not improve or pain relief is not achieved 
with recommended doses.

27Chapter
655Common Malignancies
258� Breast Cancer  
Breast cancer  is the commonest cancer affecting women. Early 
detection of this cancer is possible through monthly breast self-
examination and is recommended for women of child-bearing age. 
Periodic screening through clinical breast examination is required for 
women below 40 years (1 in every 3 years) and yearly for women above 
40 years. Mammography is recommended every 2 years for women 40 
years and above.
Five treatment modalities are available, but each patient’s treatment 
is personalized and depends on the biological characteristics of the 
tumour, stage of disease and other patient factors. Two percent of breast 
cancers  in Ghana occur in males.
Box 27-1:   Risk factors
 yFemale sex
 yAge 
 yGenetic disposition (Family history of breast cancer)
 yPrevious personal history of breast cancer
 yProlonged exposure to oestrogen
 yEarly menarche
 yLate menopause
 yNulliparity
 yOestrogen therapy (contraceptives, HRT )
 yHigh fat intake, Alcohol and tobacco
Causes 
 y Unknown
Symptoms
 y Lump in the breast
 y Change in size or shape of breast
 y Swelling in axilla
 y Swelling of upper limb
 y Peau d’orange
 y Skin nodules
 y Ulceration

— Breast Cancer  —
Standard  Treatment Guidelines, 7th Edition, 2017
656 y Nipple discharge
 y Nipple retraction
 y Eczema /ulceration of nipple or areola
Signs
 y Breast lump
 y Peau d’orange 
 y Skin tethering, nodules or ulceration
 y Nipple retraction
 y Bloody nipple discharge
 y Palpable axillary nodes
Box 27-2:   Symptoms and signs of metastatic disease
 yBone pain
 yPathological fractures
 yBack pain
 yParaplegia
 yCough  – from Lung metastases
 yBreathlessness from pleural effusion
 yHeadache , vomiting  altered consciousness, localizing signs – from Brain 
metastasis
Investigations
 y Mammography 
 y Ultrasonography of the breast
 y Fine needle aspiration for cytology 
 y Core biopsy
Treatment 
Treatment objectives
 y Achieve a cure
 y Prevent local and distant metastasis
 y Prolong survival in metastatic disease
 y Relieve pain and suffering
Non-pharmacological treatment
 y Psychological support and counselling 
 y Palliative care
 y Surgery 
 y Radiotherapy
Pharmacological treatment 
 y Chemotherapy
 y Hormonal therapy
 y Immunotherapy
Referral Criteria 
All cases of suspected breast cancer must be referred for specialist 
attention.

28Chapter
657General Management Of 
Poisoning
259� General Management of Poisoning 
Poisoning represents the harmful effects of toxic amounts of any 
substance on the body. In many cases, only mild symptoms and signs will 
develop. However, suspected poisoning should always be considered a 
medical emergency since the situation may rapidly evolve to become 
critical. 
Many deaths due to poisoning can be prevented with early initiation 
of good supportive care and general treatment measures. Symptoms and 
signs of poisoning depend on the specific exposure, and may be local, 
systemic, or both. Effects may occur immediately, or several hours or days 
later. 
The severity depends on many factors, including the type  of 
substance, the route  of exposure (ingestion, inhalation, injection, dermal 
application, etc.), the dose  and duration  of exposure, and patient or 
environmental factors . 
Obtaining the original container or a sample of the substance is often 
most helpful, along with a thorough history and physical examination and 
laboratory analysis to look for characteristic features of poisoning with 
specific agents. 
Judicious use of antidotes for poisoning with specific substances may 
be added to general treatment measures based on these findings. 
A Poison Control Centre exists in Ghana to support health 
professionals in developing rational and timely strategies for diagnosis 
and treatment of poisoning. 
Causes 
 y Household chemicals 
 y Pesticides 
 y Medications 
 y Toxic plants 
 y Venomous bites and stings 
 y Toxic alcohols  
 y Industrial chemicals 

— General Management of Poisoning  —
Standard  Treatment Guidelines, 7th Edition, 2017
658Symptoms
 y Nausea , vomiting
 y Diarrhoea
 y Abdominal pain
 y Difficulty in breathing
 y Palpitations
 y Skin rash
 y Headache
 y Confusion
 y Lethargy , weakness
Signs
 y Abnormal vital signs (pulse, temperature, respiratory rate)
 y Small pupils (miosis) 
 y Large pupils (mydriasis)
 y Excessive sweating 
 y Hypersalivation
 y Frequent urination 
 y Diarrhoea
 y Wheezing
 y Flushed dry skin 
 y Dehydration
 y Shock
 y Low urine output (oliguria, anuria) or retention
 y Abdominal tenderness
 y Jaundice
 y Altered mentation
 y Tremors
 y Seizure
 y Coma
Investigations
 y Blood glucose (random)
 y FBC
 y BUE and Creatinine
 y Urinalysis
 y ECG
 y Liver function tests
 y Clotting time 
 y Coagulation profile  
Note 28-1
Investigations should be individualised to the exposure. The Poisons Control 
Centre and/or clinical pharmacologist may advise in specific cases.

— General Management of Poisoning  —Chapter 28:  General Management Of Poisoning
659Treatment 
Treatment objectives
 y Provide resuscitation 
 y Provide good supportive care  
 y Prevent or limit absorption 
 y Enhance elimination 
 y Prevent or manage organ damage
 y Prevent recurrence
Non-pharmacological treatment
 y Airway protection
 y Decontamination 
 y Detain patient for close monitoring 
 y Resuscitation when necessary  
 y Gastric lavage if indicated
 y Education and counselling   
Pharmacological treatment 
A.     Gastrointestinal decontamination, acute poison ingestion or oral 
overdose 
1st Line Treatment
Evidence Rating: [C]
 y Activated charcoal powder , oral, 
Adult s and Children
50 g initially (1 g/kg, max. 100 g) given as 50 g/500 ml slurry in water
Then
20-50 g every 2-6 hours as required 
Note 28-2
Precautions: 
routine use not recommended, most effective within 2-4 hours of ingestion; 
Contraindications:
 yAny aspiration risk (e.g. kerosene, coma ) 
 yPatients at risk of gastrointestinal haemorrhage, perforation or obstruction 
(e.g. ingestion of caustics)
(See table below on antidotes for specific poisons)
Table 28-1:   Presentation of common Poisons and their Antidotes
Class Toxic syndrome Antidote(s) Evidence 
Rating
Opioids Small pupils, lethargy/coma , 
reduced bowel sounds, 
respiratory depressionNaloxone  for 
respiratory 
depressionA
Benzodiazepines Lethargy /coma , respiratory 
depressionFlumazenil  for 
respiratory 
depressionC

— General Management of Poisoning  —
Standard  Treatment Guidelines, 7th Edition, 2017
660Class Toxic syndrome Antidote(s) Evidence 
Rating
Organo -
phosphate/
Carbamate  
Pesticides
(Cholinergic 
agents)Excessive salivation, tears, 
nausea, vomiting , diarrhoea, 
urination, bradycardia, 
wheezing, agitation or coma , 
seizure, hypotension, muscle 
weakness +/- fasciculationAtropine  for 
bradycardia, 
excessive salivation, 
or wheezing
Diazepam  for 
agitation, seizureA
A
Organochlorine / 
Chlorinated 
Hydrocarbon  
Pesticides
(e.g. DDT , 
lindane , 
heptachlor , 
endosulfan , etc)Usually abrupt onset: 
nausea, vomiting , diarrhoea, 
dizziness, headache, 
paresthesia, agitation, 
hallucination, seizure, coma , 
tremor, cough, hypotension, 
cardiac dysrhythmia, rash, 
renal +/- hepatic failure Diazepam  for 
agitation, seizure
Cholestyramine
N-acetylcysteine  if 
hepatomegaly
Avoid startling 
the patient or 
giving adrenaline, 
salbutamol, 
other stimulant 
medicationsA
C
C
Pyrethrin  and 
Pyrethroid  
InsecticidesBurning or tingling in the 
mouth, paresthesias, 
tremors, seizure, coma , 
gastrointestinal upset, 
tachycardia, hypotension, 
diaphoresis, excess 
salivation, hyper-reflexiaDiazepam  for 
agitation, seizure
Symptomatic careA
Warfarin -based 
Anticoagulants 
(e.g. many rat 
poisons)Bruising, bleeding from 
gums, any other bleeding, 
headache, flanks or 
abdominal pain, pallor, 
shock, blue-green vomitus Phytomenadione  if 
elevated INR
Fresh Frozen Plasma  
+/- whole blood 
transfusion if severe 
bleedingB
Bleach, soaps, 
detergents, and 
corrosives (acids 
& alkalis)Nausea , vomiting , oral 
ulcers, mouth/throat/
abdominal pain, gastroin -
testinal bleeding, shock, 
breathlessness, tachycardiaKeep NPO until pain 
relieved
Proton pump 
inhibitor 
+/- H2-blocker (e.g. 
Ranitidine)
Anti-emetic for 
nausea, vomiting
Avoid: forced emesis, 
activated charcoal , 
gastric lavageC

— General Management of Poisoning  —Chapter 28:  General Management Of Poisoning
661Class Toxic syndrome Antidote(s) Evidence 
Rating
Paracetamol Nausea , vomiting , 
abdominal pain +/- 
tenderness, hepatic failure, 
coagulopathy, shock
May be asymptomaticN-acetylcysteine  
Anti-emetics
Proton pump 
inhibitorsB
B
Iron Nausea , vomiting , 
diarrhoea, abdominal pain 
+/- tenderness, bloody 
emesis or stools, shock, 
hepatic failureDesferrioxamine
Anti-emetics
Proton pump 
inhibitorsA
Paraquat  
(herbicide)Mouth and/or throat pain 
+/- ulcers, breathlessness, 
hypoxia, wheezing, 
abdominal pain, renal 
failure, hepatic failureNo antidotes; give 
symptomatic and 
supportive care
Dialysis may be 
indicated
Avoid: supplemental 
oxygen unless 
patient is hypoxic or 
in moderate/severe 
respiratory distress
Toxic alcohols  
(methanol , 
ethylene glycol )Lethargy , coma , shock, 
impaired vision (methanol ), 
renal failure (ethylene 
glycol )Ethanol  or 
Fomepizole
Dialysis may be 
indicatedB
Cyanide Headache , confusion, 
nausea, vomiting , breath -
lessness, seizure, coma , 
shockHydroxocobalamin  or 
Sodium ThiosulfateB
Referral Criteria 
Refer patients for specialist management if they do not improve with 
general supportive care or if they require specific antidotes.  

29Chapter
662Medicines Use In The Elderly
260� Medicines Use in the Elderly 
Prescribing for older patients presents unique challenges. Many 
medications need to be used with special caution because of age-related 
changes in the absorption, distribution, metabolism, and excretion of the 
drug as well as the physiologic effects of the drug. In particular, physiologic 
changes in body composition, renal and hepatic functions play vital roles 
in determining changes in drug levels and the risk of adverse drug events 
in the elderly. 
There is also the issue of multi-morbidity in the elderly, which 
leads to the prescribing of multiple medications. The more medications 
prescribed for an elderly person, the higher the risk of adverse effects and 
other drug interactions.
The ‘Beers criteria’ (The American Geriatrics Society 2012 Beers 
Criteria Update Expert Panel) gives a list of medications considered 
inappropriate for older patients; either because of ineffectiveness or high 
risk for adverse events.
Causes of Adverse Drug Events 
 y Polypharmacy 
 y Use of inappropriate medications 
 y Underutilization of appropriate medication  
 y Transitions in care settings 
Management 
Treatment objectives
 y Prevent Adverse Drug Events (ADE) 
Preventive measures
 y Education on drug use for the elderly and their families or caregivers
 y Proper drug history taking by the healthcare provider
 y Quality measures of drug prescribing
 y Avoidance of inappropriate medications
 y Appropriate use of indicated medications
 y Monitoring for side effects and drug levels

— Medicines Use in the Elderly  —Chapter 29:  Medicines Use In The Elderly
663 y Avoidance of drug-drug and drug-food interactions
 y Involvement of the patient/family and integration of patient 
values
 y Maintenance of an accurate list of all medications that a patient is 
currently using 
 y Periodic ‘polythene bag check-ups’; i.e. instruct patients to bring all 
pill bottles and containers on each medical visit (including empty 
packets and containers); these should be checked against the 
medication list
 y Patients should be made aware of potential drug confusions i.e. 
sound-alike names, look-alike pills, and combination medications
 y Inform patients of both generic and brand names, including spelling, 
as well as the reasons for taking their medications 
 y Medicine organisers prepared by the pharmacist, can also be helpful 
in ensuring that patients take their medications correctly
Box 29-1:   Medication Question Checklist
1. Is there a clear indication for this medication?
2. Is it working?
3. Are there side effects?
4. Is the patient taking the medication routinely?
5. Does the medication need lab monitoring?
6. Is it still needed?
Box 29-2:  Principles of Rational Drug Prescribing for Elderly Patients
1. Periodically update and review the medication list
2. Work with the community pharmacist
3. Educate the patient about the medication
4. Consider an adverse drug event (ADE) as a cause of any new patient symptom
5. Simplify the medication regimen
6. Start one medication at a time, at lowest possible dose

30Chapter
664Local Anaesthetic Agents  
261� Local Anaesthetic Agents
Local anaesthetic (LA) agents  are drugs that reversibly block nerve 
transmission.  They are used to provide anaesthesia to specific areas of 
the body and can also be used for analgesia.  
Local anaesthetics also affect transmission in motor nerves; hence, 
motor weakness may occur following a local anaesthetic, depending on 
the site of application.
Adrenaline  is added to local anaesthetics to delay absorption and 
thus prolong their action. The usual concentration of adrenaline added to 
a local anaesthetic is 1:200,000.
Local anaesthetics with adrenaline should never be used where the 
blood supply is by end arteries e.g. should not be used for digital nerve 
blocks. They are also contraindicated in intravenous regional anaesthesia 
(IVRA) .
Commonly used LAs in our sub-region are lignocaine and bupivacaine.    
A.     Lidocaine  (Lignocaine )
 y Advantage - rapid onset of action
 y Duration - about 1 hour
 y Maximum dose of plain lidocaine - 3 mg/kg (approx. 200 mg in adult)
 y Maximum dose of lidocaine with adrenaline - 7 mg/kg
 y Lidocaine  is not recommended for spinal anaesthesia
B�     Bupivacaine
 y Advantage - long acting 
 y Disadvantages - cardiotoxic, slow onset of action
 y Maximum dose is 2 mg/kg (for both plain and with adrenaline added)
Note 30-1
Bupivacaine  should be used with caution. Apart from general resuscitative mea -
sures, intralipid 20% is effective for the treatment of cardiotoxicity. 
C.     Ropivacaine
 y Advantage - long acting, less cardiotoxic  
 y Maximum dose is 3 mg/kg

— Local Anaesthetic Agents —Chapter 30:  Local Anaesthetic Agents 
665Uses of local anaesthetic agents
 y Topical 
 y Local infiltration
 y Nerve blocks
 y Intravenous regional anaesthesia
 y Spinal anaesthesia (subarachnoid block)
 y Epidural anaesthesia/analgesia
 y Nebulisation for anaesthetizing upper airway
 y Inravenous preparation of lignocaine used as an antiarrhythmic 
Prevention of local anaesthetic toxicity
 y Always aspirate before injecting, to prevent inadvertent intravascular 
injection
 y Do not inject large volumes at a time 
 y Caution when injecting into areas of high vascularity 
Symptoms and signs of local anaesthesia toxicity
 y Peri-oral tingling, tinnitus, light headedness
 y Visual disturbances, slurred speech
 y Altered consciousness, seizures, loss of consciousness, respiratory 
arrest
 y Hypotension, cardiac arrhythmias, cardiac arrest
Treatment of local anaesthetic toxicity
 y Stop injection of LA
 y Start ABC  (Airway, Breathing, Circulation) of resuscitation
 y Give 100% oxygen. If necessary intubate patient
 y Give Midazolam  (3-5 mg) or diazepam (5-10 mg) to treat seizures. If 
seizures persist, an anaesthetist can give thiopentone 1-2 mg/kg or 
more midazolam and paralyse, intubate and ventilate patient
 y Treat cardiovascular instability with IV fluids, inotropes, and when 
bupivacaine or ropivacaine has been used, give Intralipid 20% using 
regime below
 y If cardiac arrest occurs, start CPR and call for help
Use of 20% intralipid in treatment of local anaesthetic toxicity (follow -
ing bupivacaine or ropivacaine)
In addition to other resuscitative measures outlined above:
 y Give an intravenous bolus of Intralipid 20%, 1.5 ml/kg fast (approx. 
100 ml for a 70kg patient)
 y Start an infusion of 20% Intralipid at 0.25 ml/kg/min (approx. 400 ml 
over 20 mins for a 70 kg patient)
 y Repeat initial bolus twice at 5 minute intervals, if adequate circulation 
has not been restored
 y Maximum dose of 12 ml/kg of Intralipid 20% should not be exceeded

31Chapter
666Structured Approach to the 
Seriously Ill Child
262� Structured Approach to the Seriously Ill Child
A seriously ill child is one whose vitals are compromised. A 
structured approach in determining the cause and subsequent successful 
management of the child is necessary. Rapid assessment and urgent 
intervention are the major requirements in the approach. 
Triaging soon after their arrival in hospital for emergency signs 
like severe respiratory distress or coma  and priority signs like high 
temperature, restlessness or severe pain is important.  
Presentations of serious illness may be classified under the following 
problem areas; airway/breathing, cardiac, shock and neurological 
disability.
The structured approach includes: 
 y Primary assessment
 y Resuscitation
 y Secondary assessment
 y Emergency treatment
 y Definitive care
AIRWAY/BREATHING PROBLEMS
Causes 
 y Severe Pneumonia  
 y Bronchiolitis 
 y Upper airway obstruction or stridor
 y Others  
Signs And Symptoms
 y Depends on condition   
Approach
 y Primary assessment  
 y Can child speak? Indicates airway patency 
 y Can infant cry? Indicates airway patency
 y Adequacy of breathing assessed by recession, respiratory rate, 
grunting, inspiratory or expiratory noises, flaring of the alae nasi

— Structured Approach to the Seriously Ill Child —Chapter 31:  Structured Approach to the Seriously Ill Child
667 y Effectiveness of breathing is assessed by breath sounds, chest 
expansion and abdominal excursion
 y Final effects of inadequate respiration are determined from the 
heart rate, skin colour and mental status
 y Pulse oximetry desirable. A saturation of less than 90% while 
breathing air or less than 95% while breathing oxygen is very low
 y High flow oxygen should be given to all children with respiratory 
difficulty or hypoxia.  In a child with inadequate ventilation, bag valve 
mask oxygenation or intubation may be required
Investigations 
 y Chest X-ray
 y Arterial blood gas 
 y Peak flow (if asthma a possibility)
Management
If a chin lift or jaw thrust can secure airway then do so, otherwise 
consider intubation
RESPIRATORY; if bubbly noises heard, airway full of secretions, 
suction required
Harsh stridor  with barking cough and severe respiratory distress, 
more likely to be upper airway obstruction, nebulise with adrenaline (5ml 
of 1:1000 in oxygen)
If symptoms had a sudden onset and there is history of inhalation, 
consider laryngeal foreign body. Call an ENT surgeon immediately
Children with a history of asthma and respiratory distress require 
nebulized salbutamol 2.5 mg or 5 mg if 7 years plus and oxygen
CIRCULATION/CARDIOVASCULAR
When normal capillary refill time is more than 2 seconds, then there 
is no problem with cardiac output. Cardiac arrest predominantly occurs 
secondary to hypoxia or hypovolaemia. Primary myocardial disease is 
rare. 
Causes
 y Heart failure 
 y Arrhythmias  (heart rhythm abnormalities)
Approach
 y Primary assessment, with regard to circulation;  
 y Heart rate
 y Pulse volume 
 y Capillary refill 
 y Blood pressure  
 y Look for tachycardia, bradycardia, abnormal pulse volume, 
hypotension or hypertension, hepatomegaly, murmurs and 
peripheral oedema
 y Check the effects of circulatory inadequacy on other organs by

— Structured Approach to the Seriously Ill Child —
Standard  Treatment Guidelines, 7th Edition, 2017
668 y checking the respiratory rate 
 y skin appearance and temperature
 y mental status and urinary output
Investigations 
 y Urea electrolytes 
 y Chest X-ray 
 y ECG 
 y Full blood count 
 y Blood culture 
Management
 y Address airways and breathing before commencing external cardiac 
massage
 y If cardiac output is not responding to CPR, reconsider the adequacy 
of airway and breathing support
SHOCK (INADEQUATE CIRCULATION)
Causes
 y Severe gastroenteritis
 y Diarrhoea
 y Cardiac disease
Management
Resuscitation – every child in shock should have oxygen at a high flow 
rate. Venous or intraosseous access should be obtained and an infusion of 
normal saline at 20 ml/kg given
In drowsiness with sighing respirations check blood sugar and acid 
base balance.  Treat diabetic ketoacidosis with IV normal saline and insulin
In an unconscious child with pinpoint pupils consider opiate 
poisoning. Try naloxone.
Gastrointestinal: Usually presents with shock from fluid loss.  
Symptoms include vomiting , abdominal pain or bloody stools; signs may 
include abdominal tenderness or a mass. Consider surgical intervention
Give boluses of fluid to shocked children if first one not effective. 
Consider IV antibiotics in shocked children with no obvious fluid loss
NEUROLOGICAL DISABILITY 
Causes
 y Status epilepticus (continuous seizures without regaining 
consciousness)
 y Meningitis
 y Encephalitis 
 y Strokes in Sickle Cell Disease  
 y Cerebral malaria 

— Structured Approach to the Seriously Ill Child —Chapter 31:  Structured Approach to the Seriously Ill Child
669Signs
 y Altered conscious level 
 y Convulsions  
 y Altered pupil size and reactivity
 y Abnormal posture
 y Meningism
 y Papilloedema 
 y Hypertension
Investigation
 y Urea and electrolyte
 y Blood sugar 
 y Blood culture
Management
 y If low blood sugar, give 5 ml/kg of 10% dextrose by rapid infusion
 y Prolonged fits – give rectal diazepam. If convulsions persist begin 
status epilepticus protocol using phenobarbitone, phenytoin  and 
midazolam IV in that order.
 y If evidence of raised intracranial pressure. Give Mannitol . 
 y In a child with depressed conscious level and convulsions consider 
meningitis . Give cefotaxime/Aciclovir . 
SYSTEMIC CAUSES
Causes  
 y Poisoning (ingestion of kerosene, corrosives, pesticides, paracetamol ) 
 y Hypoglycaemia  (think of severe malaria)
 y Diabetic ketoacidosis    
 y Angio-oedema
Symptoms
 y Rash, urticarial rash 
 y Fever  
 y Abdominal pain 
 y Vomiting  
 y Excessive thirst or excessive drinking
Signs
 y Severe dehydration
 y Deep and rapid respiration
 y Smell of ketones in breath
 y Pin-point pupils, large pupils
 y Tachypnoea
 y Sighing respirations
 y Hypothermia 
 y Hyperthermia

— Structured Approach to the Seriously Ill Child —
Standard  Treatment Guidelines, 7th Edition, 2017
670Treatment 
Treatment objectives
 y Depends on the cause
Note 31-1
If diagnostic clues point to poisoning then emergency treatment and emergen -
cy treatment of specific poisons becomes paramount. If history and signs point 
to diabetic ketoacidosis, then normal saline is the initial fluid to start together 
with insulin. 
Non-pharmacological treatment
 y Reassure or console the child 
 y Team work
Pharmacological treatment 
A.     Oxygen  therapy 
1st Line Treatment
 y Seriously ill children may need supplemental oxygen. 
B�     Convulsing child  
Evidence Rating: [A]
 y Lorazepam  or diazepam, phenobarbitone, or phenytoin  or midazol -
am in that order
C.     Suspected meningitis    
Evidence Rating: [A]
 y Cefotaxime
D�     Suspected Croup   
Evidence Rating: [A]
 y Nebulised adrenaline  
And 
 y Dexamethasone
Or 
 y Prednisolone  
E.     Suspected Asthma
Evidence Rating: [A]
 y Salbutamol  
 y Ipratropium bromide
 y Hydrocortisone
 y Prednisolone
 y Aminophylline  
Referral Criteria 
Refer the seriously ill child to the appropriate specialist. 

 
FORMS
671Ghana National Drugs Programme 
Ministry of Health 
Feedback on Standard Treatment Guidelines (STG)
Personal Details
1� Full Name
2� Phone 1]
2]
3� Email 
Organisation Details
4. Organisation Name
Feedback 
5� Heading/STG 
Topic or Disease 
Condition
6� Comments or 
Feedback 
7� Priority High [       ]   Moderate [          ] Low [          ]
8� Date of submission Day [          ]   Month[          ]     Year[             ]
Notes
The completed form can be sent to:
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P . O. Box MB 582
Accra, Ghana
It can be also sent via email to: gndp@ghndp�org
This form can also be filled online or uploaded at: www �ghndp�org/stgeml/feedback 
Note: You may choose to submit feedback either online or via mail.
Standard Treatment Guidelines Feedback form v1

 
Standard Treatment Guidelines, 7th Edition, 2017
672Ghana National Drugs Programme 
Ministry of Health 
Feedback on Essential Medicines List (EML)
Personal Details
1� Full Name
2� Phone 1]
2]
3� Email 
Organisation Details
4. Organisation Name
Feedback 
5� Heading/Title/
Medicine
6� Comments or 
Feedback 
7� Priority High [       ]   Moderate [          ] Low [          ]
8� Date of submission Day [          ]   Month[          ]     Year[             ]
Notes
The completed form can be sent to:
The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P . O. Box MB 582
Accra, Ghana
It can be also sent via email to: gndp@ghndp�org
This form can also be filled online or uploaded at: www �ghndp�org/stgeml/feedback 
Note: You may choose to submit feedback either online or via mail.
Essential Medicines List Feedback form v1

 
FORMS
673REPORTING	FORM	FOR	ADVERSE	EVENTS	FOLLOWING	IMMUNISATION	(AEFI) 	
							MOH -Ghana	Health	Service/Food	&	Drugs	Authority 	
SMC/SMD/GEN - 10/1.0  
	
Vaccine	Safety/AEFI	Surveillance 	 Ministry	o f	Health	/	Ghana	 Health	Service/Food	and	Drugs	 Authority 	April	2017	    *Mandatory fields   
Reporting :  Sub- District:                                                                   District :                                                                      Region  
AEFI Reporting ID Number                                Vaccination Card /Booklet              Yes         No 
 Region C ode           District Code         Year           Serial Number   
 					      				   
If no, state other source of information : 
A. PATIENT DETAILS  
*Name :  
Sex:  M    F   
Mother’s Name (if child):  
Contact Phone No:  
Vaccination centre:  
Community:  *Date of birth (DD/MM/YYYY) : _ _/_ _/_ _ _ _  
OR Age at onset: Years     Months   Days  
OR  Age Group:  <  1 Year      1 to 5 Years         > 5 
Year s 
*Address (landmarks and other contact information):  
*B. DESCRIPTION OF AEFI  
 Severe local reaction       >3 days   beyond nearest joint  
 Seizures                          febrile      afebrile  
 Abscess  
 Sepsis                                            
 Encephalopathy    
 Toxic shock syndrome                     
 Thrombocytopenia  
 Anaphylaxis   
 Fever≥38°C                        
  Other (specify)................................   
Date  AEFI started (DD/MM/YYYY) :  __ __  / __ __  / __ __ __ __      
 
Time AEFI started                                 Hr Min 
Signs and symptoms - please give a summary of the case, including any 
prior disease(s)/condition and patient’s medicines before vaccination)  
 
 
 
 
Indicate treatment given for the AEFI:  
*C. OUTCOME OF AEFI  
*Serious¶:  Yes  No;  è  If Yes   Death   Life threatening   Disability    Hospitalization   Congenital anomaly  
 
 Other important medical event (Specify________________________________________________ )  
 
*Outcome:      Recovering      Recovered     Recovered with sequelae     Not Recovered   Unknown  
 
 Died  If died, date of death  (DD/MM/YYYY) :   __ __  / __ __  / __ __ __ __  Autopsy done: Yes  No Unknown   
D. DETAILS OF ALL VACCINE (S) ADMINISTERED  
VACCINE(S)  DILUENT (if applicable)  
*Name  *Date and time of 
Vaccination  *Route (if  
injection 
indicate 
L/R site)  *Lot  / 
Batch 
No. Manufacturer  Expiry 
Date  Manufacturer  *Lot / 
Batch 
No.  Expiry 
Date  Date and time 
of 
reconstitution  
Date  Time  Date  Time  
            
            
            
            
E. REPORTER DETAILS  
 
*Name:                                                                   Profession/Designation:                                                                 Tel No.:  
 
Name of Institution:                                                                 Today’s Date: _ _  /_ _  /_ _ _ _                         Signature:  
 
For District Level Office  
 
Date Report Received:     _ _  /_ _  /_ _ _ _   
Checked by:   
Designation:  
 
Investigation needed :  Yes    No  
If yes, date started:  _ _  /_ _  /_ _ _ _  
 
For National/Central Level Office   
Date Report Received:  ___   /___  /______  Checked by:  Designation:  
 
Comments (include results of Causality Assessment): 
 
¶All serious AEFIs & AEFI clusters (two or more cases of the same adverse event related in time, place or vaccine administered ) should be investigated.  


 
Standard Treatment Guidelines, 7th Edition, 2017
674


675Index 
A
ABA  243
Abatacept  557
ABC  98, 665
Abdominal Trauma  588
Abdominal tuberculosis  46
Abnormal Vaginal Bleeding  371
Abnormal Vaginal Discharge  373
ABO  102
Abortion  359, 362, 363, 364, 366, 367, 368
Acetaminophen  652
Acetylcysteine  186, 404
Aciclovir  258, 259, 260, 263, 404, 669
Acne Vulgaris  276
Acquired Immune Deficiency Syndrome  461
ACT  482, 489, 491, 493
Actinomycin D  111
Activated Charcoal Powder  57, 659, 660
Acupuncture  562
Acute Abdomen  585, 651
Acute Allergic Reaction (Anaphylaxis)  644
Acute Bacterial Sialoadenitis  539
Acute Bronchitis  180
Acute Chest Syndrome (ACS)  69, 73, 113, 334, 
337
Acute Coronary Syndrome  113, 117
Acute Cystitis  406
Acute Epiglottitis  519
Acute Glomerulonephritis  388, 393
Acute heart failure  136, 137, 138, 388
Acute Hepatitis  37
Acute Kidney Injury  392, 406
Acute Lower Abdominal Pain  379
Acute lymphoid leukaemia (ALL)  75
Acute myeloid leukaemia (AML)  75
Acute Necrotizing Ulcerative Gingivitis  536
Acute-on-chronic osteomyelitis  597, 601
acute-on-chronic septic arthritis  597, 601
Acute orthopaedic infections  597
Acute osteomyelitis  597, 601, 604, 611, 620Acute Otitis Media  529
Acute Rheumatic Fever  161, 163, 164
Acute septic arthritis  597, 601
Acute Sinusitis  526
Acute Symptomatic Control  238
Adalimumab  557, 560
Adapalene  278
Addison’s disease  307
ADHD  207
Adjuvant chemotherapy  387
Adrenaline  517, 533, 645, 664
Adrenal Insufficiency  307, 311
Adult respiratory distress syndrome (ARDS)  
171
Aedes aegypti  92
AIDS  461, 495
AKI  392, 404, 405, 406
Albendazole  500, 501, 502
Alcoholic Delirium Tremens  231
Alcoholic Hallucinosis  229
Alcoholic Seizures  229
Alcohol Withdrawal Syndromes  229
Aldosterone antagonists  150
Alendronate  623, 624
Alfuzosin  410
Alginate-containing antacids  26
Allergic rhinitis  175, 279, 526
Allopurinol  75, 77, 79, 574
Alpha-blockers  150
Alprazolam  238
Amblyopia  511, 512, 513
Amenorrhoea  382
Aminophylline  178, 646, 670
Amiodarone  55, 303
Amitriptyline  216, 219, 235, 260, 563, 565, 
566
Amlodipine  149, 150, 154
Amoebiasis  11, 12
Amoebic dysentery  14
Amoebic Liver Access  33
Amoxicillin  24, 31, 60, 92, 172, 182, 186, 357, 

 
Standard  Treatment Guidelines, 7th Edition, 2017
676361, 363, 365, 525, 527, 530, 537, 538, 546, 
605, 649, 650
Ampicillin  99, 499, 648, 649, 650
Amyloidosis  390
ANA  389, 391, 555, 558, 568, 578
Anaemia  12, 62, 64, 106, 121, 317, 331, 364, 
398, 399, 400, 578
Anaemia In Pregnancy  331
Anaerobes  539, 647
Anakinra  557, 560, 576
Analgesia in Labour  336, 337
Anaphylaxis  82, 122, 273, 644, 646
Angiotensin Converting Enzyme Inhibitor  149
Angiotensin Receptor Blocker  149
Aniridia  110
Anorexia  12, 33, 37, 53, 55, 262, 388, 396, 586
Antenatal Care  89, 314, 324, 337, 338, 339
Antibiotic Prophylaxis in Surgery  45, 336, 338, 
538, 647
Anticoagulation  119, 126, 129, 133, 138, 160
Anti–cyclic citrullinated peptide (CCP) anti -
body  558
Anti-Double stranded DNA  578
Anti D Rh Immune Globulin  362
Anti Nuclear Antibodies (ANA)  558
Anxiety  23, 48, 49, 114, 115, 214, 215, 229, 
233, 234, 235, 236, 237, 238, 239, 241, 267, 
384, 550, 551, 560, 564, 565, 620
Anxiety Disorders  233
Aortic dissection  113
Aphthous Ulcers  544
Apnoea  84, 98
Applied Behaviour Analysis (ABA)  243
Aqueous cream  270
Aqueous soap  270
Arrhythmias  156, 161, 667
Artemether  485, 487, 491, 493
Artemether + Lumefantrine  483, 493
Artemisinin Combination Therapy (ACT)  482, 
489, 491
Artesunate  484, 485, 487, 488, 489, 490, 491, 
493
Artesunate + Amodiaquine  483, 484
Arthralgia  39, 577, 580
Arthrodesis  553, 555, 616
Arthropathy  549, 577
Arthroplasties  553
Ascites  36, 39, 41, 42, 46, 47, 48, 54, 122, 135, 
390
Ascitic fluid accumulation  47
ASD  242, 243
Asphyxia  100
Aspiration pneumonia  133, 170, 568
Aspirin  48, 66, 73, 116, 119, 120, 121, 131, 133, 163, 175, 272, 470
Asteatotic eczema  279
Asterixis  37, 43, 55, 397
Asthma  25, 121, 149, 175, 176, 177, 178, 179, 
180, 187, 318, 670
Ataxia  166, 232, 261
Atazanavir  463
Atenolol  116, 119, 120, 150, 153, 158, 159
Atherosclerosis  115, 118
Atomoxetine  208
Atopic Eczema  270, 279, 280
Atorvastatin  120, 131, 301, 302
Atrial Fibrillation  129, 133, 137, 139, 156, 157, 
158, 159, 160
Atrial flutter  156, 158, 159
Atropine  18, 19, 353, 515, 517, 660
Attention Deficit Hyperactivity Disorder 
(ADHD)  207
Autistic Spectrum Disorder  242
Avascular Necrosis  621
Azathioprine  55, 557, 570, 580, 581
Azithromycin  85, 92, 172, 173, 174, 183, 186, 
188, 248, 251, 264, 276, 376, 481, 507, 526, 
528, 531, 547
Azoospermia  382
B
Back pain  472, 560, 619, 656
Bacterial Endocarditis and Prophylaxis in Den -
tistry  538
Bacterial Skin Infections  245
Bacterial vaginosis  359, 375
Bacteriodes  541
Bacteroides  608
Barium meal  23
Barium swallow  26, 28
BCG  80, 82
Beclometasone  179
Beclomethasone  179
Behcet’s syndrome  544
Belimumab  580
Bendroflumethiazide  149, 153
Benign Prostatic Hyperplasia  408
Benign Prostatic Hyperplasia (BPH)  408, 409
Benzathine benzylpenicillin  163, 164
Benzathine Penicillin  251
Benzatropine  224
Benzhexol  224
Benzodiazepines  659
Benzodiazepine withdrawal  239, 240
Benzoic acid compound ointment  253, 255
Benzoyl peroxide  278
Benztropine  224, 225

INDEX677Benzyl benzoate  269
Benzylpenicillin  87, 497, 585
Benzyl Penicillin  92
Beta-blockers  149, 150
Beta-haemolytic streptococci  189
Betamethasone  281, 282, 286, 355, 357, 554, 
576, 614
Bethamethsone  356
Biliary tree disease  113
Bilirubin  35, 36, 56, 101, 102, 103, 104, 105
Bilirubin encephalopathy  35, 101, 103
Biperidine  225
Bipolar Disorder  226
Birth asphyxia  97
Birth Injuries  104
Bisacodyl  21
Bisoprolol  116, 120, 139, 150, 158, 159
Bisphosphonates  569, 620
Biventricular failure (BVF)  134
Blackouts  165
Bleeding  24, 36, 62, 65, 66, 67, 93, 318, 332, 
371, 397, 532, 537, 543, 593, 618
Bleeding Disorders  65
Bleeding peptic ulcer  24
Blood transfusion  32, 65, 72, 106, 333, 337, 
394, 587
Blue stone  614
Boils  245
Bone Marrow Failure  62
Bordetella pertussis  84
Bradyarrhythmias  156
Bradycardia  98
Breast Cancer  655
Bromocriptine  383
Bronchial Asthma  175
Bronchiectasis  187, 189
Bruxism  549
Budesonide  178, 179, 185, 516
Bullous pemphigoid  267
Bullous Reaction  273
Bupivacaine  654, 664
Buprenorphine  242
Burkitt’s lymphoma  77
Burns  393, 624, 630, 651
Bursitis  570
Buruli Ulcer  9, 249, 250
C
Cachexia  54, 472
Calamine lotion  84, 263, 270
Calcitonin  620
Calcium  25, 149, 150, 153, 197, 330, 395, 397, 
398, 405, 556, 568, 569, 580, 617, 619, 620Calcium Channel Blockers  25, 149, 150
Calcium gluconate  395, 398
Calcium pyrophosphate dihydrate (CPPD)  575
Calcium with Vitamin D supplements  569, 580
Campylobacter  11
Candesartan  120, 139, 150
Candida  252, 255, 283, 284, 535
Candida albicans  283, 535
Candidiasis  269, 374, 376, 535
Cannabis withdrawal  239, 240
Carbamate  660
carbamazepine  55
Carbamazepine  201, 202, 228, 229, 261, 551
Carbimazole  306
Carbocysteine  182, 187
Carboplatin  109, 111
Carcinoma of the Cervix  386
Cardiac Arrhythmias  121, 134
Cardiac failure  46
Cardiac neurosis  113
Cardiogenic shock  114, 120, 122, 138
Cardiomegaly  141
Cardiomyopathies  134, 157
Carvedilol  138, 150
Cataract  288, 510
Cefixime  376
Cefotaxime  46, 99, 498, 499, 520, 670
Ceftazidime  499
Ceftriaxone  45, 46, 110, 112, 174, 190, 338, 
376, 380, 402, 481, 496, 498, 499, 542, 588
Cefuroxime  14, 60, 172, 248, 402, 403, 407, 
408, 517, 519, 520, 522, 526, 528, 531, 589, 
594, 628, 649
Celecoxib  553, 556, 559, 562, 576, 579, 592, 
596, 622, 626
Cellulitis  249, 470, 604
Centrally acting agents  150
Cephalhaematoma  36, 102, 104, 105
Cerebrospinal meningitis  495
Certolizumab  557
Cervicitis  376
Cervico-Facial Abscess  540
Cetirizine  168, 263, 268, 270, 271, 273
Cetrimide  266, 276
Chemosis  505
chest pain  28, 69, 115, 116, 145, 170, 180, 317
Chest Pain  28, 113
chickenpox  259
Chicken pox  261, 262
Childhood Immunisable Diseases  80
Chlamydia trachomatis  106, 374
Chloral hydrate  212
Chloramphenicol  107, 497, 505, 508, 512
Chlordiazepoxide  232

 
Standard  Treatment Guidelines, 7th Edition, 2017
678Chlorhexidine  266, 276
Chlorhexidine solution  266, 276
Chlorinated Hydrocarbon  660
Chlorphenamine  273, 281
Chlorpheniramine  169, 263, 268, 271, 646
Chlorpromazine  88, 212, 222, 224, 227
Cholera  15
Cholestatic jaundice  36
Cholestyramine  37, 660
Chondrocalcinosis  575
Chronic Active Hepatitis  40
Chronic Asthma  178
Chronic Bronchitis  183
Chronic Hepatitis  38
Chronic kidney disease (CKD)  147, 148, 396, 
398, 399, 400
Chronic lymphoid leukaemia (CLL)  75
Chronic myeloid leukaemia (CML)  75
Chronic Osteomyelitis  601
Chronic Otitis Media  531
Chronic Periodontal Infections  543
chronic pyelonephritis  152
Chronic Septic Arthritis  601
Ciclopirox  253, 255, 613
Ciclopirox olamine  253, 255
Cinnarizine  51
Ciprofloxacin  14, 31, 45, 46, 174, 380, 402, 
407, 481, 498, 508, 532, 588, 600, 602, 603, 
604, 649
Cisplatin  405
Citalopram  219
Clarithromycin  24, 85, 250, 285
Clavulanic acid  357, 365
Clindamycin  174, 191, 278, 375, 491, 492, 
497, 537, 539, 540, 542, 543, 547, 594, 599, 
603, 606, 608, 609, 612, 627, 649, 650
Clobetasol propionate  614
Clomifene citrate  383
Clonazepam  565
Clonidine  242, 567
clopidogrel  66
Clopidogrel  116, 119
Closed Fractures  590
Clostridium perfringens  608
Clostridium tetani  86, 87
Clotrimazole  253, 255, 256, 269, 281, 284, 
376, 613
Cloxacillin  99, 110, 112, 190, 248, 517, 584, 
598, 599, 602, 603, 607, 612, 627, 629
Coagulase negative staphylococci  647
Coagulation factor  68
Co-amoxiclav  173, 174, 182, 186, 188, 190, 
191, 248, 264, 338, 403, 518, 520, 525, 527, 
530, 541, 543, 546, 584, 599, 603, 606, 607, 609, 650
Cocaine  203, 210, 214, 239, 240
Codeine  18, 19, 72, 182, 563, 592, 597, 600
Codeine containing cough preparations  182
Codeine phosphate  72
Cognitive Behaviour Therapy  215, 218, 220, 
235, 236, 237, 238, 242
Colchicine  146, 574, 576
Cold sores  257
Colonoscopy  20
Coma  43, 44, 84, 143, 328, 329, 388, 468, 486, 
496, 511, 583, 658, 659, 660, 661, 666
Combined conjugated oestrogens and pro -
gestogen,  385
Common Cold  167
Community acquired pneumonia  170
Compelling indications for the choice of anti -
hypertensives  149
Concentrated red cell transfusion  67
Congenital Heart Disease  140
Congestive cardiac failure (CCF)  134
Conjugated oestrogens  373, 385
Conjunctivitis  83, 505, 506, 507
Constipation  19, 86, 304, 480, 564
Contact Dermatitis  271, 279, 282
Conversion disorder  165
Convulsions  81, 97, 143, 196, 298, 328, 329, 
495, 595, 669
COPD  121, 122, 123, 183, 187
Copper sulphate stone  614
Corneal Ulcer  506
Coronary Heart Disease  121
Coronary vasospasm  113
Corona virus  167, 180
Corynebacterium diphtheriae  91
Cost-effectiveness  3
Costochondritis  113
Cough  33, 82, 114, 127, 134, 167, 175, 184, 
189, 470, 472, 515, 517, 524, 527, 656
CPPD  575
Crash  240
C-reactive protein  115, 118, 162, 171, 555, 
558, 571
Creatinine kinase-MB (CK-MB)  116, 118, 123, 
155
Crepitus  590, 593
Cretinism  303
Croup  517, 670
Cryoprecipitate  68
Cryptococcus neoformans  495
CSM  495, 498
Cushing’s Syndrome  147, 152, 217, 288, 310, 
311
Cyanide  661

INDEX679Cyanosis  43, 84, 86, 97, 122, 127, 141, 176, 
184, 516, 518, 520, 644
Cyclizine  51, 52
Cyclobenzaprine  566
Cyclophosphamide  109, 111, 580, 581
Cyclosporin  405, 557, 580
Cystitis  385, 401, 406, 407, 408
Cytomegalovirus  274
D
DaCosta’s syndrome  113
Dalteparin  126, 128, 629
Darbepoietin alfa  400
D-Dimer test  124, 128
DDT  660
Decompensated liver cirrhosis  40
Deep Vein Thrombosis (DVT)  123, 124, 125, 
126, 127, 128, 133, 160, 604
Dehydration  11, 12, 13, 15, 16, 17, 18, 20, 44, 
48, 49, 50, 69, 70, 74, 83, 84, 125, 143, 230, 
262, 293, 294, 307, 322, 323, 336, 337, 393, 
406, 468, 486, 487, 541, 572, 573, 586, 620, 
658, 669
Delirium Tremens (DT)  231
Delusions  210, 221
Denosumab  620
Dental Caries  534
Depression  48, 49, 183, 209, 215, 216, 217, 
218, 220, 226, 227, 267, 337, 384, 560, 564, 
565, 659
Dermatitis  267, 270, 279, 280, 283, 285, 462
Dermatitis herpetiformis  267
Desferrioxamine  661
Desmopressin  67, 68
Dexamethasone  52, 133, 310, 356, 357, 498, 
516, 670
Dextromethorphan  182
Dextrose  44, 71, 72, 98, 101, 178, 199, 204, 
232, 299, 308, 323, 355, 395, 398, 405, 489, 
490, 491, 516
Dextrose saline  44, 232, 491, 516
Diabetes Mellitus  147, 149, 267, 287, 318, 
338, 339, 354, 390, 396
Diabetes Mellitus in Pregnancy  338
Diabetic Ketoacidosis  121, 203, 205, 293, 669
Diarrhoea  11, 12, 18, 19, 49, 83, 93, 307, 393, 
394, 529, 658, 668
Diazepam  25, 88, 198, 199, 205, 212, 213, 
220, 225, 228, 232, 233, 236, 238, 330, 353, 
549, 551, 562, 660
Diclofenac  71, 72, 195, 242, 260, 337, 381, 
553, 554, 556, 559, 562, 565, 571, 572, 574, 
576, 579, 591, 596, 600, 623, 626, 653Digital rectal examination  20
Digoxin  137, 139, 159, 160
Dihydroartemisinin-Piperaquine  483
Diloxanide furoate  34
Diphenoxylate  18
Diphtheria  81, 90, 91
Diphtheria antitoxin  91
Diplopia  512, 513
Discoid eczema  279
Dislocations  595, 622
disopyramide  20
Disorders Of The Musculoskeletal System  552
Disorders Of The Respiratory System  167
Disorders of the Skin  245
Disseminated intravascular coagulation (DIC)  
66, 68, 364
Dizziness  63, 148, 157, 164, 298, 332, 384, 
586
Dizziness and Blackouts  164
DKA  205, 293
DMARDs  580
Dobutamine  138
Domperidone  27, 50, 51
Doxorubicin  111
Doxycycline  15, 172, 278, 376, 380, 546
D-penicillamine  557
DPT  81
Drug-induced liver injury (DILI)  55
Drug resistant tuberculosis (DR-TB)  476
Drugs and the Liver  55
Drug susceptibility testing (DST)  474
dsDNA  578
Duloxetine  566
Duodenal ulcers  22
DVT Prophylaxis  125
DVT Treatment  125
Dysarthria  130
Dyslipidaemia  147, 300
Dysmenorrhea  358
Dyspepsia  23, 25, 577, 586
Dysphagia  27, 91, 130, 519
Dyspnoea  54, 114, 121, 127, 134, 152
E
E45 cream  280
Ear, Nose And Throat Disorders  515
Ecchymosis  66, 93
Eclampsia  196, 324, 325, 328, 331, 393
Econazole  613
Eczema  175, 245, 246, 258, 267, 270, 279, 
280, 281, 283, 284, 285, 656
Efavirenz  463, 464
Empyema  33, 94, 95

 
Standard  Treatment Guidelines, 7th Edition, 2017
680Emtricitabine  463, 466
Enalapril  153
Endobronchial TB  475
Endocrine and Metabolic Disorders  287
Endocrine and metabolic disorders with eye 
complications  514
Endometriosis  358, 382
Endosulfan  660
Enoxaparin  119, 125, 126, 128, 138, 628
Entamoeba histolytica  11, 33, 34
Entecavir  40
Enteric fever  479
Enterobacteriaceae  647
Enterococci  406
Ephedrine  528
Epidermidis  597, 611
Epidermophyton  252
Epilepsy  81, 165, 196, 200, 201, 202, 203, 205, 
213, 219, 242
Episcleritis  506
Epistaxis  532
Epoietin beta  400
Epstein-Barr  73
Erbs Palsy  105
Erectile dysfunction  288, 382
Ergometrine  362
Erysipelas  249, 470
Erythema multiforme  273
Erythrasma  283, 285
Erythromycin  15, 85, 163, 164, 172, 183, 186, 
246, 276, 278, 285, 357, 363, 376, 526, 528, 
531, 606
Escherichia coli  11, 406, 495, 597
Esomeprazole  23, 24, 27, 28, 29, 556, 569, 
579, 628
Esotropia  512
Estrogen therapy (ET)  620
Etanercept  557, 560
Ethambutol  474, 475
Ethanol  661
Ethinylestradiol + levonorgestrel  373
Ethinylestradiol + norethisterone  373
Ethosuximide  202
Ethylene glycol  661
Etoposide  109, 111
Eusol  266
Exchange transfusion  102
Exotropia  512
Expanded Programme on Immunisation (EPI)  
38, 61
Exposure Keratopathy  511
Extensive Caput Succedaneum  104, 105
Extra-pyramidal reactions  220
Eye Disorders  503F
F75  60
Febrile neutropenia  110, 112
Female Infertility  382
Ferric sodium gluconate complex  400
Ferritin  335, 399
Ferrous fumarate  64, 317
Ferrous gluconate  333, 400
Ferrous sulphate  64, 317, 333, 400
Fever  18, 33, 37, 43, 74, 76, 78, 83, 90, 93, 
94, 95, 110, 114, 122, 145, 162, 170, 171, 180, 
184, 188, 189, 194, 210, 231, 245, 257, 259, 
262, 274, 275, 356, 364, 379, 388, 401, 468, 
470, 471, 472, 479, 480, 483, 495, 496, 519, 
521, 523, 529, 537, 539, 541, 546, 558, 570, 
571, 573, 577, 586, 598, 604, 609, 611, 620, 
669
Fibromyalgia  561, 563, 567
Filariasis  390
Finasteride  410
Five In One  80, 81
Flaccid paralysis  90
Flucloxacillin  55, 191, 246, 248, 264, 523, 540, 
606, 607, 612, 626
Fluconazole  29, 110, 112, 376, 536, 613
Flumazenil  659
Fluoroquinolones  499
Fluoxetine  218, 235, 237, 566
Flupenthixol  224
Fluphenazine  224
Fluticasone  179, 185
Focal and segmental glomerulosclerosis 
(FSGS)  390
Focused Antenatal Care  314
Folate Deficiency  65
Folic Acid  62, 65, 72, 232, 317, 333
Folliculitis  246
Fomepizole  661
Foreign body in the eye  504
Fractures  105, 590, 592, 593, 619
Fresh Frozen Plasma  45, 67, 68, 94, 660
Fulminant liver failure  40
Fungal Skin Infections  251, 252
Furosemide  48, 136, 137, 138, 333, 389, 391, 
394, 398
Furuncle  245
Furunculosis  246
Fusidic acid  285
G
Gabapentin  567
Gangrene  288, 364, 514

INDEX681Gardnerella vaginalis  374
Gastric ulcers  22
Gastroenteritis  14, 48, 49, 668
Gastro-esophageal Reflux Disease  25, 28, 113
General Emergencies  644
Generalised Anxiety Disorders  234
Gentamicin  31, 87, 99, 110, 112, 190, 365, 
402, 403, 517, 532, 542, 587, 599, 629, 648, 
649, 650
Gestational diabetes  288, 338, 339
Glaucoma  506, 508, 509
Glibenclamide  291, 292
Gliclazide  292
Glimepiride  292
Glomerular filtration rate (eGFR)  396
Glomerular filtration rate (GFR)  399
Glucagon  299
Glucose-6-phosphate dehydrogenase (G6PD) 
deficiency  35, 36, 62, 102, 316, 320, 332, 393, 
480, 494
Glycerol  21
Glyceryl trinitrate  116, 119
Gnathopathy  70
Goitre  302, 304, 305, 306
Gold salts  557
Golimumab  557
Gonioscopy  509
Gonococcus  406
Gonorrhoea  376
Gottron’s papules  568
Gottron’s sign  568
Gout  149, 300, 311, 570, 572, 574, 575
Granisetron  52, 109, 111
Grave’s disease  305
Griseofulvin  252, 253, 254, 614
Guaifenesin  181
Gynaecological Disorders  358
H
Haemarthrosis  570
Haematemesis  54
Haematological Disorders  62
Haematuria  63, 110, 152, 388, 401, 406
Haemolysis  35, 62, 102, 393
Haemophilia A  67, 68
Haemophilia B  68
Haemophilus influenzae  94, 170, 180, 495, 
519, 523, 527, 529, 597
Haemophilus Influenzae type b Disease  94
Haemoptysis  127, 187, 189
Haemorrhagic Stroke  131
Haemorrhoids  29, 31, 62
Hallucinations  218, 221, 353Haloperidol  211, 223, 224, 227, 230, 585
Halothane  43, 55
Hand Infections  610
HBSC  69
HBSS  69
HBS βthalassaemia  69
Headache  90, 93, 155, 193, 239, 259, 262, 
364, 470, 471, 483, 651, 656, 658, 661
Head Injuries  582
Heartburn  25, 49
Heart Failure  121, 134, 135, 138, 142, 164
Helicobacter pylori  22, 24, 78
HELLP (Haemolysis Elevated Liver Enzymes 
Low Platelet) Syndrome  393
Hemianopia  130
Hemihypertrophy  110
Hemiparesis  143
Heparin  66, 125, 126, 129, 133
Hepatic Encephalopathy  42, 45, 46, 54
Hepatitis  35, 36, 37, 38, 39, 40, 41, 42, 43, 54, 
56, 73, 81, 96, 388, 390, 391, 461, 462, 464, 
471, 555, 568, 578
Hepatocellular Carcinoma  53, 54
Hepatomegaly  36, 37, 54, 69, 141
Heptachlor  660
Heroine  239
Herpes Simplex Infections  257
Herpes Simplex Virus  106, 257, 274, 374
Herpes Virus  73
Herpes Zoster  113, 259, 260, 261, 262
Herpetiform ulcers  544
Hiatus hernia  25, 28, 113
High potency Vitamin B  44
HLA-B27  562
Hodgkin’s Lymphoma  77, 79
Hole-in-Heart  140
Hookworm  499, 500
Hormone Replacement Therapy (HRT)  385, 
620, 655
Hospital acquired pneumonia  170
How to prepare ORS  16
HRZE  473, 474
Human Immune Deficiency Virus  11, 12, 39, 
41, 42, 58, 59, 73, 82, 170, 180, 187, 196, 210, 
252, 255, 259, 263, 274, 279, 280, 307, 316, 
318, 320, 321, 332, 333, 368, 380, 386, 388, 
390, 391, 461, 462, 464, 471, 472, 473, 474, 
475, 495, 535, 544, 555, 568, 578, 608, 609, 
615, 621
Human Immune Tetanus Globulin  366
Human Papilloma Virus [HPV]  386, 462, 548
Human Tetanus Immunoglobulin  88
Hydralazine  150, 154, 156, 331
Hydrochlorothiazide  149

 
Standard  Treatment Guidelines, 7th Edition, 2017
682Hydrocortisone  177, 178, 268, 270, 271, 275, 
281, 283, 284, 285, 308, 309, 310, 517, 518, 
529, 614, 645, 670
Hydrops fetalis  104
Hydroxycarbamide  73
Hydroxychloroquine  557, 569, 580, 581
Hydroxycobalamin  661
Hydroxymethyl cellulose  512
Hyoscine butylbromide  25
Hyperbilirubinaemia  35, 102, 338
Hypercalcaemia  19, 48, 73, 338
Hypercyanotic attack  141, 142, 143, 144, 145
Hyperemesis Gravidarum  322
Hypermetropia  513
Hyperpyrexia  486
Hypertension  110, 146, 152, 310, 318, 323, 
324, 325, 331, 354, 388, 389, 395, 397, 398, 
405, 532, 669
Hypertension in children and adolescents  152
Hypertension In Pregnancy  323
Hypertensive Emergencies  154
Hypertensive encephalopathy  152, 154, 196, 
389
Hyperthyroidism  11, 147, 233, 234, 302, 303, 
305, 619
Hypertonic Saline  584
Hypoalbuminaemia  39, 41, 42, 390
Hypoglycaemia  165, 203, 204, 210, 298, 338, 
669
Hypothyroidism  19, 63, 102, 147, 157, 217, 
300, 302, 303, 563
I
Ibuprofen  71, 146, 163, 195, 242, 260, 359, 
404, 469, 524, 535, 545, 550, 551, 553, 559, 
562, 572, 576, 592, 596, 600, 623, 626, 653
Idiopathic inflammatory myopathies (IIM)  568
Imipramine  209, 219, 235, 237
Immune globulin  580
Immunisation  38, 60, 80, 81, 84, 86, 88, 89, 
317, 318
Impetigo  246
Impotence  382
Indomethacin  559
Infarctive Strokes  131
Infliximab  557, 560
Influenza virus  180
INR  36, 39, 44, 45, 47, 54, 56, 57, 66, 126, 129, 
372, 660
Insomnia  214, 217, 229, 239, 397
Insulin Premix  291
Interferon  40, 42, 405
Intermittent Preventive Treatment in Pregnan -cy (IPTp)  492, 493, 494
Intertrigo  255, 283, 284
Intrauterine contraceptive device (IUCD)  371, 
373, 379
Intravenous immunoglobulin  570
intravenous regional anaesthesia (IVRA)  664
Invasive Pneumococcal Diseases (IPD)  95
Ipratropium bromide  177, 178, 185, 670
IPTp with sulfadoxine-pyrimethamine (IPTp-
SP)  493
Iron Deficiency Anaemia  25, 64
Iron dextran  64
Iron (III) hydroxide Polymaltose complex  317
Iron preparation  32
Iron sucrose  64, 400
Ischaemic Heart Disease  115, 134, 157
Isoniazid  43, 55, 474, 475, 476
Isosorbide Dinitrate  117, 121
Itraconazole  254, 257, 282, 284, 613
J
Jaundice  33, 35, 37, 39, 43, 49, 53, 54, 55, 63, 
69, 93, 98, 101, 102, 103, 105, 332, 335, 471, 
658
Juvenile Idiopathic Arthritis  557
K
KDIGO  392
Keratitis  506
Keratomalacia  503
Keratopathy  512
Kernicterus  35, 101, 102, 103
Ketamine  353, 354
Ketoconazole  55
Ketoconazole shampoo  282
Klebsiella  170, 189, 406
Klebsiella pneumoniae  170, 189
Klumpke’s Palsy  105
Koplik spots  83
Kwashiorkor  58, 59
L
Labetalol  150, 155, 156, 331
Lactulose  21, 44, 45
Lagophthalmos  511
Lamivudine  40, 463, 464, 466
Lamotrigine  228
Large Chronic Ulcers  265
Laryngotracheobronchitis (LTB)  515
Leflunomide  557
Legionella pneumophila  170

INDEX683Lethargy  39, 43, 55, 100, 397, 496, 581, 598, 
658, 659, 661
Leukaemia  75, 76, 570
Levothyroxine  305
Lichen planus  267
Lichen simplex chronicus  267
Lidocaine  654, 664
Lignocaine  664
Lindane  76, 660
Liquid paraffin  21, 31
Lisinopril  120, 138, 139, 150, 392, 404
Listeria  499
Lithium  228, 229, 406
Local anaesthetic (LA) Agents  664
loperamide  18
Lopinavir  463, 466
Lorazepam  52, 198, 211, 216, 220, 228, 232, 
238, 585, 670
Losartan  120, 139, 150, 154, 404
Lower urinary tract symptoms (LUTS)  408, 409
Ludwigs Angina  540
Lung Abscess  189
Lymphadenopathy  472, 546, 558, 577
M
Magnesium sulphate  330, 355
Magnesium trisilicate  23, 29
Major depression  216, 217
Malaria  205, 317, 331, 332, 388, 393, 470, 
482, 492, 493, 620, 621
Malaria In Pregnancy  331, 492
malassezia furfur  252, 255
Malathion  269, 271
Malignancies  655
Malignant Lymphoma  77
Malnutrition  58, 59
Management algorithm for Acute Parac -
etamol Poisioning  56
Management of Acute Pain  651
Management of the Hot Swollen Joint  570
Mania  216, 226, 227
Mannitol  131, 584, 669
Mantoux test  472, 561, 615
Marasmus  58, 59
Marijuana  210, 214, 221, 239
Masticatory muscle dysfunction  549
M. catarrhalis  527
MDR-TB  477
Measles  81, 82, 83, 503, 515
Mebendazole  320, 500, 501
Medicines and the Kidney  403
Medicines Use In The Elderly  662
Medroxyprogesterone acetate  373Mefenamic acid  359, 372, 373, 381
Mefipristone  368
Melatonin  216, 244
Membranous nephropathy  390
Membranous proliferative glomerulonephritis 
(MPGN)  390
Meniere’s disease  165
Meningitis  48, 94, 95, 96, 171, 193, 194, 196, 
203, 205, 210, 470, 472, 474, 475, 482, 487, 
495, 496, 499, 529, 668, 669, 670
Menopause  384
Meropenem  499
Metformin  291, 292
Methadone  242
Methanol  661
Methicillin resistant Staph. aureus  608
Methotrexate  405, 557, 560, 563, 570, 576, 
580, 581
Methoxy polyethylene glycol epoietin beta  
400
Methyldopa  150, 324
Methylphenidate  208, 244
Methylprednisolone  554, 576, 578
Metoclopramide  27, 50, 51, 53, 109, 111, 119, 
137, 323, 361, 366
Metolazone  391
Metoprolol  116, 120, 139, 150, 158, 160
Metronidazole  14, 24, 31, 32, 34, 45, 87, 174, 
191, 357, 361, 363, 365, 375, 380, 517, 518, 
519, 520, 522, 523, 542, 584, 587, 588, 589, 
594, 627, 628, 629, 648, 649
Miconazole  253, 255, 256, 270, 281, 284, 285, 
376, 536, 613, 614
Microsporum  252
Midazolam  198, 665
Migraine  193, 195, 564
Miliaria  267, 270
Milk of Magnesia  21
Minimal change disease (MCD)  390
Minocycline  557
Minor Withdrawal  229
Misoprostol  361, 363, 366, 367, 368, 369, 370
Mist Kaolin  18
Mitral valve prolapse  113
M. kansasii  472
M. malmoensi  472
M. microti  472
Mometasone  281, 282, 286
Monilia  283, 535
Montelukast  179
Moraxella catarrhalis  180
Morphine  19, 25, 55, 71, 119, 128, 136, 144, 
272, 337, 361, 366, 563, 587, 591, 596, 600, 
627, 654

 
Standard  Treatment Guidelines, 7th Edition, 2017
684Mouth Ulcers  544
MRSA (Methicillin resistant)  170
Multi Drug Resistant-TB (MDR-TB)  477
Multiple myeloma  73
Multivitamin  338
Mupirocin  246, 247
Myalgia  145, 564, 577, 580
Myasthenia gravis  513
Mycobacterium africanum  472, 615
Mycobacterium bovis  472, 615
Mycobacterium tuberculosis  472, 495, 601, 
615
Mycobacterium ulcerans  249
Mycophenolate  570, 580, 581
Mycophenolate mofetil  570, 581
Mycoplasma pnuemoniae  170, 274
N
N-Acetylcysteine  56, 57, 204, 660, 661
Naloxone  659
Naproxen  553, 559, 562, 572, 576, 592, 596, 
622, 626
Nausea  37, 55, 56, 93, 114, 118, 155, 165, 
229, 236, 240, 294, 307, 358, 393, 483, 577, 
658, 660, 661
Nebulised adrenaline  670
Necrotizing Fasciitis  608
Neisseria gonorrhoea  106, 374
Neisseria meningitides  495
Neomycin  529
Neonatal conjunctivitis  106, 503
Neonatal Hypoglycaemia  98, 100
Neonatal Jaundice  35, 101
Neonate  97, 100, 101, 102, 103, 106, 356, 503
Nephroblastoma  110
Nephrotic Syndrome  46, 300, 390
Nerve injuries  105
Nevirapine  55, 463, 464
Newborn  35, 82, 97, 100, 101, 264, 321, 338, 
354, 357
New York Heart Association (NYHA) Classifica -
tion  134
Niclosamide  502
Nifedipine  150, 153, 325, 355
Nitrofurantoin  407
Non-erosive GERD  26
Non-Hodgkin’s Lymphoma  77, 79
Non-Specific Skin Infections  264
Non-ST-segment elevation myocardial infarc -
tion (NSTEMI)  118
Norethisterone  372, 373
Norfloxacin  45
Normal Saline  72, 98, 144, 156, 199, 266, 275, 323, 361, 489, 490, 505, 646
Norovirus  11
NSAID-associated duodenal or gastric ulcer 
and gastro-duodenal erosions  23
NSAIDs  11, 22, 26, 242, 337, 396, 397, 404, 
559, 572, 574, 581, 653
Nutritional Disorders  58
NYHA  134
Nystagmus  49, 232
Nystatin  29, 536, 613
O
Obesity  25, 147, 152, 311, 604
Occlusal disharmony  549
Occupational therapy  555, 559, 562
Odontogenic Infections  545
Oesophageal candidiasis  28, 29
Oesophageal manometry  28
Oesophageal pain  27
Oesophageal spasm  113
Oesophagitis  25
Oestrogen cream  385
Ogilvie syndrome  20
Oilatum soap  281
Olanzapine  212, 222, 223, 227, 230
Oligospermia  382
Omeprazole  23, 24, 26, 27, 28, 29, 555, 569, 
579, 628
Onchocerciasis  267
Ondansetron  52, 109, 111, 112, 323
onychomycosis  254
Open Fractures  592
Opioid withdrawal  239, 240
Opisthotonus  86
Oral and Dental Conditions  534
Oral Candidiasis  255, 535
Oral Squamous Cell Carcinoma  548
Organochlorine  660
ORS  16, 17, 19
Osteoarthritis  552
Osteogenesis Imperfecta  623
Osteomalacia  616
Osteoporosis  619
Osteotomies  553, 622
Otitis media  49, 58, 82, 84, 94, 95, 167, 193, 
462, 482, 529, 532
Overweight  311, 312
Oxygen  86, 98, 119, 128, 136, 142, 144, 173, 
177, 183, 185, 197, 353, 516, 518, 645, 670
Oxygen Therapy  98
Oxymetazoline  533
Oxytocin  361, 363, 366, 367

INDEX685P
Packed red cells  65, 72, 75, 77, 79, 104, 333
Pain Originating from the Oesophagus  27
Pamidronate  623
Panic Disorders  236
Pap smear  386, 462
Paracetamol  38, 43, 44, 55, 56, 57, 70, 71, 83, 
133, 168, 173, 181, 195, 204, 246, 258, 263, 
275, 359, 408, 469, 471, 505, 522, 524, 528, 
530, 534, 538, 540, 544, 547, 556, 562, 565, 
580, 584, 587, 591, 596, 601, 624, 626, 652, 
654, 661, 669
Paracetamol toxicity  56
Paraplegia  74, 656
Paraquat  661
Parkinson’s disease  511
Paromomycin  34
Paroxysmal supraventricular tachycardia  159
PCV 2  81
PCV 3  81
Pediculosis  267, 271
Pegylated Interferon Alpha 2a  40, 42
Pegylated Interferon Alpha 2b  42
Pelvic Inflammatory disease (PID)  379, 380, 
382
Penicillin allergy  246, 248, 357, 497, 531, 537, 
540, 606
Penicillin V  163, 164
Penta-Vaccine  80, 81
Peptic Ulcer Disease  22, 62, 113, 114
Pericardial effusion  121, 171
Pericarditis  113, 114, 145, 397
Permethrin  268
Pernicious anaemia  63
Persons living with HIV infection (PLHIV)  461
Pertussis  81, 84
Pertussis vaccine  81
Petechiae  63, 66, 93
Pethidine  25, 361, 366, 587, 591, 596, 627, 
654
Phaeochromocytoma  152, 234
Pharyngitis  523
Phenobarbital  88, 201
Phenobarbitone  88, 99, 199, 233
Phenoxymethyl penicillin  163, 164
Phenytoin  55, 199, 201, 207, 669, 670
Phosphocitrate  576
Photophobia  495, 505, 509, 511
Phototherapy  103, 105
Physiotherapy  67, 74, 90, 105, 553, 555, 558, 
562, 571, 575, 612, 615, 622, 625
Phytomenadione  106, 660
PID  379, 380, 382Pimples  276, 277, 310
Pioglitazone  293
Pityriasis  255
Pityriasis Versicolor  255
Pityrosporum orbiculare  255
Pityrosporum ovale  255, 279
Plamodium malariae  483
Plasma Cell Myeloma  73
Plasma replacement  394
Plasmodium. See Malaria
Plasmodium falciparum  482
Plasmodium malariae  390
Plasmodium ovale  483
Platelet Concentrate  68
red cell concentrate  68
Platelet transfusion  68, 75, 77, 79
Pleural effusion  113, 127, 171, 390
Pneumococcal Conjugate Vaccine (PCV)  95
Pneumococcal Disease  95
Pneumococcal (PCV)  80
Pneumococcal Polysaccharide Vaccine 
(PPSV23)  95
Pneumococcus  499, 531
Pneumocystis jiroveci  170
Pneumonia  113, 114, 121, 169, 276, 470, 666
Pneumothorax  121, 171
Polio  80, 81
Poliomyelitis  89
Poliovirus  90
polyarthritis  554, 570, 573
Polycystic ovarian syndrome  277, 382
Polymerase chain reaction (PCR)  262
Polyvinyl alcohol  512
Post Exposure Prophylaxis  464
Post Herpetic Neuralgia  193, 259, 260
Potassium citrate  408
Povidone iodine  260, 266, 276
PPH  337, 370, 393
PPI  24, 29
Praziquantel  502
Prazosin  150
Prednisolone  146, 164, 178, 179, 186, 275, 
309, 475, 516, 555, 559, 563, 569, 572, 574, 
576, 579, 581, 645, 670
Pregabalin  261, 551, 563, 567
Pregnancy in the sickle cell disease  334
Premature Rupture of the Membranes  356
Prematurity  97, 100, 141
Preterm labour  319, 354
Preterm Labour in Premature Delivery  354
Priapism  69, 76
Primary Glomerular Disease  390
Primary infertility  382
Probenecid  576

 
Standard  Treatment Guidelines, 7th Edition, 2017
686Procaine Penicillin  542
Proctoscopy  20, 30
Proctosigmoidoscopy  20
Promethazine  53, 225, 263, 273, 323, 361, 
366, 646
Propantheline bromide  25
Propionibacterium acnes  277
Propranolol  142, 144, 153, 195, 236, 307
Proptosis  511
Propylthiouracil  306
Prostate specific antigen (PSA)  409
Prostatism  409
Protein energy malnutrition  58
Proteus mirabilis  406
Proteus vulgaris  531
Prothrombin time  44, 66, 372
Prurigo  267
Pruritus  30, 36, 55, 263, 267, 268, 288, 397
PSA  409
Pseudo-gout  575
Pseudomonas  170, 499, 531
Pseudo seizures  213
Psoriasis  283, 572
Psychiatric Disorders  207, 209
Psychoeducation  222, 227, 232
Psychogenic Seizures  213
Psychosis  220, 480
Psychostimulant withdrawal  240
Psychotherapy  194, 213, 218, 227, 232, 559
Puerperium  123, 314, 316, 336, 338, 339, 493
Pulmonary arterial hypertension  134
Pulmonary Embolus (PE)  113, 121, 127, 160
Pulmonary thromboembolism  123
Purified factor IX  68
Purified factor VIII  68
Purpura  39, 63, 66
Pyelonephritis  354, 355
Pyloric stenosis  49, 85, 92, 249, 264, 547
Pyrazinamide  474, 475
Pyrethrin  660
Pyrethroid  660
Pyrexia  133
Pyridoxine  474, 475
Pyrimethamine  317, 493
Q
Quinine  487, 488, 491, 492, 493
R
Rabeprazole  24, 27
Radiocontrast  404
Ramipril  138, 139, 150Rapid Diagnostic Test (RDT)  211, 335, 480, 
482, 483, 621
Reactive Erythema  273
Ready to Eat Therapeutic Food (RUTF)  60
Recombinant Factor VIII  67
Red Eye  506
Reed Sternberg (RS) cell  77
Relaxation training  215, 237
Respiratory Syncytial Virus (RSV)  167
Retained placenta  318
Retinoblastoma  108
Retropharyngeal Abscess  521
Retrovirus  274
Rhesus  102, 319, 361, 362, 363, 364, 367, 368
Rhesus factor  367
Rhesus Isommunization  363
Rheumatic heart disease  134, 157, 161
Rheumatoid arthritis  554, 557
Rheumatoid factor  555, 558, 561
Rhinoviruses  167
Ribavirin  42
Rickets  616
Rifampicin  250, 474, 475, 477
Rifaximin  45
Ringer’s lactate  17, 18, 144, 323, 330, 331, 
394
Risperidone  222, 223, 227, 243
Rituximab  557, 563, 570, 580, 581
Rivaroxaban  66
Robaxin  562
Ropivacaine  664
Rosuvastatin  120, 131, 301, 302
Rotavirus  11, 18, 19, 80, 81
Rotavirus vaccine  19
RPR  265, 316, 320
RUTF  60
S
Salbutamol  176, 177, 178, 179, 184, 185, 355, 
646, 670
Salicylic acid  270, 280
Salmonella  11, 480, 597
Salt-poor human albumin solution  48
Saxagliptin  292
Scabies  267, 268
SCD  334, 335
Schistosoma mansoni  390
Schizophrenia  209, 220
Scleritis  506
Scurvy  618
Seasonal Malaria Chemoprevention (SMC)  
494
Seborrhoiec dermatitis  267

INDEX687Seborrhoiec Eczema  279, 281
Secnidazole  375
Seizures  98, 100, 130, 133, 155, 196, 197, 201, 
213, 229, 239, 388, 470, 577, 582
Selective estrogen receptor modulators 
(SERMs)  620
Selenium sulphide  256, 282
Senna  21, 31
Septicaemia  94, 95, 247, 249, 401, 482, 612
Septic granuloma  614
Sertraline  219, 235, 237
Severe Malaria  486
Severe or Erosive GERD  27
Sexually Transmitted Infection (STI)  373, 379, 
442
Shea butter  280
Shigella  11
Sickle Cell Disease  62, 69, 95, 113, 334, 335, 
337, 513, 621, 668
Sickle Cell Disease In Pregnancy  334
Sickle Cell Disease – Retinopathy  513
Sickle-cell Vaso-occlusive Crisis  620
Sick newborn  97
Sigmoidoscopy  30
Silver nitrate  106
Simple linctus  181
Simvastatin  121, 301
Sinus bradycardia  156
Sinusitis  194, 526
Sirdalud  562
Sitagliptin  292
SLE  63, 577
Sleep hygiene  562
Sodium Bicarbonate  144, 395, 398, 490
Sodium Chloride  67, 71, 91, 168, 178, 308, 
330, 331, 363, 394, 646
Sodium Thiosulfate  661
Sodium valproate  201, 202, 227, 229
Soluble Insulin  291, 395, 398
Soothing agent (with or without steroids)  31
Spirochaetes  537
Spirometry  176, 184
Spironolactone  47, 139, 150
Splenomegaly  36, 70, 76, 78, 483
Spots  83, 276
Squint  108
Stable Angina  113
Stable angina pectoris  115
Stable chronic bronchitis  184
Staph. epidermidis  597
Staphylococci  106, 499, 541, 608, 610
Staphylococcus aureus  170, 171, 180, 189, 
245, 247, 274, 495, 519, 521, 527, 529, 539, 
597, 604, 608, 611, 647Staphylococcus saprophyticus  406
Status Epilepticus  199
Stevens-Johnson syndrome  273, 274, 511
STI  320, 373, 374, 375, 379
Still’s disease  557
Stimulus control therapy  215
Strabismus  108, 512, 513
Strept. faecalis  597
Streptococcus  95, 106, 170, 180, 247, 495, 
519, 521, 523, 526, 529, 538, 539, 541, 545, 
604, 608, 647
Streptococcus mitis  538
Streptococcus pneumonia  170, 527
Streptococcus pneumoniae  95, 180, 495, 519, 
529
Streptococcus pyogenes  170, 247, 519, 604
Streptococcus salivarius  538
Streptococcus sanguis  538
Streptomycin  250, 474, 475
Strept. pyogenes  597, 611
Stridor  84, 91, 515, 518, 519, 521, 666, 667
Stroke  48, 73, 123, 129, 131, 132, 133, 146, 
147, 149, 154, 155, 158, 160, 165, 166, 170, 
196, 197, 203, 205, 294, 311
Strongyloides  499, 502
Strontium  620
Structured Approach to the Seriously Ill Child  
666
ST-segment elevation myocardial infarction 
STEMI  118, 120, 121
Subarachnoid haemorrhage  130, 154
Subconjunctival haemorrhage  506
Subgaleal Haemorrhage  104, 105
Substance Use disorders  239
Sulfasalazine  557
Sulphadoxine  493, 494, 495
Sulphamethoxazole-Pyrimethamine (SP)  317
Superficial Fungal Skin Infections  252
Systemic arterial hypertension  134
Systemic Lupus Erythematosus  388, 390, 577
Systemic onset arthritis (Still’s disease)  557
Systemic thromboembolism  158, 160
T
Tachycardia  98, 100, 127, 135, 141, 143, 165, 
189, 234, 236, 298, 364, 468, 644
Tachypnoea  127, 135, 141, 175, 189, 468, 
486, 516, 518, 669
Tacrolimus  405, 581
Tamsulosin  410
TB meningitis  472
Temporo-mandibular joint  549
Temporo-mandibular joint dysfunction  549

 
Standard  Treatment Guidelines, 7th Edition, 2017
688Tenofovir  40, 405, 463, 464, 466
Terazosin  410
Terbinafine  253, 254
Teriparatide  620
Tetanol  318, 366
Tetanus  81, 86, 87, 88, 89, 318, 366, 594, 625, 
627, 628, 629
Tetanus Prophylaxis  366
Tetracaine hydrochloride  505
Tetracycline  15, 278, 507, 508, 512
Tetralogy of Fallot (TOF)  140
The Acutely Disturbed Patient  209, 228
The Unconscious Patient  203
Thiamine  204, 232
Thiazide Diuretics  149
Thrombocytopaenia  68, 110, 112, 261
Thyroid eye disease  511
Thyrotoxicosis  134, 138, 157, 158, 226, 302, 
303, 305, 306, 307, 318
TIA  129, 131, 165, 166
Tiabendazole  502
TIBC  335
Tinea  256, 257, 267, 283
Tinea capitis  252
Tinea corporis  253
Tinea cruris  253
Tinea manuum  253
Tinea pedis  253, 254
Tinea Versicolor  256, 257
Tinidazole  34
Tiotropium  185
Tizanidine  566
TMJ  549
Tocilizumab  557
Tocolysis  355
Todd’s paralysis  197
Tofacitinib  557
Tolbutamide  292
Tonsillitis  471, 523
Toxic alcohols  657, 661
Toxic epidermal necrolysis (TEN)  274
Toxic multi-nodular goitre  305
Toxoplasma  495
TPHA  316
Tramadol  54, 72, 195, 563, 565, 653
Tranexamic acid  68, 373
transient ischaemic attack (TIA)  129
Transposition of the Great Arteries (TGA)  140
Trauma And Injuries  582
Treatment Induced Hypoglycaemia  298
Treponema pertenue  250
Tretinoin  278
Triamcinolone  554, 576
Triazolam  216Trichomonas vaginalis  374
Trichomoniasis  375
Trichophyton  252
Trigeminal neuralgia  193
Trigerminal neuralgia  550
Trigerminal Neuralgia  550
Trihexyphenidyl  224
Trimethoprim/Sulphamethoxazole  85
Troponin  116, 118, 123, 155
Tuberculosis  62, 471, 615
Tuberculosis in orthopaedics  615
Typhoid Fever  35, 161, 193, 393, 479, 480, 
482
U
Uncomplicated Malaria  483
Unconsciousness  100, 130, 152, 155, 203, 
205, 298, 329
Uraemia  145
Uric acid  74, 118, 148, 312, 387, 394, 571, 
572, 573, 575
Urinary Tract Infection (UTI)  309, 322, 332, 
337, 359, 401, 402, 403, 408, 470, 585
Urticaria  267, 270, 271, 272, 644
V
Vaccine-associated paralytic poliomyelitis 
(VAPP)  89
Vaginitis  375, 376
Valsatan  150
Valvular Heart Disease  121
Vancomycin  170, 497, 498, 499, 608, 610
Varicella  259, 261, 262
Varicella – zoster virus  259
Varicose eczema  279
Vasodilators  150, 154
Vaso-occlusive bone pain crises  70
VDRL  251, 265, 316
Verapamil  116, 159, 160
Vertigo  49, 164
Vestibular Nausea  51
Vibrio cholerae  11
Vildagliptin  292
Vincristine  109, 111
Viral Skin Infections  257
Vitamin A  59, 60, 83, 503, 504
Vitamin A supplementation  60
Vitamin B6  474, 475
Vitamin B12 Deficiency  65
Vitamin B12 (Hydroxocobalamin)  62, 63, 65, 
564
Vitamin-C  618

INDEX689Vitamin-C deficiency  618
Vitamin-D  616, 617, 619, 620
Vitamin K  66, 67, 106
Vomiting  11, 12, 15, 18, 19, 20, 22, 25, 37, 
48, 49, 50, 53, 56, 57, 58, 84, 93, 97, 109, 111, 
114, 118, 119, 137, 155, 165, 194, 204, 229, 
231, 240, 242, 294, 307, 309, 322, 358, 361, 
364, 366, 380, 388, 393, 394, 396, 401, 470, 
472, 483, 486, 495, 499, 509, 529, 582, 583, 
586, 589, 604, 656, 658, 660, 661, 668, 669
Von Willebrand Disease  66, 68
VRSA (Vancomycin resistant)  170
W
Warfarin  66, 126, 129, 660
Wertheim’s hysterectomy  386
Wheals  272, 273
Whitfield’s ointment  253, 255, 256, 285
WHO Grading of Trachoma  507
Wilms Tumour  110
Worm Infestation (Intestinal)  499
Worm infestations  61
Worms  499, 500
X
Xerophthalmia  503
Xylometazoline  168
Y
Yaws  250, 251
Yellow Fever  37, 81, 92
Yellow fever virus  93
Z
Zidovudine  463, 466
Ziehl-Neelsen stain  171, 521
Zinc  15, 19, 270
Zinc oxide  270
Zinc supplementation for diarrhoea  15

 
Standard Treatment Guidelines, 7th Edition, 2017
690Other Publications 
 y Ghana Assessment of Medicines Procurement and Supply Manage -
ment systems in the Public Health Sector, A country Report (2009)
 y Partners Mapping for Medicines Procurement and Supply Manage -
ment in Ghana (2009)
 y Standard Treatment Guidelines (2004)
 y Ghana Essential Medicines List (2004)
 y National Drugs Policy (2004)
 y Code of Ethics and Standards of Practice for Traditional Medicines 
Practitioners in Ghana (2003)
 y Standard of Pharmaceutical Care for Health Institutions in Ghana 
(2003)
 y Increasing Access to Medicines: An Assessment and Policy Options 
for Ghana (2003)
 y An Assessment of the Pharmaceutical Sector in Ghana (2002)
 y Logistics Management of Public Sector Health Commodities in Gha -
na: standard Operating Procedures – Regional Medical Stores to Ser -
vice Delivery Points (2002)
 y Drugs and Therapeutics Committee (DTC) Training Manual (2002)
 y Standard Treatment Guidelines (2000)
 y Ghana Essential Drugs List (2000)
 y Baseline Survey on the Pharmaceutical Sector in Ghana (1999)
 y Procurement Procedure Manual (1999)
 y Procurement Training Manual
 y Rational Drug Use Training Manual
 y Standard Treatment Guidelines, 6th Edition, (2010)
 y Essential Medicines List, 6th Edition, (2010)

